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Modern neuroimaging tools allow unprecedented opportunities for understanding 
brain neuroanatomy and function in health and disease.  Each available technique 
carries with it a particular balance of strengths and limitations, such that converging 
evidence based on multiple methods provides the most powerful approach for 
advancing our knowledge in the fields of clinical and cognitive neuroscience. In 
addition to offering fine-grained in-vivo neuroanatomical specification, neuroimaging 
methods also provide the opportunity to non-invasively explore brain function. The 
latter – widely employed in the study of cognition, and instrumental in the emergence 
of the field of cognitive neuroscience – is being increasingly used for clinical purposes 
(for example, to enhance pre-surgical lesion mapping, to avoid critical networks 
serving sensory and cognitive functions, and to improve prognostic evaluation for 
patients in minimally conscious states). Molecular imaging is providing a window on 
the biological mechanisms associated with disease progression, but rapid 
advancement in this area is contingent upon the specificity, sensitivity and delivery of 
the probes and the speed and resolution of the imaging method. Clinical near-infrared 
spectroscopy (NIRS) is a form of optical imaging increasingly employed to estimate 
location and extent of cerebral activation via the monitoring of blood haemoglobin 
levels. Its portability provides the possibility of bedside measurement, and its 
relatively low cost and straightforward application lends itself well to clinical use. 
Magnetic resonance spectroscopy (MRS), unlike conventional magnetic resonance 
imaging (MRI), provides information on the brain’s chemical environment (rather than 
neuroanatomical structure) and the data are most commonly presented as line spectra. 
This capacity for determining brain metabolite concentrations provides the basis for 
clinical investigation of, and differentiation between, neurological and neurosurgical 
conditions. For example, MRS is particularly important for differentiating between high 
and low grade gliomas, between Alzheimer’s disease and non-progressive neurological 
conditions, and in the detection of changes associated with mild cognitive impairment 
(often a precursor for dementia). Neurological conditions carry different prognoses and 
require different forms of immediate treatment and longer term clinical management, 
and MRS (particularly when combined with clinical information and MRI) can provide 
critically important information for diagnostic and evaluation purposes. 
The scope of this book is not to provide a comprehensive overview of methods and 
their clinical applications but to provide a “snapshot” of current approaches using 
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well established and newly emerging techniques. Richly illustrated overviews of 
MRI/MRS features associated with congenital brain malformations (Chapter 1, Bano) 
and inborn errors of metabolism (Chapter 2, Casimiro et al.) provide important 
reference documents for diagnostic purposes. Chapters 3 (Govender, Wilmshurst & 
Wieselthaler) and 4 (Guevara Campos & González Guevara) focus on acquired 
disorders in children. In children, disseminated encephalomyelitis is more common 
than (and a major risk factor for) multiple sclerosis (MS). Following recovery, the 
potential risk of a relapse occurring is a critical issue for long-term prognosis. 
Govender et al. present an important overview of criteria employed to predict 
recurrence and progression to MS, with particular attention given to radiological 
findings. Guevara Campos and González Guevara focus specifically on Landau 
Kleffner syndrome (LKS; sometimes called infantile acquired aphasia), in which 
language comprehension and expression impairments emerge after an initial period of 
normal development. Diagnosis (and differentiation from autism and other forms of 
learning disability) can be difficult and contingent upon encephalography (EEG) 
recordings acquired during sleep. The authors reflect on the advantages of 
magnetoencephalography (MEG) employed on its own, or in combination with EEG, 
for differential diagnosis, evaluation and management. 
In Chapter 5, Carrascosa Romero and de Cabo de la Vega consider the relevance of 
genetics and brain imaging findings in the diagnosis of diseases which result from 
abnormal development or neoplasia of cells derived from the neural crest 
(neurocristopathies). Koga and Saito (Chapter 6) provide a beautifully illustrated 
discussion of the use of neuroimaging tools to guide gamma knife radiosurgery.  
Advances in neuroimaging methods and software have greatly improved precision of 
radiosurgery for the treatment of structural abnormalities, thereby preserving the 
function of surrounding tissue. Combined methods have led to further refinements 
with, for example, high visuospatial resolution afforded by MRI combined with 
metabolic information from the lesion site (measured with 18F-fluorodeoxyglucose 
positron emission tomography; FDG-PET) to indicate location and malignancy of 
gliomas, which in turn informs radiosurgical targeting. Kapsalaki et al. (Chapter 7) 
consider MRS spectroscopic profiles for differentiation among ring enhancing lesions 
including high grade gliomas, abscesses and post-radiation necrosis. The potential for 
misdiagnosis of ring enhancing lesions is an important clinical concern and this 
overview of spectroscopic signatures associated with various candidate pathologies is 
a welcome contribution to the literature. In Chapter 8 Kapsalaki et al. turn to the 
viability of functional MRI (fMRI) for maximising glioma extirpation and limiting the 
likelihood or level of neurocognitive deficit. The chapter includes a careful 
consideration of issues associated with fMRI design and analysis, its inherent 
inferential limitations and a comprehensive review of its application during 
presurgical planning.  
The role of neuroimaging methods in managing epilepsy and identifying suspected 
areas of abnormality are described by Bragatti (Chapter 9). He includes an overview of 
the utility of structural, diffusion and functional MRI, MRS, EEG, MEG, PET, single 
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photon emission computed tomography (SPECT) and combined approaches.  Canas 
and Soares (Chapter 10) discuss transient abnormal MRI findings associated with 
seizure activity. This reversibility of neuroimaging features indicates that they are 
specifically caused by the seizures but their localization significance is unclear. The 
authors consider the role of MRI techniques for investigating and characterising these 
abnormalities. Durá-Travé et al. (Chapter 11) present an epidemiological study of 
epilepsy and epileptic syndromes in 457 children for whom MRI was performed at 
diagnosis. A number of common MRI abnormalities were observed, particularly when 
diagnosed in the first years of life, raising the possibility that imaging findings 
previously considered incidental might be clinically significant with respect to 
emergence and likely form of epileptic disorder. A role for the insula as part of a 
distributed network involved in medial temporal lobe epilepsy has been implicated as 
far back as the 1940s, but its deep position behind the operculum presents difficulties 
for investigation with depth electrodes. Afif (Chapter 12) describes the advantages of 
using an oblique (rather than orthogonal) robotic arm guided approach to explore the 
insular cortex during invasive pre-surgical evaluation of patients with epilepsy.   
Cerebral small vessel disease (cSVD) is widely prevalent in elderly people and a risk 
factor for motor and cognitive impairment (particularly of executive function) and 
possibly for parkinsonian disorders and dementia. Gunda, Várallyay and Bereczki 
(Chapter 13) explore the utility of non-conventional MRI techniques (including 
diffusion and perfusion weighted imaging (DWI/PWI) and diffusion tensor imaging 
(DTI)) for enhancing our understanding of cSVD.  Intracranial atherosclerotic disease 
(ICAD) is a major cause of ischemic stroke worldwide, but particularly associated with 
Asian populations. Khan, Naqvi and Kamal (Chapter 14) describe neuroimaging tools 
available for diagnosis and management of the disease, including diffusion weighted 
images of infarct patterns and vessel imaging using conventional angiography as well 
as other complementary approaches, such as transcranial Doppler ultrasound for 
measuring blood velocity. 
The advantages and limitations of conventional structural MRI for the diagnosis and 
monitoring of MS are discussed by Andreadou (Chapter 15). There is often a disparity 
between the level of structural abnormality seen on MRI and level of cognitive 
difficulties expressed by the patient with MS. Clinical interview and 
neuropsychological assessment are vitally impairment, not only from an initial 
diagnostic perspective but also in terms of longer term planning and care. Mike, 
Guttman and Illes (Chapter 16) consider cognitive impairment in MS and its 
relationship to grey matter findings with MRI. Although significant correlations 
between quantified measures of grey matter integrity and level of cognitive 
impairment are observed, this relationship requires further exploration and refinement 
if more targeted and appropriate long term management is to be realised. 
Idiopathic intracranial hypertension (also known as pseudotumor cerebri) is a 
neurological condition (disproportionately occurring in obese women of childbearing 
age) associated with raised intracranial pressure which is not caused by intracranial 
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mass or other disease. Rosenfeld and Kesler (Chapter 17) review presenting signs and 
the role of neuroradiological evaluation in excluding tumors or vascular lesions that 
might otherwise explain raised intracranial pressure.   
Huang, Yen and Lu (Chapter 18) review the role of SPECT in the diagnosis of 
idiopathic Parkinson’s disease and its differentiation from other conditions 
characterised by parkinsonisms such as dementia with Lewy Bodies (DLB) and 
vascular parkinsonism. Accurate diagnosis is clearly critical for treatment and 
prognosis, and the authors provide a very useful overview of recent developments in 
dopamine transporter imaging which have led to important advances in this area. 
Fragile X-associated tremor/Ataxia syndrome (FXTAS), formally identified in 2001, is a 
late-onset neurodegenerative condition occurring in carriers of a fragile X gene (FMR1) 
premutation. Rodriguez-Revenga et al. (Chapter 19) consider the possible role of MRI 
in the early diagnosis of patients for whom the underlying pathogenic process may 
begin early in life. Papadaki and Boumpas (Chapter 20) present a comprehensive 
review of the application of non-conventional neuroimaging techniques in 
neuropsychiatric systemic lupus erythematosus (NPSLE). Wide variability in the 
clustering of symptoms presents considerable challenges for diagnosis, and the 
authors present strong arguments for more widespread use of techniques sensitive to 
microstructural, haemodynamic and biochemical tissue characteristics. Bano (Chapter 
21) reviews important clinical and imaging features associated with tuberculosis of the 
central nervous system. Conventional MRI has an important role in ensuring accurate 
clinical diagnosis but the diagnostic sensitivity of infra-tentorial lesions and initial 
cerebral changes identified with this approach is questionable. MRS can be 
particularly helpful in differentiating causes of ring enhancing lesions and 
magnetization transfer imaging (MTI), diffusion and perfusion imaging can also aid in 
diagnosis and management of the condition.   
Molecular cloning has identified eight metabotropic glutamate receptor (mGluR) 
subtypes, each with distinct patterns of expression. However, the characteristic roles of 
these different mGluRs in physiological processes are not well understood. 
Identification of subtype-specific compounds may potentially act as therapeutic agents 
for the treatment of a wide range of conditions (including progressive brain disease, 
epilepsy and cerebral ischemia) all of which are associated with abnormal mGLuR 
activation. Zhang and Brownell (Chapter 22) present a superb overview of mGluR 
functions, radiotracer development and imaging findings to date, and raise important 
clinical implications and recommendations for further research. Brust and Deuther-
Conrad (Chapter 23) provide an overview of the current status of molecular imaging 
of the α7 nicotinic acetylcholine receptor, considered an important regulator of cellular 
function with probable involvement in a range of neurodegenerative diseases, 
schizophrenia, and other disorders. Ratai, Caruso and Eichler (Chapter 24) consider 
the role of advanced magnetic resonance technologies for the imaging of 
leukodystrophies which are (mostly inherited) genetic mutations that produce 
progressive cognitive and physical impairment in children previously considered well. 
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These disorders are caused by maturational white matter abnormalities and therefore 
white matter tractography (using DTI) can offer advantages over conventional MRI in 
the detectability of clinically relevant microstructural features. High field strength 
structural MR scanning (up to 7 tesla for clinical and research use in humans) is now 
available in some countries, and this greatly enhances the spatial resolution over that 
offered by standard clinical facilities (typically 1.5 or 3 tesla). Similarly, better MRS 
spectral resolution is achieved at higher field strengths due to improved signal-to-
noise and chemical-shift dispersion. The authors describe how developments in MR 
technology have provided clear clinical and practical benefits but also acknowledge 
their methodological drawbacks and limitations. Their overriding conclusions and 
recommendations are common to all fields of research in clinical neuroscience covered 
in this book: that it is only though the combined application of different neuroimaging 
methods, in which both strengths and limitations of each mode of investigation are 
taken into account, that rapid advances in knowledge of health and disease are likely 
to be realised. 
 
Peter Bright 
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1. Introduction  
More than 2000 different congenital malformations of the brain have been described in the 
literature, and their incidence is reported to be about 1 percent of all live births.1 Since the 
congenital anomalies of the brain are commonly encountered in day to day practice, it is 
very important for every radiologist to be familiar with the basic imaging findings of 
common congenital anomalies to make a correct diagnosis necessary for optimum 
management of these conditions. Magnetic resonance imaging (MRI) is very useful in 
studying these malformations. The aim of this chapter is to provide an overview of all 
important and routinely encountered congenital malformations of the brain.  
2. Normal brain development 
Congenital anomalies of the brain are extremely complex and are best studied by correlating 
with embryological development. Basic events in normal brain development includes the 
following four stages:1 
Stage 1: Dorsal Induction: Formation and closure of the neural tube 
- Occurs at 3-5 weeks 
- Three phases: Neurulation, canalization, retrogressive differentiation 
- Failure: Neural tube defects (Anencephaly, Cephalocele, Chiari malformations) and 
Spinal dysraphic disorders.    
Stage 2: Ventral Induction: Formation of the brain segments and face 
- Occurs at 5-10 weeks of gestation 
- Three vesicles (prosencephalon, mesencephalon, and rhombencephalon) form the 
cerebral hemispheres/thalamus, midbrain, and cerebellum/brain stem respectively.  
- Development of face  
- Failure: Holoprosencephalies, Dandy Walker malformation, Cerebellar 
hypoplasia/dysplasia (Chiari-IV), Joubert syndrome, Rhombencephalosynapsis, 
Septooptic dysplasia, and facial anomalies. 
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Stage 3: Migration and Histogenesis 
- Occurs at 2-5 months of gestation 
- Neuronal migration from germinal matrix to the cortex 
- Cortical organization 
- Failure of Migration: Heterotopias, Agyria-pachygyria, Polymicrogyria, Lissencephaly, 
Schzencephaly, Corpus callosal agenesis, Lhermitte-Duclos disease.  
-  Failure of Histogenesis: Aqueductal stenosis, Arachnoid cyst, Megalencephaly, 
Micoencephaly, Neurocutaneous syndrome (phakomatoses), Congenital vascular 
malformation, and Congenital neoplasms. 
Stage 4: Myelination 
- Begins at 6 months of gestation; matures by 3 years. 
- Progresses from caudal to cephalad, from dorsal to ventral, and from central to  
peripheral  
- Failure: Dysmyelinating diseases, Metabolic disorders.  
3. Classification of congenital malformation of brain  
A number of classification systems have been proposed, but with regards to our basic 
purpose, simplified classification of brain malformations has been taken into account, which 
is as follows: 1,2 
a. Disorders of Organogenesis 
- Neural tube closure 
- Diverticulation and cleavage 
- Sulcation/cellular migration 
- Cerebellar hypoplasia/dysplasia 
b. Disorders of Histogenesis 
- Neurocutaneous syndromes (Phakomatoses) 
c. Disorders of Cytogenesis 
- Congenital vascular malformations 
- Congenital neoplasms of brain 
d. Disorders of Myelination 
- Leukodystrophies    
4. Imaging features of congenital malformations of the brain 
4.1 Disorders of organogenesis 
4.1.1 The chiari malformations 
Chiari I Malformation1,2  (Figure 1) 
- Termed as tonsillar ectopia 
- Herniation of elongated peg like cerebellar tonsils into the upper cervical canal through 
the foramen magna. 
- Abnormal tonsillar descent below the opisthion-basion line  
 At least 6mm in first decade  
 5mm in the 2nd /3rd  decade 
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 4mm between 4th -8th decade, and 
 3mm by 9th decade   
- Causes of abnormal tonsillar descent  
 Congenital asymptomatic tonsillar ectopia 
 Intracranial hypotension due to chronic CSF leak (sagging brain) 
 Long-standing compensated hydrocephalus 
 Craniovertebral anomalies (Basilar invagination, Platybasia, Atlantooccipital 
assimilation)  




Fig. 1. Chiari I Malformation. Sagittal T1W MR scan of brain shows peg like low lying tonsil in 
upper posterior cervical canal (thin white arrow). The cerebellar tonsils lie more than 10mm 
below the foramen magnum. Note mild enlargement of supratentorial ventricular system. 
Chiari II Malformation1,2  (Figure 2) 
- Complex anomaly involving skull, dura, brain, spine and the cord 
- Skull and dural involvement 
 Luckenschadel (lacunar skull), concave clivus and petrous ridges 
 Small and shallow posterior fossa with low lying transverse sinuses and torcular 
herophilli 
 Hypoplastic tentorium cerebelli with gaping (heart shaped) incisura 
 Hypoplastic, fenestrated falx cerebri with interdigitating gyri 
 Gaping foramen magnum 
- Brain involvement 
 Cascading protrusion of vermian nodulus, fourth ventricle choroid plexus and the 
medulla into the spinal canal with formation of cervicomedullary spur and kink 
 Upward herniation of cerebellar hemispheres and vermis through gaping incisura 
(towering cerebellum) producing tectal deformity (beaked tectum) 
 Cerebellar hemispheres creep around to engulf the brain stem 
 Large massa intermedia 
 Hydrocephalus (90%) with serrated appearance of lateral ventricles 
 








Fig. 2. Chiari II Malformation. Sagittal T1W MR images(a,b) of brain show a small posterior 
fossa, low lying tetorium cerebelli (thick black arrow), cascade of inferiorly displaced vermis 
and choroid plexus into upper posterior cervical canal (double thin black arrow), medullary 
spur (thin white arrow), large massa intermedia(asterix). The cerebellar hemispheres extend 
antero-medially(thin white arrow) to engulf the brain stem on axial T2W(c) image. Coronal 
T1W image(d) reveals low lying torcular herophili(thick white arrow), gaping incisura and 
towering cerebellum(thin black arrow). Also note bilateral hydrocephalus. Plain axial CT 
scan(e,f) another patient shows cerebellar hemispheres engulfing the brain stem, wide 
gaping incisura plugged with upward herniating dysmorphic cerebellum(thin black arrow), 
gross gyral interdigitation and stenogyria (thick white arrow). Screening of whole spine in 
another patient with ACM-II demonstrates associated lumber myelomeningocele (asterix) 
on sagittal T2W image (g). 
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- Spine and cord involvement 
 Myelomeningocele (nearly 100%) 
 Syringohydromyelia (70-90%) 
 Diastematomyelia  
- Associated anomalies 
 Corpus callosal dysgenesis, heterotopias, polymicrogyria 
Chiari III Malformation1,2,3  (Figure 3) 
- Features of Chiari II malformation with a low occipital or high cervical encephalocele 
- The encephalocele may contain meninges, cerebellum, occipital lobe or brain stem. 
Cisterns and dural sinuses may also be present 
 
 
Fig. 3. Chiari III Malformation. Sagittal T1w MR scan shows features of ACM II, evidenced 
as a large massa intermedia (asterix), tectal beaking (thin black arrow), inferior herniation of 
the cerebellar tissue through the foramen magnum into the upper posterior cervical canal 
(thin white arrow), and a low occipiltal meningoencephalocele (thick white arrow). 
Chiari IV Malformation1,2 
- Severe cerebellar hypoplasia or dysplasia, small brain stem and large posterior fossa 
CSF space  
- No hydrocephalus and other CNS anomalies  
Cephaloceles1,2,4 (Figure 4-10) 
- Characterized by protrusion of intracranial contents through a congenital defect in the 
dura and skull 
- Usually located at or near the midline. 
- Pathological classification of cephaloceles (based on the contents of the herniated sac) 
 Meningocele (leptomeninges and CSF) 
 Meningoencephalocele (leptomeninges, CSF and brain) 
 Meningoencephalocystocele (leptomeninges, CSF, brain and ventricles) 
 Atretic cephalocele (small nodule of fibrous fatty tissue)  
 Gliocele (CSF lined by glial tissue) 
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- Anatomic classification of cephalocele (based on location) 
 Occipital - most common in America, Europe  
 Parietal 
 Temporal 
 Frontal or Frontoethmoidal (Sincipital) - most common in Asia 
 Transsphenoidal - uncommon 
 Nasal 
- The herniated brain dysgenetic and non-functional 
- Absence or erosion of the crista galli with enlargement of foramen cecum is a constant 
feature of a nasal cephalocele.  
 
 
Fig. 4. Occipital cephalocele. Sagittal T1W (a) image shows herniation of severely dysplastic 
cerebellar tissue and the occipital lobe into a large CSF containing sac through an osseous 
defect in the occipital bone(thin white arrow). Thin strand of dysplastic brain tissue or septa 
can be seen traversing the CSF within the sac. Also note small posterior fossa, and deformed 
brain stem. 2D Time-of- flight venogram (b) demonstrates no herniation of dural venous 
sinuses in the cephalocele sac. This is important information for the surgeons.  
 
 
Fig. 5. Parietal cephalocele. Sagittal T1W(a) image of brain shows a small parietal 
cephalocele containing CSF and dysplastic brain tissue(thin white arrow). 2D TOF 
venogram(b) shows non visualization of small segment of superior sagittal sinus in the 
region of osseous defect consistent with sinus thrombosis(thin white arrow). 
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- Differential diagnosis of a nasal cephalocele includes congenital nasal masses (e.g. 
dermoid) where crista galli is present but split. 
- Antenatal ultrasound and MRI are useful in evaluation of content of the sac. MR 
venography is useful to assess major dural sinuses within the herniated sac, which may 
be responsible for major bleeding during surgery. CT is useful in demonstrating bony 
defect. 
- Associated anomalies 
 Chiari II and III malformation (seen with occipital cephalocele) 




Fig. 6. Temporal cephalocele. Coronal T2W (a), axial T1W (b) and FLAIR (c) image of brain 
shows a left temporal meningoencephalocele (thin white arrow) containing dysplastic and 
disorganized left temporal lobe and CSF. Ipsilateral lateral ventricle is dilated and the 
temporal horn appears stretched towards the bony defect. 
 
 
Fig. 7. Frontal cephalocele. Axial T2W(a) and sagittal T1W(b) image of brain demonstrates a 
large frontal midline meinigoencephalocele (thin white arrow) containing dysplastic frontal 
lobes, stretched frontal horns and the CSF. Left cerebral hemisphere drsraphism is present, 
seen as a widely open CSF cleft(asterix) extending across the left external capsule region, 
and communicating posteriorly with the dilated occipital horn and anteriorly with the 
cephalocele. Ipsilateral basal ganglion show abnormal morphology. Subependymal 
heterotopia of right occipital horn (thin black arrow) and a small, narrow left sided posterior 
scizencephalic cleft (thick white arrow) is also noted. 
 




Fig. 8. Nasal cephalocele. Sagittal T1W (a), Coronal FLAIR (b), and axial T2W(c) images 
reveal a large right sided nasal meningocele containing the CSF (asterix). There is a defect in 
the skull base in the region of the cribriform plate and crista galli (thin arrow).  
 
Fig. 9. Sphenoid encephalocele. Axial (a) and coronal (b) NCCT head shows a defect in right 
lateral wall of sphenoid sinus(thin white arrow) with herniation of small portion of 
inferomedial part of ipsilateral temporal lobe (black asterix and thin black arrow). 
Associated sinusitis is seen involving the ipsilateral sphenoid sinus (white asterix). 
 
Fig. 10. Atretic occipital cephalocele. Sagittal T2W(a), axial T1W(b) image shows a small 
subcutaneous mass (thin white arrow) in high occipital region just external to a small defect 
in the calvarium. Note that the brain is not entering the cephalocele; instead, a thin strand of 
fibrous tissue is seen extending across the osseous defect, from the surface of the brain to the 
subcutaneous mass. Small posterior fossa arachnoid cyst is also seen. 2D TOF venogram (c) 
shows presence of median procencephalic vein within embryonic falcine sinus(thin white 
arrow) and absence of sagittal sinus.  
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Corpus Callosum Agenesis 1,2 (Figure 11,12,13) 
- Corpus callosum, a midline commissure connects two cerebral hemispheres 
- Develops in cephalocaudal direction, beginning with genu then followed by the body 
and splenium. The rostrum is last to develop 
- Two types: complete or partial 
- Complete callosal agenesis 
 Absence of entire corpus callosum, cingulate gyrus and sulcus  
 High riding 3rd ventricle with spoke like orientation of gyri around it 
 Widely separated, parallel and non-converging lateral ventricles.  
 Probst bundles (longitudinal white matter tracts) indent superomedial lateral 
ventricles 
 Colpocephaly (dilated occipital horns) common, frontal horns small and pointed 
 High incidence of dorsal interhemispheric cyst 
 
 
Fig. 11. Corpus callosal agenesis (partial). Sagittal T1W(a) and axial T2W (b,c) image shows 
presence of only the genu of the corpus callosum (thin white arrow), high riding third 
ventricle(thin black arrow),widely separated and parallel lateral ventricles(double thin 
white arrow).  
 
 
Fig. 12. Corpus callosal agenesis(complete). Sagittal T1W(a) and coronal T2W (b) image 
shows complete absence of the corpus callosum and cingulate sulcus (thin white arrow), 
high riding third ventricle communicating with the interhemispheric fissure(thin black 
arrow), and crescent shaped frontal horns indented medially by white matter tracts of 
Probst’s bundles(thick white arrow). Widely separated and parallel lateral ventricles with 
colpocephaly are also seen (double thin white arrow) on axial T2W image(c).  
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- Partial callosal agenesis 
 Splenium and rostrum absent or hypoplastic 
 Genu and body  present to various degrees 
- Associated anomalies 
 Migration disorders (heterotopias, lissencephaly, schizencephaly) 
 Chiari II malformation 
 Dandy-Walker malformation 
 Holoprosencephaly 
 Corpus callosal lipoma 
 
 
Fig. 13. Corpus callosal agenesis(partial) with dorsal interhemispheric cyst. Sagittal T1W(a) 
and axial T2W(b) image shows presence of the genu and anterior part of body of the corpus 
callosum while, the posterior body, splenium and rostrum is absent (thin white arrow). The 
lateral ventricles are widely separated and a moderately large dorsal interhemispheric cyst 
(asterix) is present which is seen communicating with the overlying subarachnoid space via 
a narrow schizencephalic cleft (thin black arrow). Solitary nodular heterotopia can be seen 
within the body of left lateral ventricle which is mildly dilated (thin white arrow).  
4.2 Disorders of diverticulation and cleavage 
Holoprosencephaly1,2,5 (Figure 14,15,16) 
- Characterized by complete or partial failure of cleavage and differentiation of 
developing cerebrum (prosencephalon) into hemispheres and lobes. 
- Cerebellum and brain stem relatively normal 
- Classified into three types on the basis of degree of severity 
 Alobar (most severe) 
 Semilobar ( moderately severe) 
 Lobar (mildest form) 
- Precise boundaries among these three groups does not exist, intermediate cases may be 
identified 
- Alobar Holoprosencephaly 
 Near complete lack of hemispheric cleavage 
 Cresent-shaped monoventricle  
 Absence of septum pellucidum, corpus callosum, falx cerebri, and interhemispheric 
fissure   
 Fused thalami and basal ganglia 
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 Associated anomalies: Dorsal interhemispheric cyst, severe craniofacial anomaly 
- Semilobar Holoprosencephaly 
 Partial brain diverticulation 
 H-shaped holoventricle with rudimentary occipital and temporal horns. 
Rudimentary third ventricle may be present. 
 Septum pellucidum absent, callosal splenium may be formed, falx cerebri and 
interhemispheric fissure partially developed posteriorly.  
 Thalami and basal ganglia partially separated  
 Associated anomalies: Dorsal interhemispheric cyst, variable craniofacial anomalies 
 
 
Fig. 14. Alobar holoprosencephaly. T1W coronal(a) and axial(b) MRI brain shows a large 
central monoventricule(white asterix), thin cortical mantle(thin white arrow) and fused deep 
gray nuclei seen as a small central mass of gray matter(black asterix). The crescentric 
monoventricle communicates with a large dorsal cyst (thick white arrow). (From Barcovich 
AJ. Pediatric Neuroimaging ((4th edn). Philadelphia: Lippincott Williams & Wilkins). 
 
 
Fig. 15. Semilobar holoprosencephaly. Axial T2W MRI brain shows H-shaped monoventricle 
with rudimentary third ventricle (arrow). Basal ganglia and thalami are partially fused. 
Note the presence of callosal splenium(thin black arrow) and a small dorsal 
interhemispheric cyst(asterix). (From Barcovich AJ. Pediatric Neuroimaging ((4th edn). 
Philadelphia: Lippincott Williams & Wilkins). 
 




Fig. 16. Lobar holoprosencephaly. Axial T2W MRI brain shows separated basal ganglia and 
thalami, well formed third ventricle(small closed arrows) and splenium(large closed 
arrows), rudimentary frontal horns(small open arrows) and partial midline fusion of the 
frontal lobe cortex(thin large white arrow). The azygous anterior cerebral is also 
present(curved black arrow). (From Barcovich AJ. Pediatric Neuroimaging ((4th edn). 
Philadelphia: Lippincott Williams & Wilkins). 
- Lobar Holoprosenceohaly 
 Nearly complete brain cleavage 
 Squared-off or boxlike configuration of frontal horns due to absence of septum 
pellucidum 
 Septum pellucidum absent, variable degree of anterior extension of corpus 
callosum, well formed falx cerebri and interhemispheric fissure with some 
anteroinferior fusion of hemispheres 
 Thalami and basal ganglia well separated  
 Associated anomalies: Azygous anterior cerebral artery, mild or absent craniofacial 
anomalies 
Septooptic Dysplasia (de Morsier syndrome) 1,2,6 
- Milder form of lobar holoprosencephaly 
- Characterized by hypoplastic optic nerves and optic chiasma, and absent septum 
pellucidum  
- Associated hypoplasia of hypothalamic-pituitary axis seen in 2/3rd cases 
- MR picture of small optic nerves and chiasma, widened anterior recess of 3rd ventricle 
and suprasellar cistern, and squared frontal horns   
- Associated anomalies: Scizencephaly (most common) 
4.3 Disorders of sulcation/cellular migration 
Lissencephaly (Agyria-Pachygyria) 1,2 (Figure 17,18) 
- Refers to “smooth brain” with absent or poor sulcation.  
- Can be complete (agyria) or incomplete (pachygyria). Intermediate features of agyria 
and pachygyria may coexist 
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- Three types: Type I, II, and III 
- Type I (classical) lissencephaly 
 Typical figure eight configuration of brain with oblique and shallow sylvian 
fissures. 
 Thickened cortex with flat broad gyri and smooth gray-white matter interface. 
 Colpocephaly 
 Associated with Miller-Dieker syndrome. 
 
 
Fig. 17. Lissencephaly. Axial T1W image shows a complete smooth brain with thickened 




Fig. 18. Lissencephaly with hemimegalencephaly. Axial (a) and coronal (b) T1W image of 
brain shows right sided hemimegalencephaly and lissencephaly. Right frontal lobe is 
particularly enlarged, has a disorganized, thickened, nearly agyric cortex with complete loss 
of cortico-medullary differentiation (arrow). The anterior interhemispheric fissure is 
displaced to the opposite side by the hypertrophied frontal lobe; ipsilateral frontal horn is 
also enlarged. 
- Type II(Cobblestone) lissencephaly 
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 Thickened cortex with polymicrogyric appearance. Concurrent hypomyelination of 
underlying white matter present.  
 Associated with Fukuyama congenital muscular dystrophy, Walker-Warburg 
syndrome and muscle-eye-brain syndrome. 
- Type III(cerebrocerebellar) lissencephaly 
 Microcephaly with moderately thickened cortex and hypoplastic cerebellum and 
brain stem 
Nonlissencephalic Cortical Dysplasia 1,2 (Figure 19,20,21) 
- Two types: Polymicrogyria and pachygyria 
- Polymicrogyria   
 characterized by diffusely thickened cortex with irregular, bumpy gyral pattern  
 MRI: thick cortex with flat surface, irregular gray-white matter junction  
 
 
Fig. 19. Polymycrogyria. Axial T1W(a) and T2W(b) image shows shallow sylvian fissures 
giving figure of eight appearance to the brain. The cortex is diffusely thickened and has 
irregular bumpy gyral pattern (arrow) with relative paucity of underlying white matter. The 
cortico-medullary junction is also irregular. 
 
 
Fig. 20. Patchygyria with band heterotopia. Coronal T2W (a) and axial FLAIR (b) image 
shows very few, shallow sulci and thickened gyri. Also note band heterotopia, seen as bands 
of gray matter alternating with the white matter (arrow).  
 




 Focal areas of thickened and flattened cortex with blurred gray-white matter 
junction 
- Both types of cortical dysplasia show relative paucity and marked T2 prolongation of 
underlying white matter 
 
 
Fig. 21. Focal cortical dysplasia. Axial NCCT brain shows focal cortical dysplasia seen as 
localized thickening and infolding of the cortex (arrow) in left fronto-parietal junction region 
with paucity of underlying white matter and prominence of overlying sulcus. 
Heterotopias 1,2,7 (Figure 22,23) 
- Characterized by the presence of normal neurons at abnormal sites 
- Result of arrested neuronal migration from periventricular germinal zone to the cortex 
along the radial glial fibers 
- Two types: Nodular type(common), band (laminar) type (uncommon) 
- Nodular type: 
 Multiple masses of gray matter which are of variable size 
 Common location: subependymal or subcortical 
 Focal or diffuse 
 Subependymal focal nodules indent the ventricular wall, whereas diffuse 
heterotopias border the walls of the lateral ventricle and are X-linked. 
 Heterotopias are isointense to normal gray matter in all pulse sequences and do not 
enhance on administration of intravenous contrast. They are best appreciated on 
medium tau inversion recovery sequences.  
 The differential diagnosis is subependymal nodules (SENs) of tuberous sclerosis. 
On MRI, SENs are not precisely isointense to gray matter, however, occasionally 
show enhancement after contrast administration. They are often calcified. 
 Large dysplastic and disorganized masses of ectopic gray matter may mimic 
intracranial mass, and produce severe deformity of ipsilateral ventricle. 
 Subcortical heterotopias are less frequent. 
- Band or laminar type 
 A layer of neurons interposed between the ventricle and cortex, seen as alternating 
layer of gray and white matter band 
- The cortex overlying the heterotopia is nearly always abnormal with pachygyria or 
polymicrogyria. 
 




Fig. 22. Nodular heterotopia. Axial T2W(a) and T1W medium tau inversion recovery(b) 
image shows subependymal nodular heterotopias(arrow). Also note colpocephaly, widely 
separated and parallel lateral ventricles along with a small dorsal interhemispheric cyst in a 
patient of partial callosal agenesis. 
 
 
Fig. 23. Focal cortical dysplasia with mass heterotopia. Axial T2W (a) image demonstrates a 
heterotopic mass of gray matter indenting the left lateral ventricle(arrow). On FLAIR 
coronal(b) and T1W sagittal(c) image, the ipsilateral temporal lobe has a thickened, agyric 
cortex and shows complete loss of gray-white matter differentiation. 
Schizencephaly (split brain) 1,2,8,9 (Figure 24,25)  
- Characterized by presence of heterotopic gray matter lined cleft that extends from the 
ventricular (ependyma) to the periphery (pial surface) of the brain, traversing through 
the white matter. 
- Can be unilateral or bilateral 
- Two types: Closed lip (type I) or open lip (type II) 
- Closed lip (type I) schizencephaly 
 Walls of the cleft oppose each other and there is no intervening CSF 
 Imaging shows an outpouching or nippling at the ependymal surface of the cleft   
- Open lip (type II) schizencephaly 
 Walls of the cleft are widely separated and the cleft is occupied by CSF 
 Severe form of open lip schizencephaly has an appearance which is called “basket 
brain”. 
 Closest differential is porencephalic cyst in which CSF space is lined by gliotic 
white matter, in contrast to gray matter lined schizencephaly.  
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- Associated anomalies: heterotopias, septo-optic dysplasia, absence of septum 
pellucidum and callosal dysgenesis 
 
 
Fig. 24. Bilateral closed lip scizencephaly. Sagittal T1W(a) and axial T1W medium tau 
inversion recovery(b) image shows bilateral gray matter lined tract with closely opposed 
walls(thin black arrow), extending from the lateral ventricle to the cerebral convexity. Note 
nippling in the lateral wall of bilateral lateral ventricles (thin white arrow).  
 
 
Fig. 25. Unilateral open lip scizencephaly. Axial NCCT brain shows a wide open, gray 
matter lined CSF cleft extending from left lateral ventricle to the cerebral cortex (arrow).  
Hemimegalencephaly 1,2,9,10 (Figure 18) 
- Hamartomatous overgrowth of a part or all of one cerebral hemisphere 
- MR shows enlargement of a part or whole of one cerebral hemisphere, ipsilateral 
ventricle is frequently dilated and the frontal horn is stretched. The cortex is affected by 
diffuse migration anomaly (polymicrogyria, pachygyria) and the underlying white 
matter is gliotic and dysmyelinated  
- Rarely, associated enlargement and dysplasia of ipsilateral cerebellar hemisphere and 
brain stem may be present, a condition referred as total hemimegalencephaly 
- Heterotopias may be present 
- Associated anomalies: Epidermal nevus syndrome, Klippel-Trenaunay–Weber 
syndrome, Neurofibromatosis type 1 
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4.4 Disorders of cerebellar hypoplasia/dysplasia 
Dandy-Walker Complex 1,2,11 (Figure 26,27) 
- Includes Dandy-Walker Malformation and Dandy-Walker Variant 
- Dandy-Walker Malformation Characterized by 
 Large posterior fossa with cystic dilatation of the fourth ventricle; that elevates the 
tentorium, torcular Herophili and the transverse sinuses above the lamdoid suture 
(lamdoid torcula inversion)  
 
 
Fig. 26. Dandy-Walker Variant. Axial T2W (a) and sagittal T1W(b) image shows that inferior 
half of the vermis is hypoplastic (arrow) and the fourth ventricle communicates with 
enlarged cistern magna. Associated hydrocephalus is also present. 
 
 
Fig. 27. Dandy-Walker Malformation. T1W axial(a) and sagittal (b) image of brain snows the 
classic findings of a Dandy-Walker malformation. The posterior fossa is enlarged and filled 
with a large cyst that is actually a huge fourth ventricle (asterix). The vermis is small, 
hypogenetic and is everted over the posterior fossa cyst (thick white arrow). The cerebellar 
hemispheres are hypoplastic (thin white arrow), and appear to be pushed laterally by the 
cyst on axial image and located beneath the everted vermis on sagittal image. The tentorium 
is elevated (double thin arrow). Note moderate hydrocephalus and small occipital 
encephalocele communicating with the posterior fossa cyst.  
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 Partial or complete vermian agenesis associated with hypoplastic cerebellar 
hemispheres. The hypoplastic superior vermis is everted above the cyst and the 
cerebellar hemispheres which are displaced anterolaterally against the petrous 
ridge appear “winged outward”.  
 Brain stem compressed against the clivus 
 The cistern magna, albeit present, is effaced 
 Hydrocephalus present in 80% of untreated cases  
 Associated anomalies: Corpus callosum agenesis (20-25%), heterotopias, 
schizencephaly, cephaloceles 
- Closest differentials: Mega cisterna magna and posterior fossa arachnoid cyst where 
vermis is well developed. 
- Dandy-Walker Variant characterized by 
 Inferior vermian hypoplasia with communication of fourth ventricle and cistern 
magna through an enlarged vallecula giving characteristic “Key-hole deformity”.  
 The tentorial position and posterior fossa size are normal 
 Brain stem is usually normal and hydrocephalus is uncommon.  
Mega Cistern Magna 1,2 (Figure 28) 
- Characterized by variable size dilatation of the cistern magna which, however, freely 
communicates with both the fourth ventricle and the adjacent subarachnoid spaces 
(can extend up to the straight sinus superiorly and C1-C2 level inferiorly). In severe 
cases enlargement of posterior fossa and scalloping of the occipital squamae may be 
present. 
- The fourth ventricle, vermis and cerebellar hemispheres are normal. No hydrocephalus. 
- Vermian hypoplasia may mimic mega cistern magna, hence, it is important to look at 




Fig. 28. Mega Cisterna Magna. Sagittal T1W(a) and axial T2W(b) image demonstrates an 
intact vermis with enlarged posterior fossa CSF space(asterix) that extends superiorly above 
the vermis and communicates with adjacent CSF space. Prominent scalloping of the occipital 
squamae is also seen (arrow). No hydeocephalus present. 
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Posterior Fossa Arachnoid Cyst 1,2,12 (Figure 29) 
- The posterior fossa arachnoid cyst is a CSF collection within the layers of arachnoid 
membrane which does not communicates fully with the fourth ventricle or adjacent 
subarachnoid spaces.  
-  The fourth ventricle, vermis and cerebellar hemispheres are normal but may be 
displaced by the cyst. 
- On imaging, cyst appears as a non-enhancing round to oval lesion attenuation and 
signal intensity that closely parallels CSF. 
- Differential diagnosis includes Dandy-Walker Malformation, Mega cisterna Magna.  
- Note: In general the arachnoid cysts are more frequently supratentorial (75%), 
particularly at the temporal poles. Other relative common location includes the 
posterior fossa, the suprasellar and quadrigeminal cisterns. 
 
 
Fig. 29. Posterior fossa arachnoid cyst. Sagittal T1W(a) and axial T2W(b) image shows a 
classical posterior fossa arachnoid cyst(asterix). Note normally formed but displaced fourth 
ventricle (arrow) and vermis. 
Chiari IV Malformation1,2 
- Severe cerebellar hypoplasia or dysplasia, small brain stem and large posterior fossa 
CSF space  
- No hydrocephalus and other CNS anomalies  
Joubert’s Syndrome (Congenital Vermian Hypoplasia) 1,2,13,14 (Figure 30) 
- Characterized by inherited vermian dysgenesis, enlarged superior cerebellar peduncles 
and a high riding fourth ventricle. 
- On MR imaging, the vermis is completely or partially absent. Superior fourth ventricle 
is bat-wing or umbrella shaped (on axial image) and has a convex roof (on sagittal 
image). The superior cerebellar peduncles are elongated, thin, running parallel to each 
other. Isthmus (area of pontomesencephalic junction) is narrow. Midbrain has the 
typical “molar tooth” appearance. 
- Hydrocephalus is absent 
- All patients of Joubert’s syndrome should be screened for occipital encephalocele (30%), 
callosal dysgenesis, cortical dysplasia, hypothalamic hamartoma, and ocular, hepatic & 
renal diseases. 
 




Fig. 30. Joubert’s syndrome (Congenital vermian hypoplasia). Axial T1W image(a) at level of 
mid brain shows characteristic “molar tooth” appearance of the midbrain secondary to the 
narrow isthmus (thin white arrow) and elongated superior cerebellar peduncles (thick black 
arrow). Note severe vermian hypoplasia(arrow head). On sagittal T1W(b) image the fourth 
ventricle has a peculiar upward convex appearance(thin white arrow). Note narrow 
isthmus(thick white arrow). 
Rhombencephalosynapsis 1,2,15 (Figure 31) 
- Rare abnormality characterized by vermian agenesis or hypogenesis combined with 
midline fusion of cerebellar hemispheres, peduncles and dentate nuclei. 
- On MR imaging, the folia and sulci are continuous throughout the midline on axial 
section and monolobated cerebellum lies in mid-sagittal plane on sagittal image. The 
Posterior fossa is small. 
- Associated anomalies: ventriculomegaly (common), callosal dysgenesis, absent septum 
pellucidum, cephalocele and schizencephaly.  
 
 
Fig. 31. Rhombenencephalosynapsis. T1W axial(a) and FLAIR coronal(b) MR image 
demonstrates lack of normal vermis and midline fusion of the cerebellar hemispheres(thin 
white arrow). Also note markedly enlarged cisterna magna(asterix) indenting the posterior 
aspect of fused cerebellar hemispheres. 
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Tectocerebellar Dysraphism 1 
- Rare abnormality characterized by vermian hypo-aplasia, occipital cephalocele, and 
marked deformation of quadrigeminal plate and the brain stem. Fusion of colliculi 
forms a tectal beak which points towards the site of the cephalocele. The cerebellar 
hemispheres usually engulf the brain stem. 
- Associated anomalies: hydrocephalus and other supratentorial abnormalities. 
Lhermitte-Duclos Disease 1,2 (Figure 32) 
- Also known as dysplastic gangliocytoma of the cerebellum 
- Uncommon cerebellar dysplasia characterized by gross thickening of the cerebellar 
folias with or without mass effect. 
- MR imaging demonstrates a pseudomass having laminated or folial pattern of 
increased signal on T2-weighted scans. The lesion may or may not enhance after 
administration of contrast. Mass effect and displacement of fourth ventricle may occur. 




Fig. 32. Lhermitte–Duclos syndrome. Axail T2W (a), coronal FLAIR(b), and sagittal T1W(c) 
MR image demonstrates a large laminated-appearing T2W/FLAIR hyperintense  and T1-
weighted hypointense mass involving the right cerebellar hemisphere. Note gross 
thickening of the cerebellar folias (arrow). No perilesional edema present. However, mass 
effect on the fourth ventricle with moderate hydrocephalus can be seen. Proton MR 
spectroscopy (d) reveals normal metabolites peak. 
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- Associated anomalies: Cowden syndrome (common), megalencephaly, heterotopias, 
cortical dysplasia, multiple visceral hamartomas and neoplasms.   
4.5 Disorders of histogenesis 
“Neurocutaneous syndromes” or “Phakomatoses” constitute a group of congenital 
malformations which are characterized by cutaneous lesions associated with CNS 
anomalies. Some of the common neurocutaneous syndromes are described below.  
Neurofibromatosis 1,16,17 (Figure 33-42) 
Neurofibromatosis type 1 (NF 1)  
- Also known as Von Recklinghausen disease or peripheral neurofibromatosis 
- Accounts for > 90% of all NF cases 
- Incidence = 1:2000 to 3000 live births 
- Diagnostic criteria: two or more of the following findings are present 
 Six or more café-au-lait spots(≥5mm in pre-pubertal children and ≥15mm in post-
pubertal period) 
 One plexiform neurofibroma or two or more neurofibromas of any type 
 Two or more pigmented iris hamartomas(Lisch nodules) 
 Optic nerve glioma  
 Axillary or inguinal freckling 
 Osseous lesions such as dysplasia of greater wing of sphenoid, pseudoarthrosis 
 First degree relative with NF-1 
- CNS lesions present in 15-20% cases. These include 
 Optic nerve glioma (most common CNS lesion), may extend to involve the optic 
chiasma, optic tract, optic radiation and the lateral geniculate bodies. 
 Nonoptic gliomas may involve the brain stem, tectum, and periaqueductal region. 
 Plexiform neurofibroma is a hallmark of NF-1. It is an unencapsulated 
neurofibroma along the path of major cutaneous nerve of the scalp and neck, which 
commonly involves the first (ophthalmic) division of trigeminal nerve. It is often 
associated with dysplasia of sphenoid bone and bony orbit.  
 Non-neoplastic hamartomatous lesions (80%) of basal ganglia and white matter. 
Majority of lesions show no mass effect or contrast enhancement. These lesions 
may increase in size or number in early childhood, diminishes with age and rarely 
observed into adulthood. 
 Other intracranial lesions include astrocytic proliferation of the retina, intracranial 
aneurysms, vascular ectasia and a progressive cerebral arterial occlusion disease 
akin to moya-moya pattern. 
 Spinal lesions may include cord astrocytoma / hamartoma, dural ectasia and 
lateral/anterior intrathoracic meningoceles. 
 Skeletal dysplasias may include hypoplasia of sphenoid bone and bony orbit, 
kyphoscoliosis, scalloping of posterior aspect of the vertebral bodies  
Neurofibromatosis type 2 (NF 2)  
- Also known as central neurofibromatosis 
- Incidence = 1:50,000 live births 
- Cutaneous manifestations rare 
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- CNS lesions present in 100% cases. These include  
 Bilateral acoustic schwannomas, hallmark of NF-2 
 Schwannomas of other cranial nerves. Trigeminal nerve is next most frequently 
involved nerve, albeit, any cranial nerve may be affected (with the exception of the 
olfactory and optic nerves). 
 Meningiomas, often multiple 
 Choroid plexus calcification    
 Spinal lesions include cord ependymomas, meningiomas, or multilevel bulky 







Fig. 33. Neurofibromatosis type 1: Opticochiasmatic–hypothalamic pilocytic astrocytomas. 
Axial T2-weighted (a) and coronal FLAIR (b) MR image shows enlargement of bilateral 
optic chiasma (thin black arrows) and ill-defined hyperintensity involving the 
hypothalamus(thin white arrow) and adjacent brain. Coronal T1-weighted post contrast 
image (c) demonstrates mild to moderate enhancement of the optic chiasma/hypothalamus 
but marked enhancement of the lesions involving the adjacent brain parenchyma. Moderate 
obstructive hydrocephalus is also present. FLAIR coronal images (d-f) of the same patient 
shows further extension of the optic pathway glioma to involve bilateral medial temporal 
lobes, basal ganglia region, mid brain and pons (thin white arrow). These lesions appear as 
ill-defined areas of high signal intensity on Flair images. The enlarged optic chiasma (thin 
black arrow) and obstructive hydrocephalus are also seen in these images.  
 









Fig. 34. Neurofibromatosis type 1: Optic nerve glioma with multiple meningiomas. Post 
contrast T1-weighted axial(a), coronal(b) and sagittal(c) MR images of brain reveal markedly 
enhancing right optic nerve glioma(thin white arrow) which extends posteriorly to involve 








Fig. 35. Neurofibromatosis type 1: Plexiform neurofibroma with sphenoid wing dysplasia. 
T2W axial(a) and coronal(b) MRI brain shows right temporal and infratemporal plexiform 
neurofibroma(thin white arrows). Lateral part of the right sphenoid wing is absent and the 
dysplastic temporal lobe is seen protruding through the dehiscent sphenoid bone into the 
orbit(thin black arrow). FLAIR axial image(c) of the same patient shows multiple 
hyperintense nonneoplastic hamartomatous lesions involving bilateral basal ganglia and left 
midbrain region(arrows). 
 










Fig. 36. Neurofibromatosis type 1: Plexiform neurofibroma with sphenoid wing dysplasia. 
Contrast enhanced CT brain, coronal (parenchymal window)(a) and axial (bone window)(b) 
view shows left sided plexiform neurofibroma of subcutaneous soft tissue(thin white arrow)  









Fig. 37. Neurofibromatosis type 1: Vascular abnormalities. Axial T2W MR image of brain(a) 
shows severe left sphenoid wing dysplasia and subcutaneous soft tissue plexiform 
neurofibroma(thin white arrow). Associated left internal carotid artery aneurysm (thick 
white arrow) is seen on T2-weighted axial image(a) and TOF angiogram(b). 
 








Fig. 38. Neurofibromatosis type 1: Peripheral Plexiform neurofibroma. Sagittal T1W post 
contrast image of lower limb (a) of another patient shows diffuse plexiform neurofibroma of 
left leg. Screening of brain revealed T2-hyperintense (b) focus in left basal ganglia region 
showing minimal contrast enhancement(c) but no mass effect, consistent with non-






Fig. 39. Neurofibromatosis type 1: various spinal lesions. MRI of three different patients 
showing various spinal lesions found in NF-1. Axial T2W (a) and sagittal T1W post contrast 
(b) image of cervical spine demonstrates a large right paravertebral neurofibroma with 
intraspinal extension causing widening of  ipsilateral neural foramen(thin white arrow). 
Sagittal T2W MRI of cervico-thoracic spine(c) shows multiple intradural extamedullary 
neurofibromas (thin white arrows). Solitary intramedullary hyperintense lesion (thin black 
arrow), which did not enhance after contrast administration (not shown) probably 
represents the benign white matter lesion similar to that observed in the brain. T2W-sagittal 
MRI spine (d) of another patient with NF-1 shows lumbar canal dural ectasia with posterior 
vertebral scalloping (arrows).  
 














Fig. 40. Neurofibromatosis type 1: various spinal lesions. MRI of three different patients 
showing various spinal lesions found in NF-1. Axial T2W (a) and sagittal T1W post contrast 
(b) image of cervical spine demonstrates a large right paravertebral neurofibroma with 
intraspinal extension causing widening of ipsilateral neural foramen(thin white arrow). 
Sagittal T2W MRI of cervico-thoracic spine(c) shows multiple intradural extamedullary 
neurofibromas (thin white arrows). Solitary intramedullary hyperintense lesion (thin black 
arrow), which did not enhance after contrast administration (not shown) probably 
represents the benign white matter lesion similar to that observed in the brain. T2W-sagittal 
MRI spine (d) of another patient with NF-1 shows lumbar canal dural ectasia with posterior 
vertebral scalloping (arrows). 
 










Fig. 41. Neurofibromatosis type 2: Axial T1W post contrast MR images(a-c) of brain 
demonstrate bilateral acoustic schwannomas(thin white arrows). Right schwannoma 
appears as a large homogenous enhancing right CP angle mass with intracnalicular 
extension and the left one is seen as a small intracanalicular enhancing mass. Multiple 
meningiomas(thin black arrows) are also present seen as enhancing extra-axial masses in 
right medial temporal and bilateral frontal regions. Right optic nerve meningioma is also 
seen completely filling the intraconal space. Non-contrast sagittal T1W(d) and coronal T2W 
image(e) of whole spine of the same patient demonstrates low cervical region 
meningioma(d) and multiple rounded lumbar region nerve root schwannomas(e), best 
appreciated on MR myelogram(f). 
 




Fig. 42. Neurofibromatosis type 2: Nonneoplastic choroid plexus lesions. Axial NCCT brain 
of another patient with NF-2 shows extensive nonneoplastic bilateral choroid plexus 
calcification(arrows). 
Tuberous sclerosis1,16,18 (Figure 43,44) 
- Also known as Bourneville disease or multiple hamartomatous syndrome 
- Incidence=1:10,000 to 50,000 live births 
- Classical triad of popular facial lesions (adenoma sebaceum), seizure disorder and 
mental retardation 
- CNS lesions include 
 Cortical tubers or hamartomas present in 95% cases of TS, are characteristic lesions 
at pathologic examination. On MR imaging, these lesions may expand and distort 
the affected gyri and show age-related signal changes. Enhancement following 
contrast administration occurs in less than 5% cases. Calcification of theses lesions 










Fig. 43. Tuberous sclerosis. Axial T2W MRI brain(a) demonstrates multiple hyperintense 
cortical tubers(thin black arrows), bilateral hyperintense giant cell tumors at the foramen of 
monro (thick white arrows) and multiple hypointense subependymal nodules(thin white 
arrows). On corresponding axial T1W images (b) the cortical tubers appear hypointense to 
gray matter; while the giant cell tumors and subependymal nodules appear isointense to the 
gray matter. Corresponding axial T1W post contrast images(c) demonstrate non-
enhancement of the cortical tubers, mild enhancement of the subependymal nodules and 
marked enhancement of giant cell tumors. On corresponding axial NCCT(d)  the cortical 
tubers are hypo to hyperdense in attenuation, while the giant cell tumors and 
subependymal nodules appear calcified.  
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 Subependymal nodules or hamartomas (SENs) present in 95% cases of TS, are the 
hallmark of tuberous sclerosis. They are most commonly located on the ventricular 
surface of caudate nucleus, just behind the foramen of Monro followed by atria and 
temporal horns of lateral ventricles, third and fourth ventricle. On MR imaging, 
these nodules are usually hypointense to white matter on T2-weighted sequences 
(because of calcification) and may show minimal contrast enhancement. Closest 
differential includes nodular heterotopias which parallel cortex in signal on all MR 
pulse sequences and do not enhance after administration of intravenous contrast. 
 Subependymal giant cell astrocytoma (SGCAs) present in 15% cases of TS, are 
located at or near the foramen Monro. On MR imaging, SGCAs show intense, 
uniform contrast enhancement. These lesions are frequently calcified. Obstructive 
hydrocephalus is common with SGCAs. 
 Dysplastic/disorganized benign white matter lesions. MR imaging shows four 
distinct patterns of these lesions: (i) straight or curvilinear bands that extends from 
the ventricle through the white matter to the cortex, (ii) wedge-shaped lesions, (iii) 
tumefactive or conglomerate foci, and (iv) cerebellar radial bands. Like cortical 
tubers, these lesions also show age-related signal changes, and contrast 
enhancement in about 15% cases.  
 Other CNS lesions include retinal hamartomas (50%), intracranial aneurysms, 
vascular ectasia and a progressive cerebral arterial occlusion disease akin to moya-
moya pattern. 
- Non-CNS lesions include hamartomatous growths in multiple organ system. 
 
 
Fig. 44. Tuberous sclerosis. Axial T2W(a), T1W(b) and T1W post contrast image(c) of another 
patient demonstrates multiple cortical tubers appearing hyperintense on T2WI, hypointense 
on T1WI and showing no post contrast enhancement. 
Sturge-Weber Syndrome 1,16 (Figure 45,46) 
- Also known as encephalotrigeminal angiomatosis 
- Characterized by facial port wine vascular nevus flammeus in the trigeminal nerve 
distribution (1st division most commonly involved), leptomeningeal venous 
angiomatosis of ipsilateral brain, hemiparesis, homonymous hemianopia and seizure. 
- Pathologically, there is leptomeningeal venous angiomatosis with congenital absence of 
cortical veins; therefore the blood is shunted towards the hypertrophied deep 
medullary veins and thence to the choroid plexus. This results in venous stasis and 
vascular congestion with hypoxia of the affected cortex. Slowly progressive atrophy 
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and dystrophic calcification of brain underlying the angioma occurs. The angioma itself 
does not calcify. 
- Usually unilateral, rarely bilateral  
- Occipital and posterior parietal lobe on the side of facial angioma is most commonly 
involved. 
- Tram-track or gyriform pattern of cortical calcification underlying the leptomeningeal 
angioma is diagnostic of the syndrome. The calcification is unusual before two years of 
age. Calcifications are best seen on plain CT, T2W and GRE image.  
 
 
Fig. 45. Sturge-Weber syndrome. Unenhanced axial CT brain shows diffuse right cerebral 
hemispheric atrophy with dystrophic clacification (gyriform) of occipito-parietal cortex(thin 
white arrows). Associated enlargement of ipsilateral subarachnoid space, lateral ventricle 




Fig. 46. Sturge-Weber syndrome. Unenhanced axial CT of brain(a) demonstrates gyriform 
calcification (thick black arrow) of left parieto-occipital cortex. After administration of 
contrast (b) there is marked enhancement of overlying leptomeningeal venous angiomas 
(thick white arrow). 
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- Severe cortical atrophy results in marked dilatation of ipsilateral ventricle, thickening of 
calvarium and prominence of ipsilateral sinuses.  
- The pial angiomas, cortical infarcts and enlarged ipsilateral choroid plexus show 
intense post contrast enhancement. Abnormal medullary and subependymal veins are 
demonstrated on CEMR and MR angiogram. 
- Ocular lesions in the form of sclera and choroidal angiomas may be seen on MRI in one-
third cases. 
- Associated anomalies: Klippel-Trenaunay syndrome 
Von Hippel-Lindau syndrome1,16 (Figure 47) 
- Is a multisystem disease characterized by presence of cysts, angiomas, and neoplasms 
of the CNS and abdominal viscera. 
- CNS lesions include 
 Cerebellar (75%), retinal (50%) and spinal cord (25%) hemangioblatomas. 
Supratentorial hemangioblatomas are extremely rare. 
 On MR imaging, majority of hemangioblastomas have cystic appearance with 
intensely enhancing mural nodule. Between 20-40% tumors are solid. Contrast 
enhanced MRI has increased sensitivity for detection of small lesions. Flow voids in 
the afferent and efferent vessels supplying the tumor can often be detected. The 
angiographic appearance of the hemangioblastoma is highly characteristic, 




Fig. 47. Von Hipple-Lindau syndrome: Cerebellar hemangioblastoma. Axial T1W (a) MRI 
brain shows a right cerebellar hemispheric cyst with a mural nodule containing a 
curvelinear flow voids (arrow). Corresponding post contrast image (b) shows enhancing 
vessels within the mural nodule (arrow). 
5. Summary   
Congenital malformations of the brain are both complex and multiple. The neuroradiologic 
diagnosis of such anomalies requires a basic understanding of normal brain development 
and pathogenesis. The aetiologies associated with development anomalies may result from a 
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variety of insults from genetic to environmental. Abnormalities associated with the neural 
tube and the neural plate generally occur within the first 28 days of gestation. On the other 
hand, abnormalities associated with cellular proliferation and migration in the CNS 
generally occur after the 28th day of gestation. This chapter will cover malformations 
associated with both of these periods. 
Congenital anomalies of the brain are commonly encountered in day to day practice. 
Nevertheless, diagnosing it correctly is of paramount importance. Imaging plays an 
important role in reaching the correct diagnosis necessary for optimum management of 
these unfortunate conditions. It is as important for every radiologist to be familiar with basic 
imaging findings of common congenital anomalies, as it is for the paediatrician. 
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1. Introduction 
Inborn errors of metabolism (IEM) are a heterogeneous group of genetic disorders, 
classically caused by enzyme deficiency. They are associated with different pathogenic 
mechanisms from enzyme substract accumulation or product deficiency to formation of an 
abnormal, toxic molecule. Occasionally, the deficient protein has non-enzymatic functions 
such as membrane transport or others, making the boundaries of IEM difficult to establish. 
IEM are individually rare (orphan diseases) but relatively numerous as a group, since more 
than 500 different entities have been identified (Scriver et al., 2001). Overall, their incidence 
is estimated to be 1:1,500 (Raghuveer et al., 2006).  
The age of onset varies. Signs and symptoms of IEM present a considerable overlap among 
the diverse IEM and many other diseases, not allowing the differential diagnosis on a 
clinical basis. There is no correlation between genotype and phenotype, in general. Most 
symptoms are apparent at or soon after birth, but clinical onset may occur prenatally or at 
any age, including adulthood. Multisystem involvement is frequent, with the presence of 
nervous system manifestations in most patients, either at disease onset or during the 
evolution.   
IEM are most probably underdiagnosed. In spite of all contributions from varied fields of 
medical science, etiological diagnosis is not achieved in a significant percentage of suspected 
patients. Despite being frequently difficult, diagnosis may be done selectively based on 
clinical features or pre-symptomatically by neonatal screening and achieved by biochemical, 
enzymatic and/or genetic studies. The diagnosis of IEM is challenging due to their rarity 
and clinical heterogeneity. To address these diagnostic problems, several schemes based on 
clinical, biochemical, neuroradiological, morphologic, enzymatic and genetic criteria have 
been proposed.  
Neuroimaging techniques are essential for assessing brain structures, namely white matter 
and/or gray matter involvement (Barkovich, 2007). They are undoubtedly useful in 
neurologically affected patients’ diagnosis and follow-up. Neuroradiological features of 
many IEM overlap and are stage-dependent. Patients occasionally show distinctive patterns 
of central nervous system involvement in magnetic resonance imaging (MRI). These 
patterns may characterise some disorders, especially during the early stages, or they can 
show guiding characteristics, or reveal non-specific changes. In later phases, the MRI 
findings are similar for most IEM with neurological involvement, often presenting diffuse 
loss of brain tissue and increased water in the remaining tissue. For this reason, it is 
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important to submit the patient to a brain MRI early in the course of the disease, when some 
key features are more evident (Barkovich, 2007). 
Although the majority of patients present non-specific changes on MRI, a systematic pattern 
recognition approach to involved brain structures is useful, as it narrows differential 
diagnosis. It occasionally points to a diagnosis and allows the reduction of the biochemical 
and genetic work-ups. According to brain MRI in early stages, IEM can be classified into 
disorders primarily involving gray matter, diseases primarily involving white matter and 
disorders involving both gray matter and white matter (Barkovich, 2006, 2007). The proton 
magnetic resonance spectroscopy (MRS) may be more sensitive to detect early abnormalities 
in the brain. However, only a few metabolic diseases present with specific MRS findings.   
Other neuroimaging techniques, such as positron emission tomography (PET) and single 
photon emission computed tomography (SPECT), could be useful in the diagnosis and 
follow-up of IEM. Nonetheless, they are not widely available on a routine clinical basis. 
This section will review the most relevant IEM, based on a practical pattern-recognition 
approach to brain MRI and its correlation to clinical, biochemical and genetic features. 
2. Disorders primarily involving gray matter 
IEM primarily involving gray matter, known as poliodystrophies, can affect cortical or deep 
gray matter in the early phases. This differentiation should be made in order to accurately 
discriminate a range of diseases.  
2.1 Disorders primarily involving cortical gray matter 
During an acute phase, neuroimaging reveals sulcal effacement, cortical swelling and 
restricted diffusion when the damage affects primarily the cortical gray matter (Barkovich, 
2005). The imaging findings during a chronic phase are: sulcal volume increasing, cortical 
thinning and cortical low attenuation on computed tomography (CT) scan, and T1 and T2 
prolongation on MRI (Campistol, 1999). Nevertheless, in later phases, lesions can progress 
and spread to other brain structures (including deep gray matter, white matter and the 
cerebellum) (van der Knaap & Valk, 2005), showing non-specific patterns. 
The primary involvement of cortical gray matter is commonly found in neuronal ceroid 
lipofuscinoses, mucolipidosis type I and GM1 gangliosidosis. Generally, findings on 
imaging studies are non-specific in these disorders. 
2.1.1 Neuronal ceroid lipofuscinoses 
The neuronal ceroid lipofuscinoses (NCL) are inherited lysosomal storage diseases 
characterized by the accumulation of autofluorescent ceroid lipopigments in the lysosomes 
of neurons and other cell types. Together, they constitute the commonest group of 
progressive neurodegenerative diseases in children, and are inherited in an autosomal 
recessive mode. The adult form of NCL is rare and demonstrates either an autosomal 
recessive or a dominant mode of inheritance (Haltia, 2003). The main features of these 
diseases include visual failure, seizures, progressive physical and mental decline, and 
premature death. Diagnosis, based on the age of clinical presentation, is made by enzymatic 
or genetic studies. Ultra-structural analysis of white blood cells or skin can be used to 
orientate biochemical and genetic tests in atypical cases (Williams et al., 2006). 
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The major imagiological features in NCL are cerebral and cerebellar atrophy, cortical 
thinning associated with mild hyperintensity of the cerebral white matter and hipointensity 
of the thalami on T2-weighted images (T2-WI) (Incerti, 2000). Infantile and late infantile 
variants show rapid progression of enlargement of ventricles and sulci of the brain. In the 
juvenile and adult forms, however, cerebral atrophy is frequently slight in the course of the 
disease, or may remain totally absent (Autti et al., 1996). Cerebellar atrophy is common and 
may be the earliest finding in late-infantile and juvenile forms of NCL. In late infantile form, 
the first finding is usually a rapid progression of cerebellar atrophy (Fig. 1.), whilst in 
infantile and juvenile forms this progression is slower (Järvelä et al., 1997). T2-WI 
hyperintensity in white matter, which is usually less intense than in leukodystrophies, tends 
to spare the subcortical areas and initially involves the posterior periventricular region. 
Later in the disease, corpus callosum may also become thinner (Incerti, 2000). 
 
 
            (a)                                                    (b)                                               (c) 
Fig. 1. Late infantile NCL. (a) Midline sagittal T1-WI demonstrates cerebellar atrophy. Axial 
T2-WI show mild thalamic hypointensity (b) and cortical thinning (c). 
Diffusion-weighted imaging (DWI) can be very useful in detecting variances in 
abnormalities of cerebral water diffusion in the late infantile form, showing increased 
whole-brain apparent diffusion coefficient (ADC) values. It correlates with patient’s age, 
disease severity and duration (Dyke et al., 2007). MRS can give additional hints to the 
diagnosis of infantile and late infantile forms, and be helpful in the differential diagnosis. In 
infantile NCL, MRS spectrum revealed progressive changes, with a complete loss of N-
acetylaspartate (NAA), as well as marked reduction of creatine and choline, and increase in 
myo-inositol and lactate in gray matter and white matter. In late-infantile NCL, MRS 
spectrum revealed reduction of NAA in gray matter and white matter and an increase of 
myo-inositol, creatine and choline in white matter (Brockmann et al., 1996). 
2.2 Disorders primarily involving deep gray matter 
When the damage primarily affects the deep gray matter, neuroimaging reveals many 
different patterns, with involvement of particular structures. Some of them are more specific 
in a group of diseases, allowing for the narrowing in differential diagnosis. CT scan can be 
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normal, or disclose calcifications or hypodensity areas in deep gray matter. MRI sensibility 
is higher, although CT is best suited for calcification detection.   
The list of IEM affecting deep gray matter is extensive. Globus pallidus hyperintensity in T2-
WI can be seen in succinic semialdehyde dehydrogenase deficiency, methylmalonic 
acidemia, urea cycle disorders, guanidinoacetate methyltransferase deficiency, pyruvate 
dehydrogenase deficiency and isovaleric acidemia (Barkovich, 2005, 2007). Additionally, 
globus pallidus hypointensity, with or without central hyperintensity, is highly 
characteristic of Hallervorden-Spatz disease. Striatum hyperintensity in T2-WI can be seen 
in some mitochondrial respiratory chain disorders (MRCD) such as Leigh’s syndrome and 
mitochondrial encephalopathy with lactic acidosis and stroke-like episodes – MELAS, the 
glutaric acidurias, propionic acidemia and molybdenum co-factor deficiency (Barkovich, 
2005, 2007). Many of these IEM can concomitantly involve the white matter so some will be 
discussed later in this chapter.  
2.2.1 Pantothenate kinase-associated neurodegeneration  
Pantothenate kinase-associated neurodegeneration (PKAN), formerly known as 
Hallervorden-Spatz disease is an autosomal recessive disorder characterized by 
neurodegeneration with brain iron accumulation. Many patients have mutations in the 
pantothenate kinase 2 gene (PANK2). Two distinct groups were identified. Classical PKAN 
presents in early childhood, usually before age 6 years, has uniform presentation and is 
characterized by rapid progression of extrapyramidal and pyramidal signs, intellectual 
impairment, pigmentary retinal degeneration and abnormal eye movements. Atypical 
PKAN, which is less common, has a wider clinical spectrum and slower progression. 
PANK2 mutations are associated with all classic PKAN and one third of atypical disease 
cases (Hayflick et al., 2003). PKAN is suggested by typical MRI features, and the diagnosis is 
made by molecular genetic testing (Zhang et al., 2006).  
 
 
    (a)                                                        (b) 
Fig. 2. Pantothenate kinase-associated neurodegeneration (PKAN). (a) and (b) Axial FLAIR 
show hypointensity with a central region of hyperintensity in the globus pallidi. 
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Some patients’ CT scans show low or high density areas in the globus pallidus. Low-
density foci are a sign of tissue destruction, while the high-density foci reflect dystrophic 
calcification (Barkovich, 2005). All patients with PANK2 mutations had the specific 
pattern of T2-WI globus pallidus central hyperintensity (destruction and gliose) with 
surrounding hypointensity (iron deposition), known as the eye-of-the-tiger sign (Fig. 2.). 
This sign was not present in patients without mutations. Patients with PANK2 mutations 
could be distinguished by the occurrence of isolated globus pallidus hyperintensity on 
T2-WI before the hypointensity developed (Hayflick et al., 2006). Patients without 
PANK2 mutations revealed globus pallidus T2-WI hypointensity, without central 
hyperintensity. In the later stage of the disease, it can be seen evidence of iron deposition 
in the substantia nigra pars reticulata, cerebral and cerebellar atrophy. These signs were 
frequently and more severely seen in PANK2 mutation-negative patients (Hayflick et al., 
2006). 
MRS can show markedly decreased NAA/creatine ratio in the globus pallidus and 
substancia nigra, with increased myo-inositol/creatine ratio (Parashari et al., 2010).  
2.2.2 Creatine deficiency syndromes  
Creatine deficiency syndromes (CDS) are a newly described group of IEM affecting creatine 
metabolism. Three disorders have been described: guanidinoacetato methyltransferase 
(GAMT) deficiency, arginine:glycine amidinotransferase (AGAT) deficiency and creatine 
transporter defect (SLC6A8). GAMT e AGAT deficiencies (creatine synthesis pathway) have 
an autosomal recessive inheritance, whereas SLC6A8 defect is an X-linked disorder. All CDS 
can cause developmental delay, intellectual disability, behavioural problems, movement 
disorders, seizures, and severe disturbance of expressive language (Schulze, 2003). These 
clinical manifestations can be partially reversed by oral creatine supplementation and 
dietary manipulation, even in same patients with the creatine transporter defect (Chilosi et 
al., 2008; Mercimek-Mahmutoglu et al., 2010). CDS are suggested by marked reduction or 
complete absent of the creatine peak on MRS. Diagnosis relies on measurement of 
guanidinoacetate, creatine, and creatinine in urine and plasma and molecular genetic testing 
of the gene involved. If molecular test results are inconclusive, AGAT enzyme activity, 
GAMT enzyme activity, or creatine uptake in fibroblasts can be evaluated (Mercimek-
Mahmutoglu & Stöckler-Ipsiroglu, 2009). 
MRI and mainly MRS are very important tools to suggest CDS diagnosis and follow therapy 
response (Chilosi et al., 2008). In GAMT deficiency MRI can be normal or reveal T2-WI 
hyperintensity on globus pallidus, mild myelination delay or white matter hyperintensity. 
MRI is normal in AGAT deficiency (Barkovich, 2005); SLC6A8 defect MRI can show brain 
atrophy (Póo-Argüelles et al., 2006).     
MRS shows spectrum changes even without MRI signal abnormally. Markedly reduction 
or absence of creatine peak, which is easily seen on long echo time (TE) spectrum, is the 
classical sign shared by all three disorders, in gray matter and white matter. GAMT 
deficiency reveals a broad guanidinoacetate peak at 3.78 ppm, on short TE sequences, 
which can be reduced (but not normalized) with dietary restriction of arginine associated 
to the supplementation of creatine and ornithine. In GAMT and AGAT deficient patients, 
but not in most of those with SLC6A8 deficiency, the creatine peak slowly increases under 
treatment (Fig. 3.). 
 




(a)                                                                     (b) 
Fig. 3. Creatine deficiency due to GAMT deficiency. (a) Multivoxel MRS spectrum (TE =144 ms) 
of the basal ganglia, before therapy, shows a markedly reduced creatine peak, and normal 
choline (Ch) and NAA peaks. (b) Multivoxel MRS spectrum (TE = 144 ms) of the basal 
ganglia, after 6 months therapy, shows a creatine (Cr) peak increasing.  
3. Disorders primarily involving white matter 
When the damage affects primarily the white matter, there is hypodensity on CT scan, and 
T1 and T2 prolongation on MRI. In later phases, the atrophy is the main feature. Knowledge 
of normal brain myelination, its appearance on different MRI sequences and normal 
variations, is crucial to accurately approach the range of disorders primarily involving white 
matter. When the damage affects primarily the white matter, it is important to find out if the 
white matter has never myelinated completely (hypomyelination), or if the myelin has been 
developed and destroyed afterwards (demyelination) (Barkovich, 2007). Since many of these 
IEM can also involve the gray matter, some will be discussed later in this chapter. 
3.1 Hypomyelination diseases  
The hypomyelination is observed in a small number of IEM, like Pelizaeus-Merzbacher 
disease and Salla disease. MRS findings may be useful in their differentiation (Barkovich, 
2005).  
3.1.1 Pelizaeus-Merzbacher disease  
Pelizaeus-Merzbacher disease (PMD) is a recessive X-linked neurological disorder caused by 
a mutation in the proteolipidic protein 1 (PLP1) gene, which results in defective central 
nervous system myelination. The connatal PMD phenotype presents during the neonatal 
period or in the first weeks of life, with nystagmus, stridor, hypotonia, severe spasticity and 
motor deficits, cognitive impairment, seizures and, later on, absence of speech. Death 
usually occurs in the period from infancy to third decade. The classic PMD phenotype 
presents in the first 5 years of life, with nystagmus, hypotonia, titubation, ataxia, slow motor 
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development and extrapyramidal movements, like dystonia and athetosis. Death usually 
occurs between the third and the seventh decades. PMD is suggested by typical neurologic 
findings, X-linked inheritance pattern, and general changes on MRI. Molecular genetic 
testing of PLP1 is also available. 
 
 
               (a)                                                             (b) 
Fig. 4. Pelizaeus-Merzbacher disease. (a) and (b) Axial T2-WI show abnormal high signal 
intensity in cerebral white matter, representing hypomyelination. 
As in most white matter diseases, CT scan changes are non-specific, revealing white matter 
hypodensity and atrophy in later stages. MRI shows discordance of myelin maturation 
caused by a lack of myelination. In the connatal form, a complete absence of myelin in the 
brain is demonstrated (Fig. 4.) (van der Knaap & Valk, 1989). In classical forms in the early 
stages, MRI shows a brain with normal appearance, but more immature than expected. 
During infancy, myelin development of the brain progresses in an orderly and predictable 
fashion. Absence of these predictable patterns should raise the consideration for PMD. In 
late and severe cases, MRI reveals diffusely T2 hyperintensity and generalized volume 
reduction in the white matter with thinned corpus callosum and cortical sulci enlargement 
(Plecko et al., 2003).   
MRS is very useful for evaluating both axonal integrity and myelination. However, reports 
may vary, which might be related to different clinical phenotypes, genotypes, or stages of 
disease progression (Pizzini et al, 2003). The pattern of metabolite abnormalities in 
individuals with PLP1 duplication appears to be distinctive, showing increased levels of 
NAA, creatine, glutamine and myo-inositol, which helps the differentiation of PMD from 
other leukodystrophies (Hanefeld et al., 2005). 
3.2 Demyelination diseases  
MR imaging has become the primary imaging modality in demyelinating diseases, playing 
an essential role in the identification, localization, and characterization of these pathologies. 
Demyelination processes can primarily involve subcortical white matter or periventricular 
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white matter. This differentiation should be made to ensure an effective imagiological 
approach and facilitate differential diagnosis. 
3.2.1 Disorders primarily involving subcortical cerebral white matter 
Early subcortical white matter demyelination can be seen in megalencephalic 
leukoencephalopathy with subcortical cysts, Alexander disease, some organic acidurias, 
Kearns-Sayre syndrome, galactosemia and diverse MRCD.  
3.2.1.1 Megalencephalic leukoencephalopathy with subcortical cysts  
Megalencephalic leukoencephalopathy with subcortical cysts (MLC), also known as van der 
Knaap disease, is an autosomal recessive disorder caused by mutations in the MLC1 gene. 
This gene encodes a protein mainly expressed in astrocytic endfeet at the blood-brain and 
cerebrospinal fluid-brain barriers (Boor et al., 2007). MLC is characterized by development 
of macrocephaly through the first year of life, generally up to the 98th percentile. Head 
circumference stabilizes afterwards. Initially, the psychomotor development is relatively 
normal or only mildly delayed. Later on, motor development delay, cerebellar ataxia, 
dysarthria, spasticity, and sometimes extrapyramidal signs ensue. Seizures, usually 
responsive to medication, are also observed in some children. MLC diagnosis can be made 
by recognition of typical neurologic signs and symptoms, and its distinguished brain MRI 
features. Molecular genetic testing of MLC1 is available (van der Knaap & Scheper, 2008). 
The MRI is characterized by diffusely abnormal and mildly swollen cerebral white matter, 
showing enlargement of the gyri, and subcortical cysts in posterior frontal and temporal 
lobes (Barkovich, 2005). Central white matter is better preserved, especially the corpus 
callosum, internal capsule and brainstem. The presence of cerebellar white matter T2 
hyperintensity is mild. Follow-up MRI reveals cerebral atrophy, and subcortical cyst growth 
can be present in some cases (van der Knaap et al, 1995). 
Abnormal white matter shows increased diffusivity on DWI (Gelal, 2002). MRS reveals 
reduced NAA in T2 hyperintensity areas (Morita et al., 2006). 
Tc-99m-ethyl cysteinate dimer SPECT reveals hypoperfusion in the abnormal cerebral white 
matter seen on MRI (Kiriyama et al., 2007).  
3.2.1.2 Alexander disease  
Alexander disease, or fibrinoid leukodystrophy, is caused by a gene mutation encoding glial 
fibrillary acidic protein (GFAP), leading to profound cellular dysfunction (Cecil & Kos, 
2006). The pathological hallmark is the accumulation of ubiquitinated intracytoplasmic 
inclusions in astrocytes, called Rosenthal fibers. The infantile form, the most frequent, is 
present in the first 2 years of life, typically with macrocephaly and frontal bossing, 
psychomotor retardation, seizures, pyramidal signs and ataxia. Patients survive weeks to 
several years. Diagnosis is based on MRI features. Molecular genetic testing, for GFAP gene, 
is available (Gorospe, 2010).  
CT scan shows low attenuation in frontal white matter with posterior progression to involve 
parietal region, internal capsules, and sometimes caudate heads. Frequently the tips of 
frontal horns show contrast-enhancement. There are 5 criteria on MRI to diagnose 
Alexander disease, according to van der Knaap: (1) extensive cerebral white matter changes 
with frontal predominance; (2) a periventricular rim with high signal on T1-WI and low 
signal on T2-WI; (3) signal abnormalities with swelling or volume loss in the basal ganglia 
and thalami; (4) brainstem signal abnormalities; and (5) contrast enhancement of one or 
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more of the following structures: ventricular lining, periventricular rim tissue, white 
matter of the frontal lobes, optic chiasm, fornix, basal ganglia, thalamus, dentate nucleus, 
or brainstem structures. The association of 4 or more criteria is relatively specific for 
Alexander disease. The imagiological pattern of enhancement provides specific 
information that can lead to correct diagnosis. Subcortical white matter is affected early in 
the course of the disease. The frontal changes correspond to prolonged T1 and T2 
relaxation times, and tend to involve the parietal white matter and the internal and 
external capsules (van der Knaap et al., 2001). The progression of disease can lead to 
cavitations in the white matter (Vargas, 2009). 
DWI reveals increased diffusion in the affected regions (Barkovich, 2005). MRS shows 
elevated myo-inositol and decreased NAA in the lesions (Cecil & Kos, 2006). 
3.2.2 Disorders primarily involving periventricular cerebral white matter 
Early periventricular white matter lesions can be seen in Krabbe disease, GM2 
gangliosidoses, metachromatic leukodystrophy, X-linked adrenoleukodystrophy, vanishing 
white matter disease, phenylketonuria, maple syrup urine disease, Lowe syndrome, 
Sjögren-Larsson syndrome and mucolipidosis type IV.  
3.2.2.1 Metachromatic leukodystrophy 
Metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by decreased 
activity of arylsulfatase A, resulting in failure of myelin breakdown and reutilization in the 
central and peripheral nervous systems. There are three clinical forms: late infantile MLD (50-
60% of the cases), juvenile MLD (20-30%), and adult MLD (15-20%) (Fluharty, 2008). The late 
infantile MLD presents before age 2 years with weakness, hypotonia, delayed psychomotor 
development, impairment of speech, spasticity, seizures and compromised vision and hearing. 
Death usually occurs before age 5. MLD is suspected by neurodegeneration and evidence 
 
 
             (a)                                                              (b) 
Fig. 5. Metachromatic leukodystrophy. Axial (a) and coronal (b) T2-WI show abnormal 
hyperintensity in the periventricular white matter, predominantly around the posterior 
body and trigones of the lateral ventricles, sparing subcortical U fibers.   
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of leukodystrophy on MRI. Diagnosis is suggested by increased urinary excretion of 
sulfatides and/or decreased arylsulfatase A activity, and is confirmed by genetic testing. 
Metachromatic lipids deposits can be seen in the nervous system tissue (Fluharty, 2008). 
CT scan shows confluent attenuation of periventricular white matter density. MRI reveals 
progressive symmetrical prolongation of T1 and T2 relaxation times in periventricular white 
matter. The cerebral white matter located around the posterior body and trigones of lateral 
ventricles is involved earlier in late infantile MLD (Fig. 5.), whereas frontal white matter is 
involved in cases of late onset. Subcortical U fibers are spared early but not in the later 
stages of the disease course. No enhancement has been reported. Later signs include 
cerebral atrophy. Higher resolution images reveal leopard skin pattern or tigroid pattern in 
the centrum semiovale that correspond to areas combining demyelination and normal 
regions. The progression of disease leads to involvement of the internal capsule, corpus 
callosum and corticospinal tracts. 
DWI reveals restricted diffusion in affected areas (Sener, 2002). MRS shows decreased levels 
of NAA and increased levels of myo-inositol and choline (Cecil & Kos, 2006). 
3.2.2.2 Krabbe disease 
Krabbe disease, or globoid cell leukodystrophy, is an autosomal recessive 
neurodegenerative disorder, caused by a deficiency of the lysosomal enzyme 
galactocerebrosidase, a key enzyme in metabolic pathways of myelin turnover and 
breakdown. Its deficiency results in galactosylsphingosine accumulation, a central and 
peripheral nervous system neurotoxin. The most frequent (85-90%) form of Krabbe disease 
has an infantile onset (Wenger, 2008). It presents with irritability between 3 and 6 months 
after birth and progresses with motor deterioration, feeding problems and atypical seizures. 
Eventually, the child develops decerebrate posture (Cecil & Kos, 2006) and dies before age 2 
years. Diagnosis is made by measuring the activity of galactocerebrosidade in leukocytes or 
in cultured skin fibroblasts and can be confirmed by genetic studies. A molecular genetic 
test is available for carrier detection. 
CT features during the initial stage of the disease may show symmetric high-attenuation in 
the thalami, caudate nuclei, corona radiate, posterior limbs of the internal capsule, 
brainstem and cerebellar dentate nuclei. Early in the course of the disease, MRI shows T1 
and T2 prolongation in the cerebellar nuclei, posterior limbs of the internal capsules and 
cerebellar white matter. The subcortical U fibers are spared until late in Krabbe disease (Fig. 
6.). Symmetric enlargement of the optic nerves may be seen (Cecil & Kos, 2006).  
Enhancement in junction between deep white matter and subcortical U fibers is rare (Vargas 
et al., 2009), but may be a common feature for cranial nerves and the cauda equina (Given et 
al., 2001). Thalami can be normal in the early stages, or reveal decreased T1 and T2 
relaxation times due to calcium deposition (Cecil & Kos, 2006). Later in the disease course, 
hyperintensity predominantly involves the parietal lobes, with extension to the callosal 
splenium, and severe, progressive atrophy.  
DWI reveals restriction diffusion in the early phases of the disease, mainly in the subcortical 
white matter, caudate head, and anterior limb of internal capsule; in later stages it shows 
increased diffusion in the white matter (Engelbrecht et al., 2002). Elevated choline and myo-
inositol, and reduced NAA have been found in the white matter MRS of infantile onset. 
Lactate elevation has also been reported (Zarifi et al., 2001). On the other hand, in an adult 
onset case, white matter spectrum changes were much less marked, and revealed only a 
mild elevation of creatine (Farina et al, 2000). 
 




       (a)                                                (b)                                                    (c) 
Fig. 6. Krabbe disease. Axial T2-WI show high signal intensity in the cerebellar white matter 
(a), cerebellar dentate nuclei (b), and periventricular white matter with sparing of the 
subcortical white matter (c).   
3.2.2.3 X-linked adrenoleukodystrophy 
X-linked adrenoleukodystrophy (ALD) is a peroxisomal disorder affecting the central 
nervous system, adrenal cortex, and testicles. It is caused by mutations in the ALD gene that 
encodes for a peroxisomal membrane protein. It is associated to accumulation of very long 
chain of fatty acids in different tissues and in plasma. Several different forms of ALD have 
been reported. The childhood cerebral form, the most common, with a clinical onset 
between ages 4 and 8 years, manifests with behavioural and school performance problems, 
progressive impairment of cognition, vision, hearing and motor function. Within 2 years, it 
leads to total disability, and to death within 5 to 8 years (Cecil & Kos, 2006). The 
adrenomyeloneuropathy (AMN) generally manifests in the late twenties and progresses 
over decades with paraparesis and sphincter and sexual dysfunction. Clinical manifestations 
associated to MRI features may lead to diagnosis. High concentration of very long chain 
fatty acids in plasma and/or cultured skin fibroblasts reinforces it. Molecular genetic testing 
is clinically available. 
Three distinct zones have been described in white matter lesions, with direct influence in 
imagiologic features. An inner zone (Zone A) of astrogliosis and scarring; an intermediate 
zone (Zone B) of active inflammation and demyelination, with axons spared; and an outer 
zone (Zone C) of ongoing demyelination in absence of inflammation. A Zone D has been 
referred, which is peripheral to Zone C and characterized by impending demyelination 
(Eichler et al., 2002). In early stages, ALD CT scan and MRI have a typical appearance. 
Symmetric white matter changes occur predominantly in the peritrigonal regions and across 
the corpus callosum splenium with relative preservation of the subcortical U fibers. Spread 
progression occurs outwardly and cephalad as a confluent lesion, until most of the white 
matter is involved. CT shows symmetric low attenuation in a butterfly distribution, across 
the corpus callosum splenium, surrounded by an enhancing zone peripherally, due to 
inflammation. In the earliest stage, the lesion may be restricted to the splenium (Barkovich, 
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2005). On MRI the Zone A reveals T1 and T2 prolongation; the Zone B appears isointense on 
T1-WI and isointense or slightly hypointense on T2-WI, showing enhancement if 
paramagnetic contrast is administered; and the Zone C reveals minimally hypointense on 
T1-WI and hyperintense on T2-WI, without enhancement (Melhem et al., 2000). Symmetric 
abnormal T2 hyperintensity along the corticopontine and corticospinal tracts, and auditory 
pathways are common (Fig. 7.). Cases of predominantly frontal lobe involvement may occur 
with lesion of corpus callosum genu, anterior limbs and genu of the internal capsules, 
sporadically with lesion of cerebellar white matter. Atypical cases with unilateral 
involvement have also been reported, as well as calcifications in parieto-occipital region 
(Barkovich, 2005). MRI in AMN, compared to ALD, shows more frequently an involvement 
of cerebellar white matter and brainstem corticospinal tract and less commonly, cerebral 
lesion (Barkovich, 2005).  
 
 
           (a)                                                  (b)                                                  (c) 
Fig. 7. X-linked adrenoleukodistrophy. (a) Axial T2-WI shows hyperintensity in the occipital 
white matter and corpus callosum splenium. (b) Axial T1-WI postcontrast shows 
enhancement leading edge of inflammation. (c) Axial T2-WI shows hyperintensity in the 
corticospinal tracts within the pons.  
DWI shows an increased apparent diffusion coefficient (ADC) in Zone A (Schneider et al., 
2003). MRS reveals abnormal spectrum within regions of abnormal imaging, as well as 
normal appearing white matter. Spectrum profile in normal appearing white matter 
discloses elevated choline levels. Raised choline and myo-inositol levels reflect the onset of 
demyelination. An increase in choline, myo-inositol and glutamine levels suggests active 
demyelination and glial proliferation. Decreased NAA and glutamine levels reflect neuronal 
loss and injury. High lactate peak is consistent with inflammation (Cecil & Kos, 2006). 
Detection of MRS abnormalities in asymptomatic patients or in those with stable MRI can 
predict disease progression.  
3.2.2.4 Vanishing white matter disease 
Vanishing White Matter (VWM), or childhood ataxia with central nervous system 
hypomyelination, is an autosomal recessive disease caused by mutation in one of the five 
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genes involved in eukaryotic translation initiation 2B. It may result in impairment of the 
ability of cells to regulate protein synthesis in response to stress (Pronk et al., 2006). Its 
phenotype varies widely from antenatal onset with early death, to adult onset with 
slowly progressive disease. In late onset cases, motor and mental development is 
normally or mildly delayed at first. Chronic progressive or subacute neurological 
deterioration, with cerebellar ataxia, spasticity, and variable optic atrophy frequently 
occurs between the ages of 2 and 6 years. Epilepsy is not a major sign of the disease, and, 
unlike motor abilities, mental capacities are relatively preserved. Episodes of rapid 
deterioration can occur after minor trauma or infection, ending in unexpected coma. 
Death happens a few years after onset (van der Knaap et al., 1998). Diagnosis is based on 
clinical manifestations, MRI features, and mutation identification in one of the five 
mentioned genes (Schiffmann et al., 2010).   
CT scan reveals symmetric and diffuse white matter low density in the cerebral 
hemispheres. MRI is typical, showing symmetric and diffuse white matter anomalies. 
Subcortical involvement occurs during early stages of disease, with swelling and 
enlargement of gyri. On the later stages, white matter reveals signal intensity which is close 
to, or similar to cerebrospinal fluid in every sequence (Fig. 8.). On FLAIR and T1-WI there is 
a radiating, stripe-like pattern, on sagittal and coronal images; and a dot-like pattern in the 
centrum semiovale, on the axial images, which corresponds to remain tissue strands. 
Overtime, cystic lesions develop. Cerebellar atrophy may be seen, mainly involving the 
vermis. Dorsal pons hyperintensity is seen at the beginning; in later stages, involvement of 




            (a)                                                 (b)                                                 (c) 
 
Fig. 8. Vanishing white matter disease. (a) Sagittal T1-WI shows abnormal cerebral white 
matter hypointensity. T2-WI shows hyperintensity involving central tegmental tract in the 
dorsal pons (b) and cerebral white matter (c).  
MRS in the white matter shows marked decrease in NAA, creatine and choline peaks, or 
even virtual absence of all parenchymal metabolites, with presence of lactate and glucose. 
Gray matter spectrum is nearly normal, with a small increase in lactate and glucose, and a 
decrease in NAA peaks (van der Knaap et al., 1998).  
 
Neuroimaging – Clinical Applications 
 
50
4. Disorders involving both gray and white matter 
When the damage affects the gray matter and white matter, it is important to recognize if 
the lesions involve deep gray matter, or if, in addition to the white matter, the cortical gray 
matter is the only one to be affected (Barkovich, 2005, 2007). 
4.1 Disorders involving white matter and cortical gray matter 
This group of IEM includes peroxisomal disorders such as Zellweger syndrome, Alpers 
disease, Menkes disease, mucopolysaccharidoses and mucolipidoses (Barkovich, 2005). 
4.2 Disorders involving white matter and deep gray matter  
The list of IEM with white matter and deep gray matter involvement is wide, but the 
identification of the nuclei that is early affected can help narrowing the differential 
diagnosis. The involvement of thalami is present in GM1 and GM2 gangliosidoses, Krabbe 
disease, and Wilson’s disease. The lesion of globi pallidi is present in Canavan disease, 
methylmalonic acidemia, MSUD, Kearns-Sayre syndrome, L-2-hydroxyglutaric aciduria, 
and urea cycle disorders (Barkovich, 2005). When the involvement is seen in striata, the 
differential diagnosis should include glutaric aciduria type I, propionic acidemia, 
ethylmalonic acidemia, Wilson’s disease, MELAS and Leigh syndrome. 
4.2.1 Canavan disease 
Canavan disease, or spongiform leukodystrophy, is an autosomal recessive disorder, 
characterized by deficiency of N-acetylaspartylase resulting in abnormal accumulation of N-
acetylaspartic acid. Three clinical forms - neonatal, infantile, and late onset - are recognized 
(Traeger & Rapin, 1998). Most commonly, Canavan disease presents within the first 6 
months of life with hypotonia, lack of head control, macrocephaly, irritability and 
development delay. Later on, spasticity, optic atrophy and seizures ensue (Cecil & Kos, 
2006). Death occurs within the teens. Suspicion of diagnosis is based on clinical 
manifestation and MRI features. Diagnosis is confirmed by demonstration of high 
concentration of N-acetylaspartic acid in the urine. Molecular genetic testing is clinically 
available (Matalon & Bhatia, 2009). 
CT scan shows diffuse hypodensity in the cerebral and cerebellar white matter (Barkovich, 
2005). MRI shows symmetric areas of diffuse confluent white matter areas of T1 and T2 
prolongation. The subcortical U fibers are preferentially affected in the beginning of the 
disease. Globi pallidi are frequently involved, as well as thalami. In some cases internal and 
external capsules (Cheon et al, 2002), cerebellar white matter and brain stem can also be 
affected (Matalon & Bhatia, 2009). In the later stages, there is a diffuse atrophy of white 
matter.  
MRS in white matter shows marked elevation of the NAA peak, which is classically 
assumed to be exclusive for Canavan disease, although it can also be seen some times in 
Salla disease and PMD (Varho et al, 1999).  
4.2.2 Maple syrup urine disease 
Maple syrup urine disease (MSUD), an autosomal recessive disorder, is caused by 
deficiency of the branched-chain alpha-ketoacid dehydrogenase (BCKAD) complex, leading 
to accumulation of the branched-chain amino acids (BCAAs), allo-isoleucine and branched-
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chain ketoacids (BCKAs) in tissues and plasma (Strauss et al., 2009). MSUD manifests as 
heterogeneous clinical and molecular phenotypes. Several clinical forms have been 
described with manifestations from early acute neonatal to chronic intermittent forms 
diagnosed in adolescents. Classic MSUD causes maple syrup odor in urine and cerumen, 
soon after birth. At age 2-3 days newborns present with irritability, poor feeding and 
ketonuria. At age 4-5 days lethargy, apneia, opisthotonus and stereotyped movements 
occur; followed by coma and central respiratory failure at age 7-10 days. High protein 
ingestion or any cause of enhanced catabolism like infection, injury or surgery, can lead to 
acute leucine intoxication with cerebral oedema and neurological impairment (Morton et al., 
2002). In less severe cases, patients reveal normal or moderately retarded 
neurodevelopment, later presenting with metabolic crises similar to classic MSUD. 
Suspicion of diagnosis, based on clinical manifestations (and eventually MRI features in late 
onset cases), can be confirmed by elevation of BCAAs, allo-isoleucine and BCKAs in tissues 
and plasma. Molecular genetic testing is also clinically available (Strauss et al., 2009). In 
Portugal, extended newborn screening detects MSUD, frequently in a pre-symptomatic 
stage. 
Cranial ultrasonography can be useful in symptomatic neonates, showing symmetric 
hyperechogenicity of periventricular white matter, basal ganglia (mainly globi pallidi) and 
thalami (Fariello et al., 1996).  
 
 
      (a)                                                      (b) 
Fig. 9. Maple syrup urine disease. Axial T2-WI show hyperintensity in the brainstem and 
cerebellar white matter (a), globus pallidi and thalami (b). 
Acute classic MSUD form shows signs of diffuse oedema, characterized by hypodensity on 
CT scan, and T1 and T2 prolongation on MRI. Severe localized oedema (MSUD oedema) is 
seen in myelinated areas at birth, namely deep cerebellar white matter, posterior brain stem, 
cerebral peduncles, thalami, posterior limb of internal capsule, posterior centrum semiovale, 
and globi pallidi (Fig. 9.) (Brismar et al., 1990). Forms with later onset reveal lack of 
myelination superimposed upon lesions located at the same regions affected by MSUD 
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oedema in acute classic form. Brain sequel depends on the time it takes to reverse metabolic 
decompensation (Barkovich, 2005). 
DWI is very important, as the oedema may be hard to identify in T2-WI due to 
nonmyelinated brain hyperintensity. Regions with acute MSUD oedema show restricted 
diffusion with decreased ADC value. Diffusion-tensor imaging (DTI) reveals decreased 
anisotropy in the same areas (Parmar et al., 2004). In acute phase, MRS with long TE reveals 
elevated levels of lactate and presence of an abnormal BCAAs and BCKAs peak at 0.9 ppm. 
These changes can reverse completely after metabolic correction (Jan et al., 2003).   
4.2.3 L-2-hydroxyglutaric aciduria 
L-2-hydroxyglutaric aciduria is an autosomal recessive disease caused by mutations in L-2-
hydroxyglutarate dehydrogenase gene, with accumulation of L-2-hydroxyglutac acid in 
urine, cerebrospinal fluid and plasma. It is characterized by slowly progressive neurological 
dysfunction with cerebellar ataxia, psychomotor retardation, seizures, macrocephaly, and 
extrapyramidal and pyramidal signs (Steenweg et al., 2010).  It presents in childhood, 
frequently after a period of normal psychomotor development. Diagnosis is suggested by 
typical MRI features and by measurement of L-2-hydroxyglutaric acid in urine, 




            (a)                                                  (b)                                                (c) 
Fig. 10. L-2-hydroxyglutaric aciduria. Axial T2-WI show hyperintensity of the subcortical 
WM and globus pallidi (a), dentate nuclei (b), putamina and caudate nuclei (c). 
CT scan shows symmetrical hypodensity in subcortical white matter, globi pallidi, and 
frequently dentate nuclei (Topçu et al., 1996). MRI reveals hyperintensity in the same 
locations listed above, with a preferential involvement of the frontal over the occipital white 
matter. The periventricular white matter is spared, as well as internal capsule, corpus 
callosum, cerebellar white matter, and brainstem. Sometimes involvement of putamina and 
caudate nuclei are seen (Fig. 10.). Globi pallidi, and sometimes cerebellar vermis and 
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hemisphere, reveal atrophy. Swelling of the cerebral white matter with broadening of gyri, 
rarefaction of the subcortical white matter and atrophy of cerebral white matter were also 
reported (Steenweg et al., 2009). 
DWI shows increased diffusion in the white matter lesions. MRS is usually normal, but it 
can reveal a slight decrease of NAA peak, in short TE (Aydin et al, 2003). 
4.2.4 Glutaric aciduria type I 
Glutaric aciduria type I is an autosomal recessive disorder resulting from a deficiency in 
glutaryl-CoA dehydrogenase with accumulation of glutaric, 3-hydroxyglutaric and 
glutaconic acids and secondary carnitine deficiency. Typically the disorder presents with an 
acute encephalopathy between 6 and 18 months of age, in a previously healthy or mildly 
motor retarded, macrocephalic child. In some cases, a slowly progressive course with 
mental retardation, hypotonia, dystonia, choreoathetosis, spastic quadriplegia and 
macrocephaly is seen (Hoffmann & Zschocke, 1999). Diagnosis is suggested by classical MRI 
features that are highly typical, and made by measurement of glutaric, 3-hydroxyglutaric 
and glutaconic acids in urine. Molecular genetic testing is clinically available (Seashore, 
2009). In Portugal, broad neonatal screening detects glutaric aciduria type I in a pre-
symptomatic phase. 
CT scan shows diffuse white matter hypodensity and/or cerebral atrophy, most prominent 
in the frontal and temporal regions (Yager et al., 1988). MRI reveals symmetric widening of 
the Sylvian fissure, frontotemporal volume loss, and delayed myelination. Putamen T2 
hyperintensity is predominantly seen, either alone or in combination with the caudate 
nucleus. Globus pallidus is less affected. Later in the course of disease, periventricular white 
matter T2 hyperintensity, basal ganglia and cerebral atrophy are seen. Sometimes 
imagiological studies reveal acute or chronic subdural haematomas (Fig. 11.), implying 
differential diagnosis with nonaccidental trauma (Neumaier-Probst et al., 2004). 
 
 
           (a)                                                (b)                                                   (c) 
Fig. 11. Glutaric aciduria type I. Axial T2-WI show putamina and globi pallidi 
hyperintensity (a), expansion of pericerebral fluid spaces anterior to the temporal lobes (b), 
periventricular white matter hyperintensity, cerebral atrophy and left frontoparietal 
subdural hematoma (c).   
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DWI shows restricted diffusion in acute basal ganglia lesions. MRS shows decreased 
NAA/creatine ratio at the basal ganglia in encephalopathic patients (Pérez-Dueñas at al., 
2009). 
Fluoro-2-deoxyglucose PET reveals decreased glucose uptake in the cerebral cortex, basal 
ganglia and thalami (Al-Essa et al., 1998). 
4.2.5 Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes 
(MELAS) 
MELAS is a multisystem mitochondrial disorder, with early normal psychomotor 
development and onset typically between the ages 2 and 10 years. It is characterised by 
neurological manifestations including seizures, encephalopathy, recurrent headaches and 
stroke-like episodes (hemiparesis and hemianopsia). Diagnosis is based on an association of 
clinical findings, MRI features and molecular genetic testing. Mitochondrial DNA mutation 
A3243G is found in 80% of MELAS patients. Sometimes, pathogenic mutations may be 
undetectable in mtDNA from leukocytes, and it is necessary to resort to other tissues, such 
as skeletal muscle, which is the most reliable for diagnosis (DiMauro & Hirano, 2010).  
Stroke-like lesions are often transient, affecting mainly the gray matter and are not restricted 
to specific vascular territories, unlike embolic and thrombotic infarction (Barkovick, 2005). 
They are usually fluctuating. Acute ischemic episodes show swelling and hypodensity on 
CT scan, and T1 and T2 prolongation on MRI, commonly involving the temporo-parieto-
occipital lobes and basal ganglia (Fig. 12.).  
With regard to DWI findings, reports are discordant. Some early reports demonstrate an 
increased diffusion in stroke-like lesions. However the number of reports revealing a 
decreased diffusion in these areas has increased. Thus, the absence of vasogenic oedema 
should not weaken the possibility of MELAS in favour of ischemic stroke. MRS shows a 
decrease in NAA and an increase in lactate in stroke-like lesions (Fig. 12.) (Tzoulis & 
Bindoff, 2009). An increase in lactate is also seen in embolic and thrombotic infarction, so 
this finding is not specific of MELAS.   
   
 
          (a)                                                   (b)                                                  (c) 
Fig. 12. MELAS. (a) Axial FLAIR shows hyperintensity in left temporal lobe. (b) Axial DWI 
(b=1000) shows restriction diffusion of the lesion. (c) Single voxel proton MRS (TE = 135 ms) 
of the lesion shows a lactate doublet (Lac). (This case is a courtesy of Dr. Fernando Matias) 
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SPECT shows hyperperfusion in the acute stage of stroke-like episodes, and hypoperfusion 
in the chronic stage (Tzoulis & Bindoff, 2009). PET and xenon reveal increased blood flow 
and decreased glucose uptake and oxygen extraction fraction in the lesion areas (Barkovich, 
2005). 
4.2.6 Leigh syndrome 
Leigh syndrome, or subacute necrotizing encephalomyelopathy, is caused, in the majority of 
the cases, by a dysfunction of the mitochondrial respiratory chain (particularly complexes I, 
II, IV or V), the coenzyme Q, or the pyruvate dehydrogenase complex (Finsterer, 2008). Most 
children are normal at birth and manifested usually by the end of the first year of life. The 
onset is commonly insidious, and the course may be intermittently progressive for some 
years. Clinical presentation can be highly variable, and includes psychomotor retardation, 
feeding difficulties, recurrent episodes of vomiting, failure thrive, signs of brainstem, 
cerebellar and basal ganglia dysfunction, and lactic acidosis (Medina et al., 1990). Diagnosis 
is suggested by clinical criteria and MRI features. Molecular genetic testing allows for a 
specific etiological diagnosis. 
Neuroradiological findings in Leigh syndrome are symmetrical hypodensities on CT, and T1 
and T2 prolongation on MRI, in the basal ganglia and thalami. Lesions can involve the 
substantia nigra, periaqueductal gray matter within the midbrain, inferior colliculus, 
inferior olivary nuclei, inferior cerebellar peduncles, medulla, solitary tract in the medulla, 
central tegmental tract and reticular formation in the dorsal pons (Barkovich 2005). Less 
commonly, the red nuclei and cerebellar dentate nuclei are involved. Basal ganglia are often 
affected before the brainstem, but in some patients, brainstem lesions appear without basal 
ganglia alterations (Fig. 13.). Sometimes, MRI reveals delayed myelination. In most patients,  
 
 
         (a)                                                    (b)                                                   (c) 
Fig. 13. Leigh syndrome. Axial T2-WI show hyperintensity in the striata (a), dorsal midbrain 
and cerebral peduncles (b). (c) Multivoxel proton MRS (TE = 144 ms) of the basal ganglia 
shows a decreased of NAA peak and a lactate doublet (Lac).  
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cerebral white matter is generally involved in the later stages of disease (Arii & Tanabe, 
2000). In some cases, a marked global atrophy can be seen, over time. Some MRI patterns 
may suggest an implicated mutation. In SURF-1 mutation, associated to complex IV 
deficiency, basal ganglia are less involved, and the brainstem, subthalamic nuclei, cerebellar 
nuclei and cerebellar peduncles are commonly involved. ATPase 6 mutation, which is 
associated to maternally inherited Leigh syndrome (MILS), shows anterior putamina, globi 
pallidi and dorsal mesencephalon and pons lesions. In the absence of hypoxia, ischemia or 
infection, symmetric involvement of deep gray matter is very suspicious of a mitochondrial 
defect (Saneto et al., 2008). 
DWI shows reduced diffusion in acute lesions and increased diffusion in chronic ones. MRS 
reveals increase in lactate and a small decrease of NAA in lesions, and alongside the 
imagiological features of conventional MR it supports the diagnosis of Leigh syndrome 
(Barkovich, 2005). 
5. Conclusion 
MRI plays an essential role in the diagnosis of IEM. It shows high sensitivity in the detection 
of some of these disorders and evaluation of their severity. Despite of the nonspecificity of 
many features, a systematic pattern recognition approach to brain structures involved is 
useful, as it narrows differential diagnosis. MRS can help in this process and may disclose 
anomalies, even if there are no lesions detectable with conventional MRI. Further 
investigation and accurate characterization of neuroradiological features are needed in order 
to gather a wider range of specific patterns. These would allow more patients to be 
adequately classified. 
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1. Introduction 
Acquired Demyelinating disorders of the central nervous system in children span a wide 
spectrum. These conditions may be mono-phasic and self limiting or multi-phasic. Children 
may present with mono-focal (optic neuritis) or multi-focal (Acquired demyelinating 
encephalomyelitis) clinical findings. 
These demyelinating disorders also share many common clinical, radiological and 
laboratory features. Early classification of whether the disease is either mono- or multi-
phasic has diagnostic and therapeutic implications. Identification of patients who present 
with a first demyelinating event and are at risk for evolution to multiple sclerosis, allows 
disease modifying therapeutic agents to be initiated early and thus preserve brain function. 
The aetiology of acquired demyelinating conditions is multi-factorial namely – genetic, post-
infectious, post-immunization and possibly due to a T-cell mediated auto-immune response 
to myelin basic protein triggered by an infection or immunization.  
This chapter will cover the aetiologies, consensus definitions, clinical presentation, neuro-
imaging, evolution and therapeutic advances in acquired demyelinating disorders in 
children. The pivotal role of neuro-imaging in unraveling the pathology, aetiology and 
diagnosis of these disorders is also highlighted. 
Clinical and neuro-imaging features of other acquired white matter lesions (via infections, 
toxins, nutritional deficiencies, and osmotic myelinolysis) disease are also discussed. 
2. Definitions 
The International Paediatric Multiple Sclerosis Study group in 2007 proposed consensus 
definitions for the demyelinating disorders in children (Krupp et al., 2007). This group was 
convened to define an operational classification system for the demyelinating disorders. 
Consensus definitions aid in standardization of diagnosis, investigation, management and 
further research of these conditions. 
3. Imaging techniques for white matter disorders 
Magnetic Resonance Imaging (MRI) is the diagnostic modality of choice for evaluating 
white matter disorders. Sophisticated applications of magnetic resonance technology, such  
 








A first clinical event with a presumed inflammatory or 
demyelinating cause, with acute or sub-acute onset that 
affects multifocal areas of the CNS and must include 
encephalopathy 
Recurrent ADEM New event of ADEM with a recurrence of the initial 
symptoms and signs, 3 or more months after the first 
ADEM event, without involvement of new clinical 
areas by history, examination, or neuro-imaging 
Multi-phasic Demyelinating 
Encephalomyelitis (MDEM) 
ADEM followed by a new clinical event also meeting 
criteria for ADEM, but involving new anatomic areas 
of the CNS as confirmed by history, neurologic 
examination, and neuro-imaging. The event must 
develop within 3 months of the initial event. 
Neuromyelitis Optica (NMO) Must have optic neuritis and acute myelitis as major 
criteria and a spinal MRI lesion extending over three or 
more segments or be NMO positive on antibody testing 
Acute Transverse Myelitis 
(ATM) 
A focal inflammatory disorder of the spinal cord 
resulting in motor, sensory and autonomic dysfunction 
Schilder’s Disease A sub-acute demyelinating disorder characterized by 
bilateral large and vaguely symmetrical lesions 
Paediatric Multiple Sclerosis 
(MS) 
A clinical syndrome of multiple clinical demyelinating 
events involving 
more than one area of the central nervous system with 
dissemination in time and space on imaging* 
Clinically Isolated Syndromes 
(CIS) 
A first acute clinical episode of 
CNS symptoms (without encephalopathy) with a 
presumed inflammatory demyelinating cause; for 
which there is no prior history of a demyelinating 
event 
*Important caveats in the definition of Paediatric MS put forward by the study group include: 
1. The combination of an abnormal CSF (presence of Oligoclonal bands or an elevated IgG index) and 
two lesions on the MRI, of which one must be in the brain, can also meet dissemination in space 
criteria. 
2. The MRI can meet the dissemination in space criteria if it shows 3 of the following 4 criteria (1) 
nine or more white matter lesions or one gadolinium enhancing lesion, 2) three or more 
periventricular lesions, 3) one juxta-cortical lesion, 4) an infra-tentorial lesion. 
3. MRI can be used to satisfy criteria for dissemination in time following the initial clinical event, 
even in the absence of a new clinical event if new T2 or gadolinium enhancing lesions develop 
within 3 months of the initial clinical event. 
4. A second non-ADEM event in a patient is insufficient to make the diagnosis of paediatric MS if the 
first event meets the criteria for ADEM. MS can only be diagnosed if there is further evidence of 
dissemination in time on the MRI (new T2 lesions > 3months since the second event) or a new 
clinical event (> 3months since the second event). 
Table 1. Definitions of Acquired Demyelinating Disorders (Adapted from Krupp et al 2007) 
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63 
as magnetization transfer imaging, magnetic resonance spectroscopy, and diffusion tensor 
imaging, provide quantitative information about the extent of damage that occurs in the 
white matter.  
1H magnetic resonance spectroscopy (MRS) is a valuable technique to non-invasively 
acquire in-vivo information about biochemical processes in patients with neurologic 
disorders. MRS measures N-acetyl-aspartate (NAA), total creatine, choline-containing 
compounds, and lactate. NAA has been considered a marker of neuronal integrity, 
whereas the levels of choline and lactate are indicative of cell membrane turnover and 
anaerobic glycolysis (Bizzi et al., 2001).  NAA is located almost exclusively in neurons and 
neuronal processes and thus provides information about neuronal integrity (De Stefano et 
al., 1995). 
MRS studies on patients with white matter disorders have shown reduction in NAA in areas 
that appear normal on conventional MRI studies suggesting that a significant amount of 
axonal damage is present in these patients (Arnold et al., 1990; van Der Knaap et al., 1992). 
Abnormalities in NAA on MRS have also shown a correlation with long term functional 
outcomes. The author suggests that the extent of axonal damage rather than demyelination 
may be more reliable in monitoring disease evolution in primary white matter disorders (De 
Stefano et al., 2000). 
Diffusion-weighted MR imaging (DWI) provides further information that may not be 
apparent on conventional MR images. Engelbrecht et al showed that diffusion restriction 
precedes brain myelination and is further increased during myelination (Engelbrecht et 
al., 2002). 
4. Acquired Demyelinating Encephalomyelitis (ADEM)  
ADEM initially described by Lucas (1790) is characterized by acute onset of diffuse 
neurological signs with multi-focal white matter involvement. In 1931 a series of case 
studies was reported in The Lancet. McAlpine described 3 sets of patients with ADEM:  
-post-vaccination, post-infectious, and those with spontaneous occurring disease. The 
International Paediatric MS study group further defined ADEM (see Table 1). 
4.1 Pathogenesis 
The aetiology of ADEM is not completely understood. The pathogenesis is thought to be 
auto-immune mediated. The seasonal distribution and high rate of antecedent infections 
(Dale et al., 2000; Murthy et al., 2002; Govender et al., 2010) reported in ADEM suggest a 
link to an infectious aetiology. Infectious diseases are common in childhood however the 
rate of preceding infection reported in these series exceed the rate of childhood infectious 
diseases described (30-50%). The auto-immune reaction is thought to be on the basis of 
molecular mimicry. The offending infection serves as an antigenic trigger and shares 
epitopes with various autoantigens of myelin such as myelin basic protein, proteolipid 
protein, and myelin oligodendrocyte protein (Alvord et al., 1987). This theory shares 
many similarities with experimental allergic encephalitis. A second theory is that the 
antigenic trigger activates T cells which cross the blood-brain barrier and react against 
similar myelin epitopes. ADEM was associated with the class II alleles HLA-DRB1*01 and 
HLA-DRB*03 in a Russian study (Idrissova et al., 2003). Pathological studies of children 
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with ADEM showed that peripheral and cerebrospinal lymphocytes have increased 
reactivity to myelin basic protein (Lisak and Zweiman, 1977). Viral infections described in 
the context of ADEM include Herpes Simplex Virus-1, Cytomegalovirus (CMV), HIV 
(Human Immunodeficiency virus), Measles, Mumps, Rubella, Ebsteinne Barre Virus 
(EBV) and Varicella Zoster Virus (VZV). ADEM occurs after one of every 1000 cases of 
measles, with a fatality rate of 20% (Tselis and Lisak, 1998). Bacterial antigens implicated 
include Mycoplasma, Campylobacter, Streptococci and Borrelia Burgdofferi. Dale et al. 
described a subgroup of ADEM associated with Group A β hemolytic streptococcus, 
abnormal basal ganglia imaging and elevated antibasal ganglia antibodies (Dale et al., 
2001).  Some studies fail to identify the agent responsible for the pre-demyelinating 
infection (Murthy et al., 2002). The authors postulate that the inciting agents are 
uncommon or unusual organisms that can not be identified by routine laboratory testing. 
Vaccines, specifically the influenza, rabies and smallpox vaccines have also been reported 
to precipitate ADEM (Saito et al., 1998). Post-vaccination ADEM is thought to be the result 
of immune mediated mechanisms rather than the cyto-pathic effects of the virus. ADEM is 
reported after the administration of drugs such as sulfonamides and streptomycin, further 
supporting an immunological basis of the pathogenesis. 
4.2 Epidemiology 
There are few epidemiological studies of ADEM in children. Prevalence studies are also 
complicated by the use of inconsistent case-definitions of ADEM. The estimated incidence in 
California is 0.4/100,000 population per year (Leake et al., 2004) and in Canada is 
0.2/100,000 per year (Banwell et al., 2009). The mean age of presentation of ADEM in 
children ranges from 5-8 years (Hynson et al., 2001; Tenembaum et al., 2007). There is no 
specific ethnic distribution (Leake et al., 2004). Some studies indicate a slight male 
predominance (Murthy et al., 2002; Tenembaum et al., 2007). Prevalence in resource poor 
countries would be expected to be higher because of the significant frequency of childhood 
infections. However it is probably under-estimated because of limited access to health care 
facilities and MRI facilities.  
4.3 Clinical presentation 
ADEM has a wide clinical spectrum of presentation. The hallmark of the disease is an 
acute presentation of multifocal neurological signs with encephalopathy consistent with 
diffuse brain involvement usually following a viral infection or immunization. 
However, events may range from sub-clinical episodes diagnosed by MRI showing 
mult-ifocal white matter lesions, to a more fulminant presentation with seizures and 
encephalopathy. Seizures are reported to be more common in children compared to 
adults with ADEM (Tenembaum et al., 2007). Fever and meningism are also common in 
ADEM prompting treatment for meningo-encephalitis in the initial management (Dale 
et al., 2000). Multi-focal neurological signs are pathognomic for ADEM and include 
hemiparesis, paraparesis, cranial nerve involvement and ataxia. Atypical presentations 
include concomitant peripheral nervous system involvement (Kinoshita et al., 1996), 
presentation as an isolated acute psychotic episode (Moscovich et al., 1995) or with  
an extra-pyramidal syndrome (dystonia and behaviour disturbances) (Dale et al.,  
2001). 
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4.4 Laboratory investigations 
In the absence of specific biological markers diagnosis is based on a combination of 
historical features, clinical and MRI characteristics. Other investigations are usually done 
to exclude other differential diagnosis (e.g. meningitis, metabolic encephalopathies). In 
resource poor settings where the burden of disease is predominantly infectious illnesses 
and because of the overlap of symptoms, infectious aetiologies must be excluded first. 
Peripheral blood leucocytosis is documented in ADEM (Jacobs et al., 1994). CSF studies in 
ADEM are usually abnormal (in > 67% of cases), typically showing a moderate pleocytosis 
with an elevated protein content (Miller et al., 1956; Govender et al., 2010). CSF 
Oligoclonal bands synthesis may occur in ADEM; however this tends to disappear when 
the patient recovers.  
Electrophysiological studies have limited value in ADEM. Slow-wave abnormalities on 
electro-encephalogram are compatible with an encephalopathic state (Dale et al., 2000). The 
spindle coma pattern has been described in a child with post measles ADEM (Bortone et al., 
1996). Visual evoked potentials though are useful in detecting asymptomatic optic tract 
lesions (Dale et al., 2000). 
4.5 Neuro-imaging 
MRI is the investigation of choice. Since CT is often non-diagnostic for white matter lesions 
in patients with ADEM, this study is often normal or shows non-specific hypo-densities in 
the white matter. 
Lesions are most easily recognized on T2 weighted (T2WI) and FLAIR MRI sequences. T2WI 
are more sensitive than T1 weighted images (T1WI) in detecting lesions (Sheldon et al., 
1985).  T1WI shows hypo-intense lesions. The lesions of ADEM are multi-focal and often do 
not correlate with clinical signs. Lesions tend to involve the cerebellum, the cerebral cortex 
and brainstem (Figure 1 a-g). They usually involve the sub-cortical, central and 
periventricular white matter. Lesions are typically hyper-intense, patchy, asymmetric and 
ill-defined. Diffusion-weighted imaging (DWI) and apparent diffusion co-efficient (ADC) 
maps may be helpful to prognosticate outcome. Low ADC values and restricted diffusion on 
DWI may suggest a worse outcome as this may indicate permanent tissue damage 
(Barkovich., 2007). A case study of ADEM with MRS reported reduced NAA and an 
elevation of choline and lactate (Gabis et al., 2004). These authors suggest a place for H MRS 
studies in longitudinal follow-up studies of ADEM to assess the response to 
immunomodulating therapies. Deep grey matter lesions in the thalami and basal ganglia 
have also been described (Baum et al., 1994; Govender et al., 2010) (Figure 2a-e).  Lesions in 
the corpus callosum are uncommon and considered atypical for ADEM (Figure 3).  Contrast 
enhancement of lesions post gadolinium administration indicates activity of the lesions 
(Figure 4). This correlates with the pathological finding of inflammation and demyelination 
in experimental allergic encephalitis.  Non-enhancing and partially enhancing lesions in the 
presence of enhancing lesions have been described in ADEM and are thought to be because 
of lesions of differing ages and the evolution of the disease over several weeks (Schwaz et 
al., 2001;, Govender et al., 2010). 
Concomitant spinal cord lesions have been described in ADEM (Hynson et al., 2001;, Murthy 
et al., 2002;, Govender et al., 2010) (Figure 5a,b). Spinal cord lesions in ADEM typically have 
ill-defined margins, extend over multiple vertebral segments, are thoracic in location and 
result in mild cord expansion (Singh et al., 2002). 
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Fig. 1. A - Flair axial MRI demonstrating bilateral asymmetrical cortex and sub-cortical 
white matter high signal intensities consistent with ADEM. B- T2 axial MRI demonstrating 
right ill-defined peritrigonal white matter high signal intensity lesion consistent with 
ADEM. C- Flair axial MRI demonstrating bilateral, fairly symmetrical high signal intensities 
in the posterior white matter consistent with ADEM. D - Flair axial MRI demonstrating 
bilateral asymmetrical high signal intensity lesions in the sub-cortical and deep white matter 
consistent with ADEM. E- Flair axial MRI demonstrating bilateral asymmetrical high signal 
intensity lesions in the cortex and sub-cortical and deep white matter consistent with 
ADEM. F - Flair axial MRI demonstrating hyper-intense lesions in the brachium ponti 
consistent with ADEM. G - T2 axial MRI of the brain demonstrating large hyper-intense 
pontine lesion with surrounding oedema 
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Fig. 2. A- Flair axial MRI of the brain demonstrating bilateral symmetrical hyper-intense 
thalamic lesions. B- T2 coronal MRI of the brain demonstrating bilateral symmetrical 
rounded hyper-intense thalamic lesions as well as a large hyper-intense pontine lesion. C- 
Flair axial MRI demonstrating bilateral high signal intensity lesions in the basal ganglia and 
deep white matter on the left consistent with ADEM. D- Flair axial MRI demonstrating 
asymmetrical basal ganglia and white matter high signal intensities consistent with ADEM. 
E- DWI of 2D shows no evidence of restricted diffusion. 
 
Fig. 3. T2 sagittal midline brain MRI demonstrating a well-defined rounded lesion in the 
splenium of the corpus callosum, which is unusual for ADEM. 
 




Fig. 4. T1 with contrast axial MRI demonstrating multiple hypo-intense white matter lesions 
of varying sizes, some with ring enhancement. This patient was diagnosed with ADEM. 
   
                                                    A                             B 
Fig. 5. A- T2 sagittal MRI of the cord showing diffuse abnormal high signal intensity 
throughout the cord with cord expansion in the cervical region. There was no associated 
enhancement. This together with the brain lesions seen in 5B is consistent with ADEM. B- 
Flair axial MRI demonstrating bilateral high signal intensity lesions in the basal ganglia and 
deep white matter on the left consistent with ADEM. 
 




There are no standard treatment protocols as there are insufficient large scale studies to form 
consensus for optimal management. Supportive care (e.g. respiratory support for patients with 
brainstem involvement, anti-epileptics for seizure control) in the acute phase is vital.  
Therapies recommended are mainly immunomodulating agents targeting the immune-
based mechanism of the disease. Corticosteroids are considered the mainstay of treatment 
based on the rapid improvement in symptoms following therapy (Straub et al., 1997;, 
Tenembaum et al., 2007). However widely varying doses, formulations, duration of therapy 
and tapering have been reported with corticosteroid use (Hynson et al., 2001; Murthy et al., 
2002; Tenembaum et al., 2007; Govender et al., 2010). A single study reported worse 
outcomes in patients who received corticosteroids (Boe et al., 1965). Methylprednisone, 
dexamethasone and ACTH are used. Most reports in paediatric patients have used IV 
methylprednisolone (10 to 30 mg/kg/day) or dexamethasone (1 mg/kg) for 3 to 5 days 
(Dale et al., 2000; Hyson et al 2001; Tenembaum et al 2002; Govender et al., 2010) followed by 
a taper for 4 to 6 weeks with full recovery reported in 50 to 80% of patients. In resource poor 
countries high dose corticosteroids must be used with caution and only commenced once 
commonly occurring infections like tuberculosis and cytomegalovirus (CMV) are excluded. 
Outcomes on efficacy of corticosteroid treatment are mainly compared to historical controls. 
Worse outcomes are linked to shorter duration of treatment (Tenembaum et al., 2007). Other 
treatment modalities suggested include intravenous immunoglobulin, plasmapheresis and 
glatiramer acetate (Abramsky et al., 1977; Stricker et al., 1992; Finsterer et al., 1998). There is 
some evidence to suggest that patients may respond to a combination of 
methylprednisolone and immunoglobulin if they fail to respond to either separately 
(Straussberg et al., 2001). 
4.7 Prognosis 
ADEM is by definition a monophasic illness (variants are discussed in Section 4.8). Mortality 
during the post-measles ADEM period in the 1950’s was reported as 10-30% (Johnson et al., 
1985). At follow-up, approximately 60-80% of children have no neurologic deficits (Menge et 
al., 2007). This study also reports a mortality rate of 5%. The extent and site of lesions on the 
initial MRI do not predict the clinical outcome. Motor deficits persist in 8-30% (Dale et al., 
2000; Tenembaum et al., 2007) of patients and include paraparesis, hemiparesis and ataxia. 
Neuro-cognitive deficits are also documented post ADEM (Hahn et al., 2003; Jacobs et al., 
2004).  These include deficits in short term memory, verbal processing skills and complex 
attention. Patient with early onset ADEM (<5year of age) were also more likely to have 
cognitive deficits and behaviour problems (Kumar et al., 1998). Follow-up MRI’s showed 
complete or partial resolution of abnormalities in the majority of cases (Kesslering et al., 
1990; Dale et al., 2000; Tenembaum et al 2007; Govender et al., 2010). However, residual 
gliosis and demyelination persist in some patients (Kesselring et al., 1990). Clinical as well as 
imaging follow-up (at least 3 months later) (Figure 6) is important to monitor for evolution 
to MS. Risk factors for relapse are discussed in greater detail in Section 10. 
4.8 Variants of ADEM 
Definitions for Recurrent and Multi-phasic ADEM are described in Table 1. 
Acute Hemorrhagic Leukoencephalitis is a rare, hyper-acute form of ADEM with a mortality 
rate of about 70% (Davies et al., 2006). Pathological studies show a necrotizing vasculitis 
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with haemorrhage, oedema and a neutrophilic infiltration (Stone and Hawkins, 2007). 
Seventy percent of survivors have neurological deficits (Stone and Hawkins, 2007).  
 
  
                                                A                                                              B 
Fig. 6. A- T2 axial MRI demonstrating asymmetrical basal ganglia and white matter high 
signal intensities consistent with ADEM. B- T2 axial MRI in same patient at 3 months follow-
up showing resolution of lesions. 
5. Transverse myelitis 
5.1 Epidemiology 
Acute Transverse myelitis (ATM) is a focal inflammatory disorder of the spinal cord 
resulting in motor, sensory and autonomic dysfunction with evidence of inflammation on 
CSF or MRI studies. The initial definition was proposed by the Transverse Myelitis 
Consortium Working Group in 2002 and refined by the more recent consensus definitions 
for paediatric demyelinating disease (Krupp et al., 2007). The incidence is reported as 1- 8 
per million people per year (Berman et al., 1981). There are no gender or ethnic differences in 
the prevalence of ATM (Berman et al., 1981). ATM is often difficult to distinguish clinically 
from ischaemic cord lesions, fibro-cartilagenous emboli or traumatic spinal cord lesions. 
ATM is also an important differential diagnosis for acute flaccid paralysis in childhood. 
5.2 Pathogenesis 
The aetiology of ATM is thought to be immune-mediated. In 30-60% of patients ATM is 
para-infectious (Jeffrey et al., 1993; Kalra et al., 2009). Molecular mimicry and super-antigen 
mediated mechanisms have been postulated (Kaplin et al., 2005). Positive anti-GM1 
antibodies following Campylobacter and CMV infections have been implicated in the aetio-
pathogenesis. Neuromyelitis optica—immunoglobulin G is an aquaporin-4–specific water 
channel antibody, which has been associated with neuromyelitis optica and longitudinally 
extensive transverse myelitis in adults (Lennon et al., 2004). This is discussed further in 
Section 6. 
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5.3 Clinical presentation 
Clinical presentation is that of acute or sub-acute onset of bilateral spinal cord dysfunction 
(that may be asymmetrical) with associated sphincter dysfunction and pain. A sensory level 
may not be easily elicitable in the paediatric population. The clinical features depend on the 
location of the lesion. High cervical cord lesions can present with respiratory failure. The 
thoracic segment is the commonest site of cord involvement in ATM (Kneubusch et al., 1998). 
5.4 Investigations 
Initial evaluation of a patient with an evolving myelopathy must include a gadolinium 
enhanced MRI of the spine to exclude a compressive myelopathy. If there is no evidence of a 
compressive lesion a lumbar puncture should be performed. CSF pleocytosis and an 
elevated protein (IgG index) on the CSF support a diagnosis of ATM. Brain MRI and eye 
examination with visual evoked potentials are recommended to exclude demyelination in 
other parts of the neuro-axis. 
Other investigations recommended include para-infectious markers- EBV, VZV, CMV, Herpes 
Simplex virus serology and stool for campylobacter cultures. If there are signs of a systemic 
inflammatory disorder, auto-immune screens and serum angiotensin converting enzyme 
levels should be performed to exclude other causes of an acute myelopathy (e.g. vasculitides). 
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Fig. 7. A- T2 sagittal MRI of the cord showing diffuse abnormal increased signal intensity 
consistent with transverse myelitis. B- T1 sagittal MRI of the cord showing no abnormal 
signal intensity. There was no contrast enhancement. C- T2 sagittal MRI of the distal cord 
showing diffuse abnormal increased signal intensity consistent with transverse myelitis. D- 
T2 axial MRI of the cord showing abnormal increased signal intensity consistent with 
transverse myelitis. E- T2 sagittal MRI of the cord showing diffuse abnormal increased 
signal intensity and cord swelling consistent with transverse myelitis. 
 




MRI of the spinal cord usually shows nonspecific localized hyper-intense signal on T2WI 
sequences with, in some cases, segmental cord enlargement and/or focal enhancement 
(Figure 7 a-e). Acute partial transverse myelitis described in adults is characterized by MRI 
lesions that are asymmetrically placed and spanning fewer than 2 vertebral segments in 
length; these patients have been found to have a greater risk of progression to multiple 
sclerosis (Ford et al., 1992). Longitudinally extensive myelitis (spanning > 3 vertebral 
segments) is shown to have a lower risk of progression to MS in adults (Pittock et al, 2006). 
Lesions of ATM in children are typically longitudinal, demonstrate rim enhancement and 
are centrally located.  
5.6 Treatment 
Previous case series did not demonstrate any benefit from the use of low dose 
corticosteroids (Dunn et al., 1986; Adams et al., 1990).  Recent reports demonstrate the benefit 
of high dose corticosteroids (10-30mg/kg per day for 3-5 days) on recovery (Defrense et al., 
2001; Sebire et al., 1997). Compared to historical controls patients treated with steroids 
walked independently sooner. If there is no clinical response to steroids within 5-7 days 
plasma exchange was used as adjunctive therapy in isolated case reports. Supportive 
measures include respiratory support and early management of a neuropathic bladder. 
5.7 Prognosis 
Various studies have looked at prognostic indicators for ATM. Jain et al. (1983) described 
backache at onset, acute course (within hours), spinal shock and a cervical sensory level as 
poor prognostic features. Other studies did not demonstrate this (Govender et al., 2010). 
Early recovery (within one week of presentation), age less than 10 years at presentation and 
lumbosacral spinal level on clinical assessment were significant predictors of a good 
outcome (De Goede et al., 2010). The extent of lesions on MRI has not shown consistent 
correlation with outcome (Pradhan et al., 1997; Adronikou et al., 2003). Berman et al’s series 
(1987) described more than one-third of the patients with ATM making a good recovery; in 
one-third of patients recovery was only fair; 14 patients failed to improve and 3 demised. 
In the series by Dunne et al (1986) that assessed the risk of progression to multiple sclerosis 
in children with ATM, definite evidence of multiple sclerosis did not develop in any of the 
patients. In the series by Pidcock et al of the 47 children with acute transverse myelitis, 2 
experienced recurrent transverse myelitis, 1 was diagnosed with neuromyelitis optica, and 1 
developed multiple sclerosis on follow-up (Pidcock et al., 2007). 
6. Neuromyelitis Optica (NMO) 
The association between myelitis and optic problems was first described in 1870 by Thomas 
Clifford Allbutt (Murray, 2005). In 1894 Eugene Devic described 16 patients with visual 
impairment who developed paraparesis, sensory deficits and sphincter dysfunction within 
weeks. They recognized that these symptoms were the result of inflammation of the optic 
nerve and spinal cord. NMO is a recurrent demyelinating disorder affecting the optic nerves 
and the spinal cord. Modifications to the definition of NMO in 2005 incorporated the 
inclusion of patients with brain lesions, and included the NMO-IgG antibody as a 
confirmatory test.  
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The Mayo Clinic proposed a revised set of criteria in 2006. The new guidelines for diagnosis 
requires both absolute criteria and two of the three supportive criteria to be present to make 
a diagnosis of NMO (Wingerchuck et al., 2006). 
Absolute criteria: 
1. Optic neuritis 
2. Acute myelitis 
Supportive criteria: 
1. Brain MRI not meeting criteria for MS at disease onset 
2. Spinal cord MRI showing contiguous T2-weighted signal abnormality extending over 3 
or more vertebral segments, indicating a relatively large lesion in the spinal cord 
3. NMO-IgG seropositive status. 
The association of NMO with the serum autoantibody marker NMO-IgG was reported in 
2004 (Lennon et al., 2004).
 
NMO-IgG is 73% sensitive and 91% specific for distinguishing 
NMO from classical MS. The new diagnostic criteria allows for the diagnosis of NMO in 
patients who are NMO-IgG antibody negative. NMO antibodies play a key role in the 
pathogenesis. These antibodies are directed against the aquaporin-4- receptors located in the 
cell membrane of astrocytes (Pearce, 2005). Aquaporin-4 is the most abundant channel 
facilitating water transport across membranes in the brain. NMO-IgG is also detected more 
commonly in patients with NMO symptoms who have clinical or serological evidence for 
SLE than in those who do not (McAdam et al., 2002). 
6.1 Clinical characteristics 
Clinical characteristics include painful visual loss, weakness, sphincter dysfunction and 
sensory deficits. Loss of red color vision, a relative afferent pupillary defect and visual field 
defects are other features of optic neuritis in children.  Other complications such as ataxia 
and respiratory failure result from extension of cervical cord lesions into the brainstem.  
6.2 Investigations 
Diagnostic evaluation includes an MRI of the brain. During acute optic neuritis attacks, an 
orbital MRI may identify optic nerve gadolinium-enhancement. MRI of the brain is usually 
normal. However, brain lesions located in the hypothalamus, brainstem, and periventricular 
areas have been described in children who have typical features of NMO (Pittock et al., 
2005). These are considered to be the aquaporin-4 rich areas of the brain.  
Patients with signs of myelitis should have a spinal MRI with contrast. The lesions are 
typically longitudinally extensive, centrally based in the cord and extend over three or more 
vertebral segments. All patients should have a serological test for the NMO-IgG antibody. A 
negative test however does not exclude the diagnosis. CSF pleocytosis also supports the 
diagnosis. In patients with longitudinal myelitis and no visual symptoms, visual evoked 
potentials can sometimes detect asymptomatic visual pathway dysfunction.  
6.3 Treatment 
The recommended treatment for acute attacks of myelitis or optic neuritis is high dose 
methylprednisone. Prophylactic long-term immunosuppression is recommended for 
established NMO and patients who have a single attack of myelitis and are NMO-IgG 
positive (Wingerchuck et al., 2005). There are no efficacious preventative therapies 
demonstrated by controlled trials in NMO. Intravenous immunoglobulin is an alternative 
for patients who do not respond to corticosteroids. 
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Characteristics of NMO that help to distinguish it from classical MS include: 
 Prominent CSF pleocytosis (more than 50 WBC)  with a polymorphonuclear cell 
predominance (Mandler et al., 1993; O Riordan et al., 1996) 
 Lower frequency of CSF oligoclonal banding (15-30% in NMO compared to 85% in MS) 
 Bilateral symmetrical optic neuritis 
 At disease onset, the brain MRI scan is normal or reveals nonspecific white matter 
lesions 
 MRI of the spinal cord showing longitudinally extensive, central lesions (MS lesions are 
more peripherally located in the cord and extend over one to two segments in length) 
7. Schilder’s disease/myelinoclastic diffuse sclerosis 
This disorder was initially described by Schilder in 1912 and later clarified by Poser (1992). 
There are further reported cases of solitary, large plaque like lesions, which were 
histologically confirmed to be foci of demyelination (Kumar et al., 1998; Gutling and Landis, 
1998). The aetiology is unclear; however an association with tuberculosis was described in 3 
South African children (Pretorius et al., 1998). Schilder’s Disease occurs predominantly in 
children (peak age 5-14 years) (Afifi et al., 1994). 
The Poser criteria (1992) for diagnosis are: 
 one or two roughly symmetrical large plaques (greater than 2 cm diameter) 
 pathological analysis is consistent with sub-acute or chronic myelinoclastic diffuse 
sclerosis 
 adrenoleukodystrophy and peripheral nervous system involvement must be excluded.  
7.1 Clinical presentation 
The clinical presentation is non-specific and includes neuroregression, seizures, ataxia or 
signs of raised intra-cranial pressure. 
7.2 Neuro-imaging 
The lesions of Schilder’s Disease are typically large and plaque-like and have also been 
termed tumefactive demyelination. MRI is the most accurate modality of delineating the 
lesions that are often confused with brain neoplasms or abscesses. Making the distinction 
between demyelination and infection/malignancies early is important to prevent 
unnecessary surgical procedures and toxic therapies like radiation and chemotherapy 
(McAdam et al., 2002).  MRI studies demonstrate 1 or 2 large confluent lesions in the deep 
white matter, usually the centrum semiovale (Figure 8 a-f). Lesions are at least 2 cm in 
size in 2 of 3 dimensions. No additional lesions should be observed on imaging of the 
brain or spinal cord- this would suggest MS or ADEM. On T1WI, tumefactive 
demyelination lesions reveal a hypo-intense central area with a thick surrounding band of 
moderately increased intensity. Lesions are centrally hyper-intense on T2WI. 
Enhancement, when present, is incomplete. The lesions are characterized by enhancement 
limited to one side of the lesion; usually the rim facing the lateral ventricles (McAdam et 
al., 2007). Demyelination can be distinguished from other ring enhancing lesions (brain 
abscesses, tumors, parasitic infections) by the presence of other demyelinating plaques 
elsewhere in the central nervous system.  
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Fig. 8. A & B – T2 axial MRI demonstrating multiple well-defined hyper-intense white 
matter foci surrounded by more ill-defined areas of increased white matter signal intensity 
consistent with Schilder’s Disease. C- Flair axial MRI demonstrating multiple hyper-intense 
lesions of varying sizes within the white matter with some areas of suppression within the 
plaques consistent with Schilder’s Disease. D- Flair parasagittal MRI demonstrating large 
flame- shaped white matter plaque with some areas of suppression within the lesions 
consistent with Schilder’s Disease. E & F- T1 with contrast axial MRI demonstrating multiple 
non- enhancing hypo-intense lesions of varying shapes and sizes within the white matter.  
Other supportive diagnostic tests include an elevated CSF protein and an elevation of CSF 
IgG in 50-60% of patients with Schilder’s Disease. Many patients with a large ring enhancing 
lesion will have a brain biopsy mainly to exclude other disorders. 
7.3 Treatment 
The treatment of choice is high dose intravenous corticosteroids. A rapid clinical and 
radiological response to high dose corticosteroids favors the diagnosis of demyelination.  
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8. Multiple Sclerosis (MS) 
MS is defined in Table 1 (Krupp et al., 2007). MS in children is likely an under-recognized 
phenomenon that poses a unique set of challenges in terms of diagnosis and management. Early 
accurate diagnosis of MS is vital to facilitate early institution of disease modifying agents.  
8.1 Epidemiology 
Childhood onset MS is an uncommon entity however, an estimated 2- 5% of patients with 
MS have onset of symptoms of MS before 16 years of age (Duquette et al., 1987; Boiko et al., 
2002). The youngest reported patient with MS presented at 10 months of age. This was an 
indigenous African child who died at 6 years of age after 11 episodes of relapsing 
neurological symptoms (Shaw and Alvord, 1987). Similar to adult studies, a female 
preponderance is reported for MS in adolescence (Duquette et al., 1987; Govender et al., 
2010). However there is no gender predilection in children presenting with MS under 6 
years of age (Banwell et al., 2007). 
A crude period prevalence for patients of European ancestry was 25.63 per 100 000 and for 
patients of indigenous African descent was 0.22 per 100 000 (Bhigjee et al., 2007). Adult 
studies have described a more severe clinical and radiological phenotype in patients of 
African indigenous ancestry compared to patients of European ancestry (Kaufmann et al., 
2003; Bhigjee et al., 2007). A retrospective single centre analysis showed a significantly 
higher relapse-rate in African-American children, compared with whites, suggesting a more 
aggressive disease course in the former group (Boster et al., 2009). 
8.2 Pathogenesis 
Genetic and environmental factors are implicated in the aetiology of MS. Twin studies show a 
20-30% higher risk of disease in monozygotic twins compared to dizygotic twins. Allelic 
variation in the MHC class II region exerts the single strongest effect on genetic risk 
(Ramgopalan SV et al., 2009).  The HLA DR1B is the gene marker associated with higher risk of 
MS (Ness et al., 2007). Alleles of IL2RA, IL7RA (Hafler et al., 2007), the ecotropic viral 
integration site 5 (EVI5) (Hoppenbrouwers et al., 2008) and kinesin family member 1B (KIF1B) 
genes (Aulchenko et al., 2008) have recently been shown to increase susceptibility to MS. 
Epidemiological studies implicate environmental factors such as geographical variations 
(Kurtzke and Hyllested, 1979), season of birth (Sadovnick et al., 2007) and migration patterns 
(Pugliatti et al., 2006) in the aetiology of MS. Emerging evidence  supports sunlight or 
vitamin D as an important environmental factor in aetiology (Ramgopalan SV et al., 2009). 
Children exposed to parental smoking also have a higher risk of MS (Mikaeloff et al., 2007). 
8.3 Sub-types of MS 
The National MS Society in the US in 1996 categorized MS into four internationally 
recognized forms (Lublin and Reingold, 1996). 
Relapsing-remitting: refers to MS that has exacerbations/relapses followed by symptom-free 
periods of remission. This is the commonest form of MS in children (Ruggierri et al., 2004). 
Primary Progressive: It is characterized by gradual clinical decline from the time of disease 
onset with no distinct periods of remission or relapses. There maybe plateau periods during 
the disease but no periods of being symptom free. This entity, though rare in children, is 
reported (Duquette et al., 1987; Govender et al., 2010). 
Secondary Progressive: This type begins with a relapsing remitting course which may last 
several years before the onset of the secondary progressive stage. Secondary progressive 
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multiple sclerosis is a second-stage, chronic, progressive form of the disease where there are 
no periods of remission, only breaks in attack duration with no recovery from symptoms. 
Relapsing progressive: have a steady neurologic decline but also suffer clear superimposed 
attacks. This is the least common of all subtypes. 
An acute/ Malignant MS (Marburg variant) form presenting with a fulminant, rapidly fatal 
disease has also been described. 
8.4 Clinical presentation 
Children present with a wide variety of clinical symptomatology including motor, sensory, 
visual, cerebellar and brainstem dysfunction (Shaw and Alvord., 1987; Sindern et al., 1992; 
Ghezzi et al., 1997; Dale et al., 2000; Boiko et al., 2002;  Pohl et al., 2006; Govender et al., 2010). 
Motor manifestations are described as the most common clinical presentation (Duquette et al., 
1987; Sindern et al., 1992; Pohl et al., 2006). Polysymptomatic presentation is reported to be more 
frequent in childhood onset MS compared to adults (Ghezzi et al., 1997; Dale et al., 2000; Boiko et 
al., 2002). However monosymptomatic presentation is also reported in children (Duquette et al., 
1987). Encephalopathy and seizures also occur in MS (Gusev et al., 2002). Eye involvement is 
described in up to 50 % of children with MS (Pohl et al., 2006). Optic neuritis in MS is more likely 
to be unilateral (Dale et al., 2000).  Optic tract involvement may be asymptomatic and diagnosed 
only by abnormal visual evoked potentials (Pohl et al., 2006). Fatigue in children is more 
frequent compared to adults with MS (Gusev et al., 2002). Cognitive decline is reported in 30-
66% of children with MS (Banwell and Anderson 2005; Banwell et al., 2007a). 
8.5 Laboratory evaluation 
Diagnostic evaluation is to exclude other conditions affecting predominantly the white 
matter and to look for supportive evidence for MS. The workup should also include CSF 
studies (including cell count, total protein, IgG index, evidence of oligoclonal bands, and 
cytology) (Hahn et al., 2007). CSF Oligoclonal bands are reported in 72-84% of children with 
MS (Sindern et al., 1992; Dale et al., 2000). Oligoclonal bands may be absent initially and only 
develop during the course of the illness. Leucocytosis in the peripheral blood, though 
described in MS (Dale et al., 2000; Govender et al., 2010),  is uncommon and non-specific. 
Neuro-physiological testing such as visual and auditory evoked potentials are also of 
diagnostic importance in detecting sub-clinical evidence of demyelination. 
8.6 Imaging 
Lesions of MS are typically multiple, discrete, plaque-like and involve predominantly the 
white matter (Mikaeloff et al., 2004). Commonly involved areas in MS include the corpus 
callosum, periventricular and sub-cortical white matter (Fig 9a-g). Lesions of MS are 
typically iso- or hypo-intense on T1WI, and hyper-intense on T2W1 and FLAIR sequences. 
Enhancement of active lesions post-gadolinium may be solid, ring-like or arc-like (Fig 10a-c). 
Children tend to have fewer lesions and less enhancement (Banwell et al., 2007b). However, 
some children lack typical MRI findings of MS and have either large tumefactive lesions 
with peri-lesional oedema (Hahn et al., 2004) or deep grey matter involvement. Basal 
ganglia affectation in MS, though described, is uncommon (Figure 11 a,b). Younger children 
with MS may also have more diffuse, bilateral ill defined lesions (Mikaeloff et al., 2004). The 
International Pediatric MS Study Group strongly recommended additional imaging of the 
entire spinal cord to identify other sites of demyelination (Figure 12 a,b). The cervical spinal 
cord is the commonest region involved in MS.  
 




                                                    A                                           B 
  
                                                    C                             D 
   
                              E                                      F                                     G 
Fig. 9. A- T2 parasagittal MRI of the brain demonstrating flame-shaped hyper-intense lesion 
perpendicular to lateral ventricle consistent with MS. B- Flair axial MRI demonstrating 
multiple asymmetrical hyper-intense plaque-like lesions in the centrum-semiovale. Features 
are consistent with MS. C -Flair axial MRI of brain demonstrating 2 periventricular hyper-
intense white matter lesions consistent with MS. D- Flair axial at level of lateral ventricles 
demonstrating asymmetrical hyper-intense white matter lesions consistent with 
demyelination and MS. E- Flair axial of brain demonstrating hyper-intense right parietal 
white matter plaque-like lesion and left subtle white matter hyperintensity consistent with 
MS. F- Flair axial of brainstem demonstrating pontine and brachium pontis high signal 
intensity lesions consistent with demyelination. G-Flair axial MRI demonstrating rounded 
hyper-intense lesion in left brachium pontis consistent with demyelination. 
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                    A                                               B                                            C 
Fig. 10. A- T1 with contrast parasagittal MRI of brain demonstrating rim-enhancing plaque-
like lesion typical of active demyelination in a patient with MS. B- T1 with contrast axial 
MRI demonstrating ring enhancement of left brachium pontis lesion consistent with active 
demyelination in a patient with MS. C- T1 with contrast axial MRI demonstrating ill-defined 
irregular marginal enhancement of the plaque-like lesions consistent with active 
demyelination in a patient with MS. 
 
  
                                                A    B 
Fig. 11. A- Flair axial MRI of brain demonstrating 2 lesions in the right basal ganglia. This is 
unusual for MS. B- Flair axial MRI demonstrating multiple hyper-intense lesions in the 
periventricular white matter as well as left basal ganglia(atypical) consistent with MS. 
MRS reveals a reduction in NAA and an elevation in choline, lipids and lactate in active 
lesions (Smith AB, 2009).  Volumetric MRI studies reveal progressive loss of tissue in white 
matter tracts early in the course of the disease (Miller et al., 2002). A single study of 
Magnetization transfer imaging and Diffusion tensor imaging in children with MS 
suggested that there was no evidence of white matter degeneration in normal appearing 
white matter areas (Tintore et al., 2000). 
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Fig. 12. A- T2 sagittal MRI of cervical spine in a patient with MS demonstrating an ill-defined 
expansile hyper-intense lesion in the proximal cord consistent with demyelination. B- T1 
with contrast sagittal MRI of cervical spine in a patient with MS demonstrating ill-defined 
contrast enhancement of the lesion in 12A consistent with active demyelination. 
8.7 Treatment 
MS is a chronic condition with significant impact on all aspects of the  family’s life. 
Management should be trans-disciplinary involving psychologists, physiotherapists, 
occupational therapists and school teachers. 
8.7.1 Management of relapses 
The mainstay of managing relapses is high dose corticosteroids. High dose IV 
corticosteroids (10-30mg/kg/day) for 3-5 days, is usually used with an optional oral 
tapering dose. High dose oral steroids were found to be efficacious in adults (Morrow et al., 
2004). Plasmapharesis and IVIG are alternatives to be considered if steroids are not effective 
(Hahn et al., 1996; Duzova and Bakkaloglu, 2008). 
8.7.2 Disease modifying therapy 
These therapies are known to alter the disease course and outcomes. They reduce the 
frequency and severity of relapses (Mikaeloff et al., 2001; Kornek et al., 2003; Tenembaum 
and Segura, 2006;). Patients on therapy are shown to have better outcomes compared to 
untreated patients (Mikaeloff et al., 2008). First line agents include Interferon beta 1a, 1b and 
Glatimer acetate. Case reports of second line therapies used include Natalizumab, 
Cyclophosphamide and Mitoxantrone.  
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Study  No. of patients Treatment Outcomes 
Ghezzi et al, 2007 52 Interferon beta 1a Reduction in 
relapse rate 




24 Interferon beta 1a Reduction in 
relapse rate 
Kornek et al,  2003 7 Glatimer Acetate Reduction in 
relapse-2/7 
Stable EDSS- 3/7 
Huppke et al, 2008 3 Natalizumab Induction of 
remission in all 




* EDSS: Extended Disability Status Scale 
Table 2. Studies of specific treatment interventions in MS 
8.8 Prognosis 
Most children with MS follow a relapsing, remitting course with increasing neuro-
disability (Boiko et al., 2002). A slower rate of progression of disease compared to adults 
suggests more plasticity and potential for recovery in the developing CNS (Simone et al., 
2002). Children tend to have more relapses in the first 2 years of the disease (Simone et al., 
2002; Mikaeloff et al., 2006). Patients with childhood-onset MS also take longer to reach the 
stage of severe disability but reach irreversible neurological disability at a younger age 
compared to patients with adult onset disease (Renoux et al., 2007). More severe disease 
was noted in girls; when the time between the first and second attacks was <1 year; for 
childhood-onset multiple sclerosis fulfilling MRI diagnostic criteria at onset; for an 
absence of severe mental state changes at onset; and for a progressive course (Mikaeloff et 
al., 2006). 
9. Clinically isolated syndromes 
These episodes may be mono-focal (the clinical features can be attributed to a single CNS 
site) or multi-focal if the clinical features can not be explained by a single lesion. These 
include isolated optic neuritis, transverse myelitis, brainstem (Fig 13 a-d) or cortical lesions. 
Typically in contrast to ADEM there is no associated fever or encephalopathy. A CIS often 
poses a diagnostic and therapeutic challenge. Multiple lesions (> 4 lesions) (Morissey et al., 
1993) on the MRI increase the risk of evolution to MS. In adult studies up to 80% of patients 
with a CIS evolve MS (Brex et al., 2002). Brainstem lesions in CIS are associated with a worse 
prognosis (Tintore et al., 2010). Children with CIS tend to have more infra-tentorial lesions  
 




                                         A                                                                    B 
  
                                          C                                                                       D 
Fig. 13. (B&C same patient) Clinically Isolated Syndrome. A- T2 axial MRI demonstrating 
abnormal increased signal in the brainstem which was the only abnormal lesion. Clinically 
this patient had a CIS. B- T2 fat saturation axial MRI demonstrating a left swollen hyper-
intense optic nerve with resultant proptosis. Features consistent with a unilateral Optic 
Neuritis. Remainder of brain and spine were normal. C- T2 fat saturation sagittal oblique 
MRI demonstrating a left swollen hyper-intense optic nerve. Features consistent with a 
unilateral Optic Neuritis. Remainder of brain and spine were normal. D- T2 fat saturation 
axial MRI of the optic nerves demonstrating abnormal high signal intensity within the 
proximal portions of the nerves and swelling of the nerves. Features consistent with Optic 
Neuritis (worse on the right). Remainder of brain and spine were normal. 
 
Acquired Demyelinating Disorders of the CNS in Children 
 
83 
Characteristic ADEM 1st  MS event 
Demographics Age of presentation Younger Onset >10yrs 




 History of Pre-
demyelinating event 
More frequent Less frequent 
 Seasonal distribution More frequent Less frequent 
 Family history of 
demyelinating disease 
Not present More frequent 
Clinical 
Presentation 
Seizures More frequent Less frequent 
 Encephalopathy More frequent Less frequent 
 Headache, fever More frequent Less frequent 
 Optic Neuritis Bilateral More frequent 
Unilateral 





Elevated CSF protein Less frequent More frequent 
 Leucocytosis in CSF More frequent Less frequent 






 Serum Leucocytosis More frequent Less frequent 
MRI 
Characteristics 
Lesion definition Ill Defined Well-defined 
 Lesion load Greater Lower 
 Periventricular Lesions Less frequent More frequent 
 Juxta-cortical Lesions More frequent Less frequent 
 Cortical Lesions More frequent Less frequent 
 Corpus Callosum 
Involvement 
Less frequent More frequent 
 Brainstem/ Cerebellum More frequent Less frequent 
 Spinal Cord 
Involvement 
More frequent Less frequent 
 Deep Grey matter 
involvement 
More frequent Less frequent 
 Contrast enhancement Less frequent More frequent 
Outcome Cognitive deficits Less frequent More frequent 
 No neuro deficit after 1st 
event 
Less likely More likely 
Table 3. Markers comparing ADEM to a first episode of MS 
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of active  
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 Isolated CNS angiitis, CADASIL (adult disorder-rare in children) 
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 Metachromic Leukodystrophy, Krabbe’s Disease, Alexander’s 
disease 



















 Vitamin E, Folate deficiency 




-T1WI ↓, T2WI↑ 
-Sparing of sub-
cortical U Fibres  
 Lead, Isoniazid 
Infiltrative Sarcoidosis Cranial neuropathies, 









 Histiocytosis Visual disturbances, 
hypothalamic dysfunction
-Hypothalamic/ 







 Rapid correction of Hypo-
or hypernatraemia 
-Symmetric 









Table 4. Main differential diagnosis of acquired white matter diseases on MRI 
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(Ghassemi et al., 2008). This may be related to the differences in myelination patterns and 
maturation in children compared to adults. A radiologically isolated syndrome (RIS) is 
defined by incidental MRI findings suggestive of MS in an asymptomatic patient lacking 
any history, symptoms, or signs of MS (Okuda et al., 2009). 
10. Risk of recurrence after a first demyelinating event 
Predicting the risk of a first episode of demyelination evolving on to MS is important as new 
immunomodulating therapies become available. Early initiation of disease modifying 
therapy reduces the risk of relapse and long-term disability (Jacobs et al., 2000). Patients with 
“ADEM” progressing to MS vary from 0-29% (Belman et al., 2007). Multiple historical, 
clinical, laboratory and radiological criteria are used to predict the risk of recurrence/ 
progression to MS (Table 3). 
A seasonal pattern, a history of a precipitant, seizures, bilateral optic neuritis and 
encephalopathy are considered more likely in ADEM compared to MS (Dale et al., 2005). 
Inflammatory markers, a high cerebrospinal fluid protein and leucocytosis are also more 
common in ADEM (Kesselring et al., 1990). MRI characteristics that are predictive of 
evolution to MS include well defined lesions that are peri-aqueductal or perpendicular to 
the corpus callosum (Dale et al., 2000),  deep grey matter involvement and lesions that 
enhance post contrast (Govender et al., 2010). 
11. Differential diagnosis of white matter disease in children 
The differential diagnosis for a child who presents with a neurological symptom and white 
matter lesions on neuro-imaging is vast and includes infectious diseases, leukodystrophies, 
tumors, vasculitides, toxins and vitamin deficiencies. In resource poor countries, CNS 
infections must be excluded first as they are common and have acute therapeutic 
implications. 
CNS infections must be excluded in children presenting acutely especially with fever and 
encephalopathy. CNS infections that may present with multifocal white matter lesions 
include HTLV-1, Borreliosis and Subacute Sclerosing Panencephalitis. In resource poor 
settings HIV Encephalopathy (Figure 14 a,b) is common and is also characterized by 
confluent white matter lesions. Progressive Multi-focal Leukoencephalopathy (Figure 14 c), 
is also common in immuno-compromised patients. 
Neurometabolic disorders, such as Adrenoleukodystrophy (Figure 14 d,e), presents with 
primary white matter disease. 
Osmotic Myelinolysis (Figure 14 f,g) is thought to be related to osmotic shifts associated 
with rapid correction of fluid and electrolyte abnormalities (especially sodium 
abnormalities). Malnourished children are at greater risk for developing myelinolysis. 
Lesions typically occur in the pons but have also been reported in extra-pontine sites such as 
the basal ganglia, cerebral cortex and cerebellar peduncles. 
Nutritional deficiencies such as vitamins B12, E and folate deficiencies may also cause 
white matter lesions. 
Drugs and toxins implicated in demyelination include tin, lead, isoniazid and radiation. 
Collagen Vascular Diseases refer to a group of auto-immune mediated disorders. The 
neurological manifestations are diverse. Neuro-imaging may show multi-focal white matter 
lesions- involving the cortex, cerebellum or spinal cord.  
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Fig. 14. A & B- T2 axial MRI demonstrating diffuse brain shrinkage/atrophy with ex-vacuo 
dilatation of the ventricles and abnormal increased signal intensity in the deep white matter 
bilaterally. This patient has features of HIV encephalopathy. C- Flair axial MRI 
demonstrating bilateral symmetrical increased signal intensity in the frontal white matter. 
This patient was diagnosed with PML. D- T2 axial MRI demonstrating bilateral symmetrical 
confluent abnormal increased white matter signal intensity in the posterior white matter 
consistent with Adrenoleukodystrophy. E- T1 with contrast axial MRI of same patient as 
14D demonstrating peripheral enhancement of the white matter lesions. F- T2 axial MRI 
demonstrating well-defined rounded hyper-intense lesion in the pons. Note peripheral 
sparing of the pons. (Compared to figure 14G). Features consistent with Osmotic/ Pontine 
Myelinolysis. G- T1 with contrast sagittal MRI of the same pontine lesion as 14F showing no 
contrast enhancement. Features consistent with Pontine Myelinolysis. 
 




Acquired demyelinating disorders in children are a diverse, challenging group of conditions 
that are probably under-diagnosed. Early recognition is essential for optimal patient 
management as some of these disorders cause significant long-term sequelae. Advances in 
the last decade include establishing consensus definitions and improvement in neuro-
imaging techniques. These advances set the stage for international collaborative studies to 
better define other areas such as understanding the aetio-pathogenesis, identifying 
biomarkers and standardizing treatment protocols of this diverse group of conditions. 
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The first recording of electromagnetic fields in the brain, or magnetoencephalography 
(MEG), were performed in 1968 at the Massachussets Institute of Techonology in Boston, by 
the David Cohen team, exploring alpha rhythm with the aid of a single sensor machine 
(Cohen,1968). In 1972 Cohen again studied alpha rhythm in normal subjects, and response 
to hyperventilation in a patient with partial complex seizures (Cohen, 1972). Until the mid-
eighties, MEG equipment had a single sensor that in practice meant, in addition to spatial 
limitation of the study, that is was necessary to prolong the studies excessively until it was 
possible to gather the required data. 
Magnetoencefalography, with up to 148 channels, has been more useful in dipole 
localization and evaluating transcallosal spread than traditional EEG, given the limited 
channels in the 10-20 system. At present, over hundred MEG installations worldwide 
contribute to our knowledge about the function and development of the human brain 
(Pateau, 2002). Most MEG studies have been conducted with adult subjects, but some MEG 
data already exist on children. Pediatric MEG studies have mainly focused on epilepsy 
surgery, on the Landau-Kleffner syndrome and related disorders, on sensory cortex 
properties in progressive myoclonus epilepsies, and on dyslexia. 
MEG is a noninvasive technique that measure the magnetic fields generated by intracellular 
current flow in the dendrites of the pyramidal neurons of the brain cortex. The fluctuations 
of the magnetic field produced by this flow of current can be recorded from the outside of 
scalp and can subsequently be used to locate the cortical generators of that activity with a 
temporal resolution measured in millisecond. These characteristic made MEG an invalidly 
useful tool to study the brain centers of cognitive functions. The way, MEG had served to 
show that there is a neuronal  dynamic neuronal involved in the language process 
(Pulvermuller,et al.,2003;Wilson,et al.,2005;Pammer,et al.,2004) and that, measuring the 
magnetic fields derived from that activity helps to locate the sources of electrical activity 
electric in the human brain in a  noninvasive manner(Ray & Bowyer,2010). 
Despite being a relatively new technique, MEG is fast becoming an essential tool for clinical 
physicians, including neurophysiologist, to give an accurate diagnosis Although the main 
applications of the technique are found in the area of presurgical evaluation, epilepsy and 
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brain tumors (Frye,et al.,2009), especially in the functional localization of epileptic focus, 
another condition in for which it may be useful include autism (Roberts,et al.,2008), stroke 
vascular, (Tecchio,et al.,2007) schizophrenia,(Rutter,et al.,2009) Parkinson’s disease 
(Stoffers,et al.,2008) and language disorders.  
The integration  of MEG with other functional techniques such as PET (positron emission 
tomography, SPECT (single photon emission computed tomography) and fMRI (functional 
magnetic resonance) and MRS (magnetic resonance spectroscopy ) has been an important  
contribution to increasing our  knowledge of the  biologic substrates of the various 
neurocognitive process  and shows  the importance of certain areas determine in  behaviors. 
However, these techniques fail to provide information on the functional organization paths 
of the neuronal networks involved in cognition (Del Rio,et al., 2005). 
The capacity of MEG to define the epileptogenic area and its propagation paths has been 
confirmed by validating the data obtained by using that technique with those obtained by 
means of electroccorticography or recording made with intracranial electrodes (Del Rio,et 
al.,2005). 
Once of the aspects in which MEG can more quickly define its contributions are without and 
doubt its application to presurgical study of patients with epilepsy resisted to medical 
treatment (Shibasaki,et al., 2007). 
 
 
Fig. 1. A, Biomagnetometer in a electrically shielded room. Patients can be comfortably 
studied in a seated or supine position. 
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MEG´s special sensitivity towards the currents discharges in the cerebral sulci and fissures 
have fostered the study of patients with Landau-Kleffner syndrome, for whom an 
epileptogenic area is proposed in the persylvian region. In these patients, MEG has had an 
impotant role for the selection of patients who are candidates to multiple subpial transection 
treatment (Pateau,et al.,1999). 
The contribution of MEG to epilepsy surgery does not simple lie in more accurate or exact 
definition of the epileptogenic area alone, but, in addition, MEG contributes non invasive 
alternatives to locate eloquent cortex area that must be preserved during a surgical 
procedure (Sibasaki,et al., 2007). 
1.2 Basic principles of MEG 
A moving electric charge is always associated with an electric field and concomitant 
magnetic field surrounding the axis movement fig 2a. Electroencephalogram (EEG) and 
MEG signals are belied to reflect synchronous postsynatic currents in thousands of parallel 
apical dendrites. Despite being ultimately due to the same primary currents, EEG and MEG 
signals differ at some important points (Paetau, 2002). First, only tangential currents, 
parallel to the head surface, give rise to an extracranial magnetic field. Because the apical 
dendrites typically run perpendicular to the cortex surface, MEG signal mainly arise in 
fissure walls fig2b. The EEG signals, on the other hand, are dominated by radial currents, 
while the tangential ones may require signal averaging to be detected. The complementary 
sensitivity to current warrants combined use of EEG and MEG whenever possible. Second, 
in homogeneous tissue conductivity of the human head tends to spread out the signal, but 
does not alter the magnetic fields. Therefore, tumors, cysts, calcified lesions and skull 
defects cause less distortion on MEG than EEG signals (Vander,et al., 1998). Third, signal 
attenuation in EEG is caused by poorly conducting tissue, while the magnetic field fades off 
proportionally to the second power of the distance from the source. Infant and persons with 
small heads should preferably be studies with systems composed of two part-head devices 
adjustable according to the head size or with specially designed baby devices. Fourth, 
different practical problems hamper data acquisition. MEG sensors are in a rigid helmet and 
the head as to be kept immobile with respect to the helmet. Long Term recordings or 
recordings of major motor seizures area far not possible with MEG, but continuous 
monitoring of the head position may offer relief to some of the movement problems. Finally, 
MEG and EEG have partly differing artifact profiles: MEG is less sensitive to muscle artifacts 
than EEG. On the other hand, magnetic materials moving with respiration (Traces from 
craniotomy drills, some shunt materials, tooth braces, cochlear implants, etc) may cause   
serious artifacts or even destroy the MEG data. 
1.3 MEG in acquired epileptiform regression syndromes 
Acquired epileptic regression syndromes are disabling childhood disorder, were a 
previously healthy child deteriorates over a week to months. The children may or may not 
show overt seizures, but their EEG usually displays almost continuous epileptiform spike 
and wave activity, especially during sleep. In acquired epileptic aphasia or the Landau-
Kleffner syndrome (Landau, 1957), the regression affects receptive language and /or 
auditory perception. Epileptiform spike-and wave discharges appear during the first few 
weeks, and have been proposed to causally related to cognitive disability. Some LKS 
children develop giant auditory N100m response with similar auditory cortex sources and  
 




Fig. 2. Physical basis of MEG signals. (a) The intracellular current I in the apical dendrite of a 
pyramidal cell is associated with a surrounding magnetic field B. (b) In the brain, pyramidal 
cells typically are perpendicular to cortex surface, and may be radial (white arrows), oblique 
or tangential (dark arrows) to the scalp. Only the tangential currents and the tangential 
component of oblique currents contribute to the extracranial magnetic field, which can be 
detected by sensitive SQUID magnetometers. (c) Dipolar magnetic field pattern viewed 
above. B in indicates the magnetic flux into the head and B out the flux out from the head. 
An equivalent current dipole (ECD; the thick black arrow) represents the concerted action 
lines of all fissural dipoles. Its orientation is parallel to the isofield lines and it is located 
underneath the steepest gradient halfway between the in- and out-flowing flux. Its depth 
determines the distance between the two extremes, and its strength is proportional to the 
number of active pyramidal cells.  
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reactivity as the normal N100m, but with morphology and amplitude identical lo the 
patient’s epileptic spikes (Pateau, 2002). LKS Patient’s verbal auditory agnosia can, 
therefore, be understood as local epilepsy of the auditory cortex, activated by sounds. MEG 
alone or combined with EEG has proved useful in identifying the sources of epileptic 
activity in LK, as well as in childhood epileptic autistic regression disorders (Sobel et 
al.,2000;Muñoz Yunta et al.,2008). 
2. Landau-Kleffner syndrome 
In 1957 Landau and Kleffner described six children with acquired aphasia syndrome and 
epileptic seizures with encephalographic alterations (Landau, 1957). The syndrome had two 
basic symptoms: on the one hand an acute or sub-acute acquired aphasia in previously 
normal children, and on the other, a paroxysmal encephalographic plot with spikes and 
waves more frequently located in region temporal region that may reach an epileptic stage 
during the slow stage. Convulsive seizures, if shown come before or follow the beginning of 
the slow speech impairment but these epileptic discharges in the electroencephalogram are 
invariably present (Guevara Campos & González Guevara, 2007). It may be accompanied by 
behavior or demeanor disorders, such as hyperactivity, expression of aggressive, 
rebelliousness and autistc features.  
The etiology of the LKS is unknown. Although encephalitis has been proposed as an 
etiology, some of empirical evidence has raised doubts. For example, the course of LKS is 
very different from that of Rasmussen chronic encephalitis and temporal lobotomy 
histology in two cases of LKS was not consistent with encephalitis (Rasmussen & Mc Cann 
1968; Coke et al., 1988). Based on the results of conventional angiography in some patients 
with LKS, Pascual-Castroviejo (Castroviejo et al., 1992) proposed vasculitis as an etiology. 
These investigators treated patients with calcium blockers with a favorable response. Others 
have considered whether an underlying autoimmune mechanism may contribute to the 
pathogenesis of LKS give the fact autoimmune processes may be involved in the 
pathogenesis of child development disorders and epilepsy (Nesimalova et al., 1992). This 
idea is supported by Connolly (Connolly et al., 2006). Who reported an increase in IgM 
autoantibodies to endothelial cells and IgG autoantibodies to myelin basic protein as 
compared to healthy controls. A small number of brain lesions have been reported in 
association with the LKS, including neurocysticercosis (Bhatia et al., 1994), toxoplasmosis 
(Michalowiez et al., 1989), temporal lobe astrocytoma (Solomon et al., 1993), and temporal 
lobe glioma (Solomon et al., 1993). The increased risk of LKS in monozygoyic twins and 
siblings suggests a genetic etiology (Feekery et al., 1993). Thus, it is very likely that the 
etiology of the LKS is variable with several etiologies. It would be useful to classify LKS as 
cryptogenic or symptomatic. The cause of epilepsy and continuous aphasia still remains a 
mystery (Deonna, 1991). 
3. Clinical manifestations 
3.1 Aphasia 
Single photon emission computed tomography imaging demonstrated hypometabolism in 22 
of his 25 patients (O´Regan et al., 1998), suggested that aphasia occurs as a manifestation of a 
hypometabolic encephalopathy secondary to a local postictal state (O´Regan et al., 1998). 
Positron emission tomography has shown dynamic changes in the metabolism of glucose in 
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the temporal lobe during episopdes of aphasia (Luat, et al., 2006). Temporary changes in the 
positron emission tomography images suggest that the metabolism of glucose in LKS cannot 
be attributed only to the epileptiform interictal activity (Luat, et al., 2006).  
MEG offers the possibility to study the organization of the neuronal networks involved in 
language processes and shows with high precision, and in a noinvasive fashion, the spatial 
and temporal patterns of brain activity related to this cognitive function in order to 
determine the neurocognitive reorganization of language in several diseases such as aphasia 
or epilepsy, and the relationship of this functional reorganization to behavioral language 
problems (Ortíz et al., 2009).  
Although aphasia is present in all patients, it constitutes the first manifestations in only half. 
Its onset may be abrupt or progressive over several days or weeks (Guevara Campos, et al., 
1989). Typically, the aphasia is receptive; the child begins to have difficulty-understanding 
language to the point that deafness may suspected. The capacity for oral expression gets 
impaired quickly; mutism is frequent. Non-verbal skills are usually preserved, thereby 
allowing sign language to be used for some degree o communication. Writing is preserved 
in older children (Deonna, 1991). The integrity of the thalamic auditoy pathways is 
confirmed by normal brainstem potentials. Alterations the evoked cortical latencies support 
posterior temporal region dysfunction (Zouari & Choyakh, 1997). 
Expressive aphasia was present in two of the original Landau -Kleffner patients (Landau & 
Kleffner, 1957), and 6 of the 77 cases studies by Dugas, (Dugas, et al., 1992). A detailed study 
of aphasia shows that it is possible to find virtually every type, including semantic 
pragmatic disorders (Paquier, et al., 1992). 
The course of the aphasia found in the LKS is one of its most disconcerting characteristic. A 
relationship between one age of onset and the long term results has been reported the 
younger the child the worse the prognosis for the recuperation of speech. The effect are 
devastating in young child that have no yet developed linguistic abilities since the cortical 
mechanisms to process speech cannot develop. In older children, the effects are less serious 
because they have already learned language (Bishop, 1985). In general total recovery is very 
difficult, and variable difficulties persist in oral communication in most case. Non –verbal 
communication can be unaffected, but there is the possibility that it may not be even  when 
it is present (Baynes,et al.,1998). 
3.2 Epilepsy 
Most researchers support the hypothesis than paroxysmal activity produces a functional 
disconnection of the cortical areas related to speech. The exact origin of epileptic activity has 
been shown through brain mapping techniques. Paroxysms have been shown to be located 
in the depths of Sylvian fissure through dipole modeling (Nakano,et al.,1989). This is 
supported by results of positron emission tomography, single photron emission computed 
tomography and magnetoencephalography studies (Baumgartner & Pataraira, 2006). 
MEG and EEG record synchronous postsynaptic currents in thousands of cortical pyramidal 
cell apical dendrites, with a temporal resolution at the level of the millisecond. Although 
EEG reflects cortical currents of all orientations, MEG is mainly sensitive to fissure currents 
and, therefore, provides an optimal method to identify the fissure generators of LKS spikes. 
During a single spike-wave complex, spike propagation from a fissure wall to the adjoining 
convexity can take between 10 and 30 ms, and propagation time between left and right 
perisylvian areas are similar. Both MEG and EEG can differentiate between primary 
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(independent) spike foci and secondary spikes (Paetau, 2009) MEG and EEG are necessary 
for the spatial and temporal understanding of the perisylvian region and epileptic networks 
in Landau –Kleffner syndrome. 
The 4 potential roles for MEG in the localization of the ictal onset zones (IOZ) and functional 
cortex: 1) MEG confirmations of localization based on traditional noninvasive methods, 
allowing epilepsy surgery to proceed without long term intracaneal EEG monitoring; 2) 
MEG demonstration of bilateral, multifocal, or diffuse ictal onset, indicating an unfavorable 
candidate for epilepsy surgery; 3) MEG locations adjacent to or distant from that of 
traditional methods or focally , when traditional methods suggest multifocal activity, 
potentially altering clinical decision making regarding epilepsy surgery ; and 4)MEG 
localization of eloquent cortex to guide surgical trajectory. These data will serve to refine 
prospective studies on the optimal use of MEG in the localization of the IOZ and functional 
cortex in children with treatment-resistant epilepsy (Schawartz,et al.,2008). 
Epileptic seizures constitute the first manifestation in approximately half the cases of LKS. 
Beaumanior (Beaumanior, 1992) found that nightly partial seizures were most common, 
followed by generalized tonic-clonic, atypical absences and, rarely, myoclonic absences. 
Extremely rare cases have been reported of partial complex seizure patients with 
automatism (Deonna, 1991; Guevara Campos et al., 1989). Clinical seizures only appear in 
around 70% of the patients. A third of clinical seizure patients have isolated single seizures. 
Status epileptic occurs in some (Hirsch, et al.,1990).Seizures are not very frequent in patients 
between the ages of 5 to 10 years of age (Pablo,et al.,2002) After the age of 10 years  old, only 
one fifth of  the patients experiences sporadic seizures. Seizures rarely persist in older 
adolescence. (Guevara Campos, et al., 1989)  
In most cases, monotherapy with anti-epileptic is effective to control the seizure but not the 
aphasia (Deonna, 1991). In most the patients, no close relationship is established between 
the frequency of the seizures and the degree aphasia, which can be serious even in absence 
of seizures (Guevara Campos &González Guevara, 2007). Seizures almost always disappear 
in adulthood, although rare cases have been reported in the literature or refractory epilepsy 
that persists until adulthood (Beaumanoir, 1992). 
3.3 Paroxysmal alterations of the EEG  
The behavioral and cognitive alterations characteristic of patients with LKS are believed to 
be secondary to epilepsy rather than structural damage to the central nervous system. The 
affirmation is based on the fact that frequent and intense epileptic discharges are focally 
located in language areas important for speech and the fact recovery, either spontaneous or 
induced by treatment , is always associated with the disappearance of EEG paroxysmal 
activity (Guevara Campos & González Guevara,2007). 
In the theory of the pathogenic mechanisms that lead to the LKS syndrome there is general 
consensus on the epileptiform discharges normally active in the non REM sleep stage and 
the regression of speech. The spikes on the etectroencephalograms are usually temporal, 
central-temporal or bilateral parietal-occipital and synchronous. Experiences with brain 
injuries have shown that a healthy hemisphere is sufficient to acquire normal speech. 
Therefore, the regression of speech in LKS suggests a bilateral dysfunction of the auditory 
cortex and related speech cortex, both hemisphere having independent epileptic injuries or a 
unilateral injury that induces the functions paralysis of the healthy hemisphere due to 
bombarding of epileptic discharges through commissural injuries (Paetau, 2009). 
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Magnetoencephalography detect extra-cranial magnetic fields. Spike generated in the 
perisylvian convexities are detected only with the EEG, while the spikes generated by the 
intrasylvian region are selectively seen by MEG. The spike generated by EEG and the MEG 
are detected by using equivalent dipoles that represent the cortical activity of the pyramidal 
neurons in the cortex. MEG localizes 1-2-cm generated cortical spikes with spatial precision 
and a one millisecond resolution.  
MEG studies that, in approximately 80% of LKS patients, epileptic discharges are bilateral 
and are generated in the auditory and speech cortex, and are related. Approximately 20% of 
children with LKS have a unilateral pacemaker in the perisylvian region that triggers the 
secondary bilateral synchrony of the spikes. This 20% could recover the speck ability after 
performing a supial intracortical transaction in the pacemaker (Paetau, 2009). 
EEG abnormalities are present in all patients. The background rhythms are usually normal, 
but theta slowing is occasionally present in the same regions as the spike. Spike paroxysms 
or spike and wave complexes can be unilateral or bilateral and may be focal, multifocal or 
diffuse (Beaumanoir, 1992). Discharges are bitemporal in 50% of the patients and in the 
parietal-occipital regions in 30% of the patients. Discharges are usually active by sleep. 
Paroxysms are frequently similar to those found in Benign Rolandic Epilepsy. There is a 
clear activation of the epileptiform activity in Rolandic epilepsy during sleep that can 
transform into continuous spike and wave. In such patients the sleep index never reaches 
85% (Deonna, 1991). Most of the foci are localized to the temporal or temporal central region 
and are more commonly found in the left hemisphere. 
Bilateral foci are frequent (Beaumanoir, 1992); they tend increase by more than 85% during 
sleep and can transform into continuous spike and wave sleep (CSWS) or electrical status 
epilepticus during slow sleep (ESES). The term CSWS is used synonymously with that ESS. 
The discharges in ESES are located in the frontal or frontocentral region, while they tend to 
located in the temporal or parietal areas in LKS. The seizures seen in patients with ESES are 
similar to the ones of LKS, but drop, myoclonic and unilateral clonic seizures may be more 
common. The nature of the cognitive deterioration is more diffuse in ESES than in LKS. The 
correlation between the EEG paroxysmal activity and the neuropsychological deficits 
supports the opinion that these are a direct result of the epileptic process, thus permitting 
the consideration that both LKS and ESES syndrome belong to the group epileptic 
encephalopathies (Aicardi, 1999). 
Hyperventilation and photostimulation activation mancuvers are rare positive. The 
disappearance of the spike and wave complexes in sleep fortells the improvement of aphasia 
and it may be a good index of the efficacy of treatment (Li et al., 1996). However, neither full 
nor partial recovery of aphasia is never noted before CSWS disappears (Aicardi, 1999).  
The EEG constitutes the basic tool to follow up on anti-epileptic therapy aimed at 
suppressing the marked paroxysmal alterations shown in the EEG, most specially the 
activity of the CSWS (Li et al., 1996). 
3.4 Behavioral changes  
Behavioral changes are extremely common in patients with LKS (Dugas,et al.,1992). These 
include hyperkinesias, outburst of wrath, rebelliousness and aggressive expressions. Some   
of these behaviors may be a related the frustration associated to speech difficulties. Autistic 
features and autism with all its components are very frequent and in some cases, they can 
even control the clinical manifestations (Nesimalova, et al., 1992). Hyperkinesia is usually 
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described as psychomotor disorder; hyperkinesia and slight verbal auditory agnosia occurs 
in the early stages of LKS; it can be mistaken for cases of attention deficit with hyperkinesia. 
Personality disorders, aggressiveness and depression are also evident (Guevara Campos & 
González Guevara, 2007). Neville (Neville,et al.,1998) have pointed out the fact that many 
children with LKS show various degrees of motor disorder. Thirteen out a total of 30 
children with LKS showed moderate motor disorders expressed as clumsiness, slowness 
and imprecise movements with six showing serious dysfunctions (Neville,et al.,1998). 
4. Diagnostic studies 
In general diagnostic research has not clear defined the etiology of LKS. In a child with 
language regression or apparent deafness, it is mandatory to perform an EEG   that includes 
a recording during extended sleep (Aicardi, 1999). Neither the evoked potentials nor 
auditory test have contributed useful data for diagnosis (Zouari & Choyakh, 1997; Pablo et 
al., 2002). The analysis of cerebral fluid is almost always normal, although case in which a 
slight elevation of total protein has been reported (Perniola,et al.,1993). Axial computer 
tomography and magnetic imaging are always normal, although non-specific finding, such 
as white matter changes or structural damage, have been reported (Perniola,et al.,1993). In a 
small number of patients single photon emission computed tomography and positron 
emission tomography have revealed perfusion and glucose metabolism abnormalities in the 
temporal lobes (Luat,et al.,2006;Guerreiro,et al.,1996;Da Silva et al.,1997).There have been 
case report about the use of MEG in patients with LKS (Sobel,et al.,2000). 
Magnetoencephalography can provide excellent pre-surgery localization of epileptiform 
activity as well as functional language mapping if surgical treatment, such as multiple 
subpial transection, the role MEG in evaluating patients with epilepsy continues to evoive. 
MEG is sensitive to epileptic activity originating from depths of sulci, such as the fissure, 
because it reveals magnetic fields generated by transmembrane synaptic currents oriented in 
a plane tangential to the skull surface (Seppo,et al.,2010). The precise locations afforded by 
MEG compared with EEG can sometimes obviate the need for invasive video EEG recording 
as well as direct the placement of intraoperative   electrodes when surgery is being 
considered for patients with medically intractable epilepsy, Specially, for patients with LKS, 
MEG is useful in confirming the diagnosis and may prove useful in preoperative localitation 
if subpial intracortical trasction becomes widely accepted for the treatment of intractable 
cases. Magnetoencephalography has added valuable data in presurgical planning in 
determining the location of the dominant focus along and within the sylvian fissure during 
secondary discharges see in CSWS (Smith, 2004). 
5. Conclusions 
MEG and EEG are fundamentally different functional magnetic resonance imaging (fMRI), 
positron emission tomography (PET) or other anatomical imaging methods, where the 
spatial resolution is based on voxel size. The most important advantage of MEG and EEG 
over any present functional imaging modality is their submillisecond temporal resolution. 
At present, MEG provides the most efficient single tool for real time tracking of distributed 
brain activities during a number of cognitive tasks or epileptic discharges. The MEG finding 
have impacted patient management in nearly every case and have been universally accepted 
by pediatric neurologist and pediatric neurosurgeon as beneficial for their patients. 
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Specially, these benefits include substantiated decisions not to offer surgical resection, 
decisions to move ahead with intracranial grid placements; and lesion detection in the 
setting of nonlesional structural imaging. 
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1. Introduction  
The concept of neurocristopathy was introduced by Bolande in 1974 to describe a group of 
diseases arising from aberrations in the development, migration and differentiation of the 
embryonic neural crest (NC). This cell lineage differentiates into pigmentary and neural cells 
and forms part of the autonomous nervous system, nervous enteric plexus, as well as 
endocrine glands (adrenals, parathyroid gland) and chemoreceptors (carotid and aortic 
bodies). Neurocristopathies derived from a failure in NC development and range from 
alterations in intestinal ganglion cells, as seen in Hirschsprung’s Disease or in intestinal 
neuronal dysplasia, to alterations in skin pigmentation (such as neurofibromatosis, 
Waardenburg-Shah syndrome and piebaldism) (Spritz, 1997). In recent years, fostered by 
the increasing research on the NC ontogeny (Trainor, 2005), the notion of cristopathies has 
widened (Bolande, 1997), particularly with the inclusion of craniofacial syndromes of cranial 
crest mesoectodermal origin, often accompanied by morphological brain abnormalities 
(Couly & Aicardi, 1988), as well as the association with other diseases (Martucciello et al., 
2005), including chromosomopathies (Down syndrome), embryopathies (fetal alcohol and 
fetal cocaine syndromes) and tumors of the endocrine system (multiple endocrine neoplasia 
type IIB).  
Based on the accumulating knowledge of the role of NC in development, Jones (1990) 
proposed a new classification of cristopathies according to the pathological mechanism 
involved. The first group includes the defects and disorders originally defined as 
neurocristopathies including pheochromocytoma, neurofibromatosis, and the multiple 
endocrine adenomatoses. These diseases can be explained as dysplasia of neural crest 
derivatives. Affected individuals rarely exhibit actual morphological malformations but do 
carry a risk for impaired growth of crest-derived tissue. The second group corresponds to 
defects and disorders which derive from migrational abnormalities primarily of cranial NC 
cells such as frontonasal dysplasia, the DiGeorge sequence, velo-cardio-facial syndrome and 
Waardenberg syndrome represent true malformations. The genetic origins of some of these 
syndromes have been identified: microdeletions at the locus 22q11.2 (DiGeorge sequence 
and velo-cardio-facial syndromes) and mutations in the PAX3, MITF, EDNRB, EDN3 and 
SOX10 genes (Waardenberg syndrome I-IV types) 
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Hirschsprung’s disease (HSCR) or aganglionic megacolon is perhaps the best-studied 
neurocristopathy. HSCR is a congenital defect characterized by complete absence of 
intramural neuronal ganglion cells in the myenteric (Auerbach's) plexus and the submucosal 
(Meissner's) plexus from distal portions of the intestinal tract caused by failure in the 
migration of these cells from the NC. HSCR is a disorder with multifactorial etiology 
including genetic factors (Kusafuka & Puri, 1998). Mutations in at least 8 genes have been 
associated with HSCR, most of the mutations occurring in the RET gene. According to 
epidemiology studies (Amiel & Lyonnet, 2001; Luis et al., 2006; Polly & Coran, 1993), HSCR 
appears as an isolated trait in 70% of cases. HSCR is associated with a chromosomal 
abnormality in 12% of cases, of which trisomy 21 (Down syndrome) represents >90%. A 
recent report raises the incidence of Down syndrome up to a 17.6 % of HSCR patients 
(Carrascosa-Romero et al., 2007). Association with other congenital multimalformative 
syndromes and isolated dysmorphic conditions anomalies are found in up to 18% of HSCR 
patients. The ones occurring at a frequency above that expected by chance include 
gastrointestinal malformation, cleft palate, polydactyly, cardiac septal defects, and 
craniofacial anomalies. HSCR has also been connected with nervous system malformations 
related to alterations in the development of the anterior segment of the NC: defects in the 
closure of the neural tube such as anencephalia and myelomeningocele, as well as 
impairment of neuronal migration and brain dysgenesis (Carrascosa-Romero et al., 2007; 
Juliá et al., 2003; Shahar & Shinawi, 2003). 
2. Evidence that glial cell are critical participants in every major aspect of 
brain development, function, and disease 
Astrocytes are the most abundant cell type in the mammalian brain. Interest in astrocyte 
function has increased dramatically in recent years because of their newly discovered roles 
in synapse formation, maturation, efficacy, and plasticity. However, our understanding of 
astrocyte development has lagged behind that of other brain cell types. We do not know the 
molecular mechanism by which astrocytes are specified, how they grow to assume their 
complex morphologies, and how they interact with and sculpt developing neuronal circuits. 
Recent work has provided a basic understanding of how intrinsic and extrinsic mechanisms 
govern the production of astrocytes from precursor cells and the generation of astrocyte 
diversity. Moreover, new studies of astrocyte morphology have revealed that mature 
astrocytes are extraordinarily complex, interact with many thousands of synapses, and tile 
with other astrocytes to occupy unique spatial domains in the brain. A major challenge for 
the field is to understand how astrocytes talk to each other, and to neurons, during 
development to establish appropriate astrocytic and neuronal network architectures 
(Freeman, 2010). Astrocytes influence synaptic transmission in many ways. They secrete 
distinct factors that promote synaptogenesis, neurotransmitter release, and postsynaptic 
receptors (Barres, 2008); in addition, they release so-called gliotransmitters in response to 
stimulation and contribute to the calcium waves that correlate with blood flow (Haydon & 
Carmignoto, 2006; Volterra A & Meldolesi, 2005). However, they also participate directly in 
synaptic transmission through the expression of high-affinity transporters for 
neurotransmitters.  
Emerging evidence indicates that signalling between perisynaptic astrocytes and neurons at 
the tripartite synapse plays an important role during the critical period when neural circuits 
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are formed and refined. Cross-talk between astrocytes and neurons during development 
mediates synaptogenesis, synapse elimination and structural plasticity through a variety of 
secreted and contact-dependent signals. Recent live imaging studies reveal a dynamic and 
cooperative interplay between astrocytes and neurons at synapses that is guided by a 
variety of molecular cues. A unifying theme from these recent findings is that astrocytes can 
promote the development and plasticity of synaptic circuits. Insight into the molecular 
mechanisms by which astrocytes regulate the wiring of the brain during development could 
lead to new therapeutic strategies to promote repair and rewiring of neural circuits in the 
mature brain following central nervous system (CNS) injury and neurodegenerative disease 
(Stevens, 2008).  
3. Neuron-to-glia signalling in the central and enteric nervous system – 
Implications for neural disease 
Dysfunction of non-neuronal cells such as astrocytes and microglia have been involved in 
the process of neurodegeneration in the CNS. In fact, they have been proposed as 
therapeutic targets since their selective survival is capable of slowing down the process of 
neuronal death in animal models of neurodegenerative disease (Boillee et al., 2006; 
Yamanaka et al. 2008). In a healthy individual, astrocytes seem to respond to synaptic 
activity in the CNS in a synapse-specific way and, in turn, they appear to precisely regulate 
synaptic activity. These processes have been shown to involve the activity and expression of 
plasma membrane transporters (Bergles et al., 1999). The excitatory amino acid transporters 
(EAATs) control spillover of glutamate from one synapse to another. Besides this, they also 
prevent accumulation of glutamate at the synapse and subsequent toxicity and they serve to 
recycle the released transmitter for packaging and subsequent release. Most transporters are 
expressed at the nerve terminal, where they are well positioned to serve both functions. 
However, the major EAAT isoforms GLAST (human EAAT1) and GLT1 (human EAAT2) 
are expressed by glia and localize to astrocytic processes that reside at varying distances 
from the synapse. Recent experimental in vivo work has shown that presynaptic terminals 
regulate astroglial GLT1/EAAT2 expression (Yang et al., 2009). The regulation of GLT1 
expression by presynaptic input also raises important questions about cause and effect in 
neural degeneration. It is very clear that loss of GLT1/EAAT2 causes severe toxicity, and 
downregulation may occur in ALS. However, several works (Bergles et al., 1999; Yang et al., 
2009) suggest that the downregulation observed may reflect rather than cause neuronal loss. 
Indeed, downregulation in the absence of neural input might have less deleterious 
consequences than in the intact state, where the release of more glutamate has greater 
potential to produce toxicity. Neuronal regulation presumably serves to coordinate 
glutamate clearance with glutamate release. However, a defect in the signalling mechanism 
might trigger the degenerative process without a primary disorder of the neuron, and even 
secondary changes in EAATs expression may propagate the neuronal injury. 
Glia in the peripheral nervous system also respond to neuronal activity. Enteric glia are 
intimately associated with the neurons from the enteric nervous system (ENS) This 
association is similar in morphology and molecular nature to that shown by neurons and 
glia in the CNS. Astrocyte-like enteroglial cells are actively involved in enteric neuronal 
activity via neurotransmitter receptors. In the ENS, the purine adenosine triphosphate (ATP) 
is released together with noradrenaline and acetylcholine by enteric neurons (Al-Humayyd 
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& White, 1985; Nurgali et al., 2003). ATP plays a pivotal role in regulating synaptic 
transmission in CNS astrocytes (Abbracchio & Ceruti, 2006) and it is involved in controlling 
gastrointestinal motility, secretomotor function, blood flow, and synaptic transmission 
(Bornstein, 2008; Christofi, 2008; Ren & Bertrand, 2008). Enteric glia express purinergic 
receptors and has been reported to respond to ATP in vitro (Gomes et al., 2007; Zhang et al., 
2003) which suggested enteric glia participation in functional gastrointestinal responses to 
nerve signalling. More recently, activation of enteric neurons using electrical field 
stimulation of interganglionic fiber tracts in a longitudinal muscle myenteric plexus 
preparation from Guinea pig colon was able to elicit enteric glial cell activity as assesses by 
intracellular Ca2+ imaging in situ through P2Y4 ATP receptors (Gulbransen & Sharkey, 
2009), providing the first evidence of neuron-to-glia signalling in the ENS. Further to this, 
the same team using a combination of techniques to selectively stimulate or eliminate 
intrinsic and extrinsic populations of neurons found that enteric glia are specifically 
activated by sympathetic postganglionic neurons innervating the colonic myenteric plexus 
(Gulbransen et al., 2010). This result supports the notion that glia are not indiscriminate 
detectors of neuronal activity and can discern activity from specific neural pathways. 
Interestingly, the case of a HSCR patient with a SOX10 gene mutation has recently been 
reported showing neurological impairment entirely due to glial maldevelopment including 
peripheral dysmyelinating neuropathy and enteric neuroglia deficiency (Shimotake et al., 
2007). This discovery has driven renewed interest for neuron-to-glia interactions and 
neuroimaging in the field of neurocristopathies.  
4. Hirschsprung disease (HSCR) or aganglionic megacolon and its 
association with other malformations 
HSCR is a cause of functional intestinal obstruction with an incidence of 1/5000 alive 
newborns (NB) (Lister & Irving, 1990; Amiel & Lyonnet, 2001). However, the incidence has 
been shown to vary significantly among ethnic groups:  1.5, 2.1, and 2.8 per 10 000 live births 
in Caucasians, African-Americans, and Asians, respectively, in the state of California (Amiel 
& Lyonnet, 2001). For comparison, in our Albacete Health Service Area the incidence is 1.6 
per 5000 alive NB (Carrascosa-Romero et al., 2007). Although there are many sporadic cases, 
a heterogeneous familial incidence has also been described involving several genetic factors 
(Amiel & Lyonnet, 2001).  
There is abundant literature connecting HSCR with other malformations (Table 1), 
frequently including cleft palate, iris coloboma and congenital cardiac defects, among others 
(Amiel & Lyonnet, 2001; Scriver et al., 2002). Often, HSCR may appear as part of a well-
known neurocristopathy syndrome such as piebaldism (MIM 172800),  Shah-Waardenburg 
(MIM 277580), congenital central hypoventilation (Haddad, MIM 209880) or Riley-Day 
(MIM 223900) syndromes, or associated to other types of dysmorphic syndromes, such as 
Aarskog (MIM 100050), Rubinstein-Taybi (MIM 180849), or Smith-Lemli-Opitz syndromes 
(MIM 270400), where HSCR is not always present but shows an incidence higher than 
expected by chance. Of interest, Carrascosa-Romero et al., 2007 also reported an unusual 
case of HSCR associated with FG syndrome (MIM 305450), a X-linked heterogeneous genetic 
disorder characterized by hair whorls, broad thumbs and severe constipation (Romano et 
al., 1994), presenting with severe mental retardation. 
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SYNDROMES MIM KEY CLINICAL FEATURES 




WS4 (Shah-Waardenburg) 277580 Pigmentary anomalies (white forelock, iris 
hypoplasia, patchy hypopigmentation), deafness. 
Hipopigmentación- Sordera-
Ceguera Yemenite  
601706 Hearing loss, eye anomalies (microcornea, 
coloboma, nystagmus), pigmentary anomalies 
BADS (black locks, 
oculocutaneous albinism, 
sensorineural deafness) 
227010 Hearing loss, hypopigmentation of the skin and 
retina 
Piebaldism 172800 Patchy hypopigmentation of the skin and hair 
Haddad 209880 Congenital central hypoventilation 
MEN2A 171400 Medullary thyroid carcinoma, 
phaeochromocytoma, hyperplasia of the 
parathyroid 
Riley-Day 223900 Autonomic nervous system anomalies 
HSCR MANDATORY   
Goldberg-Shprintzen 609460
235740
Cleft palate, hypotonia, microcephaly, mental 
retardation, dysmorphic facial features 
Hypertelorism, deafness, polydactyly, unilateral 
renal agenesis 




Postaxial polydactyly, ventricular septal defect 
Hypoplasia of distal phalanges and nails, 
dysmorphic features 
Preaxial polydactyly, heart defect, laryngeal 
anomalies. 
Brachydactyly type D 
BRESHECK  300404 Brain abnormalities, Retardation, Ectodermal 
dysplasia, Skeletal malformation, HSCR, Ear/eye 
anomalies, Cleft palate/Cryptorchidism and 
Kidney dysplasia/hypoplasia 
Mesomelic dysplasia, Werner 
type 




Mowat-Wilson 255730 Dysmorphic facial features, microcephaly, mental 
retardation, agenesis of corpus callosum, heart 




Bardet-Biedl 209900 Pigmentary retinopathy, obesity, hypogenitalism, 
mild mental retardation, postaxial polydactyly 
Kauffman-McKusick 236700 Hydrometrocolpos, postaxial polydactyly, 
congenital heart defect. 
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Smith-Lemli-Opitz 270400 Growth retardation, microcephaly, mental 
retardation, hypospadias, 2–3 toes syndactyly, 
dysmorphic features 
Cartilage-hair hypoplasia 250250 Short limb dwarfism, metaphyseal dysplasia, 
immunodeficiency 
HSCR RARELY ASSOCIATED   
Fukuyama congenital 
muscular dystrophy 
253800 Muscular dystrophy, polymicrogyria, 
hydrocephalus, mental retardation, seizures.  
Clayton-Smith 258840 Dysmorphic features, ichthyosis, hypoplastic toes 
and nails 
Kaplan 304100 Agenesis of corpus callosum, adducted thumbs, 
ptosis, muscle weakness 
Okamoto 308840 Agenesis of corpus callosum, hydrocephalus, cleft 
palate. 
Table 1. Syndromes associated with HSCR (reprinted and adapted from Scriver CM et al, 
eds. “The metabolic and molecular bases of inherited diseases” 8th ed. Chap 251. New York: 
McGraw-Hill: 6231-55.) 
For other syndromes, HSCR is a mandatory feature for diagnosis such as BRESHECK (Brain 
Abnormalities, Retardation, Ectodermal dysplasia, Skeletal malformation, Hirschsprung 
disease, Ear/eye anomalies, Cleft palate/Cryptorchidism and Kidney dysplasia) (MIM 
300404) and the subtypes of HSCR with limb anomalies (MIM 235750, 235760, 604211 and 
306980). HSCR is also a mandatory feature for Goldberg-Shprintzen megacolon syndrome 
(GOSHS MIM 609460)(Goldberg & Shprintzen, 1981). This syndrome is characterized by 
microcephaly, hypertelorism, short stature, cleft palate, learning problems, and seems to be 
caused by homozygous nonsense mutations in  KIAA 1279 located at 10q22.1. GOSHS 
presents various common characteristics with the Mowat-Wilson syndrome (MIM 235730), 
which will be discussed below in section 5. 
HSCR has also been connected with malformations of the nervous system: defects in the 
neural tube closure such as anencephaly (Mathew, 1998) and meningomyelocele (Merkler et 
al., 1985), as well as anomalies in neuronal migration and or cerebral dysgenesis (Cass, 
1990), predominantly agenesis of corpus callosum (Sayed & Al-Alaigan, 1996). These 
phenomena have been regarded as alterations in the embryonic development of the anterior 
portion of the NC (Currie et al., 1986; Hurst et al., 1986). The actual incidence of associated 
brain anomalies has been studied for other neurocristopathies. For example, Couly & 
Aicardi (1983) reported that of a group of 3000 children presenting with facial 
dysembryoplasias, 13 %  also showed brain malformations. Another study showed up to 82 
% (18 out of 25) of children with uni- or bilateral maxillomandibular neurocristopathies 
(Goldenhar's, Franceschetti's first arch syndromes or transient forms) also presented 
morphological and motor anomalies of the brain stem and its corresponding cranial nerves, 
as assessed by neurological and cerebral computed tomography examinations (Couly & Le 
Lievre-Ayer, 1983). However, we have failed to find previous literature studying the 
incidence of brain malformations associated with HSCR. Available reports dealt with 
isolated cases (Turkdogan-Sozuer et al., 1998), sometimes under other denominations such 
as GOSHS. All these cases nonetheless share a common denominator: psychomotor delay, 
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associated to alterations in the CNS, generally:  microcephay, agenesis of corpus callosum, 
white matter atrophy, ventricular dilatation. Few reports describe pachygyria, 
polymicrogyria as well as cerebellar hypoplasia in HSCR patients (Carrascosa-Romero et al., 
2007), perhaps due to the fact that neuroimaging studies are rarely performed on this type of 
patients. Our team did study the incidence of brain malformations associated with HSCR in 
our Albacete Health Service Area. In our study we found 10 cases of isolated HSCR versus 7 
cases of HSCR associated with other structural anomalies or psychomotor retardation, 
which indicated a high incidence of anomalies associated with HSCR (41,1%) in our 
territory. 
4.1 Molecular genetics in HSCR: The RET proto-oncogene 
Segregation studies in nonsyndromic HSCR have shown sibling recurrence risk ranging 
from 1 to 33 %, and it is considered a multifactorial disorder, the effect of genes 
predominating over environmental factors (relative risk of 200). The higher susceptibility for 
HSCR in some families allowed establishing the locus 10q11. 2q21.2 as a genetic origin of the 
disease (Fewtrell et al., 1994.)  The RET proto-oncogen is located in this region and has been 
shown to be highly involved in neurocristopathies (Amiel & Lyonnet, 2001). The RET proto-
oncogen is a tyrosine-protein kinase receptor essential for the glial cell-derived neurotrophic 
factor  (GDNF) actions preventing neuroectodermal cell apoptosis (Mograbi et al., 2001). De 
Pontual et al., 2006, genotyped RET in 143 patients with two syndromic HSCR entities: 
congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by 
PHOX2B and ZFHX1B gene mutations, respectively, finding that there were both RET 
dependent and RET independent HSCR cases. Besides this, RET mutations have been found 
only in 50 % of familial and 15 % to 20 % sporadic HSCR cases (Attie et al., 1995). Therefore, 
notwithstanding the importance of the mutations in the RET gene, there are other genes 
involved in human HSRC: neurturin (NTN), endothelin B receptor (EDNRB), endothelin-3 
(EDN3), endothelin-converting enzyme (ECE1), as well as the SOX10 and SIP1 genes (Amiel 
& Lyonnet, 2001; Mollaaghababa & Pavan, 2003). 
Substance P -a neurotransmitter specific marker of neuronal differentiation- has been found 
downregulated in HSCR suggesting a role for peptidergic innervation in the pathogeny of 
this disease (Tam, 1986). The possible connection between the above mentioned genes, 
substance P and GDNF and the causal mechanism the alteration of neuronal migration in 
the NC morphogenesis is not yet clear, since a high proportion of genetic anomalies cannot 
be identified using a standard screening of genomic DNA. A multiple origin is likely 
including other types of molecular parameters. For example, elevated levels of maternal 
homocysteine have been established as a risk toxicity factor for congenital defects during 
embryonic development, particularly anomalies in the neural tube closure and 
neurocristopathies (Brauer & Tierney, 2004), whereas a prophylactic role has been observed 
for folic acid in both types of pathologies (Antony, 2007). 
5. Mowat-Wilson syndrome 
Mowat-Wilson syndrome (MWS, MIM 235730) is a condition that involves multiple 
congenital defects described by Mowat et al., 1998. They reported a series of six children 
presenting mental retardation, microcephaly, and short stature with a distinctive facial 
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phenotype accompanied by other variable types of congenital anomalies. Five of these 
patients also had HSCR and one presented an interstitial deletion of chromosome 2, del 
(2)(q21q23). These children strongly resembled the patient earlier reported by Lurie et al. 
1994, with HSCR and dysmorphic features also associated with del (2) (q22q23). They 
concluded that these children had a distinct syndrome for which HSCR was not a 
mandatory feature and that could be caused by a contiguous gene syndrome, or a single 
gene disorder, or disruption of a critical region within 2q22-23. In 2001, two independent 
teams (Cacheux et al., 2001; Wakamatsu et al., 2001) identified the cause of MWS as either a 
heterozygous deletion or truncation mutations in the Zinc finger E-box-binding homeobox 2 
gene, ZEB2, (MIM 605802, previously called ZFHX1B) which encodes a smad interacting 
protein 1 (SIP1) located in the above mention chromosome region 2q22-23. 
Since the first description by Mowat et al (1998), approximately 200 patients have been 
reported and over 100 mutations have been described (Dastot-Le Moal et al., 2007). The 
phenotype/genotype correlation for these mutations is very variable, not only for a given 
mutation (Cerruti-Mainardi et al., 2005; Zweier et al., 2003) but also within the same family 
(McGaughran et al., 2005). The syndrome has been identified in several ethnic groups 
(Dastot-Le Moal et al., 2007), with similar clinical features in all populations. The 
male/female ratio is approximately 1,42:1 (Adam et al., 2006; Horn et al., 2004). 
The prevalence of MWS is currently unknown, but it seems probable that the syndrome is 
under-diagnosed, particularly in patients without HSCR (Cerruti-Mainardi et al., 2005). For 
this reason the identification of the facial phenotype is of special relevance for the initial 
clinical diagnosis (Garavelli L & Cerruti-Mainardi, 2007). The clinical features of the face are: 
high forehead, frontal bossing, eyebrows are large, medially flaring and sparse in the middle 
part, hypertelorism with hollow but large eyes, big and uplifted ear lobes with a central 
depression, saddle nose, open mouth, with M-shaped upper lip, frequent smiling and 
occasional drooling (Fig. 1, a and b), and a prominent but narrow and triangular pointed 
chin that further elongates with age ( Fig. 2, a and b).  
At birth, patients show growth parameters with values within normal percentiles but they 
develop microcephaly and short stature progressively with age. The facial phenotype also 
evolves in older children. For example, the eyebrows become thicker, broad and 
horizontal, with an increased wide middle separation and medial sparseness. The nasal 
tip lengthens and becomes more depressed, the columella is more prominent, the nasal 
profile becomes convex, the face tends to elongate and the jaw is more pronounced. The 
uplifted ear lobes do not change significantly with time and are an excellent diagnostic 
clue (Mowat et al., 2003) (Fig. 3). 
The clinical manifestations of MWS in the about 200 cases described presenting with ZEB2 
mutations have been recently reviewed Garavelli and Cerruti-Mainardi, 2007. In brief, the 
distinct facial phenotype is present in 97% of the patients, at least moderate but usually 
severe mental retardation in all the cases, microcephaly is present in 81%, epilepsy in 73%, 
HSCR in 57%, constipation in 26%, and congenital heart disease (principally, patent ductus 
arteriosus, pulmonary stenosis, ventricular and atrial septal defects, pulmonary artery sling, 
Tetralogy of Fallot and aortic coarctation), in 52% of the cases; urogenital/renal anomalies 
were demonstrated in 51 % of the patients (of which 51% presented hypospadias, 36% 
cryptorchidism and 12.8 % several renal defects). Oropharyngeal and gastrointestinal 
malformations include pyloric stenosis, arched palate, among others. Musculoskeletal 
Neurocristopathies: Role of Glial Cells, 
Genetic Basis and Relevance of Brain Imaging for Diagnosis 
 
117 
anomalies occur in many patients and eye defects have also been demonstrated (4.1% of the 
published cases). Microcephaly is a common feature and is present in 81% of the published 
cases. Brain anomalies reported so far include hypoplasia or agenesis of corpus callosum, 
present in 43% of the published cases, cortical atrophy (Garavelli et al., 2003), pachygyria 
and cerebellar hypoplasia (Silengo et al., 2004), hippocampal formation hypoplasia 
(Kääriäinen et al., 2001) and frontotemporal hypoplasia with temporal dysplasia (Cacheux et 
al., 2001, Mowat et al., 2003). These findings may be under-represented because not all 
published cases employed brain imaging 
 
  
(a)                                                                                  (b) 
Fig. 1. Clinical facial features in MWS: a) In the neonate, excess nuchal skin and scarce fine 
hair can be observed together with high forehead, prominent frontal bone, large wide 
eyebrows, but thinning in the middle part, hypertelorism, strabismus, epicanthus, large 
hollow eyes that originate prominent cheek bones, wide nasal bridge and open mouth, with 
M-shaped upper lip b) Some years later: saddle nose, prominent rounded nasal tip. The 
large and uplifted ear lobes with a central depression do not change significantly with age. 
Regarding differential diagnosis, the facial phenotype of patients with MWS is very 
characteristic. However, due to the frequent presence of HSCR, epilepsy and mental 
retardation it may initially be mistaken as GOSHS, as we previously mentioned in section 
4. The patients with GOSHS share clinical features such as HSCR, epilepsy and mental 
retardation, but have different facial features (high nasal bridge, synophrys, long curled 
eyelashes, palpebral ptosis, and cleft palate). The differential diagnosis can be carried out 
on the basis of facial phenotype and confirmed by mutational analysis of the ZEB2 gene. 
This is important for genetic counseling, since GOSHS is autosomal recessive, whereas 
MWS is a sporadic condition. Since individuals with MWS often show an ataxic-like gait 
and a smiling, sociable personality, combined with absent speech, microcephaly and 
seizures, they can be given a presumptive diagnosis of Angelman syndrome (Williams et 
al., 2001).  
 







Fig. 2. Clinical facial features in MWS: 10 years old. Dysmorphic facial features: wide forehead, 
hypertelorism con antimongoloid palpebral fissure, large dense eyebrows, long eyelashes, 
low-set ears, prominent uplifted ear lobes, saddle nose, thin upper lip, the face becomes long 
and thin, with prognathism, and a long, pointed or "chisel-shaped" chin, smiley face. 
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Fig. 3. Clinical facial features in MWS. The ear lobes are very typical. They are large and 
uplifted with a central depression and have been described as being like "orecchiette pasta" 
or like "red blood corpuscles" in shape. They do not change significantly with time (with the 
exception of the central depression, which is less obvious in adults) and are an excellent 
diagnostic clue 
However, the distinct facial features of MWS, in addition to the other typical congenital 
anomalies, should allow distinguishing these two conditions. Differential diagnosis is also 
necessary for MWS patients presenting with hypospadias and mental retardation to avoid 
misdiagnosis as Smith-Lemli-Opitz syndrome, Opitz G/BBB syndrome or X-linked mental 
retardation-alpha thalassemia syndrome. Again, facial phenotype should be the clue for 
correct diagnosis. 
In this context, we have recently diagnosed a patient with MWS with the help of molecular 
genetics and neuroimaging (Carrascosa Romero et al., 2009), which we consider an 
interesting and illustrative case. This patient presented a typical facial phenotype and 
molecular genetics analysis showed a heterozygous deletion mutation in the ZEB2 gene 
never described before in the literature. Parents showed no genetic anomalies. Our MWS 
patient showed some previously described malformations such as patent ductus arteriosus, 
Tetralogy of Fallot, atrial septal defect (small ostium secundum) and presented with HSCR. 
Magnetic resonance imaging (MRI) of the brain (Fig. 4, a and b) revealed agenesis of corpus 
callosum and colpocephaly with an important elevation of the third ventricle, cortical 
dysgenesis showing pachygyria in the left perisylvian region and decreased mielinization at 
the biparietal level. The patient also showed severe mental retardation, happy and smiling 
behavior, developed epilepsy when two years of age and was not able to walk until 4 years 
old. The finding of CNS demyelinization, detected with neuroimaging, is of special interest. 
This decrease in oligodendroglia maybe meaningful in the context of neurocristopathies 
given the role of these cells in nervous system maturation, particularly in the regulation of 
ventral neuroectodermal progenitor cell fate (Jakovcevski et al., 2009; Pucharcós et al., 1999) 
 








Fig. 4. a and b. Magnetic resonance imaging (MRI) of our MWS patient brain. Image analysis 
revealed agenesis of corpus callosum and colpocephaly with an important elevation of the 
third ventricle, cortical dysgenesis showing pachygyria in the left perisylvian region and 
decreased mielinization at the biparietal level. 
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5.1 The ZEB2 gene: Expression and role in neurocristopathies 
As mentioned above, at least 100 mutations have been described for the ZEB2 gene (Dastot-
Le Moal et al., 2007) connected with MWS -including the mutation found for our patient 
(Carrascosa Romero et al., 2009)- which reveals the importance of this gene for the 
development of this disease. 
The ZEB2 gene is 70 Kb long consists of 10 exons and 9 introns and encodes SIP1 (Smad 
interacting protein 1). Although its mechanisms of action on morphogenesis and 
neurogenesis still remain to be clarified, its clinical implications suggest that ZEB2 is 
involved in the development of the cells from the NC (ENS, craniofacial mesoectoderm), 
CNS, and cardiac septation, as well as in the development of the median line (agenesis of 
corpus callosum, urogenital/renal anomalies, pyloric stenosis)(Zweier et al., 2002; Ishihara 
et al., 2004). 
Using mass spectrometry, Verstappen et al. 2008, found that ZEB2 associated with 
multiple subunits of the NURD complex, which plays a key role in transcriptional 
repression. Mi2-beta (CHD4; 603277) was identified as a specific cofactor for ZEB2-
mediated repression of E-cadherin (CDH1; 192090). The N-terminal 289 amino acids of 
ZEB2 were sufficient for interaction with NURD complex subunits. In vitro studies in 
Xenopus oocytes showed broad Zeb2 expression at the gastrula stage, with stronger 
expression in neural tissues and neural crest cells at the neurula stage, suggesting a role in 
neural development. Endogenous Mi2-beta expression broadly overlapped Zeb2 
expression, and antisense morpholino knockdown of Mi2-beta resulted in reduced Zeb2-
mediated repression of Bmp4 (112262) and decreased induction of neural marker Ncam 
(116930). Further studies showed that a mutant ZEB2 protein (605802.0014), differing in 
the first 24 amino acids from the wildtype protein and causing a mild form of Mowat-
Wilson syndrome (235730), was unable to interact with the NURD complex and showed 
decreased transcriptional repression of Bmp4. 
To investigate the breadth of clinical variation associated with mutations in ZFHX1B, 
Yamada et al. 2001, studied DNA samples from 6 patients with clinical features similar to 
those described for ZFHX1B deficiency, except that they did not have Hirschsprung disease. 
The results showed the R695X mutation (605802.0002) to be present in 3 cases, with 3 novel 
mutations being identified in the other 3 patients. All mutations occurred in 1 allele and 
were de novo events. The results demonstrated that ZFHX1B deficiency is an autosomal 
dominant complex developmental disorder and that individuals with functional null 
mutations present with mental retardation, delayed motor development, epilepsy, and a 
wide spectrum of clinically heterogeneous features suggestive of neurocristopathies at the 
cephalic, cardiac, and vagal levels. 
To clarify the molecular mechanisms underlying the clinical features of Hirschsprung 
disease-mental retardation syndrome, Van de Putte et al. 2003 generated mice that carried a 
Zfhx1b mutation comparable to those found in several human patients. They showed that 
Zfhx1b knockout mice did not develop postotic vagal neural crest cells, the precursors of the 
enteric nervous system that is affected in patients with Hirschsprung disease, and displayed 
a delamination arrest of cranial neural crest cells, which form the skeletomuscular elements 
of the vertebral head. This suggests that the gene product is essential for the development of 
vagal neural crest precursors and the migratory behavior of cranial neural crest in the 
mouse. Furthermore, they showed that the gene product was involved in the specification of 
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neuroepithelium. SIP1-knockout embryos died around embryonic day 9.5, with failed 
neural tube closure, lack of a sharp boundary between the neural plate and the rest of the 
ectoderm, and lack of the first branchial arch. It was found that conditional deletion of Zeb2 
in mouse neural crest precursors was lethal at embryonic stages. Mutant mice displayed 
craniofacial and gastrointestinal malformations similar to those of patients with Mowat-
Wilson syndrome. In addition, mutant mice had defects in the heart, melanoblasts, and 
sympathetic and parasympathetic anlagen (Van de Putte et al., 2007). 
A single layer of neuroepithelial cells lining the embryonic neural tube gives rise to the 
entire repertoire of neurons, astrocytes, and oligodendrocytes in the adult central nervous 
system. Seuntjens et al. 2009, found that conditional SIP1 deletion in young mouse neurons 
induced premature production of upper layer neurons at the expense of deep layers, 
precocious and increased generation of glial precursors, and elevated numbers of astrocytes 
at early postnatal stages. Microarray analysis showed that Ntf3 (162660) and Fgf9 (600921) 
were over- and prematurely expressed in mutant brains. In the absence of SIP1, there was 
also a premature peak of MAPK (176948) signalling in neural progenitor cells. It was 
concluded that SIP1 functions in the postmitotic compartment of the neocortex to control the 
expression of growth factor genes that feed back to progenitor cells to regulate production 
of the neurons and glial cells required for corticogenesis.  
6. Conclusion: Relevance of brain imaging and genetics in the diagnosis of 
neurocristopathies 
The association of HSCR (either isolated or within the context of a specific malformation 
syndrome) with neuronal migration anomalies is so strong (23.5%), that we recommend 
performing a full evaluation of HSCR patients including: a) specialized molecular genetic 
studies, b) a complete neurological exploration for all patients diagnosed with HSCR and c) 
neurologist-monitored brain imaging studies in search for cerebral dysgenesis. Conversely, 
when confronting cases of children presenting with mental retardation, dysmorphic features 
and severe constipation, anorectal manometry seems advisable to rule out HSCR. 
The development of neuroimaging techniques is now making possible the detailed 
identification of cerebral dysgenesis compatible with neuronal migration impairments that 
are at the root of a wide range of brain diseases including epilepsy and mental retardation. 
The application of neuroimaging techniques in combination with molecular genetics to 
patients diagnosed with neurocristopathies has an extraordinary potential to connect 
genotype to phenotype and discover possible brain malformations associated with the 
mutations causing these syndromes. 
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1. Introduction 
Radiosurgery is a therapeutic technique to deliver high dose radiation to the target. It 
induces radiobiological responses of lesions while minimizing radiation effect to the 
surrounding area. Gamma knife is one of the representative devices for stereotactic 
radiosurgery, which is exclusively designed for treatment of cerebral disorders. Gamma 
knife was developed as the first radiosurgical device in 1967. Professor Lars Leksell at the 
Karolinska Institute in Sweden developed a stereotactic frame for functional neurosurgery 
in early 1950s and combined the technique of frame fixation with focused irradiation. The 
primary role of gamma knife radiosurgery is to control small well-demarcated lesions such 
as metastatic brain tumors, meningiomas, schwannomas, and pituitary adenomas while 
preserving function of surrounding brain tissue. It has been used as a primary treatment or 
in combination with surgery, and some applications have been accepted as standard 
treatment. Treatment of cerebral arteriovenous malformations has also been drastically 
changed after emergence of this technology. Arteriovenous malformation in deep locations 
such as the basal ganglia, thalamus and the brainstem came to be safely treated by 
radiosurgery. Stereotactic radiosurgery is also employed in the control of functional 
disorders such as mesial temporal epilepsy and trigeminal neuralgia. As such, gamma knife 
has been widely accepted in clinical practice in the field of neurosurgery (Koga et al., 2010). 
On the other hand, the risk of radiation-induced adverse events is not negligible and puts 
limitations to this technology. Accurate target definition is one of the most important factors 
to reduce complications because it can reduce unwanted radiation to surrounding normal 
tissue. The target of radiosurgery is primarily visualized by radiological studies such as 
angiography, computed tomography and magnetic resonance imaging. Owing to this, the 
accuracy of treatment largely depends on neuroimaging technology. After introduction of 
gamma knife, technology of neuroimaging has also been drastically changed as an example 
of magnetic resonance imaging. Not only neuroimaging itself, but also software to utilize 
different kinds of imaging modalities for treatment planning of radiosurgery has been 
developed in the past decades. During almost a half century since treatment of gamma knife 
radiosurgery was applied for the first patient, technology of radiosurgery has progressed in 
line with the advances in neuroimaging technology. In this chapter, we discuss 
technological advances in neuroimaging and consider i) how these have driven more 
sophisticated radiosurgical treatments and ii) the impact on post radiosurgical outcomes. 
 




Fig. 1. Structure of gamma knife 
Treatment machinery of gamma knife (left). The helmet has approximately 200 portals 
(collimator, right) through which gamma rays from 60Co are emitted. Those finely 
narrowed beams of radiation meet at the focal point of gamma knife and give a high 
target dose. 
 
Diagnosis Number of Treatment 
Metastatic brain tumor 185,070 (36.8%) 
Glioma 26,437 (5.3%) 
Other malignant tumor 9,389 (1.9%) 
Meningioma 64,115 (12.8%) 
Vestibular schwannoma 46,835 (9.3%) 
Pituitary adenoma 38,553 (7.7%) 
Other benign tumor 26,816 (5.3%) 
Vascular lesion 65,084 (12.9%) 
Trigeminal neuralgia 32,798 (6.5%) 
Epilepsy 2,399 (0.5%) 
Other functional disorder 3,264 (0.6 %) 
Ocular lesion 1,966 (0.4%) 
Total 502,726 
Table 1. Number of gamma knife treatment in the world until 2008 
2. Integration of three-dimensional images into treatment planning 
Arteriovenous malformation has been treated by gamma knife radiosurgery since it was 
introduced at first. Emergence of gamma knife has improved treatment outcomes of cerebral 
arteriovenous malformations, especially deeply located lesions (Sasaki et al., 1998). The goal 
of radiosurgery for arteriovenous malformations is obliteration of nidus and prevention of 
devastating hemorrhage. Histopathological study of arteriovenous malformation after 
radiosurgery showed damage of endothelial cells, followed by thickening of the intimal 
layer caused by smooth-muscle cell proliferation, and finally obliteration of the lumen by 
cellular degeneration and hyalinization (Schneider et al., 1997). Minimum dose of 20 Gy to 
the nidus could completely obliterate nidus in approximately 90% in the dose response 
analysis for arteriovenous malformations (Flickinger et al., 2002). In our experience, the rates 
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of nidus obliteration confirmed by angiography were 72% at 3 years and 83% at 5 years 
(Shin et al., 2004). In early years of gamma knife treatment, treatment planning for 
arteriovenous malformation was made based only on angiogram. Because conventional 
angiogram was two-dimensional projection image, it was difficult to comprehend three-
dimensional structure of lesions only by angiogram especially when nidus was large or 
morphologically complicated. Computed tomography or magnetic resonance imaging could 
depict three-dimensional structure of nidus of arteriovenous malformation, although 
angiography could show more precise angioarchitecture. Therefore, use of computed 
tomography or magnetic resonance imaging jointly with angiography for treatment 
planning facilitated recognizing three-dimensional structure of nidus and reduced the 
morbidity associated with gamma knife radiosurgery (Shin et al., 2004). More recently, 
integration of three-dimensional rotational angiography into treatment planning of 
radiosurgery for arteriovenous malformation has been attempted (Conti et al., 2011). 
Because three-dimensional rotational angiography can provide both sufficient temporal and 
spatial resolution, three-dimensional angioarchitecture of nidus can be easily understood by 
using this technology, and reports of outcomes including obliteration rates and morbidity 
after treatment with integration of three-dimensional rotational angiography are awaited. 
 
 
Fig. 2. Treatment planning for arteriovenous malformation based on angiogram. Two-
dimensional isodose lines (black) were superimposed to the image. It was difficult to 
recognize three-dimensional angioarchitecture from angiogram only. 
 






Fig. 3. Treatment planning for a patient with right thalamic arteriovenous malformation. 
Isodose lines (yellow and green) were simultaneously superimposed to digital subtraction 
angiogram and magnetic resonance images. Coronal and sagittal images (right upper two 
images) were simultaneously visible in combination with dose distribution and made 
recognition of three-dimensional angioarchitecture easier. 
 





Fig. 4. Three-dimensional rotational angiography in treatment planning for arteriovenous 
malformation. Nidus and feeder from internal carotid artery (red) and basilar artery 
(orange) was visible in three-dimensional manner. Drainers (purple) were distinguished 
from nidus. Isodose line of treatment planning (white line) was superimposed to the image 
and sufficient coverage by treatment dose was visually confirmed. In this view tractography 
of the corticospinal tract (green) based on diffusion tensor magnetic resonance imaging was 
also integrated. 
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3. Integration of multimodal neuroimaging studies into treatment planning 
Since gamma knife was developed, several refinements on its hardware and software have 
been made. Collimator helmet was modified when the second generation gamma knife was 
developed and computer workstation was introduced thereafter. The introduction of 
GammaPlan (Elekta Instrument AB, Stockholm, Sweden), a software for treatment planning 
workstation, achieved accurate dose planning (Cheung et al., 2000). The third generation of 
gamma knife was equipped with automatic positioning system, which was machinery that 
automatically moved the patient’s head through a stereotactic frame during irradiation. This 
model enabled more conformal treatment in shorter time and reduced unwanted radiation 
exposure to patients compared with prior models (Horstmann &  Van Eck, 2002, Kuo et al., 
2004). Thus, the advances in gamma knife radiosurgery greatly depend on the refinement 
and the development of new devices and software (Kondziolka et al., 2002, Regis et al., 
2002). In view of neuroimaging, the significant modification of gamma knife was 
development of GammaPlan 4C (Elekta Instrument AB, Stockholm, Sweden), which has 
started to be utilized since 2004. This software enabled coregistration of multimodal 
neuroimages even taken without frame fixation (Koga et al., 2009). For example, when 
lesions and bony structures or the orbital fat were indistinguishable on magnetic resonance 
imaging for planning, coregistered computed tomography helped clearly contour tumor 
margin along the bony structures. 
 
 
Fig. 5. Treatment planning for a patient with recurrent skull base carcinoma. Computed 
tomography (middle) and positron emission tomography (lower) was integrated. 
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Positron emission tomography (PET) enabled access to metabolic information of lesions at 
the time of treatment planning for radiosurgery (Levivier et al., 2007, Levivier et al., 2000, 
Levivier et al., 2002). In our experience, we utilized [18F] fluorodeoxyglucose (FDG) PET in 
patients with malignant tumors to visualize the possibly active component among diffuse 
enhancement on magnetic resonance images. For example, in a case of recurrent 
glioblastoma multiforme, ambiguously enhanced lesion on magnetic resonance imaging 
was suggested to be highly malignant area, because the coregistered FDG-PET showed high 
uptake at the corresponding area, and this region was irradiated. As another example, 1-
11C-acetate PET was utilized for evaluation of extent of meningioma and response of lesions 




Fig. 6. Treatment planning for a patient with recurrent glioblastoma. An enhanced lesion in 
the right temporal lobe shown by magnetic resonance imaging (upper). Corresponding area 
was confirmed as high uptake region by FDG-PET (lower). This lesion was irradiated with 
margin dose of 20 Gy (yellow line). 
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4. Integration of structural and functional imaging into treatment planning 
Diffusion tensor tractography, one of the major recent advances in neuroimaging, enabled 
clear visualization of various fibers inside the white matter of the brain, which was not 
visualized by conventional imaging modalities (Masutani et al., 2003). Clinical application of 
diffusion tensor tractography were mainly reported as diagnostic tools, and the report on its 
therapeutic application was quite limited (Maruyama et al., 2005). Although the pointed 
limitation of tractography is its reliability claiming that there is no guarantee that fibers do 
not exist where the tracts is not drawn (Holodny et al., 2005, Yamada et al., 2009), 
intraoperative fiber stimulation analysis proved that tractography reflected functioning 
pyramidal tracts to some extent (Kamada et al., 2009). Integration of tractography into intra-
operative navigation was also developed at our institute (Kamada et al., 2005). However, it 
contains risks of inevitable brain shift caused by craniotomy or tumor removal, thus leads to 
poorer accuracy. On the other hand, such a shift does not occur in the setting of integration 
of tractography into radiosurgery. At our institute, integration of diffusion tensor 
tractography into radiosurgical treatment planning was started in 2004. While there were a 
variety of white matter fiber tracts, we considered that the pyramidal tract would be the 
most important tract in preventing morbidity of radiosurgery because its injury caused 
motor paresis and led to decline of activity of daily living. (Andrade-Souza et al., 2006, 
Hadjipanayis et al., 2001) At the same time, the pyramidal tract was practically the easiest 
one to draw from the technical point of view. (Yamada et al., 2009) The optic radiation and 
the arcuate fasciculus would be next important and was more difficult to draw. (Catani et 
al., 2005, Yamamoto et al., 2007) Injury of the optic radiation causes visual disturbance. 
Verbal function requires participation of a distributed neural system in the dominant 
hemisphere, and we integrated the arcuate fasciculus tractography in order to preserve this 
function. For the time being, we are introducing above three tracts, considering them as 
critical white matter structures to be preserved. By analyzing relationship between 
occurrence of radiation-induced neuropathy and the maximum dose received by each tract, 
tolerable doses of each white matter tract were estimated. The estimated tolerable dose for 
the corticospinal tract was approximately 20 Gy. The dose was 8 Gy for the optic radiation, 8 
Gy and 20 Gy for temporal and frontal fibers of the arcuate fasciculus, respectively 
(Maruyama et al., 2008, Maruyama et al., 2005, Maruyama et al., 2007). Among 144 patients 
with arteriovenous malformation who underwent radiosurgical procedure after integration 
of tractography was started, one patient experienced worsening of pre-existing dysesthesia, 
one patient exhibited mild transient hemiparesis, and the other two patients who were 
treated before integration of arcuate fasciculus tractography was started experienced 
transient speech disturbance during median follow-up of 23 months. Overall, the rate of 
radiation-induced neuropathy was 2.8%. Since the rates of radiation-induced neuropathy 
were generally reported as five to 20% (Andrade-Souza et al., 2005, Flickinger et al., 1999, 
Maruyama et al., 2005, Pollock et al., 2004, Sasaki et al., 1998), permanent and transient 
morbidity was suggested to be potentially reduced by integrating diffusion-tensor 
tractography into treatment planning of radiosurgery (Koga et al., 2011). Two major 
concerns regarding this new technique were i) whether integration of tractography 
significantly reduced morbidity and ii) whether alteration of dose planning using 
tractography compromised obliteration of arteriovenous malformation, which was regarded 
as cure of this disease. To unveil these issues, further follow-up and accumulation of data of 
patients who underwent tractography-integrated radiosurgery are awaited. 
 







Fig. 7. Treatment planning for a patient with ruptured arteriovenous malformation in the 
right basal ganglia. Magnetic resonance imaging for treatment planning and integrated 
diffusion-tensor tractography of the right corticospinal tract showed that the tract (orange) 
was passing through just behind the nidus of arteriovenous malformation. Therefore, dose 
distribution at around the posterior portion of the nidus modified so as the dose received by 
the right corticospinal tract not to exceed 20 Gy, which was considered as tolerable dose of 
the corticospinal tract. This patient presented mild left hemiparesis at the onset of cerebral 
hemorrhage. However, no further worsening of hemiparesis was observed until last follow-
up at 23 months after gamma knife treatment. 
 





Fig. 8. Treatment planning of gamma knife stereotactic radiosurgery for a patient with 
unruptured arteriovenous malformation in the right occipital lobe. Magnetic resonance 
imaging for treatment planning and integrated diffusion-tensor tractography of the right 
optic radiation showed that the tract (orange) was passing through just lateral to the nidus 
of arteriovenous malformation. Therefore, dose distribution around the nidus was modified 
and dose fall-off to the lateral side of nidus was adjusted to be steeper by blocking a part of 
beams from cobalt sources so as the dose received by the right optic radiation not to exceed 
8 Gy, the dose considered as tolerable dose of the optic radiation, while margin of the nidus 
was irradiated by 20 Gy. This patient presented with headache at the onset. The patient had 
presented no signs of left visual field defect during the clinical course until the last follow-
up at 16 months after radiosurgery. 
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Diffusion tensor tractography was used for CyberKnife stereotactic radiosurgery as well. 
The technique was utilized in treatment planning for several kinds of cerebral disorders 
such as arteriovenous malformation, hemangioma and metastatic brain tumor. They 
successfully reduced the dose received by the optic tract and the corticospinal tract by 
integrating diffusion tensor tractography of these fibers. They further utilized blood 
oxygenation level-dependent functional magnetic resonance imaging to visualize the 
primary motor cortex and reduced the dose delivered to the cortex (Pantelis et al., 2010). 
Outcomes of this type of treatment are awaited. 
As another example of functional imaging, magnetoencephalography was useful to detect 
firing neurons not only in the cortex, but also in the deeply located structures (Stefan et al., 
1990). Since very early stage of gamma knife radiosurgery, magnetoencephalography was 
used to visualize epileptic foci in treatment planning for focal epilepsy (Hellstrand et al., 
1993). Further, magnetoencephalography was as useful to detect functioning cortex as 
functional magnetic resonance imaging. Use of magnetoencephalography in combination 
with magnetic resonance imaging and cerebral angiography enabled understanding the 
relationship between angioarchitecture of arteriovenous malformation nidus and the 
adjacent sensorimotor cortex (Kamiryo et al., 2002). 
5. Role of neuroimaging in follow-up study after radiosurgery 
Accumulation of radiological knowledge is also important to appropriately follow-up 
patients after treatment. One of the most difficult issues regarding follow-up of patients 
with malignant tumors who underwent radiosurgery is differentiation of tumor recurrence 
and radiation effect including radiation necrosis. Tumor recurrence necessitates additional 
treatment including surgical resection. On the other hand, radiation necrosis usually 
responds to administration of steroid. Therefore, these two pathologies should be 
appropriately differentiated to be appropriately treated. An analysis of correlation between 
magnetic resonance imaging after radiosurgery and histopathological data revealed that a 
distinct lesion margin on T2-weigheted images as well as a contrast-enhanced margin on T1-
weighted images was highly correlated with tumor recurrence, and that the pathology was 
associated with a higher rate of necrosis when the lesion border on T2-weighted images did 
not correspond to the contrast-enhanced T1 lesion volume (Kano et al., 2010).  
Another example is the findings that predict the risk of hemorrhage from completely 
obliterated arteriovenous malformations treated by gamma knife radiosurgery. Although 
complete obliteration of the nidus can be considered as cure of arteriovenous malformation 
which was treated by radiosurgery, the risk of hemorrhage from obliterated nidus still 
slightly remains. The annual bleeding rate from completely obliterated arteriovenous 
malformation was 0.3% (Shin et al., 2005). A study of contrast-enhanced magnetic resonance 
imaging findings in angiographically obliterated arteriovenous malformation revealed that 
increment of the enhanced regions within 1 year of angiographic obliteration compared with 
the previous measurement was highly associated with hemorrhage after angiographical 
obliteration. They concluded that patients with this finding should be carefully followed-up 
by contrast-enhanced magnetic resonance imaging, while contrast-enhanced studies could 
be reduced for those without the increment of contrast-enhanced area in the first year after 
obliteration (Kunishima et al., 2010). 
 




As described above, radiosurgery using gamma knife was quite dependent on 
neuroimaging technology because the target of radiosurgery was solely defined by 
imaging studies. Introduction of basic three-dimensional imaging studies such as 
computed tomography and magnetic resonance imaging made recognition of three-
dimensional structure of the target on planning more feasible compared with the 
planning solely based on two-dimensional projection images such as angiography. In 
fact, analyses of patient outcomes after radiosurgery proved that the use of three-
dimensional imaging studies for treatment planning had reduced the morbidity 
associated with unwanted irradiation. Thus, more accurate target definition enabled by 
advances in imaging technology truly resulted in safer treatment even in this example of 
simple progress in the very early stage of brain radiosurgery. Technological advances in 
computed tomography and magnetic resonance imaging themselves achieved not only 
images of higher resolution but also imaging studies of completely different quality such 
as images of vessels and wide variety of sequences of magnetic resonance imaging. 
Further, metabolic imaging such as positron emission tomography became widely 
accepted in the field of neuroimaging as well. Technological progress of treatment 
planning software for gamma knife radiosurgery made it possible to utilize wide variety 
of neuroimaging studies for process of target definition in planning. By this way, 
technology of gamma knife radiosurgery could incorporate the fruit of development in 
neuroimaging and more sophisticated treatment planning based on concise target 
definition became feasibly available. Furthermore, development such as imaging of 
neural fibers which was “invisible” on ordinary imaging modalities and visualization of 
neural function was peculiar to the field of neuroimaging. Protecting neural function of 
the central nervous system is one of the most important goals of brain radiosurgery. 
Therefore, as most recent advance in imaging technology, these modalities of 
neuroimaging were indispensable for development of radiosurgery. Although 
introduction of neurostructural or functional imaging into treatment planning of brain 
radiosurgery just became realistic, several recent data suggested that modification of 
treatment planning to protect white matter visible on diffusion tensor magnetic 
resonance imaging and functioning cortex visualized in functional magnetic resonance 
imaging from excessive irradiation during stereotactic radiosurgery contributed to 
preservation of neural function associated with these structures. Since these kinds of new 
technology are quite recent progress, it is true that outcomes of patients who underwent 
radiosurgery using new technology must be carefully followed-up for long period after 
treatment. However, brain radiosurgery has been developed in this manner in line with 
recent drastic advances in neuroimaging technology, and technological progress in both 
radiosurgery and neuroimaging is still in continuation. Therefore, development of safer 
and more effective brain radiosurgery will be continued in the future as long as progress 
of neuroimaging technology is on its way. 
7. Acknowledgment 
We are grateful to Dr. Taichi Kin at the University of Tokyo for his help in making a three-
dimensional computer image of arteriovenous malformation and radiosurgical planning 
used in this chapter. 
 




Andrade-Souza, Y. M., Zadeh, G., Scora, D., Tsao, M. N. & Schwartz, M. L. (year 2005). 
Radiosurgery for basal ganglia, internal capsule, and thalamus arteriovenous 
malformation: clinical outcome, Neurosurgery 56(1): 56-64. 
Andrade-Souza, Y. M., Ramani, M., Scora, D., Tsao, M. N., TerBrugge, K. & Schwartz, M. L. 
(year 2006). Radiosurgical treatment for rolandic arteriovenous malformations, J 
Neurosurg 105(5): 689-697. 
Catani, M., Jones, D. K. & ffytche, D. H. (year 2005). Perisylvian language networks of the 
human brain, Ann Neurol 57(1): 8-16. 
Cheung, Y. C., Yu, K. N., Ho, R. T. & Yu, C. P. (year 2000). Stereotactic dose planning system 
used in Leksell Gamma Knife model-B: EGS4 Monte Carlo versus GafChromic 
films MD-55, Appl Radiat Isot 53(3): 427-430. 
Conti, A., Pontoriero, A., Farago, G., Midili, F., Siragusa, C., Granata, F., Pitrone, A., De 
Renzis, C., Longo, M. & Tomasello, F. (year 2011). Integration of Three-Dimensional 
Rotational Angiography in Radiosurgical Treatment Planning of Cerebral 
Arteriovenous Malformations, Int J Radiat Oncol Biol Phys. 
Flickinger, J. C., Kondziolka, D., Lunsford, L. D., Pollock, B. E., Yamamoto, M., Gorman, D. 
A., Schomberg, P. J., Sneed, P., Larson, D., Smith, V., McDermott, M. W., Miyawaki, 
L., Chilton, J., Morantz, R. A., Young, B., Jokura, H. & Liscak, R. (year 1999). A 
multi-institutional analysis of complication outcomes after arteriovenous 
malformation radiosurgery, Int J Radiat Oncol Biol Phys 44(1): 67-74. 
Flickinger, J. C., Kondziolka, D., Maitz, A. H. & Lunsford, L. D. (year 2002). An analysis of 
the dose-response for arteriovenous malformation radiosurgery and other factors 
affecting obliteration, Radiother Oncol 63(3): 347-354. 
Hadjipanayis, C. G., Levy, E. I., Niranjan, A., Firlik, A. D., Kondziolka, D., Flickinger, J. C. & 
Lunsford, L. D. (year 2001). Stereotactic radiosurgery for motor cortex region 
arteriovenous malformations, Neurosurgery 48(1): 70-76; discussion 76-77. 
Hellstrand, E., Abraham-Fuchs, K., Jernberg, B., Kihlstrom, L., Knutsson, E., Lindquist, C., 
Schneider, S. & Wirth, A. (year 1993). MEG localization of interictal epileptic focal 
activity and concomitant stereotactic radiosurgery. A non-invasive approach for 
patients with focal epilepsy, Physiol Meas 14(2): 131-136. 
Holodny, A. I., Watts, R., Korneinko, V. N., Pronin, I. N., Zhukovskiy, M. E., Gor, D. M. & 
Ulug, A. (year 2005). Diffusion tensor tractography of the motor white matter tracts 
in man: Current controversies and future directions, Ann N Y Acad Sci 1064: 88-97. 
Horstmann, G. A. & Van Eck, A. T. (year 2002). Gamma knife model C with the automatic 
positioning system and its impact on the treatment of vestibular schwannomas, J 
Neurosurg 97(5 Suppl): 450-455. 
Kamada, K., Todo, T., Masutani, Y., Aoki, S., Ino, K., Takano, T., Kirino, T., Kawahara, N. & 
Morita, A. (year 2005). Combined use of tractography-integrated functional 
neuronavigation and direct fiber stimulation, J Neurosurg 102(4): 664-672. 
Kamada, K., Todo, T., Ota, T., Ino, K., Masutani, Y., Aoki, S., Takeuchi, F., Kawai, K. & Saito, 
N. (year 2009). The motor-evoked potential threshold evaluated by tractography 
and electrical stimulation, J Neurosurg 111(4): 785-795. 
 
Neuroimaging – Clinical Applications 
 
142 
Kamiryo, T., Cappell, J., Kronberg, E., Woo, H. H., Jafar, J. J., Llinas, R. R. & Nelson, P. K. 
(year 2002). Interactive use of cerebral angiography and magnetoencephalography 
in arteriovenous malformations: technical note, Neurosurgery 50(4): 903-910; 
discussion 910-901. 
Kano, H., Kondziolka, D., Lobato-Polo, J., Zorro, O., Flickinger, J. C. & Lunsford, L. D. (year 
2010). T1/T2 matching to differentiate tumor growth from radiation effects after 
stereotactic radiosurgery, Neurosurgery 66(3): 486-491; discussion 491-482. 
Koga, T., Maruyama, K., Igaki, H., Tago, M. & Saito, N. (year 2009). The value of image 
coregistration during stereotactic radiosurgery, Acta Neurochir (Wien) 151(5): 465-
471; discussion 471. 
Koga, T., Shin, M. & Saito, N. (year 2010). Role of gamma knife radiosurgery in 
neurosurgery: past and future perspectives, Neurol Med Chir (Tokyo) 50(9): 737-748. 
Koga, T., Maruyama, K., Kamada, K., Ota, T., Shin, M., Itoh, D., Kunii, N., Ino, K., Terahara, 
A., Aoki, S., Masutani, Y. & Saito, N. (year 2011). Outcomes of Diffusion Tensor 
Tractography-Integrated Stereotactic Radiosurgery, Int J Radiat Oncol Biol Phys. 
Kondziolka, D., Maitz, A. H., Niranjan, A., Flickinger, J. C. & Lunsford, L. D. (year 2002). An 
evaluation of the Model C gamma knife with automatic patient positioning, 
Neurosurgery 50(2): 429-431; discussion 431-422. 
Kunishima, K., Shin, M., Kunimatsu, A., Aoki, S., Sasaki, H., Koga, T., Itoh, D., Mori, H., 
Abe, O., Ohtomo, K. & Saito, N. (year 2010). Contrast-enhanced magnetic resonance 
characteristics of arteriovenous malformations after gamma knife radiosurgery: 
predictors of post-angiographic obliteration hemorrhage, Neurosurgery 67(1): 100-
109; discussion 109. 
Kuo, J. S., Yu, C., Giannotta, S. L., Petrovich, Z. & Apuzzo, M. L. (year 2004). The Leksell 
gamma knife Model U versus Model C: a quantitative comparison of radiosurgical 
treatment parameters, Neurosurgery 55(1): 168-172; discussion 172-163. 
Levivier, M., Wikier, D., Goldman, S., David, P., Metens, T., Massager, N., Gerosa, M., 
Devriendt, D., Desmedt, F., Simon, S., Van Houtte, P. & Brotchi, J. (year 2000). 
Integration of the metabolic data of positron emission tomography in the dosimetry 
planning of radiosurgery with the gamma knife: early experience with brain 
tumors. Technical note, J Neurosurg 93 Suppl 3: 233-238. 
Levivier, M., Wikler, D., Jr., Massager, N., David, P., Devriendt, D., Lorenzoni, J., Pirotte, B., 
Desmedt, F., Simon, S., Jr., Goldman, S., Van Houtte, P. & Brotchi, J. (year 2002). 
The integration of metabolic imaging in stereotactic procedures including 
radiosurgery: a review, J Neurosurg 97(5 Suppl): 542-550. 
Levivier, M., Massager, N., Wikler, D., Devriendt, D. & Goldman, S. (year 2007). Integration 
of functional imaging in radiosurgery: the example of PET scan, Prog Neurol Surg 
20: 68-81. 
Liu, R. S., Chang, C. P., Guo, W. Y., Pan, D. H., Ho, D. M., Chang, C. W., Yang, B. H., Wu, L. 
C. & Yeh, S. H. (year 2010). 1-11C-acetate versus 18F-FDG PET in detection of 
meningioma and monitoring the effect of gamma-knife radiosurgery, J Nucl Med 
51(6): 883-891. 
 
Role of Neuroimaging in Brain Radiosurgery 
 
143 
Maruyama, K, Kawahara, N, Shin, M, Tago, M, Kishimoto, J , Kurita, H, Kawamoto, S, 
Morita, A & Kirino, T (year 2005). The risk of hemorrhage after radiosurgery for 
cerebral arteriovenous malformations, N Engl J Med 352(2): 146-153. 
Maruyama, K., Kamada, K., Shin, M., Itoh, D., Aoki, S., Masutani, Y., Tago, M. & Kirino, T. 
(year 2005). Integration of three-dimensional corticospinal tractography into 
treatment planning for gamma knife surgery, J Neurosurg 102(4): 673-677. 
Maruyama, K., Kamada, K., Shin, M., Itoh, D., Masutani, Y., Ino, K., Tago, M. & Saito, N. 
(year 2007). Optic radiation tractography integrated into simulated treatment 
planning for Gamma Knife surgery, J Neurosurg 107(4): 721-726. 
Maruyama, K., Kamada, K., Ota, T., Koga, T., Itoh, D., Ino, K., Aoki, S., Tago, M., Masutani, 
Y., Shin, M. & Saito, N. (year 2008). Tolerance of pyramidal tract to gamma knife 
radiosurgery based on diffusion-tensor tractography, Int J Radiat Oncol Biol Phys 
70(5): 1330-1335. 
Masutani, Y., Aoki, S., Abe, O., Hayashi, N. & Otomo, K. (year 2003). MR diffusion tensor 
imaging: recent advance and new techniques for diffusion tensor visualization, Eur 
J Radiol 46(1): 53-66. 
Pantelis, E., Papadakis, N., Verigos, K., Stathochristopoulou, I., Antypas, C., Lekas, L., 
Tzouras, A., Georgiou, E. & Salvaras, N. (year 2010). Integration of functional MRI 
and white matter tractography in stereotactic radiosurgery clinical practice, Int J 
Radiat Oncol Biol Phys 78(1): 257-267. 
Pollock, B. E., Gorman, D. A. & Brown, P. D. (year 2004). Radiosurgery for arteriovenous 
malformations of the basal ganglia, thalamus, and brainstem, J Neurosurg 100(2): 
210-214. 
Regis, J., Hayashi, M., Porcheron, D., Delsanti, C., Muracciole, X. & Peragut, J. C. (year 2002). 
Impact of the model C and Automatic Positioning System on gamma knife 
radiosurgery: an evaluation in vestibular schwannomas, J Neurosurg 97(5 Suppl): 
588-591. 
Sasaki, T., Kurita, H., Saito, I., Kawamoto, S., Nemoto, S., Terahara, A., Kirino, T. & 
Takakura, K. (year 1998). Arteriovenous malformations in the basal ganglia and 
thalamus: management and results in 101 cases, J Neurosurg 88(2): 285-292. 
Schneider, B. F., Eberhard, D. A. & Steiner, L. E. (year 1997). Histopathology of 
arteriovenous malformations after gamma knife radiosurgery, J Neurosurg 87(3): 
352-357. 
Shin, M., Maruyama, K., Kurita, H., Kawamoto, S., Tago, M., Terahara, A., Morita, A., Ueki, 
K., Takakura, K. & Kirino, T. (year 2004). Analysis of nidus obliteration rates after 
gamma knife surgery for arteriovenous malformations based on long-term follow-
up data: the University of Tokyo experience, J Neurosurg 101(1): 18-24. 
Shin, M., Kawahara, N., Maruyama, K., Tago, M., Ueki, K. & Kirino, T. (year 2005). Risk of 
hemorrhage from an arteriovenous malformation confirmed to have been obliterated 
on angiography after stereotactic radiosurgery, J Neurosurg 102(5): 842-846. 
Stefan, H., Schneider, S., Abraham-Fuchs, K., Bauer, J., Feistel, H., Pawlik, G., Neubauer, U., 
Rohrlein, G. & Huk, W. J. (year 1990). Magnetic source localization in focal 
epilepsy. Multichannel magnetoencephalography correlated with magnetic 
resonance brain imaging, Brain 113 ( Pt 5): 1347-1359. 
 
Neuroimaging – Clinical Applications 
 
144 
Yamada, K., Sakai, K., Akazawa, K., Yuen, S. & Nishimura, T. (year 2009). MR tractography: 
a review of its clinical applications, Magn Reson Med Sci 8(4): 165-174. 
Yamamoto, A., Miki, Y., Urayama, S., Fushimi, Y., Okada, T., Hanakawa, T., Fukuyama, H. 
& Togashi, K. (year 2007). Diffusion tensor fiber tractography of the optic radiation: 
analysis with 6-, 12-, 40-, and 81-directional motion-probing gradients, a 
preliminary study, AJNR Am J Neuroradiol 28(1): 92-96. 
7 
The Role of Magnetic Resonance 
Spectroscopy in the Diagnosis of  
Ring Enhancing Lesions 
Eftychia Kapsalaki1, Efstathios D. Gotsis4,  
Ioannis Tsougos2 and Konstantinos N. Fountas3 
1Department of Radiology,  
2Department of Medical Physics, 
3Department of Neurosurgery, 
University Hospital of Larisa, School of Medicine, University of Thessaly, Larissa,  
4Diagnostic Center Euromedica, Athens, 
Greece 
1. Introduction 
Ring-enhancing intracranial lesions constitute a common and quite puzzling diagnostic 
dilemma. These lesions may present as solitary or multiple on a routine brain MRI, and are 
characterized by a contrast enhancing halo and a non enhancing center. The central part 
may present with low signal intensity on T1, and high signal intensity on T2 weighted 
images. They are usually surrounded by a variable amount of edema. They may be located 
anywhere in the brain, although the junctional zone of gray-white matter is their most 
common location [Omuroet al., 2006; Smirniotopoulos et al., 2007]. Their size may vary from 
a few millimetres to several centimetres.   
The differential diagnosis of ring enhancing lesions is quite large. It may include neoplasms, 
infections, inflammatory processes, or vascular pathologies. The incidence of each 
pathological entity depends highly on the geographical region and the study population. It 
is well documented that infections and inflammatory processes are more common in 
developing countries, while neoplasms and demyelinating lesions are more frequent in 
developed countries. Clinical history is not always helpful in their differential diagnosis, 
since more than 50% of CNS infections may present without fever and no obvious inflicting 
incident. Moreover, other laboratory tests may not be able to help in their differential 
diagnosis. In addition, the presenting symptomatology and the clinical examination of these 
patients are non-specific and frequently overlapping, making thus the establishment of an 
accurate diagnosis quite difficult. 
Routine brain MR imaging is very sensitive in the identification of ring enhancing lesions 
but it cannot distinguish between neoplastic and non neoplastic lesions, in a large 
percentage of these cases. Frequently, the differentiation of a tumor from an infection is 
quite difficult, based solely on conventional MRI. Therefore, advanced MR imaging 
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techniques as Diffusion Weighted Imaging (DWI), Perfusion Weighted Imaging (PWI), and 
proton Magnetic Resonance Spectroscopy (1HMRS) have been employed in the differential 
diagnosis of these lesions, with variable success rates. These studies are employed in 
combination with conventional MRI as complimentary imaging tests, and may significantly 
increase its specificity. 
In this chapter, the role of 1HMRS in the differential diagnosis of ring enhancing lesions is 
going to be discussed. The basic principles of 1HMRS, as well as, the typical spectroscopic 
profiles of the most commonly encountered ring enhancing lesions, are also presented. 
Furthermore, the implementation of other MR advanced techniques as DWI and PWI 
along with 1HMRS in the evaluation of patients harbouring ring enhancing lesions, are 
analyzed.  
2. Basic principles of 1HMRS 
Proton MR Spectroscopy (1HMRS) is a noninvasive imaging technique that may contribute in 
the preoperative diagnosis of patients with MR ring enhancing lesions. 1HMRS depends on a 
change in the resonance frequency of the nuclei within the molecules, regarding their chemical 
bonds, which is based on the chemical shift theory. The resonance frequency difference 
(chemical shift) is expressed as parts per million or ppm, a value that is independent of the 
amplitude of the external magnetic field. The value of the chemical shift provides information 
about the molecular group carrying the hydrogen nuclei, and thus it provides differentiation 
among several metabolites. Water peak is located at 4,7 ppm, and is much greater than the 
obtained signal from other hydrogen containing compounds typically identified in the brain 
parenchyma. Therefore, water signal needs to be suppressed for identifying any other 
metabolites. The reference frequency used, set at zero ppm, is that of tetra-methyl silane 
molecule Si-(CH3)4, which is symmetrical and has a single proton resonance.  
In order to perform in vivo 1HMRS, a strong magnetic field of at least 1.5T is required. It is 
generally accepted that, the higher the magnetic field strength, the more metabolites can 
be identified. Specific sequences for spectroscopic signal acquisition are either Single 
Voxel Spectroscopy (SVS), which receives the spectrum from a single voxel only, or 
Chemical Shift Imaging (CSI), which measures spectra in projection, on a slice (2D CSI), or 
a volume (3D CSI).  
3. Normal brain metabolites  
Proton MRS obtains information about brain tissue metabolism, which cannot be performed 
by conventional MRI scans [Wilson et al., 2009]. The principal metabolites, which are most 
commonly identified and evaluated in brain 1HMRS, and their characteristic frequencies and 
concentrations, are summarised in table 1. 
At a first glance, a normal brain spectrum contains five to ten resonance peaks (figure 1). N-
Acetyl-Aspartate (NAA) is considered to be a unique neuronal marker, reflecting the number 
of intact neurons in the gray matter, and the density of intact axons in the white matter 
[Majos et al., 2004]. In general, reduction of NAA is produced by benign and malignant 
lesions in various proportions, and is indicative of normal neuronal tissue destruction. More 
specifically, NAA concentration decreases may occur with neuronal dysfunction caused by 
ischemia, trauma, inflammation, infection, tumor, neurodegenerative processes or reactive 
gliosis. Therefore, NAA is considered to be a highly sensitive but not specific marker. 
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Choline (Cho) constitutes an essential compound of cellular membranes, and is considered to 
be a sensitive marker of cellular membrane metabolism [Miller et al., 1996]. Hence, variation 
in choline represents a wide range of abnormalities reflecting cell membrane destruction. 
Characteristically, tumors, inflammatory processes, demyelinating processes, and hypoxia 
show increased concentrations of Cho. Contrariwise, the concentration of Cho is decreased 
in cerebral abscesses.  
 
Metabolite  




N-Acetyl-Aspartate(NAA) 2.02 ppm /  7.9-16.6 mmol/kg Neuronal cell marker.  
Choline (Cho) 3.2 ppm /  0.9-2.5 mmol/kg 
Marker of cell membrane 
metabolism. 
Creatine / Phosphocreatine 
(Cr) 
3.0 ppm /  
5.1-10.6 mmol/kg 
Compounds related to energy 
metabolism. 
Alanine(Ala) 1.5 ppm /  0.2-1.4 mmol/kg 
Is characteristic of meningeal 
tumors 
Lipids (Lip) 0.9, 1.4 ppm /  >1.0 mmol/kg Membrane breakdown product. 
Lactate (Lac) 1.33 ppm /  0.4 mmol/kg 




3.6 ppm /  









Acetate 1.9 ppm Characteristic in abscess 
Succinate / Pyruvate 2.4 ppm Characteristic in abscess 
Table 1. Summary of the principal metabolites that are most commonly evaluated in 
Magnetic Resonance Spectroscopy (MRS) 
Total Creatine (Cr) is a composite peak from the methyl and methylene protons of Cr and 
phosphorylated creatine, (PCr). The concentration of total creatine was thought to be 
relatively constant in the brain. However, with the development of quantitative MRS 
analysis techniques, it has been demonstrated that the concentration of total Cr is not 
constant. It has been shown that Cr concentrations may vary among different brain regions 
and among various pathological entities, thus, the usage of Cr as a reference signal should 
be applied with extreme caution [Howe et al., 2003]. The concentration of Cr is reduced in 
tumors and hypoxia, while Cr is totally absent in cerebral abscesses.  
Lipids are normally absent from a normal brain MR spectrum, and their appearance 
represents necrosis. Increased concentrations of lipids may be observed in high grade 
primary and metastatic tumors, but also in abscesses and all necrotic lesions [Gotsis et al., 
1996]. 
 




Fig. 1. Typical normal brain MR Spectrum showing the concentrations of Myoinositol (mI), 
Choline (Cho), Creatines (Cr), N-Acetyl-Aspartate (NAA),lipids (lip)and lactate (Lac) 
Lactate signal appears in the same region of proton MR spectrum as lipids, therefore, it may 
be difficult to be distinguished. Lactate represents a product of anaerobic glycolysis [Barker 
et al., 1994; Negendank et al., 1996]. Its concentration is increased in ischemia, but also in 
high grade gliomas, as well as in pyogenic abscesses. 
MyoInositol is a rather complex sugar alcohol, which gives rise to four groups of resonances. 
Its exact function is not completely known, although it has been proposed as a glial marker 
[Kallenberg et al., 2009]. Its concentration is reduced in high grade gliomas, but is also 
identified in meningiomas and demyelinating lesions.  
Alanine peak appears near, and is often overlapped, by the lipids peak. It represents a 
discriminating metabolite of tumors of meningeal origin [Shino et al., 1999], but it is also 
identified in pyogenic anaerobic abscesses and cysticercosis [Kapsalaki et al., 2008]. 
Aminoacids (acetate and succinate) are not identified in a normal brain spectrum. Their 
presence is characteristic of brain abscesses.  
In a routine clinical spectroscopic study, analysis of the obtained spectrum consists of 
measurement of the absolute concentrations of the identified metabolites, and calculation of 
the concentration ratios of the abovementioned metabolites. The most commonly used ratios 
include NAA/Cr, Cho/Cr, and NAA/Cho. Analysis of the accumulated data provides a 
characteristic metabolic profile, assigned to specific pathological entities. 
4. Technical limitations of 1HMRS   
The clinical use of proton MR spectroscopy presents several technical limitations and pitfalls 
[Castillo et al., 1996; Fountas et al., 2000; Preul et al., 1996; Rand et al., 1999; Shukla-Dave et 
al., 2001]. Proton MRS lasts approximately 15 min and requires the patient's cooperation for 
avoiding motion artifacts.  In single voxel MRS, the obtained region of interest should be 
appropriately placed at the center of the studied lesion, to avoid signal contamination from 
the surrounding tissues [Kimura et al., 2001]. It has been reported that even the slightest 
malpositioning of the voxel may result in up to 50% signal contamination of the obtained 
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spectrum, which may result in misinterpretation of the obtained spectroscopic study and 
subsequent imaging misdiagnosis. Moreover, calcifications, necrotic areas, and adjacent 
bony structures should be meticulously excluded from the obtained spectrum. Despite the 
recent advances in commercially available MRS software packages, the method remains 
operator dependent, and its accuracy is associated with the experience of the performing 
spectroscopist and the involved neuroradiologist. 
5. Characteristic MR Spectroscopic profiles of the most common ring 
enhancing lesions 
5.1 High grade astrocytomas  
Proton MRS provides information regarding the metabolic profile of a glioma indicating the 
concentrations of various metabolites in the lesion. The commonly identified spectrum of a 
high grade glioma in proton MRS presents reduced concentration of NAA, because of 
destruction of normal neurons, markedly elevated concentrations of Cho due to 
exponentially increasing cellular populations and increased cell membrane turnover, and 
decreased Cr due to a major shift in the utilized cellular metabolic pathways. In regard to 
the commonly calculated metabolic ratios, the higher the Cho/NAA ratio is, the higher the 
astrocytoma grade. Therefore, 1HMRS may suggest the area of highest malignancy within a 
non-homogenous glioma and accurately guide an open or stereotactic surgical biopsy. Lac 
appears infrequently in all grades of astrocytomas. Lipids are detected in high quantity in 
necrotic gliomas, in the area of the necrosis (figure 2). 
 
     
      (a)                                                                                    (b) 
Fig. 2. a: Proton MR Spectrum of a high grade tumor. DD includes glioblastoma and 
metastatic lesion. 2b: The presence of increased concentration of Cho in the surrounding 
brain edema is suggestive of an infiltrative lesion, as a glioma versus a metastatic lesion. 
It is well known that gliomas are highly infiltrating brain tumors, and their borders are 
typically ill-defined and cannot be accurately identified during their surgical removal 
[Croteau et al., 2001; Fountas et al., 2004; Mikkelsen & Edvardsen, 1995]. Performing MRS in 
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the surrounding edema may facilitate the identification of the glioma borders, and detect the 
presence and the extent of infiltration of a glioma. The identification of increased Cho and 
decreased NAA in the surrounding edema is indicative of infiltration, and is not 
characteristic of other ring enhancing lesions.  
5.2 Metastatic lesions  
The spectra of a ring enhancing metastasic tumor characteristically present very high 
concentrations of lipids, which are most probably associated with the presence of necrotic 
areas. Choline levels may also be elevated due to increased cell membrane destruction and 
turnover. However, the spectra of high grade gliomas and metastatic ring enhancing lesions 
are not easily distinguished [Burtscher et al., 2000; Opstad et al., 2004]. In such cases, spectra 
from the surrounding edema may provide additional important information. If normal 
concentrations of Cho and NAA are measured in a ring-enhancing lesion, this is more likely 
to be a metastatic lesion. Moreover, in metastatic lesions there is almost no Cr peak 
identified, which is not the case in high grade gliomas. (figure 3) 
 
  
        (a)                                                                                    (b) 
Fig. 3. a: The obtained spectrum demonstrates a very high peak representing severely 
increased concentration of lipids, which compresses all other metabolites, and suggests a 
highly necrotic lesion. Differential diagnosis between metastasis and glioma in this case is 
not possible. 3b: A normal spectrum of the surrounding brain edema suggests that the lesion 
is more compatible with a metastatic rather than an infiltrative tumor (glioma).  
5.3 Recurrent astrocytomas versus post-radiation necrosis  
Tumor recurrence and radiation-induced necrosis have similar MRI characteristics, and their 
distinction is usually difficult based solely on conventional MRI. Positron Emission 
Tomography (PET) has been suggested for differentiating between tumor recurrence and 
post-radiation necrosis [Kim et al., 2010; Tsuyuguchi et al., 2003] However, PET is a quite 
expensive imaging modality, with very limited distribution in clinical centers. Nevertheless, 
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1HMRS has a significant role in their differentiation, considering that in a recurrent glioma 
the presence of Cho with increased concentration is identified, and the Cho/Cr and 
Cho/NAA ratios are significantly increased, with absolute values higher than 1.76 
[Weybright et al., 2005; Schlemmer et al., 2002]. On the contrary, in cases of post-radiation 
necrosis, there is a marked reduction in the concentrations of all normally detected 
metabolites, along with a marked increase of lipids concentration. A study by Tarnawski and 
coworkers [Tarnawski et al., 2002] indicates that 1H-MRS has a clear prognostic value for 
predicting survival in gliomas, and provides a clear diagnosis of recurrence following 
radiation therapy. In the presence of inflammation, increased levels of Cho may be detected. In 
such cases, differentiation between radiation necrosis and tumor recurrence with 1HMRS alone 
is almost impossible. Other imaging modalities need to be combined, as perfusion MRI. 
5.4 Abscesses  
Cerebral abscesses contain no normal neurons and no membranous structures in their 
necrotic lesional center (Fountas et al., 2000; Lai et al., 2005). Therefore, no peaks of NAA, 
Cr, or Cho should be detected. A typical abscess spectrum shows the presence of cytosolic 
amino acids (leucine, isoleucine, and valine) [Garg et al, 2004; Kadota et al., 2001; Lai et al., 
2002; Remy et al.,1995; Tsui et al., 2002], which are the products of proteolysis caused by 
enzymes released from neutrophil cells. Because these metabolites have never been detected 
in neoplasms, their detection is strongly indicative of a cerebral abscess [Kapsalaki et al., 
2008]. Lactate is also detected in a large number of cerebral abscesses (figure 4).  
Proton MR spectroscopy may also contribute in the identification of the causative organism 
of an abscess [Lai et al. 2002]. Anaerobic microbial agents are characterized by the presence of 
lactate, cytosolic amino acids, alanine, acetate, succinate, and lipids. Aerobes and facultative 
anaerobes are characterized by the presence of lactate, cytosolic amino acids, and the 
occasional presence of lipids. Streptococcal abscesses are characterized by the presence of 
lactate, while Staphylococcal infections are associated with the presence of lipids and lactate 
 
 
Fig. 4. Characteristic MR spectrum of an abscess. Note the absence of Cho, Cr, and NAA and 
also the increased concentrations of various aminoacids (acetate, alanine, lactate).   
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[Himmelreich et al., 2005]. It is apparent that identification of the etiologic factor of an 
abscess contributes significantly in its prompt and timely treatment. Moreover, 1HMRS may 
contribute in the evaluation of the evolution and treatment response of a cerebral abscess. 
Sequential spectroscopic analysis of a brain abscesses may detect changes in the 
concentrations of the initially detected metabolites, providing thus a non-invasive 
methodology for evaluating the evolution of  a cerebral abscess, and also its response to the 
administered antibiotic treatment. 
5.5 Subacute infarct  
Markedly elevated lactate is the key spectroscopic feature of cerebral hypoxia and ischemia, 
because of a major metabolic shift to anaerobic glycolysis. Choline is also elevated, with 
variable concentrations, while NAA and Cr concentrations are reduced. If cerebral infarction 
ensues, concentration of lipids will also increase. Furthermore, additional MR based 
advanced imaging modalities, such as Diffusion and Perfusion Weighted Imaging, may 
significantly contribute in the differential diagnosis in these cases [Parsons et al., 2000]  
5.6 Demyelination 
Proton MRS is a very useful tool in evaluating solitary tumefactive multiple sclerosis (MS) 
lesions. In acute MS lesions inflammation is the initial pathological change, while in more 
chronic lesions demyelination occurs. Proton MRS may be a quite sensitive imaging 
modality for evaluating axonal damage. At the initial presentation of MS, a typical spectrum 
shows decreased concentration of NAA, increased Choline and myo-inositol (MI) 
concentrations, and elevated concentration of Lactate, due to inflammation. With 
progression of an MS plaque, 1HMRS shows normalization of MI and Lac levels, while Cho 
and NAA may remain unchanged. Thus, an MS spectrum may not be always diagnostic of a 
demyelinating lesion (figure 5). Taking into account the increased concentration of lactate at  
 
  
         (a)                                                                                  (b) 
Fig. 5. (a) Characteristic proton MR spectrum of an acute MS plaque. Note the presence of 
slightly increased Cho, decreased concentration of NAA, and slightly increased 
concentration of Lactate (b) Spectrum obtained from a cerebellar demyelinating lesion. This 
spectrum is not suggestive of demyelination and may be erroneously diagnosed as a 
spectrum suggestive of a low grade glioma.   
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the initial phase, this finding may contribute to the establishment of an accurate diagnosis. 
However, it has to be emphasized that in cases that a demyelinating process is suspected, 
completion of the diagnostic investigation with other imaging and laboratory studies is 
often necessary [De Stefano & Filippi, 2007; Rovira & Leon, 2008; Takenaka et al., 2011]. 
6. Contribution of Diffusion Weighted Imaging (DWI) and Perfusion Weighted 
Imaging (PWI) in the distinction of ring enhancing lesions 
6.1 Diffusion Weighted Imaging 
Diffusion-weighted imaging (DWI) is an MRI technique, which is based on the Brownian 
motion of molecules. Diffusion-weighted imaging detects the tracing of the microscopic 
motion of water molecules, thus reflecting the microstructure of local tissue. Free motion of 
water molecules in all directions is called isotropic diffusion, while motion of water 
molecules in a specific direction, like a myelinated axon, is called anisotropic diffusion. The 
diffusion data can be presented as signal intensity, or as an image map of the apparent 
diffusion coefficient (ADC). Calculation of the ADC requires two or more acquisitions with 
different diffusion weightings. Increased signal intensity on DWI corresponds to restricted 
diffusion and low ADC, while low signal intensity on diffusion-weighted images 
corresponds to normal diffusion and a high ADC.  
DWI is a method detecting the diffusion properties of water molecules, and is restricted in 
subacute ischemia, brain abscesses, and lymhomas. It is usually not restricted in cystic 
lesions. Application of DWI has been extensively described in the literature [Bükte et al., 
2005; Chang et al., 2002]. Cystic lesions and necrotic brain tumors, primary or metastatic, 
that have a “cystic” central area, show normal diffusion, since the cystic area is caused by 
liquefaction (necrosis) of the tumor, that permits free motion of the molecules. However, 
several studies report the presence of restricted diffusion in necrotic brain gliomas, making 
the use of other imaging modalities mandatory [Chang et al., 2002;  Holtas et al., 2000; Lai et 
al., 2007]. On the contrary, in brain abscesses the cystic part reflects the presence of 
inflammatory cells, debris and possibly bacteria, that restrict the free motion of the 
molecules, and thus cause restricted diffusion, which appears with increased signal 
intensity. However, diffusion may also be restricted in several cases of malignant brain 
tumors, in acute demyelinating lesions, and in acute encephalitis. In such cases, the 
employment of 1HMRS, along with DWI may contribute in the differentiation of these 
lesions.  
6.2 Perfusion Weighted Imaging  
Perfusion Weighted Imaging (PWI), is the dynamic contrast imaging of the passage of 
intravenously injected paramagnetic contrast agent. Perfusion Weighted Imaging requires 
the acquisition of fast T2* images. After bolus intravenous contrast administration, the T2* 
images show drop of signal intensity, and as time passes, data are obtained in the form of  
cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT). A 
time-intensity curve is generated for each voxel in each MR slice. The time-to-peak (TTP) is 
the time from the start of the scan until the maximum contrast attenuation occurs. The mean 
transit time (MTT) is the time it takes the contrast bolus to pass from the arterial to the 
venous side of the cerebral circulation. The entire area under the curve is a measure of 
relative cerebral blood volume (rCBV). Moreover, a measure of relative cerebral blood flow 
(rCBF) is calculated by dividing the rCBV by the MTT. 
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Perfusion Weighted Imaging is important in the diagnosis of brain tumors and the 
differentiation of recurrent gliomas from post-radiation necrosis. Malignant high grade 
gliomas demonstrate neovascularization that is detected by PWI, showing a correlation 
between microvessel density and histological tumor grade. The higher the tumor grade is, 
the higher the rCBV will be (Sugahara et al., 1998; Provenzale et al., 2006). Perfusion 
weighted imaging is of particular importance in the distinction of post-radiation necrosis 
from glioma recurrence. Especially, when PWI is employed in association with 1HMRS, the 
sensitivity and specificity of both methods increase significantly. When PWI shows a low 
Cerebral Blood Volume through the area of contrast enhancement, this usually suggests 
post-radiation necrosis, while high rCBV along with increased levels of Cho, and markedly 
increased Cho/Cr, Cho/NAA ratios are more suggestive of glioma recurrence. It has to be 
pointed out, however, that despite all these recent imaging advances, differentiation of post-
radiation necrosis from glioma recurrence may not be possible, and the employment of PET 
scan may be required in these cases.  
7. Conclusions 
The presence of ring enhancing lesions on brain MRI studies constitutes a frequent and quite 
challenging diagnostic dilemma. The differential diagnosis of lesions presenting as ring 
enhancing is quite extensive, and varies significantly with patient’s age and the 
geographical region. Unfortunately, clinical history and symptomatology along with 
conventional MRI cannot accurately differentiate and establish a diagnosis of these lesions. 
Proton MRS may contribute in their differential diagnosis and may enhance, alone or in 
combination with other advanced MR Imaging modalities, the specificity and the diagnostic 
accuracy of conventional MRI. Proton MRS is a non invasive MR based diagnostic modality, 
which provides a direct spectroscopic signature of the examined brain parenchymal area 
and its underlying pathology, and an indirect evaluation of the lesion’s metabolism. 
Detection of certain brain metabolites and calculation of their absolute and relative 
concentrations, are utilized in spectroscopic analysis. N-acetyl-aspartate,  Cho, Cr, Lac, 
Lipids, MI, cytosolic aminoacids, and metabolic ratios of NAA/Cho, NAA/Cr, and Cho/Cr 
are the most commonly calculated metabolites. Changes in their concentrations may 
contribute in the differential diagnosis of ring enhancing lesions, since specific spectroscopic 
profiles exist for most of these lesions. High grade gliomas, metastatic tumors, abscesses, 
evolving infarcts, and demyelinating lesions demonstrate a specific and characteristic 
spectrum. In addition, employment of DWI and PWI, may further increase the diagnostic 
accuracy of 1HMRS and conventional MRI in all these cases. Differentiation of post-radiation 
necrosis from tumor recurrence remains puzzling, despite all these advanced MR modalities 
and may require the employment of other imaging methodologies, such as PET. It has to be 
emphasized that 1HMRS carries significant technical limitations, and requires an 
experienced spectroscopist and neuroradiologist in order to avoid misinterpretation of the 
obtained data, and subsequently misdiagnosis of the studied lesion.  
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1. Introduction 
It is generally accepted that tumor extirpation constitutes the treatment goal in cases of 
intracranial tumors. It is also well known that intracranial gliomas are infiltrative lesions 
with ill-defined borders, and their total resection is often quite challenging. Moreover, the 
presence of a glioma in an eloquent cortical area may make its extirpation even more 
difficult. It has been demonstrated that extensive glioma resection is associated with 
prolonged survival and better quality of life, and the overall outcome of patients with 
intracranial gliomas is associated with the extent of the tumor’s surgical resection [Lacroix et 
al., 2001; McDonald et al., 1999; National Comprehensive Cancer Network, 2007; Sanai & 
Berger, 2008; Stafford et al., 1998). Therefore, every effort to achieve maximal tumor 
resection without jeopardizing vital neuronal functions becomes of paramount importance 
in cases of intracranial gliomas. Exact knowledge of the cortical topography, accurate 
identification of all eloquent cortical areas as well as delineation of their relationships with 
the tumor, constitute key elements in avoiding all functional cortical areas, while aggressive 
tumor resection is accomplished.   
It is well known that conventional imaging studies providing pure structural anatomical 
information are not sufficient for identifying and localizing functional cortical areas, since 
there are frequent anatomical variations, and cortical functional center shift due to brain 
distortion and plasticity, particularly in glioma cases. Various methodologies have been 
developed for identifying different functional areas of the cerebral cortex and accurately 
localize them, in regard to the studied tumor on each individual case. Intraoperative 
electrophysiological studies such as recording of Somato-Sensory Evoked Potentials (SSEPs), 
Motor Evoked Potentials (MEPs), Direct Cortical Stimulation (DCS), and spontaneous 
Electro-Myo-Graphy (sEMG) are considered the gold standard for cortical mapping and 
delineation of functional cortical networks. The major drawback of these methodologies 
however, is the fact that all are invasive tests and cannot provide all this valuable 
information preoperatively. Thus, the development of non-invasive tests for cortical 
mapping seems to be mandatory. Recently, advanced imaging and electrophysiological 
studies such as Positron Emission Tomography (PET), brain SPECT imaging, functional 
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Magnetic Resonance Imaging (fMRI), Magneto-Encephalo-Graphy (MEG) and Magnetic 
Source Imaging (MSI), as well as high-density Electro-Encephalo-Graphy (hdEEG), have 
been employed, with various success rates, in cerebral cortical mapping. The wide clinical 
application of MRI, the high spatial resolution of fMRI compared with all other functional 
methods, its non-invasive character, and its low cost compared with all other methods, have 
made fMRI the most popular methodology for cortical functional mapping. Functional MRI 
can provide the neurosurgeon with critical information for a safe and aggressive surgical 
planning, thus, allowing maximal tumor resection and minimizing the possibility of a new 
postoperative neurological deficit.  
2. Functional magnetic resonance imaging: Advantages and drawbacks  
Since its introduction, during the 1990s, functional Magnetic Resonance Imaging has proven 
to be a powerful technique for the non-invasive imaging of various brain functional centers, 
such as motor, sensory, language, vision, odor and others. Functional MRI can 
constructively help towards a safe pre-operative or radiation treatment planning for various 
pathologies. In neurosurgical practice, fMRI is used in order to assess suitability of patients 
for resection of tumors and/or resective epilepsy surgery. In neurosurgery, the aim is to 
maximize the removal of pathological tissue with the minimum post-operative functional 
deficit. Therefore, the pre-operative knowledge of the proximity of the pathological tissue to 
the eloquent cortex is of fundamental importance for accurate and safe neurosurgical 
planning. Functional MRI provides information regarding anatomical variations, as well as 
tumor related shift of functional cortical centers.  
Functional MRI is based on a physiological phenomenon called the Blood-Oxygenation-
Level-Dependent (BOLD) contrast. BOLD is strongly coupled, to neuronal activity and 
cerebral hemodynamics [Roy & Sherrington, 1890]. The BOLD signal expresses small 
changes in the volume of the oxygenated blood in a specific brain volume during increased 
neuronal activity. When an examinee is subjected to a stimulus, there is an increased 
neuronal activity of the corresponding cluster of neurons responsible for this particular 
function. This is translated into a regionally increased metabolic demand. In order for this 
demand to be met, the supply of oxygenated blood locally increases, via dilation of the 
surrounding capillaries. The regional cerebral blood flow (CBF) and volume (CBV) increase 
with a surplus of oxygen (2%-6%). This produces an increased ratio of oxygenated versus 
de-oxygenated blood in the local system of capillaries and veins, in regard to the adjacent 
idle neurons. Oxygenated blood contains oxy-hemoglobin, a diamagnetic material, while 
deoxygenated blood contains de-oxyhemoglobin, a paramagnetic material. Microscopically, 
this decreased paramagnetism causes less signal loss on T2* weighted images [Ogawa et al., 
1990]. Therefore, a relative signal increase is generated during the active neuron period, 
with respect to the passive neurons’ period. The pulse sequence that is used in order to 
image the BOLD effect is the Gradient-Echo Echo-Planar-Imaging (GE-EPI), which is T2* 
weighted, i.e. sensitive to magnetic susceptibility effects [Stehling et al., 1991]. Thus, the 
BOLD fMRI response to a neuronal activity is a hemodynamic response function, which is 
the change in BOLD fMRI signal due to a short period of neural activity. Hemodynamic 
Response Factor reflects variations in vascular physiology generated by a neuronal activity.  
The major advantage of fMRI is its non-invasive character, especially when compared to the 
electrophysiological cortical stimulation studies. In addition, it has a relatively low cost, is 
reproducible, has a short examination time compared to the electro-cortical stimulation 
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studies, and is well tolerated by the vast majority of patients [Giussani et al., 2010 G]. 
Moreover, fMRI may be performed in pediatric patients, which is not the case for 
intraoperative cortical stimulation studies during an awake craniotomy.  Functional MRI 
can test multiple language tasks, and check larger cortical areas for auxiliary language 
networks [Giussani et al., 2010]. Comparing fMRI with other non-invasive techniques, such 
as Magneto-Encephalo-Graphy (MEG) and high-density Electro-Encephalo-Graphy (EEG), 
fMRI has the advantage of studying both cortical and intrasulcal areas, as well as deep brain 
areas. It has been demonstrated that fMRI has higher spatial resolution than MEG/MSI, 
PET, SPECT, and hdEEG, and comparable temporal resolution to the MEG/MSI. 
Furthermore, fMRI does not require intravascular injection of contrast media or 
radioisotopes.  
Several drawbacks of fMRI may however limit its clinical applications. Most importantly, 
only cooperative patients may undergo an fMRI study, since motion artifacts secondary to 
head movements, respiratory movements, and cardiac pulsation may influence the quality 
of the obtained study. Moreover, the patient’s ability to understand the functional paradigm 
and promptly perform the necessary tasks, are essential in obtaining a high quality fMRI. It 
has to be emphasized that fMRI constitutes an indirect measurement of neuronal activity, 
and it indicates where this indirect measurement takes place, without however describing 
the exact underlying mechanism. Besides, fMRI does not exhibit the neuronal networks, 
which interconnect the various functional clusters of neurons that collaborate for the 
performance of a particular function. Furthermore, there are other aspects that require 
attention in interpreting fMRI findings, such as the HRF and the BOLD signal. The HRF is 
a function: i) of the studied brain area, its regional blood volume and blood flow, ii) of the 
patient, and iii) of the employed stimulus. Similarly, the BOLD signal may be influenced 
by: i) hypoxia, ii) hypercapnia, iii) presence of cerebral vascular pathologies, iv) lack of 
sleep, v) anemia, vi) smoking, vii) various brain degenerative pathologies, viii) proximity 
of large veins to the activated neuronal clusters (vein effect), and ix) previous brain 
anatomical injuries.  
Since fMRI is based on magnetic susceptibility, hemorrhage within a brain tumor may alter 
the accuracy of the BOLD effect and misplace the location of the detected signal.  Particular 
attention should be taken in such cases and further preoperative, possibly invasive studies, 
need to be performed. In high grade gliomas, the presence of neovascularization, the 
induction of neuro-chemical changes in the cytosol and the subsequent alteration of the 
regional cerebral blood flow and the oxygen extraction fraction, the presence of arterio-
venous shunting, and the presence of tumor-associated edema and mass effect causing 
mechanical vasoconstriction, as well as the presence of scar tissue secondary to a previous 
craniotomy may result into significant BOLD signal changes [Atlas et al., 1996; Giussani et 
al., 2010; Haberg et al., 2004;  Krishnan et al., 2004 ]. It has been demonstrated, that in 10-31% 
of the performed fMRI studies the obtained data cannot be processed, and this percentage in 
glioma populations ranges between 0-30% [Haberg et al., 2004]. Moreover, gliomas are 
usually surrounded by edema and cause mass effect. During the fMRI study the activation 
area is located in the brain tissue that may be displaced by the lesion. At the time of the 
craniectomy, decompression of the brain occurs and alteration of the measured distances 
between the activation area and the brain tumor may take place. Therefore, we need to refer 
to the anatomical structures, especially the sulci, rather that the actual distance between the 
brain tumor and the activation area, when evaluating an fMRI study.   
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2.1 Neurosurgical considerations and clinical experience 
It is widely accepted that surgical resection of intracranial gliomas is the treatment method 
of choice. Glioma resection reduces the tumor’s mass effect on the surrounding brain, 
reduces the tumor-associated edema, ensures the establishment of an accurate histological 
diagnosis, and induces residual tumor cells into active mitotic process thus making them 
more vulnerable to the adjuvant administered radiotherapy and chemotherapy. It has been 
demonstrated that extensive resection of gliomas is associated with prolonged survival and 
better quality of life [Lacroix et al., 2001; McDonald et al., 1999; National Comprehensive 
Cancer Network, 2007; Sanai & Berger, 2008; Stafford et al., 1998]. Accurate knowledge of 
the anatomical relationship of a glioma with neighboring eloquent cortical areas is of 
paramount importance for maximizing tumor resection, minimizing the chance of 
postoperative neurological deficit, and thus maximizing the patient’s safety. Functional MRI 
has been employed for more than 15 years in the preoperative evaluation of patients 
harboring intracranial gliomas for identifying, accurately localizing, and intraoperatively 
avoiding functional cortical centers [Atlas et al., 1996; Berntsen et al., 2010; Bizzi et al., 2008; 
Fandino et al., 1999; Fitzgerald  et al., 1997; Giussani  et al., 2010; Haberg et al., 2004; Hirsch 
et al., 2000; Hoenig et al., 2005; Krasnow et al., 2003; Krishnan et al., 2004; Lehericy et al., 
2000; Li et al, 2010; Lurito et al., 2000; Mueller et al., 1996; National Comprehensive Cancer 
Network, 2007; Petrovich et al., 2005; Pouratian et al., 2002; Puce et al., 1995; Roux et al., 
Ruge et al., 1999; 2003; Rutten et al., 2002; Sanai & Berger, 2008; Schulder et al., 1998;  
Signorelli et al., 2003; Tieleman et al., 2007; Tomczak et al., 2000; Yetkin et al., 1997; Yousry et 
al., 1995] (Figures 1 & 2). Several clinical studies have been performed comparing fMRI with 
intraoperative electrophysiological stimulation studies, with varying results, and frequently 
contradictory conclusions [Atlas et al., 1996; Berntsen et al., 2010; Bizzi et al., 2008; Fandino 
et al., 1999; Fitzgerald  et al., 1997; Giussani  et al., 2010; Haberg et al., 2004; Hirsch et al., 
2000; Hoenig et al., 2005; Krasnow et al., 2003; Krishnan et al., 2004; Lehericy et al., 2000; Li 
et al, 2010; Lurito et al., 2000; Mueller et al., 1996; National Comprehensive Cancer Network, 
2007; Petrovich et al., 2005; Pouratian et al., 2002; Puce et al., 1995; Roux et al., 2003; Ruge et 
al., 1999; Rutten et al., 2002; Sanai & Berger, 2008; Schulder et al., 1998;  Signorelli et al., 2003; 
Tieleman et al., 2007; Tomczak et al., 2000; Yetkin et al., 1997; Yousry et al., 1995]. 
Unfortunately, the utilized methodologies vary significantly among these studies, their 
populations are frequently limited and non-homogenous, and a large number of them are 
retrospective studies. Therefore, their results are not comparable, in the vast majority of 
cases. However, a systematic review of the existent clinical studies show that fMRI 
constitutes a routine clinical practice in many neuro-oncology centers around the world, 
which provides the opportunity to the performing  neurosurgeon for a more realistic and 
accurate preoperative discussion with the patient, a wiser decision-making process, a safer 
surgical planning, and a more aggressive tumor resection [Atlas et al., 1996; Berntsen et al., 
2010; Bizzi et al., 2008; Fandino et al., 1999; Fitzgerald  et al., 1997; Giussani  et al., 2010; 
Haberg et al., 2004; Hirsch et al., 2000; Hoenig et al., 2005; Krasnow et al., 2003; Krishnan et 
al., 2004; Lehericy et al., 2000; Li et al, 2010; Lurito et al., 2000; Mueller et al., 1996; National 
Comprehensive Cancer Network, 2007; Petrovich et al., 2005; Pouratian et al., 2002; Puce et 
al., 1995; Ruge et al., 1999; Roux et al., 2003; Rutten et al., 2002; Sanai & Berger, 2008; 
Schulder et al., 1998;  Signorelli et al., 2003; Tieleman et al., 2007; Tomczak et al., 2000; Yetkin 
et al., 1997; Yousry et al., 1995]. Several studies also emphasize that fMRI can localize more 
accurately motor and sensory cortical areas than language areas, and therefore they indicate 
the necessity for employing complimentary intraoperative electrophysiological stimulation 
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studies, in cases of tumor proximity to language-associated cortical areas [Berntsen et al., 
2010;  Giussani et al., 2010;  Hirsch et al., 2000; Roux et al., 2003; Ruge et al., 1999]. 
 
 
Fig. 1. Preoperative fMRI demonstrating the displacement of the motor cortex and its 




Fig. 2. Preoperative fMRI demonstrating activated hand motor cortex and its relationship to 
a loe grade glioma during a left fist clentcing paradigm. 
In one of the earliest published prospective, clinical studies comparing preoperative fMRI 
and DCS for identifying cortical motor areas, Yousry et al. [Yousry et al., 1995] reported a 
series of six patients with gliomas. All participants underwent preoperative fMRI at 1.5T for 
localizing the motor cortex [Yousry et al., 1995]. A repetitive opening-closing of the hand 
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paradigm was used for the fMRI, while DCS was intraoperatively employed for 
identification and localization of the motor strip [Yousry et al., 1995]. They found that the 
fMRI accuracy in localizing the motor cortex was 100% when error margin was confined to 
10mm [Yousry et al., 1995]. Likewise, Puce et al. [Puce et al., 1995] in a series of four tumor 
cases, found in their prospective study good agreement between preoperative fMRI and 
intraoperative DCS/SSEP, regarding localization of the sensori-motor cortex. Their fMRI 
protocol included sponge squeezing as a motor task, and electrical stimulation of the 
median nerve, palm light brushing, and palm air blowing as sensory tasks [Puce et al., 1995]. 
Mueller et al. [Mueller et al., 1996] reported 10 patients with intracranial tumors and 2 
patients with intracranial vascular lesions undergoing preoperative fMRI at 1.5T for sensori-
motor cortex localization, and intraoperative DCS. Their fMRI protocol included index-
thumb tapping as a motor task, and palm light scratching as a sensory task [Mueller et al., 
1996]. They found that fMRI accuracy was 100% in their retrospective study [Mueller et al., 
1996]. They also reported that they had no postoperative motor deficits, when their resection 
distance was more than 5 mm from the fMRI identified motor cortex [Mueller et al., 1996]. 
At approximately the same time, Schulder et al. [Schulder et al., 1998] reported a series of 12 
patients with various intracranial tumors undergoing preoperative fMRI at 1.5T and 
intraoperative DCS/SSEP studies, for sensori-motor cortex localization. They reported that 
fMRI accuracy in their prospective study was 100%, while they concluded that maximal 
tumor resection and no new postoperative neurological deficits were observed in their series 
[Schulder et al., 1998]. Contrariwise, Atlas et al. [Atlas et al, 1996] reported a series of seven 
patients with gliomas, undergoing preoperative fMRI at 1.5T. Their fMRI protocol included 
single- or multi-stage active finger tapping as motor tasks [Atlas et al, 1996]. They reported 
that in 28.5% of their cases fMRI failed to identify the motor cortex, while they postulated 
that glioblastomas and high-grade gliomas may alter the obtained BOLD signal [Atlas et al, 
1996]. Fandino et al. [Fandino et al., 1999] reported similar findings from a series of 11 
patients with central area tumors, undergoing preoperative fMRI at 1.5T and intraoperative 
DCS for motor cortex localization. They considered that there was concordance between 
their fMRI and DCS findings when there was a discrepancy of less than 20 mm [Fandino et 
al., 1999]. They found that fMRI accuracy in their series was 82% [Fandino et al., 1999]. 
In a more recent study, Lehericy et al. [Lehericy et al., 2000] reported their results from a 
retrospective study of 26 patients with intracranial tumors, undergoing preoperative fMRI 
at 1.5T and intraoperative DCS for motor cortex localization. Their fMRI protocol included 
active flexion/extension of fingers/toes, and lip contraction as motor tasks [Lehericy et al., 
2000]. They found 92% agreement between fMRI and DCS results, while fMRI accuracy was 
100% when error margin was 15 mm [Lehericy et al., 2000]. Similarly, Hirsch et al. [Hirsch et 
al, 2000] reported their results from a large prospective study of 125 patients with various 
intracranial pathologies, and of 63 healthy volunteers. All their participants underwent 
fMRI at 1.5T unit for sensori-motor, language, and visual cortex localization [Hirsch et al, 
2000]. Their fMRI protocol included active finger tapping as a motor task, passive tactile 
hand stimulation as a sensory task, and picture naming by silent speech and object or name 
listening as language tasks [Hirsch et al, 2000]. They were able to localize with  fMRI the 
central sulcus in 100% of their healthy volunteers and in 98.4% of their patients [Hirsch et al, 
2000]. They were also able to localize by fMRI the Wernicke’s and Broca’s areas in 91% and 
77%, respectively, in their patients, while the respective percentages were 100% and 93% for 
their volunteers [Hirsch et al, 2000]. The primary visual cortex was identified by fMRI in 
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100% of their tested cases [Hirsch et al, 2000]. Haberg et al. [Haberg et al., 2004] reported a 
series of 21 patients with gliomas, undergoing preoperative fMRI at 1.5T for localizing 
sensori-motor and language associated cortical areas. Their fMRI protocol included active 
thumb-index opposition, active toe flexion, and active tongue movement as motor tasks, and 
thinking of a short action-verb and silent construction of a short noun as language 
paradigms [Haberg et al., 2004]. They reported that 80% of their patients were able to 
successfully finish their fMRI studies, while in 20% of their cases fMRI was unsuccessful due 
to EPI signal voids, secondary to previous craniotomy, head motion artifacts, and patient’s 
inability to perform the task. They found that 73% of their patients had no postoperative 
neurological deficits, while 27% had a new permanent postoperative deficit [Haberg et al., 
2004]. It has to be emphasized however, that 43.3% of these patients developing new 
deficits, knew that before the operation, from the obtained fMRI [Haberg et al., 2004]. 
Similarly, Krishnan et al. [Krishnan et al., 2004] reported their results from a prospective 
study including 54 patients with various intracranial tumors. All their patients underwent 
preoperative fMRI at 1.5T and intraoperative DCS/SSEP studies for localization of motor 
cortex [Krishnan et al., 2004]. They examined their total resection rates and the observed 
morbidity in association with the distance of the resection margin from the fMRI defined 
motor cortex [Krishnan et al., 2004]. They found that when this distance was > 15 mm their 
resection rate was 85.7%, while 53% of their patients remained neurologically unchanged 
postoperatively and 47% were improved [Krishnan et al., 2004]. When this distance was 
between 10-15 mm, total resection was achieved in 86.6% of their patients, 13.3% developed 
new postoperative neurological deficits, 60% remained unchanged, while 37.3% were 
improved [Krishnan et al., 2004]. When the distance was between 5-10 mm, total resection 
was observed in 83.3%, while 50% remained neurologically stable, and the remaining 50% 
were postoperatively improved [Krishnan et al., 2004]. Finally, when this distance was 
between 0-5 mm, total resection was accomplished in 85%, neurological worsening occurred 
in 35%, 50% remained stable, while 15% were improved [Krishnan et al., 2004]. They 
pointed out that the obtained BOLD signal may be varying with the utilized functional 
paradigm, and they concluded that fMRI is a valuable tool in surgical planning [Krishnan et 
al., 2004]. 
Li et al. [Li et al, 2010] in a recent study reported their experience from five patients with 
gliomas, undergoing preoperative fMRI at 3T and intraoperative DCS for motor cortex 
localization. They found that the accuracy of fMRI was 100% in their series, and postulated 
that 3T field provides an increased BOLD signal [Li et al, 2010] . Berntsen et al. [Berntsen et 
al., 2010] reported their results from a prospective study including 51 patients with 
various intracranial lesions (33 patients with gliomas), undergoing preoperative fMRI for 
sensori-motor cortex localization. Interestingly, 3.9% of their patients did not undergo 
surgery because of the preoperative MRI and fMRI findings. They reported that 13% of 
their patients could not finish their fMRI study, either due to reduced cooperation or 
excessive head motion artifacts [Berntsen et al., 2010]. They reported that in 42% of their 
cases more than 95% of the tumor was resected, while their mean residual tumor was 11% 
(range: 0-94%) [Berntsen et al., 2010]. They also found, that 88% of their patients had 
stable postoperative neurological status, while 12% experienced some worsening 
[Berntsen et al., 2010]. The lesion to eloquent area distance was related to the amount of 
tumor residual, and this relationship was statistically significant in their series [Berntsen 
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et al., 2010]. They postulated that fMRI accuracy depends highly on the skills of the 
obtained data analyst [Berntsen et al., 2010]. 
Several clinical studies with significantly varying results have been published in regard to 
the language-associated cortical areas identification and localization by employing fMRI 
[Bizzi et al., 2008; Fandino et al., 1999; Fitzgerald et al., 1997; Giussani et al., 2010; Lurito et 
al., 2000; Mueller et al., 1996; Pouratian et al., 2002;  Roux et al., 2003;  Ruge et al., 1999; 
Rutten et al., 2002; Signorelli et al., 2003; Tomczak et al., 2000; Yetkin et al., 1997]. Mueller et 
al. [Mueller et al., 1996] reported their results from a series of 12 patients (10 tumor and 2 
vascular cases) undergoing fMRI and intraoperative language mapping for language-
associated cortical areas localization. Their fMRI protocol included audible and silent word 
generation paradigms [Mueller et al., 1996]. They reported that their fMRI findings were 
concordant to their intraoperative findings in 100% of their cases [Mueller et al., 1996]. 
Similarly, Yetkin et al. [Yetkin et al., 1997] reported a series of 28 patients (but only five 
tumor cases), undergoing preoperative fMRI at 1.5T for language mapping and 
intraoperative DCS. Their fMRI protocol included silent word generation and number 
counting tasks, while their DCS protocol included text recitation and number counting 
[Yetkin et al., 1997]. They found that the fMRI accuracy in localizing language centers was 
100% when the error margin was 20 mm, and 86% when the error margin was 10 mm 
[Yetkin et al., 1997]. Likewise, Ruge et al. [Ruge et al., 1999] reported their results from a 
series of 21 patients with various intracranial tumors undergoing preoperative fMRI at 1.5T 
for language mapping and intraoperative DCS. Their fMRI protocol included object naming 
and word listening, while their DCS paradigms were object naming and number counting 
[Ruge et al., 1999]. They found concordance between the fMRI and DCS findings in 100% of 
their cases [Ruge et al., 1999]. Fitzgerald et al. [Fitzgerald et al., 1997] reported their findings 
from a series of 11 patients (but only 8 tumor cases), undergoing preoperative fMRI at 1.5T 
and intraoperative DCS for language mapping. Their fMRI tasks were word reading, verb 
generation, text listening, and word listening, while their DCS paradigms included object 
naming and number counting [Fitzgerald et al., 1997]. They reported 81% sensitivity and 
53% specificity for fMRI when the margin error was 10 mm, while the respective 
percentages were 92% and 0% when the margin error was 20 mm [Fitzgerald et al., 1997]. 
Similarly, Signorelli et al. [Signorelli et al., 2003] reported two glioma cases undergoing 
fMRI at 1.5T and reported excellent fMRI accuracy and high reproducibility. 
Contrariwise, Lurito et al. [Lurito et al., 2000] reported three glioma cases undergoing 
preoperative fMRI at 1.5T and intraoperative DCS for language mapping. They employed 
object naming and number counting tasks for both fMRI and DCS [Lurito et al., 2000]. They 
reported good but imperfect correlation between fMRI and DCS findings [Lurito et al., 
2000]. Likewise, Tomczak et al. [Tomczak et al., 2000] reported a large series of 41 tumor 
cases (34 gliomas), undergoing preoperative fMRI at 1.5T and intraoperative DCS for 
language mapping. Their fMRI paradigm was a semantic test for word relations, while their 
DCS protocol included speech comprehension, word production, object naming, and text 
reading [Tomczak et al., 2000]. They reported agreement between their fMRI and DCS 
findings in only 33.3% of their cases [Tomczak et al., 2000]. 
Pouratian et al. [Pouratian et al., 2002] in a more recent study of 10 patients (none of them 
with glioma) undergoing preoperative fMRI at 3T and intraoperative DCS for language 
mapping, found that fMRI was more accurate in localizing language-associated areas in the 
frontal lobe than the temporal and parietal lobes. The observed fMRI sensitivity and 
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specificity were 100% and 66.7%, respectively for the frontal lobe, while the respective 
percentages for the temporal and parietal lobes were 96.2% and 69.8% [Pouratian et al., 
2002]. Their fMRI protocol included object naming, word generation, auditory 
responsiveness, visual responsiveness, and sentence comprehension, while their DCS 
protocol included only object naming [Pouratian et al., 2002]. Roux et al. [Roux et al., 2003] 
reported their results from a series of 14 tumor patients (11 gliomas, 3 meningiomas) 
undergoing preoperative fMRI at 1.5T and intraoperative DCS for language mapping. Their 
fMRI and DCS protocol included object naming and verb generation paradigms [Pouratian 
et al., 2002]. They reported 59% sensitivity and 97% specificity for fMRI, and they concluded 
that fMRI cannot be used alone for surgical planning, in critically-located tumors in the 
language cortical areas [Pouratian et al., 2002]. 
Rutten et al. [Rutten et al., 2002] reported their findings from a series of 13 epilepsy patients 
undergoing preoperative fMRI and intraoperative DCS for language mapping. Their fMRI 
protocol included object naming and verb generation paradigms, while their DCS protocol 
included only object naming [Rutten et al., 2002]. They reported 100% sensitivity and 61% 
specificity for fMRI in their study [Rutten et al., 2002]. Likewise, Bizzi et al. [Bizzi et al., 
2008] reported a large series of tumor cases (28 gliomas, 2 metastatic tumors, and 1 
meningioma) undergoing preoperative fMRI at 1.5T and intraoperative DCS for language 
mapping. Their fMRI and DCS protocol included solely a verb generation paradigm [Bizzi et 
al., 2008]. They found that fMRI had 80% sensitivity and 78% specificity in their series [Bizzi 
et al., 2008]. 
2.2 Future directions of preoperative fMRI in gliomas 
Further development of fMRI techniques may strengthen its role in the preoperative 
evaluation of patients with gliomas. The wide clinical application of higher magnetic fields 
may increase fMRI’s quality. It has been demonstrated that higher magnetic fields change 
the relaxation rate R2 and thus provide better BOLD signal and more accurate fMRI studies 
[Hoenig et al., 2005; Krasnow et al., 2003; Tieleman et al., 2007] Higher strength magnets 
allow fMRI studies to be performed in shorter times, and provide the opportunity for almost 
real time imaging of cortical activation during stimulation [Scarabino et al., 2007].  The 
development of advanced software packages, allowing further decrease of susceptibility 
artifacts, may well improve the quality and the accuracy of fMRI [Li  et al., 2010]. 
Moreover, the development of more concrete paradigms and protocols may further 
improve fMRI’s accuracy and reproducibility. It has been shown that loud speech tasks 
provide more accurate fMRI data than silent speech tasks [Petrovich et al., 2005]. 
Therefore, the development of multi-stage, loud language tasks examining several aspects 
of language may further increase fMRI’s accuracy. The implementation of other advanced 
MR imaging techniques such as Diffusion Tensor Imaging and intraoperative fMRI and 
DTI may allow better identification and localization not only of the cortical language-
associated centers but also their interconnecting networks, and thus may make glioma 
resection safer [Nimsky, 2011]. 
The development of paradigms and protocols for testing higher cognitive functions such as 
memory, emotion, affect, and other high-cognitive functions may further increase the 
applicability of fMRI in the preoperative evaluation of patients with gliomas. These 
potential fMRI developments along with the technological evolution of the frameless neuro-
navigational systems may allow more aggressive and safer resection of gliomas of eloquent 
cerebral cortex.  
 




Functional MRI constitutes a non-invasive imaging modality that lends itself to the 
identification and localization of eloquent cortical areas and cerebral functional mapping. Its 
ability to depict neuronal activity is based on the Blood-Oxygenation-Level-Dependent 
(BOLD) phenomenon, which is correlated with the relative concentrations of oxy- and 
deoxy-hemoglobin in an activated cerebral region. It represents thus, an indirect evaluating 
tool of neuronal activity. The acquisition of Gradient Echo-Echo Planar Imaging (GE-EPI) 
T2* sequences is required for fMRI studies. Strength of at least 1.5T is required for obtaining 
an adequate resolution fMRI, while several studies postulate that higher magnetic field MR 
units may provide better quality and more accurate fMRI studies. Functional MRI is 
characterized by higher spatial resolution than PET, hdEEG, MEG/MSI, or SPECT 
functional studies, while its temporal resolution is comparable, if not better, to that of all 
other functional imaging methodologies. Moreover, MR units are easily accessible, and 
definitely more widely distributed than any of the other methodologies.  
Identification and localization of motor, sensory, and language-associated cortical, but also 
deep-sited areas can be performed with fMRI. Various performance tasks and protocols 
have been proposed and utilized in clinical practice, with variable success rates. It can be 
postulated that active thumb-index opposition, active hand squeezing, and active finger 
tapping are the most commonly employed motor tasks. Palm light brushing, palm air-puff 
blowing, and median nerve electrical irritation are the most commonly applicable sensory 
tasks. Object naming, word generation, and number counting are the most popular speech 
tests, although a wide variability occurs in language tests, and several issues (silent vs. loud 
language testing) remain still controversial. It has to be emphasized that the selection of the 
appropriate performance tasks (especially for language) frequently needs to be 
individualized. Another issue that requires attention is the application of the same language 
tests during fMRI and intraoperative DCS, when both studies are performed, for 
standardizing the comparison of these methodologies.  
The role of preoperative fMRI in the management of patients with intracranial gliomas is of 
paramount importance. Functional MRI allows the preoperative localization of sensori-
motor and language associated areas, and their relationships with the studied tumor. This 
information enables the neurosurgeon to discuss with the patient the possibility of total 
tumor resection, the chance of postoperative neurological deficits, and the calculation of the 
benefit to risk ratio. Furthermore, it provides the opportunity for a safer surgical planning, 
and potentially for a more aggressive tumor resection. Functional MRI allows cortical 
mapping even in cases that DCS during awake-craniotomy is impossible, as in pediatric or 
psychologically unstable patients. The vast majority of the published clinical studies 
demonstrate that the accuracy of fMRI in localizing sensori-motor cortex is extremely high, 
while that of language-associated cortical areas is lower. There are several studies 
postulating that fMRI language-associated cortical areas may be inaccurate, particularly in 
cases of temporal or parietal localization of speech areas. Additionally, the presence of scar 
tissue due to a previous craniotomy, the presence of neovascularization in cases of high 
grade gliomas, the presence of tumor-induced cellular chemical changes, and the proximity 
of large veins to the tumor, may confound the accuracy of fMRI.  
The development of novel, high-reproducibility, high-resolution software fMRI packages, 
along with the application of higher magnetic field strength may further increase fMRI’s 
accuracy, and minimize the confounding effect of various glioma-associated parameters. 
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The preoperative evaluation with fMRI of higher cognitive functions may allow even safer 
glioma surgical resection in the near future. 
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1. Introduction 
Epilepsy is one of the most common neurologic disorders, and affects about 50 million 
people around the world. It is a heterogeneous condition characterized by recurrent 
spontaneous epileptic seizures. There are no age, sex or race discriminations, although 
incidence of the first epileptic seizure has a bimodal distribution, with peaks in childhood 
and after 60 years of age (Engel & Pedley, 2008). 
According to their localization, epilepsies and epileptic seizures should be classified as focal 
(or partial) and generalized. Partial seizures begin in a restricted portion of cerebral cortex. 
Partial seizures are associated with a restricted area of the of the cerebral cortex and are 
clasified as either simple or complex, depending on the level of conscious awareness. Simple 
partial seizures are characterized by brief specific neurologic dysfunction, contingent upon 
the localization of the epileptogenic focus. By definition, they do not compromise 
consciousness during the event, and might manifest as motor signs (with a focus involving 
the primary motor area), sensitive symptoms (focus in the primary somatosensory area), 
autonomic or psychic signs (mesiobasal areas). Complex partial seizures affect the patient’s 
consciousness from the onset of the event. Both simple and complex partial seizures can 
propagate to the whole brain and become secondarily generalized seizures. Examples of 
primary generalized seizures are absence seizures, tonic-clonic generalized seizures, and 
myoclonic seizures. All those three seizure types are generated by epileptic discharges 
involving both cerebral hemispheres from their onset. By extension, focal epilepsies are 
characterized by recurrent spontaneous partial seizures, and generalized epilepsies have 
generalized seizures as their main seizure type. 
Epilepsies can be idiopathic (without an identifiable structural cause), symptomatic (due to 
a structural lesion), or cryptogenic (with a presumed lesion, not detectable by current 
available neuroimaging methods). Broadly, idiopathic epilepsies (partial or generalized) 
begin in the childhood years, have a good prognosis, and go into remission during 
adolescence. The symptomatic generalized epilepsies encompass a group of epileptic 
syndromes with very poor prognosis, characterized by extremely refractory seizures and 
accompanied by neurodevelopmental delay. The symptomatic partial epilepsies depict a 
large spectrum of epileptic disorders caused by several types of brain lesions. A significant 
percentage of patients who have seizures not responsive to antiepileptic drugs is affected by 
this type of epilepsy. Surgical treatment becomes a good therapeutic option for these 
patients, and the identification of the structural cortical lesion causing their epilepsies is 
primordial for a good postsurgical prognosis (Panaiyotopoulos, 2010). 
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Although the basic phenomena of the epilepsies are basically neurophysiologic in their 
nature, neuroimaging techniques have provided valuable contributions for a greater 
understanding on this matter. Magnetic resonance imaging (MRI) has revolutionized 
assessment and management of patients with refractory epilepsies. Several pathological 
processes affecting the central nervous system can be identified using MRI and related 
techniques. Brain lesions classically associated with epilepsy, like hippocampal sclerosis, 
cortical malformations, gliosis, vascular disorders, and small brain tumors often were not 
visualized using old techniques, named cranial skull X-ray and brain computed tomography 
(CT). When it is possible to detect a structural lesion underlying an epileptic condition, the 
prognosis can be better defined, and the most appropriate treatment (e.g., drug vs. surgery) 
can be indicated with greater confidence (Mc Donald et al., 2000). 
Standard MRI has a fundamental role in epilepsy surgery: to identify the epileptogenic 
lesion, depicting its topographic relationships with eloquent regions of the brain. Magnetic 
resonance spectroscopy (MRS) measures metabolites in a defined region of interest, and 
provides important lateralization information for temporal lobe epilepsies, and localization 
of neocortical epilepsies. Functional MRI (fMRI) focuses on the identification of eloquent 
cortex to be spared in planning epilepsy surgery, with the intention to improve outcomes by 
minimizing postoperative deficits. Diffusion MRI allows visualization of brain tracts, 
improving the study of epileptic circuitries. Magnetoencephalography (MEG) is a 
technology used to record spontaneous and evoked magnetic fields generated by cortical 
neuronal activity, and provides additional data to spike detection primarily performed by 
electroencephalogram (EEG). Because epilepsy is a functional disorder, several invaluable 
data can be obtained studying epileptic patients with positron emission tomography (PET) 
and single photon emission computed tomography (SPECT). PET can map numerous 
physiochemical brain processes, and ictal SPECT allows measurement of brain perfusion 
patterns during seizures, which is useful in the preoperative assessment of epileptic 
patients. Current software development enables integration between a variety of imaging 
data, aiming to minimize the use of invasive techniques in the investigation of surgical 
candidates, reducing risk and maximizing results (Duncan, 2009). 
 In this chapter, the role of different neuroimaging techniques in the study and management 
of epilepsy will be described and evaluated. A brief description of the technique will be 
followed by indications and main findings contributing for the comprehension of the 
epileptic disorders. Because detection of a brain lesion is the first step for a successful 
surgical treatment of epilepsy, emphasis in the presurgical assessment of epilepsy surgery 
will be given. 
2. Structural magnetic resonance imaging 
Brain MRI is an important tool to define the presence of a structural abnormality responsible 
for epilepsy. Acquiring appropriate epilepsy-focused MRI of high quality and diagnosing 
the important lesions with high sensitivity and specificity are imperative to the definition 
and understanding of structural brain abnormalities in patients with epilepsy. Moreover, 
surgical treatment of epileptic patients has a better general outcome when a structural lesion 
is identified by MRI and further resected. However, brain MRI may be normal in up to one 
third of patients undergoing anterior temporal lobectomy for refractory temporal lobe 
epilepsy (Radhakrishnan et al, 1998).  
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The technique of MRI is based on the intrinsic properties of atomic nuclei of charge, spin, 
and magnetism. These properties are enhanced in certain nuclei such as hydrogen, 
phosphorus, and sodium, which are natural components of the brain tissue. They behave as 
bar magnets and, when submitted to a magnetic field, will align along the direction of the 
field. In addition, the nucleus possesses another intrinsic property, which gives it a 
continuous rotary motion around the nuclear axis.  This property is called nuclear spin, or 
spin angular momentum. Because of the combination of nuclear magnetism and spin, the 
nucleus rotates around both the direction of an external magnetic field and its own axis. The 
frequency of the precession around the magnetic field is characteristic of the particular 
nucleus and the direct linear relationship between frequency and the strength of the 
magnetic field is fundamental to NMR. This is the ground of the improvement of signal-to-
noise ratio (SNR) in MR images acquired in a 3 T scanner is improved with respect to 
images acquired in a standard 1.5 T scanner, as there is a doubling of the fundamental 
precession frequency. 
There are two discrete possibilities for the direction of the precession: one for the nucleus 
aligned along the direction of the external magnetic field and another one in the opposite 
direction (anti-aligned). The former state of alignment is preferred and the majority of nuclei 
will assume this state (low energy). However, a certain proportion of the nuclei will be anti-
aligned (high energy) and it is this population difference that underlies the phenomenon of 
NMR. In the presence of a pulse of electromagnetic waves whose energy corresponds to the 
difference between these two states, the energy from these waves will be absorbed by the 
system and the populations of spins in the two states will be equalized. This perturbed state is 
temporary and, once the application of the electromagnetic waves is terminated, the nuclei will 
return to the initial state. The energy previously absorbed by the system will hence be returned 
in the form of a signal that can be detected by a suitably placed receiver coil. By imposing 
conditions on the system using magnetic field gradients, this signal will reflect not only the 
nuclear species from which it originated but also its spatial location. A spatially encoded map 
of these signals can thereby be formed. As water (H2O) forms more than 80% of the human 
body, the nucleus of the hydrogen atom is especially suitable for this technique.  
Dedicated protocols for imaging in epilepsy patients have been developed to focus the 
suspected regions of interest (Jackson and Badawy, 2001). A typical clinical scanning protocol 
for a patient with refractory epilepsy may include T1-weighted imaging, T2-weighted 
imaging, fluid-attenuated inversion–recovery (FLAIR) imaging, and threedimensional volume 
acquisition sequences. This protocol is the basis of the initial screening study used to obtain 
structural information with good morphology and signal data (Table 1).  
T1-weighted imaging (short repetition time [TR] and echo time [TE]) is commonly used to 
initially define the brain anatomy; thus cerebrospinal fluid (CSF) is black, gray matter is 
gray, and white matter is bright. These images take longer and have thicker slices and often 
incomplete brain coverage, but they can be extremely helpful in difficult cases. T2-weighted 
images (long TR, long TE) usually show the CSF as white and the gray matter of higher 
signal (brighter) than the white matter. These images typically show pathology as areas of 
increased signal and are used to assess whether the tissue is abnormal. On FLAIR images, 
the CSF appears dark, which helps to identify lesions with long T2 relaxation times. 
Pathology still looks high in signal (bright). In the case of epilepsy, the issue of most concern 
relates to subtle signal changes in the mesial temporal regions on coronal images, in which 
these artifacts need to be interpreted with an experienced eye. 
 
Neuroimaging – Clinical Applications 
 
176 
 TR TE TI Flip Thickness Matrix 
T2 cor FSE 5000 85  90 4 skip 1 512 x 256 
FLAIR cor 8000 129 2200 90 4 skip 1 256 x 224 
T2 cor IR 5500 20 200 90 4 skip 0 256 x 256 
T1 sag 2000 7,5 750 90 5 skip 2 256 x 256 
T2 ax FSE 5000 85  90 5 skip 2 512 x 256 
Table 1. Protocol used in MRI exams for epileptic patients at the Service of Radiology of 
Hospital de Clínicas de Porto Alegre. 
A variety of pathologic etiologies are able to be detected using a dedicated epilepsy 
protocol, with characteristic appearances that may be present, including mesial temporal 
sclerosis, cortical dysplasia, primary tumors of the brain, vascular malformations, and 
encephalomalacia. Mesial temporal or hippocampal sclerosis is the most important single 
cause of intractable MTLE found in surgical series, and it is the most common target for 
people with epiepsy that requires surgical treatment for refractory complex partial seizures 
in adulthood. A large body of data confirms the validity of structural abnormalities detected 
on MRI in pathologically proven HS. HS is histologically characterized by gliosis and 
neuronal loss in the hippocampus. However, extrahippocampal pathology is often found 
elsewhere in the temporal lobe, including white matter (Wieser et al., 2004). The key 
abnormalities in HS are hippocampal atrophy and hyperintense signal on T2-weighted 
images (Figure 1). 
 
 
Fig. 1. T2-weighted MRI of right hippocampal sclerosis. Note atrophy and hyperintensity of 
right hippocampus. 
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Other MR findings associated with HS include loss of ipsilateral hippocampal head 
digitations, widening of the temporal horn (Figure 2), and loss of the white matter adjacent 
to the collateral sulcus (Table 2). In surgical series of TLE, 43-72% of patients with the 
histopathologic features of MTS can be shown (Wieser et al., 2004).  
 
 





Loss of internal architecture 
Signal changes
Temporal lobe (extrahippocampal) findings 
Dilation of temporal horn
Temporal lobe atrophy 
Anterior temporal white matter signal 
changes




Table 2. MRI findings in hippocampal sclerosis. 
Dual pathology is present in at least half of all cases of HS. It is nearly always ipsilateral. 
This can take one of two forms. In the first case, there is a lesion, clearly unrelated to the HS 
(Figure 3), and it is usually on the same side as the HS. In the second, the MRI shows 
changes in other parts of the brain that might be related to a common injury that caused 
both the HS and changes such as unilateral atrophy and anterior temporal lobe changes. 
Malformations of cortical development (MCD) comprise a number of pathological entities 
that result from derangements of normal cortical development as a result of either abnormal 
neuronal proliferation, migration, or organization (Barkovich et al., 2005). Developmental 
disorders of cortex constitute 4% to 25% of all epileptogenic lesions in adults and 10% to 
50% in pediatric epilepsy series (Guerrini, 2005).  
Focal cortical dysplasias and diffuse cortical dysplasias are heterogeneous groups of 
developmental disorders defined by an abnormal cerebral cortical cytoarchitecture. Focal 
cortical dysplasia (FCD) is the most common form of focal developmental disorder, 
diagnosed in 20-30% of patients with medically intractable localization-related epilepsy.  
 




Fig. 3. Right hippocampal sclerosis. In addition, there are several bilateral periventricular 
hyperintense small lesions. 
 
 
Fig. 4. Axial FLAIR: left frontal hyperintense subcortical lesion, diagnosed as a focal 
dysplasia by pathological exam.  
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MRI has greater resolution than CT imaging and demonstrates abnormal gyral thickening 
(Figure 4) with underlying T2-weighted white matter changes (Colombo et al., 2003). 
Hemimegalencephaly is a disorder of neuronal migration that results in a unilaterally 
enlarged dysplastic hemisphere. Focal seizures occur in the majority and are typically 
intractable to AEDs. Hemimegalencephaly may occur as an isolated finding or be associated 
with other conditions including neurofibromatosis, hypomelanosis of Ito, and the linear 
nevus syndrome. Brain MRI or CT reveals an enlarged hemisphere with cortical dysplasia 
with thickening of the mantle or gyri, calcification, other neuronal migrational abnormalities 
such as schizencephalic clefts (see later), and other anomalies such as agenesis of the corpus 
callosum. While widespread pathologic changes are seen in the affected hemisphere, 
microscopic abnormalities have also been noted in the seemingly unaffected hemisphere 
(Jahan et al., 1997). 
Tuberous sclerosis complex (TSC), also known as Bourneville’s disease, is one of the 
common, multisystem, autosomal dominant, neurocutaneous syndromes. TSC presents 
frequently with infantile spasm or seizures when the congential hamartomas affect the CNS 
in addition to other organ systems. Imaging techniques such as CT head scan and MRI scans 
are diagnostic in many cases, with calcified tubers being readily identified by CT brain 
scans. Tuber calcification and cortical atrophy are common findings, though cortical atrophy 
and ventricular dilation are more frequently seen with severe epilepsy and with mental 
retardation. Tuberous sclerosis has imaging features that aresimilar to those of Taylor-type 
dysplasia. There may not be a clear topographic correlation between tubers and the active 
epileptogenic zone. 
Lissencephaly (including both agyria and pachygyria) is the most severe of the known 
malformations from abnormal neuronal migration. Less severe defects in the same genes 
and developmental processes result in subcortical band heterotopia. In this group of 
malformations, neurons begin migration but are unable to complete it. The imaging findings 
of lissencephaly vary with the severity of the mutation (Guerrini and Parrini, 2010). When 
very severe, the cortex is markedly thickened and almost no sulci are formed; when less 
severe, the cortex is less thickened and a variable number of shallow sulci separate broad 
gyri. In some cases, a ‘cell-sparse zone’ is identified between the thin outer cortical layer and 
the thicker inner cortical layer of neurons whose migration has been arrested. 
There are three main groups of heterotopia: periventricular (usually nodular: PNH), 
subcortical (either nodular or laminar) and leptomeningeal, of which only the first two can 
be detected by imaging. Nodular heterotopia is one of the more common (15-20%) forms of 
cortical malformation, responsible for 2% of patients with epilepsy. Subcortical band 
heterotopia or ‘double cortex’ is a mild form of lissencephaly and classified in that group. 
The term “polymicrogyria” defines an excessive number of abnormally small gyri that 
produce an irregular cortical surface with lumpy aspect. Polymicrogyria can be localized to 
a single gyrus, involve a portion of one hemisphere, be bilateral and asymmetrical, bilateral 
and symmetrical or diffuse. Mild forms are difficult to recognize on neuroimaging. The 
imaging appearance of polymicrogyria varies with the patient's age (Takanashi and 
Barkovich, 2003). In newborns and young infants, the malformed cortex is very thin with 
multiple, very small undulations. After myelination, polymicrogyria appears as thickened 
cortex with irregular cortex white matter junction (Guerrini et al., 2008). 
Schizencephaly refers to a full-thickness cleft in the cortex extending to the lateral ventricle 
and lies near the sylvian fissure. Schizencephaly may be unilateral or bilateral and 
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represents  a neuronal migrational disorder that affects the telencephalon. If the cortical 
walls are touching the condition is referred to as “closed lip” and, if separated by CSF, then 
“open lip schizencephaly”. It is thought that schizencephaly and polymicrogyria are similar 
entities. This is based on the fact that the clefts are lined by polymicrogyria and 
mechanistically schizencephaly is at the end of the spectrum in polymicrogyria. Whether 
this is the case in all patients is not known at present. 
Pathology plays an important role in determining which patients have seizures. Tumor 
histology influences seizure frequency, with a seizure incidence of 80-90% for 
oligodendrogliomas, 60-75% for astrocytomas, 55% for meningiomas, 55% for metastases, 
and 35-40% for malignant gliomas. Astrocytic tumors constitute about 20% of lesions 
detected in patients with epilepsy and often involve the parahippocampal gyrus and the 
amygdala. Although anaplastic tumors or glioblastomas are the most frequent astrocytic 
tumors; they usually present as a primary tumor problem and are rarely seen in patients 
with intractable epilepsy. In those patients, fibrillary astrocytomas are most common. MRI 
typically demonstrates homogeneous masses, with calcifications present in up to 20% of 
cases. The location is variable, with cortical lesions extending into the white matter and 
poorly demarcated. Pilocystic astrocytomas are more frequent in children. On MRI these 
lesions are sharply demarcated and often lobular. Contrast enhancement is typically present 
as a result of prominent vascularity. Edema is rare, and calcifications are not seen. 
Xanthoastrocytomas usually occur in the first decade of life and have a good prognosis. 
Cystic components are common in this tumor, which usually occurs in the temporal or 
parietal region. Oligodendrogliomas are histologically characterized by the presence of 
compact groups of large, rounded cells with empty cytoplasm, often also with mixed glial 
components. These tumors are less frequent than astrocytomas and uncommon in patients 
referred for intractable epilepsy, but, when present, they are located within the temporal 
lobe and tend to involve the amygdala and the uncus and parahippocampal gyrus, with 
sparing of the middle and inferior temporal convolutions. The underlying white matter 
often shows tumor infiltration. Mixed glial lesions are a common tumor type in epilepsy 
(about 5% of foreign tissue lesions). Calcifications are often present. Seizures begin typically 
in childhood. These tumors are seen predominantly in young patients (b14 years). 
Gangliogliomas tend to spare the lateral temporal neocortex and involve primarily the 
mesial structures (Figure 5). 
Dysembryoplastic neuroepithelial tumors (DNETs) are a common tumor type in patients 
with intractable epilepsy [22] (Fig. 11). These tumors are usually located in the temporal 
region or, less commonly, the frontal region. Cysts are uncommon. DNETs involve both 
gray and white matter. Imaging findings are quite characteristic and, although not 
pathognomonic of this condition, should strongly suggest the underlying abnormality. 
Metastatic spread of tumor to the brain is common and constitutes approximately 20% of 
brain neoplasms. Seizures are the presenting symptom in about 30% of patients with 
cerebral metastasis. Metastases have fairly stereotyped localization (gray–white matter 
junction) and often have peripheral edema. 
eizures are the chief clinical presentation of intracranial vascular malformations, occurring 
in 24% to 69% of arteriovenous malformations (Kraemer and Awad, 1994) and 34% to 51% 
of cavernous hemangiomas (Lee et al., 1998). These abnormalities are less frequent in the 
temporal lobes than in other regions and can be divided into arteriovenous malformations, 
cavernous angiomas, capillary telangiectasia, and venous angiomas. The MRI features of 
cavernous angiomas are fairly characteristic.The lesions have a central core with mixed 
signals indicating blood by products of different stages. Within the core, methemoglobin 
 
 




Fig. 5. Heterogenous mass lesion involving the right hippocampus. This ganglioglioma was 
successfully resected. 
S appears as high signals often intermixed with lower signals. Typically, a complete rim of 
hypointensity surrounds the central core. This rim is usually hypointense on both long and 
short echoes, with marked hypointensity in the longer echo. These lesions are void of mass 
effect or surrounding edema, and they should be easily recognized. Venous angiomas are 
probably the most common vascular malformation, but they are rarely the cause of chronic 
epilepsy. For tumors and vascular lesions located in or near eloquent cortex, fMRI nad DTI 
techniques provide useful information regarding functionally eloquent cortical regions and 
important white matter tracts, which may be crucial for resecability. 
Cortical gliosis can result from a variety of inflammatory, posttraumatic, and 
cerebrovascular brain insults. Irrespective of the etiology, gliosis usually appears as a region 
of increased signal change on T2-weighted images and decreased signal on T1-weighted 
images, often associated with focal volume loss. 
Recent advances In neuroimaging techniques have provided additional benefits to the 
diagnosis of refractory epileptic patients. Modern 3T MRI scanner and sequences can 
identify focal abnormalities or clarify uncertain findings previously observed (Strandberg et 
al., 2008). A voxel-based analysis of FLAIR signal intensity detected malformations of 
cortical development in individual patients, suggesting that this method may be a useful 
adjunct to the visual reading of MRI scans (Focke et al., 2008). Recent advances in MRI 
acquisition, such as the PROPELLER sequence, give improved spatial resolution and 
definition of hippocampal substructures in vivo (Eriksson et al., 2008). Attempts have been 
made to automate hippocampal volume estimations. A voxel-based approach using 
estimations of grey matter content has given promising results. It can provide a quantifiable 
estimative of atrophy, which can aid in the decision about the presence of clinically relevant 
HA (Bonilha et al., 2009). 
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3. MRI spectroscopy   
MRI spectroscopy and functional MRI are techniques that may complement anatomic MRI. 
Magnetic resonance spectroscopy (MRS) is a dynamic test of brain neurochemistry. Minute-
to-minute changes in phosphorus permit information that reflects changes in cerebral 
energy metabolism and pH. So, MRS focuses on providing measures of small low-
concentration mobile metabolites. In the presence of magnetic field, molecules and nuclei 
that have non-zero nuclear spin absorb and emit radiofrequency signals. 
MRS has identified alterations that occur in patients with TLE with reduction in the 
neuronal components (represented by the NAA peak) and increase in the glial elements 
(creatine and choline) to serve as a noninvasive measure of in vivo function. Areas of 
interest require large areas of brain to sample, and the resolution of MRS is much lower than 
PET or SPECT. In nonlseional epilepsy, MRS can potentially detect metabolic changes 
corresponding to the epileptogenic zone. In cases of TLE with normal MRI, NAA ratios can 
lateralize the seizure focus in 20% of patients (Figure 6). 
 
 
Fig. 6. Left hippocampal sclerosis. Decreased NAA peak. 
4. Diffusion MRI 
Diffusion tensor imaging (DTI) is an imaging technique performed on a standard MRI 
scanner that is more sensitive to white matter injury than conventional brain MR imaging. 
DTI reflects the myelin integrity in vivo and the inherent properties of the cell membranes of 
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the white matter tracts that restrict the movement of water molecules. Water tends to move 
preferentially along the horizontal axis of the white matter tracts rather than perpendicular 
to them (anisotropic diffusion), though the apparent diffusion coefficient (ADC)is the 
average measure of all directions of water diffusion. The ADC has been considered the 
surrogate for white matter integrity (Alexander et al., 2007), and DTI may aid in the 
evaluation of the large fiber white matter tracts. Tractography is user-dependent and very 
time-consuming. Attempts are being made to automate parts of the process and hence 
reduce the input needed and the potential bias. 
Diffusion-weighted MR techniques are frequently used to assess early signs of cerebral 
ischemia. Diffusion changes similar to those observed in ischemia may also be present in 
tumors or infection. Diffusion imaging requires postprocessing, which allows the 
measurement of summary parameters such as diffusivity and fractional anisotropy 
DTI in malformations of cortical development has demonstrated reduced fractional 
anisotropy and increased mean diffusivity in the white matter adjacent to cortical 
dysplasias. The disorganization of the underlying white mattertracts can be detected with 
DTI fiber tractography  DTI fiber-tracking has been used to map the major motor and 
sensory tracts in surgical planning of both lesional and nonlesional epilepsy. In temporal 
lobe resections, preoperative mapping of Meyer’s loopcan help minimize postoperative 
visual field defects (Taoka et al., 2008). 
Asymmetry of  connections between temporal and frontal lobes was a predictor of naming 
difficulties following anterior temporal lobe resection, with greater lateralization of tracts to 
the dominant hemisphere being associated with greater decline in naming function (Powell 
et al., 2008). 
5. Functional MRI 
Blood oxygenation level-dependent (BOLD) signals are the basis for generating images 
created using functional MRI (fMRI). In epilepsy, there is neurovascular coupling to define 
the relationship between epileptiform neuronal activity that is able to be measured by 
various techniques including SPECT and PET in addition to fMRI. During an increase in 
neuronal activity there is a simultaneous increase in the cerebral metabolic rate of glucose 
and oxygen. Greater regional cerebral metabolic rates result in an increase in regional 
cerebral blood flow and volume to compensate for the increased demand for oxygen. The 
robust blood supply delivered to the active region of the seizing brain produces an 
“uncoupling” between the baseline physiologic cerebral metabolic rate of oxygen and the 
cerebral blood flow by delivering an increased oxygen load. The difference between the rate 
of oxygen metabolism and cerebral blood flow forms the basis of the BOLD technique used 
in generating brain fMRI. 
Functional magnetic resonance tomography (fMRI) evaluates cerebral functions, and 
functional deficits and disturbances. fMRI is pursued in particular for three reasons: 
1. To identify the seizure focus for resection  
2. To identify eloquent function to be spared during epilepsy surgery 
3. To investigate the neurobiology of epilepsy 
fMRI provides information about how the brain differs in certain epileptic syndromes or it 
can be used to assess brain abnormalities in an individual patient. fMRI can also high- 
light the link between abnormal epileptiform activity, network brain activity, and 
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cognitive function. In the clinical situation, fMRI can help to accurately delineate the 
epileptogenic zone, surrounding eloquent cortex and vital connections between eloquent 
cortical areas. 
Studies of fMRI with simultaneous EEG recordings are revealing more about the spatial 
distribution of interictal epileptic discharges, and the relation of these sites to the seizure 
onset zone, as determined with fortuitous ictal EEG–fMRI or intracranial EEG recording and 
subsequent resective surgery. Paired analyses of cerebral blood-oxygen-level-dependent 
(BOLD) signal and perfusion during generalized spike-wave activity have shown that the 
BOLD signal change is on the basis of alterations in cerebral perfusion, indicating 
preservation of normal neurovascular coupling (Hamandi et al., 2008). 
6. Magnetoencephalography 
MEG is a noninvasive direct measure of the brain’s normally inherent electrophysiologic 
capability of neurons to produce magnetic fields. Transmembrane ion movements in active 
neurons generate magnetic fields that may be recorded by external devices. Since the 
magnetic fields produced by the brain are extremely weak, sensitive superconducting 
quantum interference devices (SQUIDs) and magnetically shielded rooms are used to record 
the MEG from neuronal sources within the brain. Epileptiform discharges that have been 
identified on EEG can be measured by averaging techniques and localized to provide 
information regarding the direction of current flow. The functional information is often 
combined with structural information from brain MRI to provide three-dimensional 
information used in the selection process of patients for respective epilepsy surgery. MEG 
has a high temporal (in milliseconds) and spatial resolution (in millimeters), in contrast to 
scalp-based EEG. The depth of the generator can be more easily determined, and the sources 
are recorded extracranially and do not carry the risk that invasive electrodes present. MEG 
is unaffected by the skull in contrast to scalp-based EEG.  
MEG measures current flow tangentially at the surface of the brain, while EEG measures 
radial flow preferentially, though the two techniques are complementary, permitting 
information regarding activity along the banks of the sulci or the tops of the gyri. 
A number of studies have reported that MEG is superior to EEG with respect to spike-
detection sensitivity and localization relative to extratemporal epilepsy (Ossenblok et al., 
2007). The inverse problem of source localization is less problematic with MEG than EEG 
due to the lack of distortion of the magnetic properties with MEG as opposed to the 
electrical properties with EEG. Therefore, IEDs are in general more abundant in MEG than 
EEG, the spikes are of briefer duration, and in many patients subpopulations of IEDs are 
found with different topographic maps, indicating better localizing properties with MEG for 
interictal IEDs than with EEG. In addition, there has been clinical value noted in patients 
with recurrent seizures after epilepsy surgery through resection of clusters of MEG source 
spikes adjacent to the margins of prior resection. 
Evoked potentials (EPs) are reproducible electrical currents generated by the synchronous 
discharge of thousands of similarly oriented and grouped neurons as a response to 
particular stimuli or actions. MEG measures the magnetic correlates of EPs, referred to as 
evoked fields (EFs). Somato- sensory evoked fields (SEFs) are most routinely used for 
presurgical functional mapping for epilepsy surgery around the Rolandic region (Benifla et 
al., 2009). 
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7. Positron emission tomography 
Positron emission tomography scanning (PET) and single photon emission computed 
tomography (SPECT) are functional neuroimaging techniques that provide complementary 
information to anatomic imaging techniques to image the anatomic characteristics of the 
brain. The most common radioisotope employed for PET is 2-deoxy-2-[18F]fluoro-D-glucose 
(FDG), or 18F-fluorodeoxyglucose (FDG). FDG is transported into neurons in proportion to 
glucose consumption of neurons and is trapped rapidly in the cells. PET with FDG, 
therefore, produces a representation of cerebral energy metabolism. The other energy 
substrate for brain is oxygen, and 15O2 PET images can also reflect energy metabolism in 
brain. This radioactive tag allows heterogeneous rates of regional cerebral glucose 
utilization to be estimated. In addition to [18F]FDG to image the regional cerebral metabolic 
rate, and [15O] water to measure regional cerebral blood flow, radiolabeled ligands coupled 
with dopamine and serotonin permit assessment of neurotransmitter synthesis. 
Furthermore, benzodiazepine anagonists, NMDA, opiates, tryptophan, and serotonin 
ligands have been used to evaluate receptors in targeted areas of the brain. 
PET scanning has proven useful in the localization of seizure foci and in exploration of the 
underlying in vivo assessment of physiologic functions of epilepsy in humans (Engel et al., 
1990). Interictal regional hypometabolism with PET is seen in 60-90% of patients with TLE. 
Interictal hypometabolism with PET can be used in the decision process for selecting 
patients for surgery, invasive EEG planning, as well as predicting a more favorable 
postoperative outcome when localized hypometabolism is present, while bilateral temporal 
hypometabolism portends a poorer postoperative surgical outcome. A recent meta-analysis 
showed that in TLE, ipsilateral focal hypometabolism was a predictor of good surgical 
outcome (Willmann et al., 2007) 
PET studies with 15O water are less reliable for identification of the epileptogenic zone and 
have not been consistent in predicting postoperative seizure outcome. Still, decreased 
perfusion (similar to SPECT) is able to identify 50% of patients with epilepsy that reveal an 
alteration between metabolism and perfusion. PET studies with neurotransmitter receptor 
markers give clues to neurochemical mechanisms of epilepsy. Opiate receptors, for example, 
may increase in the region of the epileptogenic zone, possibly as an inhibitory control 
mechanism, while benzodiazepine receptors decrease. 
PET studies suffer from some limitations. They require specialized equipment and 
personnel and are expensive to obtain. PET studies average metabolic activity over minutes, 
so rapid events such as seizures are uncommonly analyzed, and briefer events are not able 
to be detected. Spatial resolution is in theory about 2-3 mm under ideal conditions (superior 
to SPECT), but in practical application the resolution may be less. Changes in cerebral blood 
flow and in the concentration of endogenous compounds that may compete with the 
radioactive label may greatly affect the results. Finally, PET gives little information on cause 
and effect. 
Depression is a common accompaniment of refractory epilepsy, and understanding the 
mechanism of this is an important goal. Increased binding of a 5HT-1A receptor antagonist, 
18F-MPPF, was found in central serotoninergic networks, particularly the raphe and 
contralateral insula, ipsilateral hippocampus and bilateral frontal cortex, and there was a 
correlation with symptoms of depression (Lothe et al., 2008) The most likely explanation 
was felt to be reduced serotonin concentrations. Longitudinal studies before and after 
cognitive behaviour therapy, and pharmacological treatment would be of great interest. 
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8. Single photon emission computed tomography 
Single photon emission computed tomography (SPECT) is a cerebral functional 
neuroimaging technique using a systemically injected or inhaled radiolabeled tracer to 
measure regional cerebral blood flow. SPECT uses radiotracers labeled with single-photon-
emitting isotopes to produce images of cerebral function that measure regional cerebral 
blood flow (rCBF), cerebral blood volume, and blood-brain barrier permeability. A 
radiotracer that is commonly employed to measure regional cerebral blood flow is 
hexamethylpropylene amine oxime (HMPAO) coupled with 99mTc (technetium), though 
other tracers have been utilized. SPECT is similar to PET in that both are functional 























Fig. 7. Ictal SPECT during a right temporal lobe seizure. 
Although ictal–interictal subtraction single photon emission computed tomography 
(SPECT) has been in use for many years as a method of inferring the location of 
epileptogenic zone, important caveats are still being documented, such as the study of 
patients with supplementary area seizures in whom ictal SPECT did not localize to the 
supplementary motor area, but to the anterior cingulate bilaterally (Fukuda eet al., 2006). 
The accuracy of ictal SPECT analysis is highest when comparing the ictal with interictal 
perfusion data. Methodologically, this can be done by traditional side-by-side visual 
evaluation. Visual comparison of interictal and ictal SPECT is less sensitive than 
subtraction ictal SPECT co-registered with MRI (SISCOM), but ictal SPECT may be 
localizing in cases when SISCOM was nonlocalizing due to interictal injection during 
subclinical seizure activity. SISCOM is sensitive, has a good spatial localization, and is the 
best method to study ictal propagation patterns in the individual patient (Van Paesschen 
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et al. 2007). For SISCOM analysis, interictal and ictal SPECT scans are co-registered using 
an automatic registration algorithm based on mutual information and the interictal image 
is then subtracted from the ictal. The difference image is smoothed and can be 
transformed into a z-score map using the mean and the standard deviation of the 
differences in all brain voxels. The mean image of the ictal and interictal co-registered 
images can be used for co-registration to the patient’s MRI. 
A meta-analysis of SPECT brain imaging in patients with temporal lobe epilepsy (TLE) 
showed a sensitivity of ictal SPECT localization of 0.97, relative to diagnostic evaluation 
without imaging, while this was only 0.44 for inter- ictal SPECT localization (Devous Sr. et 
al. 1998). Interictal SPECT perfusion imaging on its own, therefore, seems to be inefficient in 
localizing the seizure onset zone and should only be used as a baseline perfusion measure in 
the comparison of ictal perfusion images. Ictal SPECT studies of complex focal seizures of 
extratemporal lobe origin also have an excellent localizing value, but may be more difficult 
to obtain when the seizures are brief in duration. The sensitivity of ictal SPECT in 
extratemporal seizures has been reported to be around 90%. Ictal SPECT, and in particular 
SISCOM images, are predictive of postsurgical outcome independently of MRI or scalp ictal 
EEG findings (Cascino et al. 2004). 
9. Conclusion 
To understand the basis of the epileptic disorder, clear definition of the epileptic events 
(clinical and EEG, functional neuroimaging), the structural abnormalities in the brain, and 
the clinical context in which seizures occur need to be taken into account. Unless high 
quality information is obtained in all three of these domains, the basis of the epilepsy in any 
individual has not been fully assessed. Many levels of information can be acquired using 
MRI in patients with refractory epilepsy. To make use of all the options available for the 
investigation of the patient with epilepsy from the perspective of the practicing 
epileptologist, a well-structured and continuous interaction between the epileptologist and 
radiologist is necessary. This will lead to acquisition of appropriate epilepsy-focused MR 
images of high quality and diagnosis of the important lesions with high sensitivity and 
specificity. 
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1. Introduction 
When computed tomography started to be used routinely in the evaluation of patients 
presenting with seizures it became evident that some periictal abnormalities disappeared in 
follow-up studies with no specific treatment except antiepileptics. These findings suggested 
that those reversible abnormalities were not structural but functional, possibly resulting 
from the cerebral edema induced by seizure activity (Goulatia et al. 1987; Sammaritano et 
al., 1985; Sethi et al., 1985). 
With the advent of MRI and it’s increasingly use in the acute phase of seizures, these seizure-
induced abnormalities were also demonstrated, being described as periictal or reversible MRI 
abnormalities (Cole 2004; Briellmann et al., 2005); since follow-up MRI studies disclosed that 
irreversible brain damage can occur in the regions previously affected by them, they are now 
better defined as transient periictal MRI abnormalities (TPMA). In this way, TPMA should 
only be considered if two conditions are fulfilled: first, the brain MRI signal abnormalities 
demonstrated periictally must be attributable to seizures and not other causes; and second, 
that these abnormalities totally or partially reverse on subsequent MRI studies. Besides the 
detection of TPMA, MRI can provide us with a unique non-invasive diagnostic tool to better 
understand the physiopathological mechanisms underlying TPMA formation, and to identify 
and predict the brain damage induced by seizures. 
In this chapter, we review the neuroimaging features, differential diagnosis, 
pathophysiology, electroclinical-imagiological spectrum and outcome of TPMA, 
highlighting the fundamental role of multi-sequence MRI studies in their investigation.  
2. Clinical and electroencephalographic findings associated with TPMA 
TPMA have been described in several case reports (Amato et al., 2001; Bauer et al., 2006; 
Chu et al., 2001; Kramer et al., 1987; Senn et al., 2003) and small case series (Canas et al., 
2010a; Chan et al., 1996; Huang et al., 2009; Milligan et al., 2009; Raghavendra et al., 2007), 
the largest not including more than 20 patients (Canas et al., 2010b). This scarcity of reports 
contrast with the practice of clinicians involved in the evaluation of patients presenting with 
seizures, where is not so uncommon to find MRI abnormalities induced by them.  
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The exact incidence of TPMA is still unknown, with estimated values ranging from 0.007% 
(Raghavendra et al., 2007) to 29.4% (Huang et al., 2009). The best estimation of TPMA 
incidence that we presently have comes from a prospective study in which MRI was 
systematically obtained in 34 patients with status epilepticus, with TPMA being disclosed in 
20.6% of them (Goyal et al., 2009). Similar TPMA incidences were reported in the studies 
that retrospectively reviewed the MRI obtained from patients presenting with status 
epilepticus, with the periictal signal abnormalities presumably attributable to seizures 
described in 11.6% (Milligan et al., 2009) and 29.4% (Huang et al., 2009) of the patients. Since 
these results were obtained in patients presenting with status epilepticus, a condition 
associated with a higher likelihood of inducing TPMA (Cole, 2004), we think that they 
overestimate the real TPMA incidence, a supposition supported by the much lower values 
described in the overall population of patients hospitalized for the evaluation of seizure 
disorders (Raghavendra et al., 2007).     
In fact, and although TPMA have been more frequently described in convulsive status 
epilepticus, complex partial status epilepticus and seizures with a prominent motor 
component, they could be induced by virtually any type of seizure, a cluster of seizures or 
other forms of status epilepticus. TPMA can be disclosed in patients with presenting 
seizures provoked by systemic factors (such as alcohol withdrawal, infections or dialysis 
disequilibrium) or associated with structural cerebral pathologies, the most common being 
small-vessel cerebrovascular disease or post-traumatic/ post-stroke encephaloclastic lesions; 
and can also be demonstrated in patients with a previous history of epilepsy, often difficult 
to control focal symptomatic or probably symptomatic epilepsies.  
The electroencephalographic findings associated with TPMA are also vary variable, with the 
ictal electroencephalograms generally showing focal continuous or in crescendo epileptiform 
discharges, rhythmic activity or lateralized periodic epileptiform discharges; in postictal 
electroencephalograms, the most frequent findings are focal slowing with or without 
associated epileptiform discharges, lateralized or bilateral periodic epileptiform discharges, 
frontal intermittent rhythmic delta activity, or no relevant abnormalities.  
The reasons why TPMA occur in some but not all patients with seizures is still an 
unresolved issue. However, some critical variables have been proposed as determinants of 
TPMA occurrence or outcome, such as seizure type and duration, pre-existing brain lesions, 
pharmacological interventions (Cole, 2004) and possible hypoperfusion or hypoxia (Milligan 
et al., 2009). The disclosure of TPMA can also be determined by methodological factors, 
namely the MRI timing, with ictal or early postictal MRIs increasing the probability of their 
detection (Briellmann et al., 2005; Goyal et al., 2009). 
3. TPMA neuroimaging features 
TPMA may present with several MRI signal abnormalities, heterogeneous patterns and 
topographic distribution, contributing to wide neuroimaging features. The knowledge of 
these features is paramount to recognize TPMA and to make a proper differential diagnosis 
with other pathologies.  
3.1 Signal abnormalities 
To be visible on an MRI, the seizure-induced MRI abnormalities must be associated with a 
relatively widespread change in water environment (Briellmann et al., 2005). In this way, the 
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intra and/ or extracellular edema induced by seizures are generally hypointense in T1-
weighted imaging and hyperintense in fluid-attenuated inversion recovery (FLAIR) and T2-
weighted imaging, with restriction to water on diffusion-weighted imaging (DWI). A pial or 
cortico-pial contrast enhancement can also be disclosed, particularly in larger TPMAs with a 
subcortical component. In the cases in which a protonic magnetic resonance spectroscopy 
(MRS) was obtained periictally, the most consistent findings were an increase in the lactate 
levels and choline and a decrease in N-acetyl-aspartate (Castillo et al., 2001; Lazeyras et al., 
2000; Mueller et al., 2001), with the levels of myoinositol possibly fluctuating during and 
after seizures (Wellard et al., 2003). Generally, these signal abnormalities are colocalized in 
the same brain regions. 
Although the exact mechanisms underlying these seizure-induced MRI signal changes are 
still not well known, some have been proposed, mostly based on theoretical models or data 
from experimental studies (table 1). 
 
MRI sequence Measurement of Acute signal change Attributed to 
T1-weighted T1-signal Increase  Cell edema 
T2-wighted T2-signal Increase  Cell edema 
FLAIR FLAIR signal Decrease Cell edema 
DWI ADC 
Decrease  Cytotoxic edema 
Increase  Vasogenic edema 
Proton MRS 
Lactate  Increase Anaerobic metabolism 
N-acetyl-aspartate Decrease Neuronal loss/ dysfunction 
Choline Increase Increased membrane turnover 
Myoinositol Decrease Osmolyte changes 




vasodilatation, breakdown of the 
blood-brain barrier 
Table 1. MRI signal abnormalities induced by seizures.  
Several authors highlighted the prominent role of DWI in disclosing TPMA (Kim et al., 2001; 
Szabo et al., 2005). DWI is the most sensitive MRI-sequence in detecting TPMA (restriction 
to water diffusion present in more than 90% of the cases), being frequently the only reliable 
signal abnormality in small TPMAs restricted to the cerebral cortex or in TPMAs bordering 
old encephaloclastic lesions (Canas et al., 2010b). In the cases in which attenuation diffusion 
coefficient (ADC) studies were obtained,  some authors reported an increased DWI signal 
with decreased diffusivity, compatible with cytotoxic edema (Chu et al., 2001; Parmar et al., 
2006; Szabo et al., 2005), and others a decreased DWI signal with increased diffusivity, 
disclosing vasogenic edema (Hong et al., 2004; Wieshmann et al., 1997); other authors, 
including ourselves, described diverse findings in the TPMA ADC studies, with some 
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patients showing a predominantly cytotoxic or vasogenic edema, while others having 
intermixed areas of both types of edema, mainly cortical cytotoxic edema and subcortical 
vasogenic edema (Canas et al., 2010a, 2010b; Kim et al., 2001).  
The timing of MRI acquisition has been proposed by some authors as one of the factors that 
could contribute to these apparently non-congruent findings regarding the TPMA ADC 
signal abnormalities (Briellmann et al., 2005; Hong et al., 2004). Animal experiments 
disclosed that, early after a seizure, the lactate levels increase and the ADC values decrease, 
with these changes attributed to the failure of the Na+/K+-ATPase pump and anaerobic 
metabolism (Najm et al., 1997; Righini et al., 1994; Wang et al., 1996); whereas the lactate 
changes are short-lived, the ADC value is maximally decreased at 24 hours, returning to the 
control level or increasing in the following 48 to 72 hours, when T2-weighted abnormalities 
emerge (Nakasu et al., 1995; Righini et al., 1994). However, in clinical practice we can 
observe different MRI signal abnormalities, including increases and decreases in ADC 
values, in MRIs performed with similar timings regarding the seizure onset, disclosing that 
other factors must be considered. We believe that one of those factors is the diverse 
susceptibilities of different brain regions to the pathophysiological mechanisms involved in 
TPMA formation (see below).  
3.2 Topography and patterns  
The great majority of TPMAs are focal and unilateral, cortically restricted or with a cortico-
subcortical pattern. Although they can arise anywhere in the cerebral neocortex, they are 
commonly disclosed in the posterior and perirolandic regions or in the periphery of old 
encephaloclastic lesions (Silverstein & Alexander, 1998; Canas et al., 2010b). Less frequently 
they have a marked subcortical component, with mass effect and gyral effacement, 
mimicking an intracerebral neoplasm (Canas et al., 2010a; Cohen-Gadol et al., 2004; 
Hicdonmez et al., 2003); are more diffuse or bilateral; or are associated with remote signal 
abnormalities, affecting structures anatomically distant from the neocortical seizure focus, 
including the contralateral cerebellar hemisphere (cerebellar diaschisis), thalamus (more 
frequently the pulvinar), splenium of the corpus callosum, caudate and globus pallidus 
(Cole, 2004). In some cases, evanescent T2-weighted and DWI abnormalities are disclosed in 
cortical regions widely separated from the probable seizure focus, with the signal 
abnormalities of these migratory lesions and TPMA resolving almost simultaneously (Cole, 
2004; Raghavendra et al., 2007). Remote and migratory signal abnormalities are believed to 
result from seizure propagation through neuronal pathways, and are usually associated 
with larger neocortical TPMA.  
3.3 Classification 
The first classification for TPMA was proposed by Cole, who classified them into local 
(colocalized with the epileptic discharge) and remote (affecting distant structures) (Cole, 
2004). After that, two comprehensive classification systems to cover the broad spectrum of 
changes that comprise TPMA were proposed by us (Canas et al., 2010b) and other authors 
(Raghavendra et al., 2007). These two classifications are based mostly on TPMA patterns 
and signal abnormalities, facilitating their recognition by Neurologist and 
Neuroradiologists, and helping in their differential diagnosis. 
Raghavendra and colleagues classified TPMA into type I, restricted to the superficial gray 
matter; type II, affecting the superficial gray and subcortical white matter (type IIa) or with 
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the subcortical white matter involvement extending to the adjacent periventricular surface 
(type IIb); type III, with involvement of the subcortical nuclei associated with any degree of 
cortical or white matter involvement; type IV, involvement of white matter alone; and type 
V, with leptomeningeal enhancement and/ or gyriform cortical enhancement. Regarding the 
differential diagnosis, type I and IIa can mimic encephalitis, type IIb an intracerebral 
neoplasm and type V, due to the leptomeningeal involvement, meningoencephalitis; type IV 
can mimic several pathologies and in type V the ictal onset may have a poor localizing value 
(Raghavendra et al., 2007). 
Our classification has several similarities to the classification proposed by Raghavendra and 
colleagues (Raghavendra et al., 2007), although we did not find any TPMA restricted to the 
subcortical white matter (Canas et al., 2010b). We classified TPMA into type 1, restricted to 
the cerebral cortex, and type 2, cortico-subcortical. Type 2 TPMA can further have a marked 
subcortical component with mass effect, mimicking a tumor lesion (type 2A- tumor-like); be 
in the periphery/ bordering an old encephaloclastic lesion (type 2B) or be associated with 
remote signal abnormalities (type 2C) (table 2).  
 
Type Characteristics  Main MRI features Major differential diagnosis 
1 Cortically restricted Frequently only disclosed on DWI  
Small embolic stroke 
Creutzfeldt-Jacob disease 
2 Cortico-subcortical Any of the TPMA signal abnormalities 







Mass effect, frequent 
contrast enhancement; 
marked vasogenic edema  
Intracerebral neoplasm, low 
grade gliomas 
2B 
Bordering an old 
encephaloclastic 
lesion 
Frequently only disclosed 
on DWI Small embolic stroke 
2C Associated with remote lesions 
Signal abnormalities in the 
contralateral cerebellum, 
or the homolateral 






Table 2. Proposed TPMA classification 
Topographically, the great majority of type 1, type 2A and 2B TPMA are focal and 
unilateral, while most type 2C are larger (hemispheric, lobar, multilobar) and/ or bilateral. 
Tumor-like TPMA are frequently disclosed in patients with presenting seizures without a 
known etiology and generally are associated with a good outcome (Canas et al., 2010a); 
conversely, type 2C generally occur in patients with a previous history of epilepsy, and are 
associated with a high percentage of clinical and MRI sequelae (Canas et al., 2010b). The 
factors predisposing patients with similar types and duration of seizures to develop 
different types of TPMA remain to be elucidated.  
 
Neuroimaging – Clinical Applications 
 
196 
The wide spectrum of TPMA signal abnormalities, topography and patterns are shown in 
figures 1 to 7. To better understand our proposed TPMA classification, a clinical vignette is 







Fig. 1. 56 year-old female patient with 3 left focal motor seizures in 1 hour, one with 
secondarily generalization; there was no history of epilepsy and the seizure etiology was 
undetermined. The periictal MRI disclosed a pseudotumoral lesion (type 2A TPMA) around 
the right marginal sulcus, hyperintense on FLAIR, hypointense on T1 and with a cortico-pial 
pattern of gadolinium (Gad) enhancement (arrow). There was no significant diffusion 
restriction, thus suggesting vasogenic edema. (*) The follow-up MRI at 2 months showed 
resolution of the edema and contrast enhancement, with cortical laminar necrosis in the 
previously affected region; in spite of this, there were no clinical or electroencephalographic 







Fig. 2. 45 year-old male patient, with two simple motor seizures affecting the left arm, one 
with secondarily generalization; he had a left hemiparesis due to previous stroke, but no 
history of epilepsy; the presenting seizures were induced by alcohol withdrawal. The 
periictal MRI disclosed an old right parietal ischemic stroke, surrounded by focal diffusion 
restriction (arrow), gadolinium (Gad) enhancement and FLAIR hyperintensity (type 2B 
TPMA), attributable to acute seizures and not to a new small embolic stroke. (*) The follow-
up MRI at 3 months showed resolution of the periictal signal abnormalities, although the 
patient developed de novo focal epilepsy and aggravated the pre-existing left hemiparesis. 
 




Fig. 3. 73 year-old female patient presenting almost continuous clonic jerks of the left 
hemiface in the last 5 days; the etiology of the simple motor status epilepticus was attributed 
to small-vessel cerebrovascular disease. The periictal MRI disclosed a hyperintensity of the 
right precentral gyrus with subcortical involvement and mass effect on T2 and FLAIR, a T1-
weighted hypointensity, DWI restriction and no contrast enhancement; lesional MRS 
revealed a decrease in N-acetyl-aspartate (NAA) and an inverted lactate peak (type 2A 
TPMA). The Follow-up MRI after 60 months (B) shows resolution of the precentral signal 
abnormalities, with slight regional brain atrophy, mild recovery of the choline / N-Acetyl A 
ratio and lactate normalization on MRS. In spite of these residual MRI findings, there were 
no clinical or electroencephalographic sequels attributable to the TPMA. 
 
 
Fig. 4. 45 year-old male patient with consciousness impairment in the last 6 hours. The ictal 
electroencephalogram showed continuous epileptiform discharges over the left temporal 
region, diagnosing complex partial status epilepticus, attributed to alcohol withdrawal. The 
periictal MRI disclosed diffuse left hemisphere cortical swelling, T2 hyperintensity and 
diffusion restriction, associated with remote left pulvinar (arrow) T2 and DWI 
hyperintensity (type 2C TPMA). (*) The follow-up MRI at 5 months showed resolution of 
diffusion restriction signal abnormalities and edema, with marked focal atrophy and 
cortical-subcortical gliosis. The irreversible brain damage that resulted from the TPMA was 
responsible for Wernicke aphasia and de novo focal symptomatic epilepsy. 
 




Fig. 5. 59 year-old female patient with a previous history of post-stroke epilepsy. In the last 3 
days she presented with stupor, with occasional nystagmoid eye jerks. The ictal EEG 
allowed the diagnosis of subtle status epilepticus, attributed to a change in the usual 
antiepileptic medication. The periictal MRI showed bilateral cortico-subcortical T2 and DWI 
hyperintensities involving the insula, frontal and temporal lobes, the cingulum, the 
hippocampus and the pulvinar (type 2C TPMA). (*) The follow-up MRI at 3 months showed 
resolution of diffusion restriction signal abnormalities and aggravation of the diffuse 
cerebral atrophy. After the status epilepticus control, the patient remained tetraparetic and 
died after 5 months.  
 
 
Fig. 6. 35 year-old male patient with cryptogenic refractory temporal lobe epilepsy. 
Consciousness impairment with occasional clonic jerks of the left arm in the last 2 days, with 
the ictal electroencephalogram diagnosing complex partial status epilepticus. The periictal 
MRI disclosed cortical-subcortical edema and signal changes of the entire right cerebral 
hemisphere, sparing the rolandic area, with cortical diffusion restriction and cortico-pial 
contrast enhancement; concomitant contra-lateral cerebellar hemisphere and tonsil signal 
changes (crossed cerebellar diaschisis) (type 2C TPMA). (*) The follow-up MRI at 5 months 
showed resolution of the edema and contrast enhancement, with cortico-subcortical T2 and 
FLAIR hyperintensities in the previously affected areas (demyelination and gliosis), and 
generalized brain atrophy, more marked at the right frontal lobe. After the status 
epilepticus, the patient developed a left hemiparesis.  
 




Fig. 7. 78 year-old female patient with a previous history of hypertension and diabetes 
mellitus type II. Admitted with consciousness impairment and occasional jerks of the right 
arm in the last 3 days; the ictal electroencephalogram disclosed periodic lateralized 
epileptiform discharges with a higher amplitude over the left posterior regions; the 
diagnosis of complex partial status epilepticus was admitted, attributable to small-vessel 
cerebrovascular disease. The periictal MRI disclosed left parieto-occipital cortical diffusion 
restriction without significant signal changes in the other sequences (type 1 TPMA), which 
disappeared in follow-up MRIs. After few months, the patient developed de novo partial 
epilepsy easily controlled with antiepileptics. 
3.4 Differential diagnosis 
The difficult differential diagnosis between the lesions induced by seizures and other 
pathologies as been described since the earlier computed tomography descriptions 
(Silverstein & Alexander, 1998). In the MRI era those difficulties persisted, mostly due to the 
similar signal abnormalities disclosed on focal TPMA and other pathologies that may 
present with seizures, namely acute ischemic stroke, intracerebral tumors, reversible 
posterior leukoencephalopathy syndrome, encephalitis, and venous infarctions resulting 
from cerebral venous thrombosis.  
The differential diagnosis with all these pathologies is particularly relevant in a patient with 
a first seizure or presenting SE since the attending clinicians may assume that the observed 
MRI abnormalities are the cause and not the consequence of seizures, a supposition that 
may possibly lead to unnecessary diagnostic procedures. Although the clinical context in 
which seizures occur is fundamental to make a correct diagnosis, certain particularities 
resulting from a detailed MRI evaluation can also contribute for that.  
The differential diagnosis of TPMA with embolic acute stroke is mostly relevant, since both 
situations occur with a prominent cortico-subcortical water restriction on DWI studies. 
However, TPMA generally do not respect vascular territories, such as in acute stroke 
(Lansberg et al., 1999), and in uncertain cases a hyperperfusion demonstrated on perfusion 
computed tomography (Masterson et al., 2009) or MRI (Flacke et al., 2000; Szabo et al., 2005) 
favors TPMA, while hypoperfusion favors stroke. Other relevant differential diagnosis of 
TPMA, namely if they have a tumor-like appearance, is with low grade gliomas; in this 
situation, the results of the DWI studies are very helpful, with TPMA having a marked 
restriction to water diffusion, generally not present in low grade gliomas (Cha, 2006). 
Regarding encephalitis and venous infarctions resulting from cerebral venous thrombosis 
the differential diagnosis with TPMA can only be properly made after the CSF analysis and 
venous angiography, respectively, excluded these pathologies.  The patterns and signal 
abnormalities of TPMA are so similar to the ones observed in reversible posterior 
leukoencephalopathy syndrome that solely the clinical context in which they occur can help 
to make a proper differential diagnosis (Hinchey et al., 1996; Kozak et al., 2007). The same 
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applies to TPMA restricted to the cerebral cortex or associated with remote lesions, very 
similar to the MRI abnormalities observed in Creutzfeldt-Jacob disease (Meissner et al., 2008; 
Young et al., 2005).   
We must highlight that in some cases, and in spite of a detailed clinical history and MRI 
analysis, the differential diagnosis between TPMA and some of these pathologies can be 
very difficult. In these situations, the results of subsequent neuroimaging studies obtained 
some days after seizure control can be very helpful, with the disappearance of the 
abnormalities strongly favoring the diagnosis of TPMA.  
4. TPMA electroclinical-imagiological spectrum 
Although a high topographic concordance between the clinical, electroencephalographic 
and MRI findings have been described in most case reports, only recently large case series 
applied systematically these studies to determine the electroclinical-imagiological spectrum 
of TPMA. In a recent case series, Huang and colleagues reported an almost complete 
topographic concordance between the periictal MRI abnormalities and the electroclinical 
findings in 15 patients presenting with status epilepticus (Huang et al., 2009); similar 
findings were described in 10 patients with partial status epilepticus, with the periictal DWI 
abnormalities always colocalized with the ictal electroencephalographic activity disclosed 
on video-EEG (Di Bonaventura et al., 2009).  
In more heterogeneous case series, including patients with different types of seizures and 
status epilepticus, the degree of this concordance is significantly lower: in 12 patients with a 
single or a cluster of focal seizures with or without secondarily generalization, Raghavendra 
and colleagues described a 75% topographic concordance between reversible periictal MRI 
abnormalities and the electroclinical findings (Raghavendra et al., 2007); and in our own 
case series, using more strict topographic criteria, this concordance was only observed in 7 
out of 19 patients, with the others presenting several possible combinations between the 
clinical, MRI and electroencephalographic data: TPMA colocalized with 
electroencephalographic findings, with patients presenting generalized seizures; partial 
seizures concordant with focal electroencephalographic findings, with more widespread 
TPMA; partial seizures concordant with TPMA, with the electroencephalogram showing 
more diffuse abnormalities; focal TPMA, generalized seizures, and non-focal 
electroencephalographic abnormalities; colocalized electroencephalographic and clinical 
findings with “mirror-like” TPMA; and bilateral TPMA associated with diffuse 
electroencephalographic findings and generalized seizures  (Canas et al., 2010b).  
The broad electroclinical-imagiological spectrum that we and others describe can be mostly 
attributed to methodological and clinical factors (table 3). The degree of homogeneity of the 
clinical, imagiological and electroencephalographic data included for analysis seems to be a 
determinant methodological factor, with the inclusion of patients of different types of 
seizures/ status epilepticus and wide timings of MRI and electroencephalographic studies 
contributing to a lower level of concordance; conversely, a better concordance is associated 
with a short time-lag between the acquisition of these studies (figure 8) (Cole, 2004; Goyal et 
al., 2009; Huang et al., 2009). The topographic criteria used for concordance is also very 
relevant, with more broad criteria, considering concordant electroencephalographic and 
MRI findings lateralized to the probable seizure focus or admitting generalized seizures 
associated with focal MRI and electroencephalographic findings as probably generalized, 
increasing its level (Canas et al., 2010b). Sustained and prolonged focal seizures are also 
 
MRI Abnormalities Induced by Seizures 
 
201 
highly colocalized with the MRI and electroencephalographic findings (figure 9) (Cole, 2004; 
Goyal et al., 2009; Huang et al., 2009), in opposition to a systemic seizure etiology, mostly 




Homogeneity of the analyzed data  Seizure type and duration 
Time-lag between studies Seizure etiology 
Criteria for topographic concordance Seizure dynamics 
Table 3. Factors affecting the TPMA electroclinical-imagiological spectrum  
 
 
Fig. 8. 67 year-old male patient with post-stroke epilepsy. Hospitalized with recurrent motor 
seizures of the left-hemibody in the last 7 hours, triggered by low antiepileptic levels. The 
periictal MRI, obtained within 24 hours after seizure control, disclosed a DWI restriction in 
the periphery of an old encephaloclastic lesion (type 2B TPMA), which reversed on 
subsequent studies; the ictal electroencephalogram revealed a seizure-onset in right central 
region, characterized by rhythmic fast activity (arrow). The short time-lag between studies 
(ictal electroencephalogram, early postictal MRI) certainly contributed to the excellent 
electroclinical-imagiological topographic concordance observed in this case.    
Another factor that must be considered in the evaluation of the TPMA electroclinical-
imagiological spectrum is seizure dynamics. In fact, the rapid seizure propagation from a 
epileptic focus can contribute for the apparently non-concordant topographic findings that 
we described (Canas et al., 2010b): in patients presenting generalized seizures with focal 
colocalized electroencephalographic and MRI findings, the seizures most probably 
propagated from a epileptic focus defined by the results of those two exams, an hypothesis 
particularly conceivable in patients presenting structural cerebral abnormalities; when focal 
concordant clinical and electroencephalographic findings are associated with more 
widespread MRI abnormalities, the seizure focus is probably defined according to 
electroclinical criteria, with the more extensive TPMA resulting from the seizure 
propagation through neuronal pathways; and when the patients present partial seizures 
concordant with focal TPMA, with electroencephalograms showing more diffuse 
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abnormalities (namely periodic lateralized or bilateral epileptiform discharges), the seizure 
focus is probably defined according to clinical and MRI criteria. The same seizure dynamics 
probably also justifies all cases of TPMA associated with remote or migratory signal changes 
and the cases with “mirror-like” TPMA. The determinant role of seizure dynamics to the 
electroclinical-imagiological spectrum of TPMA was also previously highlighted by other 
authors (Cole et al., 2004; Goyal et al, 2009).      
 
 
Fig. 9. 23 year-old female patient admitted with behavior abnormalities in the last 3 days. 
The ictal electroencephalogram showed slowing of the background activity over the left 
hemisphere and continuous spikes and sharp-waves over the left temporal region, 
compatible with complex partial status epilepticus. The periictal MRI (A), obtained 4 days 
after seizure control, disclosed swelling of the left hippocampal formation, with cortical 
hyperintensity on FLAIR and T2-weighted images (Type 1 TPMA); constitutional alterations 
of the brain are also seen, being the probable cause of the presenting status epilepticus. After 
5 months (B), the follow-up MRI showed reversion of the signal abnormalities; and after 19 
months (C) atrophy of the left hippocampus, with mild hyperintensity on T2 and FLAIR, 
suggestive of hippocampal sclerosis. In this case, in spite of a late periictal MRI, the 
sustained and prolonged status epilepticus contributed to the topographic concordance 
between the clinical, electroencephalographic and MRI findings.  
5. TPMA outcome 
In follow-up studies, the periictal MRI abnormalities attributable to seizures may totally 
reverse or induce irreversible brain damage. In this last situation, focal cortical laminar 
necrosis, T2 and/or FLAIR hyperintensities, atrophy and a decrease in N-acetyl-aspartate 
may be observed in the regions previously affected by TPMA, disclosing gliosis and 
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neuronal loss (Briellmann et al., 2002, 2005). These focal changes will eventually lead to a 
new seizure focus and the development of the novo focal epilepsy (Bartolomei et al., 1996; 
Parmar et al., 2006) or may coexist without any clinical or electroencephalographic evidence 
of chronic epilepsy (Chu et al., 2001; Senn et al., 2003). In our own series, we found an high 
incidence (63.2%) of clinical, MRI and electroencephalographic sequelae attributable to 
TPMA, with only small TPMA induced by systemic factors or tumor-like TPMA associated 
with a better outcome (Canas et al., 2010b); these TPMA sequelae were not only showed in 
patients with presenting seizures, but also in epileptic patients, with the appearance or 
aggravation of focal neurological deficits. However, we recognized that some confounding 
factors could have influenced our results, namely the high incidence of the novo epilepsy in 
patients with presenting seizure associated with structural brain lesions (small-vessel 
cerebrovascular disease, old encephaloclastic lesions), possibly the first seizures of a focal 
symptomatic epilepsy. 
At the periictal phase there are some TPMA characteristics that can help to predict their 
outcome. One of the most relevant is the type of edema disclosed on the DWI/ ADC studies: 
if TPMA are mainly composed of cytotoxic edema, the probability of inducing irreversible 
brain damage is higher, with the consequent topographically concordant clinical and 
electroencephalographic sequels (Canas et al., 2010b; Parmar et al., 2006); on the contrary, 
the TPMA mainly composed by vasogenic edema partially or totally reverse without any 
clinical or electroencephalographic consequence (Cohen-Gadol et al., 2004; Raghavendra et 
al., 2007; Canas et al., 2010a). TPMA affecting the temporal lobe, and particularly the mesial 
structures (hippocampus and amygdala) may also be associated with a worse outcome, 
possibly leading to the development of hippocampal sclerosis and the appearance of the 
novo epilepsy (Bartolomei et al., 1998; Juhazc et al., 1998; see also figure 9). The vulnerability 
of the temporal structures to seizures was demonstrated in the neuropathological analysis of 
patients dying from status epilepticus, with a substantial cell loss and gliosis in the 
hippocampus (Nixon et al., 2001; Pohlmann-Eden et al., 2006); some MRI signal 
abnormalities have been associated with the development of permanent hippocampal 
damage, mainly the presence of periictal cytotoxic edema and a lactate peak on protonic 
 
Analyzed data Analysis of Worse outcome Better outcome 
TPMA 
characteristics 
Predominant type of 
edema  Cytotoxic  Vasogenic  
Location  Temporal  Extra-temporal 
Size Large cortico-subcortical  
Small cortically 
restricted 




cerebral disease Yes  No 
Clinical 




Etiology of presenting 
seizures 
Structural cerebral 
disease Systemic factors 
Preexisting epilepsy Yes  No 
Table 4. Proposed factors that may help to predict the TPMA outcome  
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MRS (Farina et al., 2004; Parmar et al., 2006), and a T2-weighted hyperintensity in the days 
following seizures (Provenzale et al., 2008). Finally, we demonstrated that the type of TPMA 
could help to predict their outcome, with large TPMA associated with remote lesions (type 
2C), TPMA in the periphery of cortical lesions (type 2C) and TPMA disclosed in patients 
with presenting seizures attributed to cerebral brain lesions associated with a higher 
likelihood of clinical, MRI and electroencephalographic sequels (Canas et al., 2010b).  
Based on the available literature and in our own experience, we propose the integrated 
analysis of some data for the prediction of TPMA outcome. These data, besides including 
the TPMA neuroimaging features, also consider other clinical and MRI findings (table 4). 
6. Pathophysiological mechanisms underlying TPMA formation and outcome  
Although the exact pathophysiological mechanisms underlying the seizure-induced MRI 
abnormalities are still not completely elucidated, the results of animal experiments and 
clinical observations obtained over the last years lead to a conceptual hypothesis, first 
proposed be Cole (Cole, 2004), and after supported by us and other authors (Canas et al., 
2010b). This hypothesis is based mostly on the capacity of certain brain regions to deal with 
the perfusion and energy demands triggered by seizure activity, which is determined by 
their intrinsic threshold; these hypothetical mechanisms, besides explaining some of the 
periictal MRI changes, could also help to clarify the TPMA electroclinical-imagiological 
spectrum, outcome, and some apparently contradictory findings described in the literature.   
The cortical hyperemia associated with provoked or spontaneous seizures is a common 
finding reported by neurosurgeons. Non-invasive methods, such as single-photon emission 
computed tomography, positron emission tomography, intracranial doppler and MR-
angiography, also disclosed that focal seizures are associated with high metabolic demands 
and a marked blood flow increase to the seizure focus (Juhazc et al., 1998; Theodore, 1999; 
Doherty et al., 2004). The corresponding hyperperfusion may disrupt the blood-brain barrier 
and justify the vasogenic edema and contrast enhancement observed in some cases 
(Wieshmann et al., 1997; Hong et al. 2004); that is supported by the prominent vascular 
congestion and perivascular hemosiderin deposition that was demonstrated in the rare cases 
of tumor-like TPMA that were biopsied (McClelland et al., 2005). When this increase in 
blood flow fails to compensate the focal glucose hypermetabolism, anaerobic metabolism 
takes place, with the released lactate originating a peak on MRS and contributing to a 
further damage of the blood-brain barrier. Animal models demonstrated that, if seizures are 
prolonged and/ or severe, an energy failure of the Na+/K+-ATPase pump may occur, with 
water and Na+ influx to the cell (Wang et al., 1996); this mechanism, so as an excessive 
release of glutamate (Sloviter et al., 1985) and an increased membrane ion permeability 
(McNamara, 1994), may all contribute to cytotoxic edema observed in some cases, with the 
corresponding neuronal dysfunction and/ or loss explaining the decreased N-acetyl-
aspartate level and the changes in choline and myoinositol observed in protonic MRS.  If 
this events are interrupted when the auto-regulatory vascular mechanisms still can 
compensate the high metabolic demands of seizure activity, the neuronal damage is 
minimized, which probably justifies the reversion of TPMA mainly composed of vasogenic 
edema (Wieshmann et al., 1997; Silverstein & Alexander, 1998; Cohen-Gadol et al., 2004; 
Hong et al., 2004); however, if seizure activity continues, irreversible brain damage may 
occur, justifying the worse clinical outcome of TPMA mainly composed of cytotoxic edema 
(Chu et al., 2001; Szabo et al., 2005; Parmar et al., 2006) or in which a lactate peak is revealed 
on MRS (Fazekas et al., 1995; Lazeyras et al., 2005). 
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This cascade of events occurring at the seizure focus certainly contributes to the frequently 
observed electroclinical-imagiological topographic concordance. In spite of this, a high 
incidence of focal TPMAs are found even when seizures are triggered/ provoked by 
systemic factors, are primarily generalized or are associated with diffuse EEG findings, 
contributing to the broad electroclinical-imagiological spectrum that we described (Canas et 
al., 2010b). We speculate that this can be attributed to the presence of brain regions 
intrinsically more susceptible to the TPMA pathophysiological mechanisms or to structural 
brain lesions that determine a lower seizure threshold. We show that in the presence of 
these lesions, TPMA are generally located in their periphery (type 2B TPMA), with 
topographically concordant EEG and clinical findings, suggesting that they may define the 
probable seizure focus. In the absence of these lesions, we and other authors show that 
TPMA are generally located in the posterior regions (occipital, parieto-occipital and 
temporo-occipital) (Chu et al., 2001; Kim et al., 2001, Canas et al., 2010b). The preponderance 
of TPMA in these regions could be attributed to their lower sympathetic innervation, 
making them more susceptible to the hyperperfusion induced by seizure activity, in a 
similar way to the cerebral lesions observed in reversible posterior leukoencephalopathy 
syndrome, with which TPMA share similar pathophysiological mechanisms and MRI signal 
abnormalities.  
7. Conclusion 
There is overwhelming evidence, obtained from animal experiments and human case 
reports, that acute seizures per se can induce brain damage and that MRI is a very powerful 
tool to its detection. In the clinical context where these MRI seizure-induced lesions 
generally appear the attending clinicians must be familiar not only with their neuroimaging 
features, but also with their electroclinical spectrum, allowing an accurate diagnosis. Since 
these seizure-induced MRI lesions are typically obtained fortuitously, several questions still 
remain without definite answer, namely which factors predispose only some patients to 
their development, what determine their different patterns, what are the exact 
physiopathological mechanisms underlying their formation or if the results of the periictal 
DWI and MRS studies can be reliable markers of epileptogenesis. To effectively answer 
these questions there is an urgent need for longitudinal multimodal MRI studies applied 
systematically in patients presenting with seizures.      
8. Acknowledgments  
We are very grateful to our colleagues that referred patients to our studies, namely Dr. 
Paula Breia, Dr. Sofia Calado, Dr. Ricardo Pestana and Dr. José Vale; and to the 
Neuroradiologists that helped in the MRI data review, namely Dr. Paulo Saraiva and Dr. 
Constança Jordão.    
9. References 
Amato C.; Elia M.; Musumeci S.A.; Bisceglie P. & Moschini M (2001). Transient MRI 
abnormalities associated with partial status epilepticus: a case report, European 
Journal of Radiology, Vol.38, No.1, (April 2001), pp. 50-54 
 
Neuroimaging – Clinical Applications 
 
206 
 Bauer, G.; Gotwald, T.; Dobesberger, J.; Embacher, N.; Felber, S.; Bauer, R.; Seppi, K.; 
Walser, G.; Trinka, E. & Poewe, W. (2006). Transient and permanent magnetic 
resonance imaging abnormalities after complex partial status epilepticus, Epilepsy & 
Behavior, Vol. 8, No.3, (May 2006), pp. 666-671 
Bartolomei, F., Regis, J., Donet, A. & Gastaut, J.L. (1999). Development of focal chronic 
epilepsy following focal status epilepticus in adult patients, Neurophysiologie 
Clinique, Vol.29, No3, (June 1999), pp. 271-276 
Briellmann, R.S.; Kalnins, R.M.; Berkovic, S.F. & Jackson, G.D. (2002). Hippocampal 
pathology in refractory temporal lobe epilepsy: T2-weighted signal change reflects 
dentate gliosis, Neurology, Vol.58, No2, (January 2002), pp. 265-271 
Briellmann, R.S.; Wellard, R.M. & Jackson, G.D. (2005). Seizure-associated abnormalities in 
epilepsy: evidence from MR imaging, Epilepsia, Vol.46, No5, (May 2005), pp. 760-
766 
Canas, N.; Soares, P.; Calado, S.; Pestana, R.; Ribeiro, C. & Vale, J. (2010a). Pathophysiology 
and long-term outcome of reversible tumor-like lesions induced by presenting 
status epilepticus, Journal of Neuroimaging, Vol.20, No.2, (April 2010), pp. 169-174 
Canas, N.; Breia, P.; Soares, P.; Saraiva, P.; Calado, S.; Jordão, C. & Vale, J. (2010b). The 
electroclinical-imagiological spectrum and long-term outcome of transient periictal 
MRI abnormalities, Epilepsy Research, Vol.91, No.2-3, (October 2010), pp. 240-252 
Castillo, M.; Smith, J.K. & Kwock L. (2001). Proton MR spectroscopy in patients with acute 
temporal lobe seizures, AJNR American Journal of Neuroradiology, Vol.22, No1, 
(January 2001), pp. 152-157   
Cha, S. (2006). Update on brain tumor imaging: from anatomy to physiology, AJNR 
American Journal of Neuroradiology, Vol.27, No3, (May 2006), pp. 475-487   
Chu, K.; Kang, D.W.; Kim, J.Y.; Chang, K.H. & Lee, S.K. (2001). Diffusion-weighted magnetic 
resonance imaging in nonconvulsive status epilepticus, Archives of Neurology, 
Vol.58, No6, (June 2001), pp. 993-998 
Chan, S.; Chin, S.S.M.; Kartha, K.; Nordli, D.R.; Goodman, R.R.; Pedley, T. & Hilal, S.K. 
(1996). Reversible signal abnormalities in the hippocampus and neocortex after 
prolonged seizures, AJNR American Journal of Neuroradiology, Vol.17, No9, (October 
1996), pp. 1725-1731 
Cohen-Gadol, A.A.; Britton, J.W.; Worrell, G.A. & Meyer, F.B. (2004). Transient cortical 
abnormalities on magnetic resonance imaging after status epilepticus: case report, 
Surgical Neurology, Vol.61, No5, (May 2004), pp. 479-82 
Cole A.J. (2004). Status epilepticus and periictal imaging, Epilepsia, Vol.45, (Suppl. 4), pp. 72-
77 
Di Bonaventura, C.; Bonini, F.; Fattouch, J.; Mari, F.; Petrucci, S.; Carnì, M.; Tinelli, E.; 
Pantano, P.; Bastianello, S.; Maraviglia, B.; Manfredi, M.; Prencipe, M. & 
Giallonardo, A.T. (2009). Diffusion-weighted magnetic resonance imaging in 
patients with partial status epilepticus, Epilepsia, Vol.50, (Suppl. 1), pp. 45-52 
Doherty, C.P.; Cole, A.J.; Grant, P.E.; Fischman, A.; Dooling, E.; Hoch, D.B.; White, T.H. 
& Cosgrove, G.R. (2004). Multimodal longitudinal imaging of focal status 
epilepticus, Canadian Journal of Neurological Sciences, Vol.31, No.2, (May 2004), 
pp. 276-281 
 
MRI Abnormalities Induced by Seizures 
 
207 
Fabene, P.F.; Marzola, P.; Sbarbati, A. & Bentivoglio, M. (2003). Magnetic resonance 
imaging of changes elicited by status epilepticus in the rat brain: diffusion-
weighted and T2-weighted images, regional blood volume maps, and direct 
correlation with tissue and cell damage, Neuroimage, Vol.18, No.2, (February 
2003), pp. 375-89 
Farina, L.; Bergqvist, C.; Zimmerman, R.A.; Haselgrove, J.; Hunter, J.V. & Bilaniuk, L.T. 
(2004). Acute diffusion abnormalities in the hippocampus of children with new-
onset seizures: the development of mesial temporal sclerosis, Neuroradiology, 
Vol.46, No.4, (April 2004), pp. 251-157 
Fazekas, F.; Kapeller, P.; Schmidt, R.; Stollberger, R.; Varosanec, S.; Offenbacher, H.; 
Fazekas, G. & Lechner, H. (1995). Magnetic resonance imaging and spectroscopy 
findings after focal status epilepticus, Epilepsia, Vol.36, No.9, (September 1995), pp. 
946-949 
Flacke, S.; Wullner, U.; Keller, E.; Hamzei, F. & Urbach, H. (2000). Reversible changes in 
echo planar perfusion- and diffusion-weighted MRI in status epilepticus, 
Neuroradiology, Vol.42, No.2, (February 2000), pp. 92-95 
Goulatia, R.K.; Verma, A. ; Mishra, N.K. & Ahuja, G.K. (1987). Disappearing CT lesions in 
epilepsy, Epilepsia, Vol.28, No.5, (September-October 1987), pp. 523-527 
Goyal, M.K.; Sinha, S.; Ravishankar, S. & Shivshankar, J.J. (2009). Peri-ictal signal changes in 
seven patients with status epilepticus: interesting MRI observation,  Neuroradiology, 
Vol.51, No3, (March 2009), pp. 151-61 
Hicdonmez, T.; Uktu, U.; Turgut, N.; Cobanoglu, S. & Birgili, B. (2003). Reversible postictal 
MRI change mimicking structural lesion, Clinical Neurology and Neurosurgery, 
Vol.105, No.4, (September 2003), pp. 288-290 
Hinchey, J.; Chaves, C.; Appignani, B.; Breen, J.; Pao, L.; Wang, A.; Pessin, M.S.; Lamy, C.; 
Mas, J.L. & Caplan, L.R. (1996). A reversible posterior leukoencephalopathy 
syndrome, New England Journal of Medicine, Vol.334, No.8, (February 22, 1996), pp. 
494-500 
Hong, K.S.; Cho, Y.J.; Lee, S.K.; Jeong, S.W.; Kim, W.K. & Oh, E.J. (2004). Diffusion changes 
suggesting predominant vasogenic oedema during partial status epilepticus, 
Seizure, Vol.13, No.5, (July 2004), pp. 317-321 
Huang, Y.C.; Weng, H.H.; Tsai, Y.T.; Huang, Y.C.; Hsiao, M.C.; Wu, C.Y.; Lin, Y.H.; Hsu, 
H.L. & Lee, J.D. (2009). Periictal magnetic resonance imaging in status epilecticus, 
Epilepsy Research, Vol.86, No.1, (September 2009), pp. 72-81 
Juhasz, C.; Scheidl, E. & Szirmai, I. (1998). Reversible focal MRI abnormalities due to status 
epilepticus. An EEG, single photon emission computed tomography, transcranial 
Doppler follow-up study, Electroencephalography and Clinical Neurophysiology, 
Vol.107, No6, (December 1998), pp. 402-407 
Kim, J.-A.; Chung, J.I.; Yoon, P.H., Kim; D.I., Chung, T.-S.; Kim, E.-U. & Jeong, E.-K. (2001). 
Transient MR signal changes in patients with generalized tonicoclonic seizure or 
status epilepticus: periictal diffusion-weighted imaging, AJNR Am J Neuroradiology, 
Vol.22, No6, (June-July 2001), pp. 1149-1160 
Kozak, O.S.; Wijdicks, E.F.; Manno, E.M.; Miley, J.T. & Rabinstein, A.A. (2007). Status 
epilepticus as initial manifestation of posterior reversible encephalopathy 
syndrome, Neurology, Vol.69, No9, (August 2007), pp. 894-897 
 
Neuroimaging – Clinical Applications 
 
208 
Kramer, L.E.; Luders, H.; Lesser, R.P.; Weinstein, M.R.; Dinner, D.S.; Morris, H.H. & 
Wyllie, E. (1987). Transient focal abnormalities of neuroimaging studies during 
focal status epilepticus, Epilepsia, Vol.28, No5, (September-October 1987), pp. 528-
532 
Lansberg, M.G.; O’Brien, M.W.; Norbach, A.M.; Moseley, M.E.; Morrell, M. & Albers, G.W. 
(1999). MRI abnormalities associated with partial status epilepticus, Neurology, 
Vol.52, No5, (March 1999), pp. 1021-1027 
Lazeyras, F.; Blanke, O.; Zimine, I.; Delavelle, J.; Perrig, S.H. & Seeck, M. (2000). MRI, (1)H-
MRS, and functional MRI during and after prolonged nonconvulsive seizure 
activity, Neurology, Vol.55, No11, (December 2000), pp. 1677-1682 
Masterson, K.; Vargas, M.I. & Delavelle, J. (2009). Postictal deficit mimicking stroke: role of 
perfusion CT, Journal of Neuroradiology, Vol.36, No.1, (March 2009), pp. 48-51 
McClelland, S.; Libien, J.M.; Chin, S.S.; Adams, D.J.; Resor, S.R.; Chan, S. & Goodman, R.R. 
(2005). Unusual findings in brain biopsies of two patients with acute magnetic 
resonance imaging lesions associated with focal seizures, Epilepsia, Vol.46, No.9, 
(September 2005), pp. 1495-1501 
McNamara, J.O. (1994). Cellular and molecular basis of epilepsy, The Journal of Neurosciences, 
Vol.14, No6, (June 1994), pp. 3413-3425 
Meissner, B.; Kallenberg, K.; Sanchez-Juan, P.; Krasnianski, A.; Heinemann, U.; Varges, 
D.; Knauth, M. & Zerr, I. (2008). Isolated cortical signal increase on MRI 
imaging as a frequent lesion pattern in sporadic Creutzfeldt-Jakob disease, 
AJNR American Journal of Neuroradiology, Vol.29, No8, (September 2008), pp. 
1519-1524 
Milligan, T.A.; Zamani, A. & Bromfield, E. (2009). Frequency and patterns of MRI 
abnormalities due to status epilepticus, Seizure, Vol.18, No2, (March 2009), pp. 104-
108 
Mueller, S.G.; Kollias, S.S.; Trabesinger, A.H.; Buck, A; Boesiger, P. & Wieser, H.J. (2001). 
Proton magnetic resonance spectroscopy characteristics of a focal cortical cortical 
dysgenesis during status epilepticus and in the interictal state, Seizure, Vol.10, No.7, 
(October 2001), pp. 518-524 
Najm, I; Wang, Y; Hong, S.C; Luders, H.O.; Ng, T.C. & Comair, Y.G. (1997). Temporal 
changes in proton MRS metabolites after kainic acid-induced seizures in rat brain, 
Epilepsia, No38, No1, (January 1997), pp. 87-94 
Nakasu, Y.; Nakasy, S.; Morikawa, S.; Uemura, S.; Inubushit, T. & Handa, J. (1995). 
Diffusion-weighted MRI in experimental sustained seizures elicited with kainic 
acid, AJNR American Journal of Neuroradiology, Vol.16, No6, (June-July 1995), pp. 
1185-1192 
Nixon, J.; Bateman, D. & Moss, T. (2001). An MRI and neuropathological study of a case of 
fatal status epilepticus, Seizure, Vol.10, No8, (December 2001), pp. 588-91. 
Parmar, H.; Lim, S.H.; Tan, N.C. & Lim, C.C. (2006). Acute symptomatic seizures and 
hippocampus damage: DWI and MRS findings, Neurology, Vol.66, No11, (June 
2006), pp. 1732-1735 
Pohlmann-Eden, B.; Gass, A.; Peters, C.N.; Wennberg, R. & Blumcke, I. (2004). Evolution of 
MRI changes and development of bilateral hippocampal sclerosis during long 
 
MRI Abnormalities Induced by Seizures 
 
209 
lasting generalized status epilepticus, Journal of Neurology, Neurosurgery, and 
Psychiatry, Vol.75, No6, (June 2004), pp. 898-900. 
Provenzale, J.M.; Barboriak, D.P.; VanLandingham, K.; MacFall, J.; Delong, D. & Lewis, D.V. 
(2008). Hippocampal MRI signal hyperintensity after febril status epilepticus is 
predictive of subsequent mesial temporal sclerosis, AJR American Journal of 
Roentegenology, Vol.190, No.4, (April 2008), pp. 976-983 
Raghavendra, S.; Ashalatha, R.; Krishnamoorthy, T.; Kesavadas, C.; Thomas, S.V. & 
Radhakrishnan, K. (2007). Reversible periictal MRI abnormalities: clinical correlates 
and long-term outcome in 12 patients, Epilepsy Research, Vol.73, No1, (January 
2007), pp. 129-136 
Righini, A.; Pierpaoli, C & Alger, J.R. (1994). Brain parenchyma ADC alterations associated 
with experimental complex partial status epilepticus, Magnetic resonance imaging, 
Vol.12, No6, pp. 865-871 
Sammaritano, M; Andermann, F.; Melanson, D.; Pappius, H.M,; Camfield, P; Aicardi, J. & 
Sherwin, A. (1985). Prolonged focal cerebral edema associated with partial status 
epilepticus, Epilepsia, Vol.26, No.4, (July-August 1985), pp. 334-339 
Senn, P.; Lovblad, K.O.; Zutter, D.; Bassetti, C.; Zeller, O.; Donati, F. & Schroth, G. (2003). 
Changes on diffusion-weighted MRI with focal motor status epilepticus: case 
report, Neuroradiology, Vol.45, No4, (April 2003), pp. 246-249  
Sethi P.K.; Kumar B.R.; Madan V.S. & Mohan V. (1985). Appearing and Disappearing CT 
scan abnormalities in seizures, Journal of Neurology, Neurosurgery, and Psychiatry, 
Vol.49, No.9, (September 1985), pp. 866-869  
Silverstein, A.M. & Alexander, J.A. (1998). Acute postictal cerebral imaging. AJNR 
American Journal of Neuroradiology, Vol.19, No.8, (September 1998), pp. 1485-
1488 
Sloviter R.S. & Dempster D.W. (1985). "Epileptic" brain damage is replicated qualitatively in 
the rat hippocampus by central injection of glutamate or aspartate but not by 
GABA or acetylcholine, Brain Research Bulletin, Vol.15, No1, (January 1985), pp. 39-
60 
Szabo, K.; Poepel , K.; Pohlmann-Eden, B.; Hirsch, J.; Back, T.; Sedlaczek, O.;  Hennerici, M. 
& Gass, A. (2005). Diffusion-weighted and perfusion MRI demonstrates 
parenchymal changes in complex partial status epilepticus, Brain, Vol.128, Pt 6, 
(June 2005), pp.  1369-1376 
Theodore, W.H. (1999). Cerebral blood flow and glucose metabolism in human epilepsy, 
Advances in Neurology, Vol.79, pp. 873-881 
Wang, Y.; Majors, A. ; Najm, I. ; Xue, M. ; Comair, Y. ; Modic, M. & Ng, T.C. (1996). 
Postictal alteration of sodium content and apparent diffusion coefficient in 
epileptic rat brain induced by kainic acid, Epilepsia, Vol.37, No10, (October 1996), 
pp. 1000-1006 
Wellard, R.M.; Briellmann, R.S.; Prichard, J.W.; Syngeniotis, A & Jackson, G.D (2003). 
Myoinositol abnormalities in temporal lobe epilepsy, Epilepsia, Vol.44, No6, (June 
2003), pp. 815-821 
Wieshmann U.C.; Symms M.R. & Shorvon S.D. (1997). Diffusion changes in status 
epilepticus, Lancet, Vol.350, No9076, (August 16, 1997), pp. 493-494 
 
Neuroimaging – Clinical Applications 
 
210 
Young, G.S.; Geschwind, M.D.; Fischbein, N.J.; Martindale, J.L.; Henry, R.H.; Liu, S.; Wong, 
S.; Liu, H.; Miller, B.L. & Dillon, W.P. (2005). Diffusion-weighted and fluid-
attenuation recovery imaging in Creutzfeldt-Jacob disease: high sensitivity and 
specificity for diagnosis, AJNR American Journal of Neuroradiology, Vol.26, No6, 
(June-July 2005), pp. 1551-1562 
11 
Central Nervous System Findings on  
Magnetic Resonance Imaging  
in Children with Epilepsy 
Teodoro Durá-Travé1, Maria Eugenia Yoldi-Petri1,  
Joaquin Esparza-Estaún2, Fidel Gallinas-Victoriano1,  
Sergio Aguilera-Albesa1 and Amaia Sagastibelza-Zabaleta1 
1Neurology Pediatric Unit, 
2Department of Neuroradiology, Navarra Hospital Complex, Pamplona 
 Spain 
1. Introduction 
Epilepsy is a relatively frequent pathology in child populations, with an annual incidence 
rate ranging from 41 to 67 per 100 000 cases1-7. In the past decade, many important advances 
related to epilepsy have arisen. On one hand, new diagnostic methods (video 
electroencephalography monitoring, structural and/or functional neuroimaging, metabolic 
and genetic analysis, etc) facilitate the diagnosis and the syndromic classification; on the 
other hand, the availability of the new antiepileptic drugs is conditioning new therapeutic 
possibilities8-11.  
The International League Against Epilepsy classification for epilepsy and epileptic 
syndromes suggests prognosis consequences, because it allows estimating outcome and 
therapeutic responses12-15. In this way, structural neuroimaging plays an important role in 
the evaluation, management, and treatment of the child with epilepsy. The role of 
neuroimaging is to detect an underlying cerebral lesion that may be causally related to the 
child’s seizure disorder. Magnetic resonance imaging (MRI) is the elective of all structural 
imaging tool. MRI is considerably superior to X-ray CT in terms of its sensitivity and 
specificity for identifying subtle abnormalities. The principal role of MRI is in the definition 
of the structural abnormalities that underlie seizure disorders (tumours, malformations of 
cortical development, hippocampal sclerosis, neurocutaneous diseases, vascular 
malformations, traumatic lesions, strokes, residual lesions, etc.) and to contribute to the 
aetiologic diagnosis and classification of the different epilepsies and epileptic syndromes, 
and thereby provide an accurate prognosis for patients11,16-18. In Spain, there is limited 
information about its current use in the initial evaluation of pediatric epilepsy and about its 
performance during the initial diagnosis of epilepsy, which suggests that a descriptive study 
of MRI findings in epilepsy in children would be necessary. 
The aim of this study is to analyze the epidemiological characteristics and proportional 
distribution of the epilepsy and epileptic syndromes in children, and to describe the central 
nervous system findings on MRI in these patients.  
 





The study is based on data obtained from 457 medical records of a random selection among 
the patients diagnosed with epilepsy in the Paediatric Neurology Unit of the Navarre 
Hospital Complex in Pamplona who were examined from January until December 2009. The 
patients were included on the condition that MRI was performed at diagnosis according to a 
standardized paediatric seizure protocol.  
The Navarra Hospital Complex of Pamplona is the neuropediatric reference center in 
Navarra and is the place where the neuropediatric and neurophysiology and magnetic 
resonance imaging units are located. The functional and structural organization of the 
health service in Navarre provides referral of all patients with suspected seizures or 
epilepsy from the health care centers or secondary hospitals (located in Tudela and Estella) 
to the reference hospital. A neuropediatric examination and follow-up are performed, and, 
finally, a syndromic diagnosis is established in most patients. 
Information recorded from every patient includes epidemiologic data (sex, age at onset, and 
personal and familial history of epilepsy and febrile seizures) and clinical data (seizure 
types, neurologic findings, and associated pathologic conditions), as well as the results of 
complementary studies (electroencephalogram and neuroimaging, including genetic, 
metabolic, and neurophysiologic studies when required) in order to classify seizures 
according to etiology as idiopathic, symptomatic or cryptogenic. 
The International League Against Epilepsy criteria for epileptic seizures and epileptic 
syndromes and guidelines for epidemiologic studies have been applied for diagnosis and 
classification12-15,19. Therefore, epilepsy was diagnosed at the time of a second unprovoked 
seizure, and multiple seizures in a 24-hour period were considered a single episode. Patients 
with neonatal seizures only, febrile seizure and other acute symptomatic seizures were 
excluded. The syndromic diagnosis corresponding to each patient was discussed by 
members of the neuropediatric unit, and a final diagnosis was reached based on 
concurrence of the members. 
3. Magnetic resonance imaging 
MRI was performed in all patients at the onset of diagnosis according to a standardized 
paediatric seizure protocol. The standardized pediatric seizure protocol consisted of the 
following scanning sequences: 
- T2-weighted fast spin-echo (FSE) images and proton density-weighted in axial plane 
with 5 mm thick slices. 
- T2-weighted Fluid attenuated inversion recovery (FLAIR) images in the coronal plane, 
with 5 mm thick slices. 
- T1-weighted FLAIR images in the sagittal plane, with 5 mm thick slices.  
- T1-weighted FLAIR images in the axial plane, with 3 mm thick slices.  
- Diffusion-weighted (DW) images in the axial plane.  
Complementary sequences: 
- T2-weighted gradient-echo images in the axial plane, with 5 mm thick slices, for the 
detection of calcifications or hemosiderine deposits.  
- T2-weighted FSE images in the coronal plane, with 3 mm thick slices, for the study of 
temporal lobe seizure foci.  
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The scoring system used for MRI examinations in this study classifies various abnormal 
features by location20. Abnormal features include volume loss, leukomalacia/gliosis, 
encephalomalacia, other white-matter lesions, heterotopia, cortical dysplasia, other gray-
matter lesions, mass lesions, vascular lesions, ventricular enlargement, prominence of the 
extra-axial spaces, hippocampal atrophy or signal abnormality, and others structural 
abnormalities.  
Abnormalities on MRI were classified as either significant or nonsignificant based on a 
system of classification previously developed21-23. A significant abnormality was defined as 
a MRI finding reasonably likely to be related to seizure disorder. These were defined as at 
least one of the following: leukomalacia/gliosis, encephalomalacia, any gray-matter lesion, 
mass lesion, hemorrhage, vascular lesion, hippocampal abnormality, ventricular 
enlargement >1.5 cm, or prominence of extra-axial fluid spaces >1.0 cm.  
Some potential overlap in scoring encephalomalacia and leukomalacia/gliosis was 
recognized. Encephalomalacia was generally thought to signify ‘‘cystic encephalomalacia’’ 
and to involve cortical regions. If there was some signal abnormality consistent with gliosis 
adjacent to an area of encephalomalacia, this was scored as encephalomalacia. If there were 
other discrete areas of abnormal signal consistent with gliosis, these were scored as 
(additional) areas of leukomalacia/gliosis.  
All of these studies were read and coded by two neuroradiologists with experience involved 
in this study. Rater was blind to other rater scoring and to other clinical data (e.g., 
electroencephalogram findings), except for knowing that the child had presented with a 
seizure. 
The computer program SPSS 17.0 for Windows (Chicago, Illinois, USA) was used to perform 
the statistical analysis (descriptive study). 
4. Results 
Age distribution was 78 infants (from 1 to 12 months of age), 157 in early childhood (from 1 
to 6 years), 134 school-aged children (from 6 to 10 years), and 88 adolescents (from 10 to 15 
years).  
4.1 Infants 
The sample consisted of 78 patients (37 males and 41 females). In infants, most of the 
seizures were symptomatic (53.8%), whereas others were idiopathic (25.6%) or cryptogenic 
(20.5%). Table 1 shows the distribution of the epilepsies and epileptic syndromes in infants. 
Epilepsies attributed to and organized by structural or metabolic conditions (34.6%) and 
West syndrome (30.8%) were the most prevalent syndromes.  
Epilepsies attributed to and organized by structural or metabolic conditions (n=27) were 
secondary to perinatal asphyxia (figure 1), purulent meningitis, congenital malformations of 
the brain (figure 2), Aicardy syndrome (figure 3), inherited metabolic disorders, 
phakomatoses (figure 4) and venous thrombosis. Among patients diagnosed with West 
syndrome, etiology was symptomatic in 62.5% of the cases (n=15); this means, 6 cases 
related to perinatal ischaemic or anoxic lesions, 3 cases with Down syndrome, 2 cases with 
tuberous sclerosis, and 1 case related with pathologies as subcortical band heterotopia 
(figure 5), semilobar holoprosencephaly, neonatal meningoencephalitis (figure 6) and 
perinatal intracranial hemorrhage.  
 















Fig. 1. Chronic-atrophic stage and cystic periventricular leukomalacia: Spin echo (SE) T-2 
image showing periventricular white matter atrophy and small cystic lesions adjacent to 
right ventricle. 
 















Fig. 2. Open lip schizencephaly: SE T-2 weighted image showing localized parenchymal 
defects as a split between subarachnoid and ventricular space. Small low-signal 
periventricular lesions related to calcifications (clinical suspicion of perinatal infection). 
 




















































Fig. 3. (a, b, c). Aicardi syndrome: FLAIR T1 images showing choroid plexus cysts that 
expand the occipital horn in left ventricle, subependymal heterotopia adjacent to both lateral 
ventricles, agenesis of the corpus callosum that causes a parallel layout of the lateral 
ventricles and left microphtalmia with posterior lens luxation. 
 































Fig. 4. (a, b). Tuberous sclerosis: SE 3800/11 images displaying subependymal hamartomas  
bulging towards the ventricular space, giant cell astrocytomas near the foramen of Monro 
(the right ventricle astrocytoma showing calcifications), brain hamartomas seen as 
hyperintense subcortical lesions and portions of dysplastic white matter which follow the 
pathway of neuronal migration, revealed as linear tracks of radial layout in the white 
matter. 
 
















Fig. 5. Band heterotopia: FLAIR T1 images show a thick band of heterotopic grey matter, 
which is separated from the cortex by a thin layer of myelinated white matter. 
 














Fig. 6. Frontal bilateral porencephalic lesions as sequelae of meningitis. SE T2 image shows 
two large frontal porencephalic lesions, being the left one comunicated with the frontal 
horn. 
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Of 78 infants in this study, 42 (53.8%) demonstrated at least one MRI abnormality. Thirty-
three (42.3%) manifested MRI abnormalities that were classified as significant because they 
were considered to be potentially related to the seizure condition. 
Table 2 presents the number of infants with MRI abnormalities. Because different 
abnormalities can affect the same locations for a given child, the sum of abnormalities 
may exceed the total number of children. Of 42 children with at least one MRI 
abnormality, the most common abnormalities included white-matter lesions (28.7%), 
volume loss (22.8%), gray-matter lesions (18.8%) and ventricular enlargement >1 cm 
(13.9%).  
 
West syndrome  24 
Myoclonic epilepsy in infancy 5 
Benign familial infantile epilepsy 3 
Benign non-familial infantile epilepsy 1 
Dravet syndrome 10 
Reflex epilepsy (tactile evoked myoclonic seizures) 1 
Epilepsies of unknown cause (generalised or focal) 7 
Epilepsies associated with structural or metabolic conditions 
Perinatal insults 
Cerebral infections 
       Bacterial meningitis (Str. pneumoniae)  
Malformations of cortical development 
       Schizenphalies  
       Focal cortical dysplasia 
       Polymicrogiria 
Other cerebral malformations 
       Aicardi syndrome 
       Holoprosencephaly 
Inherited metabolic disorders  
      Non-ketotic hyperglycinemia 
      Tay-Sachs disease 
      Alpers disease 
      Mucopolysaccharidosis (Hunter syndrome) 
Neurocutaneous disorders 
      Tuberous sclerosis complex 
Vascular lesion  





















Table 1. Distribution of the different epilepsies and epileptic syndromes in infants (n=78) 
 




MRI abnormality (n=101) n (%) 
Volume loss 
    Generalized 
    Hemisphere 
    Lobe 
    Cerebelar  







White matter lesions 
     Leukomalacia/gliosis  
     Encephalomalacia  






    Heterotopias  
    Cortical dysplasias 






    Hemorrhage 




Ventricular enlargement  
    <1.5cm 




Prominence of extra-axial fluid space  
    <1.0cm 




Other structural abnormalities 
    Agenesis of the corpus callosum 
    Delayed myelination 
    Enlarged perivascular spaces in the corpus callosum  






Boldface rows represented “significant abnormalities”  
Table 2. MRI abnormalities found in infants diagnosed with epilepsy  
4.2 Early childhood 
The sample was made up of 157 patients (85 males and 72 females). In early childhood, 
distribution was idiopathic (44,6%), cryptogenic (29.9%) or symptomatic (25.5%). Table 3 
shows the distribution of the epilepsies and epileptic syndromes in this period. Epilepsies in 
which nature of the underlying causes is yet unknown (29.9%) and epilepsies attributed to 
and organized by structural or metabolic conditions (24.8%) were the most prevalent 
syndromes.  
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Epilepsies associated to structural or metabolic conditions (n=39) were secondary to 
perinatal asphyxia (figure 7), cerebral infections (figure 8), congenital malformations of 
the brain, inherited metabolic disorders, phakomatoses (figure 9), chromosomal 
abnormalities, arterial infarction (figure 10), arteriovenous malformations and 
supratentorial tumors.  
Of 157 early infants in this study, 45 (28.7%) had at least one MRI abnormality. Thirty-two 
(20.4%) showed MRI abnormalities that were classified as significant because they were 




Fig. 7. Porencephalic cyst: T2-weighted SE image displays a wide cyst in the left frontal lobe, 
which is connected to the lateral ventricle and causes a slight lateral midline displacement of 
the brain.  
 















Fig. 8. Neurocysticercosis: T1-weighted SE images (gadolinium-enhanced) shows small 
cystic intraparenchymal lesions and peripheral enhancement.  
 





















































Fig. 9. (a, b, c). Tuberous sclerosis: T1-weighted FLAIR images reveal cerebral hamartomas 
as low signal intensity subcortical lesions, subependymal hamartomas casted on the 
ventricular space and small giant cell astrocytomas adjacent to the foramen of Monro. 
 







Fig. 10. Post-stroke sequelae in the right middle cerebral artery: T2- weighted SE image 
showing residual encephalomalacia with volume loss and ex vacuo enlargement of the right 
ventricle. An area of periventricular leukomalacia in the left occipital lobe can be 
appreciated.  
Table 4 presents the number of early infants with MRI abnormalities (the sum of 
abnormalities may exceed the total number of children because different abnormalities 
can affect the same locations for a given patient). In this group of 45 children with at least 
one MRI abnormality, the most common abnormalities included white-matter lesions 
(28.7%), volume loss (19.1%), gray-matter lesions (21.3%) and ventricular enlargement 
(14.9%). 
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West syndrome 2 
Myoclonic epilepsy 4 
Febrile seizures plus 1 
Panayiotopoulos syndrome 9 
Epilepsy with myoclonic atonic seizures 10 
Benign epilepsy with centrotemporal spikes 18 
Late onset childhood occipital epilepsy (Gastaut type) 1 
Epilepsy with myoclonic absences 1 
Childhood absence epilepsy 13 
Lennox-Gastaut syndrome 1 
Epilepsy with continuous spike-and-wave during sleep 7 
Landau-Kleffner syndrome 1 
Autosomal-dominant nocturnal frontal lobe epilepsy 1 
Epilepsies of unknown cause (generalized or focal) 46 
Epilepsies associated with structural or metabolic conditions
Perinatal insults 
Cerebral infections 
      Cysticercosis 
      Herpes simplex encephalitis   
      Malaria 
Malformations of cortical development 
      Focal cortical dysplasia 
      Heterotopias 
      Polymicrogiria 
      Schizenphalies  
Others cerebral malformations 
       Dandy-Walker malformations 
Inherited metabolic disorders  
      Alpers disease 
      Others  
Neurocutaneous disorders 
      Tuberous sclerosis complex 
Chromosomal abnormalities 
       Down syndrome (trysomy 21) 
       Angelman syndrome 
       Deletion 8p23 
       Deletion 5q syndrome 
       Duplication 15q syndrome 
Stroke 
       Middle cerebral artery infarction 
Vascular malformations 
      Arteriovenous malformation 
Tumors   































Condition with epileptic seizures that do not require a diagnosis of epilepsy
Infantile convulsions with mild gastroenteritis
 
3 
Table 3. Distribution of the different epilepsies and epileptic syndromes in early childhood 
(n=157)  
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MRI abnormality (n=94) n (%) 
Volume loss 
    Generalized 
    Hemisphere 
    Lobe 
    Cerebelar   







White matter lesions 
     Leukomalacia/gliosis  







    Heterotopias 
    Cortical dysplasias 






    Hemorrhage     
2 (2.1%) 
2 
Ventricular enlargement  
    <1.5cm 




Prominence of extra-axial fluid space  
    <1.0cm 




Mass lesion 1 (1.1%) 
Other structural abnormalities 
   Hemisphere asymmetry 
   Cerebellar tonsils descent  
   Choroid plexus cyst 
   Pineal cyst 
   Mega cisterna magna 
   Arteriovenous malformations 
   Delayed myelination 










Boldface rows represented “significant abnormalities”  
Table 4. MRI abnormalities found in early childhood diagnosed with epilepsy  
4.3 School-aged children 
The sample was made up of 134 patients (72 males and 62 females). In school-age children, 
seizures were idiopathic in 55.2%, cryptogenic in 25.4% and symptomatic in 19.4%. Table 5 
shows the distribution of the epilepsies and epileptic syndromes in school-aged children. 
Epilepsies in which the nature of the underlying causes is yet unknown (29.1%), benign 
epilepsy with centrotemporal spikes (25.4%) and childhood absence epilepsy (18.7%) were 
the most prevalent syndromes.  
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Epilepsies attributed to structural or metabolic conditions (n=39) were secondary to 
perinatal asphyxia, cerebral infections, congenital malformations of the brain (figure 11), 
phakomatoses, arterial infarction, arteriovenous malformations (figure 12), suprasellar 










Fig. 11. Subependymal heterotopia: T2-weighted SE image shows a gray matter nodule 
protruding over the occipital horn of the right ventricle.  
 


































Fig. 12. (a, b). Arteriovenous malformation (AVM):T1-weighted SE images post contrast-
enhancement features a tangle of blood vessels in the left parieto-occipital region. Some of 
them show enhancement and others show absence of blood flow.  
 















Fig. 13. Suprasellar arachnoid cyst: T2-weighted SE image shows a cystic suprasellar lesion 
which displaces the III ventricle and causes lateral ventricle hydrocephalus. 
 
























Fig. 14. (a, b). Chemotherapy-induced toxicity in a boy diagnosed with acute lymphoblastic 
leukemia. T2-weighted SE images reveal cerebral involvement as patches with hyperintense 
areas in periventricular white matter, right occipital cortico-subcortical area and the right 
corpus striatum. In addition, there is a porencephalic lesion in the left thalamic region. 
After going through the records of the 134 school-aged children, we found that 28 (20.9%) 
had at least one MRI abnormality recorded. Twenty-one (15.7%) presented MRI 
abnormalities that again were considered as significant because they were potentially 
related to the seizure condition. 
Table 6 presents the number of school-age children with MRI abnormalities. From the 28 
children with at least one MRI abnormality, the findings included white-matter lesions 
(23.4%), gray-matter lesions (23.4%), volume loss (17%) and prominence of extra-axial fluid 
space (12.8%) 
 




Panayiotopoulos syndrome 5 
Benign epilepsy with centrotemporal spikes 34 
Late onset childhood occipital epilepsy (Gastaut type) 4 
Reflex epilepsy (photosensitive epilepsies) 1 
Childhood absence epilepsy 25 
Lennox-Gastaut syndrome 1 
Epilepsy with continuous spike-and-wave during sleep  4 
Landau-Kleffner syndrome  1 
Epilepsies of unknown cause (focal/generalized) 39 
Epilepsies associated with structural or metabolic conditions 
Perinatal insults 
Cerebral infections 
    Subdural empyema 
    EBV encephalitis 
Malformations of cortical development 
     Subependymal heterotopia 
     Band heterotopia (double cortex)  
     Focal cortical dysplasia 
     Polymicrogyria 
Others cerebral malformations 
     Chiary I malformations 
Tumors 
    Desmoplastic neuroepithelial tumors 
Neurocutaneous disorders 
    Tuberous sclerosis complex 
Stroke  
    Middle cerebral artery infarction 
Vascular malformations 
     Arteriovenous malformations 
     Cavernous malformations 
Prominence of extra-axial fluid space  
     Suprasellar arachnoid cyst 
Drug toxicity 


























Table 5. Distribution of the different epilepsies and epileptic syndromes in school-aged 
children (n=134 ) 
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MRI abnormality (n=47) n (%) 
Volume loss 
    Generalized 
    Hemisphere 





White matter lesions 
     Leukomalacia/gliosis  
     Encephalomalacia  






    Heterotopias  
    Cortical dysplasias 





Mass lesion 1 (2.1%) 
Vascular lesion 
    Hemorrhage    
2 (4.3%) 
2 
Ventricular enlargement  
    <1.5cm 




Prominence of extra-axial fluid space  
    <1.0cm 




Other structural abnormalities 
    Calcifications 
    Lobe asymmetry 
    Cerebellar tonsils descent  
    Arteriovenous malformations 







Boldface rows represented “significant abnormalities”  
Table 6. MRI abnormalities found in school-aged childhood diagnosed with epilepsy  
4.4 Adolescents 
The sample was consisted of 88 patients (39 males and 49 females). In this group of 
patients, seizures were idiopathic in 69.3%, cryptogenic in 19.3% and symptomatic in 
11.4% of them. Table 7 shows the distribution of the epilepsies and epileptic syndromes in 
adolescents. Idiopathic generalized epilepsies with variable phenotypes (46.6%) and 
cryptogenic focal epilepsies and/or unknown cause (19.3%) were the most prevalent 
syndromes.  
Epilepsies associated to structural or metabolic conditions (n=9) were secondary to perinatal 
asphyxia, malformations of the brain, strokes (figure 15), vascular malformations, 
chromosomal abnormalities and ependimal cyst (figure 16). 
 













Fig. 15. Right cerebral hemisphere atrophy after ischemic lesion: T2-weighted SE image 
presents a volume loss in the right hemisphere, atrophy of cortical gyri, leukomalacia and ex 
vacuo enlargement of lateral ventricle. A hyperintense nodule, compatible with spongiotic 
intramyelinic change (neurofibromatosis), can be appreciated in the left globus pallidus. 
 
















Fig. 16. Ependymal cyst: T2-weighted SE image shows a cystic lesion that expands the left 
occipital horn and a small brain herniation inside the interpeduncular cistern. 
 




Benign epilepsy with centrotemporal spikes  13 
Panayiotopoulus syndrome 3 
Late onset childhood occipital epilepsy (Gastaut type) 1 
Idiophatic generalized epilepsies with variable phenotypes 
     Juvenile absence epilepsy  
     Juvenile mioclonic epilepsy 





Progressive mioclonus epilepsy (Lafora disease) 1 
Reflex epilepsies (photosensitive epilepsies) 2 
Epilepsies of unknown cause (generalized or focal) 17 
Mesial temporal lobe epilepsy with hipocampal sclerosis 1 
Epilepsies associated with structural or metabolic conditions 
 
Perinatal insults 
Malformations of cortical development 
      Focal cortical dysplasia 
Stroke  
      Vascular malformations 
      Vasculopathies (neurofibromatosis) 
Vascular malformations 
      Venous malformations  
Chromosomal abnormalities 
       Mycrodeletion 17p13.3 
Prominence of extra-axial fluid space  
      Arachnoid cyst  
      Ependimal cyst 

















Table 7. Distribution of the different epilepsies and epileptic syndromes in adolescents 
(n=88) 
Of 88 infants in this study, 19 (21.6%) revealed at least one MRI abnormality. Fourteen 
(15.9%) manifested significant MRI abnormalities (they might to related to the seizure 
condition). 
Table 8 presents the number of adolescents with MRI abnormalities (the sum of 
abnormalities may be higher than the total number of children). In 19 studies with at least 
one MRI abnormality, the most common abnormalities included white-matter lesions 
(28.1%), volume loss (15.6%), gray-matter lesions (12.5%) and prominence of extra-axial 
fluid space (12.5%). 
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MRI abnormality (n=32) n (%) 
Volume loss 
    Generalized 
    Hemisphere 
    Lobe 






White matter lesions 
     Leukomalacia/gliosis  





    Cortical dysplasias 





    Hemorrhage     
1 (3.1%) 
1 
Ventricular enlargement  
    <1.5cm 




Prominence of extra-axial fluid space  
    <1.0cm 




Other structural abnormalities 
    Lobe asymmetry 
   Cerebellar tonsils descent  
   Absence of the posterior pituitary 






Boldface rows represented “significant abnormalities”  
Table 8. MRI abnormalities found in adolescents diagnosed with epilepsy  
4.5 Whole sample 
The whole group was 457 patients (233 males and 224 females). Etiology was considered 
idiopathic in 225 (49.2%), cryptogenic in 114 (24.9%), and symptomatic in 118 (25.8%). Table 
9 shows the distribution of the epilepsies and epileptic syndromes in the overall sample.  
There was at least one MRI abnormality in 134 patients (29.3%). One hundred (21.9%) had 
significant MRI abnormalities (potentially related to the seizure condition). 
Table 10 presents the number of children with MRI imaging abnormalities. As we 
previously said, the sum of abnormalities may exceed the total number of children, since 
different abnormalities can affect the same locations in one given patient. Of 134 children 
with at least one MRI abnormality, the most common abnormalities included white-matter 
lesions (27.6%), volume loss (19.6%), gray-matter lesions (19.6%) and ventricular 
enlargement (12%). Table 11 shows the distribution of MRI abnormalities found according 
to age. 
Neuroimaging studies achieved in two patients diagnosed with benign epilepsy with 
centrotemporal spikes, two patients with childhood absence epilepsy, one patient with 
juvenile myoclonic epilepsy, and other patient with juvenile absence epilepsy revealed MRI 
abnormalities classified as significant: leukomalacia periventricular (4 cases) or areas of 
gliosis (2 cases). 
 




West syndrome 26 
Myoclonic epilepsy in infancy 9 
Benign familial infantile epilepsy 3 
Benign non-familial infantile epilepsy 1 
Dravet syndrome 10 
Childhood  
Febrile seizures plus 1 
Panayiotopoulos syndrome 17 
Epilepsy with myoclonic atonic seizures 10 
Benign epilepsy with centrotemporal spikes 65 
Autosomal-dominant nocturnal frontal lobe epilepsy 1 
Late onset childhood occipital epilepsy (Gastaut type) 6 
Epilepsy with myoclonic absences 1 
Lennox-Gastaut syndrome 2 
Epilepsy with continuous spike-and-wave during sleep 11 
Landau-Kleffner syndrome 2 
Childhood absence epilepsy 38 
Adolescence  
Juvenile absence epilepsy 20 
Juvenile mioclonic epilepsy 13 
Epilepsy with generalized tonic-clonic seizures alone 8 
Progressive mioclonus epilepsy (Lafora disease) 1 
Less specific  age relationship  
Reflex epilepsies 4 
Distinctive constellation  
Mesial temporal lobe epilepsy with hipocampal sclerosis 1 
Epilepsies that the nature of the underlying cause is yet unknown (generalized 
or focal) 
109 
Epilepsies associated with structural or metabolic conditions  
Perinatal insults 25 
Cerebral infections 7 
Cerebral malformations 22 
Inherited metabolic disorders 7 
Neurocutaneous disorders 7 
Tumors 2 
Stroke 7 
Vascular malformations 4 
Vascular lesions 1 
Chromosomal abnormalities 8 
Prominence of extra-axial fluid space 4 
Drug toxicity 1 
Condition with epileptic seizures that do not require a diagnosis of epilepsy  
Infantile convulsions with mild gastroenteritis 3 
Table 9. Distribution of the different epilepsies and epileptic syndromes arranged by age at 
onset (n=157)  
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MRI abnormality (n=275) n (%) 
Volume loss 
    Generalized 
    Hemisphere 
    Lobe 
    Cerebelar    







White matter lesions 
     Leukomalacia/gliosis  
     Encephalomalacia  






    Heterotopias 
    Cortical dysplasias 






    Hemorrhage 




Ventricular enlargement  
    <1.5cm 




Prominence of extra-axial fluid space  
    <1.0cm 




Mass lesion 2 (0.7%) 
Other structural abnormalities 
   Hemisphere asymmetry 
   Lobe asymmetry 
   Cerebellar tonsils descent  
   Choroid plexus cyst 
   Pineal cyst 
   Mega cisterna magna 
   Arteriovenous malformations 
   Delayed myelination 
   Agenesis of the corpus callosum 
   Absence of the posterior pituitary 
   Calcifications 














Boldface rows represented “significant abnormalities”  
Table 10. MRI abnormalities found in children diagnosed with epilepsy  
 










Infants 33 (42,3%) 42 (53,8%) 
Early infants 32 (20,4%) 45 (28,7%) 
School-aged childhood 21 (15,7%) 28 (20,9%) 
Adolescents 14 (15,9%) 19 (21,6%) 
Total 100 (21,4%) 134 (29,6%) 
Table 11. Distribution of MRI abnormalities found according to age 
5. Discussion 
The community of Navarra has a population of 605 876 inhabitants (2008 census, National 
Institute of Statistics), 88 055 of whom are children (<15 years of age; 45 105 boys [51.2%] 
and 42 950 girls [48.5%]). Although there are no data about the prevalence of infantile 
epilepsy in Spain, the extrapolation of published data7,24-26 allows estimating that the 
selected population would account for a high percentage of epilepsy diagnosed children in 
Navarra. That means, it is a wide enough population to consider as representative for this 
territory, and, also, the results would contribute to determining the epidemiological 
characteristics of epilepsy in children. A routine RMI has been requested in all patients with 
epilepsy as it has been our practice for several years in this Pediatric Neurology Unit in 
order to aid the formulation of syndromic and etiological classification and, therefore, there 
is no reason to suspect any statistical bias in the results and conclusions. 
According to the data, we confirm that age seems to represent a main factor in the clinical 
expression of the different childhood epilepsy phenotypes. In fact, relative distribution of 
the different seizure types and epileptic syndromes was different for each age group, as seen 
in our series. For example, some epileptic syndromes were predominant in some age 
groups, such as epilepsies associated  to structural or metabolic conditions and West 
syndrome in infants, epilepsies in which the nature of the underlying causes is yet unknown 
and epilepsies associated to structural or metabolic conditions in early childhood, or absence 
and focal benign epilepsies with centrotemporal spikes in school-aged children and 
idiopathic generalised epilepsies with variable phenotypes in adolescents. Thus, when 
referring to childhood epilepsy, it would be useful to make reference to the age group of the 
patients, because characteristics for the epilepsies and epileptic syndromes during 
childhood seem to be close to the structural and functional changes in the brain since birth 
to adolescence27-30.  
Our major finding of this study was that the use of MRI at diagnosis of epilepsy in children 
demonstrated a high rate of abnormalities findings. There was an inverse relationship 
between the prevalence of significant MRI abnormalities and age at diagnosis. Thus, the 
prevalence in the first year of life was 42.3%, in early childhood was 20.4%, in 
schoolchildren was 15.7%, and in adolescents was 15.9%. White-matter lesions were more 
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commonly associated with epilepsies and epileptic syndromes in children at any age, 
whereas many other children displayed epileptogenic lesions involving the cortex or gray 
matter. In addition, volume loss, considered a priori to be a non significant abnormality, was 
also very frequent in this population. Ventricular enlargement, especially mild, was also 
fairly frequent (12% of total sample).  
Structural neuroimaging is recommended for all children with recently diagnosed 
localization-related or generalized epilepsy who do not have the clinical and electrographic 
features characteristic of classical idiopathic focal or generalized epilepsy (these include 
benign epilepsy with centrotemporal spikes, childhood absence epilepsy, juvenile absence 
epilepsy, and juvenile myoclonic epilepsy)16,31-33. However, this series shows how structural 
abnormalities judged to be etiologically related to the seizure conditions have been found in 
idiopathic focal or generalized epilepsy, which are consistent with other published data 
23,34,35. This possibility suggests that clinicians should consider obtaining structural 
neuroimaging with an MRI when feasible for all patients with epilepsy, because MRI 
abnormalities may be present even in children with apparently benign syndromes or 
cryptogenic seizures, and the discovery of an epileptogenic lesion has potential implications 
for diagnosis, prognosis and treatment. 
Our data cannot be easily compared with those in other studies because the populations 
are somewhat different23,31-33,36. Our study attempted to acquire MRI scans on all children, 
whereas previous studies excluded some syndromes or children with seizure onset in 
infancy and early childhood. Therefore, this series extends earlier work by other 
investigators in several ways. First, imaging was limited to MRI, the current anatomic 
‘‘gold standard’’. Second, imaging was performed at   diagnosis. Third, we applied a 
standardized classification system to MRI findings which permits to present a 
comprehensive and systematic description of imaging findings. Finally, data were coded 
directly from magnetic resonance images by two neuroradiologists who read the images 
firsthand. 
In conclusion, the use of MRI and a reliable standardized scoring system in a large sample of 
children after their diagnosis of epilepsy identified a high rate of abnormalities (134 of 457, 
29.3%). This may have important implications for practice guidelines in this population. 
First, some findings that might have been regarded as incidental in the past (e.g., volume 
loss/ventricular enlargement, and others white-matter abnormalities) appear to be present 
at the onset of seizures and may therefore be clinically significant. Second, the detection of 
abnormalities in epileptic syndromes other than localization-related 
symptomatic/cryptogenic syndromes supports an argument for routine MRI at the onset of 
any seizure condition. 
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1. Introduction 
The human insular lobe was initially described by the anatomist Reil JC (Reil, 1809). This 
lobe is the first in the cerebral cortex that develops and differentiates in the fetus (Streeter, 
1912; Kodam, 1926; Afif et al., 2007). A recent study demonstrates that the formation of 
insular cortex begins by its inferior region that will later become the limen insula (Afif et al., 
2007). This cortical development progresses in parallel with that of the middle cerebral 
artery (MCA) and its branches in the superior and posterosuperior axis (Afif et al., 2007). 
The insula consists of three short and two long gyri separated by the central insular sulcus, 
which defines the anterior and posterior insula (Varnavas & Grand, 1999; Ture et al., 1999; 
Naidich et al., 2004; Afif & Mertens, 2010). The opercularization is the result of important 
development of the surrounding insular cortex (frontal, parietal and temporal lobes). 
Progressive development over the entire surface of the insular cortex encloses the sylvian 
fissure.  
Due to its deep anatomic position and dense surrounding vascular network, few studies 
involving direct electrical stimulation (ES) of the insular cortex during surgical procedures 
have been reported (Penfield & Jasper, 1954; Penfield & Faulk, 1955; Oppenheimer et al., 
1992; Duffau et al. 2001, 2009). 
Immunocytochemistry, functional imaging, direct ES, and lesion studies suggest an 
important role for the insular cortex. Such roles include language production and 
grammatical processing (Raichle, 1991; McCarthy et al., 1993; Wise et al., 1999; Price, 2000, 
2001; Ackermann & Riecker, 2004; Isnard et al., 2004; Riecker et al., 2005; Friederici et al., 
2006; Kato et al., 2007; Afif et al., 2010a), pain modulation (Tarkka & Treede, 1993; Frot & 
Mauguiere, 1999; Ostrowsky et al., 2000; Peyron et al., 2004; Craig, 2004; Isnard et al., 2005; 
Brooks et al., 2005 ; Schreckenberger et al., 2005; Mazzola et al., 2006; Henderson et al., 2006, 
2007; Afif et al., 2008b), visceral sensory processing (Ostrowsky et al., 2000; Dupont et al., 
2003; Isnard et al., 2004), bradycardia  (Seeck et al., 2003), dysphagia (Danieles & Foundas, 
1997) and auditory processing (Manes et al., 1999; Lewis et al., 2000; Shergill et al., 2000; 
Bamiou et al., 2003; Afif et al., 2010b).  
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Until recently the insular cortex has not been investigated using depth electrodes because 
of its anatomical location in the depth of the sylvian fissure and its close anatomical 
relationship with segments of the middle cerebral artery constituting a “vascular screen” 
at the surface of the insula (Ture et al., 1999, 2000; Varnavas & Grand, 1999; Afif & 
Mertens, 2010).  
Recently, however, Stereoelectroencephalographic (SEEG) recordings on epileptic patients 
with electrodes stereotactically implanted deep in the brain using either the lateral trans-
opercula approach (Isnard et al., 2000; Isnard et al., 2004; Isnard and Mauguiere, 2005; 
Ryvlin et al., 2006) or the oblique approach guided by robotic arm (Afif et al., 2008a), have 
implicated the insular cortex in seizure generation and initial propagation.  
These observations emphasize the need to explore this anatomical structure further during 
invasive pre-surgical evaluation of epileptic patients. Functional studies of the insula should 
be treated in terms of its gyral and sulcal anatomy. The oblique approach (trans-frontal or 
trans-parietal) implantation of the electrodes guided by a robotic arm can explore the 
different insular regions (sulci and gyri) by avoidance of the sylvian vascular network which 
prevents access to these regions by the lateral approach.  
2. Patient selection criteria 
The non-invasive pre-surgical evaluation included in all cases high resolution magnetic 
resonance imaging (MRI) (with coronal T1-weighted images perpendicular to the 
hippocampal axis and T2-weighted images parallel to the hippocampal plane), 
neuropsychological tests, and prolonged electroencephalography (EEG) video monitoring. 
MRI scans showed unilateral hippocampal sclerosis in 17 patients (56.6%) cortical dysplasia 
in five patients (16.7%), and a cavernoma in two patients (6.7%). Six patients (20%) were 
considered cryptogenic (Table 1). Two patients harbored a dysplastic tissue within the 
insular cortex. The mean duration of epilepsy was 19.4 ± 11 years.  
Stereoelectroencephalographic SEEG recordings were judged necessary, in all centers using 
this technique, when non-invasively obtained data were insufficiently concordant, 
discordant, inconclusive, and/or suggested an early involvement of highly eloquent areas. 
SEEG exploration within these patients included deep and superficial structures, including 
the amygdala, hippocampus, cingulate gyrus, SI, SII areas and temporal cortex, with a total 
of 12 to 16 electrodes per patient by implanting electrodes using the lateral orthogonal 
approach (mean 14 electrodes / patient).  
Electrode implantation into the insular lobe was justified on clinical grounds in each case, 
either because patients experienced gustatory hallucinations, laryngeal discomfort or 
throat tightening, paresthesiae or tonic-clonic movements of the face, unpleasant 
paresthesiae affecting large somatic territories and hyper salivation (Isnard et al., 2000; 
Isnard et al., 2004), or because scalp video-EEG data suggested the onset of the first ictal 
electrical change in the perisylvian opercula area or an early spread to the suprasylvian 
opercular cortex and insula.  
The exploration of the insular cortex was elaborated by deferent hospital centers according 
to the classical lateral trans-opercula (orthogonal) approach (Isnard et al., 2000; Isnard et al., 
2004; Isnard & Mauguiere, 2005). An original oblique approach (trans-frontal or trans-
parietal) was elaborated by the center of university hospital of Grenoble (France) to explore 
the insula (Afif et al., 2008a, 2008b, 2010b).  
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P. Age (y) 
Lat. 
R/L Sexe Past history 
Age at 1st 
Seizure 
MRI
1 15 R. f 6 y HcS
2 28 R. m H.T. 20 y Normal
3 19 R. f FC (6 mo) 6 mo HcS
4 35 R. f FC (1 y) 12 y HcS
5 37 R. m H.T. (18 y) 23  y T. dysplasia
6 11 L. m 1 y TP. dysplasia. 
7 13 L. m  6 y Normal
8 20 R. f 11 mo F. dysplasia  
9 22 R. f H.T. (4 y) 14 y FP. dysplasia 
10 34 R. f 3  y Normal
11 38 R. m H.T. (14 y) 14 y HcS 
12 41 R. f Meningitis (3 y) 12 y HcS 
13 18 R. m 15 y HcS
14 44 L. M Meningitis (2 y)+ FC (3 y) 6 y 
HcS
15 42 R. m  10 y HcS 
16 41 R. f 13 y HcS
17 40 R. m FC (10 mo) 2 y HcS
18 18 R. f FC (2,5 y) 9 y HcS 
19 42 R. m 14  y HcS 
20 26 R. f FC (18 mo) 18  y HcS
21 52 R. m H. T. (20 y) 20 y Amygdala Cavernoma  
22 18 R. m FC (16 mo) 3 y HcS, F. Cavernoma 
23 27 R. m H.T. (9  mo) 16 y HcS 
24 26 L. f FC (20 mo) 10 y HcS 
25 13 R. m West syndrom(10 mo) 18 mo 
F. + insular cortical 
dysplasia 
26 9 R. m  1 y Orbito-insular cortical dysplasia
27. 37 R. m H.T. (3mo) +FC (9 mo) 3 y 
HcS 
28 53 R. m H.T. (5y) 9 y Normal
29 14 R. m 5  y Normal
30 7 R. f  2.5 y Normal
Table 1. Patient details P.: patient; MRI: MR imaging; y: year; mo: month; Lat.: hemispheric 
dominance for language; L.: left; R.: right; m: male; f: female; H.T.: head trauma; FC: febrile 
convulsion; HcS: hippocampal sclerosis. 
2.1 Stereotactic implantation of intra-cerebral electrodes 
Targeting of the insular cortex was performed using 3D presurgical T1- MRI images (Imaging 
parameters included 3D T1 gradient Echo 20/4.6/30 injected sequence, 1.5 mm thickness, gap: 
0) computed with stereotactic software (VoximR, IVS solution, Chemnitz, Germany). The 
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avascular characteristics of each trajectory were systematically evaluated by stereotactic and 
stereoscopic digital cerebral teleangiography (Pixray; Bioscan system, Geneva, Switzerland), as 
described elsewhere (Bancaud et al., 1967; Talairach et al., 1988; Kahane et al., 1993).  
Following coagulation of the dural entry point, insular electrodes were implanted  
through a 2 mm burr hole using either an anterior (transfrontal) approach (Fig. 1  A,C) 
 
 
Fig. 1. Locating the insular cortex electrodes: Lateral (A) and frontal (B) X-rays of the patient’s 
head after intracerebral electrode implantation. y’: Anterior oblique electrode (“transfrontal”) 
targeting the anterior and middle short gyrus of the insula; x’: Posterior oblique electrode 
(“transparietal”) targeting the post-central gyrus of the insula; boxes indicate the electrode’s 
contacts within the insular cortex. (C): corresponding sagittal patient diagram showing 
intrinsic anatomical insular structures and implanted electrodes (small letters). We constructed 
an individual diagram for each patient using different slices from pre-surgical T1-MRI images, 
in the AC-PC reference system. The box around electrode y’ represents the contacts within 
both the anterior and middle short insular gyrus; the box around electrode x’ represents the 
contacts within the post-central insular gyrus. (D): image fusion of the pre-operative 3D MRI 
and the post-operative contrast-enhanced 3D CT scan, using VOXIM stereotactic software. We 
could then identify the anatomical position of each electrode with reference to the cortical gyri 
and sulci. The sagittal slice is co-planar to electrode x’; each perpendicular line on the electrode 
trajectory pass through one electrode contact. 
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with an entry point in the middle frontal gyrus, or a posterior (transparietal) approach (Fig. 
1 A, D), entering the brain at the level of the inferior parietal cortex, or both approaches. 
Similarly to other groups, the lateral orthogonal approach used for all deep brain electrodes 
(SEEG) stereotactically implanted outside the insular cortex. Electrode insertion was guided 
by a robotic arm (Neuromate, Renishaw mayfield, Nyon, Switzerland) connected to the 
stereotactic frame and driven by stereotactic planning software (VoximR, IVS solution, 
Germany). 
In fact, the choice of the oblique approach to explore the insular cortex was decided because 
the orthogonal approach is less adapted to explore the insula due to several points (Afif et 
al., 2008b): I) The first one, that the insula lies almost parallel to the sagittal plane in the 
depth of sylvian fissure behind of the opercula which overlapping irregular folds of the 
lateral insular surface. II) The second one, that the thickness of the insular cortex is less than 
the distance covered by two contiguous contacts (up to 5mm), so in SEEG, only one contact 
of a laterally (trans-opercula) introduced electrode would lie within the insular cortex (Fig. 
2). The second contact will be in the mesial part within the extreme capsula or in the lateral 
part within the opercula. III) The third one, that the dense network of vessels overlying the 
lateral surface of the insular cortex (Varnavas & Grand, 1999; Ture et al., 1999; Afif & 
Mertens, 2010) prevents the safely access to this region by a lateral orthogonal approach and 
only the peripherical region near the periinsular sulci can be reached safely.  
 
 
Fig. 2. Example of an orthogonal insular electrode (axial slice): Image fusion of the 
preoperative 3D MRI and the postoperative contrast-enhanced 3D CT scan of the axial slice 
using VOXIM stereotactic software. E: Orthogonal trans-opercula insular electrode in SEEG, 
one contact (n°: 1) in the mesial part within the extreme capsula, one contact (n°: 2) within 
the insular cortex and one contact (n°: 3) in the lateral part within the frontal opercula. 
The methodology targeted the insular cortex using an oblique approach, which allowed 
exploration of a larger surface of the insula by one electrode without passing through the 
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opercula. Most patients were explored by means of at least one trans-frontal insular 
electrode, while the choice to use an additional trans-parietal electrode was reserved for 
patients showing a rapid posterior spread of the ictal electrical discharge on EEG (Afif et al., 
2008a). Electrodes (DIXI Besançon, France) were 0.8 mm in diameter, with 10 to 18 contacts, 
of 2 mm in length and 1.5 mm apart, depending on the length of the electrode (Fig. 3). This 
allowed to sample different insular regions using only one electrode and to avoid passing 
through the opercula.  
 
 
Fig. 3. (A) Drawing of an electrode with 15 contacts:  U.: electrode length of 15 contacts = 51 
mm, Ø: diameter of the electrode = 0.8 mm, length of each contact = 2 mm, distance between 
the two contacts = 1.5 mm. (B) Robotic arm: in the position of an anterior (trans opercular) 
oblique insular electrode trajectory.   
2.2 Determining the anatomical location of the insular contacts   
Due to the complex anatomy of the insula (its located in the depth of the sylvian fissure and 
the arteriovenous dense vascular network on the lateral surface of the insula) (Fig. 4) it was 
necessary to identify with high accuracy the localization of electrical contacts. Two 
anatomical and one electrophysiological procedure were utilized to accurately establish the 
location of all contacts clearly located in the insular cortex. 
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Fig. 4. View of the left insula, showing the MCA collaterals (insular and opercular arteries) 
and the sylvian venous system on the lateral surface of the insula (in the interior of the 
cycle) and the supra-sylvian region.  
2.2.1 Anatomy-based procedures 
- Individual insular diagrams:  
This diagram was constructed for each patient using different sagittal slices of presurgical 
T1 MRI images referenced to the bicommissural plane (AC-PC) reference system (Fig. 1 C). 
The electrode contacts localization was identified in reference to insular gyri and sulci in the 
sagittal diagram (Afif et al., 2008b, 2010b). 
- Individual 3D neuro-imaging:  
To increase accuracy, a postoperative contrast-enhanced 3D CT scan was performed. All 
stimulation sites were anatomically located via image fusion between pre-implantation 3D 
MRI and post-implantation 3D CT scans (Afif et al., 2008b, 2010b). So, the cortical location 
and anatomical position of each contact were identified in reference to insular gyri in the 
three dimensions (sagittal, axial and coronal) (Fig. 5). No calculation was needed to 
reference the anatomical position of the electrical contacts to a standardized system since 3D 
anatomical localization was obtained by distortion free 3D CT performed immediately after 
electrode implantation. 
In order to represent each stimulation response in a homogeneous manner, a template of the 
insula, including its sulci and gyri was used. The stimulation sites were located on each 
patient’s individual diagram, before locating it on the insular template with respect to the 
insular gyri from the individual diagram (Fig. 6). 
 


















Fig. 5. Example of an oblique insular electrode. Image fusion of preoperative 3D MRI and 
post-operative contrast-enhanced 3D CT scans using VOXIM stereotactic software. This 
technique enabled us to identify the contact locations in three dimensions (sagittal, axial and 
coronal). Axial (A) and frontal (B) section crossing the trajectory of electrode y at the level of 
the contact E in figures (C) and (D). Lateral (C) and frontal (D) reconstruction of an oblique 
electrode (y) inserted into the posterior insula using a trans-parietal trajectory. This example 
clearly demonstrates how oblique implantation enables the exploration of a large part of the 
posterior insular cortex. E: one contact in the oblique electrode; Ant.: anterior; Post.: 
posterior.  
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Fig. 6. Our strategy to present the electrical stimulation data. Lateral (A) and (C) individual 
insula reconstruction in bi-commissural references of 2 patients with the stimulation sites 
“  in figure (A) and  in figure (C)”. (B) and (D) individual insular diagram (sagittal view) 
with the stimulation sites between the two contacts stimulated of the 2 patients in figures A 
and C. (E) template of the insula, including its sulci and gyri, the stimulation sites were 
located on the insular template with respect to the insular gyri from the individual diagram. 
2.2.2 Electrophysiological identification  
The localization protocol was based on electrophysiological data enabling us to distinguish 
between gray and white matter since electrical activity (both voltage and rhythm) decreases 
significantly in white matter (Fig. 7). All contacts were individually checked by bipolar 
recording their spontaneous electrical activity.  
 







Fig. 7. Bipolar EEG recordings from a right oblique insular electrode. Right oblique insular 
electrode (y) is shown on a patient’s individual diagram. Contact n°: 1 (the deepest) and 
contact n°: 15 (the most superficial). Test recordings were performed on contiguous bipolar 
electrodes from y = 1-2 to y = 14-15. Electrical activity shows typical cortical voltage and 
rhythms from bipolar electrodes y = 1-2 to y = 9-10. Activity drops to typical white 
substance levels from bipolar electrodes y = 10-11 to y = 14-15. Analysis of this EEG activity 
identifies contact y = 9 as the last one exploring the insular cortex. 
3. Stimulation procedure 
After implantation, EEG recordings were obtained for several hours per day to monitor 
interictal and ictal activity. Simultaneous video and EEG recordings were performed 
enabling a complete online clinical examination of the patient by later analysis. 
Following the previously described clinical protocol, ES was applied to every bipole of 
contiguous contacts selected for EEG recordings (Munari et al., 1993). According to previous 
studies (Ranck, 1975), the current spread linked to a stimulation intensity of 3 mA is able to 
stimulate excitable nervous elements up to a maximum distance of 5 mm. We chose bipolar 
stimulation known to involve a smaller cortical volume compared to monopolar 
stimulation, thus leading to more accurate anatomical localization of less than 5 mm around 
the stimulated bipole (Nathan et al., 1993). To increase this accuracy by diminishing the 
current spread, we used only current intensities of bipolar stimulation between 0.2 and 3 
mA (Afif et al., 2008b). 
The aim of the stimulation protocol was to reproduce part of, or all, the ictal clinical 
symptomatology and map functionally eloquent areas which needed avoiding during 
surgery. ES was performed at low frequency (LF) 1Hz (pulse width = 3 ms) and high 
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frequency (HF) 50Hz (pulse width = 1 ms) using a constant current, rectangular pulse 
generator (Micromed Treviso, Italy). Stimulations were performed after confirming a 
normal baseline activity of depth EEG recording. During stimulation the electrode 
containing the stimulated bipole was disconnected from recording amplifiers; electrical 
activity recordings continued on the other deep brain electrodes. ES was performed at both 
low frequency (LF; 1Hz; pulse width= 3 ms) and high frequency (HF;50Hz; pulse width= 1 
ms). Stimulations usually lasted for 40 s at 1Hz, and 5 s at 50Hz. The patients were asked to 
report any symptoms they felt as soon as possible and were then immediately examined and 
questioned. Data on stimulation-evoked phenomena (Kahane et al., 1993; Afif et al., 2008b), 
only those phenomena not associated with electrical after-discharge and clearly not due to 
current spread out of insula were considered (Jefferys & Traub, 1998). Verification of the 
absence of afterdischarge could be obtained by analyzing the electrical signals obtained 
during cortical activity recordings on the electrode containing the stimulated bipole as soon 
as it was reconnected, and on all other deep brain electrodes during and after the 
stimulation procedure. All stimulation sites were stimulated by both LF and HF protocols 
starting with LF (Afif et al., 2008b). 
4. SEEG data 
Three groups of patients were identified according to insular involvement during SEEG-
recorded seizures (Table 2). Group 1 showed no insula involvement during seizures (Fig. 8a) 
including patients with temporal lobe epilepsy (TE) and/or with frontal lobe epilepsy (FE). 
Group 2 showed no insular involvement at seizure onset but involvement after a short delay 
during seizure evolution (Fig. 8b) including patients suffered from TE and from temporo-
frontal lobe epilepsy (TFE). Group 3 showed insular involvement at seizure onset (Fig. 8c). 
Seizures arose either from the insula alone or from both the insula and the frontal 
operculum. 
Compared to the initial hypothesis, SEEG changed the final location of the diagnosed 
epileptogenic zone in 43.3% (Afif et al., 2008a). In this study, three patients out of six with an 
initial hypothesis as suffering from FE were finally considered as having insulo-frontal 
epilepsy (IFE). Ten out of 14 patients with an initial hypothesis of TFE were finally 
considered as TE in seven patients, FE with secondary propagation to insula in one patient, 
and insulo-temporo-frontal epilepsy (ITFE) in the remaining two patients. Thus the SEEG 
data reduced the proposed surgical resection or disconnection zone in 57.1% in whom the 
initial hypothesis was TFE (Table 2).   
Another study (Afif et al., 2010a) has shown the importance of SEEG data obtained by 
recordings and ES of intra-insular oblique electrodes insertions guided by a robotic arm 
during invasive pre-resection evaluation of epilepsy to identify the insular origin of the 
evoked clinical responses. This study suggests relationships between insular seizure 
semiology and evoked clinical responses by ES of insular contacts i.e., the patients with 
insular involvement at seizure onset or after a short delay during seizure evolution present 
speech disturbances such as speech arrest, dysarthria, crying and verbal automatism (chic, 
chic,..) after seizures. These patients reported a speech arrest induced by intra insular HF 
stimulations during a counting exercise. However, the patients show no insular involvement 
during seizures. No speech disturbances were described during or after seizures. These 
patients reported no speech arrest induced by intra insular ES. 
 





P. E.Z. hypothesis 
E.Z. after 
SEEG Group Surgery 
Outco
me 
1 R. T.(i) R. T. 1 T. Discon. Ia 
2 R. T.(i) R. T. 1 T. Discon. Ia 
3 L. T.(i) L. T. 1 T. Lobect Ia 
4 L. T.(i) L. T. 1 T. Lobect. Ib 
5 R. T.(i) R. T. 1 T. Lobect. Ic 
6 L. T.F.(i) L. T. 1 T..Lobect. III 
7 L. T.F.(i) L. F. 1 F. Lobect. Ia 
8 L. F.(i) L. F. 1 F. Lobect. Ia 
9 R. F.(i) R. F. 1 F. Lobect. Ia 
10 R. F.(i) R. F. 1 F. Lobect. IV 
11 R. T.(i) R. T.(I*) 2 T. Discon. Ia 
12 R. T.(i) R. T.(I*) 2 T. Discon. Ia 
13 L. T.(i) L. T.(I*) 2 T. Lobect. Ia 
14 L. T.F.(i) L. T.(I*) 2 T. Discon. Ia 
15 R. T.F.(i) R. T.(I*) 2 T. Discon. Ia 
16 R. T.F.(i) R. T.(I*) 2 T. Lobect. Ia 
17 L. T.F.(i) L. T.(I*) 2 T. Lobect. Ia 
18 R. T.(i) R. T.(I*) 2 T. Lobect. Ib 
19 L. T.F.(i) L. T.(I*) 2 T. Lobect. IIb 
20 L. T.F.(i) L. T.(I*) 2 T. Lobect. IIb 
21 L. T.(i) L. T.(I*) 2 T. Lobect. IId 
22 R. T.F.(i) R. T.F.(I*) 2 T. Lobect. +   F. Lesionect. Ia 
23 R. T.F.(i) R. T.F.(I*) 2 F. T. Lobect. Ia 
24 R. T.F.(i) R. T.F.(I*) 2 T. Lobect+ F. Discon. Ia 
25 R. T.F.(i) R. T.F.(I*) 2 T.+F.+ Insula   Lobect. Ia 
26 R. T.F.(i) R. I.T.F. 3 T.+F.+ ant. Insula  Lobect. III 
27. R. T.F.(i) R. I.T.F. 3 T.+F.+ ant. Insula  Lobect. IV 
28 L. F.(i) L. I.F. 3 No surgery NA 
29 L. F.(i) L. I.F. 3 No surgery NA 
30 R. F.(i) R. I.F. 3 No surgery NA 
 
 
Table 2. Summary of the localization of the epileptogenic zone before and after SEEG and 
case grouping relative to insular involvement and the surgical outcome. TP: temporo-polar; 
FP: fronto-polar; F: frontal; T: temporal; (i): insular involvement was suspected during 
seizures prior to SEEG; (I*): secondary insular involvement demonstrated after SEEG 
evaluation; T.F.: temporo-frontal; I.T.F.: insulo- temporo-frontal; I.F.: insulo-frontal; Discon.: 
disconnection; Lobect.: lobectomy; Lesionect.: lesionectomy; Outcome according to Engel’s 
classification with at least two year follow-up. 
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Fig. 8a. No insular involvement during seizure (Group 1) (SEEG trace and individual 
implantation lateral diagram with an oblique insular electrode). The ictal discharge (fast 
activity) begins (first arrow) in the lesion FCD (frontal cortical dysplasia) (L’) and the 
anterior cingulate gyrus (H’) and then (second arrow) becoming more evident later. later 
(arrowheads) the ictal discharge propagates to the mesial prefrontal cortex (P’ and F’). Other 
regions are less involved with no involvement of the insular cortex. SMA: supplementary 
motor area, DLPF: dorsolateral prefrontal, DLPM: dorsolateral premotor. 
 
 
Fig. 8b. Earlier insular involvement during seizure (Group 2) (SEEG trace and individual 
implantation lateral diagram with an oblique insular electrode). The ictal discharge (fast 
spikes) begins in the hippocampus (first arrow) then involves the temporal pole and the 
amygdala (fast activity). The insula becomes involved 3 sec later; the cingulate gyrus 2 sec 
later (arrowheads). Different parts of the insula are successively involved. Note how the 
insular discharge is firstly recorded at different levels along the axis of the insular oblique 
electrode (Ya and Yb) before becoming visible over the recording contacts of the 
perpendicular insular electrode (Q). T: temporal, P: parietal, F: frontal, C: central, Cing: 
cingulate, DLPF: dorsolateral prefrontal. Letters refer to the recording electrodes.  
 





Fig. 8c. Insular involvement at seizure onset (Group 3) (SEEG trace and individual 
implantation lateral diagram with an oblique insular electrode). The ictal discharge (fast 
activity) begins in the insula (arrow), involving part of the mesial frontal cortex a few 
seconds later followed by the dorsolateral frontal cortex and the parietal cortex 
(arrowheads). Note that only the anterosuperior portion of the insula is involved at seizure 
onset. T:  temporal, F: frontal, P: parietal, Cing: cingulate, SMA: supplementary motor area, 
DLPF: dorsolateral prefrontal, DLPM: dorsolateral premotor, G: gyrus. Letters refer to the 
recording electrodes. 
5. Surgical treatment and outcome 
On the basis of SEEG data analysis, 27 patients underwent a tailored surgical resection or 
disconnection (Afif et al., 2008a). Temporal lobe surgery was performed in 17 cases, frontal 
lobe surgery in 4 cases, temporo-frontal resection in 3 cases, temporo-frontal resection 
associated with removal of the anterior part of the insula in 2 cases, and total insulectomy in 
one patient who was seizure free (Engel’s class I) (Engel et al., 1993).  
Overall, (Table 2) 20 of the 27 operated patients (74 %) were seizure free (Engel’s class I) 
following surgery, three had rare seizures (Engel’s class II), two had a worthwhile 
improvement (Engel’s class III), and two showed no improvement. With respect to insular 
involvement, eight of the ten operated patients in Group 1 were seizure free (80%), one was 
classified in Engel’s class III, and one in Engel’s class IV. In Group 2, surgery relieved 
seizures in 12 out of 15 patients (80%) while the remaining three patients suffered rare 
seizures. Surgery was unsuccessful in those patients in Group 3 who underwent surgery 
(one in Engel’s class III, one in Engel’s class IV).  
With respect to the epileptogenic zone assessed by SEEG, 13 patients out of 17 were seizure 
free in TE, three were classified as Engel’s class II and one as Engel’s class III. In FE, three 
out of four patients were classified as Engel’s class I and one as Engel’s class IV. In TFE, all 
four patients were classified as Engel’s class I. Neither of the two patients with initial insular 
involvement became seizure free following operation (Table 2). 
The data strongly suggest the usefulness of insular recording to better predict the 
postoperative outcome and reduced the proposed surgical resection or disconnection zone 
in the epilepsy.  
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6. Functional data 
Only clinical responses evoked by ES in the absence of after discharge were analyzed (Afif et 
al., 2008b, 2010a, b). These studies are the first to report clinical responses evoked by ES of 
the insular cortex in terms of gyral and sulcal anatomy and to propose an 
anatomofunctional organization scheme of this cortex. The image fusion between the 
postoperative 3D CT scan with all electrodes still in place and the preoperative 3D MRI 
enabled us to localize the stimulated sites in three dimensions with respect to the individual 
gyri and sulci. 
All the insular structures present responses by the ES. The relative lack of response to direct 
ES observed in the anterior short gyrus and pole could be due to under-exploration of these 




















Ant. short gyrus 11 8 4 5.4 % 1 4.8 % 
Mid. short gyrus 42 17 27 20.89 % 10 32.5 % 
Pre central 
gyrus 49 19 13 23.88% 10 15.6% 
Post central 
gyrus 57 20 36 28.3% 13 43.3% 
Post. Long gyrus 17 8 3 8.4 % 3 3.7 % 
Insular pole 3 1 0 1.49 % 0 0 % 
Table 3. Anatomical positions of electrode contacts and observed responses in insular 
structures. Ant.: anterior. Mid.: middle. Post.: posterior. Nmb. Of Stim. Cont.: number of 
stimulated contacts inside the structure. Nmb. of Pats.: number of patients undergoing 
stimulation to this structure. Nmb. of Clin. Resp.: number of clinical responses in this 
structure. Stim. Cont. versus total: the number of stimulated contacts in this structure as a 
percentage of the total number of contacts inside the insular cortex. Nmb. of Pats. with Resp.: 
number of patients with clinical responses in this structure. Resp. versus total: the number of 
clinical responses to ES in a structure as a percentage of the total number of responses.  
The main responses evoked in this study were classified as sensory (paresthesiae and 
localized warm sensations), motor, pain, auditory, oropharyngeal, speech disturbances, or 
neuro-vegetative phenomena. All these responses started immediately after the onset of the 
electrical stimulus and disappearing with the termination of the stimulus. Table 3 presents 
the percentage of evoked responses for each insular region.   
6.1 Speech disturbances 
Two different types of speech disturbances were reported (Fig. 9 a): i) speech arrest evoked 
by HF stimulation of the middle short gyrus (four responses) and one response occurred 
after stimulating the post-central insular gyrus. ii) episodes of reduced voice intensity in one 
patient evoked by HF stimulation from a bipolar electrode in the left insula (dominant 
hemisphere), just superior to the site that induced speech arrest. LF stimulation at this site 
did not evoke a response (Afif et al., 2010a, 2010b).  
 




Fig. 9. Insular sites responding to electrical stimulation. The sites corresponding to clinical 
responses were first located on each patient’s individual diagram before being transferred 
onto the insular template with respect to the insular gyri from the individual diagram. (a): 
Speech disturbances; (b): Pain; (c): Somesthetic responses; (d): Motor responses; (e): 
Auditory responses. 
The term “speech arrest” used in this study refers to those patients unable to continue 
counting and speaking during stimulation. The patients later described an inability to 
continue counting because of an inability to speak (speech arrest) without other associated 
phenomena, such as pharyngeal constriction, memory deficits, difficulties in performing the 
movements required for speech, panic or a sensation of asphyxia. 80% of speech arrest 
responses involved stimulation of the non-dominant hemispheres, thus suggesting that the 
dominant cerebral hemisphere may function independently the dominant insula.  
One of the patients presented a lowering of the voice intensity responses following 
stimulation of the bipole situated above and adjacent to the one in which stimulation evoked 
speech arrest in the middle short gyrus. It is possible that these responses could be the 
consequence of a disturbance in motor control (pharyngeal construction and breathlessness 
sensation) or due to current spread to the adjacent area producing speech arrest. 87.5% of 
the speech disturbances resulted from stimulating the middle short gyrus of the anterior 
insula at the anterior edge of the pre-central insular sulcus in both dominant and non-
dominant hemispheres (Afif et al., 2010a). The one remaining response (12.5%) was induced 
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by stimulating the post-central insular gyrus, in the same region which also precipitated 
pharyngeal constriction (Fig. 9 a).  
The present study suggests the high restriction of the speech activity (articulation, 
phonation, etc) to the middle short gyrus of the anterior insula. In this study, all patients 
with insular involvement at seizure onset or after a short delay during seizure evolution 
present speech disturbances after seizures and after intra insular HF stimulations during a 
counting exercise (Afif et al., 2010a). 
A few studies have been published that used stereotactically implanted deep brain 
electrodes (SEEG), inserted in a lateral orthogonal way, to stimulate the human insula 
directly (Ostrowsky et al., 2000; Isnard & Mauguière, 2005). These studies suggest that the 
insula is involved in speech disturbances, but localization information for specific gyral or 
sulcal involvement was not provided. The functional imaging studies have demonstrated 
the activation of the insula during language-based tasks and grammar exercises (Raichle, 
1991; McCarthy et al., 1993; Wise et al., 1999; Riecker et al., 2000, 2005; Friederici et al., 2006). 
Lesion studies reported speech disturbances relating to the infarctions of the insular cortex 
(Ferro et al., 1982; Shuren, 1993; Dronkers, 1996; Nagoa et al., 1999) 
6.2 Pain 
Two different types of painful responses were reported (Afif et al., 2008b): I) Pain in the 
craniofacial region evoked by HF stimulation either as a highly unpleasant headache or a 
bilateral throat pain that spread to the mouth and was accompanied by a highly unpleasant 
sensation of suffocation. All sites had been previously stimulated at LF without inducing 
pain, except for one patient who reported a pinprick sensation, as described further 
below. II) Pinprick sensations described occurring either bilaterally or ipsilaterally during 
LF and HF stimulations. These responses were reported in the upper limbs, the neck and 
abdomen, spreading to the chest and shoulders. All pain-inducing sites were located in 
the superior part of the middle short gyrus, in both dominant and non-dominant 
hemispheres (Fig 9 b). No similar responses were reported from other sites within the 
insular cortex. These findings cannot be due to under-exploration of other insular areas 
since contacts located in the middle short gyrus only represented 27.2% of all the insular 
contacts. Indeed, the post-central gyrus and posterior long gyrus represented 36.7 % of all 
insular contacts and, furthermore, stimulation here induced 47% of all observed 
phenomena (Table 3) (Afif et al., 2008b, 2010b). These present studies are the first to report 
human painful responses evoked by ES of the insular cortex in terms of gyral and sulcal 
anatomy and suggest a pain somatotopy within the middle short gyrus of the anterior 
insula, with a posterior representation of the head and a more anterior representation of 
the upper limbs and trunk (Fig. 10 A).  
Few studies have been published using ES of human insular cortex. The present data 
complement those observed by Penfield and Faulk (1955) which reported a tingling feeling 
in the upper extremity (arm, hand and fingers) induced by direct stimulation of the anterior 
insula. No specific location in reference to gyri and sulci was given. Other studies 
(Ostrowsky et al., 2000; Ostrowsky et al., 2002; Isnard & Mauguière, 2005), used 
stereotactically implanted deep brain electrodes (SEEG) inserted orthogonal (trans opercula) 
to the mid-sagittal plane. These studies suggest that the posterior insula processes both 
painful and painless somesthetic sensations. Recently, Mazzola et al. (2009) suggested the 
involvement of the posterior two thirds of the insula in processing pain. Using the insular 
 




Fig. 10. Somatotopic organization of pain and sensorimotor responses. (A): pain results from 
stimulating the middle short gyrus of the insula, with a posterior representation of the head 
and a more anterior representation of the upper limbs and trunk. (B): sensorimotor 
responses from stimulating the post-central insular gyrus, showing an inferior 
representation of the head and a more superior representation of the upper and lower 
limbs. 
orthogonal approach exploration, it would be more appropriate to describe the phenomena 
induced by ES as operculo-insular phenomena (the thickness of the insular cortex is less 
than the distance covered by two contiguous contacts (Fig. 2), so the bipolar ES will 
stimulate the overlapping adjacent structures “opercula” of the insula). Moreover, due to 
the dense network of vessels overlying the insular cortex (Fig. 4), only the peripheral region, 
near the peri-insular sulci can safely be reached by a lateral orthogonal approach (Afif et al., 
2008b, 2010b). 
Several functional imaging studies suggest that the posterior operculo-insular complex has a 
role in pain discrimination and localization (Hua et al., 2005; Baumgärtner et al., 2006). 
Other studies have identified a region in the anterior insula that becomes activated by 
noxious stimuli (Brooks et al., 2002, 2005; Henderson et al., 2007). It is interesting to note that 
the clinical responses evoked by ES within the anterior insular part are usually ipsi- or 
bilateral to the original peripheral stimulus (Tarkka & Treede, 1993; Henderson et al., 2006; 
Afif et al., 2008b).  
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6.3 Somesthetic responses  
Sensory responses (28.2% of responses evoked by stimulation sites within the posterior 
insula) were described as pins and needles or localized warmth contralateral to the ES sites 
(Fig. 9 c) (Afif et al., 2010b). All these responses were evoked by HF stimulation. Two 
different types were distinguished: i) Painless paresthesiae or “pins and needles” were 
reported in the upper limbs, lower limbs and the neck. 71.4% of these responses were 
evoked by ES in the non-dominant hemisphere. All responses resulted from electrode 
contacts stimulated in the post-central insular gyrus. However, paresthesiae in the upper 
and lower limbs occurred with stimulation in the superior portion of this gyrus. ii) Painless 
sensations of localized warmth were reported as occurring in the cranial region, 
contralateral, limbs and in the elbow, evoked by HF stimulation. All these responses were 
evoked by ES to the middle part of both post-central and posterior insular gyrus. 
Oppenheimer et al. (1992) noted reports of sensations of warmth when applying ES to the 
insular cortex, although the precise anatomical site was unknown. 
6.4 Motor responses 
Motor responses (28.2% of responses evoked by stimulation sites within the posterior insula) 
were observed in the patients contralateral to the stimulated side (8 responses induced by 
LF and 3 responses by HF) (Afif et al., 2010b). Three different types were distinguished (Fig. 
9 d): i) Myoclonic phenomena in the upper and lower limbs, evoked by LF stimulation to the 
post-central insular gyrus. ii) Involuntary movements involved the upper and lower limbs. 
All of these responses resulted from stimulation to the non-dominant hemisphere, (from the 
post-central and posterior insular gyrus). iii) Upper limb tremors were evoked by 
stimulating the anterior and posterior edges of the pre-central insular sulcus in the 
dominant hemisphere.    
In our study the majority of the sensorimotor responses (85.3% of cases) resulted from ES in 
the peri-central area of the insula, especially the post-central insular gyrus. The sites that 
induced motor responses also overlapped with those eliciting sensory responses. A new 
finding which has emerged from our data is that both types (motor and sensory responses) 
indicated a somatotopic organization in the post-central insular gyrus similar to the peri-
Rolandic cortex, with an inferior representation of the head and a more superior 
representation of the arms and legs (Fig. 10 B). It is difficult to determine whether spatial 
discrimination exists between motor and sensory sites, or whether it results from different 
motor and sensory neuron densities (neuronal population maps, Roland & Zilles, 1998), as 
in the supplementary motor area (Lim et al., 1994). In our study, HF stimulation evoked 
sensory responses, whereas LF evoked motor responses. Our data complement previous 
studies that suggest that stimulating the posterior insula can evoke somesthetic sensations 
(Ostrowsky et al., 2000; Isnard et al., 2004).  
6.5 Oropharyngeal responses  
Eight responses were evoked in 4 patients by HF (0.8 to 2.6 mA) stimulation to the peri-
central insular cortex and post-central insular gyrus (Fig. 4 E). Four of these responses were 
described as a pharyngeal constriction and one as a swallowing sensation associated with 
mastication. The three remaining responses occurred while stimulating the upper part of the 
middle short gyrus in one patient, who described a feeling of suffocation in the throat.  
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6.6 Auditory responses  
Two types of responses were observed (Fig. 9 e): i) bilateral auditory tinnitus evoked by ES 
within the upper part of the post-central insular gyrus in the non-dominant side. These 
responses were different from those known to occur when stimulating the Heschl gyrus, 
which are contra lateral hallucinations ii) predominantly contra lateral auditory buzz 
evoked by stimulating the anterior short gyrus. Auditory buzz might be mediated by a 
distributed network of the anterior insula with the other structures as the anterior cingulate 
gyrus, hippocampus, parahippocampal gyrus and the thalamus. The data obtained by 
stimulating the anterior short gyrus complement those from functional imaging studies 
(Bamiou et al., 2003; Lewis et al., 2000). Another study suggests the activation associated 
with auditory buzz in the anterior cingulated gyrus, insula, inferior frontal gyrus, middle 
temporal gyrus, thalamus, left hippocampus and parahippocampal gyrus (Shergill et al., 
2000). 
7. Advantages and complications of oblique versus lateral trajectory for 
placement of insular electrodes 
The insula represents a thin layer of grey matter with a width usually less than 5mm and 
lies almost parallel to the sagittal plane, which consequently allows the placement of a less 
of two contacts for each electrode implanted orthogonally (Fig. 2) compared to a mean of 7.5 
contacts for each electrode implanted with an oblique approach (Afif et al., 2008a).  
Firstly, our methodology to target the insula using an oblique approach guided by a robotic 
arm allows the electrode to cover a larger surface of insula and thus explore the different 
anatomical parts of the insular cortex without limits in contrast to an orthogonal trans-
opercular approach (Afif et al., 2008a). Secondly, the orthogonal approach may distort any 
data collected due to anatomical limitations not permitting access to the greatest part of the 
insula largely covered by the sylvian vascular branches (Fig. 4) (Ture et al., 1999; Varnavas 
& Grand, 1999; Afif & Mertens, 2010). Thirdly, our trajectory enabled the exploration of 
between two and three distinct insular gyri or even the anterior and posterior insula with 
one single electrode. This should prove useful when delineating the epileptogenic zone and 
enable precise tailoring of resection when necessary. 
This study provides new arguments in favor of the use of a stereotactic procedure to insert 
depth recording electrodes in difficult to reach areas such as the insula. 
The safety of stereotactic depth electrode implantation has been addressed in numerous 
studies with severe morbidity with permanent deficit related to electrode implantation 
ranging from 1 % to 2 % in these series (Binnie et al., 1994; Guenot et al., 2001; Sindou et al., 
2006; Tassi et al., 2005).  Recently, De Almeida et al. (2006) reported a higher risk of 
hematoma (2.9 % per hemisphere) in cases where SEEG was performed in frontal epilepsy 
and when four or more electrodes were implanted. Cossu et al. recently reported the oblique 
implantation of electrodes in stereotactic conditions in adults (Cossu et al., 2005a) and in 
children (Cossu et al., 2005b). For these authors, this procedure was mandatory in targeting 
the frontal or parietal mesial regions, the orbito-basal region, the amygdala and the 
hippocampus. The oblique approach has also been used to record epileptic activity (Rektor 
et al., 2002, 2003) from the basal ganglia. In our institution we believe that a safe 
implantation of electrodes within the insula can be achieved using an oblique stereotactic 
approach guided by a robotic arm, coupled with preoperative MRI and stereotactic 
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angiography. In our study, we observed no morbidity related to the surgical implantation of 
the oblique insular electrodes. 
8. Conclusion 
Oblique electrodes implanted using a robotic arm in the insular cortex permit the safe 
exploration of different insular regions and limit potential electrical contamination from 
adjacent areas, especially the opercular cortex. Insular recordings provide additional pre-
surgical information to allow a tailored surgical approach when necessary and avoid 
surgery in cases of insular seizure where the insula cannot be removed.  
We are not yet able to target one specific part of the insular cortex related to associate 
clinical phenomena of the epilepsy seizures. The previous results of the insular stimulation 
studies were not provided in reference to gyral and sulcal anatomy. Consequently, wider 
sampling of the different sulci and convolutions of insular lobe seems necessary to gather 
enough information to either exonerate or implicate the insula in a patient’s epileptic 
network. The association of lateral electrodes in the temporal or frontal lobe and oblique 
electrodes in the insular cortex seems at present to be a good compromise to study multi 
lobar epilepsy. 
The broad sampling of this area by oblique electrodes implanted within the insular cortex 
has allowed us to construct an original representation that links function to anatomy, 
according to insular gyri and sulci. The data of this study maybe permeates to target a 
specific structure of the insular cortex related to the epilepsy seizures manifestations using a 
functional organization of the insular gyri.    
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1. Inroduction 
Cerebral small vessel disease (cSVD) is a spectrum of clinical and imaging abnormalities 
linked to the pathology of small penetrating arteries and arterioles in the brain irrigating 
subcortical structures1. Accumulating data suggest that cSVD is the most prevalent 
neurological disorder in the ageing society of the developed world2, 3. The prevalence of its 
seemingly asymptomatic manifestations –silent brain infarcts- increases with age from 
approximately 6-7% at 60 years to 28% at 80 years of age according to a recent review4. In 
another study lacunar infarcts were found in 23% of all subjects over 65 years, and in 43% of 
subjects over 80 years of age5. Its acute, symptomatic manifestations –lacunar strokes- 
account for approximately 20% of all ischemic strokes6-8. Thus improved management of 
cSVD based on better understanding of the disease is of great importance. 
cSVD is characterised by the arteriolosclerosis and/or microatheromatosis of small calibre 
(50-500 μm) cerebral arterial vessels caused by various pathologies1. Its most common, 
sporadic form is related to age and vascular risk factors including hypertension and diabetes 
in particular. Inherited forms are increasingly recognised with CADASIL (Cerebral 
Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) 
being the most prevalent genetic cSVD caused by the mutation of NOTCH 3 gene encoding 
a transmembrane receptor of vascular smooth muscle cells9, 10. CADASIL -affecting young to 
middle aged, otherwise healthy individuals- provides a pure model for cSVD and therefore 
has been extensively studied 11.  Inflammatory, infective and immunologically mediated 
forms are usually part of systemic diseases of diverse origin characterised by central 
nervous system vasculitis 12. Cerebral amyloid angiopathy (CAA) –a pathological hallmark 
of Alzheimer’s disease- affects small vessels both cortically and subcortically and may also 
lead to ischemic changes, although it is particularly associated with recurrent lobar 
haemorrhages12. In this chapter we will only focus on the most common and well studied 
age and vascular risk factor related form of cSVD and CADASIL. 
cSVD predominantly affects perforating end-arteries branching usually perpendicularly 
from a large parent artery. These penetrating arteries irrigate the so called perforator areas 
including the basal ganglia and internal capsule (lenticulostriate arteries from the anterior 
cerebral artery (ACA) A1 segment and middle cerebral artery (MCA) M1 segment), the 
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thalamus (thalamoperforators from the posterior cerebral artery (PCA) and posterior 
communicating artery (PCoA)), the pons (pontine perforators from the basilar artery (BA)) 
and the hemispheric deep white matter -centrum semiovale (perforators from the cortical, 
leptomeningeal arteries)13-16. 
The pathological changes in cSVD lead to luminal narrowing, decreased autoregulation 
and vasoreactivity, and vessel wall damage in the cerebral microvessels resulting in their 
i. gradual stenosis, ii. sudden occlusion or iii. rupture. As a consequence the subcortical 
brain tissue suffers from i.: diffuse chronic hypoperfusion and ischemia leading to the 
progressive disintegration of cerebral white matter17; ii.: acute localised ischemia 
resulting in lacunar infarcts18; ad iii.: acute major haemorrhages or microbleeds 12, 19. In 
an advanced state of the disease cerebral atrophy invariably occurs as a remote and/or 
diffuse consequence of vascular lesion burden20. The pathogenesis of cSVD 
manifestations is summarized in Figure 1. The gradual ischemic tissue damage clinically 
manifests in progressive vascular cognitive impairment (mainly executive dysfunction) 
and physical disability (gait disturbances, pseudobulbar palsies, urinary incontinence 
etc.), whereas acute focal ischemia presents with the so-called lacunar syndromes. 
Cerebral microbleeds are usually asymptomatic and their clinical significance is yet to be 
determined. 
In this chapter we will summarize recent knowledge about the MRI characteristics of 
cSVD. Since the cerebral microvasculature cannot be currently visualized in vivo, the 
consequent parenchymal lesions (lacunar infarcts, white matter lesions, microbleeds and 
atrophy) have been adopted as markers of cSVD12. We will not discuss the issue of major 
haemorrhages. 
2. Lacunar infarcts 
2.1 Definition 
According to the “lacunar hypothesis” first proposed by Fisher small subcortical infarcts of 
a diameter less than 15 mm –called lacunar infarcts (LI)- result from the sudden occlusion of 
penetrating arteries due to cSVD in typical locations -the perforator areas (see above) 18. 
Infarcts of this type have been linked to particular clinical syndromes with a relatively good 
prognosis called the lacunar syndromes, most frequent of which are the classical ones:  pure 
motor stroke, pure sensory stroke, ataxic hemiparesis, dysarthria-clumsy hand syndrome 
and sensorimotor stroke.  The concept of lacunar stroke that entered stroke classifications 
was based on postmortem and CT based studies both with considerable limitations. The 
pathological studies were limited by the low mortality of lacunar strokes and by the 
anatomical changes occurring in the chronic stage and/or during fixation. CT has a low 
sensitivity to detect small infarcts in certain locations (posterior fossa, cortex) and in the 
acute stage and cannot differentiate between fresh and old lesions. The advent of MRI and 
especially its newer techniques such as diffusion weighted imaging (DWI), perfusion 
weighted imaging (PWI) and diffusion tensor imaging (DTI) has slightly modified our 
understanding of LIs21. 
2.2 Conventional MRI 
Because of their small size visualizing LIs is much more problematic than that of larger 
territorial infarcts. Compared to CT conventional MRI sequences such as T1 weighted, T2  
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Fig. 1. Pathogenesis of cSVD manifestations. Abbreviations can be found in the text. 
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weighted imaging (T1/2WI) have a better spatial resolution, can image the posterior fossa 
without artifacts and have a better signal/noise ratio. LIs in the chronic stage appear as fluid 
filled cavities: hypointensities (black holes) on T1WI and hyperintensities on T2WI 
isointense with CSF.  More recent LIs can be seen as hyperintensities on T2WI 
corresponding to brain tissue with increased water content (oedema). The widely used T2 
based fluid attenuation inversion recovery (FLAIR) sequence that nulls the hyperintense 
signal of free water (mainly CSF) has some advantages over the T2WI. FLAIR is more 
sensitive in the detection of small, recent infarcts in the proximity of CSF spaces like those in 
the cortex or next to the ventricles.  It can better estimate the age of LIs, because the signal of 
bulk water in chronic infarcts (cavitations) is nulled as well, whereas the increased bound 
water content of acute infarcts (solid tissue) is hyperintense 22. Acute lesions on FLAIR give 
a relatively stable high signal for several weeks as opposed to the fluctuations in intensity 
seen on T2W images 23, 24 (Figure 2). However very early ischaemia within the first few 
hours especially in the lacunar dimension cannot be seen on any of the conventional MR 
sequences, because the signal abnormality only appears 6-8 hours after symptom onset. 
2.3 DWI 
Acute stage imaging has been revolutionised by the introduction of diffusion weighted 
imaging (DWI) that shows intracellular cytotoxic oedema resulting from  critical cerebral 
ischaemia within the first few minutes after stroke onset  25. The energy failure of brain cells 
results in the accumulation of intracellular bound water leading to a reduced diffusion of 
free water. This appears as marked hypointensity on the apparent diffusion coefficient 
(ADC) map which translates into high DWI signal 26-28.  In the case of cortical ischemia the 
reduced ADC returns to normal in 5-10 days 24, 29, while it stays low for a considerably 
longer period in subcortical disease. Consequently the hyperintensity due to diffusion 
restriction is also visible for longer30. Finally the ADC increases in the chronic stage 
indicating tissue disintegration/necrosis and vasogenic  oedema 31. At the same time the 
lesion appearing hyperintense on DWI may remain visible further on as the developing T2 
lesion is also seen as high signal (T2 shine through). Therefore DWI and ADC map images 
have to be interpreted together to judge the age of an ischaemic infarct 32, 33. The sensitivity 
of this sequence within 6 hours of symptom onset is of 95% and its specificity is of 
practically 100% for territorial infarcts 34. Although understandably less for small subcortical 
infarcts, it is still the only reliable tool to visualise hyperacute LIs making it indispensable 
for acute phase therapy decisions (Figure 2). 
2.4 DTI  
A great proportion of LIs occur along the course of motor pathways whose affection well 
correlates with the severity of clinical symptoms and mainly determines prognosis. The 
extent of damage to these pathways can be judged by the diffusion tensor imaging (DTI) 
that is capable of visualizing white matter tracts 35. This imaging method is based on the 
principle that cell membranes constrain the diffusion of water molecules which therefore 
diffuse longitudinally along axons in the white matter. By measuring diffusion from several 
directions the net orientation of axons in a voxel of white matter can be determined as a 3 
dimensional vector –a „tensor”.  From these vectors projections of fibres can be generated 
and displayed as maps of white matter anatomy e.g. in a color-coded way where different 
colors stand for different directions, and colour brightness for the degree of anisotropy  
 
 





Fig. 2. Subacute lacunar infarct in the posterior limb of the left internal capsule in a 
hypertensive patient on axial FLAIR (A) and DWI trace (B) image. 
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(color-coded directional image)36, 37. Fiber tracking is a further development that enables 
examiners to visualize fibers passing through a certain region of interest (ROI) or linking 
two ROIs thus delineating functional systems such as the corticospinal tract (CST). This 
method has been used to specifically localize small infarcts with regard to the functional 
pathway of the CST with good topographical accuracy 38-40 . Nevertheless, only a limited 
number of such tractography studies have been published to date, and few techniques have 
been assessed for their ability to track through lesions which disrupt tracts. 
2.5 Size criterion 
The size of LIs according to the classical definition is less than 15 mm –a rather arbitrary 
criterion based on early autopsy studies representing a healed, chronic state 18. Since then 
we know that LIs in the acute stage can be significantly larger later undergoing shrinkage by 
about half their original size 41. Furthermore surprisingly large infarcts can be caused by 
single perforator occlusion due to anatomic variations of the branching pattern of the 
lenticulostriate arteries. More or even all of the penetrating arteries may arise from one 
common stem 15, 42. Therefore the size criterion for LIs can lead to stroke type 
misclassification and should be reconsidered43.  
2.6 Differentiation of underlying mechanisms 
Apart from cSVD small subcortical infarcts may be caused by emboli of arterial or cardiac 
origin or critical hypoperfusion in watershed areas due to stenosing large artery disease 
(LAD). As determining stroke subtype is crucial for further management it is important to 
make an early etiological diagnosis. Acute lesion patterns on DWI help us to differentiate 
between the underlying pathomechanisms 44. The co-existence of a small striatocapsular and 
one or more distal small cortical lesions points to an embolus originally stuck in the M1 
segment obstructing the orifices of the lenticulostriate arteries and later on fragmented and 
washed further up into one or more small cortical branches of the MCA45, 46. This scenario is 
also possible in the posterior circulation -although much less frequently- with the picture of 
a small brainstem lesion together with a PCA territory thalamic or cortical infarct. Multiple 
small subcortical lesions in the same vascular territory are associated with LAD (arterio-
arterial embolism), whereas those in different territories/bilaterally suggest a proximal 
embolic origin (heart or aortic arch) 47. In the latter case it is not clear whether they result 
from repeated embolism or a single embolic shower 44.  
It has also been proposed that multiple small infarcts may also be due to cSVD affecting 
several vessels contemporaneously 48. As mentioned earlier subcortical lesions can remain 
hyperintense on DWI for much longer than cortical ones. Thus several lesions in diffferent 
vascular territories could arise contemporaneously (i.e. within a few weeks of each other) 
but not simultaneously and all appear hyperintense on DWI falsely raising the suspicion of 
an embolic origin.  In addition the small perforators arising perpendicularly from large 
vessels seem hardly accessible for fast moving emboli from an anatomical point of view. 
Therefore the purely embolic origin of multiple small subcortical DWI lesions in multiple 
vascular territories remains debated.  
Partial borderzone infarcts in the watershed of superficial and deep perforators of the MCA 
and/or ACA may also appear similar to LIs. They can be seen as a single small lesion or a 
chain of them (rosary-like pattern) in the centrum semiovale alongside and slightly above 
the lateral ventricle. The demonstration of ipsilateral carotid artery disease and consequent 
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hypoperfusion shown by a perfusion deficit on perfusion weighted imaging (PWI) far 
exceeding the lesion area leads to diagnosis 49, 50. 
2.7 Differentiation from other small cerebral lesions 
LIs –especially when occurring without overt clinical symptoms, as incidential findings- 
may be difficult to distinguish from other hyperintense focal abnormalities on T2 weighted 
images. Studies correlating these lesions on in vivo and postmortem MR images with brain 
autopsy findings have identified the following pathologies: silent LIs, dilated Virchow-
Robin spaces (VRS), foci of demyelination 51 due to incidental multiple sclerosis 52 or 
insufficient circualtion 53 54, gliosis, minute cysts and ventricular diverticuli 55, 56. Distinction 
between an infarct, a focal gliosis and a plaque of demyelination is usually impossible on 
entirely imaging grounds, while the relationship of a diverticulum or cyst to the ventricles 
and their round shape are differential features 56.  
VRSs are small perivascular spaces surrounding cerebral perforating arteries along their 
way through the parenchyma serving as drainage pathways for the cerebral interstitial fluid 
57. They are small (<1 mm) CSF isointense foci round shaped in cross section or linear in 
longitudinal section and run perpendicular to the brain surface 58-60. Dilated VRSs, that can 
resemble lacunes, appear as an irregular or ectatic focal expansion of the otherwise regular 
and smooth VRSs 60. They are still generally smaller than lacunes usually not exceeding 3 
mm in diameter 61, whereas lacunes are larger and wedge shaped 59, 60. Dilated VRSs have 
been associated with ageing 62, hypertension 63, widespread white matter lesions 64, sporadic 
cSVD65 61, CADASIL66, reduced cognitive function 64, and vascular dementia 65, 67. However 
their real clinical significance is a subject of controversy. It is generally accepted that dilated 
VRSs are related to brain shrinkage around perforating vessels thus representing brain 
atrophy68. In this perspective they can both be regarded as common ageing phenomenon or 
as a marker of various pathologies. The distinction between normal and pathologically 
dilated VRSs can be made by judging the appearance of the adjacent brain tissue and the 
clinical context 60. 
2.8 Silent cerebral infarcts 
With the increasing use of MRI and the improving image quality an increasing number of 
patients are found to harbour small cerebral infarcts without any apparent stroke-like 
symptoms. It has now become clear that LIs only cause clinically evident stroke if they hit 
main sensorimotor pathways or occur in deep, subcortical nuclei. However the majority of 
them fall outside of these strategic locations and thus remain silent. Studies have shown 
that in the general population the prevalence of silent infarcts is fivefold higher than that 
of stroke, and they can be present in more than one fourth of people over 60 years of age 
69-72. They have approximately the same risk factors as symptomatic lacunes with 
hypertension being the most important 71, 72; and their presence more than doubles the 
risk of subsequent vascular events, cognitive impairment and dementia 4, 73. The extent of 
asymptomatic small vessel disease at the time of index stroke has a significant prognostic 
value for all outcomes 41, 73. These findings have led to a modified understanding of 
cerebrovascular disease according to which strokes and TIAs –i.e. overt clinical 
symptoms- are only the tip of the iceberg of cSVD manifestations21. Silent infarcts are the 
underwater majority. It has not yet been evaluated though – and remains doubtful at 
present- whether the same diagnostic workup and risk factor management would be 
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justifiable upon finding a silent infarct as for a clinical stroke. Although by definition 
silent infarcts lack clinically overt stroke symptoms they progressively lead to less evident 
cognitive dysfunction, general physical disability and depression.  Therefore these infarcts 
should be referred to as “covert” rather than “silent”4, 74.  
3. White matter lesions 
3.1 Definition 
White matter lesions seen in elderly patients and those with arterial hypertension are 
usually bilateral and more or less symmetrical areas of increased signal on T2 and FLAIR 
images (hence the name: white matter hyperintensities, WMH) located in the hemispheric 
deep white matter, the basal ganglia and the pons (Figure 3). The term “leukoaraiosis” 
meaning rarefaction of white matter is a description from the CT era of the same 
phenomenon75. WMHs are generally regarded as a consequence of ischemic brain tissue 
disintegration due to cSVD. Pathological studies found varying degrees of tissue damage 
appearing as WMH: from selective loss of myelin, to loss of myelin, axons and 
oligodendroglia consistent with incomplete infarcts, to near complete infarcts with 
astrogliosis76-79. 
3.2 Differential diagnosis 
Multifocal or diffuse white matter lesions resembling those caused by cSVD can be found 
in a wide range of central nervous system (CNS) pathologies. These are summarized in 
Table 1. Their differential diagnosis is based on the complex evaluation of patient history, 
clinical context, other diagnostic tests and some differences in MRI appearance. Some of 
these WMHs are also ischemic in origin such as those caused by hypoperfusion 1. in 
watershed areas due to large artery stenosis, or 2. in different vascular territories due to 
various types of CNS vasculitis.  These latter can occur either as an isolated CNS affection 
(primary CNS vasculitis), or as part of a systemic disease (SLE, Sjörgen syndrome, Behcet 
disease, antiphospholipid syndrome, sarcoidosis etc.) Others are a consequence of 
multifocal demyelination in multiple sclerosis (MS) and its variants or in central 
pontine/extrapontine myelinolysis. As opposed to cSVD MS is characterized by ovoid-
shaped lesions perpendicular to the ventricles (Dawson fingers), frequently found in the 
corpus callosum, some of which may enhance contrast material. Plaques may also be 
located in the optic nerves, cerebellum and spinal cord. WMH caused by transient 
vasogenic edema due to the neurotoxic effect of various complex conditions 
(preeclampsia/eclampsia, severe hypertension, allogenic bone marrow transplantation, 
organ transplantation, autoimmune diseases and high dose chemotherapy) has been 
termed as Posterior reversible encephalopathy syndrome (PRES). The typical pattern of 
WMH in PRES resembles the watershed zones with a parietal and occipital (posterior) 
predominance. The subcortical white matter but also the cortex is involved to varying 
degrees and the lesions always regress80. White matter lesions of unclear nature can be 
seen in some infective diseases /postinfective conditions such as HIV, Lyme-disease or 
Syphilis related encephalopathies, Progressive multifocal leukoencephalopathy (PML), 
Subacute sclerosing panencephalitis (SSPE) or Acute disseminated encephalomyelitis 
(ADEM); and metabolic disorders like leukodystrophies, phenylketonuria and 
mitochondrial diseases (MELAS)81, 82.  
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Table 1. CNS pathologies causing multiple/diffuse white matter lesions. Abbreviations can 
be found in the text. 
3.3 Evaluation with conventional MRI 
The severity of white matter damage on T2 and FLAIR images can be assessed 
semiquantitatively by various visual rating scales (proposed by Fazekas83, Schmidt84, 
Scheltens85, Wahlund86 and others) that take into account the location, pattern and extension 
of WMH87. The mostly used Fazekas-scale which evaluates WMH in two distinct locations: 
periventricular and deep subcortical white matter is presented in Table 2. The mildest forms 
are seen as smooth periventricular and punctuate deep WMH, whereas irregular 
periventricular, early confluent and confluent deep WMH represent an increasing severity 
of tissue damage. Furthermore the three dimensional extension of WMH can be quantified 
by volumetric evaluation88, 89. WMH volumetry is more reproducible and more sensitive for 
lesion progression than visual scales90. However the severity of white matter lesions as 
assessed by any of the above methods showed only moderate correlations with the clinical 
status represented by scores of disability and cognitive impairment91-93. 
 
 periventricular deep subcortical 
0 absence no or a single punctate lesion 
1 „caps” or pencil-thin lining multiple punctate lesions 
2 smooth „halo” beginning confluency of lesions 
3 irregular PVH extending into deep WM large confluent lesions 
Table 2. Fazekas visual rating scale for WMH (0-6 points)83 
Ischemia 
 Watershed hypoperfusion in large artery stenosis 
 Primary CNS vasculitis 
 Secondary CNS vasculitis (SLE, Sjörgen syndrome, Behcet disease, 
antiphospholipid syndrome, sarcoidosis etc.) 
 
Demyelination 
 Multiple sclerosis and variants 
 Central pontine/extrapontine myelinolysis 
 
Vasogenic oedema 
 PRES  
 
Unclear origin 
 Infective/postinfective: HIV-, Lyme-, Syphilis- encephalopathy, PML, SSPE, 
ADEM 
 Metabolic: leukodystrophies, phenylketonuria, MELAS 
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3.4 Evaluation with non-conventional MRI 
The whole spectrum of microscopic brain tissue changes due to cSVD appears uniformly 
as WMH on conventional T2 based MR sequences. In order to obtain information on the 
degree of underlying tissue damage, non-conventional MRI techniques have been 
developed such as T1- and T2 relaxation time mapping, magnetisation transfer imaging 
(MTR) and diffusion tensor imaging (DTI)94, 95. This latter technique, that measures the 
degree and orientation of tissue water diffusivity, has been widely used in various 
cerebral diseases and conditions including cSVD96. As diffusivity partly depends on the 
density of cells in a given tissue volume (cell membranes and intracellular particles 
restrict water diffusion), the increase in diffusivity (as measured by a non-oriented 
derivate of the tensor, the mean diffusivity, MD) is proportional to the degree of 
ultrastructural tissue disintegration97, 98. Region of interest (ROI) based measurements 
detected increased MD inside but also outside of WMH, in the normal appearing white 
and subcortical grey matter99, 100. DTI can thus show tissue damage „invisible” for 
conventional MRI. In diffuse cerebral pathologies however -such as cSVD - a global, 
approach of whole brain diffusion histograms is more informative about the overall 
disease severity than a ROI analysis. Accordingly, MD histogram parameters have been 
reported to correlate more with clinical scores than WMH visual rating scales and 
volumetric data in cSVD both cross sectionally and longitudinally. Furthermore they were 
more sensitive than clinical scales in detecting change over time 101-106. There are data 
indicating that the much simpler, quicker and widely available (DWI) derived ADC can 
be used similarly to DTI derived MD to quantify brain damage due to cSVD (findings of 
Gunda et al. to be published)(Figure 3 and 4). Therefore these quantitative MRI 
techniques seem to be a promising tool in the quantified monitoring of cSVD and could 
possibly act as surrogate markers in future therapeutic trials. 
4. Cerebral microbleeds 
4.1 Definition 
Gradient echo (or T2* weighted) imaging is a sequence highly sensitive of blood. With its 
increasing use the number of visible haemorrhagic brain lesions has grown considerably 
and even millimetre-sized bleedings in the parenchyma have become detectable.  Cerebral 
microbleeds (cMB) appear as small (<5 mm), homogenous, rounded foci of low signal 
intensity on T2* images107(Figure 5).  The signal loss is caused by hemosiderin –a 
paramagnetic blood degradation product that remains in macrophages for several years 
after haemorrhage indicating previous blood extravasation108.  Thus the age of cMBs cannot 
be determined by MRI but the total haemorrhage burden can be assessed. Cerebral 
microbleeds appear larger on T2* images than the real tissue lesions due to the “blooming 
effect” of the MR signal109. The few studies relating cMBs on MRI to histopathological 
findings revealed focal hemosiderin deposits from the rupture of small vessels showing 
evidence of arteriolosclerosis or occasionally amyloid angiopathy clearly indicating an 
underlying small vessel pathology110, 111.  
4.2 Differential diagnosis 
CMBs need to be distinguished from other causes of focal signal loss on T2* images. These 
include: flow voids of small arteries in cross-section that can be followed on 
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Fig. 3. Diffuse white matter lesions in a 70 year-old hypertensive patient on axial FLAIR 
image (upper row) and ADC map (lower row). Note the increased diffusion (ADC) 
corresponding to areas of WMH (FLAIR). 
consecutive/neighbouring slices; the usually symmetrical calcifications or iron deposits in 
the globi pallidi that appear hyperdense on CT; type IV cavernous malformations and 
capillary teleangiectasias; foci of hypointensity compatible with hemorrhagic shear injury in 
head trauma, and even artefacts of metallic materials released from mechanical heart 
valves112, 113. Etiological differentiation of signal loss is based on the location, number and 
distribution of lesions, associated imaging findings and patient history. 
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Fig. 4. ADC histogram of the patient on Figure 3 (green line) compared to a normal control 
(dashed blue line) (X: diffusivity in 10 -5 mm2/s, thresholded at 180; Y: relative frequency of 
voxels in %). 
 
 
Fig. 5. Multiple cMBs in a 48 year-old hypertensive patient on axial T2* image. 
4.3 Epidemiology 
CMBs have been found in various patient populations as well as healthy elderly. Their 
occurrence was the most frequent in patients with intracerebral haemorrhage (ICH) and 
lacunar infarcts (due to hereditary or sporadic cSVD), less so in ischemic stroke patients of 
other subtypes. The most comprehensive review on cMB published in 2007 pooled data 
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adults; 34% in ischemic stroke patients; and 60% in patients with ICH.  The prevalence 
according to ischemic stroke subtype was 54% in lacunar-, 36% in atherothrombotic - and 
19% in cardioembolic stroke. 38% of CADASIL patients had cMB. CMBs were more 
prevalent among patients with recurrent than first-ever stroke (44 vs 23% for ischemic and 
83 vs 52% for haemorrhagic stroke)114.  
4.4 Clinical significance 
CMBs were found to be associated with age, hypertension, other manifestations of cSVD 
(lacunar infarcts and WML), previous ischemic stroke and ICH, and an increased risk of 
recurrent lacunar infarct or ICH in those with lacunar infarct or ICH114. These findings further 
emphasize the common pathophysiological basis for cMB, LI, WML and ICH. Studies have 
shown that the anatomical distribution of ICHs is similar to that of cMBs in individual 
patients, but it is not the pre-existing cMBs that evolve into major haemorrhages115. Similarly 
several cases have been reported where patients with cMBs developed major haemorrhage 
after thrombolysis or antiplatelet therapy remote from the cMBs116. Thus cMBs can be 
considered as markers of a diffuse, bleeding-prone microangiopathy. This raised the important 
question whether patients with cMB are at an increased risk of ICH when treated with 
antiplatelet, anticoagulant or thrombolytic agents. For the time being there is no sufficient 
evidence to give a definite answer (some studies reported an increased risk, others not, all of 
them underpowered to draw firm conclusions)116-120.  However some stroke centres already 
incorporate cMBs in their treatment decisions.  
In conclusion cMBs are markers of a haemorrhage-prone cSVD and predictors of recurrent 
vascular events (be it ischemic or haemorrhagic). At present they cannot be considered as a 
contraindication to antithrombotic or thrombolytic therapies, but may play a role in the 
individual stratification of haemorrhagic risk, and may be incorporated in the design of 
clinical trials of anticoagulation/antiaggregation drugs. 
5. Brain atrophy 
Brain atrophy is best evaluated on T1WI and appears as shrinkage of brain parenchyma 
with a reduction of cortical thickness and an increase of internal and external CSF spaces. It 
can be assessed by visually rating the degree of ventricular dilatation and sulcal widening, 
by measuring the width of sulci or ventricles in a standard location, or by different three-
dimensional volumetric methods that have now become the methods of choice.  
Brain atrophy is a common phenomenon in normal ageing that increases progressively 
beyond the age of 65 years121. This process can be accelerated by numerous cerebral 
pathologies causing diffuse brain tissue loss such as degenerative diseases (like Alzheimer’s 
disease and other primary dementias)122, demyelinating diseases (MS)123 and 
cerebrovascular disorders (Figure 6).  In these latter conditions, the importance of brain 
atrophy has only recently been recognised.  A number of imaging studies using quantitative 
brain volumetry demonstrated atrophy in both focal and diffuse cerebrovascular diseases124-
127. Brain atrophy correlated strongly with the clinical status and cognitive scores, and 
proved to be a sensitive marker of disease progression in cSVD104, 128, 129. It is now widely 
accepted that purely subcortical cSVD can lead to cortical volume loss129, 130. How 
subcortical ischemic damage leads to cortical atrophy is not fully elucidated, but the diffuse 
and/or remote effect of lacunar lesions and tissue microstructural changes through 
Wallerian degeneration, secondary axonal loss due to deinervation and local or remote 
neuronal apoptosis are possible mechanisms20, 124, 131, 132.  
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Fig. 6. Widespread WMH and diffuse brain atrophy in a 89 year-old hypertensive patient on 
axial FLAIR images. 
 
 
Table 3. Utility of different MRI sequences in cSVD. Abbreviations can be found in the text. 
T1   
 cavitated, chronic LIs appear hypointens („black hole”) 
 good for evaluation of brain atrophy and cortical thickness, volumetry as surrogate 
marker 
T2  
 subacute LIs appear hyperintens (fluctuating); good visualisation of VRS 
 white matter damage appears as WMH; good for judging deep WMH 
FLAIR  
 (sub)acute LIs give more stable high signal; good for detection of periventricular LIs, 
differentiates acute (hyperintens) from chronic (hypointens) LIs 
 white matter damage appears as WMH; good for judging both deep and 
periventricular WMH 
T2*  
 cMBs appear as small, hypointense foci, marker of bleeding-prone microangiopathy 
DWI   
 the only method to visualize (hyper)acute LIs that give high signal on DWI, low 
signal on ADC; acute lesion patterns guide differential diagnosis 
 chronic LI gives low signal on DWI, ultrastructural tissue damage causes increased 
diffusivity (high signal on ADC map), whole brain ADC histogram as surrogate 
marker? 
DTI  
 localisation of LIs in relation to WM tracts (tractography) 
 ultrastructural tissue damage causes increased diffusivity (high signal on MD map), 
whole brain MD histogram as surrogate marker 
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Brain atrophy is an aspecific finding and can be regarded as the final common pathway in 
the pathophysiology of various cerebral pathologies. As in degenerative diseases, atrophy is 
now recognized as a strong marker of disease progression in cSVD and thus could serve as a 
surrogate marker in future clinical trials similarly to whole brain diffusion histogram 
parameters133. 
6. Conclusions, perspectives 
New and continuously developing MRI sequences and postprocessing techniques have 
greatly helped to explore and better understand cSVD. Diffusion MRI methods have proved 
to be particularly useful in: i. visualizing hyperacute LIs thus guiding acute phase therapy 
and etiologic diagnosis (DWI); ii. detecting ultrastructural changes even in otherwise normal 
appearing WM, and quantifying the global burden of tissue damage in cSVD (whole brain 
DTI/DWI histogram measures). Brain atrophy –a phenomenon previously considered to be 
related to cortical disease- is now recognised as a marker of cSVD based on studies using 
volumetric measures. In the future an increasing use of quantitative MRI techniques 
(diffusion histograms, volumetry) can be expected as they are more sensitive to the full 
spectrum of cSVD expressions, and could provide surrogate markers for disease progression 
in future therapeutic trials for patients with cSVD. The utility of different MRI sequences in 
cSVD is summarized in Table 3. 
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1. Introduction 
Ischemic stroke is now universally accepted as a heterogeneous disease. The need to 
properly classify stroke subtypes is increasingly driven by the realization that different 
mechanisms may require different treatments. Also the risk of recurrent vascular events 
differs among various ischemic stroke subtypes. 
Intracranial atherosclerotic disease (ICAD) is fast emerging as the predominant mechanism 
of ischemic stroke in the world and particularly in patients of Asian origin (Kim et al, 2006 
and Sacco et al, 1995). Also, ICAD is reported to have the highest risk of recurrent ischemic 
cerebrovascular events being quoted between 25-30% in two years (Wong et al, 2003 and 
Mazighi et al, 2006). 
2. Epidemiology 
It is now well recognized that intracranial atherosclerotic disease predominantly affects 
patients of Asian, African and Hispanic origin. Since these are the regions of the world 
which are going to harbor the majority of the world’s stroke population, it is expected that 
the disease burden of intracranial atherosclerosis is also going to increase.  
The rates of ICAD reported from Asian countries range between 33-56% depending on what 
cutoff for stenosis is taken (Huang et al, 1997 and Lee et al, 2003). Caucasians predominantly 
have extracranial atherosclerosis and rates of intracranial disease vary between 1 and 24% 
(e.g., Sacco et al., 1995; Wityk et al., 1996). 
Data on the prevalence of asymptomatic stenosis are relatively scarce. Warfarin versus 
Aspirin in Symptomatic Intracranial disease (WASID) trial reported presence of 27% 
asymptomatic disease in patients who also had symptomatic stenosis (Nahab et al, 2008). 
Studies of healthy Japanese and Korean populations report asymptomatic disease in 3-3.5% 
(Park et al, 2006 and Wong et al, 2007). There is a growing need to identify the 
asymptomatic entity as the process of atherosclerosis can potentially be stalled by timely 
risk factor management. Several diagnostic modalities are now available and evolving but 
the focus so far is on the diagnosis of the disease at a stage when it becomes symptomatic. 
In this chapter we describe the various radiological presentations of stroke secondary to 
intracranial atherosclerotic disease followed by a description of the tools available for 
diagnosing the condition. Non invasive modalities are the main focus as the prevalence of 
the disease increases and the need to identify asymptomatic disease is also increasingly felt. 
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Additionally, with a greater number of patients now being offered endovascular treatment, 
there is a need to have cost-effective, minimally invasive and reliable methods to follow 
these patients up. 
3. Infarct patterns 
Literature now exists on infarct patterns associated with intracranial large artery 
atherosclerosis. The underlying mechanisms leading to ischemia in the diseased arterial 
territory include artery-to-artery embolism, thrombosis leading to complete occlusion or to 
local branch occlusion and hemodynamic compromise (Wong et al, 2002). A combination of 
these factors may also co-exist in some patients. Depending on the mechanism of ischemia, 
the infarct pattern may differ.  
3.1 Border-zone Infarctions 
Border-zone infarctions have been described with intracranial atherosclerotic disease for 
decades. Recently the concept of border-zones has been revisited and two types of border-
zone infarctions have been described (Yong et al, 2006). Internal border-zone infarctions 
involve the area between the territory of anterior, middle and posterior cerebral arteries and 
the territory supplied by the lenticulostriate, anterior choroidal and Heubner arteries. The 
term cortical border-zone is used for areas located between the cortical supply of the 
anterior and middle cerebral arteries (anterior cortical border-zone) and between middle 
and posterior cerebral arteries (posterior cortical border-zone). It is proposed that the two 
types of infarctions may have different underlying pathophysiology. 
3.1.1 Cortical border-zone infarctions 
For the cortical border-zone infarctions, artery-to-artery embolism has been proposed as 
causative since the 1980’s. Several studies (Torvik et al, 1982, Pollanen et al, 1990, Masuda et 
al, 1994, Belden et al, 1999) describe border-zone or watershed infarctions resulting from 
atheromatous large vessel intracranial disease. With Transcranial Doppler monitoring this 
mechanism has been further validated. Using this modality, impaired clearance of emboli 
has been documented with middle cerebral artery (MCA) stenosis and patients with this 
condition were found to have multiple small cerebral infarcts especially in the border-zone 
territories of MCA with anterior and posterior cerebral arteries (Wong et al, 2002).  
3.1.2 Internal border-zone infarctions 
For internal border-zone infarctions, hemodynamic compromise is believed to be the 
proximate cause. Infarct patterns described include single lacunes in internal border-zone or 
a string of pearls or scattered pearl appearance on diffusion weighted imaging (DWI) 
(Turtzo et al, 2009). The underlying mechanism is believed to be a gradual reduction in the 
perfusion pressure in the stenosed artery. This leads to development of collateral blood 
supply from branches of extracranial carotid artery. With progression of disease, these 
collaterals are unable to maintain the hemodynamics and maximal hypoperfusion occurs in 
the terminal zones of the distribution of MCA and its perforators. These are the internal 
border-zone areas and the association of these infarcts with increased oxygen extraction 
fraction has been documented suggesting hemodynamic compromise as the likely 
mechanism (Yamauchi et al, 2009). 
 
Neuroimaging of Intracranial Atherosclerotic Disease 
 
303 
3.2 Cortical territorial infarctions 
Cortically based infarctions in the territory of MCA (anterior territorial infarctions) and PCA 
(posterior territorial infarctions) have also been described with large vessel atherosclerotic 
disease. The proposed mechanism is again artery to artery embolism. In case of anterior 
circulation, as opposed to cardioembolic infarcts, these are usually smaller, and limited to 
one of the three MCA territories. This can be explained based on the size of cardiac emboli 
which are larger and likely to give rise to large infarcts. However, with larger emboli 
occluding proximal MCA or distal internal carotid arteries (ICA), large territorial infarctions 
may also be seen particularly in the absence of effective collaterals (Rovera et al, 2005). The 
ischemic cortical lesions may co-exist with smaller cortical or subcortical acute lesions 




Fig. 1. Diffusion Weighted Images of Infarct Patterns seen with ICAD. A) Multiple infarcts 
in Right MCA territory, B) Deep MCA perforator infarct along with patchy cortical infarcts, 
C) cortical infarct in posterior MCA territory, D) String of pearls pattern in Internal border-
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In the posterior circulation, large artery atherosclerosis involving the vertebrobasilar arteries 
leads to infarctions in the territories of posterior inferior cerebellar artery (PICA), superior 
cerebellar artery (SCA) and PCA. Small territorial and nonterritorial cerebellar infarcts are 
also described with vertebrobasilar disease (Amarenco et al, 1994). 
3.3 Lacunar infarctions 
Lacunar infarctions in the centrum semiovale have also been described with intracranial 
atherosclerotic disease. When large (>1.5 cm) and present in the internal border-zone, these 
are thought to result from hemodynamic compromise. When small (<1.5 cm) they may arise 
secondary to artery to artery embolism. In this case, they may be accompanied by other 
small acute infarcts in the same large artery territory (Bogousslavsky and Regli, 1992). 
Posterior circulation lacunes have also been described with large vessel disease, particularly 
when they occur in isolation. 
3.4 Perforator artery infarctions 
With atherosclerotic involvement of MCA, local branch occlusion has also been described 
leading to deep perforator artery infarctions. Pial infarctions, those occurring in the vascular 
territories supplied by the superior and inferior branches of MCA have also been described 
with MCA disease (Lee et al, 2005). Thrombotic occlusion in the former and distal 
embolization in the latter is thought to be the underlying mechanism. 
3.5 Multiple acute brain infarctions 
Multiple acute brain infarctions, particularly in the same arterial territory have also been 
described (Roh et al, 2000 and Kang et al, 2003). The mechanism is believed to be distal 
embolizations from large vessel unstable plaque. Such infarcts are typically located in a 
single anterior or posterior arterial territory, but anatomic variations may explain other 
patterns such as involvement of anterior and posterior circulations simultaneously in case of 
a fetal-PCA or posterior communicating artery patency, or involvement of bilateral ACA 
territories in case of a single ACA supplying both hemispheres. 
4. Imaging of vessels 
The diagnosis of intracranial atherosclerotic disease rests on either direct visualization of the 
vessels or determination of their flow characteristics. Several non-invasive modalities like 
magnetic resonance angiography (MRA), computerized tomographic angiography (CTA) 
and transcranial doppler (TCD) are now available for screening and diagnostic purposes. 
However, the gold standard for diagnosis is still catheter based conventional angiography.  
4.1 Catheter based conventional and Digital Subtraction Angiography (DSA) 
DSA has been the reference standard for evaluation of intracranial stenosis and occlusion for 
decades. The technique involves injection of a radio-opaque dye via an intra-arterial 
catheter. Usually the femoral or radial arteries are used. Cerebral angiography is performed 
after catheterizing the cerebral arteries. The term digital subtraction angiography is used 
when a computer based software subtracts two images that are obtained before and after 
administration of contrast media. Modern DSA also incorporates three-dimensional 
reconstructed images which provide even better details.  
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DSA has several advantages over other modalities used for assessing intracranial stenosis. It 
provides excellent visualization of the anatomy of the vessel, the severity and length of 
stenosis and the presence of collateral circulation. However, the major disadvantage lies in 
the high skill required to perform the study. Another disadvantage is the morbidity 
associated with the procedure including stroke, arterial dissections, puncture site infection, 
thrombosis of punctured artery leading to limb ischemia and formation of pseudo-
aneurysms. In addition to this it carries the risk of nephrotoxicity associated with iodinated 
contrast used in the procedure. 
 
  
Fig. 2. DSA images showing disease in Right vertebral artery. A) Tight stenosis in Right 
vertebral artery, B) Post stenting restoration of flow.(Image Courtesy: Dr. Tanveer-ul-Haq, 
Associate Professor ,Section Head, Vascular and Interventional Radiology, Radiology 
Department, Aga Khan University Hospital , Karachi, Pakistan) 
When conducted for diagnostic purposes, risk associated with the procedure has gone down 
over the past years. The most recent estimate quotes the risk of stroke at 0.03% and of 
arterial dissections at 0.14%. The non-neurologic complications related to the arterial 
puncture were also not commonly seen (Fifi et al, 2009). In a dedicated unit for cerebral 
angiographies, the risk of neurologic complications can approach zero (Thiex et al, 2010). 
Interestingly, the risk of neurological adverse events was higher in patients with known 
intracranial atherosclerotic disease who underwent cerebral angiography in the WASID 
trial. 2% of these patients experienced neurological symptoms although all were transient 
and 6.1% had non-neurologic complications (Cloft et al, 2011). 
Given the disadvantages of DSA and the increased morbidity and potential mortality 
associated with it, non-invasive modalities are increasingly being utilized for assessment of 
intracranial atherosclerotic disease. 
4.2 Magnetic Resonance Angiography (MRA) 
4.2.1 Phase contrast (PC) and Time of Flight (TOF) MRA 
Phase contrast MRA utilizes the velocity differences and hence the phase shifts in moving 
spins to provide image contrast in flowing vessels. The phase of magnetization from the 
A B
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moving spins is taken as non-zero and that from the stationary spins is zero. Time of Flight 
MRA depends on the flow and movement of protons in blood through the imaging plane. It 
derives contrast between flowing blood and stationary tissues by manipulating the 
magnitude of magnetization. From the moving spins the magnitude is large and from static 
spins it is small. Both techniques can be used using two or three-dimensional acquisition 
although 3-D images have a long acquisition time.  
The main advantage of the modality lies in its non-invasive nature. There is no radiation 
exposure and no iodinated contrast exposure. It requires very little user interaction for 
acquisition and processing of images. When compared to the gold standard DSA, TOF-MRA 
has sensitivity in the range of 70% for intracranial stenosis and 81% for occlusion and a 
negative predictive value of 98% for stenosis and 99% for occlusion (Bash et al, 2005). 
Another study identified 87% negative predictive value for detecting a greater than 50% 
stenosis (Feldmann et al, 2007). These results may be slightly improved by use of Maximum 
Intensity Projections (MIP). 
There are however, several limitations when using PC and TOF MRA for intracranial 
stenosis evaluation. Firstly since it depends on changes in blood flow, it is prone to motion 
artifacts and to changes in the direction of the flow. The spatial resolution is also inferior to 
DSA and CTA. Another major drawback is its inability to distinguish between high grade 
stenosis and occlusion. Stenotic lesions are sites where complex, slow or in-phase flow 
characteristics are seen (Furst et al, 1995). Because of this there are proton spin dephasing 
artifacts and flow signal intensity loss is seen at severely narrowed sites. In addition, TOF 
technique requires longer imaging time. 
 
 
Fig. 3. TOF-MRA images of intracranial stenosis. A) Stenosis seen in bilateral PCAs, B) 
Severe atherosclerotic disease in supraclinoid ICA, bilateral MCA and ACA. (Image 
Courtesy, Stroke Fellowship Program, Aga Khan University Hospital, Karachi, Pakistan) 
4.2.2 Contrast Enhanced (CE) MRA 
Some of the disadvantages of TOF and PC MRA can be overcome with the use of 
gadolinium dye. CE-MRA utilizes the time of flight technique along with use of contrast 
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agent to shorten the T1 of the blood so that in the first pass of the contrast agent, the arteries 
show up in striking contrast to the surrounding stationary tissues and veins. The CE MRA 
provides better anatomic delineation of vascular structures and can better assess areas of 
changing flow direction. This is because the technique depends on the intrinsic T1 signal of 
blood, rather than the flow characteristics and is minimally affected by dephasing seen with 
complex flow.  
A certain degree of expertise is needed to time the image acquisition to minimize venous 
contamination. If the image is taken too early, arteries will not contrast enhance and if it is 
taken too late, the image will be contaminated by contrast uptake in the veins and 
surrounding tissues. For external carotids it is a widely used technique, but for assessment 
of intracranial vasculature it is still underutilized. 
4.2.3 Quantitative MRA (QMRA) 
Quantitative MRA (QMRA) is a newer technique that utilizes TOF and Phase contrast MRI 
to determine the vessel anatomy and measure blood flow. This allows for hemodynamic 
assessment of areas supplied by stenotic vessels. The technique has been shown to be 
particularly useful in prognosticating future risk of stroke in symptomatic vertebrobasilar 
disease. Those found to have a low distal flow on QMRA had a 71% stroke free survival at 2 
years as opposed to a 100% stroke free survival for those with a normal flow (Amin-Hanjani 
et al, 2005). 
QMRA has also found utility in assessment of flow before and after stent placement (Brisman, 
2008). More importantly for in-stent restenosis it is now an evolving non-invasive technique. In 
these patients, CTA and MRA are not of use due to the artifacts produced by the stent and 
DSA continues to be the mainstay for assessment of stent thrombosis. Recently QMRA has 
shown promise as a screening tool for in-stent stenosis with 100% sensitivity and negative 
predictive value and 92% specificity (Prabhakaran et al, 2009). QMRA can also be used to 
determine regional blood flow and indicate the adequacy of collateral flow and overall 
cerebral hemodynamics in patients of intracranial atherosclerotic disease (Zhao et al, 2007). 
4.2.4 High Resolution MRI (HR-MRI) 
Another emerging technique is HR-MRI which allows for imaging of the atherosclerotic 
plaque. It creates sufficiently thin slices through the vessel wall to allow for determination of 
plaque size, composition and biological activity (Yuan et al, 2006). This modality can also 
help discriminate from other non-atherosclerotic etiologies of vessel narrowing. 
Determination of plaque composition in terms of lipids, fibrous tissue and calcium and 
plaque activity in terms of inflammation can help determine whether a plaque is vulnerable 
or stable. HR MRI can also detect intraplaque hemorrhage which is another marker of 
plaque instability and can help predict risk of future vascular events (Turan et al, 2009 and 
Altaf et al, 2007). Furthermore, imaging the plaque directly can help determine presence of 
non-stenotic lesions which are generally missed with conventional MRA. Particularly in the 
evaluation of basilar artery, it was found that HR MRI detected atherosclerotic disease as a 
cause of pontine infarction in 42% of cases where TOF MRA and CE MRA had failed to 
show any basilar disease (Klein et al, 2010). Recently the technique has also found utility in 
guiding endovascular intervention of basilar artery (Jiang et al, 2011).  
In future, HR MRI can potentially provide targets for intervention at an early stage of 
intracranial atherosclerotic disease, detect non stenotic athterosclerotic lesions, and predict 
future risk of vascular events based on plaque morphology and characteristics. 
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4.3 Computerized Tomography Angiography (CTA) 
Computed tomography (CT) angiography is a relatively new non-invasive procedure that 
allows for accurate visualization of vascular structures and differentiates them from 
adjacent bone and soft tissues. Helical or Spiral CTA is acquired with the X-ray tube 
continuously rotating in a 360 degree turn while the table transports the patient slowly 
through the scanner. The slice thickness and the scan time for each helical series determine 
the extent of anatomic coverage. Axial images are stacked to form a volume of image data 
that can be processed in various formats like maximum intensity projection, multiplanar 
reformation and shaded surface display. This allows for 3 dimensional reconstruction of 
vessels similar to DSA. 
An iodinated contrast is injected through a peripheral vein and both arterial and venous 
phases can be easily obtained. Unlike MRA, CTA is not dependent on flow characteristics of 
the blood. Instead it relies on relative penetrance of the contrast agent within the blood 
vessel. New scanners allow smaller slice thickness and hence greater resolution. 
Additionally, three-dimensional reformatting allows for excellent appreciation of anatomic 
relationships between bones, soft tissues, and the vascular system. Spiral or helical CTA is 
now used commonly for the evaluation of intracranial stenosis and provides excellent 
anatomic visualization.  
The sensitivity of CTA for detection of intracranial occlusion is almost 100% compared to 
DSA (Nguyen-Huynh et al, 2008 and Bash et al, 2005). For detection of stenotic lesions 
greater than 50%, the sensitivity is 97.1% and specificity is 99.5%. With this high sensitivity 
and specificity it is an excellent tool for screening people with intracranial stenosis. Helical 
CTA has also been shown to be superior to DSA in detecting vessel patency in posterior 




Fig. 4. CTA image demonstrating stenotic lesions in right vertebral, right M2 segment and 
left M1 segment of MCA. (Image Courtesy: Dr. Tanveer-ul-Haq, Associate Professor ,Section 
Head, Vascular and Interventional Radiology, Radiology Department, Aga Khan University 
Hospital , Karachi, Pakistan.) 
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The major advantage of CTA lies in its non-invasive nature compared to DSA and better 
image quality compared to MRA. It takes less time for acquisition of images; it is not 
affected by motion artifacts and is independent of hemodynamic effects seen with MRA. 
There is also a high inter-reader reliability in quantitation of stenotic lesions (Bash et al, 
2005). Another major advantage over MRA lies in the ability of CTA to accurately depict 
areas of low flow distal to severely stenotic vessels (Skutta et al, 1999 and Bash et al, 2005). It 
was previously thought that petrous and cavernous ICA are regions elusive to CTA due to 
bony or calcium artifacts (Skutta et al, 1999 and Hirai et al 2002). However, newer studies do 
not report this problem likely because of better post processing and acquisition techniques 
(Bash et al, 2005). 
Limitations of CTA include radiation exposure and risk of nephrotoxicity with the use of 
intravenous contrast agent. Another limitation to the technique is skill required for optimal 
contrast gradient-timing to avoid venous contamination and for post processing of the 
images to avoid contamination with surrounding structures. For accurate visualization of 
vessels to avoid over or underestimation of stenosis, there is a need for optimally adjusting 
window and level settings (Bash et al, 2005). CTA may be inferior to MRA in certain respects 
as it provides no information on flow characteristics across a stenotic lesion. 
4.4 Transcranial Doppler (TCD) 
Transcranial Doppler (TCD) is a useful, non invasive, real time and portable mechanism of 
investigating 50 to 99% stenosis of the intracranial arteries. Ultrasound is a travelling wave 
of energy that has a frequency of more than 20,000 Hz which is above the audible range for 
humans. The Doppler effect, first described by Christian Andreas Doppler, is the change or 
shift in the frequency or wavelength of a wave due to relative movement between the sound 
scatterer and the receiver. In TCD, the Doppler effect can be used to determine the speed 
and direction of flow in blood vessels. Many red blood cells move at varying speeds through 
an insonated vessel and the TCD sample volume is relatively large. The signal received from 
any sample volume within a vessel is a mixture of the different Doppler frequency shifts 
forming a spectrum that is displayed visually. 
Low frequency ultrasound can penetrate the skull; the temporal bone is the thinnest portion 
of the skull and allows successful insonation. An inadequate temporal window is a major 
cause of insufficient evaluation of cerebral vessels during TCD. The prevalence of this 
finding is 14.5% and is increased in non white females greater than 60 years of age. 
(Ratanakorn, 1998). The temporal window allows the ICA, MCA, ACA to be sampled, the 
occipital allows the posterior circulation to be reviewed, and the ophthalmic allows the 
collateral information to be gathered.  
Spectral waveforms are identified by their direction, depth of insonation, velocity 
characteristics, and spectral measurements are then performed to report the following 
parameters for the cerebral circulation: Mean Flow Velocity (MFV) and the Pulsatility 
Index (PI). 
   MFV=PSV +2 EDV)/3  (1) 
      PI= (PSV-EDV) /MFV   (2) 
where PSV= Peak Systolic Velocity and EDV= End Diastolic Velocity 
MFV correlates well with vessel patency and degree of arterial stenosis. The PI is an indirect 
measure of peripheral resistance. Post stenotic vessels with blunted waveforms have low 
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resistance and chronic hypertensives have high PI. In addition TCD can provide information 
on the presence or absence of microembolic signals and the progression and regression of 
stenosis.  
The advantages of TCD are that the vessels are insonated non- invasively, at the bedside and 
repeatedly without any harm to the patients. The limitations of TCD include a lack of 
windows, operator dependency, and the fact that lesser degrees of stenosis are not picked 
up and that direct evaluation is limited to the basal intracranial vessels. 
TCD is a useful adjunct to the diagnosis of ICAD in the following ways 
1. Non invasive diagnosis of 50 – 70% stenosis and response to therapy  
Velocity thresholds that predict a significant MCA stenosis have been reported. As a rule in 
a vessel with straight walls a 50% diameter reduction doubles the velocity and a 70 % 
stenosis can quadruple the velocity at the exit of the stenosis compared with a prestenotic 
segment or to the contralateral side.  
The criteria that are used include MFV, Peak systolic velocity (PSV) and stenotic to 
prestenotic ratios. The velocity criteria for determining the degree of stenosis in the different 
vessels are reported from the SONIA study that in addition, reported the Positive and 
Negative predictive values (PPV and NPV). When using non invasive imaging it is 
important to correlate the status of the extracranial carotid artery. Collateral flow and 
decreased volume flow from the proximal carotid stenosis without adequate collateral flow 
results in false positive and false negative interpretations respectively. To further help avoid 
false positives a prestenotic to post stenotic MCA velocity ration of 1 :>2 should be used in 
addition to the MFV threshold.  
The relative portability of TCD has led to wide scale applications in population screenings to 
detect asymptomatic disease and to follow the regression of stenosis and response to 
therapy in large scale interventional studies. It has therefore been used as a biologic 
surrogate marker much like carotid Intima media Thickness (IMT). However, it is not clear 
at this point whether the regressive changes in TCD can predict clinically important 
amelioration of outcomes.  
2.  Characterization of Microembolic Signals (MES)  
When following standardized assessment, the detection of microembolic signals in stenotic 
arteries in real time can predict the appearance of stroke (Garami and Alexandrov, 2008). 
Microembolic signals are common in patients with large artery disease and are an 
independent marker of future stroke risk of intracranial stenosis. In the CLAIR study (Wong 
et al, 2010) the administration of two antiplatelet agents reduced the appearance of MES in 
patients with Intracranial stenosis who were given aspirin and clopidogrel within 7 days of 
their stroke. Whether this reduction in microembolic activity results in reduction of the 
occurrence of stroke remains to be tested in large scale clinical trials. 
3. Adequacy of Collaterals and Vasomotor Reactivity  
Collaterals have a significant effect on stroke outcomes, and with very severe stenoses they 
are shown to have a protective effect as opposed to lesser degrees of stenoses in which case 
the presence of collaterals signifies a greater instability (Liebeskind et al, 2010). TCD can 
help in evaluation of collaterals at the circle of Willis. Leptomeningeal and other secondary 
collaterals cannot be evaluated with this technique. Contrast addition to the imaging can 
help improve its sensitivity. Tests of vasomotor reactivity are also used to assess the 
adequacy of collaterals. A vasodilatory challenge can be given such as acetazolamide, or 
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CO2 inhalation or apnea. Impaired vasomotor reactivity with CO2 has been tested with TCD 
and shown to correlate with stroke risk in patients with carotid stenosis (Visser et al, 2000).  
4.5 Hemodynamic monitoring 
Direct visualization of the vessels using the above techniques gives a reliable estimate of the 
anatomic degree of stenosis. Since intracranial atherosclerotic disease is a slowly progressive 
condition, it leads to chronic hypoperfusion and development of collaterals. The 
development of collaterals does not guarantee their persistence and they are also prone to 
hemodynamic fluctuations and occlusion secondary to artery to artery embolization in cases 
where they originate from cortical vessels. These collaterals can also be visualized using the 
vessel imaging techniques already described. Whether these collaterals are adequate to 
maintain perfusion in the territory of stenotic vessel needs evaluation with other modalities 
of which TCD has already been discussed. 
Blood flow through the capillaries is referred to as perfusion and this is responsible for 
delivering oxygen to the brain tissue. Cerebral blood flow (CBF) and blood volume (CBV) 
are indicators of brain perfusion. Regional cerebral blood flow is proportional to the 
regional cerebral metabolism. Initial compensatory mechanism to deal with a decrease in 
perfusion is vasodilatation. Once maximum vasodialtion has occurred, oxygen extraction 
fraction increases to maintain the metabolic needs of the cerebral tissue. Regional 
cerebrovascular reserve (rCVR) is another parameter that can be measured to gauge the 
vasodilatory capacity of the arterioles. 
Several techniques are now available to measure perfusion through the brain. These include 
positron emission tomography (PET), single-photon emission CT (SPECT), xenon-enhanced 
CT, perfusion CT and MRI, and TCD. Addition of acetazolamide challenge to various 
imaging modalities increases their sensitivity for picking up decreased rCVR. 
PET imaging measures cerebral oxygen extraction fraction (OEF) and has been the gold 
standard so far for identifying hemodynamic failure (Derdeyn et al, 2002). It allows for 
measurement of CBF, CBV and Mean Transit Time (MTT). It is currently being used to select 
patients with poor hemodynamic reserve, secondary to ICAD, eligible for external to 
internal carotid bypass. The benefit of this procedure can then also be gauged by imaging, 
translating as improved oxygen perfusion in previously occluded areas. Small retrospective 
studies have shown the outcome of external to internal bypass to be favorable (Nagata et al, 
1991 and Mendelowitsch et al, 2004). PET is restricted in its utility because of its high cost 
and limited availability. 
SPECT can be similarly utilized to measure rCVR and when used with acetazolamide 
challenge it provides additional information regarding hemodynamic status of the brain 
(Ozgur et al, 2001). This again has been utilized to judge the dependency on external 
carotid-internal carotid (EC-IC) and leptomeningeal collaterals. Use of acetazolamide 
challenge allows for assessment of vasomotor reactivity (VMR) as well which when 
impaired predicts future stroke. Although SPECT is more widely available compared to 
PET, its disadvantage lies in longer imaging time and inferior spatial resolution (Eskey and 
Sanelli, 2005). 
Two major trials are currently ongoing to recruit patients with poor hemodynamic reserve 
secondary to atherosclerotic disease and to evaluate the effectiveness of the bypass 
procedure. These include the Carotid Occlusion Surgery Study in US (COSS) (Grubb et al, 
2003) which is using PET and the Japanese EC-IC bypass Trial (JET) (Mizumura et al, 2004) 
which is utilizing SPECT for hemodynamic monitoring. They have so far validated the 
imaging modalities to recruit candidates for the procedure. 
 
Neuroimaging – Clinical Applications 
 
312 
Perfusion studies using CT and MRI can also reliably estimate CVR in patients with 
intracranial stenosis. Perfusion CT provides quantitative values for CBF, CBV and MTT and 
has recently been shown to have a significant correlation with SPECT parameters. MTT was 
the most predictive of a decreased CVR in this study even without use of acetazolamide 
challenge(Kim et al, 2009). 
Xenon-enhanced computed tomography (XeCT) has been in use for the past two decades to 
measure cerebral blood flow and is frequently utilized by revascularization experts to 
calculate the cerebrovascular reserve capacity (Wintermark et al, 2001). Its major advantage 
lies in its superior spatial resolution, accuracy, and reproducibility. Xenon gas is inhaled and 
its concentration is measured in the brain by CT scanner. There is a potential for adverse 
reaction to the gas besides radiation exposure and motion artifacts can also affect image 
quality (Wintermark et al, 2005). 
To conclude several techniques are available for assessment of cerebral hemodynamics. 
Each carries its own advantages and disadvantages. PET due to its expense and limited 
availability is restricted in its utilization, but SPECT and Perfusion CT are reasonable 
alternatives.  
5. Conclusion 
Intracranial atherosclerosis is the progressive atherosclerotic stenosis of the arteries at the 
base of the brain. This condition is responsible for 10 – 50% of ischemic strokes worldwide. 
It is more common in Asians, Hispanics, Blacks and South East Asians and thus in absolute 
numbers is probably the most common cause of stroke in the world. Radiologically, it 
presents with border-zone ischemia, either in the internal border-zone area or the distal 
cortical area, with discrete cortical infarction or a lacunar perforator infarction with 
involvement of the parent vessel. The intracranial  stenosis  and its associated collaterals can 
be best  quantified by  catheter angiography, however this is invasive and not entirely 
without risk. Non invasively, MRA, CTA and TCD all offer valuable and complementary 
information. MRA can assess flow and stenosis, however it may overestimate preocclusive 
stenosis. CTA may be useful in these settings where actual anatomic accuracy is needed to 
differentiate preocclusive stenosis from complete occlusion since it is not flow dependent. 
TCD provides real time hemodynamic information to delineate the mechanism of stroke in 
the individual patient – whether it is a flow related hemodynamic stroke, whether or not 
regression has occurred or that the patient has microemboli from platelet aggregation. 
Additionally TCD has good negative predictive value in reporting 50 – 90% stenosis. It is 
postulated that stenosis of less than 50% may also be responsible for stroke through 
embolizations from unstable plaque. However, very little is known about this entity except 
that High resolution MRI can visualize these plaques in vivo. For those with high grade 
progressive stenosis, the prognosis clearly depends on the extent of collateralization. This 
can be investigated with PET, SPECT and perfusion CT to best select patients for EC_IC 
Bypass procedures which are currently investigational.  
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1. Introduction  
Multiple sclerosis (MS) is a chronic disabling autoimmune disorder of the central nervous 
system histopathologically characterized by inflammation, multifocal demyelination, axonal 
damage and neuronal loss. Focal intensive demyelination and white matter infiltration by 
lymphocytes and mononuclear cells are pathological hallmarks of the disease (Ferguson et 
al., 1997; Lucchinetti et al., 2000).   
Complementary to the clinical evaluation, conventional magnetic resonance imaging 
(cMRI) plays a prominent role for diagnosis and assessment of patients with multiple 
sclerosis. It provides reliable detection and quantitative estimation of focal white matter 
lesions in vivo. Modern criteria involve MRI parameters for the diagnosis of MS and for 
predicting conversion to clinically definite MS in patients who present with a first clinical 
episode (eg, unilateral optic neuritis) suggestive of disease onset. A diagnosis of multiple 
sclerosis is based on showing disease dissemination in space and time and excluding 
other neurological disorders that can clinically and radiologically mimic multiple 
sclerosis. However, neurological impairment of patients with MS is poorly associated 
with the lesion load observed on conventional MRI scans. The discrepancy between 
clinical and conventional MRI findings in MS is explained, at least partially, by the low 
sensitivity of conventional MRI in the detection of grey-matter involvement and diffuse 
damage in white matter.  
In order to overcome these limitations new uses of conventional MRI methods have 
evolved and nonconventional MRI techniques have been developed. These advances are 
expected to help in understanding the underlying disease processes and the accumulation 
of irreversible disability and therefore are promising tools in studies of disease evolution 
and clinical trials.   
Optical coherence tomography (OCT) -a new, sensitive and non-invasive transpupillary 
imaging method- is able to provide accurate and quantitative measurements of axonal loss 
in retina and therefore holds promise as a biomarker for neurodegeneration in MS. 
This chapter reviews the use of cMRI techniques to diagnosis and follow-up of patients with 
MS. It also summarizes the evolving non-conventional MRI and non-invasive optical 
techniques, which are sensitive to different aspects of MS pathology and are promising to 
further increase our understanding of disease pathophysiology and the mechanisms 
accounting for the accumulation of irreversible disability.  
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2. MRI and the diagnosis of multiple sclerosis 
Since multiple sclerosis is a histopathological diagnosis, clinical criteria have been 
developed for the diagnosis of MS during life. Initial diagnostic criteria were based on 
clinical features alone to show disease dissemination in space and in time (Schumacher et 
al., 1965). The introduction of MRI in clinical practice resulted in improved investigation of 
multiple sclerosis (Young et al., 1981). Paraclinical evidence to support clinical findings in 
cases of diagnostic uncertainty was first proposed by Poser and colleagues (Poser et al., 
1983). Given that MRI is the most sensitive paraclinical test and that comparable MRI 
abnormalities may be found in a variety of other diseases and in healthy volunteers, criteria 
have been developed by which MRIs can be classified as suggestive of multiple sclerosis or 
not (Fazekas et al., 1988; Paty et al., 1988; Barkhof et al., 1997; Tintore et al., 2000). 
With the increased availability of MRI scanners and the high sensitivity and ability of MRI 
to provide evidence for disease dissemination in both space and time, subsequent consensus 
criteria relied on MRI findings to complement clinical and other paraclinical data for the 
diagnosis of MS (McDonald et al., 2001). The 2001 McDonald diagnostic criteria for multiple 
sclerosis included MRI evidence of dissemination in space (DIS) and dissemination in time 
(DIT), which allowed a diagnosis of multiple sclerosis to be made in patients with clinically 
isolated syndrome (CIS) (McDonald et al., 2001). The DIS criteria were those developed for 
brain MRI by Barkhof and colleagues (1997) and Tintore and colleagues (2000), in addition 
to allowing one spinal-cord lesion to substitute for a brain lesion. Evidence for DIT requires 
either a gadolinium enhancing lesion after at least 3 months from CIS onset, or a new T2 
lesion developing on a scan subsequent to a reference scan obtained at least 3 months after 
CIS onset (Table 1). 
The incorporation of MRI findings to the diagnostic criteria improved the ability to diagnose 
MS and exclude alternative diagnoses. Apparently MRI started to play a prominent role in 
establishing a firm and clear diagnosis of multiple sclerosis and predicting conversion to 
clinically definite MS in patients who present with a first clinical episode (eg, unilateral optic 
neuritis) suggestive of disease onset. The necessity of early and accurate diagnosis became 
particularly important with the advent of disease modifying treatments. Subsequently, the 
McDonald criteria were revised in 2005 by Polman and colleagues, to simplify their use and 
increase their sensitivity while maintaining their specificity. These revised criteria 
strengthen the use of spinal cord lesions in MS diagnosis, allowing a spinal cord lesion to 
substitute for an infratentorial brain lesion. In 2006, new simpler imaging criteria were 
proposed with similar high specificity for clinically definite MS (CDMS) and increased 
sensitivity (Swanton et al., 2006), in which DIS requires at least one T2 lesion in at least two 
of four locations (juxtacortical, periventricular, infratentorial, and spinal-cord) and DIT 
requires a new T2 lesion on a follow-up scan. Thereafter, new data and consensus 
underlined the need to simplify the revised McDonald Criteria in order to improve their 
comprehension and utility.  Accumulating evidence resulted recently in specific 
recommendations for revisions to the McDonald Criteria. These proposals concerned the use 
and interpretation of imaging criteria for DIS and DIT and were based on the simplified 
criteria of Swanton and colleagues (Polman et al., 2011). The 2010 revisions to the McDonald 
Criteria simplify the diagnostic process with fewer required MRI examinations, allowing a 
more rapid diagnosis of MS, with preserved or improved specificity and sensitivity 
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compared with past Criteria (Table 2). However, even these latest revisions do not address 
issues of lesion morphology except to emphasize the importance of Gd enhancement and 
insufficiently deal with lesion location. Distribution and morphology provide important 
clues to the suspected nature of the detected lesions. In addition, misapplication of the 
McDonald criteria can lead to misdiagnosis in subjects without relevant clinical symptoms. 
Therefore, a diagnosis of MS based on incidental findings on MRI alone, should be avoided 
(Polman et al., 2011). 
 
Clinical Presentation Additional Data Needed 
 2 or more attacks (relapses) 
 2 or more objective clinical lesions 
None; clinical evidence will suffice  
(additional evidence desirable but must be 
consistent with MS)  
 2 or more attacks 
 1 objective clinical lesion 
Dissemination in space, demonstrated by:   
 MRI 
 or a positive CSF and 2 or more MRI lesions 
consistent with MS 
 or further clinical attack involving different 
site 
 1 attack 
 2 or more objective clinical lesions 
Dissemination in time, demonstrated by:  
 MRI 
 or second clinical attack  
 1 attack 
 1 objective clinical lesion 
(monosymptomatic presentation) 
Dissemination in space demonstrated by:  
 MRI 
 or positive CSF and 2 or more MRI lesions 
consistent with MS 
and  
Dissemination in time demonstrated by:  
 MRI 
 or second clinical attack 
Insidious neurological progression  
suggestive of MS  
(primary progressive MS) 
Positive CSF  
and  
Dissemination in space demonstrated by:  
 MRI evidence of 9 or more T2 brain lesions 
 or 2 or more spinal cord lesions 
 or 4-8 brain and 1 spinal cord lesion 
 or positive VEP with 4-8 MRI lesions 
 or positive VEP with <4 brain lesions plus 1 
spinal cord lesion 
and  
Dissemination in time demonstrated by:  
 MRI 
 or continued progression for 1 year 
Table 1. 2001 McDonald diagnostic criteria for multiple sclerosis (from McDonald et al., 
2001; with permission) 
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Clinical Presentation Additional Data Needed 
 2 or more attacks (relapses; 
exacerbations) 1 
 2 or more objective clinical lesions or 
 Objective clinical evidence of 1 lesion 
with reasonable historical evidence of a 
prior attack 2
None3 
 2 or more attacks1 
 Objective clinical evidence of 1 lesion 
Dissemination in space, demonstrated by: 
 1 T2 lesion in at least 2 of 4 MS-typical 
regions of the CNS (periventricular, 
juxtacortical, infratentorial, or spinal 
cord) 4  
or 
 Await a further clinical attack1 
implicating a different CNS site 
 1 attack1   
 Objective clinical evidence of 2 or more 
lesions 
 
Dissemination in time, demonstrated by: 
 Simultaneous presence of 
asymptomatic gadolinium-enhancing 
and nonenhancing lesions at any time;  
or 
 A new T2 and/or gadolinium-
enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference 
to a baseline scan;  
or 
 Await a second clinical attack1 
 1 attack1  
 Objective clinical evidence of 1 lesion 
(clinically isolated syndrome) 
Dissemination in space and time, 
demonstrated by: 
For DIS: 
1 or more T2 lesion in at least 2 of 4 MS-
typical regions of the CNS (periventricular, 
juxtacortical, infratentorial, or spinal cord) 4  
or 
 Await a second clinical attack1 
implicating a different CNS site;  
and 
For DIT: 
 Simultaneous presence of 
asymptomatic gadolinium-enhancing 
and nonenhancing lesions at any time;  
or 
 A new T2 and/or gadolinium-
enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference 
to a baseline scan;  
or 
 Await a second clinical attack1 
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Clinical Presentation Additional Data Needed 
Insidious neurological progression 
suggestive of MS (PPMS) 
 
1 year of disease progression 
(retrospectively or prospectively 
determined) plus 2 of 3 of the following 
criteria: 4 
 Evidence for DIS in the brain based on 
1 or more T2 lesions in the MS-
characteristic (periventricular, 
juxtacortical, or infratentorial) regions 
 Evidence for DIS in the spinal cord 
based on 2 or more T2 lesions in the 
cord 
 Positive CSF (isoelectric focusing 
evidence of oligoclonal bands and/or 
elevated IgG index) 
1 An attack is defined as patient-reported or objectively observed events typical of an acute 
inflammatory demyelinating event in the CNS, current or historical, with duration of at least 24 hours, 
in the absence of fever or infection.  
2 Clinical diagnosis based on objective clinical findings for 2 attacks is most secure. Historical evidence 
for 1 past attack can include events with symptoms and evolution characteristic for a prior 
inflammatory demyelinating episode; at least 1 attack, however, must be supported by objective 
findings. 
3 No additional tests are required. However, it is desirable that any diagnosis of MS be made with 
access to imaging based on these Criteria.  
4 Gadolinium-enhancing lesions are not required; symptomatic lesions are excluded from consideration 
in subjects with brainstem or spinal cord syndromes. 
Table 2. The 2010 McDonald Criteria for Diagnosis of MS (from Polman et al., 2011; with 
permission) 
2.1 Characteristic findings on conventional MRI techniques       
Hydrogen protons of water are highly abundant in our body. Conventional MRI measures 
alterations in tissue water content and dynamics by proton excitation, thus enabling 
visualization of edema, inflammation, demyelination and axonal damage in MS lesions. 
Conventional MRI techniques include T2-weighted, fast fluid-attenuated inversion recovery 
(FLAIR), and T1-weighted imaging with and without gadolinium (Gd) administration. 
In routine evaluation of patients with suspected or known MS, the most useful image 
acquisition clinical protocols for cMRI are axial dual spin-echo or single late echo T2-
weighted imaging, axial and sagittal FLAIR, and pre- and post-gadolinium (Gd)-enhanced 
axial spin-echo T1-weighted imaging (Bakshi et al., 2004). On cMRI scans, detected MS 
lesions are presented as hyperintensities on T2- weighted images, hypointensities on T1-
weighted images, and Gd-enhancing foci on postcontrast images. 
2.1.1 T2-weighted imaging    
T2-weighted MRI is sensitive in detecting white matter lesions. In T2-weighted images, MS 
lesions appear as bright areas against a gray or more neutral background; this hyperintesity 
reflects an increase in water content and thus is not specific for the underlying pathology. 
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The T2 hyperintense lesions represent processes ranging from edema and inflammation to 
demyelination, remyelination, Wallerian degeneration, axonal loss and gliosis (Fillipi & 
Agosta, 2009; Markovic-Plese & McFarland, 2001). Once detected, a lesion typically persists 
in the T2 hyperintense stage for many years. The techniques that are commonly used for the 
identification of T2 hyperintense lesions are conventional spin echo, fast spin echo, and 
fluid-attenuated inversion recovery (FLAIR) (Filippi et al., 2006). FLAIR imaging is a 
technique that suppresses the CSF signal, being more sensitive to periventricular and 
cortical/juxtacortical lesions and less sensitive to infratentorial lesions than T2-weighted 
MRI (Bakshi et al., 2001). 
Given the lack of specificity of hyperintensities on T2-weighted MRI, lesion location and 
morphology plays a prominent role in distinguishing demyelinating lesions from the 
common and incidental presence of non-specific white-matter abnormalities, microvascular 
ischemia, or enlarged perivascular spaces (Fig. 1). MS lesions are primarily found in white 
matter but also in gray matter and usually affect the periventricular regions, corpus 
callosum, juxtacortical gray-white matter junction in the white matter, and infratentorial 
brain regions (brain stem, middle cerebellar peduncles and cerebellar white matter in the 
posterior fossa) (Bakshi et al., 2004; Barkhof et al., 1997). In some cases, direct involvement of 
the cerebral cortex also may be apparent (Bakshi et al., 2001). Corpus callosum is commonly 
affected in MS due to the large amount of myelinated fibres it contains. Callosal 
demyelinating lesions are usually multiple, small, nodular and characteristically involve 
callosal-septal interface. Infratentorial lesions are considered specific for multiple sclerosis 
and are typically located at the surface of the pons, the base of the fourth ventricle, and in 
the intra-axial trigeminal tract. It is important to note however that they can also be found in 
small-vessel disorder, with characteristic involvement of the central part of the pons (Kwa et 
al., 1997). Demyelinating lesions are larger (> 3mm) than punctuate non-specific white 
matter abnormalities associated with migraine and microvascular ischemia.  
Characteristically, they have an ovoid shape and appear perpendicular to the long axis of 
the ventricles in the axial plane. These typical MRI findings reflect the histopathological 
findings in multiple sclerosis. The periventricular lesions, especially in the corpus callosum, 
and the ovoid abnormalities with extensions (Dawson’ fingers) into the adjacent white 
matter correlate with the perivenular distribution of multiple sclerosis plaques  (Gean-
Marton et al., 1991). 
Between 50% and 90% of MS patients show hyperintense T2 lesions in the spinal cord, more 
frequently located in the cervical and the thoracic area (Lycklama et al., 2003; Agosta & 
Filippi, 2007). Cord lesions are usually located peripherally, occupy less than one half of the 
cord cross-sectional area and rarely involve more than two contiguous vertebral segments in 
length. Acute lesions may be associated with cord swelling. The presence of characteristic 
spinal cord abnormalities on MRI increases both sensitivity and specificity to the diagnosis 
of MS (Fillipi & Agosta, 2009).  
In 50–70% of patients presenting with CIS clinically silent MRI lesions suggestive of MS are 
found. The extent of T2 lesions on brain MRI in CIS patients can predict the future risk of 
MS. The majority of CIS patients with T2 abnormalities (56–88%), develop clinically definite 
MS (CDMS) after prolonged (7–14 years) follow-up, whereas a minority of those with 
normal MRI (approximately 20%) have a risk for conversion to definite MS (Barkoff et al., 
1997; Tintoré et al, 2006). Moreover, brain T2 hyperintense lesion load early in the clinical 
course of MS is also a predictor of long-term disability (Di Filippo et al., 2010).  
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(a) Axial FLAIR image showing typical 
ovoid periventricular hyperintense MS 
lesions 
 
(b) Axial FLAIR scan revealing 
juxtacortical lesions 
  
(c) Sagittal T2-weighted image 
demonstrating lesions in the corpus 
callosum and periventricular white matter  
with  characteristic extensions (Dawson’s 
fingers) 
 
(d) Axial T2 scan showing characteristic 
infratentorial involvement 
Fig. 1. (a-d). Axial and sagittal FLAIR and T2 images showing common sites of MS 
involvement. 
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2.1.2 T1-weighted imaging      
On noncontrast T1-weighted images (T1-WI), most T2 brain lesions are isointense in white 
matter; however, some are hypointense (van Walderveen et al., 1998). These hypointense 
lesions may be acute and reversible within 6 months or chronic (referred to as black holes) 
(Fig. 2). The acute T1 hypointense lesions are likely to represent oedema and inflammation 
or demyelination with subsequent remyelination whereas the chronic ones severe 
demyelination and irreversible axonal loss (Bagnato et al., 2003; Brex et al., 2000; Filippi et 
al., 2001; Van Walderveen et al., 1998). The percentage of newly formed hypointense lesions 
that do revert to isointensity varies between 20 and 60% (van Waesberghe et al., 1998). 
Larger size of the lesions, longer duration of Gd-enhancement and ring enhancement are 
associated with the development of persistent T1- hypointense black holes (Mineboo et al., 
2005). T1 hypointense lesions correlate better with clinical evolution and disability than T2 
lesions and therefore may be a useful biomarker of progressive tissue damage in established 
MS (Truyen et al., 1996). By contrast to chronic cerebral lesions, chronic spinal cord lesions 
are isointense on T1-weighted images (Fillipi & Agosta, 2009). 
 
  
 a) Axial T1-weighted noncontrast MRI 
showing a chronic hypointensity in the 
right frontal periventricular white matter 
(b) Corresponding hyperintensity on 
FLAIR scan. 
Fig. 2. (a-b) A chronic black hole in a 32-year-old woman with relapsing-remitting MS 
2.1.3 Postcontrast T1-weighted imaging     
On T1-weighted scans, gadolinium injection enables detection of lesions with active 
inflammation and blood–brain barrier (BBB) disruption, as it is normally excluded from the 
brain by the BBB. Gd-enhancing lesions on T1-WI typically correspond to areas of high 
signal intensity on T2-WI and, in some instances, low signal intensity on T1-WI that stem 
from edema and demyelination (Zivadinov & Cox, 2007). There are various patterns of 
gadolinium enhancement in MS lesions that usually persists for 2 – 6 weeks (Cotton et al., 
2003): homogeneous, heterogeneous, punctuate, ring, open ring enhancing and tumor-like 
(Fig. 3). Among them, the incomplete or open-ring morphology (Fig. 3a) is particularly 
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characteristic of MS lesions (Masdeu et al., 1996). Compared with homogeneously 
enhancing plaques, ring-enhancing lesions are larger and have a shorter duration of 
enhancement (Minneboo et al., 2005). Concentric ring enhancing lesions with central 
contrast pallor appear in areas of heightened local inflammation (Rovira et al., 1999). 
Results of serial MRI studies demonstrate that enhancement usually precedes or 
accompanies the appearance of most new lesions on T2-WI in all disease subtypes, even in 
primary-progressive MS (Molyneux et al., 2001). However, Gd- enhancement is more 
commonly seen in patients with relapsing-remitting (RRMS) than in patients with primary 
or secondary progressive MS (Thompson et al., 2000) and is considered sensitive to disease 
activity and predictive of future clinical relapses. Enhancing lesions do not correlate with 
long-term disability (Kappos et al., 1999), with the exception of ring-enhancing plaques that 
are usually suggestive of a more aggressive form of MS. Ring-enhancement is associated 
with severe tissue damage, persisting hypointense T1 lesions and subsequent development 
of cerebral atrophy (Morgen et al., 2001; Bagnato et al., 2003; Minneboo et al., 2005;). 
Enhancing lesions are less frequently seen in the cord (Fig. 3b)  than in the brain (Filippi & 
Agosta, 2009).  
 
  
(a) Puctuate, homogeneous, and ring 
enhancing brain lesions 
(b) Spinal enhancing lesion 
Fig. 3. Characteristic patterns of enhancement on T1-weighted scans 
2.2 Conventional MRI characteristics suggesting alternative diagnoses      
Although existing diagnostic criteria for multiple sclerosis have emphasized that alternative 
explanation for the clinical presentation must be considered and excluded before a diagnosis 
of MS can be made, they mainly focus on early diagnosis of patients presenting with a first 
clinical episode suggestive of MS (e.g., unilateral optic neuritis, internuclear 
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ophthalmoplegia, partial myelopathy). Incorporated data from magnetic resonance imaging 
are used as prognostic for the subsequent development of clinically definite MS, rather than 
diagnostic (McDonald et al., 2001; Polman et al., 2005, 2011). However, the increased 
availability of MRI scanners and the sensitivity of this technique in showing asymptomatic 
lesions of multiple sclerosis, have revealed difficulties in the application of existing MRI 
criteria, the most common of which is the incidental presence of non-specific white-matter 
abnormalities on MRI scans of patients who have headache, vertigo or a variety of other 
common disorders and the inability to differentiate these lesions from those that are typical 
for MS. Recognition of MRI features that are not suggestive of MS or even suggestive of 
another disorder is essential, as it underlines the need for extensive evaluation of patients 
presenting with such abnormalities in order to avoid misdiagnosis. 
A set of MRI signs (red flags), which suggest alternative conditions that mimic MS has been 
defined by the European MAGNIMS group (Charil et al., 2006). It is important to note 
however that these red flags (Table 3) should be considered in the appropriate clinical 
context in order to exclude the most common alternatives (Miller et al., 2008).  
The distribution of lesions is an important parameter that should be considered in the 
differential diagnosis of demyelinating lesions. In hypoxic-ischemic diseases lesions follow 
arterial anatomy, such as borderzone or watershed lesions, lacunes, multifocal basal ganglia 
lesions and cortical infarcts whereas in multiple sclerosis are perivenular (Enzinger et al., 
2006). Moreover, the corpus callosum is not usually involved in hypoxic-ischemic diseases, 
due to its rich blood supply; on the contrary, this is commonly affected in MS due to the 
large amount of myelinated fibres it contains, with characteristic involvement of callosal-
septal interface (Gean-Marton et al., 1991).  Infratentorial lesions are uncommon in small-
vessel disorder, but when they occur they are typically located in the central part of the pons 
(Kwa et al., 1997). The predominance of lesions located at the cortical or subcortical areas, as 
well as the coexistence of brain infarcts, calcification, or haemorrhages are usually 
suggestive of systemic immune mediated diseases with CNS involvement, small-vessel 
vasculitides, or antiphospholipid antibody syndrome (either primary or secondary to 
systemic immune-mediated diseases). In these disorders, enhancing lesions and T1 black 
holes are much less common than in multiple sclerosis (Theodoridou & Settas, 2008). 
Extensive brainstem and basal ganglia lesions that can be associated with swelling and 
enhancement in the acute phase and that can shrink or disappear at follow-up may be a 
manifestation of Behçet’s disease (Lee et al., 2001). Bilateral and symmetric white-matter 
lesions are other important features against the diagnosis of multiple sclerosis. Although 
adult forms of leucodystrophies, such as adrenoleucodystrophy, metachromatic 
leucodystrophy, and Krabbe disease may have a MRI pattern resembling that of MS, white-
matter lesions tend to be bilateral and symmetric (Barkhof & Scheltens, 2002).  Diffuse and 
confluent symmetrical T2-weighted hyperintensities in the deep and periventricular white 
matter with characteristic involvement of the external capsules and temporal poles are 
considered highly specific for cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leucoencephalopathy (CADASIL) and may distinguish it from MS (Andreadou 
et al., 2008; O’Sullivan et al., 2001; Singhal et al., 2005). Moreover, the cortex, corpus 
callosum and infratentorial regions (except the pons) are rarely affected in CADASIL 
(Singhal et al., 2005). Furthermore, the presence of multiple microhaemorrhagic foci, which 
can be seen on gradient-echo images, is another characteristic feature of CADASIL 
(Dichgans et al., 2002). Another feature pointing against the diagnosis of MS is significant 
asymmetry of the white-matter abnormalities, which is usually suggestive of ipsilateral 
carotid disease (Andreadou et al., 2010; Barkhof & Scheltens, 2002). 
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Brain white matter 
Normal  
Lesions 
  Morphology 





  Poorly defined lesion margins  
  Absent or rare Dawson fingers 
  Absent MRI activity at follow-up  
  Isolated lesions with ring enhancement (often complete)  
  Mass effect  
  Large lesions with absent or rare mass effect  
  Multiple bilateral microhaemorrhagic foci  
  Haemorrhages  
  Infarcts  
  Distribution 
  Substantially asymmetric distribution of lesions  
  Extensive and bilateral periventricular  abnormalities in
  isolation 
  Symmetrically distributed lesions  
  Absent or rare corpus callosum and periventricular    
  lesions 
  Frequent sparing of corpus callosum and    cerebellum 
  Lesions in the centre of corpus callosum,    sparing the
  periphery  
  T2-hyperintensity of the temporal pole, U-   fibres at the
  vertex, external capsule and insular regions 
  Predominance of lesions at the cortical/subcortical  
  junction  
  Diffuse WM involvement  
 
  Cerebral venous sinus thrombosis  
  Large and infiltrating brainstem lesions  
  Pontine lacunar infarcts 
  Anterior temporal and inferior frontal lobe involvement, 
  associated with enhancement or mass effect 
  Multifocal, asymmetrical lesions starting in a    
  juxtacortical location and progressively enlarging  
  Pattern of enhancement 
 
  Simultaneous enhancement of all lesions  
Disease  
NMO (absent or few lesions), ATM  
 
 
AMS (sometimes confluent and 
perilesional oedema),  
BCS (concentric whorls of 
alternating rings of enhancement), 









SID, PACNS, SVD  
 
Ipsilateral carotid disease 
B12D, ACD 
 
ADEM, AFL  
 
ADEM  
SVD, CADASIL  

















ADEM, PACNS, sarcoidosis 
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  Punctiform parenchymal enhancement 
 
Cortical grey matter 
Cortical/subcortical lesions crossing vascular territories 
Prevalent involvement versus white matter  
Infiltrating lesions that do not remain in grey or white 
matter boundaries 
Deep grey matter 
Bilateral lesions  
 
Lacunar infarcts  
T1-hyperintensity of the pulvinar  
Multiple discrete lesions in the basal ganglia and 
thalamus  
Large and infiltrating basal ganglia lesions  
Infiltrating lesions without respecting grey-matter or 
white-matter boundaries 
T2-hyperintense lesions in the dentate nuclei  




















Large and swelling lesions  
 
 
Diffuse abnormalities in the posterior columns  
Other 
Absence of optic-nerve lesions  
Hydrocephalus  
Dilation of Virchow-Robin spaces  
Meningeal enhancement  
 
 
Regional atrophy  
 
No “occult” changes in the NAWM  
 
Diffuse lactate increase on brain MRS  
 
 
NMO (with corresponding T1 







Susac’s syndrome, PACNS, NBD, 
meningitis, Lyme disease, 
sarcoidosis  
HHC (hippocampus and 
amygdala), NBD (brainstem) 
NMO, Lyme disease, SID (except 
in NSLE) 
MELAS 
ACD=acquired copper deficiency. ADEM=acute disseminated encephalomyelitis. AFL=adult forms of 
leucoencephalopathies. AMS=acute multiple sclerosis (Marburg type). ATM=acute transverse myelitis. 
B12D=vitamin B12 deficiency. BCS=Balo’s concentric sclerosis. CTX=cerebrotendinous xanthomatosis. 
FD=Fabry’s disease. HHC=Hyperhomocysteinaemia. HIVE=HIV encephalitis. HSE=herpes simplex 
encephalitis. MELAS=mitochondrial encephalopathy with lactic acidosis and stroke-like episodes. 
MRS=magnetic-resonance spectroscopy. NAWM=normal-appearing white matter. NBD=Behçet’s 
disease with CNS involvement. NMO=neuromyelitis optica. NSLE= neuropsychiatric systemic lupus 
erythematosus. PACNS=primary angiitis of the CNS. PML=progressive multifocal 
leucoencephalopathy. SID=systemic immune-mediated diseases. SVD=small-vessel disease. 
Table 3. MRI characteristics suggestive of alternative conditions that mimic MS (adapted 
from Charil et al., 2006; with permission). 
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By contrast to MS where MRI-detectable spinal cord lesions can be found in the majority of 
patients with established disease (Lycklama et al., 2003; Agosta and Filippi, 2007), spinal 
cord abnormalities are not observed in patients with hypoxic-ischemic disease and are 
rarely reported in other immune-mediated disorders (Bot et al, 2002), and progressive 
multifocal leucoencephalopathy (Yousry et al., 2006). Another characteristic pointing against 
the diagnosis of MS is the complete disappearance of spinal cord lesions in systemic 
immune-mediated diseases after steroid or immunosuppressive treatment (Rovaris et al., 
2000). Moreover, incidental spinal cord hyperintense foci do not occur with ageing 
(Lycklama et al., 2003). Therefore, cord MRI is helpful in patients with normal or equivocal 
brain MRI and in those more than 50 years old (Agosta & Filippi, 2007). Longitudinally 
extensive spinal cord involvement (usually three or more segments), affecting primarily the 
central part of the spinal cord on axial sections, is typically seen in neuromyelitis optica. 
Moreover, NMO myelopathy is often associated with swelling and T1 hypointensity in the 
acute and chronic stages (de Seze et al., 2002; Wingerchuk et al., 2007). 
The pattern of enhancement is another useful distinctive characteristic. Simultaneous 
enhancement of multiple white-matter lesions is usually observed in neurosarcoidosis and 
primary angiitis of the CNS (PACNS). Moreover, meningeal enhancement should raise the 
suspicion of PACNS, neurosarcoidosis or neuroBehçet’s disease (Campi et al., 2001; Zajicek 
et al., 1999). 
It is important to note that when these MRI features ‘not suggestive’ of multiple sclerosis are 
used along with the existing MS diagnostic criteria, they minimize the chance of false 
positive diagnoses and facilitate the correct diagnosis of other disorders. Therefore, it is 
suggested to be taken into account in the diagnostic work-up of patients suspected of having 
MS. In the presence of at least one MRI ‘red flag’, appropriate additional tests should be 
performed. However, in cases of equivocal findings, follow-up with repeated imaging will 
be needed to establish a firm diagnosis (Charil et al., 2006)  
3. MRI and disease progression    
Recognition of the neurodegenerative aspects of MS has rendered the development of 
techniques to measure disease progression essential. Since conventional MRI is sensitive in 
detecting disease activity, it has routinely been used to ameliorate not only the accuracy of 
multiple sclerosis diagnosis but also the prognosis. Conventional MRI assessment of lesions 
on non-contrast T1-weighted and T2-weighted scans, and on gadolinium-enhanced T1-
weighted images is now routinely used to monitor the disease course and detect therapeutic 
effects (Zivadinov & Leist, 2005). However, measures like the lesion volume and the number 
of gadolinium-enhancing and T2 lesions, are weakly associated with the clinical status and 
have insufficient sensitivity and specificity to reveal the extent of histopathological changes 
occurring in MS. Persistent T1 hypointense lesions can predict development of disability 
better than the previously mentioned lesion-based MRI measures (Zivadinov & Leist, 2005) 
as they are mainly associated with more advanced pathological processes of the disease, i.e. 
axonal loss, Wallerian degeneration and gliotic changes (Bakshi et al., 2004; Stevenson et al., 
2004). Moreover, brain and spinal cord atrophy have been shown to be powerful predictors 
of clinical impairment and disease progression. Additionally, newer nonconventional MRI 
techniques that become increasingly available hold significant promise to improve 
monitoring of MS. Accumulating evidence suggests that metrics derived from non-cMRI 
techniques correlate better with disability compared to conventional measures. 
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3.1 Detection of subclinical disease activity          
Conventional MRI can be used as a valuable tool for the assessment of disease progression, 
as it provides objective and sensitive measures of MS activity. In patients with RRMS and 
SPMS, disease activity is detected 5–10 times more frequently on cMRI scans than with 
clinical assessment of relapses (Filippi & Agosta, 2010). Despite the sensitivity of T2-
weighted images to reveal disease activity and lesions over time (Molyneux et al., 1998), no 
significant correlation between MRI findings and clinical progression has been 
demonstrated, except in patients with very early disease (Rovaris et al., 2003). Indeed, both 
brain T2 hyperintense lesion load early in the clinical course and early progression of T2 
burden of MS have been associated with the development of long-term disability (Brex et al., 
2002). However, T2 lesion load measurement is not appropriate for the assessment of the 
advanced stages of the disease (Li et al., 2006). Although differences in T2 lesion load among 
different MS phenotypes have been consistently reported, being higher in SPMS in 
comparison to benign MS, RRMS, and PPMS, no significant relationship between T2 lesion 
load and disability has been demonstrated (Filippi & Agosta, 2010). 
Gd enhancement occurs in almost all new lesions in patients with RRMS or SPMS and can 
be sometimes detected even before the onset of clinical symptoms (Filippi & Agosta, 2010). 
The number of enhancing lesions increases shortly before and during clinical relapses and 
predicts subsequent MRI activity (Molyneux et al., 1998, Kappos et al., 1999). The burden of 
MRI activity has been shown to be associated with the subtype of the disease, being higher 
in RRMS and SPMS in comparison with PPMS and BMS (Kappos et al., 1999). Moreover, 
patients with SPMS and severe disability show a lower incidence of enhancing lesions when 
compared to those with mildly disabling RRMS (Filippi et al., 1997). However, a moderate 
correlation has been demonstrated between the degree of clinical disability and the mean 
frequency of enhancing lesions in patients with RRMS and SPMS (Filippi & Agosta, 2010). 
T1 black holes and CNS atrophy are useful markers of progressive tissue damage and 
clinical evolution in established MS. In patients with either RRMS or SPMS, the increase in 
T1 lesion volume (LV) over time correlates significantly with progressive cerebral atrophy 
and the change in EDSS score (Sailer et al., 2001; Truyen et al., 1996). Moreover, in patients 
with CIS, baseline T1 hypointense lesion number and volume are strong predictors of the 
severity of executive dysfunction (Summers et al., 2008). 
3.2 Detection of brain and spinal cord atrophy          
Since the initial MRI studies in MS, marked atrophy of the brain has been found to be an 
important feature of the advanced stages of the disease (Filippi & Agosta, 2010). 
Subsequently, it was recognised as an early phenomenon that progresses over the disease 
course. Thus, conventional MRI has been used to measure atrophy of the brain tissue, whole 
or segmented in white matter (WM) and gray matter (GM). Cerebral volume loss is 
associated with changes in normal appearing white matter and grey matter (Ge et al., 2000; 
Horakova et al., 2009). It occurs in all MS subtypes (even in CIS) with a rate of 0.5-1% per 
year and is closely related to disability (Anderson et al., 2006; Bermel & Bakshi, 2006). 
Moreover, brain atrophy develops in different structures in the different clinical phenotypes 
of the disease: ventricular enlargement is predominant in RRMS, whereas cortical atrophy is 
more pronounced in the progressive forms of the disease (Pagani et al., 2005). The most 
atrophic cortical regions have been consistently found to be the frontal, temporal and 
parietal lobes (Filippi & Agosta, 2010). GM atrophy rate has been found to increase with 
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disease progression, whereas WM atrophy rate has been reported to remain constant (Fisher 
et al., 2008). Atrophy of the deep gray matter has been also observed in MS, especially in the 
posterior basal ganglia and the thalamic regions (Bermel & Bakshi, 2006; Carone et al., 2006; 
Filippi & Agosta, 2010; Henry et al., 2008). Measurement of atrophy in selected pathways, 
such as the corpus callosum and the corticospinal tract, may also improve the in vivo 
monitoring of MS progression (Martola et al., 2007). In addition, spinal cord atrophy, more 
pronounced in the progressive forms of MS, has been reported (Rovaris et al., 2001). It 
should be mentioned, however, that reduction of the cervical cord size can be observed in 
the early stages of MS (Brex et al., 2001). CNS atrophy reflects the destructive component of 
the MS disease process and contributes to irreversible neurological impairment.  
Recent advances in volumetric MRI with the use of parallel imaging techniques may 
improve the use of atrophy metrics as outcome measures in clinical trials of MS therapies. It 
should be mentioned however, that the anti-inflammatory effect of MS treatments can 
reduce brain volume (a phenomenon called pseudoatrophy effect), and consequently affect 
atrophy measurements (Zivadinov et al., 2008). Advances in neuroimaging may help 
separate true atrophy from pseudoatrophy with the use of methods that can distinguish 
axonal loss from transient changes in water content. 
3.3 MRI in disease management and evaluation of treatment outcomes          
Since MRI provides information essential in monitoring disease activity and severity of 
multiple sclerosis, it is a critical component of disease management. In addition to the 
relapse rate and progression on EDSS, MRI variables play an essential role in determining 
the short and long-term effects of MS treatments, since the approval of the first therapy for 
MS by the Food and Drug Administration in 1993 (Rovaris, 2008; Bates, 2011; Freedman, 
2011). Short-term and long-term clinical trial results have indicated that currently available 
disease-modifying therapies (DMTs) are effective in reducing MRI disease activity (Bates, 
2011; Freedman, 2011). Moreover, reduction in MRI-detected lesion burden is used as 
supportive to the clinical findings to show reduction in disease activity. Brain MRI activity is 
determined as the number of new or enlarging T2-hyperintense lesions and Gd-enhancing 
lesions, whereas the MRI burden of the disease includes the T2-lesion volume and the T1-
hypointense LV. 
Accumulating evidence suggests that MRI-derived metrics could be used to define 
treatment options and strategies in individual patients with MS (Beck et al., 2002; Rudick et 
al., 2004). In RRMS, the accumulation of two or more new T2-hyperintense lesions during a 
two-year period has been demonstrated to predict poor treatment response more reliably 
than the persistence of clinical relapses and the presence of enhancing lesions (Rudick et al., 
2004). In CIS, the subgroup of patients with enhancing lesions at baseline showed a trend for 
greater treatment benefit than patients without (Beck et al., 2002). However, only the 
integration of clinical and MRI data can be considered a reliable approach for the work-up 
of patients receiving disease-modifying treatments. 
Recently, clinical trials have incorporated cerebral volume measurement to determine the 
efficacy of novel treatments (Bermel & Bakshi, 2006). However, the current inability to 
separate true atrophy from pseudoatrophy limits the use of atrophy measures at present. 
Advances in MRI technology might contribute to a better correlation between clinical and 
MRI findings, and thus provide relevant information to improve prognosis and predict 
therapeutic response. 
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4. Nonconventional MRI techniques           
Conventional MRI is unable to disclose the extent of the damage because of its limited 
sensitivity to structural changes outside the focal lesions and its lack of specificity to the 
heterogeneous features of the disease. The hyperintense lesions  on T2-weighted images 
represent nonspecific tissue alterations as they reflect changes in water content caused by a 
variety of processes including edema, inflammation, demyelination, remyelination, 
Wallerian degeneration, gliosis and axonal loss. Furthermore, neurological impairment of 
patients with MS is poorly associated with the lesion load observed on conventional MRI 
scans (Filippi & Agosta, 2010). During the past decade, other nonconventional MRI 
techniques-including proton MR spectroscopy, magnetization transfer MRI, diffusion tensor 
MRI, double inversion recovery sequences, high-field and ultrahigh-field MR imaging, 
techniques employing cellular MR contrast agents, and functional MRI-have been 
developed to overcome these limitations, improve the sensitivity and specificity in the 
detection of MS lesions and characterize and quantify the heterogeneous pathological 
substrates of the disease. Issues encountered in emerging clinical application of these 
methods will be addressed.  
4.1 Magnetic resonance spectroscopy     
Conventional MRI describes the physical characteristics of a region of tissue relative to 
surrounding regions by measuring alterations in tissue water content and dynamics by 
proton excitation. Proton MR Spectroscopy (1H-MRS) is a non invasive method that depicts 
the chemical properties of a region of brain tissue by investigating other proton-containing 
cellular metabolites. It provides information on tissue metabolism and function of a selected 
brain area volume relative to surrounding regions. Therefore it could be used to study 
biochemical changes occurring in lesions and normal appearing white matter over the 
course of MS (De Stefano et al., 2007).  1H-MRS could also be used as a diagnostic tool, 
although it has not yet moved to clinical practice. 
Various compounds can be detected using 1H-MRS. At long echo times four major 
resonance peaks are revealed from (a) choline-containing phospholipids (Cho), (b) creatine 
and phospho- creatine (Cr), (c) N-acetyl-aspartate (NAA), and (d) lactate (Lac) methylgroup. 
NAA, normally present in axons and neurons, reflects neuronal/axonal integrity and 
therefore appears to be a sensitive biomarker of disease progression (Narayana, 2005). A 
decline in NAA levels in MS, with correlation with disability, has been shown in several 
studies. Reduced NAA was observed in lesions, cortical GM and NAWM in early RRMS 
(Kapeller et al., 2001; Chard et al., 2002). Decrease in NAA levels in chronic WM lesions has 
been reported in RRMS, SP and PPMS (Davie et al., 1997). Moreover, chronic lesions have 
higher NAA signal intensities in patients with BMS than those in patients with SPMS, 
indicating a more efficient tissue integrity recovery in patients with less severe disability (De 
Stefano et al., 2007). Transient changes in NAA levels in acute MS plaques have been also 
reported (Narayama et al, 1998). Decreases in NAA concentrations are also known to occur 
in the NAWM of MS patients (Caramanos et al., 2005). Furthermore, significant reduction in 
whole-brain NAA levels was found, more pronounced in older than younger patients 
(Gonen et al., 2000).  
Cho and Lac reflect cell membrane metabolism. Increases in these metabolites are 
considered as chemical correlates of acute inflammatory or demyelinating changes. Indeed, 
increases in Cho and Lac resonance intensities have been found in acute MS lesions (Davie 
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et al., 1994; De Stefano et al., 1995). In large, acute demyelinating lesions, decreases of Cr 
have also been seen (De Stefano et al., 1995).  
1H-MRS studies with shorter echo times can detect additional metabolites, such as lipids and 
myoinositol (mI), which are also regarded as markers of progressing myelin damage. 
Increase of levels of myoinositol, which is mainly localised in astrocytes, has been shown in 
early MS (Capeller et al., 2001; De Stefano et al., 1995) and also in chronic lesions, indicating 
neuronal injury and ongoing astrogliosis (Srinivasan et al., 2005). Amino acids acting as 
neurotransmitters, such as glutamate, glutamine, and GABA (γ-aminobutyric acid), can also 
be measured. Glutamate levels were found to be increased in acute lesions (Srinivasan et al., 
2005). A reduced concentration of glutamate and glutamine in the cortical GM of patients 
with PPMS has been found (Sastre-Garriga et al., 2005), which was significantly correlated 
with the EDSS score. Recently, the concentration of glutathione, a marker of oxidative status, 
was measured by 1H-MRS at 7.0 T and was found decreased in the NAWM and gray matter 
of MS patients compared to healthy controls (Srinivasan et al., 2010). 
MRS may provide insight into MS pathogenesis, evaluate the severity of MS and follow 
disease evolution and therefore is becoming a useful tool in the understanding of the 
disease. Moreover, MRS measures of brain metabolites seem to be better predictors of 
clinical disability than is conventional MRI. 
4.2 Magnetization transfer imaging   
Magnetization transfer (MT) is a physical phenomenon in which protons of two or more 
environments with different magnetic resonance properties exchange magnetization. MT 
MRI measures quantitatively the continuous exchange of magnetization in the brain tissue 
between macromolecular bound protons (i.e. protons associated with myelin, cell 
membranes and proteins) and protons in adjacent free water molecules, thus allowing the 
calculation of an index, the MT ratio (MTR). Diminution of this index denotes a decreased 
capacity of the bound protons to exchange magnetization with the surrounding ‘‘free’’ 
water (Filippi & Agosta, 2007). The reduction of MTR values in focal lesions is considered as 
a marker of the extent of tissue damage, primarily associated with demyelination (Schmierer 
et al., 2004; van Buchem et al., 1996). The relative specificity of MTR to myelin density has 
been demonstrated by post-mortem imaging and histopathological studies that did not 
reveal any significant association with axonal density or gliosis (Schmierer et al., 2004).  
Voxel-based analysis of MTR changes can provide indirect information about demyelination 
and remyelination in MS lesions (Chen et al., 2007). Changes of MTR of individual lesion 
voxels, as well as the mean normalized MTR over all lesion voxels during and after contrast 
enhancement have been reported (Chen et al., 2008). The mean normalized MTR of Gd-
enhancing lesions was significantly decreased at the time of lesion enhancement, partially 
recovered over the subsequent four months, and then appeared to stabilize. Moreover, 
enhancing lesions were found to have different MTR values, according to their size, pattern, 
and duration of enhancement. Specifically, MTR was lower in ring-enhancing lesions than in 
homogeneously enhancing lesions (Silver et al., 1998) and in lesions with longer duration of 
enhancement (Filippi et al., 1998a), suggesting more severe demyelination. Furthermore, 
evolution of the mean normalized MTR of individual lesions shows considerable 
heterogeneity ranging from partial recovery or stability that suggest remyelination, to 
decline over time that suggests ongoing demyelination (Chen et al., 2008). 
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In addition to increased specificity, MTI may also offer increased sensitivity for studies of 
MS. Focal changes in magnetization transfer were reported to precede the appearance of 
gadolinium-enhancing lesions (Filippi et al., 1998b). Moreover, microscopic damage in 
normal-appearing brain tissues was shown on MTI before the development of T2 lesions on 
cMRI scans (Laule et al., 2003).  
Decreased MTR has also been found in normal appearing brain tissue (NABT), in both gray 
(Ge et al., 2001; Dehmeshki et al., 2003) and white matter (Santos et al., 2002), of patients 
with established MS. These abnormalities are more pronounced in patients with the 
progressive forms of MS and tend to worsen over time (Filippi & Rocca, 2007). Moreover, 
reduced NABT MTR has been found in patients at presentation with CIS, with significant 
prognostic value for the subsequent evolution to clinically definite MS (Miller et al., 2005). 
NAWM and NAGM MTR abnormalities have been found to correlate with clinical disability 
(Ge et al., 2001; Santos et al., 2002) and cognitive impairment (Ranjeva et al., 2005). 
MTI metrics have several limitations that include lack of specificity to the various MS 
pathological substrates and lack of standard magnetisation transfer data acquisition 
protocols across different scanners (Horsfield et al., 2003). Improvement of the 
quantification and specificity of MTI with the use of new analysis methods (Chen et al., 
2008) may render this technique a reliable tool not only for studies of disease evolution, but 
also for diagnostic purposes in every day clinical practice.  
4.3 Diffusion weighted and diffusion tensor imaging   
Diffusion weighted (DWI) and diffusion tensor imaging (DTI) provide information about 
the tissue fibers by measuring the motion of tissue water molecules in vivo (Rovaris et al., 
2005). The mobility of water molecules is diminished in highly organized tissue, like white 
and gray matter, and consequently, the apparent diffusion coefficient (ADC) is lower in 
those tissues than in free water. Pathological processes that alter tissue organization can 
result in abnormal water motion, thus modifying ADC values. Tissue damage in MS, mainly 
demyelination and axonal degeneration, results in abnormal water motion, and therefore in 
alteration of the ADC values. Diffusion abnormalities may precede Gd-enhancement in 
hyperacute MS lesions.  
Diffusion tensor imaging (DTI) is a valuable technique based on the fact that diffusion of 
water molecules within white matter is much greater along the fibres than across them. The 
diffusion tensor is a mathematical description of the magnitude and predominant direction 
of water molecules movement (anisotropy) in the three-dimensional space. As the diffusion 
ellipsoid provides a description of the diffusion tensor, the individual components of the 
diffusion ellipsoid (called eigenvalues) can also be assessed separately. These components 
are the longitudinal or axial diffusivity (LD or AD), which is the principal eigenvalue of the 
DT, and the transverse or radial diffusivity (TD or RD) that is the average of the second and 
third eigenvalues of the DT. Quantitative DTI parameters, such as the fractional anisotropy 
(FA), which is a normalized measure of the degree of anisotropy, the mean diffusivity (MD), 
that is the averaged diffusion for detecting WM alterations, and the longitudinal and 
transverse diffusivities of the diffusion tensor are considered valuable tools in the 
assessment of focal and widespread white matter tissue damage in patients with MS. FA 
was found to be decreased (Werring et al., 1999) whereas MD was consistently shown to be 
increased in MS plaques as well as in normal appearing white matter of MS patients (Lowe 
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et al., 2006). However, FA values have been found to be increased in intracortical MS 
lesions, possibly reflecting intralesional loss of dendrites and activation of microglia 
(Poonawalla et al., 2008). Transverse diffusivity, which refers to the diffusion across fibers, is 
believed to be a specific marker for axonal loss and demyelination associated with MS (Oh 
et al., 2004; Lowe et al., 2006; Henry et al., 2003). Relative increase of TD has been shown in 
MS, correlating with demyelination and axonal loss (Song et al., 2005).  This finding 
suggests that fragmented or missing myelin permits greater diffusion of water molecules 
across fibers. Moreover, quantitative variables derived from DTI were found to correlate 
with clinical disability (Filippi & Agosta, 2010).  
Fiber tractography is a diffusion technique based on the directional movement of water, 
which allows the generation of non-invasive three-dimensional images of white matter fiber 
tracts. It is a promising method for in vivo segmentation of the major WM tract fiber 
bundles in the brain (Mori et al., 2002). In MS patients, DT MRI tractography can be used to 
segment clinically eloquent WM pathways, such as the corticospinal tracts, the corpus 
callosum, and the optic radiations and holds promise in enabling visualization and 
quantification of the degree of axonal loss and demyelination in vivo. However, the 
application of DTI tractography in MS is limited by the presence of both focal and diffuse 
alterations of tissue structure, which cause a decrease in anisotropy and consequently an 
increase in uncertainty of the primary eigenvector of the DT (Pagani et al., 2007). Using DT 
MRI tractography, a study in patients with optic neuritis showed reduced connectivity 
values in both left and right optic radiations compared with controls, possibly attributed to 
trans-synaptic degeneration secondary to optic nerve damage (Ciccarelli et al., 2005). DT 
MRI tractography has been also used to identify NAWM fibers at risk for degeneration, 
when they intersect T2-visible lesions (Simon et al., 2006). A recent study found increased 
interthalamic connectivity in patients with early MS as measured by DTI and tractography 
when compared with control subjects, suggesting a possible reactive structural 
reorganization of the fiber tracts within the thalami (Tovar-Moll et al., 2009).  
Technical improvements of tensor models may allow better description of water diffusion in 
more complex architectures such as those with crossing fiber tracts, better segmentation of 
fiber bundles and better understanding of the relationship between tissue structure and 
function. 
4.4 Double inversion recovery imaging     
Double inversion recovery (DIR – i.e. two inversion times are used to suppress the signal 
from both white matter and cerebrospinal fluid) is a novel imaging method that has 
markedly improved the sensitivity of MRI to detect cortical lesions in vivo (Geurts et al., 
2005). Cortical demyelination is an important part of the disease process, especially in more 
advanced stages (Kutzelnigg et al., 2005), and may contribute to the accumulation of 
irreversible disability in MS (Calabrese et al., 2009a,b; Calabrese et al., 2010; Roosendaal et 
al., 2009). Despite improvement, at present only a small number of cortical gray matter 
lesions can be detected with this technique, compared with pathological studies (Calabrese 
et al., 2007; Geurts et al., 2008).  
Cortical lesions have been detected in all the major MS clinical phenotypes, including 
patients with CIS suggestive of MS (Calabrese et al., 2009a, b). Remarkably, cortical lesions 
are more frequently seen in patients with secondary progressive MS than in those with CIS 
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or RRMS. Moreover, patients with early RRMS have a greater number of lesions than 
patients with benign MS (Calabrese et al., 2009a). Longitudinal studies have shown that new 
cortical lesions continue to form in patients with early RRMS (Calabrese et al., 2009a), and in 
those with the progressive disease phenotypes over 1 to 2-year periods of follow-up 
(Calabrese et al., 2009b; Roosendaal et al., 2009). Cortical lesion burden has been associated 
with progression of disability over the subsequent 2 to 3 years in patients with different 
disease phenotypes (Calabrese et al., 2009b), as well as with the severity of cognitive 
impairment in patients with RRMS (Roosendaal et al., 2009).  
DIR sequences at 1.5 T have not been established as yet into the clinical routine probably 
because of the relatively low signal-to-noise ratio values due to the application of two 
inversion pulses, longer acquisition times and higher propensity of artefacts. DIR 
applications at higher magnetic field strengths may overcome these major problems (Wattjes 
& Barkhof, 2009). 
4.5 Functional MRI    
Functional MRI (fMRI) is a non-invasive neuroimaging method that enables visualisation 
not only of the detailed anatomy but also of brain function. It is used to identify changes in 
brain activation in response to various stimuli and in the resting state. The fMRI signal 
reflects blood oxygenation level-dependent (BOLD) alterations associated with activation of 
neural tissue. This mechanism permits the detection of changes in the relationship between 
blood flow and local oxygen consumption. Upon initiating a task, neural activity in the 
involved brain region results in increased blood flow and consequently in increased total 
blood oxygen content (Logothetis et al., 2001; Ogawa et al., 1990). The increased blood 
oxygen produces an increase in the MRI signal, thus allowing demonstration of abnormal 
patterns of brain activation caused by tissue injury.  
fMRI is not used clinically for the diagnosis of MS; rather it is used to provide insight into 
disease progression. The most common finding in fMRI studies is increased extent or 
strength of activation of functional tissue in MS patients compared with controls, implying 
compensatory processes or reorganization of neuronal activation (Lee et al., 2000; Penner et 
al., 2003; Reddy et al., 2000; Rocca et al., 2005). At the initial stages of the disease, an 
increased recruitment of the areas normally involved in the performance of a given task, 
such as the primary sensorimotor cortex and the supplementary motor area is shown (Rocca 
et al., 2003). At later stages, bilateral activation of these regions is first observed, followed by 
a widespread recruitment of additional areas, which are usually recruited by healthy 
subjects in the performance of more complex or novel tasks (Rocca et al., 2005). Similarly, 
fMRI studies investigating various cognitive domains in MS patients have shown altered 
patterns of cortical activation (Audoin et al., 2003; Staffen et al., 2002; Hillary et al., 2003; Li 
et al., 2004; Cader et al., 2006). Moreover a relationship between cortical activation and 
fatigue has been shown in several studies suggesting that the underlying mechanism of this 
common but poorly understood symptom may be the deficiency of neuronal compensation 
(Filippi et al., 2002; White et al., 2009). 
Functional connectivity MRI (resting-state fMRI) is a newer fMRI method that measures low 
frequency oscillations (0.01–0.1 Hz) in BOLD signals across the whole brain during rest, thus 
enabling measurement of functional interactions between brain regions (Cordes et al., 2000). 
Since it studies the strength of network between anatomically separated brain regions, it is 
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considered a promising method to explore disconnectivity effects in MS (van den Heuvel &, 
Hulshoff Pol, 2010). Indeed, decreased levels of functional connectivity of regions of the 
primary motor network have been reported in patients with MS (Lowe et al., 2008). 
Since studies with fMRI have demonstrated consistently functional cortical changes in all 
MS subtypes, this method can be used to assess the role of brain plasticity and cortical 
adaptive changes in limiting the clinical manifestations of demyelination and tissue loss in 
MS and therefore explain the discrepancy between clinical and cMRI findings.  
4.6 High and ultrahigh-field MRI  
Magnet field strengths higher than 1.5 Tesla (T) improve image resolution, signal-to-noise 
ratio and chemical shift. Therefore application of high-field MRI on conventional and 
quantitative MRI methods offers advantages on brain imaging in MS, as it may give new 
insights into the microstructural damage and functional reorganization (Wattjes & Barkhof, 
2009). In patients with established MS, high-field MRI has resulted in a higher detection rate 
of T2 (Wattjes et al., 2009) and gadolinium-enhancing brain (Sicotte et al., 2006) but not 
spinal cord (Stankiewicz et al., 2009) lesions at 3.0T compared with 1.5T. In CIS patients, 
however, 3.0T imaging did not substantially affect evidence for disease dissemination in 
space (Wattjes et al., 2008). 
Ultrahigh-field MRI (referred to as imaging at field strength of 7 Tesla or more) provides 
improved brain lesion load quantification and characterization of the pathological features 
of MS lesions. It is also likely that detection of GM and spinal cord abnormalities could be 
improved by ultrahigh-field MRI (Kangarlu et al., 2007). 
Both high-field and ultra-high field MRI can improve 1H-MRS by providing better 
quantification of metabolites in lesions and the normal-appearing brain tissue (white and 
gray matter) (Srinivasan et al., 2004, 2005, 2009). Magnetisation transfer MRI, diffusion 
tensor MRI, and fMRI studies in MS may also benefit from higher field strengths (Bakshi et 
al., 2008; Wattjes & Barkhof, 2009). Indeed, subtle damage in the NAWM and NAGM 
Ceccarelli ea al., 2007), as well as diffuse microscopic damage in the absence of macroscopic 
MS lesions in the thalamus and basal ganglia has been detected by the use of high-field MRI 
(Tovar-Moll et al., 2009). Finally, higher field MRI might be important for studying iron 
deposition in the grey matter of patients with MS, which has been postulated to contribute 
to neurotoxicity (Stankiewicz et al., 2007).  
4.7 New MR contrast agents  
Conventional MRI allows follow-up of lesion development in time and space. Although in 
clinical practice the number of hyperintense lesions on T2-weighted MRI is considered as 
a biomarker of disease activity in MS, they represent nonspecific tissue alterations. 
Commonly, the identification of gadolinium-DTPA (Gd) enhancing lesions on T1-
weighted scans is considered as evidence for acute inflammation and disruption of the 
BBB. Gd, a lanthanide chelate, is an extracellular contrast agent that requires relatively 
high local concentration to achieve sufficient contrast on MRI. Gadofluorine M (Gf), a new 
Gd-based agent, has been shown in in-vivo experimental studies to have a much higher 
sensitivity than Gd-DTPA in detecting disruption of the BBB on T1-weighted MRI 
(Bendszus et al., 2008).  
The development and application of novel MR contrast agents allowing cellular and 
targeted molecular imaging hold promise in exploring inflammation and its regulation by 
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cell adhesion molecules in MS. Contrast media composed of iron particles [super-
paramagnetic particles of iron oxide (SPIO) and ultrasmall particles of iron oxide (USPIO)] 
are more sensitive compared to Gd-containing agents at similar tissue concentrations (Liu & 
Frank, 2009). The size of SPIO particles is 50–150nm whereas that of USPIO particles is 
approximately 10–50nm. These particles are partly phagocytosed by circulating 
macrophages upon injection. When circulating macrophages are attracted to inflammatory 
lesions, they can be detected in vivo by MRI, since in tissue iron particles shorten both the 
T1 and T2 relaxation time (Vellinga et al., 2008). Several recent studies support the aspect 
that SPIO/USPIO enhanced MRI allows cellular neuroimaging (Baeten et al., 2008; Chin et 
al., 2009). Preliminary studies in RRMS patients have shown that some lesions may enhance 
only with Gd, others only with USPIO, and others with both. Moreover, the same lesions 
can change their pattern of enhancement over time (Vellinga et al., 2008). Furthermore, 
USPIO-enhanced MRI may not only disclose a greater number of ‘active’ MS lesions but 
may also detect subtle and diffuse inflammatory activity in MS patients not visible on 
conventional T2-weighted  MR sequences and unrelated to Gd-DTPA enhancement 
(Vellinga et al., 2009). 
Additionally, novel cellular MR contrast agents such as polyfluorinated nanoemulsions or 
activatable paramagnetic sensors and emerging molecular imaging approaches might give 
new insights into the MS inflammatory process. Myeloperoxidase (MPO) is one of the most 
abundant enzymes secreted by inflammatory cells and, thus, may serve as a marker of 
macrophage inflammation. It has been recently shown in an animal model of EAE that 
myeloperoxidase activity in inflamed tissues can be detected and labelled in vivo by a 
myeloperoxidase sensitive ‘‘smart’’ molecular imaging probe (JW Chen et al., 2008).  
Transferring cellular and targeted molecular imaging approaches from in-vitro to in-vivo 
MRI and subsequently in clinical use holds promise for exploring MS neuroinflammation in 
the future. 
5. Optical techniques  
5.1 Optical coherence tomography (OCT)           
Optical coherence tomography (OCT) is a new, sensitive, non-invasive, transpupilary 
method that allows direct imaging and quantification of the retinal nerve fibre layer (RNFL), 
which  is principally composed of unmyelinated axons. By using an optical interferometer in 
conjunction with a low-coherence light source, OCT detects light reflections within a tissue 
and provides in vivo cross-sectional images at near microscopic resolution (Hrynchak & 
Simpson, 2000; Huang et al., 1991). Recent advances in OCT allow differentiation of major 
retinal layers and analysis of tissue thickness and volume with a resolution of about 3 μm 
(Ko et al., 2004).  
Because the retina is the only place where a tissue layer made up of axons can be imaged 
directly, and the retina and optic nerve are often affected by MS, OCT can be used to assess 
the impact of MS on the retina by measuring the RNFL thickness and macular volume. The 
reductions of RNFL thickness and macular volume are associated with axonal loss and 
secondary retinal ganglion cell loss, respectively. Therefore, OCT shows promise in the 
detection, assessment and monitoring of neurodegeneration in MS (Barkhof et al., 2009; 
Petzold et al., 2010).  
RNFL thinning has been detected with OCT about 3 months after acute optic neuritis. 
Moreover, continuing axonal loss in the affected eye for at least 12 months after optic 
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neuritis has been found, more pronounced the first 6 months after injury (Costello et al., 
2008). In addition, OCT has been shown to be predictive of a clinical outcome (poor visual 
recovery) (Costello et al., 2006). A recent meta-analysis of time domain OCT showed RNFL 
thinning in MS patients, both with and without a history of optic neuritis, more pronounced 
after optic neuritis (Petzold et al., 2010). The estimated RNFL thinning in patients with MS 
has been found to be greater than the extent expected in normal ageing and has been 
attributed to retrograde trans-synaptic degeneration and progressive loss of retinal ganglion 
cells, in addition to the more pronounced thinning observed in case of optic neuritis 
(Petzold et al., 2010). Furthermore, thinning of the RNFL in MS without optic neuritis was 
found to correlate with visual and neurological functioning, as well as with paraclinical data 
(Trip et al., 2005, 2006; Villoslada et al., 2008). 
Macular volume loss has also been reported in patients with MS compared with controls, 
correlating with loss of RNFL (Burkholder et al., 2009; Trip et al., 2006). Recently, a 
subgroup of MS patients with primary retinal pathology characterized by predominant 
macular thinning has been described with the use of OCT, in whom there appears to be 
disproportionate thinning of the inner and outer nuclear retinal layers independent of optic 
nerve pathology. Moreover, these patients were shown to have accelerated disability 
progression, implying that this primary process may be associated with a more aggressive 
form of MS (Saidha et al., 2011). 
OCT could be used for analysis of neurodegeneration in MS as well as for monitoring of 
treatment effects in trials of neuroprotective strategies in MS. Moreover, the integration of 
OCT into MS research could allow insights into the structure–function relations, thus 
improving our understanding of the pathophysiology of the disease. 
6. Conclusion   
Advances in neuroimaging have improved our ability to diagnose and monitor MS and 
have provided insight into the pathophysiology of the disease. Conventional MRI of the 
central nervous system plays a prominent role in establishing the diagnosis of MS and in 
differentiating MS-mimics and demyelinating disease subtypes. Moreover, it allows an 
earlier and accurate diagnosis of the disease, as it can support or even replace some clinical 
criteria. Early diagnosis is essential to allow earlier therapeutic intervention that appears to 
be beneficial on delaying the accumulation of irreversible neurologic damage and 
consequent disability. 
In addition cMRI is a useful tool for monitoring disease progression as it is a sensitive 
imaging biomarker that detects pathological changes prior to the onset of clinical symptoms. 
Conventional MR scans are effective in detecting clinically silent new white matter 
inflammatory lesions. In particular, Gd-enhancing lesions are predictive of future clinical 
relapses. Therefore, cMRI is routinely used for detection of subclinical disease activity and 
for decisions regarding treatment in individual patients. Moreover, most clinical trials 
involving new treatments use MRI parameters as outcome measures to show therapeutic 
effectiveness. Besides Gd-enhancing and T2 lesions, CNS atrophy measurements are being 
increasingly used as primary MRI end point in clinical trials as they have been shown to be 
powerful predictors of clinical impairment, disease progression, and the accumulation of 
long-term physical and neuropsychological disability. 
MRI serves also as a research tool in the study of MS. However, cMRI metrics have a limited 
ability to accurately determine the full extent of inflammatory and neurodegenerative 
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pathological processes in MS. The discrepancy between clinical and MRI evolution in MS 
patients, often referred to as the “clinical–MRI paradox”, has led to a growing interest in 
advanced techniques that can detect the presence of cortical lesions, subtle changes in the 
normal appearing white and gray matter, as well as adaptive functional changes that limit 
the clinical consequences of disease-related injury. The development and application of 
novel MR methods of acquisition and postprocessing aim to provide a more accurate 
characterization of tissue injury including demyelination, remyelination and axonal 
damage. These advanced approaches give also insights into the functional and metabolic 
consequences of MS. Additionally, the combined analysis of different magnetic resonance 
techniques, sensitive toward different aspects of MS, is likely to improve our understanding 
of the mechanisms responsible for the accumulation of irreversible neurological deficits in 
the disease. Emerging applications of these tools may also be useful in measuring the effect 
of therapies. Beyond MRI, novel imaging approaches such as OCT show promise in 
detecting and monitoring neurodegeneration in MS. Nevertheless,  the new techniques and 
analysis procedures need to be refined and validated before they can be properly integrated 
into clinical research and practice. Until that time cMRI metrics will continue to play an 
important role in clinical practice and in clinical trials. Overuse of MRI in clinical practice, 
however, should be avoided. It is important to keep in mind that clinical judgment remains 
essential in the management of the disease and that careful interpretation of the MRI data is 
needed to avoid misdiagnosis. 
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Multiple sclerosis (MS) is a chronic progressive disease associated with both sensory-motor 
and psychological symptoms including cognitive deficits, affective disturbances, and 
fatigue. Intellectual disability of MS patients usually manifests itself as a composition of 
subtle deficits in certain cognitive domains detectable with sensitive neuropsychological test 
batteries specially developed for the MS population (Benedict et al., 2006b; Rao, 1990). 
Nevertheless, the effect of cognitive impairment on everyday life activities, employment 
status, and social relationships is considerable (Amato et al., 1995; Rao et al., 1991b). 
Cognitive impairment may occur in the earliest stages of the disease (Achiron & Barak, 2003; 
Callanan et al., 1989; Deloire et al., 2005; Feinstein et al, 1992; Glanz et al., 2007) even in 
patients with clinically isolated syndrome (CIS) (Achiron & Barak, 2003; Feuillet et al., 2007; 
Glanz et al., 2007; Potagas et al., 2008). Cognitive deficits may develop independently from 
physical disability particularly in the early stage of the disease and in patients with benign 
MS (Feuillet et al., 2007; Glanz et al., 2007; Portaccio et al., 2009). However, the presence of 
cognitive decline has been found to predict a more progressive disease course (Portaccio et 
al., 2009; Zipoli et al., 2010). Detrimental effects on quality of life and poor disease prognosis 
underlie the importance of neuropsychological assessment of MS patients in clinical 
practice. 
Magnetic resonance imaging (MRI) is one of the most important paraclinical tools used in 
the diagnosis of MS. Quantitative measures derived from conventional and advanced MRI 
methods have been developed to monitor and predict the course of the disease, as well as 
for in-vivo non-invasive investigation of MS pathophysiology (Filippi & Rocca, 2010). 
Increasing recognition of the functional relevance and prognostic role of MS cognitive 
impairments has resulted in focused attention on MR correlates of cognitive deficit. 
Assessment of the global and regional white matter (WM) lesion burden, derived from T2- 
or T1-weighted MRI shows modest association with cognitive status (Arnett et al., 1994; 
Hohol, et al., 1997; Patti et al., 2009; Rao et al., 1989; Rovaris et al., 2001; Swirsky-Sacchetti et 
al., 1992). A stronger relationship has been obtained with quantification of the whole and 
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regional brain atrophy (Rovaris, et al., 2006; Zivadinov, et al., 2001) considered as a marker 
of irreversible tissue loss (Miller et al., 2002; Rovaris & Filippi, 1999). Non-conventional MRI 
techniques assessing diffuse brain tissue damage outside of the MRI-visible lesions provide 
potent tools to detect pathological changes underlying MS cognitive deficits than lesion-
based and atrophy measures (Filippi et al., 2010). 
Recent advances in histopathological and imaging techniques have renewed the 
appreciation of gray matter (GM) involvement in MS (Pirko et al., 2007). New 
histopathological methods have found demyelinating lesions in significant portions of the 
cortex (Albert et al., 2007; Bo et al., 2003; Kidd et al., 1999; Kutzelnigg et al., 2005; Peterson et 
al., 2001; Wegner et al., 2006). In addition, neuroimaging techniques have detected structural 
changes in the GM (Pirko et al., 2007). In this review, we summarize the results of recent 
studies correlating MRI-detectable GM abnormalities with various aspects of MS 
neuropsychological dysfunction. 
2. Gray matter pathology in multiple sclerosis 
GM pathology is detectable in the earliest disease stages (Chard et al., 2004; De Stefano et al., 
2003; Kutzelnigg et al., 2005), and becomes prominent in the progressive phase (Fisniku et 
al., 2008; Kutzelnigg et al., 2005). 
GM damage in MS may result from primary local cortical demyelinating lesions (Bo et al., 
2003; Peterson et al., 2001), and from GM atrophy secondary to axonal transections in 
destructive WM plaques or severe diffuse axonal damage in the normal-appearing WM 
leading to Wallerian (anterograde or transsynaptic) degeneration, as well as retrograde 
degeneration (Evangelou et al., 2000; Sepulcre et al., 2009; Trapp et al., 1998). However, the 
exact relationship between primary and secondary processes leading to GM damage 
remains poorly understood. Finally, other primary neurodegeneration independent from 
focal WM or GM lesions has been presumed in the early development of GM atrophy in MS 
(Sepulcre et al., 2009). 
MS is characterized by a significant number of focal cortical lesions (CLs) (Bo et al., 2003; 
Kidd et al., 1999; Kutzelnigg et al., 2005; Peterson et al., 2001). In addition, demyelination 
may occur in the deep GM structures, hippocampus, hypothalamus, cerebellum, and spinal 
cord (Geurts et al., 2009). Pathologically, CLs are characterized by a much milder 
lymphocyte infiltration, complement deposition, microglial activation, and blood-brain 
barrier disruption than WM lesions (Bo et al., 2003). Cortical demyelinisation can occur in 
conjunction with subcortical WM plaques or as small perivascular intracortical lesions. 
However, the most extensive cortical demyelination is seen as widespread and band-like 
subpial lesions, which span the cortex over long distances affecting several adjacent gyri and 
sulci. This type of CL is associated with chronic inflammation of the meninges (Kooi et al., 
2009; Magliozzi et al., 2007). 
3. Cognitive impairment in multiple sclerosis 
3.1 General intellectual abilities 
The estimated prevalence of cognitive impairment in MS ranges between 43 to 70% 
(Benedict et al., 2006b; Rao et al., 1991a) both in the earlier and later stages of the disease 
(Beatty et al., 1990; Piras et al., 2003). Cognitive impairment can be seen irrespective of 
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the duration of the disease and is only mildly associated with physical disability (Patti et 
al., 2009). However, cognitive disturbances seem to be more severe in patients with 
chronic progressive disease compared to those in the relapsing-remitting (RR) stage 
(Patti et al., 2009). Both fatigue and depression have been identified as important 
contributors to cognitive impairment of MS patients (Arnett et al., 2008; Deluca et al., 
2004). 
MS affects various aspects of general cognitive functioning, including efficiency of 
information processing, verbal and visuo-spatial memory, executive functioning, attention, 
and visual perceptual processing. Processing speed, and visual learning and memory seem 
to be most commonly affected (Benedict et al., 2006b; Rao et al., 1991a). 
3.2 Social cognition, Theory of Mind 
Deficits of general intellectual abilities significantly interfere with everyday life activities 
and decision-making. In addition, loss of employment status, restriction in social 
activities, and difficulties in inter-personal relationships frequently occur during the 
disease. Deficits of social cognition may additionally account for all of these functional 
limitations. Social cognition is a human mental ability involving the capacity to interpret 
and predict mental states of other people in terms of thoughts, intentions, desires and 
beliefs known as Theory of Mind (ToM), also referred as mentalizing and mindreading. 
ToM ability involves social-perceptual processes that enable mental state decoding from 
nonverbal cues, such as facial expression, eye gaze, and body postures. Furthermore, ToM 
involves social cognitive processes that enable complex abstract reasoning about the 
mental state of others, such as prosody and social content of speech (Stone et al., 1998). 
Social cognition might be independent, and dissociable from general intelligence 
(Shamay-Tsoory et al., 2005). Only a few studies investigated social cognition in MS; all 
demonstrated deficits in facial emotion recognition (Banati et al., 2010; Henry et al., 2009; 
Jehna et al., 2010; Krause et al., 2009; Ouellet et al., 2010) In addition, decline in complex 
cognitive inferences relating to the content of the mental state was also described (Banati 
et al., 2010; Ouellet et al., 2010). 
The neural basis of ToM abilities has been widely investigated using advanced 
neuroimaging methods in healthy subjects and in several clinical conditions showing 
social cognitive impairment particularly in high-functioning autism and schizophrenia. 
These studies support the hypothesis that integrated fronto-temporal and temporo-
parietal circuits are dedicated to mentalizing. Main nodes of these networks were found 
distributed in the posterior superior temporal sulcus, temporo-parietal junction, temporal 
pole, medial prefrontal cortex, anterior cingulate cortex, orbitofrontal cortex, and inferior 
parietal lobule, as well as in subcortical areas, particularly in the amygdala (Adolphs et 
al., 2002; Frith & Frith, 2006; Stone, et al., 1998). Another important neural mechanism 
participating in social cognitive processes is the activation of mirror neurons during 
observation of movements of others (Williams, 2008). Mirror neuron activation described 
first in macaque monkeys produces inner simulation of the viewed action thereby 
enabling the understanding of its intended goal. Electrophysiological studies of monkeys 
and human functional MRI (fMRI) studies found mirror neurons in the premotor cortex 
(frontal mirror system), as well as in the inferior parietal cortex and posterior temporal 
cortex (parietal mirror system) (Williams, 2008). 
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4. Relationship between gray matter findings assessed by MRI and cognitive 
dysfunction in multiple sclerosis 
4.1 General intellectual function 
4.1.1 Neocortical lesions 
In vivo visualization of CLs is challenging (Geurts et al., 2005a) because CLs are typically 
small compared to the usual resolution of MRI in clinical practice, have poor contrast with 
the surrounding normal GM, and have similar signal properties to those of cerebrospinal 
fluid (CSF) reducing their conspicuity in boundary areas of GM and CSF. Using 
conventional imaging techniques, CLs are missed in up to 95% of the cases (Geurts et al., 
2005b). In the past few years, large efforts have been devoted to the development of MRI 
techniques capable of visualizing at least a portion of CLs in vivo (Bagnato et al., 2006; 
Geurts et al., 2005a; Kangarlu et al., 2007; Mainero et al., 2009; Mike et al., 2011; Nelson 
Poonawalla et al., 2008; Nelson et al., 2007; Simon et al., 2010). Novel MRI methods have 
been deployed to address these challenges, including novel pulse sequences, multi-channel 
and high-resolution imaging, and ultra-high magnetic field strength (Bagnato et al., 2006; 
Kangarlu et al., 2007; Mainero et al., 2009; Mike et al., 2011; Nelson et al., 2008; Nelson et al., 
2007; Simon et al., 2010). Recently, the application of the double inversion recovery (DIR) 
sequence convincingly demonstrated that CLs are frequent in MS patients (Calabrese et al., 
2007; Calabrese et al., 2008), as has been long known from pathological studies (Brownell & 
Hughes, 1962, Lumsden, 1970). 
We employed a high-resolution 3 Tesla brain MRI protocol that combined multiplanar 
display of 3 dimensional (3D) fluid attenuated inversion recovery (FLAIR) and T1-weighted 
3D inversion recovery spoiled gradient-recalled echo (IR-SPGR) sequences to study the 
relationship between CLs and cognitive performance of MS patients (Mike et al., 2011). This 
approach took advantage of the high contrast sensitivity of FLAIR for imaging CLs 
combined with IR-SPGR to delineate the boundary between cortex and WM (Figure 1.). 
These sequences are widely available on clinical scanners from multiple vendors and can be 
integrated in clinical routine with reasonable scan times. Using this clinically applicable MRI 
method the detected CL load was comparable with the bulk of CLs assessed by specialized 
MRI methods developed for sensitive CL delineation (Calabrese et al., 2008; Mainero et al., 
2009; Nelson et al., 2008; Nelson et al., 2007; Simon et al., 2010). 
We explored the relationship between cognitive performance and lesion load of the WM and 
cortical GM compartments in an MS patient cohort including RR (n=20) and secondary 
progressive (SP) (n=6) clinical subtypes. Very few studies have examined this previously 
(Bagnato et al., 2010; Calabrese et al., 2009; Roosendaal et al., 2009). Therefore, a broad range 
of neuropsychological variables, which could potentially include cortical contributions (e.g. 
information processing speed, new learning, verbal and non-verbal memory, executive 
function) had been assessed. After controlling for age, depression and pre-morbid 
intelligence, CL number, CL volume and WM lesion volume independently predicted the 
performance of information processing speed and working memory. In addition, CL 
number also predicted verbal learning and memory. 
These findings suggested that both WM and GM lesions influence cognitive performance in 
MS. However, CLs may have a particularly important contribution to this relationship, as 
beside information processing speed performance, CL number also significantly correlated 
with verbal learning abilities. Two recent studies using DIR sequence yielded similar results 
(Calabrese et al., 2009; Roosendaal et al., 2009). 
 




Fig. 1. Cortical lesion shown on multiplanar images 
The same cortical lesion involving both the cortex and the adjoining subcortical white matter 
(Type I lesion) is shown on FLAIR (upper row) and IR-SPGR (lower row) images (arrows), 
reconstructed in sagittal, axial, and coronal planes. Note that the lesion is conspicuous on 
FLAIR, while the anatomic location relative to the white matter-gray matter boundary is 
well defined on the IR-SPGR images. 
4.1.2 T2 hypointensity imaging 
Iron deposition, a possible sign of neurodegeneration, reduces T2 relaxation times, resulting 
in hypointensity on T2-weighted images. In MS, T2 hypointensity frequently occurs in the 
thalamus and basal ganglia. T2 hypointense regions in the GM have been shown to correlate 
with cognitive impairment of MS patients (Brass et al., 2006; Neema et al., 2007). 
4.1.3 Gray matter atrophy 
Several cross-sectional and longitudinal studies have reported GM volume reduction in MS 
using manual or semi-automated segmentation methods, voxel-based morphometry (VBM) 
approach, and cortical thickness measurement (Grassiot et al., 2009). GM atrophy has been 
documented both in the deep gray matter structures (caudate nucleus, thalamus) and in 
neocortical regions. Recently, the relationship between GM volume decrease and cognitive 
performance of MS patients has been intensively investigated. 
Neocortical volume has been found to be significantly reduced in cognitively impaired 
compared to cognitively preserved patients (Amato et al., 2004). Similar findings have been 
reported with cortical thickness analyses of the global brain and parcellated brain areas 
(Calabrese et al., 2010). Compared to healthy controls, a VBM study found significant 
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decrease in GM volume only in MS patients with cognitive impairment in contrast to 
patients with normal neuropsychological performance (Morgen et al., 2006). 
Neuropsychological performance of patients with cognitive decline has been documented to 
correlate with cortical brain volume (Amato et al., 2004; Benedict et al., 2006a; Morgen et al., 
2006), as well as cortical thickness (Calabrese et al., 2010). GM volume assessed 
longitudinally decreased more progressively in MS patients with deteriorating cognitive 
performance compared to patients with stable or improving cognitive state (Amato et al., 
2007). 
The relevance of cortical damage in cognitive dysfunction of MS patients has been 
highlighted by studies of regional cortical atrophy (Calabrese et al., 2010; Morgen et al., 
2006; Tekok-Kilic et al., 2007). In a group of cognitively impaired MS patients, GM volume 
of fronto-temporal brain areas presumed to be involved in neural processing of working 
memory, information processing, and divided attention correlated with performance on the 
paced auditory serial addition task (PASAT) test performance (Morgen et al., 2006). Using a 
semi-automated parcellation analysis of the neocortex, the prefrontal GM volume resulted 
the strongest predictor of memory and information processing performance in MS patients 
(Tekok-Kilic et al., 2007). 
Impact of subcortical GM atrophy on MS cognitive performance has also been established. 
Different methods applied for quantification of deep GM structures including the measure 
of the bicaudate ratio (Bermel et al., 2002), enlargement of the third ventricular width 
(Benedict et al. 2004a, 2004b, 2006a, Christodoulou et al., 2003; Sanchez et al, 2008; Tekok-
Kilic et al., 2007), semi-automated (Houtchens et al., 2007) and automated (Benedict et al. 
2009) segmentation of subcortical GM structures provided convergent evidence for a 
relationship between deep GM damage and neuropsychological impairment. Reduction of 
thalamic volume was found to be a reliable predictor of cognitive decline in MS even after 
correction for WM lesion volume, whole brain atrophy and third ventricular with (Benedict 
et al., 2009; Houtchens et al., 2007). Strong correlations have been reported between caudate 
atrophy and impaired information processing speed (Bermel et al., 2002), as well as verbal 
learning and memory (Benedict et al., 2009). Measure of the third ventricle width has been 
used to infer the atrophy of adjacent GM structures, such as the thalamus (central atrophy). 
Enlargement of the third ventricle showed a highly significant relationship with both 
general cognitive impairment and deficits in specific neuropsychological domains even after 
accounting for the influence of global lesion load measures and whole brain atrophy 
(Benedict et al., 2004b; Christodoulou et al., 2003; Sanchez et al., 2008). 
A recent study investigated the contribution of different GM compartments to cognitive 
dysfunction in MS patients, and found both the central and cortical atrophy predictive of the 
presence of cognitive impairment in MS (Tekok-Kilic et al., 2007). 
4.1.4 Non-conventional MRI methods 
Beyond focal lesions and atrophy, MS pathology is characterized by diffuse tissue damage. 
Conventional morphological MRI methods are insensitive to detect these microscopic 
structural alterations. Quantitative MRI techniques including magnetization transfer (MT) 
MRI, diffusion tensor imaging (DTI), and proton MR spectroscopy (1H-MRS) detect brain 
tissue changes on a molecular level, and thereby are able to measure the degree of structural 
integrity in diffusely affected brain tissue. Abnormalities in the GM assessed with non-
conventional MRI methods have been well established in MS (Filippi et al., 2010; Rovaris et 
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al., 2006). Studies, addressing the clinical relevance of diffuse GM pathology in the cognitive 
impairment of MS patients are summarized in the following subsections. 
4.1.4.1 Magnetization transfer MRI 
The MT ratio (MTR) derived from MT MRI reflects the capacity of macromolecules to 
exchange magnetization with surrounding water molecules and estimates the relative 
amounts of free and bound water in the brain (Wolff & Balaban, 1994). In MS, reduced MTR 
values may indicate a relative increase in the unbound water fraction due to edema and 
inflammation, or a reduction in the bound fraction, which may reflect demyelination and 
axonal loss (Schmierer et al., 2007). MTR values derived from the cortical/subcortical brain 
tissue were significantly lower in cognitively impaired patients than in those with no 
impairment (Rovaris, et al., 2000). MTR values of the cortical/subcortical regions showed 
correlation with cognitive performance of RR MS patients (Rovaris et al., 2000). In CIS 
patients, using voxel-by-voxel statistical mapping, significant correlations were observed 
between local MTR values and PASAT scores in the right Brodmann (BA) 4 and the left 
BA40 (Ranjeva et al., 2006; Ranjeva et al., 2005). A recent study investigated GM MRI 
correlates of cognitive impairment in different stages of MS. In patients with CIS 
suggestive for MS, mean cortical MTR has been identified as the only independent 
predictor of decreased mental processing speed. However, in early RR MS cortical 
atrophy was found as the strongest correlate of the same cognitive task. These findings 
suggest that both microscopic tissue disintegrations and atrophy of the cortex are 
important determinants of MS cognitive performance, however their significance changes 
with advance of the disease (Khalil et al., 2011). In a study including benign MS patients 
(BMS), total and regional (frontal, temporal, and occipital) cortical MTR values corrected 
for WM lesion volume were able to differentiate between cognitively impaired and 
cognitively preserved MS patients. However, MTR values of cognitively preserved MS 
patients did not differ from healthy controls. These findings support heterogeneity of the 
brain structural damage in BMS associating with different clinical prognosis (Amato et al., 
2008). In patients with primary progressive (PP) MS, significant correlations have been 
observed between decrease of MTR value in specific cortical regions (right inferior 
parietal cortex, right inferior occipital gyrus) and PASAT performance (Khaleeli et al., 
2007). In a longitudinal study of PP MS patients, GM MTR independently predicted 
PASAT score at the 5-year follow-up (Penny et al., 2010). 
4.1.4.2 Diffusion tensor imaging 
DTI measures the diffusion of water molecules in the brain tissue, which is directionally 
determined along the fiber tracts. Disturbances in the structural integrity of the brain tissue 
are reflected by the increase of the mean diffusivity (MD) and decrease of the fractional 
anisotrophy (FA), parameters derived from DTI technique (Rovaris et al., 2009). 
In RRMS, MD of the NAGM moderately correlated with neuropsychological tests 
measuring semantic fluency, and information processing-working memory (Rovaris et al., 
2002). Structural GM damage of BMS patients with cognitive impairment has been 
demonstrated in a study comparing GM MD between cognitively impaired BMS patients 
and SP MS patients. MD of the GM showed no difference between BMS patients with 
cognitive deficit and low physical disability and patients with SP disease course (Rovaris et 
al., 2008). 
 




4.2.1 Focal atrophy of the neocortex impairs mentalization ability of multiple sclerosis 
patients 
Living with MS frequently associates with disturbed social life including insufficiency in 
partnerships and family roles, as well as employment status (Halper, 2007). Intact social 
cognition is fundamental for successful social functioning (Penn et al., 1997). Recently, few 
studies investigating social cognitive abilities of MS patients have reported deficits in 
emotion recognition and complex perspective taking abilities (Banati et al., 2010; Henry et 
al., 2009; Jehna et al., 2010; Krause et al., 2009; Ouellet et al., 2010). 
To investigate the impact of cortical pathology on social cognitive dysfunction, we 
performed an MRI study in a cohort of 49 MS patients. We measured the cortical thickness 
throughout the whole brain, and analyzed its association with mentalization test 
performance to indentify cortical areas involved in neural integration processes of 
mentalization in MS. Performances on neuropsychological tests were corrected for 
confounding effects of anxiety and depression. Compared to healthy subjects, MS patients 
performed significantly poorer in verbal (Irony test) and visual (Eyes test) mentalization 
tasks. These results are in line with previous reports (Banati et al., 2010; Henry et al., 2009; 
Jehna et al., 2010; Krause et al., 2009; Ouellet et al., 2010). 
Cortical thickness was assessed to quantify cortical atrophy as thinning of the cortex. 
FreeSurfer software, version 4.5 (http://surfer.nmr.mgh.harvard.edu) was applied on 3 
Tesla 3D Magnetization Prepared Rapid Gradient Echo (MPRAGE) images for automated 
reconstruction and measure of cortical thickness characterized by preciosity within a 
submillimeter range (Dale et al., 1999; Fischl et al., 1999). After correcting for confounding 
effects of age on cortical thickness, and effects of depression and anxiety on mentalization 
significant correlations were found between the Eyes test performance and cortical thickness 
of several focal areas. The Eyes test is an advanced and sensitive tool to detect subtle 
dysfunctions in facial expression recognition (Baron-Cohen et al., 2001). In the Eyes test, 
participants are required to judge mental states from photographs portraying only the eye 
region of the face. The identified frontotemporal cortical areas showing significant 
correlation with the Eyes test were also reported in previous studies documenting a widely 
distributed brain network engaged in neural processes of facial emotion recognition 
(Adolphs et al., 2002; Frith & Frith, 2006; Sabatinelli et al., 2011). Simulation theory describes 
a presumed physiologic mechanism participating in the understanding of observed motor 
actions, motor learning, and mental state decoding as well as empathizing in social-
perceptual processes (Bastiaansen et al., 2009; Williams, 2008). Firing of mirror neurons in 
the brain of the observer simulates the neuronal activation pattern required to execute the 
observed movement, and thereby enables the understanding of the underlying action goal 
(Bastiaansen et al., 2009; Williams, 2008). Mirror neurons were identified in prefrontal and 
premotor areas, and in the parietal and temporal lobe (Bastiaansen et al., 2009; Williams, 
2008). In addition, recent studies found evidence on simulation of observed sensations and 
emotions through mirror neuron activation in the primary somatosensory cortex, anterior 
insula, and amygdala contributing to empathic understanding (Bastiaansen et al., 2009; 
Williams, 2008). Previous fMRI studies demonstrated that viewing emotional facial 
expressions associates with premotor cortex activation presuming a mirror neuron 
mechanism (Bastiaansen et al., 2009). Inner simulation of the observed facial muscle group 
contractions is linked to a matching affective state based on personal experiences. 
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In conclusion, our study suggests that GM pathology in cortical regions constituting neural 
networks processing high-level mental information significantly impact the mentalization 
ability in MS. 
4.2.2 Functional MRI study of mentalization in multiple sclerosis 
Neuroanatomical correlates of emotional face expression recognition deficit in MS were also 
investigated in an fMRI study. This approach identified decreased insular and ventrolateral 
prefrontal cortex BOLD activation in MS patients with impaired recognition performance 
compared to the unimpaired group (Krause et al., 2009). 
5. Conclusion 
Cognitive impairment in MS occurs frequently as mild deficit in different 
neuropsychological domains. Clinical impact of cognitive dysfunction emerges in every day 
life situations, employment status, and social environment compromising quality of life of 
the patients. Diagnostic evaluation of neuropsychological performance in MS has also been 
proved to be significant from prognostic point of view, as presence of cognitive impairment 
may predict worse disease course. Recently, involvement of the GM in pathological 
processes underlying MS has been convergent supported by histopathological and MRI 
studies. The impact of GM damage on clinical course of the disease and its relationship with 
WM lesions is under intensive research, in which application of different MRI methods 
plays a highly important role. Application of conventional structural MRI, and non-
conventional MRI techniques has been enabled to quantify GM pathology as atrophy, CL 
load, and degree of microscopic tissue integration disturbances. Cognitive impairment has 
been demonstrated to correlate all with these different aspects of GM damage highlighting 
the relevance of MRI evaluation of the GM in MS. Future studies are needed to further 
refine the MRI-cognition relationship to improve therapeutic decisions and prognosis of MS, 
and develop potential treatment strategies targeting neuroprotection. 
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Historically, several terms have been used to depict pseudotumor cerebri (PTC). In the late 
1890's, Quincke (1893, 1897) was the first to describe and name this syndrome - "meningitis 
serosa" - patients suffering from headache, impaired visual acuity and papilledema. He 
related the symptoms to a state of elevated intracranial pressure and presumed it was 
caused by increased secretion of CSF by the autonomic nervous system. In 1904, Nonne 
(1904) termed this syndrome "pseudotumor cerebri" as the symptoms resembled a suspected 
intracranial mass. Foley (1955) renamed the condition "benign intracranial hypertension". 
However, in the late 1980's, Corbett et al (1982) altered the name to idiopathic intracranial 
hypertension, since the syndrome was not benign as once thought. In some cases, up to 25% 
of patients may lose their vision if appropriate treatment measures are not taken. At present, 
idiopathic intracranial hypertension is the accepted designation. 
1.2 Demographics and epidemiology 
Pseudotumor cerebri (PTC), also known as idiopathic intracranial hypertension (IIH) is a 
disorder of unknown etiology, predominantly affecting obese women of childbearing age 
(Ahlskog & O'Neill, 1982). In the general population, the annual incidence of PTC is 
estimated between 1-2 per 100,000 (Friedman & Jacobson, 2002, 2009). The incidence has 
been reported to have risen to 3.5 per 100,000 in women aged 20 - 44 years and may reach as 
high as 19 cases per 100,000 in women who are >20% over the ideal body weight (Durcan, 
1988; Kesler et al 2001; Radhakrishnan et al., 1993, 1994). 
PTC is uncommon in men, with female to male ratios reported approximately 4.3:1 to 8:1 
(Binder et al, 2004; Durcan, 1988). The association between obesity and PTC is well 
established, >90% of women and >60% of men who suffer from this disorder are obese 
(Friedman et al., 2002; Radhakrishnan et al, 1994). The syndrome is relatively rare in the 
pediatric population. In the pre-pubertal population, it seems that obesity is not a risk factor. 
There is an equal distribution between boys and girls with an estimated incidence of 
approximately 1 case per 100,000.  
1.3 Presenting signs and symptoms  
Headaches, the most common presenting symptom in all age groups, occur in >90% of 
patients (Binder et al., 2004; Lessell, 1992). A PTC-associated headache has no specific 
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characteristics, but is usually more severe and different than previously described 
headaches. In PTC, the headache is most commonly bifrontal or generalized, usually 
occurring daily, but may also occur intermittently, worsening in the morning. When 
cerebral venous pressure is increased by the Valsalva maneuver, the headaches are often 
exacerbated and accompanied by neck pain. 
Transient visual obscurations (TVO), the second most common symptom is more frequently 
reported in adult patients than in pediatric PTC patients, 72% vs. 2-53% respectively 
(Lessell, 1992). TVO may be unilateral or bilateral, usually lasting less than a minute and 
often precipitated by a change in posture. TVO indicate the presence of optic disc edema 
resulting in transient ischemia to the optic nerve head. Over half (60%) of PTC patients may 
experience pulsatile tinnitus as the initial complaint. Pulsatile tinnitus is thought to result 
from a turbulence created by higher to lower venous pressure around the jugular bulb 
(Binder et al., 2004). 
In patients with PTC, focal neurological deficits are extremely uncommon. An alternative 
diagnosis should be considered when these deficits occur. Nevertheless, isolated 6th cranial 
nerve paresis, thought to be attributed to nerve traction from increased intracranial pressure 
has been observed in approximately 20% of adult cases (Binder et al., 2004). However, in 
children, the incidence was found to be as high as 50% (Cinciripini et al 1999; Lessell, 1992; 
Rangwala & Liu, 2007). Paresis of the 3rd, 4th, 7th or 12th nerve is extremely rare, occurring 
mostly in the pediatric population. Young children with PTC may present with irritability 
rather than headaches (Lessell, 1992), and may consequently develop signs of a posterior  
  
 
Fig. 1. Papilledema in a 26 year old PTC female patient. 
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fossa lesion, including ataxia, facial palsy, nuchal rigidity, malaise, torticollis (Lessell, 1992; 
Rangwala & Liu, 2007). 
Papilledema is the diagnostic hallmark of PTC and is present in almost all patients (Mathew, 
1996) (Figure 1). To note, although, unilateral cases may be encountered in approximately 
10% of cases (Maxner et al., 1997; Wall & White, 1998) and a small number of patients may 
not have papilledema at all (Mathew, 1996; Wang et al., 1998; Winner & Bello, 1996), most 
cases occur either in very young infants with unfused sutures or in patients with anatomical 
variants of the endings of the optic nerve sheath (Hayreh, 1977; Killer et al., 1999). 
Post-papilledema optic atrophy can occurs in untreated or inadequately treated patients 
after variable periods of time, usually over several months; in rare cases of fulminant PTC it 
can appear within weeks of the onset of symptoms. Some patients have persistent chronic 
papilledema without obvious visual deterioration. Visual field testing is the most sensitive 
method for detecting visual dysfunction. The most common abnormalities are an enlarged 
blind spot, generalized constriction and inferior nasal field loss. 
1.4 Diagnosis 
Diagnosis criteria for PTC were reviewed (Binder et al., 2004) (Table 1) and include signs 
and symptoms attributable to increased ICP, elevated CSF pressure with normal CSF 
content and normal neuroimaging studies. Other etiologies of intracranial hypertension 
were excluded. When these criteria are present, neuroimaging is employed to rule out space 
occupying lesions and sinus vein thrombosis. Lumbar puncture is subsequently performed 
to measure CSF opening pressure. Generally, an opening pressure of >250mm of water 
measured in a patient lying in the decubitus position, with outstretched legs and as relaxed 
as possible, is indicative of increased pressure. A pressure value between 201 and 249mm of 
water is inconclusive (Corbett & Mehta, 1983); pressure equal to or <200mm of water is 
considered normal. Often, due to CSF fluctuations, low or inconclusive measurements must 
be re-evaluated, especially if the clinical picture is indicative of increased ICP.  
According to Tibussek et al (2010), a diagnosis of "probable PTC" would be indicated in 
patients, especially children, with clinical manifestations highly suggestive of PTC, but with 
a normal CSF opening pressure, presumably due to diurnal fluctuations. Rarely, in these 
circumstances, is a 24 hour intracranial CSF pressure monitoring, or transducer monitoring 
for 6 to 24 hours needed to confirm the diagnosis (Spence et al., 1980). 
2. Neuroradiological evaluation 
A detailed section in this chapter is devoted to diverse imaging modalities in patients with 
PTC. Imaging plays an important role in excluding intracranial tumors and structural or 
vascular lesions responsible for intracranial hypertension. CT, although adequate in ruling 
out hydrocephalus and most mass lesions, conditions such as sinus vein thrombosis, 
meningeal infiltration, and isodense tumors are undetected by a non-enhanced CT. 
An MRI will detect almost all changes and by incorporating MRI venography will further 
enhance the ability to detect sinus vein thrombosis disguised as PTC (Crassard & Bousser, 
2004). In rare cases, imaging of the spinal cord is essential as it excludes rare cases of spinal 
tumors that cause an increase in intracranial pressure. However, this is typically present 
with high protein levels in the CSF, therefore making it incompatible with the definition of 
PTC (Corbett & Mehta, 1983; Friedman & Jacobson, 2004; Ridsdale & Moseley, 1978). 
Traditionally, slit ventricles were thought to be present in PTC, but a quantitative analysis of 
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ventricular volume noted no differences between patients with PTC and age-matched 
control patients (Jacobson et al., 1990). 
Signs of increased intracranial pressure that may be found on imaging studies include 
empty sella (70%), flattening of posterior sclera (80%), enhancement of the prelaminar optic 
nerve (50%), distention of the perioptic subarachnoid space (45%), vertical tortuosity of the 
orbital optic nerve (40%), and intraocular protrusion of the prelaminar optic nerve (30%) 
(Brodsky & Vaphiades, 1998). 
 
1. Symptoms, if present, represent increased intracranial pressure or papilledema. 
2. Signs represent increased intracranial pressure or papilledema. 
3. Documented elevated intracranial pressure during lumbar puncture measured in the 
lateral decubitus  position  
4. Normal cerebrospinal fluid composition. 
5. No evidence of ventriculomegaly, mass, structural, or vascular lesion on magnetic 
resonance imaging or contrast-enhanced computed tomography and magnetic 
resonance venography or computerized venography for all others 
6. No other cause (including medication) of intracranial hypertension identified. 
Table 1. Clinical criteria for diagnosing idiopathic intracranial hypertension (adapted from 
Binder et al 2004) 
3. Pathogenesis 
At present, the pathogenesis of the syndrome is still unknown, however, some explanation 
must account for elevated intracranial pressure with normal neuroimaging, CSF 
constituents and neurologic examination (Corbett, 2008). Intracranial pressure is maintained 
by cerebral arterial pressure which is cerebral autoregulated, resulting in constant 
intracranial pressure.  
CSF is constantly absorbed into the superior sagittal sinus (SSS) at the pacchionian 
granulation level. This process is carried out by a pressure gradient between the CSF and the 
venous pressure in the SSS. When there is a rise in the venous pressure, the CSF pressure 
rises proportionately in order for the CSF to diffuse into the SSS. 
According to the Montro-Kellie rule (Greitz et al., 1992; Mokori, 2001), the increase in ICP 
may be a result of various factors such as an increase in CSF, brain or blood volume. 
Although many studies have been performed, it is still unclear which factor is responsible 
for the increase in ICP in cases of PTC. 
Different hypotheses have been proposed such as, an increase in cerebral blood volume 
which was originally proposed by Dandy in 1937. Raichle et al. (1978), using positron 
emission tomography (PET) found that almost no change occurred in the cerebral blood 
flow (CBF) in PTC patients, however there were markedly increased cerebral blood or water 
volumes. 
A few years later, Brooks et al (1985) using PET, found no change in cerebral 
hemodynamics. Recently, Levine demonstrated that vascular compression and dilatation 
exist in the PTC patient (Levine, 2000). 
Bateman et al. (2007) found that the total CBF measured by magnetic resonance (MR) flow 
quantification and MR venography in the PTC patient, was 46% more elevated then in the 
control group, which may be secondary to cerebral vascular autoregulation. On the other 
hand, Lorberboym et al. (2001) reported a reduction in perfusion, noted on single photon 
 
Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) an Update 
 
377 
emission CT scans in PTC patients a clear correlation between disease severity and CBF 
reduction. The proposed mechanisms for CBF changes are an increase of the cerebral 
vascular resistance, impairment of the CBF autoregulation, and a decrease of the tissue 
vascular density as a result of cerebral edema (Bateman, 2004)). 
Bicakci et al (2006) recently studied 16 patients with perfusion and diffusion MRI, finding 6 
patients with a statistically reduced CBF, and 2 with a marked increase. All other patients’ 
cerebral blood volume did not significantly increase or decrease compared with the control 
group. Both vasodilatation and compression occurred in the PTC patient depending on the 
duration of the disease. The authors claimed that a long standing increase in CSF pressure 
might result in a decrease in CBF. On the other hand, an increase in CBF may be a result of a 
failure in autoregulation in the first phases of the disease, as suggested by Bateman's study. 
4. Obstruction of venous outflow 
The absence of ventricular dilatation in an elevated ICP condition is most likely explained 
by the presence of venous hypertension. As the pressure in the SSS rises, so does the CSF 
pressure due to hindered absorption of CSF. Brain parenchimal turgor increases due to an 
impending resorption of venous blood. 
In 1995, King et al’s (1995) series of 9 PTC patients with venous hypertension in the SSS and 
proximal transverse sinuses, cerebral venography and manometry were performed.  The 
authors were able to observe the appearance of the transverse sinuses, ranging from a 
smooth tapered narrowing to a discrete intraluminal filling defect resembling mural 
thrombi. 
The authors also found a significant drop in venous pressure at the level of the lateral third 
of the transverse sinus that was not fully explained by the anatomical finding on 
venography. Furthermore this gradient was eliminated after performing a cervical puncture 
which reduced the CSF pressure.  
Karahalios et al (1996) also described a dural venous outflow obstruction found on cerebral 
venography and manometry in 5 out of 10 patients.   A high pressure gradient was observed 
while those without obstruction had elevated right atrial pressure as well as elevated 
venous sinus pressure. The authors concluded that increased venous pressure was common 
in PTC, secondary to intracranial venous outlet obstruction and without anatomical 
obstruction. 
In the same study, Karahalios proposed other hypotheses, such as obesity related 
cardiomyopathy with subsequent congestive heart failure, sleep apnea, carbon dioxide 
retention and increased intra-abdominal pressure. All these conditions benefited from 
diuretic therapy which reduced CSF production and also reduced the central plasma 
volume and hence venous pressure. 
A recent study by Nodelmann (2009) observed that jugular vein valve insufficiency in 
patients with PTC supports the hypothesis that increased ICP may be a result of a more 
general state of venous hypertension, possibly associated with obesity. 
Several studies focusing on the appearance of outflow obstruction on MRI and MRV (Farb et 
al, 2003; Johnston et al., 2002;) produced inconclusive results due to the wide variations of 
radiological appearances of posterior fossa dural sinuses, which may be confused with a 
normal anatomical variant (Lee & Brazis, 2000).  
Higgins et al (2004) published a study comparing 20 patients with PTC who had undergone 
MRV and a control group of 40 healthy volunteers, strictly selected. Patients with a history 
of headaches or other signs or symptoms related to cranial venous involvement were 
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excluded. All subjects were matched for age and sex. A significant difference was observed 
in the appearance of the lateral sinus between the 2 groups; bilateral lateral sinus flow gaps 
were seen in 13 out of 20 (65%) PTC patients compared to none in the control group. 
A new imaging method proposed by Farb et al. (2003) is auto-triggered elliptic-centric-
ordered three-dimensional gadolinium-enhanced MR venography, which may be superior 
to time of flight MR venography in its flow insensitivity and decreased artifactual signal 
loss. Using this new technique, bilateral sinovenous stenosis was found in 27 out of 29 (93%) 
PTC patients compared to only 4 out of 59 (6.5%) in the control group. The authors 
concluded that the distal transverse sinus is the area of pressure gradient as described in 
King et al's study (1995). 
Farb et al (2003) described two types of dural narrowing a “long smooth tapered 
narrowing”, indicating an extra luminal compressive stenosis, and the “acutely marginated 
apparent intraluminal filling defect”, indicating an enlarged, partially obstructing, 
intraluminal arachnoid granulation. They concluded that in PTC patients,  increased dural 
venous pressure is measurable; however, whether this is a primary cause, a contributory 
factor, or a secondary phenomenon is uncertain. 
Two opposing hypotheses can be made. The first proposes that dural sinus stenosis should 
be considered as the primary cause of PTC (fixed stenosis). Kollar et al. (2001) proposed that 
the transverse sinus is narrowed or obstructed by venous sinus thrombosis, vasculitis, 
congenital stenosis, enlarged arachnoid granulations or even heterotropic brain. 
A recently published paper by De Lucia et al (2006) supports the suggested speculation 
that PTC is a long term sequela of previous sinus vein thrombosis or of an unidentified 
thrombus (Nedelmann et al., 2009; Sussman et al., 1997). In their study, 17 PTC patients 
without radiographic evidence of thrombosis were compared to healthy controls. The 
results showed a significant predominance of hypercoagulability markers, including 
protein C deficiency, increased plasma levels of prothrombin fragment 1 and 2, 
fibrinopeptide A, gene polymorphism for factor V leiden mutation, and high titers of 
cardiolipin antibodies. 
The second hypothesis, in contrast to the fixed stenosis theory, suggests a dynamic one, 
where venous obstruction is the consequence and not the primary cause of intracranial 
hypertension. An increased intracranial pressure due to some unknown cause will result in 
a compression of the vascular compartment and dural sinuses which is in agreement with 
the Monroe-Kellie doctrine (Corbett, 2004). It is presumed that the predisposition to this 
phenomenon is due to the anatomy of the distal transverse sinus.  Studies have shown that 
after normalization of the CSF pressure, resolution of the dural sinus narrowing occurs.  
5. Endocrinological and metabolic factors 
The association between PTC, female gender and obesity suggests an endocrine basis for 
this disorder.  Reports of PTC occurring in corticosteroid deficient states such as Addison's 
disease, and following the removal of an ACTH secreting pituitary adenoma (Ross & 
Wilson, 1988), implies abnormalities in the adrenal pituitary axis. Furthermore, 
corticosteroids effectively treat PTC and corticosteroid withdrawal is associated with PTC 
(Yasargil et al., 1990). However, Soelberg Sørensen et al. (1986) found no consistent 
abnormality in pituitary, gonadal, thyroid or adrenal function.  Multiple studies have 
documented the clear association between PTC and polycystic ovaries. In one study 
conducted by Glueck et al. (2003), 15 women out of 38 PTC patients were found to have 
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PCOS; 14 were obese, with a body-mass index (BMI) >30 kg/m2 and 10 were extremely 
obese (BMI > or = 40). 
6. Excess CSF production 
Quincke (1893) was the first to describe excess CSF production. The rate of CSF production 
can be measured through invasive procedures (Walker, 2001). Donaldson found an 
increased CSF rate, while other studies failed to demonstrate CSF hypersecretion in PTC 
patients ( Binder et al., 2004; Walker, 2001).  A noninvasive technique (MRI) to measure CSF 
production by recording the flow through the cerebral aqueduct produced highly variable 
results, which did not support the theory of CSF overproduction in PTC patients (Gideon et 
al., 1994). In an attempt to rule out this theory, experimental infusion of artificial CSF was 
injected into the lateral ventricles of dogs which led to ventricular enlargement, not a PTC- 
like syndrome (Greitz et al., 1992; Walker, 2001). 
7. CSF outflow reduction 
This theory, supported by most studies, proposes the pathogenesis of CSF outflow 
obstruction into the venous system, although existing reports are still controversial. Studies 
have shown that PTC is associated with CSF outflow impairment (Calabrese et al., 1978; 
Cameron, 1933; Malm et al., 1992; Martins, 1974) and no histological evidence of arachnoid 
villi granulation dysfunction. Controversy exists as to whether impairment of CSF outflow 
at the arachnoid granulation level may be pathophysiological. In infancy, agenesis, 
deficiency, or dyslasia of the arachnoid villi and granulations result in hydrocephalus, not 
PTC (Gilles & Davidson, 1971).  
Studies have demonstrated that in cases of elevated intracranial pressure attributed to high 
protein concentration in the CSF, (spinal tumor, Guillian-Barre syndrome), some patients 
develop hydrocephalus while others develop a PTC- like syndrome (Feldmann et al., 1986; 
Raichle et al., 1978; Ridsdale & Moseley, 1978; Ropper & Marmarou, 1984). It has been 
suggested that a high concentration of protein in CSF, may lead directly to impairment of 
CSF outflow. 
8. Chronic inflammation  
Recent reviews by Binder et al (2004) suggest that increased levels of cytokines and leptins 
(an adipocyte derivative hormone that circulates in the plasma at levels in proportion to 
body fat) in the CSF, may contribute to chronic inflammation and pathogenesis of 
intracranial hypertension in PTC patients. 
Hypercoagulable states, devoid of obvious dural sinus thrombosis, have been reported 
associated with and in some cases used to explain PTC's mechanism. Kesler reported on 
several individuals found to have antiphospholipid antibodies and hyperfibrinogenemia 
related to thrombosis (Kesler et al. 2000; Kesler et al., 2010). 
9. Drug associated 
Numerous published reports and studies have described the correlation between certain 
drugs and vitamins and the development of increased intracranial pressure. These include 
antibiotics such as tetracycline or minocycline (Giles & Soble, 1971), fluoroquinolones 
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(Winrow & Supramaniam, 1990), naladixicacids (Cohen, 1973), sulfamethozaxole (Ch’ien, 
1976) and hormonal treatments such as oral contraceptives, growth hormones, progesterone 
(Hamed et al., 1989; Rogers et al., 1999; Walsh et al., 1965), corticosteroid withdrawal 
(Neville & Wilson,1970), lithium (Saul et al, 1985) and  vitamin A use and its derivatives 
(Morrice et al., 1960, Spector & Carlisle, 1984; Visani, 1996) in doses exceeding 50,000 UI in 
adults and over 20,000 UI in children. 
10. Systemic conditions 
In the literature, various systemic diseases have been found to be associated with PTC, the 
most common being uremia (Campos & Olitsky, 1995) Toxic conditions, hypervitaminosis A 
tetracycline therapy, lithium,prolonged steroid therpy, Steroid withdrawal,. Other diseases 
include anemia (Capriles, et al. 1963), dysthyroidism (Campos & Olitsky, 1995; Huseman & 
Torkelson, 1984), Addison's disease (Condulis et al., 1997) cerebral sinus thrombosis, and 
sleep apnea. . 
11. Ancillary tests 
11.1 Neuroimaging 
The rationale for neuroimaging studies in PTC patients is twofold: prior to obtaining the 
cerebrospinal fluid, a brain imaging study is required to exclude any condition that would 
put the patient at risk of herniation, such as a tumor and to assure no secondary cause of 
increased ICP. The recommended study type has been modified together with the advance 
in neuroimaging technology. A CT scan is generally adequate as to ensure that the patient is 
not at risk when undergoing a lumbar puncture. The resolution is insufficient to exclude 
posterior fossa abnormalities, isodense lesions gliomatosis cerebri or venous sinus 
thrombosis. As either neuroimaging is acceptable, MRI of the brain with gadolinium is 
preferred over CT scanning with contrast. 
11.2 MRI  
Brain MRI is typically normal in the PTC patient, with a ventricular size normal for the 
patient’s age. An asymptomatic empty sella is a well known neuroimaging finding in 
patients with increased intracranial pressure and may be present in over 50% of cases 
(Silbergleit et al., 1989). The empty sella (Figure 2) is attributed to longstanding effects of 
pulsatile CSF under high pressure, leading to downward herniation of an arachnocele 
through a defect in the diaphragma sella (George, 1989). The incidence of empty sella 
ranged from 10% when plain radiographs of the skull were analyzed (Sorenson et al., 1989) 
to 94% when third-generation CT scans were analyzed (Gibby et al., 1993). 
Over the past few decades, other radiographic evidence of increased ICP in PTC patients has 
been detected using various neuroimaging techniques. Flattening of the posterior sclera is 
the most sensitive sign of elevated intracranial pressure, and was observed in 80% of 
patients with pseudotumor cerebri in Brodsky's study (Brodsky & Vaphiades, 1988). The 
flattening indicated transmission of elevated perioptic CSF pressure to the compressible 
posterior sclera. Jacobson (1995) found similar findings of bilateral posterior scleral 
flattening and distension of the perioptic subarachnoid space on MR imaging (Figure 3)in a 
patient with elevated intracranial pressure and unilateral papilledema. Furthermore, he 
emphasized that the constellation of acquired hyperopia and choroidal folds may indicate 
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the presence of pseudotumor cerebri in rare patients whose distal optic nerves are 
structurally resistant to developing papilledema. 
A study by Jinkins et al (1996) found intraocular protrusion of the swollen optic disc in 10 
out of 15 patients with pseudotumor cerebri while examining the prelaminar optic nerves 
via MRI.  The optic disc appeared hypointense to vitreous on T2-weighted images. 
Upon administration of intravenous gadolinium, enhancement on T1 and T2 was produced 
in areas where the blood-brain barrier was absent or disrupted.  Intraocular enhancement of 
the swollen disc was found in 50% of MR images of patients with PTC resulting from diffuse 
prelaminar capillary leakage secondary to severe venous congestion. Distension of the 
perioptic subarachnoid space was present in 45% of patients with pseudotumor cerebri. A 
finding of intraocular protrusion of the prelaminar optic nerve can be visualized well on CT 
scanning (Lam et al., 1997; Jinkins et al., 1996), however, on MRI, no signal differential 
between the swollen optic disc and the vitreous cavity was observed (Connolly et al., 1992; 
Foley & Posner, 1975; 1989; Gass et al., 1996; Gideon et al., 1995; Mashima et al., 1996; 
Silbergleit et al.). 
 
 
Fig. 2. MRI image demonstrating an empty sella in a 26 year old PTC patient 
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Brodsky (1998) observed vertical tortuosity of the optic nerves in 8 out of 20 (40%) patients 
with pseudotumor cerebri compared to only one control subject. Since some tortuosity may 
exist in normal subjects, the ability of axial MR imaging to display relatively minor degrees 
of horizontal tortuosity, makes it a relatively nonspecific finding. Furthermore, vertical 
tortuosity of the orbital optic nerve is often accompanied by a “smear sign” on T1-weighted 
images where the midportion of the optic nerve is displaced from the field of view, causing 
it to appear obscured by a “smear” of orbital fat. The optic nerve tortuosity or kinking in 
patients with elevated intracranial pressure is attributable to the distal fixation of the optic 
nerves by the globes tethered to the orbits by their rectus muscles and check ligaments. 
Every patient suspected of PTC must routinely undergo an MRV or CTV examination. Both 
exams are equally reliable in identifying sinus vein thrombosis and therefore the decision of 




Fig. 3. Coronal T2 MRI image, demonstrating excess of CSF surrounding the optic nerves 
 




PTC is consistently associated with venous outflow disturbances. Sinus venous stenosis are 
found on MR venography in the large majority of PTC patients and may have various 
conformations, ranging from functional smooth narrowing of sinus segments associated or 
not associated with definite flow gaps, to segmental hypoplasia or aplasia of one or more 
central venous collectors. Stenosis is currently believed to be a consequence of primary 
altered cerebrospinal fluid (CSF) pressure since it may normalize after CSF subtraction with 
lumbar puncture or shunting procedures (De Simone et al., 2010). 
At present, the pathophysiologic mechanism of the elevated intracranial pressure in PTC 
remains unknown. Evidence suggests that perturbed venous efflux from the head may play 
a role in the etiology of the disease. Many studies suggest that elevated intracranial venous 
pressure, an underlying component of PTC, is the result of intracranial venous hypertension 
due to raised central venous pressure or disturbances of transverse sinuses (TSs) outflow 
(Brodsky et al., 1998;  Friedman & Jacobson, 2002; Gass et al., 1996; Jacobson et al., 1990). 
Occasionally, the clinical picture of PTC is the only clue to the presence of cerebral venous 
thrombosis, which may be a potentially devastating condition. Thus, every patient 
diagnosed with PTC must undergo an MRV or CTV to rule out this condition. 
MRV is a noninvasive technique effective in visualizing cerebral venous sinuses (Mattle et 
al., 1991). Different MRV sequences offer the capability of investigating cerebral sinovenous 
outflow from multiple orientations such as two-dimensional time-offlight (2D-TOF) and 
three-dimensional phase-contrast (3D-PC) techniques. However, all these techniques have 
limitations and pitfalls (Ayanzen et al., 2000; Pipe, 2001).  
A prospective study by Farb et al. (2003) suggested an auto-triggered elliptic-centric-ordered 
three-dimensional gadolinium enhanced MR venography (ATECO MRV) to evaluate the 
cerebral venous outflow of patients with PTC in combination with a novel scoring system. 
They found substantial bilateral sinovenous stenoses in 27 out of 29 (93%) patients with PTC 
compared to only 4 out of 59 in the controls and concluded that using ATECO MRV and a 
novel grading system for quantifying sinovenous stenoses, the authors could identify PTC 
patients with a sensitivity and specificity of 93%. 
Higgins et al. (Higgins et al., 2004) described a distinctive pattern in the signal phase of 
contrast MRV in PTC patients. They found "signal gaps" in both lateral sinuses of PTC 
patients, unobserved in their control group. These "signal gaps" may indicate that flow 
velocities over that specific segment are outside the range prescribed in their study.  
This finding does not necessarily mean that a thrombus is present nor does it inevitably 
indicate that abnormal arachnoid granulations might have caused a local alteration of blood 
flow. However, it does raise the possibility of stenosis or occlusion. 
Higgins et al. (2002) reported the first patient with refractory PTC and transverse sinus 
stenosis treated with a stent.  Direct cerebral venography and manometry confirmed the 
presence of stenoses with raised pressure, proximal to the obstructions. Dilation of one of 
the sinuses with a stent reduced the pressure gradient with dramatic symptomatic 
improvement. 
Current evidence (Higgins et al., 2003; Metellus et al.; Ogungbo et al., 2003; 2005; Rajpal et 
al., 2005) suggests that selected patients with PTC may benefit from a transverse sinus (TS) 
stent. Restoring the patency of stenotic TSs with a stent in patients with refractory IIH 
resulted in a resolution or significant improvement in headache and papilledema. 
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11.4 CT and CTV  
Neuroimaging utilizing CT offers rapid image acquisition, wide availability and excellent 
spatial resolution.  The speed and ability of a CT to detect acute blood or bone abnormality 
makes this technique very valuable in traumatic cases. 
Due to the rise in availability of MRI and MRV during the past few decades, and their 
known advantages over CT scans, the use of a CT as a neuroimaging tool in diagnosing PTC 
patients has lessened over the years.  Current studies in the literature are focusing mainly on 
MRI and MRV findings in neuroimaging rather the CT.  
Almost 25 years ago, Jinkins (1987) first reported on the reversal of the optic nerve head in a 
variety of conditions associated with increased intracranial pressure, including 
pseudotumor cerebri. Enlarged optic nerve sheaths have also been observed in patients with 
pseudotumor cerebri. Weisberg (1985) found that 2/28 patients had enlarged optic nerves, 
although no measurements were provided and no control values were available. Six out of 
28 patients were described as having a “small-sized ventricular system.” These 
examinations were performed on a second-generation CT scanner, without controls and in a 
non-blinded manner. 
Almost two decades ago, Gibby et al. (1993) published a paper on CT findings in their PTC 
patients. The purpose of their study was to evaluate and compare orbital and cerebral CT 
findings in PTC patients with those of age and sex matched controls. Ventricular size in both 
groups was evaluated.  Their findings matched Huckman et al’s (1976) who found no 
differences between ventricular sizes of patients with pseudotumor cerebri and those of a 
control population. 
Empty sellae have been associated with many conditions causing increased intracranial 
pressure. Gibby et al. in 1993 observed empty sellae in 5% of 788 autopsies (Kesler et al., 
2001). In the PTC group, 16 (94%) out of 17 patients had at least partial empty sella. The 
degree of empty sellae was significantly greater than in the controls. The high prevalence 
noted in patients with pseudotumor cerebri is compatible with their chronic elevated 
intracranial pressure, which averaged 370 mm H2O. CT angiography uses a high speed 
spiral scanner, providing excellent vessel resolution with a 3-dimensional capability, 
comparable to an MRA. The technique requires iodinated dye and ionizing radiation and 
takes approximately 15 minutes. Sensitivities in detecting aneurysms >3mm or stenosis 
>70% are approximately 95%. Some centers prefer the use of a CTA over an MRA in 
identifying cerebral aneurysms, including those causing ocular motor cranial nerve palsies. 
11.5 Visual field perimetry 
Visual field testing by either automated Humphrey static or manual Goldmann perimetry 
reveals enlargement of the physiological blind spot in virtually all patients with PTC. Other 
common visual field defects include inferonasal loss and generalized constriction of the 
fields. Central defects, arcuate and altitudinal defects may occur but are highly unlikely.  
However, if found, a search is warranted for another cause, unless a large serous retinal 
detachment from a high-grade optic edema, spreading to the macula area, is found. 
Almost all PTC patients suffer from some type of visual field loss over time. In prospective 
(Wall & George, 1987; Wall & George, 1991) studies of patients with PTC, visual field loss in 
at least 1 eye (other than an enlargement of the blind spot due to the edematous optic nerve) 
was found in 96% of patients using a Goldmann perimetry, a disease specific strategy and in 
92% with automated perimetry. Approximately one third of this visual field loss was mild 
and was usually not noticed by the patient (Wall & George, 1991). 
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Wall et al’s study (1991) showed that with treatment, about 50% of patients experience a 
significant visual field improvement. They further demonstrated that the only subgroup of 
patients who had a worsening of their visual fields were those with a recent weight gain. 
This was the only factor significantly associated with a decline in vision. 
11.6 Ultrasound of optic nerve  
Ultrasound has been used to identify intracranial hypertension by measuring the optic 
nerve sheath diameter. The modality is extremely safe and does not have any 
contraindications for use, except for ocular globe injuries (Munk et al., 1991). In most 
modern medical facilities, multipurpose ultrasound units with high-frequency transducers 
(>7.5 MHz) provide high lateral and axial precision (Berges et al., 2006). 
Hayreh (1964) in an experimental study of monkeys and humans showed that the 
subarachnoid spaces surrounding the optic nerve is in continuity with the intracranial 
cavity, and therefore changes in cerebrospinal fluid pressure may be transmitted along the 
optic nerve sheath (Hayreh, 1964). The retrobulbar enlarged optic nerve sheath can therefore 
inflate as a consequence of raised pressure in the cerebrospinal fluid. 
It has been confirmed that the optic nerve sheath diameter (ONSD) increases in patients 
with intracranial hypertension (Blaivas et al., 2005; Geeraerts et al., 2007; Girisgin et al., 2007; 
Karakitsos et al., 2006; Malayeri et al., 2005; Munk et al., 1991; Salgarello et al., 1996; Stone, 
2009). ONSD alterations are correlated with head CT scan results in brain injured adults 
(Karakitsos et al., 2006) as well as with the invasive and noninvasive measurements of the 
ICP (Soldatos et al., 2008). 
During US evaluation, it is important to perform a 30 test to evaluate excess of fluids within 
the arachnoid sheaths of the optic nerve. The patient is asked to turn approximately 30 
toward the probe placed temporally on the globe. The measurements in abduction are 
compared with the measurements at the primary position. If fluid excess is present, the 
diameter at 30 will be smaller than that found in the primary position. 
11.7 Optical coherence tomography (OCT) 
OCT is a non-invasive imaging technique yielding high-resolution, cross-sectional images of 
the retina. More importantly, it is a valuable modality used to identify the status of the 
retinal nerve fiber layer as well as to measure macular thickness. The technique is 
principally based on measuring the time required for light to reflect from the tissue to an 
external detector (i.e. “echo time delay”). Duration of time and intensity of the backscattered 
light corresponds directly to the depth and density of the tissue being imaged. OCT 
produces in vivo cross-sections which can be serially acquired (in thin sections) in order to 
obtain tomographic images (Schuman et al., 2004). 
The principles underlying OCT are similar to those of ultrasound imaging, except that light 
is utilized instead of sound. The axial resolution of OCT images is at least 1-2 orders of 
magnitude greater than those of ultrasound. OCT images of the retina provide a spatial 
resolution as low as 3-5 microns (Huang et al., 1991; Schuman et al., 2004). 
Currently, two main types of OCT are utilized in practice: the time-domain, employing 
low-coherence interferometry for imaging tissue structures, and the spectral-domain OCT. 
Spectral-domain imaging provides faster and more spatially detailed images than the 
time-domain method. In addition, spectral domain OCT allows for imaging at a speed of 
18,000 to approximately 40,000 A-scans per second, fast enough to eliminate artifacts from 
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eye movements. It also provides a greater resolution of the retina with subsequent better 
visualization of the laminar structure and clarification of details at the cellular level 
within the nuclear layers (Choi et al., 2008). Several reports have also described 
particularly good reproducibility of RNFL and optic disc measurements with the newer 
spectral-domain technique (Gonzalez-Garcia, et al., 2009; Leung et al., 2009; Menke et al., 
2008). 
Computer-aided image processing algorithms have been developed to estimate NFL 
thickness from circumpapillary OCT images acquired in cylindrical sections surrounding 
the optic disc. A circumpapillary scan pattern of a typically ¾ mm diameter is used, because 
it effectively intercepts all nerve fibers originating from the optic disc, thus enabling a 
quantitative measurement of the circumferential variations in NFL thickness around the 
optic disc as well as  visualization of the nerve fiber bundles. 
Studies have demonstrated the effectiveness of time-domain OCT in providing a 
quantitative measure of the severity of disease, response to treatment and follow up 
monitoring of patients with PTC (Ophir et al., 2005; Rebolleda & Munoz-Negrete, 2009). 
RNFL thickness decreased correspondingly, with the improvement recorded at the patients' 
clinical evaluation. The study outcomes provided a basis for using OCT to predict which 
patients would ultimately fare better in terms of visual functional status (Rebolleda & 
Munoz-Negrete, 2009). 
Precise measurements obtained with OCT allow the physician to more accurately evaluate 
the treatment effect than the subjective interpretation of the funduscopic appearance of the 
optic nerve heads. Recently, studies have emphasized the importance of viewing the macula 
in these patients. Hoye et al. (2001) evaluated the detection and monitoring of sub-retinal 
fluids extending from the optic nerve head to the macula in patients with papilledema. The 
authors found that the fluids accounted for the reduced visual acuity in 7 out of 55 patients, 
and when the volume of sub-retinal fluids decreased, an improvement in the visual acuity 
function was noted. 
Future OCT assessment of papilledema will be evaluating the total optic nerve head disc 
volume and maximal optic nerve head height, as these measures potentially correlate with 
the response to medication and ultimate visual outcome. At present, clinical evaluation of 
the optic nerve head volume, better reflects the overall degree of optic nerve head edema 
rather than the thickness of the RNFL alone, since volume measurement incorporates the 
volume of both the total optic nerve height and the sub-retinal hypo reflective space. 
(Johnson et al., 2009).  
11.8 Fluorescein angiography 
Fluorescein angiography was initially developed as a tool for studying retinal vascular flow 
characteristics. Extensive use of fluorescein angiography and technique refinement has 
allowed the clinician and researcher to better understand the pathophysiologic and 
histopathologic changes of fundus disease in vivo. Fluorescein angiography may aid the 
clinician in accurately diagnosing papilledema by the appreciation of leakage or late 
hyperfluorescence surrounding the optic disc. Blocked hypofluorescence may be noted at 
the optic nerve head during papilledema as a result of bleeding, which is present at the level 
of the neurosensory retina, blocking the fluorescence from the underlying choroid (Rabb et 
al., 1978).  
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12. Management   
There are nonsurgical and surgical approaches to PTC, decisions based on symptomatology 
and visual function status. If a headache is controlled by common analgesics and no optic 
nerve dysfunction is observed, therapy may not be required. Asymptomatic patients with 
preserved vision and minimal papilledema warrant only frequent follow-ups as well as 
monitoring disc swelling and visual function, including visual fields (Nonne, 1904).  
12.1 Medical (nonsurgical) approach 
Acetazolamide, a carbonic anhydrase inhibitor that decreases CSF production by the 
choroid plexus, is generally accepted as first-line medication, although its efficacy has not 
been proven in prospective trials. Based on our experience, a starting regimen of 
acetazolamide 500 mg, orally two or three times per day, is preferred. The dose can be 
increased to a total of 3 grams per day, if necessary. Major side effects include diuresis, loss 
of appetite, abnormal taste (metallic taste with carbonated beverages) paresthesias of the 
lips, fingers and toes, malaise, renal colic and metabolic acidosis (Corbett et al., 1982). Most 
of these side effects resolve with potassium and magnesium-rich dietary supplements such 
as bananas and oranges. Severe adverse effects experienced with acetazolamide treatment 
include acute tubular necrosis, hepatic dysfunction, and aplastic anemia. 
Teratogenic effects in animals such as limb malformations and cortical dysgenesis have been 
reported (Quincke, 1893). Although sacrococcygeal teratoma in neonates (Tibussek et al., 
2010) have been documented in the past, there is little clinical or experimental evidence to 
support any adverse effect of the drug on pregnancy outcome in humans (Spence  et al., 
1980). If acetazolamide fails, topiramate, an anti-epileptic drug, may be used. Its therapeutic 
effects are due to its carbonic anhydrase inhibitory properties. The drug is particularly 
useful as a prophylaxis for headaches, appetite suppression and weight loss (Nonne, 1904). 
The dose should be built up slowly over weeks (25 mg/week) in order to reduce the risk of 
cognitive side effects. It is of utmost importance to regularly check the intraocular pressure 
(IOP) of patients undergoing this treatment, as elevation of IOP is a known side effect of 
topamax. 
Short-term oral corticosteroids may be considered as a treatment option in patients 
presenting with severe headaches, marked papilledema, and very high intracranial 
pressure. High doses of intravenous corticosteroid treatment may occasionally be 
administered when there is rapidly progressive vision loss or while the patient awaits 
surgery (Mathews et al., 2003). 
Treatment medication is usually given over a long period of time. ICP-lowering agents may 
be tapered and eventually discontinued when the patient’s visual status and optic nerve 
appearance have improved and stabilized. Patients should be periodically monitored post 
treatment, since recurrences are common. If symptoms reoccur, reinstitution of medications 
is usually indicated (Friedman & Jacobson, 2004).  
Weight loss is a crucial part of the treatment program, as even moderately obese patients 
may significantly benefit from a sensible diet and exercise program (Mathews et al., 2003).  
Medications known as associated risk factors for pseudotumor syndromes, such as vitamin 
A, vitamin A derivatives, and tetracycline should be discontinued if possible. 
12.2 Lumbar puncture 
In the past, repeated lumbar punctures were an acceptable treatment modality due to 
improvement of symptoms after the procedure. Nowadays, this type of treatment approach 
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is less acceptable. Currently, lumbar puncture may be indicated in pregnant women or 
when the clinical picture points to rapidly declining vision, thus temporarily lowering the 
CSF pressure while planning a more aggressive treatment (Friedman & Jacobson, 2004). In 
the past serial lumbar punctures (e.g., twice weekly) have been proposed as an alternative to 
surgery for patients with papilledema, when the disease cannot be controlled medically. 
Complications of the procedure such as infection, tonsillar herniation, radiculopathy, and 
arachnoiditis are rare. 
12.3 Surgical approach 
The most frequent and accepted indication for surgery is a progressive loss of vision despite 
maximal medical therapy. Surgery should be carried out as soon as a visual field defect 
worsens or remains unimproved despite maximal treatment. Medical treatment fails in 
approximately 18% to 22% of patients with PTC (Burgett et al., 1997; Corbett & Thompson, 
1989; Lorberboym et al., 2001; Lueck & McIlwaine, 2002; Pearson et al., 1991). According to 
Friedman et al (2004), ophthalmological indications for surgical intervention are severe or 
rapid visual loss at onset (“malignant IIH”), severe papilledema causing macular edema or 
exudates without improvement while undergoing medical treatment. Even if there is no 
consensus among the specialists (Friedman & Jacobson, 2004), surgery should be considered 
in the management of intractable headaches (Binder et al., 2004; Mathews et al., 2003). 
Surgical treatment options include optic nerve sheath fenestration (ONSF) and CSF 
diversion procedures. A CSF shunt reduces intracranial hypertension, whereas ONSF 
focuses on protecting the vulnerable optic nerve head. 
12.4 Optic nerve sheath decompression (ONSD) 
The mechanism by which ONSD works has not been clarified, but several theories have 
been suggested. Keltner (1988) suggests that it may provide a filtering effect, with a 
subsequent decrease in the local CSF pressure, improvement of the peripapillary circulation 
(Keltner, 1988), or produce a generalized decrease in ICP. According to another hypothesis, 
the scarring of the arachnoid by the procedure itself may protect the nerve head from 
elevated CSF pressure (Friedman & Jacobson, 2004). Technically, ONSD is performed by 
uncovering the optic nerve sheath through a lateral orbitotomy or through a medial 
approach via a transconjunctival incision. Multiple linear incisions are made or a window is 
cut into the anterior dural that covers the optic nerve sheath, creating a CSF drainage outlet 
(Mathews et al., 2003). 
The overall complication rate of ONSD ranges from 4.8% to 45% (151,165,166,167,168), the 
most common being extraocular motility problems due to lateral rectus palsy which is 
usually transient, and papillary abnormalities. Other complications may include long-term 
and transient blindness due to ischemic injury to the optic nerve, orbital hemorrhage, visual 
field defects and globe perforation (Friedman & Jacobson, 2004). In the majority of patients, 
post-ONSD vision stabilizes or improves in the long-term, but as many as 32% of operated 
eyes may experience deterioration following initially successful surgery (McHenry & Spoor, 
1993). A reoperation can be performed, but based on clinical experience, a shunting 
procedure is recommended in these cases.  
12.5 Lumbar peritoneal shunt (L-P shunt) 
Although an L-P shunt is considered an effective procedure, failure and low pressure-
related headaches are common. Shunts may be efficiently placed in the lumbar cistern, 
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cisterna magna, or the ventricles. The lumboperitoneal (L-P) technique has traditionally 
been the method of choice in PTC. 
A review of the literature Binder et al (2004) found that the efficacy of L-P shunting is 
maintained as long as the shunt remains patent. The failure rate for LP shunts range from 
38% to 64% (Burgett et al., 1997; Gupta et al., 2007; Johnston et al., 1988). Major causes 
include catheter obstruction, over-shunting (low pressure headaches), catheter migration, 
and lumbar radiculopathy. 
12.6 Ventriculoperitoneal (V-P) shunts 
A V-P shunt is difficult to perform due to relatively small or normal ventricle size.  
However, this technique is becoming increasingly popular in treating PTC (Binder et al., 
2004; Maher et al., 2001; Tulipan et al., 1998).  
In the long-term, V-P shunts offer advantages compared to the L-P shunt method, especially 
with regard to shunt revision (Kang, 2000; Maher et al., 2001). The procedure does not 
present the risk of inducing a Chiari I malformation, and may be less likely to over-drain. 
A wider range of shunts are available for the V-P route. Usually, PTC patients benefit from 
relatively high-pressure valves (possibly with an antisiphon system to limit over-drainage), 
which are able to retain sufficient intracranial CSF to compensate the changing intracranial 
volume conditions and limit the collapse of the ventricular system around the shunt 
catheter. Flow-regulated valves have also been proposed (Garton, 2004). 
12.7 Subtemporal decompression 
The first neurosurgical technique to treat PTC patients, by a subtemporal decompression, 
was performed in 1937 (Dandy, 1937). Dandy performed a unilateral subtemporal 
craniectomy with excellent initial results in alleviating headaches and preventing visual loss. 
The long-term efficacy of the procedure was uncertain, since a high rate of morbidity and 
complications were reported, including seizures, infections, focal brain damage, cosmetic 
disfigurement, intracranial hematomas, and further visual deterioration (Binder et al., 2004). 
After introducing stenting procedures for treating IIH, this procedure became obsolete; 
nonetheless, subtemporal decompression is still an option, when other surgical methods 
have failed.    
12.8 Endovascular stenting 
It is highly controversial whether venous sinus narrowing is the cause or the result of 
elevated intracranial pressure. Based on the frequent findings in MRI venography of 
narrowed transverse sinuses, endovascular stenting of the venous sinuses has been recently 
advocated by some authors (Higgins et al., 2002; Higgins et al., 2003; Metellus et al., 2005; 
Metellus et al., 2007; Donnet et al., 2008; Paquet et al., 2008).  
Higgins et al (2002) was the first to report on a 30 year old patient with refractory PTC, 
papilledema and bilateral TS stenosis found on an MR venogram, that was successfully 
treated with dilation of 1 of the sinuses with a stent, thus reducing the pressure gradient 
with dramatic symptomatic improvement. 
As of today, only about 40 patients with PTC, treated with sinovenous stent placement, have 
been reported in the literature. Most were women aged 15-65, symptomatic with PTC for 2 
weeks to 15 years. After stent placement, 33 out of the 40 (82.5%), reported a significant 
improvement in their headaches. Papilledema improved or resolved in 30 out of 33 (91%) 
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patients who presented with active papilledema. Although the promising initial results of 
long term efficiency of the procedure still needs to be proven, further investigation is still 
warranted to prove the procedure as a useful treatment technique. 
12.9 Pregnancy and PTC  
Current reports suggest that pregnant patients with PTC can be safely managed similarly to 
nonpregnant patients with PTC.  No increase in the rate of spontaneous abortion or fetal 
wastage has been reported. A therapeutic abortion to limit the progression of the disease is 
not indicated. (Tang et al., 2004).  
Acetazolamide had previously been considered as the preferred therapy after 20 weeks of 
gestation, since sacrococcygeal teratoma was reported with earlier use (Digre et al., 1984). A 
recent report of 12 women treated with acetazolamide for PTC during pregnancy, showed 
no adverse pregnancy outcomes in terms of fetal loss or congenital malformation. 
Acetazolamide at high doses may produce birth defects in animals, but there is little clinical 
or experimental evidence to support any adverse effect on pregnancy outcome in humans. If 
the clinical situation mandates acetazolamide use in PTC, the drug can be offered after 
appropriate informed consent (Lee et al., 20050).  Management of labor and indications for 
cesarean delivery for a parturient with PTC are controversial. Regular labor may be allowed 
with a cesarean delivery reserved for obstetric indications. 
13. Natural history and visual prognosis 
The natural history of PTC is unknown. In some cases, it is a self-limited condition, while in 
others ICP may remain elevated for many years even if systemic and visual symptoms 
resolve. In some patients, the process may last from months to years. Individuals with mild 
to moderate visual loss tend to recover vision following medical therapy. Papilledema 
usually resolves after a few weeks or months, but many patients are left with some residual 
disc elevation, especially nasally. Severe visual impairment may be a serious and permanent 
complication of PTC. PTC produces significant visual impairment in approximately 25% of 
patients. The risk of visual loss in the pediatric PTC population is similar to that of adults 
(Corbett & Thompson, 1989). Recurrent symptoms have been reported in 8 to 37% of 
patients, years after being diagnosed (Corbett & Thompson, 1989). Visual deterioration in 
PTC patients is usually gradual, but in cases of fulminant papilledema, blindness may 
appear rather quickly. In Corbett et al’s (1989)  follow up study of 5 - 41 years after the initial 
diagnosis of 57 patients, revealed severe visual impairment in 14 patients (24.6%). In Kesler 
et al's experience (2004), recurrence was frequently associated with weight gain. The long-
term prognosis and visual outcome of 54 patients with IIH was observed over a period of 6.2 
years. The results showed that recurrences occurred in almost 40% of the cases. None of 
these exacerbations occurred during the first 10 months, and none occurred while the 
patients continued treatment.  
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1. Introduction 
Idiopathic Parkinson’s disease (IPD), first described by James Parkinson in 1817, is a 
sporadic neurodegenerative disorder. The main clinical features include masked face, 
resting tremor, bradykinesia, rigidity, festinating gait, and loss of postural reflexes. The 
clinical features are most insidious and usually asymmetric at onset. The asymmetry may 
persist even in a late stage and progress slowly. The pathological findings are characterized 
by loss of pigmented dopamine neurons in the substantia nigra, particularly the pars 
compacta and locus ceruleus, and the presence of Lewy bodies. The cause of IPD remains 
unknown. 
Parkinsonism (PM) is not a single disease but a common clinical presentation. The clinical 
syndrome is characterized by tremors, bradykinesia, rigidity, and postural instability. 
Exposure to toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which 
was sold as “synthetic heroin,” manganese (Mn), carbon disulfide (CS2), carbon monoxide 
(CO), methanol, cyanide, and other organic solvents may cause brain damage, leading to 
features similar to PM. Many neurodegenerative disorders may present with PM, including 
progressive supranuclear palsy (PSP), multiple system atrophy (MSA), spinocerebellar 
atrophy (SCA), and corticobasal sundrome (CBS). Several genetic diseases, including dopa-
responsive dystonia (DRD), Wilson’s disease (WD), and Huntington’s disease (HD), may 
cause degeneration in the basal ganglia or affect the dopaminergic pathway. Furthermore, 
some dementia syndromes may be associated with PM, including vascular parkinsonism 
(multiple infarct parkinsonism), dementia with Lewy bodies (DLB), and frontotemporal 
dementia, and parkinsonism linked to chromosome 17 (FTD-17).  
The main treatment of IPD includes the use of dopamine, dopamine agonists, monoamine 
oxidase inhibitors, and catechol-o-methyltransferase inhibitors. The above medications are 
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usually effective in IPD patients, whereas their effects are usually limited in patients with 
secondary parkinsonism. Although definite diagnosis of IPD is based on typical 
pathological findings, early diagnosis is very important as it leads to early treatment. 
IPD and PM are distinguished on the basis of the onset of symptoms, symmetry of clinical 
features, characteristics of tremors, rigidity, bradykinesia, and other associated symptoms, 
such as cognitive impairment, limitation of eye ball movement, ataxia, and autonomic 
dysfunction. In addition, information concerning family history, smoking and alcohol 
exposure, diabetes with hypertension, and exposure to toxic substances are also essential for 
diagnosis. Despite differences in the clinical features of IPD and PM, definite diagnosis may 
be difficult; therefore, reliable imaging is helpful for early and accurate diagnosis. 
2. Dopamine transporter (DAT) scan 
Dopamine transport is one of the primary mechanisms that can modulate the dopaminergic 
tone via an active transport system that involves the re-uptake of dopamine. Cocaine 
analogues including (1r) 2-carbomethoxy-3-(4-iodophenyl) tropane (-CIT), and 123I-FP-
CIT have been developed as single photon emission computed tomography (SPECT) 
imaging agents. Both agents can bind at the DAT site of dopamine neuron terminals in 
normal human subjects and IPD patients. In addition, 99mTc-TRODAT-1 is a promising 
99mTc-labelled radiotracer for imaging DAT in the human brain. Since a cyclotron and well-
trained radiochemists are required for clinical usage of 123I--CIT and 123I-FP-CIT SPECT, 
they are more difficult to use in clinical settings. 99mTc-TRODAT-1 is much easier to prepare 
and can be made in many nuclear medicine departments. Previous studies have shown that 
99mTc-TRODAT-1 is very reliable in detecting dopamine neurons in the striatum; therefore, it 
is an important tool for understanding the role of DAT in various neurological diseases. 
3. DAT scan in IPD 
Similar to 123I--CIT and 123I-FP-CIT, 99mTc-TRODAT-1 activity in the basal ganglia can 
demonstrate a stable target/non-target ratio, and at a reduced level in IPD patients than in 
healthy volunteers. Serial 99mTc-TRODAT-1 SPECT images taken 2, 3, and 4 h after injection 
of 925 MBq 99mTc-TRODAT into healthy volunteers show a consistent increase of the uptake 
with time. Furthermore, the relative concentration of 99mTc-TRODAT-1 in the basal ganglia 
regions decreases significantly with age in healthy volunteers. The rate of decline is 
significantly faster in young individuals than in the elderly. The effect seems to occur during 
young adulthood, particularly in individuals younger than 40 years. The putamen/occipital 
and caudate/occipital ratios show a statistically significant difference between IPD patients 
and healthy volunteers. 
4. Secondary parkinsonism 
4.1 Toxin-induced PM 
4.1.1 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
MPTP is a byproduct of a meperidine analogue, 1-methyl-4-proprion-oxypeperidine 
(MPPP), which is a synthetic heroin. Injection of the contaminated synthetic drug may cause 
the victims to develop acute severe parkinsonian features such as bradykinesia and severe 
rigidity in about 7 days. Since its discovery, MPTP has been used in animal models of 
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parkinsonism, which is responsive to dopamine and dopamine agonist treatment. Although 
dementia and autonomic dysfunction, typical dyskinesia, prominent wearing off 
phenomena, and psychiatric impairments in MPTP victims occur more rapidly than in 
subjects with IPD, the clinical features of these individuals are indistinguishable from those 
of IPD patients. The MPTP toxin may damage the dopamine neurons in the substantia nigra 
via 1-methyl-4-phenyl-pyridinium (MPP+), a metabolite of MPTP, that may inhibit the 
production of ATP and stimulate the formation of superoxide radicals. The neurotoxic effect 
of MPTP is permanent, even though the patients have an excellent response to levodopa 
treatment. 6F-Dopa positron emission tomography (PET) of the brain showed that a 
subclinical exposure to MPTP might result in a reduction of fluorodopa uptake in the 
striatum. In some experimental studies that used brain SPECT, 99m Tc-TRODAT-1 binding 
was significantly lower in the MPTP-treated monkeys than in the control monkeys. 
4.1.2 Manganese (Mn) intoxication 
Chronic exposure to manganese may induce parkinsonism similar to IPD. However, the 
clinical features of manganism, including lower body parkinsonism, frequent gait 
disturbance (particularly cock gait), increased dystonia, and reduced action tremor, also 
differ from IPD. In addition, in Mn-induced PM, a reduced response to anti-parkinsonian 
drugs, gait-freezing during turns, and difficulty in walking backwards were also noted. 
Although relative symmetry was noted, clinical asymmetry was also reported. Unlike 
patients with multiple system atrophy, patients with manganism did not show postural 
hypotension, sexual dysfunction, and sphincter disturbance. 
Brain magnetic resonance imaging (MRI) is a promising technique to demonstrate the 
presence of manganese in the brain. T1-weighted MR images showed an increased intensity 
in the globus pallidus area of welders, smelters, patients undergoing parenteral nutrition, 
and in patients with hepatic failure. However, the increase in signal intensity in T1-
weighted MR images only indicates an exposure to manganese in recent months but does 
not indicate manganism. 
Previous PET scans with 6-FD had shown a normal nigrostriatal dopaminergic uptake in the 
caudate or putamen in manganism patients. In addition, brain PET scans with raclopride 
showed a mild decrease (less than 20%) of caudate dopamine D2 receptors. However, the 
minimal decrease of D2 receptor density could not account for the prominent clinical 
features in manganese intoxication patients. 
Both 6-FD PET and DAT are sensitive detectors for dopamine neurons. In a previous study, 
DAT density with 123I--CIT SPECT was decreased in PM patients with manganese 
exposure. However, these findings seemed to be more consistent with IPD than with Mn-
induced parkinsonism. The brain 99mTc-TRODAT-1 SPECT showed no significant changes in 
the putamen and the putamen/caudate ratio of manganism patients and normal controls. 
However, a statistically significant decrease was noted in the uptake of 99mTc-TRODAT-1 in 
the putamen area of IPD patients than in the manganism patients. Figure 1 shows the DAT 
findings in a manganism patient, an IPD patient, and a normal control. The data indicate 
that presynaptic dopaminergic terminals are not the main targets of chronic manganese 
intoxication. Pathologic changes in monkeys after manganese chloride injection included 
prominent gliosis in the globus pallidus and in the substantia nigra pars reticularis that 
differs from the target lesion-substantia nigra pars compacta in IPD.  
 




Fig. 1. The uptakes of 99mTc -TRODAT-1 brain SPECT were decreased in the corpus striatum 
particularly in the left side in a PD patient (A), and nearly normal in a patient with chronic 
manganism (B) and a normal control (C). r=right. 
4.1.3 Carbon disulfide (CS2) intoxication 
CS2 is a colorless liquid organic solvent frequently used in the production of viscose rayon 
fibers and cellophane films. Acute exposure to CS2 may cause psychosis, delirium, seizures,  
 
 
Fig. 2. Normal DAT bindings with 99mTc -TRODAT-1 brain SPECT were noted in 2 
patients with CS2 intoxication (A), and (B) but a decreased DAT binding in another 
patient who had IPD with CS2 exposure (C), as compared with those of a normal control 
(D) and a PD patient (E). r=right. 
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and even death. Chronic exposure to CS2 manifests as a diffuse encephalopathy including 
parkinsonism, intention tremor, emotional lability, and neurobehavioral disorders as well 
as polyneuropathy. Brain MRI may reveal diffuse hyperintense lesions in T2-weighted 
images in the subcortical white matter, basal ganglia, and brainstem. A brain CT 
perfusion study showed a decrease of regional cerebral flow and prolonged regional 
mean transit time in the subcortical white matter and the basal ganglia. The diffuse white 
matter lesions are better explained by vascular insufficiency than demyelination. In CS2 
intoxicated patients with parkinsonism, brain 99mTc-TRODAT-1 SPECT showed a normal 
uptake of the dopamine transporter, indicating a normal presynaptic dopaminergic 
pathway (Figure 2). Therefore, CS2 intoxication-induced parkinsonism is probably due to 
post-synaptic lesions in the basal ganglia rather than the presynaptic dopaminergic 
pathway. 
4.1.4 Carbon monoxide (CO) intoxication 
Acute CO intoxication may induce hypoxic changes in the brain with variable degree of 
consciousness disturbance from confusion, delirium, and stupor to deep coma. Most 
patients recover after appropriate oxygen therapy; however, sequelae such as dystonia 
and cognitive impairment may persist. Approximately 0.2–40% of survivors developed 
delayed encephalopathy within 2 months. The common manifestations include cognitive 
changes, sphincter disturbance, akinetic mutism, and parkinsonian features. Brain MRI 
studies showed hyperintense lesions in the basal ganglia, particularly in the globus 
pallidus and subcortical white matter. A steady improvement was found after 1–2 years of 
supportive therapy; however, residual parkinsonism may develop in some patients. 
Moreover, a poor response to levodopa is noted. Brain 99mTc-TRODAT-1 may show a 
normal uptake in the basal ganglia, indicating that the presynaptic pathway of the 
nigrostriatral system is normal.  
4.1.5 Others: Methanol and cyanide 
Acute intoxication with methanol may cause metabolic acidosis and severe anionic gaps, 
leading to blindness and parkinsonism including masked face, rigidity, bradykinesia, gait 
disturbance, and dystonia. Brain MRI may show damage in the bilateral putaminal areas. 
Acute cyanide intoxication may also cause parkinsonism such as hypomimia, rigidity, and 
gait disturbance within a few days, and subsequent dystonia and dementia. The response to 
levodopa therapy is usually disappointing. Table 1 summarizes the clinical features and 
DAT findings in toxin-induced PM. 
4.2 Other neurodegenerative parkinsonian syndromes  
4.2.1 Progressive supranuclear palsy (PSP) 
PSP, first described in the early 1900s, is a devastating neurodegenerative disease. In 1963, 
Steele, Richardson, and Olszewski reported a series of patients with pathologically 
confirmed heterogeneous system degeneration. The syndrome is characterized by 
parkinsonism, axial rigidity, frequent falls, vertical gaze palsy, pseudobulbar palsy, and 
dementia. In addition, atypical features include asymmetrical parkinsonism, dystonia, 
tremor, apraxia, and pure akinesia. The pathological changes include neuronal loss, 
neurofibrillary tangles, and gliosis in the basal ganglia, brainstem, and cerebral cortex. The 
response to levodopa treatment for parkinsonian symptoms is usually poor. The most 
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common subtypes of PSP syndrome include Richardson’s syndrome (RS) and progressive 
supranuclear palsy-parkinsonism (PSP-P). The clinical features of RS are similar to the 
classic type of PSP, whereas PSP-P has features similar to IPD, such as asymmetric onset of 
symptoms, tremor, and initial response to levodopa. 
 
 MPTP Mn CS2 CO Methanol 
Clinical features       
Parkinsonism + + + + + 
 Rigidity + + + + + 
 Tremor + Less - - - 
 Bradykinesia + + + + + 
 Loss of postural 
reflex 
+ + + + + 
 Mental disorders + + + + + 
 Cerebellar sign - Less + - - 
 Polyneuropathy - - + - - 
 Autonomic 
dysfunction 
+ + + - - 
Neuroimaging       
















N N N NA 
 Prognosis Permanent Deterioration Poor Partial 
recovery 
Blindness 
 Response to 
Levodopa  
Good No No No Poor 











+: presence; -: absence; GP: globus pallidus; N: normal; NA: not available 
MPTP: 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine; Mn: manganese; CS2: carbon disulfide; CO: 
carbon monoxide. 
Table 1. Toxins induced secondary parkinsonism 
Dopamine transporter (DAT) scans with 123I--CIT showed a reduction of DAT activities in 
the caudate and putamen areas, particularly the caudate areas in PSP patients. However, the 
dopamine D2 receptor images with IBZM were variable. The inconsistent findings are 
probably because of the grouping of both RS and PSP-P types. In our previous studies with 
Dopamine Transporter Imaging for Distinguishing  
Between Idiopathic Parkinson’s Disease and Secondary Parkinsonism 
 
407 
99mTc-TRODAT-1 scans, the mean striatal uptake was reduced in the RS group than in the 
PSP-P group, even though uptake did not reach statistical significance. The 
putamen/caudate ratios were significantly different between IPD and PSP patients. 
However, there was no difference between RS and PSP-P patients. In the IBZM scan, the 
uptake was significantly reduced in the RS group, but mildly increased in the PSP-P group. 
The data indicate that DAT imaging is helpful to distinguish PSP-P from IPD patients in the 
early stages. DAT activities showed a greater decrease in the RS group than in the PSP-P 
group. In addition, activities of the D2 receptor were reduced in the RS group but not in the 
PSP-P group. 
4.2.2 Multiple system atrophy (MSA) 
Multiple system atrophy (MSA) was originally described as 3 distinct disorders: 
olivopontocerebellar atrophy (OPCA), Shy–Drager syndrome (SDS), and striatonigral 
degeneration (SND). MSA is a sporadic progressive neurodegenerative disease 
characterized by variable degrees of parkinsonism, cerebellar ataxia, and autonomic 
dysfunction. According to the motor dysfunction, MSA can be divided into 2 subtypes: 
parkinsonian type (MSA-P) and cerebellar type (MSA-C). The pathologic changes reveal a 
variable involvement of neuronal loss in the corpus striatum, globus pallidus, substantia 
nigra, locus ceruleus, Edinger–Westphal nucleus, olivary nuclei, cerebellar peduncles, 
cerebellar Purkinje cells, intermediolateral column, and Onuf’s nucleus of the spinal cord. 
The diagnosis of MSA is still based on clinical criteria. The clinical distinction between MSA-
P and IPD is sometimes difficult, particularly in the early stages, because both have a good 
response to levodopa. 
In IPD patients, a severe reduction of DAT uptake in the putamen and relative sparing of 
the caudate nucleus is noted. However, a variable uptake of 6-18F-fluorodopa was noted in 
MSA patients. 99mTc-TRODAT-1-brain SPECT revealed a more symmetrical reduction of the 
striatal binding in MSA-P and MSA-C patients; this was in contrast with the greater 
asymmetric reduction seen in IPD patients. In addition, the reduction of P/O and S/O ratios 
is greater for the MSA-P patients than for the MSA-C patients. P/C ratios showed that MSA-
P and IPD patients have a similar pattern of nigral involvement but that MSA-C patients 
had a different pattern. 
4.2.3 Spinocerebellar degeneration (SCA) 
Hereditary ataxias are a clinically and genetically heterogeneous group of disorders 
transmitted most frequently as autosomal dominant or autosomal recessive traits. Three 
common phenotypes including SCA1, SCA2 and SCA3 (Machado–Joseph disease, MJD) are 
characterized by variable degrees of cerebellar signs, pyramidal dysfunction, anterior horn 
cell involvement, and/or peripheral neuropathy but some patients may develop 
parkinsonian symptoms, which may also respond to levodopa treatment.  
4.2.3.1 SCA1  
The early pictures include cerebellar syndrome and upper motor neuron signs. Later, 
ophthalmoplegia, slow saccades, and a sensory predominant polyneuropathy, amyotrophy, 
chorea, and dystonia may develop. Dysarthria, dysphagia, and cognitive impairment are 
also noted. The gene mutation is an unstable CAG expansion in the ataxin 1 gene on 
chromosome 6p. Brain 99mTc-TRODAT-1 SPECT imaging revealed a decrease of dopamine 
transport in the striatum. 
 




SCA2 has a wider phenotypical spectrum than SCA1. The presence of slow saccades and 
peripheral neuropathy early in the disease may lead to the diagnosis of SCA2. In addition, 
dystonia, levodopa-responsive parkinsonism, and cognitive decline are also noted. The 
mutation is a CAG expansion in the ataxin 2 gene on chromosome 12 with alleles ranging 
from 32–64 (normal, 15–31). 99mTc-TRODAT-1 SPECT of the brain showed a significantly 
asymmetric reduction of the striatal dopamine transporter in these patients; this was similar 
to the finding in IPD patients. The presynaptic impairment of nigrostriatal function is 
probably the reason for levodopa responsiveness. 
4.2.3.3 SCA3 
This is the most prevalent type of spinocerebellar ataxia. The clinical manifestations include 
cerebellar and brainstem signs such as facial and tongue fasciculations or myokymia, with 
facial atrophy, and dysphonia. Non-cerebellar eye signs such as slow saccades, impairment 
in conjugate eyeball movement, ophthalmoparesis, ptosis, eyelid retraction, and 
blepharospasm have also been reported. Dystonia is commonly seen. In addition, the 
parkinsonian features may respond to dopamine therapy. The mutation is an unstable CAG 
expansion in the ataxia 3 gene on chromosome 14 with 53–86 CAG repeats (normal limit < 
47). 99mTc-TRODAT-1 scan of the brain revealed a significant decrease in the uptake of 
tracers in MJD patients than in healthy controls. The decreased uptakes of 99mTc-TRODAT-1 
indicated a defect in the nigrostriatal dopaminergic pathway in symptomatic MJD patients 
with and without extrapyramidal signs. However, the severity of the DAT abnormality did 
not correlate well with the length of the CAG repeat, age at disease onset, or disease 
duration. 
4.2.4 Corticobasal syndrome (CBS) 
Corticobasal syndrome was first described in 1967 in 3 patients who had asymmetric motor 
symptoms with an involvement of frontoparietal atrophy and neuronal loss at autopsy. CBS 
is an adult onset and slowly progressive degeneration with asymmetric akinetic-rigid 
syndrome. A limited response to levodopa treatment is noted in such patients. Some other 
extrapyramidal symptoms include tremor, dystonia, cortical dysfunction, cortical sensory 
impairment, apraxia, and alien hand phenomenon. Brain MRI may show focal cortical 
atrophy, particularly in the parietal lobe. Brain 18F-FDG PET reveals a frequently 
asymmetric hypometabolism in both the cerebral hemispheres. Brain 99mTc-TRODAT SPECT 
reveals an asymmetric involvement in the corpus striatum with equal involvement in both 
caudate and putamen regions.  
The clinical and DAT findings in the above-described neurodegenerative diseases are shown 
in Table 2. 
4.3 Gene-related parkinsonism/dystonia degenerative diseases 
4.3.1 Dopa-responsive dystonia (DRD) 
Dopa-responsive dystonia, also known as Segawa’s disease, is characterized by foot 
dystonia since childhood, diurnal fluctuation, and a dramatic and sustained response to 
low-dosage levodopa. Some patients with DRD may also show adult-onset parkinsonism 
similar to IPD. Pathologic degeneration of dopaminergic nigral cells is found in IPD, 
whereas synthesis defects in dopamine neurons without cell loss are noted in DRD. 
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 PSP MSA SCA CBS 
 RS PSP-P MSA-P MSA-C SCA1 SCA2 SCA3  
Clinical features  
 Parkinsonism  +(sym) +(asym) + + + + + + (asym) 
  Rigidity +(axial) +(axial) + + + + + + (asym) 





  Bradykinesia + + + + + + + - 
  Loss of 
postural reflex + + + + + + + - 
  Akinetic- rigid 
syndrome + - + - - - - + 
  Dystonia +(facial) +(facial) - - + + + + 
  Retrocollis + + -(anticollis) - - - - - 
  Cognitive 
dysfunction + + + - + - - + 
  Alien hand - - - - - - - + 
  Cortical 
sensory 
impairment 
- - - - - - - + 
  Cerebellar sign - - + + + + + - 
  Ataxia - - - + + + + - 
  Slow saccade - - - + + + - 
  Peripheral  
neuropathy - - - - + + - - 
  Autonomic 
dysfunction + + + + - ? ? ? 
  EOM limitation + (VGP) + (VGP) - - + - + - 
  Ptosis - - - - - - + - 
  Fasciculation - - - - - - + - 
     Face - - - - - - + - 
     Tongue - - - - - - + - 
  Dysarthria + + + + + + + - 
  Dysphagia + + + + + + + - 
  Apraxia - - - - - - - + 











  CT/MRI +/+ +/+ +/+ +/+ +/+ +/+ +/+ +/+ 
  DAT uptake D D D (sym) D (sym) D D (asym) D D (asym) 




D NA NA NA D 
 6 FD-PET uptake NA NA D D NA NA NA D (asym) 
+: presence; -: absence; D: decrease; I: increase; sym: symmetrical; asym: asymmetrical; VGP: vertical 
gaze palsy; NA: not available 
Table 2. Clinical features and DAT data in neurodegenerative diseases 
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Molecular genetic studies revealed a mutation in GTP cyclohydrolase 1 (GCH1) in 
autosomal-dominant inherited DRD and mutations in tyrosine hydroxylase (TH) in 
autosomal-recessive inherited DRD. In DRD patients, 18F-Dopa PET reveals normal uptakes 
in the corpus striatum; these findings may distinguish DRD from IPD, which reveals a 
decreased uptake even in the early stage of IPD patients. Dopamine transporter images with 
99mTc-TRODAT-1 SPECT also show a normal uptake in DRD, indicating that presynaptic 
nigrostriatal dopaminergic terminals are normal (Figure 3). 
 
 
Fig. 3. The 99mTc -TRODAT-1 brain SPECT shows a normal uptake in the putamen and 
caudate in a patient with DRD (B) compared with those in a normal control (A) and a PD 
patient (C). A reduction of the uptake in the corpus striatum, particularly in the right side 
was observed in the PD patient. r=right. 
4.3.2 Wilson’s disease (WD) 
Wilson’s disease, hepatolenticular degeneration, is an autosomal recessive disorder 
characterized by a decreased serum concentration of ceruloplasmin, low serum copper 
concentration, and excessive deposition of copper in the liver, brain, and other organs. 
The most common neurological manifestations include akinetic-rigid syndrome, dystonia, 
and cerebellar ataxia with action tremor. Pathologically, the most severely affected lesions 
include the basal ganglia involving the putamen, caudate, and globus pallidus. A brain CT 
scan may show low-density lesions with cystic degeneration in the basal ganglia, 
particularly the putamen and globus pallidus, as well as cortical atrophy and ventricular 
enlargement. Brain MRI reveals increased signal intensities in T2-weighted images of the 
lenticular nuclei, thalamus, and brainstem including the pons, midbrain, and even the 
substantia nigra. Occasionally, double panda signs were found in the brainstem. A poor 
therapeutic response to levodopa is noted in WD patients. However, brain 6F-DOPA PET 
studies have shown an involvement of the nigrostriatal presynaptic dopaminergic pathway. 
In addition, SPECT with 123I-iodobenzamide (123I-IBZM) and PET images with 18F-
methylspiperone have showed a reduction of postsynaptic striatal D2 receptor, reflecting 
striatal neuronal damage. Some DAT studies with 123I--CIT SPECT disclosed a severe or 
differential loss of the DAT in the striatum of WD patients, indicating a presynaptic defect in 
the terminals of the nigrostriatal dopaminergic neurons. However, in some WD patients 
with akinetic-rigid syndrome, a normal presynaptic dopaminergic pathway may occur; 
brain MRI also reveals the involvement of substantia nigra in these patients. (Figure 4). 
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Fig. 4. Demonstration of 99mTc-TRODAT-1 uptake in an age-matched normal control (A), a 
WD patient (B) and a PD patient (C). Normal uptake of 99mTc-TRODAT-1 in the putamen 
and caudate nucleus was noted in a normal control and a WD patient (A and B). In PD 
patient, there was an asymmetrically decreased 99mTc-TRODAT-1 uptake, predominantly in 
the putamen (C). r=right. 
4.3.3 Huntington’s disease (HD, Westphal type) 
Huntington’s disease, the most common cause of hereditary chorea, is an autosomal 
dominant disorder caused by an expansion of an unstable trinucleotide repeat in 
chromosome 4. The most striking feature is the appearance of chorea movements that seem 
purposeless and abrupt. However, some patients may present with the so-called akinetic-
rigid variant form (Westphal variant). This form of the disease is rapidly progressive with a 
fatal outcome in less than 10 years after the onset of symptoms. Brain CT/MRI show 
enlarged ventricles with atrophy of the caudate nucleus. MRI of patients with the a kinetic-
rigid form of the disease may reveal T2 hyperintense lesions in the striatum. FDG-PET may 
show hypometabolism in the caudate and putamen regions.  
The clinical features and neuroimages of DRD, WD, and HD with Westphal variant are 
summarized in Table 3. 
4.4 Dementia syndromes with parkinsonism 
4.4.1 Vascular parkinsonism (VP) or multiple infarct parkinsonism 
Vascular parkinsonism is characterized by clinical symptoms of gait disturbance with 
freezing, lower body parkinsonism, and loss of postural reflexes. Tremor is rarely seen. The 
onset is usually insidious and the course is progressive. Brain MRI usually reveals 
hyperintense T2-weighted signals in the basal ganglia and/or white matter; these findings 
are compatible with those of multiple infarctions. Hypertension is a common risk factor for 
the disorder. A poor or insufficient response to anti-parkinsonian drugs is also noted in 
these patients. Early diagnosis of VP is important because the prognosis and response to 
treatment in these patients are different from those of patients with IPD. However, VP may 
have a wide spectrum of clinical features, which make the differential diagnosis of these 
diseases difficult. A study using DAT with 99mTc-TRODAT-1 showed that specific binding in 
the putamen and caudate areas was slightly lower in VP patients than in healthy 
individuals; however, a significant decrease in the uptake of 99mTc-TRODAT-1 in the 
 
Neuroimaging – Clinical Applications 
 
412 
striatum was noted in IPD patients. A significant striatal asymmetry was observed in IPD 
patients but not in VP patients. 
 
 DRD WD HD (Westphal) 
Clinical features    
Diurnal fluctuation + - - 
Chorea - - + 
Dystonia + + + 
Parkinsonism + + + 
Cerebellar sign - + - 
Cognitive impairment - + + 
Liver dysfunction - + - 
Autonomic dysfunction - + - 
Response to levodopa Excellent Partial No 
Neuroimaging    
CT/MRI N/N Abn/Abn Abn/Abn (caudate 
atrophy) 
DAT-SPECT N Abn NA 
FDG-PET N Abn Abn 
6 FD-PET N Abn NA 
+: presence; -: absence; N: normal; Abn: abnormal; NA: not available 
Table 3. Clinical features and DAT findings in gene- related PM/dystonia degenerative 
diseases  
4.4.2 Dementia with Lewy bodies (DLB) 
DLB is the second most common cause of neurodegenerative dementia after Alzheimer’s 
disease (AD). The diagnostic criteria of DLB were established by the consensus conference 
for DLB in 2005. In the early stage of DLB, deficits in attention, executive function, and 
visuospatial ability are very prominent. The core clinical features include fluctuation of 
cognition, visual hallucination, and spontaneous parkinsonism. Recent suggestive 
features include REM sleep behavioral disorder, severe neuroleptic sensitivity, and low 
dopamine transporter uptake in the basal ganglia on SPECT or PET imaging. Supportive 
features of DLB diagnosis include repeated falls, syncope, transient loss of consciousness, 
autonomic dysfunction, depression, systematized delusions, or hallucinations. In brain 
MRI, atrophy of the cortical or hippocampus is lower in DLB patients than in AD patients. 
In 18F-FDG PET or SPECT, maximal hypometabolism was noted in the parieto-occipital 
area in DLB patients; however, maximal hypoperfusion was noted in the tempo-parietal 
cortex in AD patients. 
Serial DAT with I-123 -CIT brain SPECT also demonstrated progressive striatal 
dopaminergic loss in DLB and Parkinson’s disease with dementia, but not in AD. These 
findings have a high specificity (94%) in distinguishing between DLB and AD. 
A brain DAT with TRODAT-1 SPECT also demonstrated a decreased uptake in the striatum, 
including the putamen and caudate regions, but the DLB patients had relatively symmetric 
lesions and IPD patients had asymmetric lesions. 
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4.4.3 Frontotemporal dementia with parkinsonism-17 (FTDP-17) 
Frontotemporal dementia (FTD) can be divided into 3 major subtypes, including 
frontotemporal lobe dementia (FTLD), semantic dementia (SD), and progressive nonfluent 
aphasia (PNFA). The characteristic behavior changes include disinhibition, social 
withdrawal, diminished insight, loss of empathy, perseverance, and stereotypic behaviors. 
Semantic dementia may present with progressive loss of semantic knowledge, and although 
speech remain fluent, it becomes empty. Semantic dementia usually manifests as a fluent  
  
 VaD DLB FTDP-17 
Clinical features    
Parkinsonism + + + 
Rigidity + + + 
Tremor - - - 
Bradykinesia + + + 
Lose of postural 
reflex + + + 
Language problem + - + 
Focal sign + - + 
Dysarthria + - - 
Dysphagia + - - 
Dementia + + + 
Hallucination + + - 
Cognitive fluctuation - + - 
Personality changes + + + 
Syncope - + - 
Autonomic 
dysfunction - + - 
Response to 
levodopa Poor Poor Poor 
Neuroimages    
  CT/MRI Abn/Abn Abn/Abn Abn/Abn 
DAT-TRODAT Normal Abn NA 
FDG-PET Abn Abn Abn 
6FD-PET NA Abn NA 
+: Presence; -: absence; Abn: abnormal; NA: not available 
Table 4. Clinical features and DAT findings in dementia syndromes 
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dysphasia with impairment in semantic verbal memory and an associative agnosia in 
individuals with more left temporal lobe involvement. Prosopagnosia may occur with right 
temporal damage. Progressive non-fluent aphasia is characterized by aphasia with 
stuttering and agrammatism. The executive function and working memory are usually 
impaired. The typical neuroimaging findings are asymmetrical atrophy of the anterior  
temporal lobe in SD and atrophy of the left inferior frontal lobe and anterior insular cortex 
in PNFA. In addition, there is overlap of clinical manifestations between AD and FTD. These 
3 subtypes of FTD often overlap motor syndromes such as amyotrophic lateral sclerosis 
(ALS) and parkinsonism.  
FTDP-17 is a distinct disease characterized by personality changes, executive dysfunction, 
memory deterioration, and parkinsonism. Motor disturbances include bradykinesia, axial 
and limb rigidity, and postural instability. Early manifestations include behavioral changes 
such as disinhibition, impaired social function, judgment and planning, and global 
dementia. Parkinsonism in FTDP-17 is unresponsive to levodopa. Table 4 summarizes the 
clinical manifestations in vascular parkinsonism, DLB, and FTDP-17. 
5. Conclusion 
The clinical features of IPD and PM are very similar, but some manifestations differ. The 
treatment and prognosis also differ. The response to treatment with levodopa is variable; 
therefore, definite diagnosis is very important. Early and accurate differentiation between 
IPD and PM has been markedly improved by recent developments in neuroimaging, 
particularly the 99mTc-TRODAT-1 SPECT, which is not only easy and economical to 
prepare and use in a wide variety of applications but also reliable in understanding the 
role of DAT in various neurological diseases. Most importantly, early and correct 
diagnosis leads to earlier and, therefore, more effective treatment with levodopa, when 
appropriate. 
Abbreviations: 
CBS: corticobasal syndrome 
-CIT: (1r) 2-carbomethoxy-3-(4-iodophenyl) tropane  
CO: carbon monoxide 
CS2: carbon disulfide 
DAT: dopamine transporter 
DRD: dopa-responsive dystonia 
DLB: dementia with Lewy bodies 
6-FD: 6-fluorodopa 
FDG: fluorodeoxyglucose  
FTD: frontotemporal dementia 
FTDP-17: frontotemporal dementia with parkinsonism linked to chromosome 17 
HD: Hungtington’s disease 
123I-IBZM scan: I-123–iodobenzamide D2 receptor scan 
IPD: idiopathic Parkinson’s disease 
MJD: Machado–Joseph disease 
Mn: manganese  
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
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MSA: multiple system atrophy 
MSA-C: multiple system atrophy-cerebellar subtype  
MSA-P: multiple system atrophy-parkinsonism subtype  
PET: positron emission tomography 
PM: Parkinsonism  
PSP: progressive supranuclear palsy  
PSP-P: progressive supranuclear palsy-parkinsonism 
RS: Richardson syndrome 
SCA: spinocerebellar atrophy  
SPECT: single photon emission computed tomography 
99mTc-TRODAT-1: Tc-99m labeled radiotracer for imaging DAT  
VP: vascular parkinsonism  
WD: Wilson’s disease 
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1. Introduction 
Fragile X syndrome (FXS, OMIM #300624) is the most common form of inherited mental 
retardation. The real incidence of the syndrome is not known, but epidemiological studies 
indicate that it is responsible for mental retardation in 1 in 4,000-6,000 males and in 1 in 
7,000-10,000 females of European descendent (for review Hagerman, 2002). In a study 
performed in Catalonia it gave an incidence of 1:2,466 male and 1:8,333 females (Rife et al., 
2003). It is also important to highlight the high incidence of premutation carriers, 1 in 1,233 
males and 1 in 411 females (Rife et al., 2003). FXS is inherited as X-linked dominant trait, 
with a reduced penetrance (80% for males and 30% for females).  
In 1991 the responsible gene was identified by positional cloning and named the fragile X 
mental retardation-1 gene (FMR1) (Oberle et al., 1991; Verkerk et al., 1991; Yu et al., 1991). 
The FMR1 gene is located in the long arm of the X chromosome at Xq27.3, it expands 17 
exons, and 40 kb of genomic DNA. It transcribes an mRNA of 3.9 kb, and the translated 
protein is called fragile X mental retardation protein (FMRP). The lack of this protein, which 
plays an important role in synaptogenesis and synaptic plasticity (Basell & Warren, 2008), is 
the cause of the FXS.  
FXS is almost exclusively caused by a dynamic mutation, a CGG repeat expansion in the 5’ 
untranslated region of the FMR1 gene (Oberle et al., 1991; Verkerk et al., 1991; Yu et al., 1991). 
In a normal situation the number of CGG repeats is polymorphic with alleles between 6 to 
about 54, with the most common allele presenting 30 CGG repeats. In this situation the CpG 
island, which is located in the promoter of the gene acting as a switch depending on its 
methylation status, is unmethylated. Thus the gene is active, FMR1 is transcribed and 
translated. Repeats at this size remain stable upon transmission. A second class of alleles 
that overlaps with the upper range of the wild-type is those with ~40-55 CGGs. This range, 
known as the gray zone, no expands to full mutation but it is transmitted slightly unstable 
to subsequent generations with the possibility of creating a premutated allele. In the 
premutation, alleles range from 55 to about 200 CGG repeats. At this situation, the FMR1 
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gene is also transcribed as the CpG island is unmethylated. Therefore, premutated carriers 
have normal or lightly reduced synthesis of FMRP and they are asymptomatic for FXS. 
However, they have risk of having affected descendence since the number of CGG is 
unstable, and in each cellular division it can increase, and can be transmitted with a higher 
number of repeats to the next generation. Finally, when the CGG number is beyond 200 
repeats (known as full mutation), the CpG island is methylated, and as consequence, the 
gene is transcriptionally silenced, and no protein is translated. These individuals are always 
affected if they are males and in about 30% of females. 
In this chapter we review the clinical, molecular and neuroradiological aspects of FXTAS 
syndrome, a late-onset neuropsychiatric degenerative disorder that occurs predominantly in 
male carriers of the FMR1 premutation. Based on our experience we describe in detail the 
different aspects that characterize the syndrome as well as the new findings. 
2. Fragile X syndrome premutation and FXTAS identification 
The possibility of clinical involvement in carriers of premutation expansions (55 to 200 CGG 
repeats) of FMR1 gene was initially discounted, since carrier mothers of FXS children have a 
normal cognitive functioning (Bennetto et al., 2001; Reiss et al., 1993). Even though, and 
contrary to expectation, there are reported several subgroups of male and female 
premutation carriers displaying features consistent with the typical clinical spectrum of FXS. 
For instance, Riddle and co-workers (1998) and Hagerman (2002) described a group of 
premutation carriers with prominent ears and joint laxity; or with learning disabilities, 
attention deficit/hyperactivity disorder (ADHD), or difficulty with math (Riddle et al., 1998, 
reviewed in Hagerman & Hagerman 2004). In addition, some carriers have emotional 
problems, including anxiety, obsessional thinking, schizotypy, and/or depression 
(Hagerman et al., 2002; Rodriguez-Revenga et al., 2008a). Such findings were observed to be 
more likely to occur in carriers with a lowered FMRP levels and particularly in those carrier 
females with larger CGG expansions (>100 repeats) (Johnston et al., 2001). 
There are, however, two forms of clinical involvement among carriers of premutation 
alleles that are not consistent with the clinical spectrum of the FXS. These two disorders 
are the primary ovarian insuffiency (FXPOI) and the fragile X-associated tremor/ataxia 
syndrome (FXTAS). FXPOI, which refers to the cessation of menses before age 40, is seen 
in ~20% of female who carry permutation alleles. Therefore, the genetic counseling for 
premutated women has to include a fertility advice since delaying the reproduction may 
not be a good option.  
FXTAS, the second form of clinical involvement described among permutation carriers, was 
identified in 2001 by Hagerman and co-workers as a late-onset neurodegenerative disorder 
(Hagerman et al., 2001). It took more than 10 years after the FMR1 gene identification to 
recognize FXTAS as a FMR1 permutation associated phenotype. One explanation for this is 
that the movement disorder experienced by older carriers, who were thought to be clinically 
normal, was not associated with the FXS (a childhood disorder) affecting children. Mothers 
of FXS children, being seen in clinics, were often expressing concerns about their fathers 
(FMR1 premutation carriers) who were experiencing problems with hand tremor and 
unsteady gait. When Hagerman and co-workers evaluated these male carriers they found 
that they all have a common neurological profile, consisting of intention tremor and gait 
ataxia (reviewed in Hagerman & Hagerman 2004). Therefore, FXTAS was firstly identified 
among older male carriers of premutation alleles, including progressive action tremor and 
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ataxia with associated radiological findings (Hagerman & Hagerman 2004). However, to 
date FXTAS has also been described among premutated women although it has been 
suggested that it occurs less frequently and that the phenotype is milder with older age at 
onset (Hagerman et al., 2001; Jacquemont et al., 2004a). An explanation for this difference is 
the presence of a second normal allele and a random X-inactivation of the premutated one; 
however, there may be additional sex-specific effects that reduce penetrance among females 
(Hagerman & Hagerman, 2004). 
Not all FMR1 premutation carriers develop FXTAS and it remains unknown which 
carriers will do so and when. It has been estimated that at least one-third of all male 
carriers will develop a FXTAS syndrome, although the penetrance increases with age, 
exceeding 50% for men aged 70-90 years. Moreover, there is significant variability in the 
progression of neurological dysfunction (Hagerman & Hagerman 2004; Jacquemont et al., 
2004a, 2004b). In an attempt to provide an estimation of FXTAS penetrance among 
premutation carriers in Spanish FXS families, we evaluated 398 families among which 151 
were composed of at least three generations. Our results showed that signs of FXTAS 
were detected in 16.5% of female premutation carriers and in 45.5% of premutated males 
older than 50 years. Overall, the mean age and the mean of CGG repeat number for the 
FXTAS men group was of 72.05 ± 6.85 and 85 ± 21.5 (mean ± SD), respectively. Similarly it 
was of 75.8 years old ± 10.2 and 82 CGG repeats ± 18 (mean ± SD) for the FXTAS women 
group (Rodriguez-Revenga et al., 2009).  
The description and characterization of FXTAS syndrome is of great interest to the 
population, because the prevalence of FMR1 premutation in the general population is 
relatively high. Several studies have been performed in order to determine the real role of 
FXTAS in undiagnosed adult patients with movement disorders. The results obtained in 
European populations ranges from 0% to 4% (Brussino et al.,2005; Macpherson et al., 2003; 
Van Esch et al., 2005; Zuhlke et al., 2004). Our studies show an estimated FXTAS 
prevalence of 2% among patients presenting with ataxia or movement disorders of 
unknown etiology (Rodriguez-Revenga et al., 2007, 2008b). Although large studies are 
necessary to better define FXTAS prevalence in this kind of population, on the basis of 
premutation male frequency in general population, the prevalence of FXTAS has been 
estimated in ~1/3,000 males aged over 50 years of age (~1/10,000 males of all ages) 
(Hagerman & Hagerman, 2004).  
3. Clinical and cognitive overview  
FXTAS syndrome is a neurodegenerative disease that eventually appears in adult subjects 
who carry a CGG repeat length between 55 and 200 trinucleotides in the FMR1 gene of 
chromosome X (Jacquemont et al., 2007). These subjects are categorized as FMR1 
premutation carriers. As stated above, it was originally described in grandparents of 
children with FXS. Different specialized centres in diagnosing and attending children with 
FXS observed that their grandparents and uncles were more likely to develop, from 50 years 
onwards, a stereotyped clinical picture characterized by unsteadiness while walking and 
action tremor in both hands (Hagerman et al., 2001).  
Neurological examination of children’s relatives disclosed the presence of predominant 
intention tremor in hands and wide-base cerebellar ataxia. Both symptoms used to follow a 
progressive course, and were often accompanied by progressive cognitive and behavioral 
disturbances (Hagerman et al., 2001).  
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Clinical descriptions published in the past 10 years have demonstrated that FMR1 
premutation carriers are very prone to develop cerebellar dysfunction from the age of 50 
years. Seveirty of symptoms usually impairs gait and associates mild to moderate 
dysmetria, repeated falls, intention tremor, and speech difficulties. The combination of 
cerebellar dysfunction, cognitive impairment and the appearance of characteristic radiologic 
features in the brain MRI has been claimed to constitute a nosological entity that has been 
named Fragile X-associated Tremor/Ataxia syndrome (FXTAS).  
In the only study about the natural history of patients with FXTAS, this syndrome has been 
observed to represent a disabling condition impacting on motor daily activities, thinking, 
and social skills after 15 years of evolution (Jacquemont et al., 2003).  
Mean age of onset of FXTAS is 60 years. Mild intention tremor, affecting both hands,  
symmetrically, is usually the first symptom. Within the first 5 years, tremor becomes more 
apparent and some balance and speech problems develop. At this stage, balance problems 
are mild and are only noticed by patients as a feeling of unsteadiness while walking for long 
periods of time or when turning. Between 5 and 15 years from disease onset balance 
problems progress in severity and are usually the main complain, provoking repeated 
falling and limiting the ability to drive, walking autonomously in the streets, or using public 
transportation. At this stage, moreover, is when the first cognitive and behavioural 
disturbances appear.  After 15 years, autonomous walk is greatly impaired, and patients 
need the help of a walker or the supervision of another person. Finally, dysphagia and 
severe ataxia are associated with immobility and recurrent urinary and respiratory 
infections (Leehey et al., 2007). 
The penetrance of FXTAS is not well established. Penetrance increases with age, and it has 
been reported to range from 15% at 50 years of age to 75% at age 80 (Jacquemont et al., 
2004b). 
Being a relatively newly described condition, the clinical spectrum of the disease has 
expanded in the past years. As in other diseases, such as Parkinson’s disease, FXTAS was 
initially conceived as a predominant motor disease. New data have evidenced that many 
clinically relevant cognitive and behavioural disturbances may also develop in FXTAS 
patients. Also, while FXTAS was originally described in males, the number of women 
developing FXTAS symptoms has increased exponentially in the past five years. Women 
have been reported to develop the same motor, cognitive and behavioural problems than 
males, although women are more likely to develop a milder form of the disease (Coffey et 
al., 2008). Nevertheless, cognitive dysfunction severe enough to accomplish criteria for 
dementia has been reported in FXTAS women with inactivation of the healthy X-
chromosome (Rodriguez-Revenga et al., 2010). 
Cognitive impairment in FXTAS is characterized by recent episodic memory problems, 
difficulties in sustained attention, and other executive problems such as organizing new 
material and inhibiting automatic responses. In males, initially mild cognitive problems can 
accomplish criteria for dementia after 5 to 10 years of evolution (Grisby et al., 2007). 
Extension of the neurodegenerative process to prefrontal and temporal structures seems to 
account for the progression of cognitive defects in FXTAS patients (Seritan et al., 2008). 
While balance problems and tremor seem to be the consequence of the progressive 
degeneration of middle cerebellar peduncles and associated cerebellar structures, both 
cognitive and behavioural problems in FXTAS are associated with diffuse cortical and 
white-matter subcortical degeneration (Hashimoto et al., 2011).  
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The dysexecutive problems of FXTAS patients affect different prefrontal dominions. 
Cognitive tasks dependent on the dorsolateral prefrontal cortex are affected since the early 
stages of the disease. Problems in working memory, set-shifting and mental flexibility have 
been described in patients with mild ataxia and tremor (Grisby et al., 2007). Later in the 
disease, cognitive alterations more dependent on the medial prefrontal cortex, such as 
difficulties in inhibiting automatic responses, arise. Response inhibition in go-no go tasks, 
inability to perform Luria’s promotor series, and signs of environmental dependency were 
seen not only to limit the ability of FXTAS’ patients to cope with cognitive strategies in the 
daily life, but also accounted for the behavioral disorders of the disease (Moore et al., 2004a). 
Memory problems develop due to both prefrontal and medial temporal dysfunction. 
Numerous eosinophylic inclusions have been observed bilaterally in the hippocampus and 
the entorrhinal cortex. Progressive deterioration and atrophy of medial temporal lobe 
structures explains the progressive nature of temporal disorientation and both verbal and 
visual recent episodic memory. (Grisby et al., 2008). In comparison with Alzheimer’s disease, 
FXTAS patients show a higher impairment in dysexecutive tasks and less memory 
impairment, and in comparison with Parkinson’s disease, visuospatial skills seem to be 
more preserved. In addition, compared to both Parkinson’s disease and dementia with 
Lewy bodies, FXTAS patients are less likely to manifest visual hallucinations and psychosis 
(Grisby et al., 2008). 
Neuropsychiatric disturbances in FXTAS are characterized by a change in premorbid 
personality. Patients with FXTAS, as in frontotemporal dementia, may develop irritability, 
psychomotor agitation, a tendency to selfishness, blunted emotions, apathy, and sometimes 
even social and personal disinhibition. Similarities with frontotemporal dementia correlate 
with the evidence of predominant medial prefrontal and anteromedial temporal atrophy in 
neuroimaging studies (Bacalman et al., 2006). 
In summary, fronto-temporal cognitive and behavioral disturbances seem to characterize 
FXTAS patients. Frontal cognitive symptoms are present in early stages and progress 
through disease evolution, medial prefrontal behavioral disturbances appear in the middle 
stages and progress also in severity, and finally, from medium to late FXTAS stages, 
temporal cognitive symptoms impair even more global cognitive function and lead to 
dementia. A better delineation of each one of these components would help to refine the 
progression of cognitive and behavioural symptoms in different FXTAS subgroups (age, 
gender, etc…). 
Other neurological disturbances described in FXTAS patients are the development of rigid-
akinetic parkinsonism with predominant axial involvement (35%), unilateral resting tremor 
(10%), peripheral neuropathy (30%), dysautonomia (40-50%; urinary urgency, erectile 
dysfunction, orthostatic hypotension), nistagmus (10%), and hyporreflexia (10%). 
In some patients, postural and intention tremor may present in isolation, making the 
diagnosis of essential tremor very likely. Reported cases stress the importance of 
considering the diagnosis of FXTAS in patients diagnosed of essential tremor who develop 
ataxia or with a family history of mental retardation (Leehey et al., 2003). Other patients 
present with isolated and progressive adult-onset ataxia. Currently, genetic testing for 
FXTAS must be considered in any patient with ataxia developing after the age of 50. The 
screening of FXTAS in a prospective series of patients with multiple system atrophy showed 
that 4% of patients with an initial diagnosis of multiple system atrophy of the cerebellar type 
were actually FMR1 premutation carriers (Kamm et al., 2005). Taking into account the 
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consequences of a diagnosis of FXTAS on genetic counselling, FXTAS should be categorized 
as a new kind of spinocerebellar ataxia (Milà et al., 2009).  
4. Molecular genetics overview 
FXTAS is an allelic disorder to the FXS, and therefore should be considered as a distinct 
neurodegenerative disorder. In fact, the molecular mechanism leading to FXTAS is distinct 
from the FMR1 silencing mechanism and/or a deficit in FMRP operating in FXS. In 
premutated patients the FMR1 gene is rarely silenced and FMRP levels are generally normal 
or only slightly lowered (Hagerman & Hagerman, 2004) (Fig.1a). The only known molecular 
abnormality among premutation carriers is the presence of markedly elevated levels (~2-8 
fold) of FMR1 mRNA (Fig.1b).  
 
  
Fig. 1. a) Schematic representation of FMRP levels detected in A: FXS affected individuals, 
N:  individuals with a normal CGG repeat number; NTM: FMR1 premutation male carriers 
and Pre: FMR1 premutation  female carriers. B) Schematic representation of FMR1 mRNA 
levels detected in A: FXS affected individuals, N:  individuals with a normal CGG repeat 
number; NTM: FMR1 premutation male carriers and Pre: FMR1 premutation  female 
carriers. 
The increased transcriptional activity of the FMR1 gene seems to be positively correlated 
with the size of the CGG repeat. That is, CGG repeats in the upper range (100-200 CGG) 
result in average 5-8 fold elevation, whereas CGGs in the lower range (50-100 CGG) result in 
an average 2-fold elevation (Kenson et al., 2001; Oostra & Willemsen, 2003; Tassone et al., 
2000a, 2000b). Although the precise mechanism for this overexpression is unknown, several 
possible mechanisms have been postulated. A feedback mechanism suggests that the cell 
attempts to compensate for reduced levels of FMRP by increasing the amount of available 
FMR1 transcript (reviewed in Galloway & Nelson, 2009; Tassone & Hagerman, 2003). 
Alternatively, it is likely that the increasing length of the CGG repeat near the FMR1 
promoter proportionally opens the chromatin, allowing more ready access to transcription 
factors (Tan el al., 2009). The presence of these elevated levels of abnormal (expanded CGG 
repeat) FMR1 mRNA led to propose an RNA “toxic gain-of-function” model for FXTAS, in 
which the mRNA itself, with the abnormal CGG repeat tract, is causative of the neurological 
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disorder (Greco et al., 2002: Hagerman & Hagerman, 2004; Hagerman et al., 2001: 
Jacquemont et al., 2003). Although several evidences support the RNA-based mechanism, 
the precise form of how the CGG-repeat RNA is responisble for FXTAS pathogenesis is not 
yet resolved (Garcia-Arocena & Hagerman, 2010) The same RNA “toxic gain-of-function” 
mechanism has been proposed for myotonic dystrophy (DM1 and DM2), in which either the 
expanded repeat tract of CUG in DM1 or CCUG in DM2 sequestered CUG-binding proteins 
that disrupts mRNA processing of other genes or transport of other mRNAs (Mankodi & 
Thornton, 2002). In fact, this model has been demonstrated for DM1 by placing an expanded 
CTG tract in 3’ UTR region of the DMPK mRNA in a transgenic mouse (Mankodi et al., 
2000). A part from this finding, FXTAS and myotonic dystrophy have another important 
similarity that supports the RNA gain-of-function mechanism. Both disorders show nuclear 
inclusions produced as a result of the binding proteins sequestered by the respectively 
mRNA, with a cytotoxic effect that lead to cell death. In a study performed by Greco and co-
worker (2002) eosinophilic intranucelear inclusions in neurons and astrocytes throughout 
the cortex and in deep cerebellar nuclei of FXTAS post-mortem samples were reported. 
Furthermore, in a subsequent study, there is described a highly significant association 
between CGG length and both the number of inclusions and the age of death, which 
correlates with the progressive character of the disease (Greco et al., 2006). The intranuclear 
inclusions associated with FXTAS have characteristic features different than those found in 
tauopathies (e.g., Pick disease), synucleinopathies (e.g., Lewy body dementias and 
Parkinson disease) or polyglutamine disorders (SCAs). It is important to note that, unlike 
the polyglutamine disorders, there is no known structurally abnormal protein with FXTAS 
(reviewed in Galloway & Nelson, 2009; Iwahashi et al., 2006). Taken together, these facts 
define FXTAS as a new class of inclusion disorder. 
In order to test the RNA gain-of-function hypothesis for FXTAS, a “knock-in” mouse model 
has been generated in which the endogenous mouse CGG repeat was replaced by a human 
CGG tract carrying 98 CGGs (Bontekoe et al., 2001; reviewed in Oostra & Willemsen, 2009). 
Further studies of the brain of these expanded-repeat mice (at 20-72 weeks) evidenced 
elevated Fmr1 mRNA levels and ubiquitin-positive intranuclear inclusions (Willemsen et al., 
2003). An increase was also observed in both the number and the size of the inclusions in 
specific brain region during the course of life (Oostra & Willemsen, 2003). The presence of 
inclusions in this mouse, that has normal levels of FMRP, provides evidences against a 
protein-deficiency model for FXTAS, and supports a direct role of the Fmr1 gene, by either 
CGG expansion per se or by elevated Fmr1 mRNA levels, in the pathology.  
There are several other animal and cell-based studies that provide evidence of direct RNA 
toxicity (Galloway & Nelson, 2010; reviewed in Garcia-Arocena & Hagerman, 2010). Most of 
these studies have demostrated a sequestartion of several candidates CGG-repeat binding 
proteins from their normal function. Remarkably, they have also demonstrated at least 
partial rescue of the wild-type phenotype by overexpressing the sequestered protein. The 
number of candidate proteins for sequestration has been lately increased and surprisingly, it 
has also been shown that inclusions are dynamic structures that expanded over time, 
resulting in giant inclusions (Sellier et al., 2010). Continuous enlargements of CGG RNA 
aggregates suggest that these repeats may constantly recruit proteins, implying a founding 
RNA-protein interaction event that would subsequently trap other proteins through indirect 
RNA-protein or protein-protein interactions (Sellier et al., 2010). The protein components of 
FXTAS inclusions fell into eight major functional categories, including: histone family; 
intermediate filament; microtubule; myelin-associated proteins; RNA-binding proteins; 
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stress-related proteins; chaperones and ubiquitin-proteasome-related proteins (reviewed 
Galloway & Nelson, 2010).  
Interestingly, an antisense transcript, ASFMR1, has recently been identified to overlap the 
CGG repeat region of the FMR1 gene (Ladd et al., 2007). Similar to FMR1, the ASFMR1 
transcript is silenced in full mutation individuals and overexpressed in permutation carriers. 
However, whether ASFMR1 contributes to the pathogenesis of either FXTAS or FXS remains 
to be determined (Tan et al., 2009). 
5. Neuroimaging findings – Conventional MRI strenghts and limitations 
FXTAS was originally described in men, older than 50 years of age, having a typical clinical 
picture of progressive intention tremor, and cerebellar ataxia (Hagerman et al 2001). 
Magnetic resonance imaging (MRI) of the brain was obtained in these patients searching for 
specific features, and the finding of hyperintensities in the cerebellar white matter and 
middle cerebellar peduncles on T2-weighted images was reported as a characteristic feature 
and called the “MCP sign” (Fig. 2a), as it was seen in nearly all FXTAS-premutated carriers, 
and not in controls (Brunberg et al., 2002). Other typical MR features described originally in 
patients with FXTAS included cerebellar, pontine, and cerebral atrophy, as well as white 





Fig. 2. MR images showing characteristic findings in FXTAS. 1a. Axial FLAIR- MCP sign 
(middle cerebellar peduncle hyperintensities); 1b. Axial T1- Cerebellar and pontine atrophy; 
1c. Coronal T1- Cerebral atrophy; 1d. Axial FLAIR- Hyperintensities in the cerebral white 
matter.  
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Thus, characteristic findings described on conventional MRI in patients with FXTAS, were 
classified into two categories -major and minor criteria-, and proposed, together with 
clinical findings, as diagnostic criteria for FXTAS (Jacquemont et al., 2003). Major criteria 
included the MCP sign, as well as white matter and brainstem hyperintensities. Cerebellar 
and brain atrophy were proposed as minor criteria (Jacquemont et al., 2003) (Table 1). 
 
Examination and Degree Observation 
Radiological:  
Major MRI white matter lesions in MCPs and or brain stem 
Minor MRI white matter lesions in cerebral white matter 
Minor Moderate-to-severe generalized atrophy 
Clinical:  
Major Intention tremor 
Major Gait ataxia 
Minor Parkinsonism 
Minor Moderate-to-severe short-term memory deficiency 
Minor Executive function deficit 
Inclusion criterion: CGG repeat number between 55 and 200. 
Note. Data described by Jacquemont et al. 2003. 
Table 1. Clinical Criteria for FXTAS. The diagnostic categories described by Jaquemont et al. 
2003 are as follows: 
Definite (1 major radiological sign plus 1 major clinical symptom) 
Probable (1 major radiological sign plus 1 minor clinical symptom or two major clinical 
symptoms)  
Possible (1 minor radiological sign plus 1 major clinical symptom)  
Early neuropathological, postmortem studies of the brain of patients with FXTAS revealed 
intranuclear inclusions in neurons and astrocytes throughout the cortex and in deep 
cerebellar nuclei, but not in Purkinje cells of the cerebellum (Greco et al., 2002). Further 
evidence has shown that there is significant cerebral and cerebellar white matter disease, 
associated astrocytic pathology in the cerebral white matter, and intranuclear inclusions in 
both brain and spinal cord (Greco et al., 2006). Additionally, there seems to be an association 
between the number of CGG repeats and the number of intranuclear inclusions in neurons 
and astrocytes, so that CGG repeat has been suggested as a predictor for clinical and 
neuropathological involvement (Greco et al., 2006). Unfortunately, there is no 
histopathological evidence from brains of premutated, non-FXTAS subjects, who died 
because of an unrelated condition, being either asymptomatic neurologically, or little 
symptomatic. This evidence would certainly add in the understanding of the pathogenetic 
processes underlying glial and neuronal damage, and eventual neurological dysfunction. 
Brain banks and collaborative actions may represent a good opportunity in this regard. 
Penetrance of FXTAS among premutation carriers has been studied, and reported to be 
relevant, mainly in men (Jacquemont et al., 2004). As premutation carriers are relatively 
common in the general population, it has been proposed that older men with ataxia and 
intention tremor should be screened for the FMR1 mutation (Jacquemont 2004). Using the 
previously described criteria for FXTAS (Jacquemont et al., 2003), a study among adult 
Spanish patients with ataxia, revealed an estimated FXTAS prevalence varying between 
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1.15% for males, and 3% for females (Rodriguez-Revenga et al., 2007). Similarly, a frequency 
of 1.6% of patients with FXTAS has been reported among adult patients with movement 
disorders who tested negative for the Huntington gene (Rodriguez-Revenga et al., 2008b). 
The importance of neuroradiological findings that could be used as an additional screening 
tool for FXTAS is demonstrated by these studies.  
In this regard, the MCP sign, which was originally proposed to be a characteristic and 
specific feature for FXTAS, that could be used for screening purposes, has been also 
reported in patients with other forms of adult-onset cerebellar ataxia, thus lacking specificity 
for FXTAS (Okamoto et al., 2003). Patients with atypical parkinsonism, and particularly 
those having a clinical picture including dysautonomia, and ataxia -a condition currently 
known as the cerebellar form of Multiple System Atrophy (MSA)-, may show the MCP sign 
on MRI, so that middle cerebellar peduncles hyperintensities in a patient with parkinsonism 
should be regarded as a non-specific finding, which can be seen in FXTAS, but also in MSA 
(Kamm  et al., 2005). Additionally, the sensitivity of the MCP sign may be less than 
previously thought, as the frequency of the MCP sign among women with FXTAS seems to 
be less (Hagerman et al., 2004), and its presence among premutated men with subtle 
neurological, psychiatric, or cognitive dysfunction remains unknown.  
As more evidence among FMR1 premutation carriers developing neurological features, and 
particularly parkinsonism, is being gained, the spectrum and variability of MRI features 
becomes broader. Also, the severity of disease, which may relate to CGG repeat number, or 
other unknown factors, may influence the presence and magnitude of MRI findings. In this 
context, a correlation between CGG repeat length and reductions in IQ and cerebellar 
volume, and increased ventricular volume and whole-brain white matter hyperintensities, 
have been reported in FMR1 premutation carriers (Cohen et al.,  2006). It may well then be 
the case, that patients with a longer duration of neurological disturbances, or a greater 
severity, are those showing the so-known “typical MRI findings” of FXTAS. In this regard, 
more evidence is needed among younger premutated patients. Additionally, premutated 
women and women with FXTAS seem to have a different phenotype (Berry et al., 2004; 
Hagerman et al., 2004; Hessl et al., 2005), so that the frequency and relevance of MRI findings 
in women may be different from that in men. In this regard, less pronounced reductions in 
cerebellar volume and a lower incidence of the MCP sign has been reported in women with 
FXTAS compared to men (Adams et al., 2007). Also, an absence of significant associations 
between reduced cerebellar volumes and increased FXTAS severity, and increased length of 
the CGG repeat expansion was reported in women, differently from men having FXTAS 
(Adams et al., 2007).   
Conventional MRI, as including T1- and T2- weighted MR images, suffers from several 
limitations as a tool to investigate patients with a neurodevelopmental disorder that develop 
a neurodegenerative process later in life, as happens in the FMR1 premutation/FXTAS 
condition. Today, with the advent of high field strength MRI, and stronger gradients, there 
are more specific sequences such as susceptibility- or gradient-echo-weighted MR-images, 
which can provide more specific assessment of mechanisms underlying neuronal 
degeneration, such as iron deposition. Iron deposition is seen with normal aging in specific 
brain structures. Up to date, increased and/or iron deposition in certain brain structures has 
not been demonstrated among FXTAS patients, to the best of our knowledge, but this may 
only be a question of time or of the cohorts being studied. 
Also, recently FLAIR imaging has somehow substituted T2-weighted imaging for the 
assessment of white matter and brainstem T2- signal changes. Findings on FLAIR images 
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may not be exactly the same as seen on T2-weighted images, and thus, more evidence is 
needed with these more recent techniques. Finally, Arterial Spin Labeling, a non-invasive 
MRI method that allows detection of specific perfusion patterns of involvement linked to 
brain metabolism, is currently being applied to several neurodegenerative brain conditions, 
and may also be useful in the context of FMR1 premutation/FXTAS. 
6. Advances in neuroimaging in FXTAS and future needs  
The advancing field of Neuroradiology, and particularly of MRI, has provided insight in 
neurodegenerative conditions. Typical MRI findings have been described, that allow prompt 
and more precise characterization of many conditions, such as FXTAS. Additionally, MRI has 
provided non-invasive markers of disease, which may be potentially useful in early and 
differential diagnosis, in prognosis, and eventually in therapeutic response. This is the case for 
triplet expansion, genetic conditions, such as Huntington´s disease (HD), which offers some 
similarities to FXTAS. Originally, conventional MRI was used and typical MRI findings were 
described in HD, but recently, more sophisticated imaging methods, such as MR-
Spectroscopy, have been applied not only to patients with HD, but also to asymptomatic 
carriers, searching for markers for early diagnosis and conversion to disease. In this regard, 
metabolic (Gomez-Anson et al., 2007) and structural (Gomez-Anson et al., 2009) MR-alterations 
in the prefrontal regions of asymptomatic HD carriers have been recently described, linked to 
neuropsychological dysfunction, and proposed as early markers for disease, related to 
underlying pathology. Knowledge in field of FMR1 premutation carriers, who will eventually 
develop FXTAS, may follow a similar course. Although until now, mainly conventional MRI 
features have been described, there is growing evidence from more sophisticated MR 
techniques, which has and will continue adding knowledge in the field.   
Advances in Neuroimaging in FMR1 premutation/FXTAS may, perhaps, come from two 
distinct contributions. Firstly, more recent developments in MR are being applied to these 
patients. This is particularly the case of functional MR techniques, which not only provide 
information about structural brain changes in these patients, but also of brain functioning. As 
an example, MR-Spectroscopy (MRS) is a technique which allows studying non-invasively 
brain metabolism in vivo. Metabolic information can be linked to cellular pools, thus to 
histopathological changes, and to neuropsychological and clinical features. There is very little 
evidence about MRS in FXTAS. However, MRS changes indicating neuronal loss/dysfunction 
have been described in the pons of patients with FXTAS having the typical MCP sign on 
conventional imaging (Ginestroni et al., 2007). More recent evidence has shown altered 
metabolism on MRS in the middle cerebellar peduncles of patients with FMR1 premutation, 
which may be more marked in FXTAS (Gomez-Anson et al., abstract 2007). These findings 
indicate a potential usefulness of MRS, adding in differential diagnosis of patients with ataxias, 
and being able, perhaps, to identify those patients that will develop FXTAS. However, more 
longitudinal evidence and larger cohorts of carriers and patients from multicentric studies are 
needed in this regard. Functional MRI may also prove to be useful in the field of, as it has been 
recently demonstrated that there is altered prefrontal cortex activity underlying executive and 
memory deficits in permutated carriers and patients (Hashimoto et al., 2011). 
Secondly, contributions from more sophisticated postprocessing tools will certainly add 
during the near future in the field. In this context, assessment and quantification of volume 
changes in the brain is now feasible non-invasively using MRI and volumetric techniques. 
One of these techniques, the Voxel Based Morphometry method (VBM) allows 
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determination of focal changes of grey and white matter density in the brain on MRI 
(Ashburner et al., 2000). However, the evidence of volumetric studies in FXTAS and 
premutation carriers is scarce (Gomez-Anson et al., 2007; Hashimoto et al., 2011; Moore et al., 
2004b). Automated postprocessing tools are also being currently applied to study regional 
changes of volume in the brain, which may be specific to a condition, and related to certain 
cognitive tasks. This is the case of the hippocampus and memory impairment, which are 
relevant in Alzheimer´s disease, for example (Sanchez-Benavides et al., 2010). Evidence of 
the application of these tools to research in the FXTAS condition is still lacking. 
The potential usefulness of neuroimaging in providing insight in FXTAS becomes more 
evident as cognitive decline in FXTAS is resulting in an important field of research. As the 
phenotypic spectrum has expanded among FMR1 premutated carriers, and FXTAS patients, 







Fig. 3. Magnetic resonance imaging findings of two female patients with dementia and 
FXTAS. A) Coronal T1-weighted, 3D MPRAGE MR image of patient 1 shows asymmetrical 
frontal, and bilateral, symmetrical, medial temporal atrophy. B) Axial 3D FLAIR of patient 1 
shows marked hyperintensities in the cerebral white matter. C) Coronal T1-weighted, 3D 
MPRAGE MR image of patient 2 shows moderate cerebral atrophy involving the frontal 
lobes, while the medial temporal lobes appeared normal.; K) Axial 3D FLAIR of patient 2 
shows no marked HI in the white matter. 
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(Sevin et al., 2009). Cognitive decline in FXTAS usually occurs in men, after a long duration 
of extrapyramidal disturbances, but it may also occur in women. Typically in men, a clinical 
picture similar distinct from Alzheimer´s disease (Seritan et al.,  2008), and more similar to 
patients with fronto-temporal lobar degeneration occurs (FTLD) (Burgeois et al., 2009). 
Although there is little evidence from MRI in these patients, particularly in women (Al Hinti 
et al.,  2007; Karmon et al., 2008), more recently, two cases of mother-to-daughter 
transmission were reported (Rodriguez-Revenga et al., 2010). In these two female patients 
with FXTAS and dementia, a radiological pattern of brain atrophy resembling that of 
patients with FTLD, was described. However, radiological heterogeneity may be large in  
this condition, as shown by the fact that prominent white matter hyperintensities were only 
seen in one case, as had been previously described (Al Hinti et al.,  2007; Karmon et al., 2008), 
the second case lacking these, as well as hippocampal atrophy (Fig. 3). 
There is very recent evidence about the use of VBM for studying the brain changes of 
FMR1 premutated carriers, with and without FXTAS, and their correlation to 
neuropsychology (Hashimoto et al., 2011). In this study, patients with FXTAS 
demonstrated a distinct pattern of grey matter volume loss, involving multiple cortical 
and subcortical regions. This included different parts of the cerebellum, as well as of the 
medial surface of the brain, including the dorsomedial prefrontal cortex, anterior 
cingulate and precuneus. Additional volume loss was seen in the lateral prefrontal cortex, 
orbitofrontal cortex, amygdala, and insula. More interestingly, there were significant 
correlations between grey matter loss in different brain regions, behavioral scales, and 
CGG repeats (Hashimoto et al., 2011). 
7. Conclusion 
FXTAS is a relatively new disorders that is currently regarded as a late-onset 
neurodegenerative disorder; however, the underlying pathogenic process may begin very 
early in life. It is essential to fathom the molecular mechanism of FXTAS and to increase our 
knowledge of disease pathology in order to understand of FXTAS disease progression. 
Although the RNA gain-of-function hypothesis for FXTAS is well accepted, further analysis 
of the pathogenic effect of the expanded CGG-repeat FMR1 mRNA are still required. A 
better understanding of the molecular basis of FXTAS should shed light on therapeutic 
approaches that will combat neurodegeneration and improve cognitive and motor 
performance. Furthermore, it can also help unraveling common mechanisms in other 
neurodegenerative diseaser which will bring hope to treatments more effective and specific 
to the underlying dysfunction.  
MRI findings in FXTAS patients classically include middle cerebellar and white matter 
hyperintensities, as well as cerebellar, pontine and brain atrophy. Neuroimaging, and 
particularly MR techniques, offer an excellent opportunity to gain insight into the FXTAS 
condition. In vivo biomarkers may be identified non-invasively, which may be potentially 
useful in improving recognition, and early characterization of patients with FXTAS, so that 
treatment strategies can be developed and applied. 
As the prevalence of premutated alleles is relatively high in general population, FXTAS may 
represent one of the more common monogenic causes of tremor, ataxia, and dementia. For 
this reason, it is probably that many carriers with FXTAS are being seen by a clinical 
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specialist without awareness of the underlying genetic basis for the symptoms. The early 
diagnosis of those patients not only benefits themselves but also the rest of the family that 
should be advised for the FXS.  
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1. Introduction 
Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disorder affecting 
multiple organ systems. 30-40 % of the patients manifest variable neuropsychiatric 
symptoms leading to significant morbidity and mortality. CNS involvement could be 
primary if directly related to SLE activity in the CNS or secondary to treatment, infections, 
metabolic abnormalities or other systemic manifestations such as hypertension (Futrell et 
al,1992). Primary NPSLE is divided into focal and diffuse disease. Focal NPSLE is 
characterized by focal neurologic deficits and is strongly associated with the occurrence of 
thromboembolic events. Diffuse primary NPSLE is a group of neurologic, psychiatric, and 
cognitive syndromes that vary from overt neurologic and psychiatric symptoms (eg. 
seizures, psychosis) to more subtle signs such as headache, mood disturbances, anxiety 
disorders or mild cognitive dysfunction. Neuropsychiatric lupus (NPSLE) manifestations 
can occur in the absence of either serologic activity or other systemic disease manifestations 
(Sibbit et al., 1999). Thus, in clinical practice the diagnosis of primary NPSLE is rather 
presumptive, after the exclusion of alternative causes of the neuropsychiatric symptoms. 
There is no single diagnostic test that is sensitive and specific for SLE-related 
neuropsychiatric manifestations. The assessment of individual patients is based on clinical, 
neurologic and rheumatologic evaluation, immunoserologic testing, brain imaging, and 
psychiatric and neuropsychological assessment. These examinations are used to support or 
refute the clinical diagnostic impression, rule out alternative explanations, and form the 
basis for prospective monitoring of clinical evolution and response to treatment 
interventions. The lack of a diagnostic gold standard makes the correct diagnosis of primary 
NPSLE a challenge. This realization has led us in developing under the auspices of the 
European League Against Rheumatology (EULAR) evidence and expert based 
recommendations for the management of NPSLE (Bertsias et al, 2010). 
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Magnetic resonance imaging (MRI) is the current modality of choice in the imaging 
assessment of NPSLE patients, due to its high sensitivity in detecting even small 
alterations in tissue water content (Sibbitt et al., 1999). However, the variable pathologic 
substrate of the NPLSE lesions result in low MRI specificity. Conventional MRI reveals 
lesions in about 50-75% of NPSLE patients, depending on the disease activity and the 
severity and kind of the neurological manifestations (focal or diffuse). In patients with 
focal symptoms conventional MRI commonly detects small, discrete, frontal–parietal 
subcortical or periventricular white matter lesions, hyperintense on T2 sequences,  that 
usually represent small acute or chronic infarcts, or even microhemorrhages. 
Unfortunately, these lesions are not specific for NPSLE and exhibit no clinical correlation. 
Additional intravenous Gadolinium administration is helpful in differentiating acute from 
chronic lesions. Mild-to-moderate cerebral atrophy could also be detected by T1 
sequences, associated with both generalized and focal brain injury.  
In NPSLE patients with diffuse neurological manifestations conventional neuroimaging 
usually fails to demonstrate abnormalities that explain these symptoms. Additionally, 
histopathological studies confirm the presence of extensive diffuse parenchymal and 
cerebrovascular injury that could not be identified by the conventional MRI techniques. On 
the contrary, brain tissue microscopic structural, hemodynamic or metabolic changes could 
be assessed by advanced, non-conventional quantitative neuroimaging techniques, such as 
Diffusion Weighted Imaging (DWI), Diffusion Tensor Imaging (DTI), Perfusion Weighted 
Imaging (PWI), Magnetization Transfer Imaging (MTI) and Magnetic Resonance 
Spectroscopy (MRS). Although not available in the current daily practice, these techniques 
are promising for the better understanding of the NSPLE, and improvement of the 
diagnostic work-up and treatment. 
We critically review the literature on brain imaging in NPSLE, with special emphasis on   
non-conventional neuroimaging techniques in order to access their contribution to 
diagnosis, understanding of the pathophysiology and clinical management. 
2. Histopathological changes in NPSLE 
The underlying pathologic basis of NP-SLE is still under investigation (Bertsias GK, 
Boumpas DT, 2010). Pathological studies revealed multiple microinfarcts,  noninflammatory 
thickening of small vessels with intimal proliferation, small-vessel occlusion, and 
intracranial embolism or hemorrhage (Van Dam et al., 1991). True vasculitis, with 
inflammatory infiltrate and fibrinoid necrosis is relatively rare, occurring in 6–9% of cases 
(Van Dam et al., 1991). Vasculopathy is most common. SLE vasculopathy affects 
predominantly arterioles and capillaries, resulting in vessel tortuosity, vascular 
hyalinization, endothelial proliferation, and perivascular inflammation or gliosis. This 
vasculopathy could be related to both acute inflammation and ischemia (Hanly et al., 1992; 
Van Dam et al., 1991).  
According to a recent histopathological study (Sibbit et al., 2010) the basic underlying 
pathologic process of NPSLE is cerebrovascular injury associated with disease activity and 
thromboembolism, resulting in focal and diffuse brain ischemia, small and large brain 
infarcts, focal and diffuse brain edema, brain hemorrhage, and focal and diffuse 
parenchymal injury. Multiple coexisting pathogenic mechanisms including, 
thromboembolism by cardiac valvular lesions, hypercoagulability, diffuse endothelial 
injury, and excitotoxicity could not be excluded (Roldan et al., 2006, 2008).  
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Four patterns of cerebrovascular disease NPSLE have been suggested: (1) an 
antiphospholipid  antibody cerebrovasculopathy characterized by bland thromboses, 
thrombotic microangiopathy, and arterial intimal fibrous hyperplasia; (2) a diffuse 
cerebrovasculopathy characterized by endothelial injury associated with increased SLE 
disease activity, glomerulonephritis, hypertension, and perhaps neuroexcitotoxic antibodies; 
(3) thromboembolic NPSLE directly caused by cardiac valvular lesions; and (4) mixed 
cerebrovascular NPSLE with simultaneous aspects of antiphospholipid- associated 
thrombosis, increased disease activity, and thromboembolic valvular lesions (Sibbit et 
al.,2010).  
3. Conventional MRI 
Conventional pre- and postcontrast-enhanced brain MRI appears normal in approximately 
one-third of both symptomatic and asymptomatic NPSLE patients (Chinn et al., 1997; 
Jennings et al., 2004). Hyperintense white matter lesions are revealed in up to 70% of SLE 
patients. In the majority of MRI studies in which white matter lesions were quantified, 
patient groups with NPSLE (active and inactive) showed a significantly higher number and 
total volume of white matter hyperintensities compared to non-NPSLE ( Appenzeller et al., 
2008; Castellino et al., 2008).  
According to a recent study (Luyendijk et al, 2011), that reviewed retrospectively the MRI 
exams of the first episode of active NPSLE in 74 patients,  4 types of findings were observed 
: 1) focal hyperintensities in white matter (49% of all patients and 84% of patients with 
abnormalities on MRI) or both white matter and gray matter (5%), suggestive of 
vasculopathy or vasculitis (Figure 1),  2) more widespread, confluent hyperintensities in the 
WM, suggestive of chronic hypoperfusion due to the same mechanisms, 3) diffuse cortical 
GM lesions (12%), compatible with an immune response to neuronal components or post-
seizure vasogenic edema, and 4) absence of MRI abnormalities, despite active signs and 
symptoms (42%). Small punctate focal white matter lesions, the most common imaging 
finding, are followed in prevalence by cortical atrophy, ventricular dilation and diffuse 
white matter changes. 
The small focal lesions- hyperintense on T2-weighted or FLAIR imaging- typically occur in 
periventricular and subcortical white matter, especially in the frontoparietal regions. They 
usually represent small resolved infarcts or focal areas of reduced neuronal density, but in 
some cases they may be the result of acute infarcts, focal edema, or even acute 
microhemorrhages (Sibbitt et al., 2010).The corresponding T1-weighted images often 
appearing normal (Ainiala et al, 2005), while FLAIR images have been shown to be more 
sensitive for detecting these lesions than T2 images. Periventricular lesions have been 
particularly associated with the antiphospholipid syndrome (APS) and can be impossible to 
differentiate on MRI from multiple sclerosis (Peterson et al., 2005). 
Although the focal hyperintense white matter lesions are often considered nonspecific-
since they are indistinguishable from age-related small vessel disease -they may occur 
much earlier and in greater numbers in SLE subjects. These findings also seem to be more 
common in patients with NP-SLE in the presence of antiphospholipid antibodies, 
although no clinical correlation was observed in most studies (Ainiala et al., 2005). In a 
large prospective population-based study involving healthy individuals, the presence of 
focal hyperintense white matter lesions was associated with cognitive impairment 
(Vermeer et al., 2003). In addition, correlations have been observed between white matter 
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hyperintensities and both cumulative SLE related injury scores, including 
neuropsychiatric damage (SLICC/ACRDI), and separate neuropsychiatric component 
scores of SLE-injury indices (neuro-SLEDAI and neuro-SLICC) (Appenzeller et al., 2008;  
Ainiala et al., 2005). 
 
 
Fig. 1. FLAIR and T1 MR images of a 44 years female with NPSLE reveal multiple focal 
punctuate lesions-hyperintense on FLAIR and hypointense or isointense on T1- at the 
periventricular and subcortical white matter, semioval center and the cortex of the left 
frontal lobe.  
Besides aging, white mater hyperintensities are also associated with hypertension, valvular 
heart disease, and migraine, conditions that commonly occur secondary or concomitantly to 
NPSLE. Consequently, it is not possible to differentiate NPSLE from other vasculopathies 
using conventional MRI. The differentiation of acute active disease from old chronic lesions 
is also difficult. It has been noted that the presence of indiscrete lesion borders, intermediate 
intensity of T2 lesions and grey matter lesions are all indicative of active disease (Sibbitt et 
al., 1999). The use of gadolinium has also been shown to be helpful in delineating active 
inflammatory lesions that usually enhance (Miller et al., 1992). Quantitation of T2 values has 
also been shown to be helpful in distinguishing active from chronic lesions (Sibbitt et al., 
1995). T2 values appear to be increased in the normal appearing frontal grey matter of 
patients with active diffuse neurological syndromes. 
MRI studies may show extensive bilateral, potentially reversible, white matter 
abnormalities in the cerebral hemispheres, the brainstem, or the cerebellum usually 
associated with active NPSLE—the so-called “acute posterior leukoencephalopathy,”( 
Sibbitt et al., 1999). The reversible lesions of acute leukoencephalopathy of NPSLE have 
been attributed to focal cerebral edema associated with blood vessel injury and 
microhemorrhages (Sibbitt et al, 2010). 
Atrophy was described in 6–12% of SLE patients (Appenzeller et al., 2005,2008) and is 
associated with multiple factors such as disease duration (Cauli et al., 1994), corticosteroid 
use (Appenzeller et al., 2005; Ainiala et al, 2005), older age (Appenzeller et al, 2005), 
Non-Conventional MRI Techniques in Neurophychiatric Systemic Lupus Erythematosus (NPSLE): 
Emerging Tools to Elucidate the Pathophysiology and Aid the Diagnosis and Management 
 
445 
antiphospholipid antibodies (Appenzeller et al., 2008; Provenzale et al., 1996) and the 
presence of hyperintense white matter lesions (Appenzeller et al., 2005; Chinn et al., 1997). 
The loss of tissue within the brain is thought to result from a combination of both myelin 
damage and axonal loss, followed by Wallerian degeneration, and the loss of extracellular 
space and vascular compartments. The histopathological findings associated with MRI-
visible cerebral atrophy were highly variable and included multiple infarcts and reduced 
neuronal density, suggesting that atrophy in NPSLE may be associated with both 
generalized and focal brain injury. However, normal histological appearance was also noted 
in some atrophic brains (Sibbitt et al., 2010). 
Cerebral atrophy is usually measured from T1-weighted MRI scans, where good contrast 
between the cerebral spinal fluid (CSF) and the brain parenchyma is observed (Appenzeller 
et al., 2008). Because high spatial resolution images allow brain volume measurement with 
the greatest accuracy and precision, three-dimensional gradient methods are generally 
preferred. As cerebral atrophy can be measured serially on MRI scans of the brain by linear 
or volumetric measurements, it has been proposed as a means of monitoring the progression 
of SLE (Appenzeller et al., 2005, 2008).  
Regional atrophy in SLE patients has also been described involving cortical and 
subcortical regions, with particular clinical significance. Selective involvement of the 
amygdala in patients with SLE and anti-NMDAR antibodies has been found (Emmer et 
al., 2006). Cognitive impairment may be present more frequently in both corpus callosum 
and hippocampal atrophy (Appenzeller et al., 2006, 2008). Mild or clinically insignificant 
spinal cord pathology has also been described in SLE, which might be secondary to 
Wallerian degeneration of long tract fibers passing through damaged areas of the brain 
(Benedetti et al., 2007). 
MR Angiography detects medium-to-large vessels involvement. Since a small vessel 
vasculopathy represents the major histopathological background of brain involvement in 
NPSLE angiographic techniques are usually negative, although angiographic arterial 
stenoses or occlusions are rarely reported (Weiner et al., 1991). Multiple mechanisms for 
angiographic arterial stenosis or occlusion have been considered, including coagulopathy, 
cardiogenic embolism, atherosclerosis from long-term steroid use and anticoagulant or 
antiplatelet therapy, vasculitis due to SLE or infection, or a combination of these processes 
(Devinsky et al., 1998). 
Conventional MRI techniques are particularly useful in NPSLE patients with acute focal 
neurologic deficits, although they cannot always differentiate lesions indicating active 
acute NPSLE from chronic lesions that represent past NPSLE. The differential diagnosis 
usually includes thromboembolic events due to vasculopathy, lupus-related CNS 
vasculitis, antiphospholipid antibodies (APL-Ab)- mediated thrombosis, microangiopathy 
(including thrombotic thrombocytopenic purpura), Libman-Sacks endocarditis, and 
accelerated atherosclerosis. The pathogenesis in many patients is probably multifactorial. 
Accurate assessment is crucial, as treatment for these alternative diagnoses differs. 
Immunosuppressive agents are typically used for suspected vasculitis, while lifelong 
anticoagulation is the mainstay of therapy for APL-Ab-mediated thromboembolic  
events.  
In diffuse NPSLE presentation conventional MRI could be unremarkable since it doesn’t 
give information about damage in normal-appearing tissue (Sibbitt et al., 1999). Non-
conventional MRI techniques, sensitive to microstructural, hemodynamic and biochemical 
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characteristics of the tissues have been developed, that could detect gray and white matter 
abnormalities in NPSLE patients, otherwise occult by conventional imaging. 
4. Advanced MRI methods 
4.1 Diffusion–weighted imaging 
Diffusion-weighted imaging (DWI) is a magnetic resonance technique that is based on the 
random, incoherent (brownian) motion of protons on the molecular scale. In free water, 
proton-containing molecules move unrestricted in all directions, a situation that is referred 
to as isotropy. In highly structured tissue, such as the corticospinal tract, molecules 
encounter fewer barriers when moving in a craniocaudal direction than in directions 
perpendicular to it. This situation gives rise to preferential molecular movement in a certain 
direction, which is known as anisotropy. DWI can be used to measure diffusivity in the 
brain, providing signal proportional to the molecular diffusion of water molecules (Schaefer 
et al., 2000).  
Diffusion Tensor Imaging (DTI) is a DWI technique that permits assessment of the 
preferential direction of proton diffusivity (Ulug et al., 1999). DTI offers increased resolution 
compared to conventional MRI regarding white matter microstructure by measurement of 
water diffusion through cellular compartments in vivo (Pierpaoli et al., 1996). Compared to 
more isotropic movement of water in gray matter, water diffusion in white matter moves 
anisotropically, meaning that water diffuses preferentially along the length of the axon 
compared to perpendicular to the axon. This anisotropic diffusion of water appears to be 
due to the highly structured axonal membranes and their associated myelin sheaths (Cascio 
et al., 2007). By tracking the diffusion of water in the brain, the measure fractional 
anisotropy (FA) and mean diffusivity (MD) can be derived. Higher FA (and lower MD) 
suggests greater axonal coherence and myelination. Measures of FA are usually considered 
to be overall measures of axonal integrity, reflecting either increased axonal caliber, 
increased myelin thickness, increased fiber coherence in a given direction, or some 
combination of these factors. In contrast, MD, is a measure of the average molecular motion 
independent of the constraints of tissue boundaries, and is affected by cellular size and 
degradations in tissue integrity (Pierpaoli et al., 1996). One way to assess the magnitude of 
diffusion is by calculating the apparent diffusion coefficient (ADC), an index of mean 
diffusivity, for individual pixels on average apparent diffusion coefficient (ADC) maps. 
Average diffusion coefficient (ADC) maps provide information on the microstructure of 
tissue and can be very useful in the detection of disease ADC values that can be assessed 
locally in regions of interest (ROIs). Another way is the generation of ADC histograms for 
the whole brain (Nusbaum et al., 2000). Such measures consisted of mean ADC values of the 
whole brain volume and descriptive parameters of ADC histograms of the whole brain, such 
as peak height. Relatively few studies have emerged showing water diffusivity changes in 
NPSLE. DWI was first used by Moritani and co-workers (Moritani et al., 2001) who detected 
acute or subacute lesions in 9 of 20 patients with SLE (45%). Two main patterns of acute or 
subacute brain parenchymal lesions were described. The first include hyperintense lesions 
with decreased ADC indicating acute or subacute infarction due to primary or secondary 
arterial stenosis or occlusion (Figure 2) and the second isointense or slightly hyperintense 
lesions on diffusion-weighted images with increased ADC representing vasogenic edema, 
with or without microinfarcts, due to small-vessel vasculopathy or hypertensive 
encephalopathy (Figure 3). 
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Fig. 2. Hyperintense lesion at the right corona radiata with increased signal intensity on 
DWI and decreased signal intensity on ADC map due to acute infarction. 
 
 
Fig. 3. Hyperintense lesion at the right semioval center with increased signal intensity on 
DWI and increased signal intensity on ADC map, due to vasogenic edema. 
DWI then was used in NPSLE patients to provide quantitative measures of the integrity of 
the entire brain (Bosma et al., 2003). Using ADC histograms of the whole brain, in a group of 
11 patients with a history of non focal NPSLE and 10 healthy volunteers they found changes 
in NPSLE patients who had no relevant changes on conventional MRI,   that correlated with 
their clinical symptoms. The ADC histograms of the NPSLE group were, on average, 
significantly lower and broader, with a significant decrease of the peak height and a 
significant increase in the number of pixels with higher ADC values compared to the 
healthy subjects. The flatter and broader histograms in the NPSLE group indicate that, in 
these patients, widespread increased motility of free-water protons occurs. The subtle white 
matter hyperintensities that were visible on conventional MR images seemed unlikely to be 
responsible for the significantly different diffusion pattern in NPSLE because their number 
and sizes were small. These findings suggest that widespread damage exists in the brain 
parenchyma of NPSLE patients, invisible with conventional MRI. However, the method 
used in that study did not permit assessment of which parts of the brain were responsible 
for the observed changes in the ADC histograms of the whole brain.  
Welsch and co-workers investigated 21 acute NPSLE patients and 21 healthy volunteers 
using also ADC histograms (Welsch et al., 2007).Whole-brain histograms, gray matter only 
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histograms, and white matter only histograms were calculated for each subject. They found 
increased mean ADC values in acute NPSLE, not only in the whole-brain histograms, but 
also in the gray matter only  and white matter only, indicating that the cerebral alterations is 
not limited to one tissue compartment.  
Zhang and co-workers used a region of interest (ROI) approach for ADC and FA 
measurements to assess a cohort of 34 patients diagnosed with SLE, and 29 healthy 
volunteers  (Zhang et al., 2007). They found early diffusion changes (higher diffusion values 
and lower FA values) in the frontal lobe, the genu of the corpus callosum, and the anterior 
internal capsule in patients with SLE, although routine MRI findings were negative. 
Another group (Hughes et al., 2007) compared 8 female NPSLE patients, with new onset of 
symptoms, to 20 healthy controls using diffusion tensor imaging (DTI) and an ROI 
approach. They found that these patients differed from controls in a wide range of normal 
appearing gray and white matter regions including the insular cortex, thalamus, parietal 
and frontal white matter, and corpus callosum. These findings are suggestive of the 
presence of subtle and widespread damage in the brain parenchyma in NPSLE patients. 
Recently Jung and co-workers  (Jung et al., 2010) using DTI and the tract-based spatial 
statistics (TBSS) analysis  technique  assessed  white matter abnormalities in 17 NPSLE 
patients, 16 SLE patients without NPSLE, and 20 age- and gender-matched controls. 
According to their findings there were no significant FA or MD differences observed 
between the SLE patients without NPSLE and the matched controls, although many of the 
SLE patients had subcortical white matter and periventricular lesions. In contrast, when 
comparing the acute NPSLE patients to controls, or the acute NPSLE patients to patients 
with SLE without NPSLE they found decreased   FA and   increased MD values especially at 
the corpus callosum and the left anterior corona radiata reflecting diffuse white matter 
abnormalities. They suggest that either the acute effects of the NPSLE disease, or its 
treatment, results in white matter changes discernable with conventional MRI techniques. 
This study provides new evidence that FA and MD may have diagnostic use in NPSLE by 
demonstrating, for the first time, regional brain specificity, and by distinguishing NPSLE 
from SLE patients, further indicating the potential diagnostic specificity of this technique for 
patients in the acute stage of this difficult disease. 
Using the same analysis technique Emmer and co-workers  (Emmer et al., 2010) investigated 
12 patients with SLE (7 with NPSLE) and 28 healthy controls with DTI and found reduction 
in the FA values of patients with SLE as compared with normal subjects, indicating reduced 
integrity at particular white matter tracts. The integrity of the subcortical white matter tracts 
of the occipital, parietal and posterior frontal lobe was relatively preserved, whereas the 
frontobasal and temporal regions including the inferior fronto-occipital fasciculus, the 
fasciculus uncinatus, as well as the fornix, the posterior limb of the internal capsule 
(corticospinal tract), and the anterior limb of the internal capsule (anterior thalamic 
radiation) seem to be predominantly involved. 
The increased ADC values, as well as the decreased FA values, could be explained by 
reduced structural integrity of the brain parenchyma with permanent loss of neurons and 
demyelination in patients with NPSLE. This will allow the interstitial water molecules to 
move freely in a less restricted environment. Normally, the ADC values decrease and the FA 
values increase by the restriction of motion in a particular direction, for example, due to the 
boundaries of myelin sheets. Alternatively, loss of structural brain integrity would allow 
interstitial water molecules to move in a more unrestricted environment, thus resulting in an 
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increase in ADC and decrease in FA. A breakdown of the myelin sheets, as in 
demyelination, would result in less restricted movement of the water molecules transverse 
to the fiber tracts. The observed increase in gray matter ADC can be interpreted as 
consistent with inflammation and/or vasculitis of the gray matter.  
It has been suggested that the abnormal diffusion findings seen in the brain of NPSLE 
patients are not mainly related to hypoxic/anaerobic events, but, rather, indicate a host 
response to injury, such as an inflammatory reaction, membrane activation, or 
demyelination (Sibbitt et al., 1997). Such a theory can be supported by histopathology 
studies in which gliosis and demyelination has been described in the brain parenchyma of 
patients with NPSLE (Hanly et al., 1992). Immune-mediated vascular or neuronal injury was 
postulated and subsequent neuronal and metabolic dysfunction resulting in edematous 
processes that increase water content in WM regions of the brain. 
The white matter damage in NPSLE could be the indirect result of subtle noxious influences 
in NPSLE, such as repeated episodes of acute inflammation in small vessels. This could 
cause priming or activation of the wall of these small vessels by complement and/or 
antiendothelial antibodies. Priming or activation of the vessel wall could subsequently lead 
to vasculopathy and microinfarcts or subtle hypoperfusion in the small vessels of the brain 
(Zvaifler et al., 1982). Altered cerebral blood flow was previously demonstrated with PET 
and SPECT in NPSLE patients (Kuschner et al., 1990; Kao et al., 1999). If hypoperfusion 
occurs, it might be responsible for the metabolic abnormalities reported in NPSLE patients, 
as suggested by decreased high energy phosphate levels in phosporus-31 MR spectroscopic 
studies and decreased brain oxygen consumption in PET studies. The end stage of this 
process might be axonal loss and associated demyelination. It is also possible that antibodies 
aimed directly against myelin, leading to direct white matter damage through a pervasive 
attack on axonal myelin sheaths or the oligodendrocytes from which they are derived. The 
involvement of the white matter could be, finally, the reflection of axonal damage through 
Wallerian degeneration caused by damage to the gray matter (Emmer et al., 2010). 
Diffusion differences affecting acute NPSLE patients could also be related to therapy, 
whereby the introduction of corticosteroids, or other immunosuppression drugs (i.e. 
cyclophosphamide), and/or disease modifying antirheumatic drugs, can affect water 
content in the brain parenchyma. Another possible mechanism may be related to platelet or 
fibrin macro- or microembolism from Libman-Sacks endocarditis or anticardiolipin 
antibodies causing multiple areas of macroscopic or microscopic ischemia, infarctions, and 
microhemorrhages with surrounding edema (Roldan et al., 2006).  
Undoubtedly, one of the more useful applications of DWI in clinical practice is the 
assessment of cerebro-vascular accidents; in these conditions DWI allows early detection 
(within 1 h) of acute ischemic insult showing a reduction of ADC due to cytotoxic edema 
which occurs rapidly after the onset of ischemia (Figure 2). DWI also permits to discriminate 
between recent (with restricted diffusivity) and old (with normal diffusivity) hyperintense 
ischemic lesions which can be otherwise undistinguishable with conventional MRI. 
Furthermore, for its ability to differentiate between vasogenic and cytotoxic edema, DWI 
could be also useful in SLE patients to discriminate between inflammatory and ischemic 
lesions (Iguchi et al., 2007). Increased diffusion occurs although conventional MRI findings 
are negative in some cases, which suggests that DTI is more sensitive and that quantitative 
diffusion measurements can be used in detecting early signs of SLE or, furthermore, 
monitoring disease evaluations. The findings of diffusion-weighted imaging may help guide 
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the choice of treatment and predict patient outcome in patients with SLE and CNS 
involvement. 
4.2 Perfusion weighted imaging 
A variety of imaging techniques have been used to assess cerebral perfusion, beginning with 
positron emission tomography (PET). PET is a nuclear medicine technique which explores 
both brain glucose metabolism and cerebral blood flow (CBF). In patients with NPSLE 
multiple areas of hypometabolism were detected in both MRI normal-appearing white and 
grey matter regions (Otte et al., 1997). Although PET has high sensitivity (abnormal in 100% 
of patients with active NPSLE), it lacks specificity and due to its high radiation dose, high 
cost and  limited availability, is  rarely applied in the  daily clinical practice. 
Over the past two decades, two more perfusion imaging techniques, single photon 
emission computed tomography (SPECT), and perfusion-weighted MRI (PWI), were 
introduced. These techniques have been used to evaluate a variety of disease states, most 
commonly acute and chronic ischemia. SPECT is based on the radio-tracer uptake by 
viable neuronal cells and explores brain perfusion that is the result of both CBF and 
neuronal integrity. The most commonly observed abnormalities detected by SPECT in 
patients with NPSLE are diffuse, focal or multifocal areas of decreased uptake 
corresponding to hypoperfusion, which -according to some authors- correlates with NP 
disease severity and activity (Colamussi et al., 1995). Other SPECT studies reported CBF 
abnormalities in NPSLE without correlation to disease activity or serological parameters. 
There is also no significant associations between perfusion parameters and NP symptoms 
(Waterloo et al., 2001). A recent voxel-based SPECT study found no difference in 
perfusion parameters between healthy controls and SLE patients with inactive NP 
involvement. However the authors found a global hypoperfusion in active NPSLE 
patients compared to healthy controls, which was mainly located in the cortical gray 
matter (Appenzeller et al, 2008). Although SPECT has high sensitivity (abnormal in 86–
100% of patients with major NPSLE) it lacks specificity (abnormal in 10–50% of SLE 
patients without NPSLE) and has limited anatomic resolution. 
The most commonly used MR perfusion technique is dynamic susceptibility contrast (DSC) 
imaging. This is a non-invasive dynamic process based on the MR signal changes during the 
first pass of the intravenously injected contrast agent (a gadolinium chelate) through the 
vasculature. The change in signal intensity is then measured and perfusion maps are 
generated, most commonly encountering cerebral blood volume (CBV), cerebral blood flow 
(CBF), time to peak (TTP), or mean transit time (MTT)values. Nowadays PWI is widely used 
in the acute stroke, for evaluation of the salvageable tissue and the brain neoplasms to detect 
neoangiogenesis. This technique could be useful in NPSLE and antiphospholipid syndrome 
(APS) patients (Figure 4) at risk of cerebro-vascular ischemic events, but reports on the use 
of PWI in NPSLE are still very few and limited.  
The first multimodality approach in patients with SLE was performed by Borelli and co-
workers (Borelli et al., 2003) using simultaneously MRI, DWI, PWI and SPECT in 20 SLE 
patients. They found that SPECT was more sensitive than PWI in detecting brain 
hypoperfused areas, probably due to the different aspects of brain perfusion explored by 
these two techniques. PWI is a dynamic process related to the blood supply to the 
anatomical districts of the brain, while  SPECT images reflect the distribution of a flow tracer 
Non-Conventional MRI Techniques in Neurophychiatric Systemic Lupus Erythematosus (NPSLE): 
Emerging Tools to Elucidate the Pathophysiology and Aid the Diagnosis and Management 
 
451 
whose uptake at the neuronal level may, however, be in part influenced by the metabolic 
status of the nervous tissue. Therefore the combination of these techniques might yield more 
information about the underlying pathogenetic mechanism of brain hypoperfusion.  
 
 
Fig. 4. Imaging of an acute ischemic lesion in a 45 yrs old female with NPSLE and 
antiphospholipid syndrome (APS), 4 hours after the onset of the symptoms. FLAIR is 
unremarkable, while the lesion is revealed on DWI and ADC map as hyperintense and 
hypointense area, respectively, due to cytotoxic edema. Dynamic Susceptibility Contrast 
(DSC) MR Perfusion technique shows mild increased cerebral blood volume ( red on CBV 
map), decreased cerebral blood flow (dark blue on CBF map) and increased  mean transit 
time (red on MTT map)  
Two recent studies with application of dynamic susceptibility contrast perfusion MRI in SLE 
patients have opposite results. In the first study 15 active NPSLE, 26 inactive NPSLE and 11 
control subjects were investigated and no signs of focal or global abnormalities in the 
perfusion parameters of the patients were found (Emmer et al., 2010). Furthermore, no 
significant differences were found when comparing patients with a specific SLE criterion 
(lupus anti-coagulant LAC, anti-cardiolipin antibodies or APS).The main limitation of this 
study is the fact that the CBF and CBV values have been calibrated to normal white matter, 
assuming that perfusion in the contralateral white matter is normal. This assumption could 
be erroneous in SLE patients with diffuse NP symptoms, like cognitive dysfunction or 
headache. 
In the second study (Gasparovic et al., 2010)the DSCMRI technique was performed in 42 
SLE patients and 19 healthy controls. They demonstrated higher CBV and CBF throughout 
cortical and white matter regions in the SLE patients (with or without lesions) relative to the 
control group. According to the authors the higher global CBF and CBV values may be due 
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to reactive physiologic or pathogenic factors underlying SLE, such as vasomotor instability, 
compensatory mechanisms for resolving injury, low-grade excitotoxicity due to antibody 
impairment of N-methyl D-aspartate (NMDA) receptors, or inflammatory factors. This 
global hyperperfusion in SEL patients is in contrast with most SPECT studies that reveal 
patchy hypoperfused areas in SLE patients. More studies should be performed to SLE and 
NPSLE patients with application of both SPECT and MRI perfusion techniques to further 
delineate this issue.  
4.3 Magnetization Transfer Imaging (MTI) 
MTI is a quantitative MRI technique that is sensitive to macroscopic and microscopic brain 
tissue changes (Grossman et al., 1994; Wolff et al., 1994) and more sensitive to the presence 
of disease than conventional MRI. In MRI, the magnetic characteristics of free-water protons 
determine the contrasts of the images. MTI is based on the magnetization transfer that 
occurs between the bound pool of macromolecule-related protons in biologic tissues and the 
pool of free water protons. In MTI, a saturating RF pulse selectively reduces the 
magnetization of the bound pool. Due to the interactions between the two proton pools, the 
magnetization of the free-water pool is also reduced, which is called the MT effect. Tissue 
factors that affect the amount of this magnetization transfer are the concentration of 
macromolecules and the surface chemistry and biophysical dynamics of the macromolecules 
(Wollf et al., 1994). Macromolecules that contribute to the MT effect in the brain are the 
cholesterol component of myelin, cerebrosides, and phospholipids (Koenig et al., 2001).  
The amount of MT is expressed by the magnetization transfer ratio (MTR) value. MTR 
values can be easily calculated in regions of interest (ROIs) to assess local tissue 
composition. In most diseases affecting the brain, MTR values are reduced, presumably due 
to dilution or destruction of macromolecules (Finelli et al., 1998). Using this approach it has 
been proved that MTI could detect abnormalities in brain tissue that are not visible in 
conventional MRI in cases of multiple sclerosis (Rovaris et al., 2000).Whole brain assessment 
can be also performed using MTR histograms for quantification of the disease burden of the 
whole brain (van Buchem et al., 1997). According to this volumetric method, the intracranial 
volume (ICV) is segmented, and the MTR values of the segmented brain are displayed as a 
histogram. Gray and white matter have different mean MTRs, which is probably mainly due 
to different concentrations of myelin. Still, the histograms for gray matter and white matter 
overlap substantially. The summation of these 2 histograms results in a histogram that is 
characteristic of the whole brain. The shape of this whole-brain histogram reflects conditions 
that affect the gray and white matter. MTR histograms of normal brains are characterized by 
the presence of a single, sharp peak, indicating that most normal brain voxels have 
approximately the same MTR values due to relative homogeneous tissue composition and 
microstructure. Demyelination, edema, atrophy and gliosis could impair MTR and the MTR 
histograms shape become flattened with decreased peak height reflecting dyshomogeneity 
of the brain tissue. In this way MTI allows the evaluation of brain tissue integridy, while 
simultaneously permits quantification of structural damage.  
Studies that compared MS patients with normal controls using MTI revealed that the MTR 
histogram peak height was the volumetric MTI parameter that differed most significantly 
(van Buchem et al., 1998). This peak height was found to be decreased in MS patients.  It was 
suggested that the peak height was a measure of the amount of residual normal brain tissue, 
and therefore inversely reflected the disease burden of the brain (van Buchem et al., 1998). In 
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several MS studies, this measure was found also to correlate with measures of cognitive and 
neurologic functioning (van Buchem et al., 1998). 
MTI has been applied in NPSLE patients without visible abnormalities on conventional 
MRI. All these studies used MTR histograms for the quantitative assessment of the whole 
brain abnormalities. Bosma and co-workers (Bosma et al., 2000) applied the MTI technique 
to 11 patients with NPSLE, 11 patients with SLE without history of NPSLE (non-NPSLE) 
and 10 healthy volunteers. In this study, for every patient, an MTR histogram was created 
after correction for the ICV and another was created after correction for brain volume. In 
MTR histograms that are adjusted for the ICV, the peak height reflects both the integrity 
of brain parenchyma and the extent of atrophy. A different distribution of the brain 
voxels, in terms of changes in MTR values due to disorders of brain parenchyma or a 
reduction in the total number of brain voxels due to atrophy, can cause a decrease in the 
peak height. The peak height of the MTR histograms corrected for brain volume is 
affected only by the aspect of brain parenchyma, and not by the volume of the brain and 
atrophy (van Buchem et al., 1998). In the group of NPSLE patients, the average peak 
height of the histograms corrected for intracranial volume and the peak height 
normalized for brain volume were significantly lower than in either the non-NPSLE 
patients or the healthy controls at the same position of the peaks. This suggests the 
presence, in NPSLE, not only of atrophy, but also of an abnormality of the remaining 
brain parenchyma. The latter disorder in NPSLE is probably primarily present in the 
normal appearing parenchyma, since the low number and small size of hyperintense 
lesions observed in these patients cannot solely account for the decreased peak height of 
the histograms. Since myelin is a major contributing factor to the MT effect in the brain, 
the decreased peak heights of the MTR histogram corrected for brain volume might have 
originated from demyelination along with axonal loss. Edema and gliosis are also 
considered to give rise to abnormal MTRs (Dousset et al., 1992). 
In another study (Bosma et al., 2000) MTI was performed to 9 patients with active 
nonthromboembolic NPSLE, 10 patients with chronic NPSLE, 10 patients with SLE and no 
history of NPSLE (non-NPSLE), 10 patients with inactive MS, and 10 healthy control 
subjects, to investigate whether volumetric MTI analysis with MTR histograms can 
demonstrate abnormalities in patients in the acute stage of diffuse NPSLE and compare 
these findings with those from chronic SLE, non-SLE and MS. The MTR histograms of both 
the non-NPSLE group and the healthy controls were similar. There was flattening of the 
histograms in the active NPSLE group, but with a shift toward higher MTRs. These changes 
indicate that the uniformity of the brain in patients with active NPSLE is lower than that in 
SLE patients with no history of NPSLE as well as that in healthy controls, suggesting that 
patients with active NPSLE can be distinguished from SLE patients with no history of 
NPSLE by use of MTR histogram analysis. The shift of the MTR histogram peak to the right 
that was observed in active NPSLE suggest an all-over improvement in the exchange of 
saturation from the pool of bound protons to that of the free water protons. Increased MTRs 
were also found in an experimental model of acute inflammation in MS, experimental 
allergic encephalomyelitis, during the early phase of inflammation in that disease (Dousset 
et al., 1992). Similar processes may occur during the active phase of NPSLE. In this study, all 
MTR histogram parameters in chronic NPSLE and MS were identical. Since NPSLE and MS 
are diseases with a different biologic behavior, it is unlikely that these similarities suggest a 
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similar pathogenesis. Instead, the similarities indicate that different diseases may give rise to 
a common final pathway (i.e., gliosis and demyelination) that results in similar changes in 
the MTR. These results also demonstrate that in the chronic stage of diffuse brain diseases, 
MTR histograms may not be able to differentiate between different diseases.  
The same group (Bosma et al., 2002) further investigated the relationship between 
quantitative estimates of global brain damage based on magnetization transfer imaging 
(MTI) and the cerebral functioning, as measured by neurologic, psychiatric, and cognitive 
assessments, as well as the disease duration in patients with NPSLE. They performed MTI to 
24 patients with NPSLE and found significant correlations between the descriptive measures 
of the MTR histograms and: a) the neurologic functioning quantified by the Kurtzke’s 
Expanded Disability Status Scale (EDSS) b) the cognitive functions with the Wechsler Adult 
Intelligence Scale Revised (WAIS-R), a standardized psychometric test for assessing  
intelligence and c) the  psychiatric functioning by the Hospital Anxiety and Depression 
Scale (HADS) questionnaire. Since the EDSS score mainly assesses motor skills, these 
findings suggest that atrophy and diffuse microscopic damage of the remaining brain 
parenchyma in NPSLE affect, among other areas, brain regions that are responsible for 
motor skills. Atrophy and diffuse microscopic cerebral damage also contribute the 
development of psychiatric symptoms, like anxiety and depression and cognitive 
impairment. There is no correlation between the quantitative estimates of global brain 
damage and age, SLE duration, or time elapsed since the first occurrence of 
neuropsychiatric symptoms suggesting that the accumulation of brain damage over time 
has a nonlinear aspect. 
Dehmeshki and co-workers (Dehmeshki et al., 2002) developed an alternative way of 
analyzing and globally characterizing MTR histograms by using multivariate discriminant 
analysis (MDA) and correctly assigned patients with MS to clinical subgroups. The same 
group proceed to a study in SLE patients in order to explore the diagnostic potential of 
MDA for assigning patients with SLE to different subgroups of patients with on the basis of 
MTR histograms (Dehmeshki et al., 2002). MTI was performed to 9 patients with active 
NPSLE, 10 patients with chronic NPSLE, 10 patients with SLE and no history of NPSLE 
(non-NPSLE), 10 patients with inactive MS, and 10 healthy control subjects. Three binary 
comparisons were made: First, comparison of active NPSLE versus past NPSLE groups 
which is important because in patients with NPSLE, a new episode of neuropsychiatric 
symptoms could be due to an active intrinsic SLE-related brain process—that is, a recurrent 
active phase of NPSLE—or to extrinsic processes such as the side effects of drug use. 
Secondly,  comparison of active NPSLE from non-NPSLE which is also important because 
an acute episode of neuropsychiatric symptoms could be due to active NPSLE or to extrinsic 
processes in patients with SLE. Finally, comparison of patients with active and/or past 
NPSLE with those who have MS which important because in patients who present with 
neuropsychiatric symptoms, the differential diagnosis includes SLE and MS, and these 
diseases are notoriously difficult to differentiate. In this study, MDA proved to be effective 
in assigning the majority of individual patients to disease categories in the given binary 
comparisons. In addition, MDA was shown to be considerably more effective for 
categorizing patient groups on the basis of MTR histograms than the conventional method 
of analyzing MTR histograms and might be of help in clinical practice. 
Steens and co-workers (Steens et al., 2004) performed MTI in 24 SLE patients with a history 
of diffuse neuropsychiatric symptoms and 24 healthy controls to assess the distribution of 
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MTI abnormalities over gray matter (GM) and white matter (WM) in SLE patients without 
explanatory MRI evidence of focal disease. MTR maps were calculated for GM and WM 
separately, and GM and WM MTR histograms were generated. Significantly lower peak 
height and mean MTR of the gray matter were found in NPSLE patients as compared with 
healthy controls indicative of parenchymal brain damage specifically in the GM in SLE 
patients with a history of NP symptoms and without explanatory focal abnormalities seen 
on MRI.  This observation supports the model of neuronal damage in diffuse NPSLE, and 
can be explained by the greater susceptibility of GM to the sequelae of small-vessel disease 
and hypoperfusion. Small-vessel disease itself may also increase blood–brain barrier 
permeability, which facilitates the entrance of antineuronal antibodies. In either case, 
because of the higher concentration of neurons in GM, the GM will be particularly affected. 
The same group (Steens et al., 2006) examined the correlation between gray and white 
matter magnetization transfer ratio (MTR) parameters and the presence of IgM and IgG 
anticardiolipins antibodies (aCLs) and lupus anticoagulant in 18 patients with NPSLE, but 
without cerebral infarcts on conventional magnetic resonance imaging. Lower gray and 
white matter mean MTR and peak location were observed in IgM aCL-positive patients than 
in IgM aCL-negative patients. No significant differences were found in MTR histogram 
parameters with respect to IgG aCL and lupus anticoagulant status, nor with respect to anti-
dsDNA or anti- ENA (extractable nuclear antigen) status. 
Various autoantibodies have been implicated in the pathogenesis of NPSLE, including 
anticardiolipin antibodies (aCLs) .Because of their prothrombotic tendency, aCLs may cause 
cerebral infarctions and as such they are correlated with focal neurological syndromes 
(Denburg, Denburg, 2003). In a study of Steens and co-workers (Steens et al., 2006) MTI 
parameters demonstrated brain damage in aCL-positive SLE patients in the absence of 
cerebral infarcts on conventional MRI. These findings suggest that, apart from giving rise to 
macroscopic cerebral infarctions, aCLs may play a role in the pathogenesis of diffuse 
microscopic brain damage in NPSLE. According to the authors there are at least three 
possible explanations for how aCLs could be involved to diffuse microscopic brain damage 
in NPSLE. First, the thrombotic tendency of antiphospholipid antibodies, including aCLs, 
may cause aggregation of thrombocytes and an increase in blood viscosity (Scolding, Joseph 
2002; Connor, Hunt 2003). This may affect blood flow in small cerebral blood vessels in 
particular and cause widespread hypoperfusion, which subsequently causes ischaemic 
damage to brain tissue. Second, aCLs may activate endothelial cells and cause a diffuse 
small-vessel vasculopathy – a neuropathological finding that was reported as long ago as 
1968 (Connor, Hunt 2003; Scolding, Joseph 2002). The resulting increase in blood–brain 
barrier permeability permits entrance to the brain parenchyma of substances such as 
circulating antibodies. Third, it has been shown in vitro that IgG aCLs themselves may 
interfere with glutamatergic pathways by a mechanism involving over-activation of the N-
methyl-d-aspartate receptor (Andreasi et al., 2001). 
Emmer and co-workers (Emmer et al., 2006) proved that changes in the clinical status of 
individual NPSLE patients correspond to changes in the MTR peak height and MTI is a 
valuable objective measure for following a clinical course in NPSLE. 19 active or inactive 
NPSLE patients underwent MTI on at least two separate occasions. Their neuropsychiatric 
status between the first and the second MRI sessions was classified as deteriorated, stable, or 
improved. In all clinically deteriorated patients the MTR peak height decreased between the 
first and second scans. In all clinically improved patients the MTR peak height increased 
 
Neuroimaging – Clinical Applications 
 
456 
between the first and second scans, indicating that brain involvement in NPSLE patients, as 
detected by MTI, is at least partly reversible. The nature of the pathophysiological substrate 
of the reversible MTR changes in NPSLE patients is unclear. According to the authors 
reversible changes in the integrity of the parenchyma are probably due to edema, since 
neuronal loss would not show such a degree of reversibility, and neuronal apoptosis is not a 
common finding in postmortem studies of NPSLE. Inflammation influences the vessel walls 
and permits extravasation of fluid and inflammatory mediators into the brain tissue that 
leads to inflammatory brain edema 
4.4 Magnetic Resonance Spectroscopy 
Proton Magnetic Resonance Spectroscopy (MRS) is an MRI technique that permits study of 
the metabolites in tissue and provides qualitative and quantitative information about some 
brain metabolites displayed as spectra. The position of metabolites peaks in the spectrum is 
determined by its molecular characteristics. Studies in humans have used hydrogen –MRS 
(H-MRS) and rarely phosphorous-MRS (P-MRS). In normal water-suppressed, localized H-
MRS of human brain at echo times (TEs) between 135 msec and 270 msec 3 major 
neurometabolites are revealed: 1. N-acetylaspartate (NAA) with peak at 2.0 parts per 
million, which can be used as a neuronal marker, because  is found exclusively in neurons. 
NAA is reduced in conditions associated with neuronal loss, such as stroke or neuronal 
degenerative disorders. However, several studies have shown reversible decreases in NAA 
in a number of conditions have also been recognized, emphasizing that neuronal 
dysfunction can also lead to a decrease in NAA (Rudkin, Arnold, 1999). 2. Choline (Cho). 
Choline peak consists of choline, phosphocholine and glycerocholine. Cho is increased 
during increased cell -membrane turn over or during active myelin breakdown when these 
choline-containing membrane phospholipids are released. Increase Cho is detected in 
demyelination, remyelination, inflammation or gliosis (Rudkin, Arnold, 1999). 3. Creatine 
and phosphocreatine (Cr).Total creatine concentration is relatively constant throughout the 
brain , and  is used as an internal reference to normalize NAA and choline. Nevertheless 
there is loss of creatine in tissue necrosis (Rudkin, Arnold, 1999). 
When performing MRS with short TE (30-35 msec) some other metabolites could also be 
revealed, such as myo-inositol (mI), which is an osmolyte and astrocyte marker and is 
usually increased in demyelination, inflammation and gliosis. Lactate is elevated in 
anaerobic glycolysis and is not seen in normal brain spectra. The lactate peak is above the 
baseline when the TE is low (20–35 msec) or high (270–288 msec). At an intermediate TE 
(135–144 msec), the lactate peak inverts to project below the baseline, a feature that enables 
its distinction from lipids and some macromolecules seen at a similar location on the 
spectrum (1.35 parts per million). 
Commonly used spectroscopic techniques include the single- voxel spectroscopy which 
allows evaluation of only small volumes of tissue, and the multivoxel technique that allows 
examination of different areas of the brain at the same time and also permits the derivation 
of metabolite maps. The selection of appropriate MRS techniques, including measurement 
parameters such as repetition time (TR) and TE, depends on the clinical question. Short TE 
(20–35 msec) evaluations are required when there is a need for detection of metabolites with 
short relaxation times, such as glutamine, glutamate or  mI,  whereas studies with  long TE 
(135–270 msec) are sufficient for the detection of the major metabolites such as NAA, Cho, 
Cr, and lactate/lipids (Rudkin, Arnold, 1999) 
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Several studies have been performed using MRS in patients with SLE with or without 
neuropsychiatric manifestations. Most of them used single voxel MRS and proved reduction 
of the NAA/Cr and NAA/Cho ratios and elevation of Cho/Cr ratio in patients with SLE, 
not only in lesions, but also in normal-appearing white matter, when compared to controls. 
Nevertheless no dinstiction between acute and chronic disease has been demonstrated 
(Sibbit et al., 1997; Davie et al., 1995; Friedman et al., 1998). The NAA/Cr ratio was 
negatively correlated to the degree of atrophy in SLE patients, suggesting that cerebral 
atrophy in SLE in associated with neuronal damage (Sibbitt et al., 1994; Chinn et al., 1997). 
Decreased NAA/Cr ratio was found in white mater lesions of patients with NPSLE with no 
correlation with neurololgic or psyschiatric involvement (Davie et al., 1995). Patients with 
white matter lesions also had a more pronounced reduction in NAA/Cr ratio, when 
compared with patients without lesions, suggesting that neurophychiatric manifestations 
are associated with a complex multifocal and diffuse neurotoxic process (Brooks et al., 1999). 
Cerebrovascular abnormalities with small vessel injury, that underlie diffuse cerebral injury 
in SLE, (small focal lesions), are primarily associated with a decrease NAA/Cr ratio, while 
medium vessel injury is primarily associated with an increased Cho/Cr ratio (Friedman et 
al., 1998). It is well known that small focal lesions are also observed in healthy adults, often 
associated with older age. However, if neurometabolic changes are observed within these 
lesions, it could be inferred that these white matter lesions represent a serious pathologic 
process resulting in focal neuronal death or injury (Brooks et al., 1997). 
The amount of reduction in NAA/Cr ratio is associated with disease activity and the 
severity of clinical manifestations (Sibbitt et al., 1997).The same group failed to demonstrate 
lactate even in severely ill patients with major NPSLE, suggesting that extensive , anaerobic 
metabolism is not a fundamental characteristic of NPSLE, although this was contraindicated 
by others (Sundgren et al., 2005).They also found that increased lipid-macromolecules peaks 
at 1,2 ppm is an indicator of disease activity representing inflammatory cell infiltration, 
membrane activation, degradation or demyelination. Appenzeller and co-workers 
(Appenzeller et al., 2005) also demonstrated that the reduction in NAA /Cr ratio correlated 
with disease activity, independently of CNS manifestations, and that NAA/ Cr ratio in 
normal-appearing white matter returned to normal range after remission. 
Sabet and co-workers (Sabet et al., 1998) proved that NAA/Cr ratio was lower and Cho/Cr 
was higher in SLE patients with antiphospholipid antibody syndrome (aPLS) compared to 
those without aPLS . However thrombotic phenomena are most closely associated with the 
Cho/Cr ratio elevation in patients with SLE.  Elevated Cho/Cr ratio was observed in focal 
lesions and normal-appearing tissues of patients with SLE-aPLS consistent with infarct, 
activation of cellular membranes, catabolism of myelin, or inflammation. Cho/Cr ratio was 
increased in normal-appearing tissues, suggesting exaggerated injury to normal-appearing 
tissue in patients with SLE-aPLS consistent with widespread microinfarction. 
Reduction of NAA/Cr ratio and elevation of Cho/Cr ratio seem to reflect the cerebral 
metabolic disturbance related to the severity of neuropsychiatric symptoms regardless of the 
presence of abnormal MRI findings (Lim et al., 2000). In that study metabolic changes at the 
basal ganglia, besides the normal appearing white matter, was also found, indicating small 
vessel injury. Reduction of NAA/Cr ratio and elevation of Cho/Cr ratio in normal 
appearing white matter, related to the severity of neuropsychiatric symptoms was also 
proved by others (Axford et al., 2001; Handa et al., 2003; Castellino et al., 2005). Axford and 
co-workers also performed quantitative absolute assessment of the metabolites and found 
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increased absolute concentration of mI in NPSLE patients symptoms, that could be the 
result of inflammation, with a trend to be reversible in patients with minor. The authors 
suggest that raised mI, but normal NAA, that characterized SLE minor, may be due to result 
of vasculitis and inflammatory sequelae, which may be reversible if treated early enough. In 
contrast with the patients with SLE minor, the patients with SLE major had both increased 
mI and decreased NAA that may reflect gliosis and irreversible neuronal loss. 
Castellino and co-workers (Castellino et al., 2005) assessed metabolites at hypoperfused and 
normoperfused brain areas according to SPECT finding and found that NAA/Cr ratio was 
reduced in hypoperfused areas, and Cho/Cr ratio was elevated in normoperfused areas, 
while new white matter lesions were developed on previous areas of hypoperfusion and 
NAA/Cr ratio reduction indicating that increased Cho/Cr ratio in normal-appearing white 
matter may predict the appearance of white matter lesions. 
The NAA reduction has been also correlated with cognitive dysfunction and extent of brain 
damage (Sibbit et al., 1997; Lim et al., 2000). Increased choline was also associated with the 
presence of cognitive dysfunction in patients with SLE (Kozora et al., 2005) a finding that 
was further proved by other studies (Lapteva et al., 2006; Filley et al., 2009). Significant 
correlation was found between cognitive scores and higher Cho/Cr ratio of the dorsolateral 
prefrontal cortex and white matter (Lapteva et al., 2006) or the left frontal white matter 
(Filley et al., 2009).  
A recent study (Brooks et al, 2010) investigated most-mortem histopathological changes at 
autopsy in NPSLE patients and matched them voxel-by-voxel with the neurometabolites. 
They found that neurometabolite abnormalities were closely associated with underlying 
histopathological changes in the brain. Elevated choline levels were independently 
associated with gliosis, vasculopathy, and edema, while reduced creatine levels were 
associated with reduced neuronal–axonal density and gliosis. Reduced NAA levels were 
associated with reduced neuronal–axonal density and the presence of lactate was associated 
with necrosis, microhemorrhages, and edema. They suggest that altered neurometabolites in 
NPSLE patients, as determined by MRS, are a grave prognostic sign, indicating serious 
underlying histologic brain injury. 
Few studies incorporated a multisequence MRI approach in patients with NPSLE to 
investigate the relationship between the different non-conventional MRI techniques. Emmer 
and co-workers (Emmer et al., 2008) applied MTI and MRS in SLE and NPSLE patients and 
healthy controls and found that there was significant association between the MTR 
histogram peak height of the whole brain parenchyma and the white and gray matter and 
the NAA/Cr ratio, indicating that demyelination and neuronal/axonal damage often occur 
together in patients with a history of NPSLE. The Cho/Cr ratio showed no significant 
association with any MTR parameters. According to another study that investigated the 
relationship between magnetization transfer imaging (MTI), diffusion weighted imaging 
(DWI), proton magnetic resonance spectroscopy (H-MRS), and T2 relaxometry findings in 
patients with primary neuropsychiatric systemic lupus erythematosus (NPSLE) (Bosma et 
al., 2004), significant correlations were found between the different metrics and cerebral 
atrophy. The correlations between MTI and DWI parameters indicate that demyelination in 
NPSLE patients is associated with increased diffusivity, due to either to a breakdown of 
myelin or a discrete increase of CSF spaces-including perivascular changes-associated with 
cerebral atrophy. The association between prolonged T2 relaxation time and increased 
diffusivity could be based not only on atrophy, but also on the presence of gliosis.  
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NPSLE is characterized by variable, focal or diffuse,  neuropsychiatric symptoms, leading to 
significant morbidity and mortality. NPSLE manifestations can occur in the absence of either 
serologic activity or other systemic lupus manifestations and there is no single sensitive and 
specific diagnostic test. Thus, in clinical practice the diagnosis of primary NPSLE is rather 
presumptive, after the exclusion of alternative causes of the neuropsychiatric symptoms. In 
patients with focal symptoms conventional MRI commonly detects small, discrete, 
hyperintense, frontal–parietal subcortical or periventricular white matter lesions, or even 
microhemorrhages, which are not specific for NPSLE and exhibit no clinical correlation. In 
diffuse NPSLE presentation conventional MRI could be totally unremarkable. 
Non- conventional MRI techniques, namely diffusion weighted imaging (DWI), diffusion 
tensor imaging (DTI), perfusion weighted imaging (PWI), Magnetization transfer imaging 
(MTI) and magnetic resonance spectroscopy (MRS) have been developed. These techniques 
are sensitive to microstructural (DWI, DTI,MTI ), hemodynamic (PWI) and biochemical 
(MRS) characteristics of the tissues, and could detect gray and white matter abnormalities in 
NPSLE patients, otherwise occult by conventional imaging. Vasculopathy is the most 
common pathologic finding in NSPLE, while true vasculitis is rather uncommon. SLE 
vasculopathy affects predominantly arterioles and capillaries and could be related to both 
acute inflammation and hypoperfusion resulting in ischemia, demyelination, axonal loss 
and gliosis. These pathologic findings lead to particular changes of the non-conventional 
MRI metrics, such as reduced increased diffusivity, decreased fractional anisotropy, 
decreased MTR values , decreased NAA levels, and elevated choline levels, not only in focal 
lesions but mostly in normal appearing white and gray matter in patients with NPSLE. 
These quantitative changes are related to disease activity and severity, cognitive 
performance, and also the presence of antiphospholipid antibody syndrome and/or   
anticardiolipin antibodies, while could affect with the prognosis of new lesions and clinical 
deterioration. Although there are some inconsistencies in the various reports published thus 
far reflecting heterogeneity in patient selection, sample size and diagnostic criteria used, , 
we believe that there is enough data to support the use in daily clinical practice at  tertiary 
care centers of non- conventional MRI techniques  for  the diagnostic work up of SLE 
patients with neuropsychiatric manifestations.  For places whereby these modalities are not 
available the EULAR guidelines recommend at a minimum an  MRI protocol (brain and 
spinal cord) that  includes conventional MRI sequences (T1/T2, FLAIR), diffusion-weighted 
imaging (DWI), and gadolinium-enhanced T1 sequences (Bertsias  et al., 2010).  
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1. Introduction 
Tuberculosis is a formidable disease worldwide because of its highly infectious nature and 
propensity for latency. The increasing prevalence of tuberculosis in both immunocompetent 
and immunocompromised individuals in recent years makes this disease a topic of universal 
concern. The disease has insidious onset and can affect virtually any organ system in the body, 
including the central nervous system (CNS). The CNS tuberculosis can mimic a number of other 
disease entities, and therefore it is important to be familiar with the various radiologic features 
of CNS tuberculosis to ensure early, accurate diagnosis. In this chapter we discuss various 
possible presentation of central nervous system tuberculosis involving the brain and spine. 
2. Pathophysiology 
Most tuberculous infections of the central nervous system are caused by Mycobacterium 
tuberculosis, as a result of hematogenous spread from a primary location, either the lung or 
gastrointestinal tract. Initially, small tuberculous lesions (Rich’s foci) develop in the CNS, 
either during the stage of bacteraemia of the primary tuberculous infection or shortly 
afterwards. These initial tuberculous lesions may be inoculated in the meninges; the subpial 
and subependymal surface of the brain or the spinal cord, and may remain dormant for 
years. Later, rupture or growth of one or more of these small tuberculous lesions produces 
various types of CNS tuberculosis. The type and extent of lesion depend upon the number 
and virulence of bacilli and the immune response of the host.1 A tubercular rupture into the 
subarachnoid space results in TB meningitis; where as deep lesions cause tuberculoma or 
abscesses. TB meningitis may cause inflammatory changes in cranial/spinal nerves and the 
blood vessels. The inflammation of blood vessels (vasculitis) subsequently results in 
thrombosis and infarction. Hydrocephalous can occur secondary to impedance of CSF 
circulation and absorption. The inflammatory exudates may also surround the spinal cord 
producing tuberculous arachnoiditis. Infrequently, infection spreads to the CNS from a site 
of discal TB, tuberculous otitis, or osteogenic tubercular foci in the spine or cranial vault.2 
Pathologically, a tuberculoma is composed of central core of caseous necrosis surrounded by 
a capsule of collagenous tissues and an outer layer of mononuclear inflammatory cells 
(including plasma cells & lymphocytes), epitheloid cells and multinucleated Langerhans’ 
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giant cells. A tuberculoma harbours few tubercular bacilli within the necrotic center and the 
capsule. Outside the capsule, there is parenchymal edema and astrocyte proliferation. 
Unlike caseous tuberculoma, a tubercular abscess has purulent center rich in tubercular 
bacilli, and lacks epithelioid giant cell granulomatous reaction in its wall.3 
3. Clinical features 
CNS TB usually has signs and symptoms of increased intracranial pressure or space-
occupying lesions in the brain or spine. Signs of meningitis includes constitutional 
symptoms (such as low grade fever, headache, nausea, vomiting, lethargy), meningismus, 
confusion, seizure, papilloedema, cranial nerve palsies (commonly second, third, fourth, 
sixth and seventh nerves), focal neurological deficits, stupor and coma. Patients with brain 
and spinal cord tuberculomas will have physical signs and symptoms consistent with the 
location of the lesion, which may include altered mental status, visual changes, 
hemiparesis/hemiplegia or seizure as seen with brain lesions; while weakness of  
extremities or bowel and bladder symptoms as seen with spinal cord lesions.4,5   
4. Classification of cns tuberculosis 
The manifestations of CNS tuberculosis are highly variable; however we have tried to 
include various possible presentations of CNS tuberculosis in this chapter as summarized in 
the box 1 given below: 
 
 Tubercular Meningitis(TBM) & its complications
 Hydrocephalus 
 Vasculitis causing infarction 
 Cranial Neuropathies 
 Pachymeningitis 
 Granulomatous basal meningitis 
 Parenchymal Tuberculosis 
 Parenchymal Tuberculomas 
 Tubercular abscesses 
 Miliary Tuberculomas 
 Focal Tubercular Cerebritis 
 Tubercular Encephalopathy 
 Tuberculoma en plaque 
 CNS Tuberculosis in HIV patients 
 Tubercular Hypophysitis 
 Tuberculosis of Calvarium and base of skull 
 Orbital Tuberculosis 
 Tubercular Otitis Media & temporal bone tuberculosis 
 Spinal Tuberculosis 
 Tubercular Spondylitis (Pott’s spine) 
- C1/C2 
- Thoracic spine 
- Thoraco-lumbar spine 
 Non-osseous spinal tuberculomas 
 Tubercular arachnoiditis(myeloradiculopathy) 
 Tubercular myelitis
Box 1. Variable presentation of CNS tuberculosis 
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5. Imaging features 
5.1 Tuberculous meningitis 
Tuberculous meningitis (TBM) is the most common presentation of CNS TB and is seen 
most frequently in children and adolescents. TBM develops when a meningeal, subpial or 
subependymal tuberculous focus (Rich focus) ruptures into the subarachnoid space or into 
the ventricular system. Important features of TBM are: 6 
1. Enhancing basal exudates 
2. Progressive hydrocephalus 
3. Vasculitis & Infarction, and 
4. Cranial neuropathies 
5.1.1 Basal exudates 
In tuberculous meningitis, there is formation of thick, gelatinous exudate as a result of cell-
mediated immunity. Initially the exudate is largely confined to basal subarachnoid areas, 
but rapidly extends to involve the basal cisterns, particularly the interpeduncular and the 
suprasellar cisterns. From these sites the exudate spreads to the ambient cistern, prepontine 
cistern, sylvian fissures, cerebral convexities, to the ependymal surfaces of the ventricles and 
over choroid plexus.7,8  On noncontrast CT,  the most common finding of cranial tuberculous 
meningitis is obliteration of basal cistern by isodense or slightly hyperdense exudates. 
Contrast enhanced CT demonstrates thickening and intense homogenous enhancement of 
the basal meninges, giving characteristic spider leg appearance [figure1]. MRI is more 
sensitive than CT in depicting these abnormalities. The basal exudates are best appreciated 
on FLAIR sequences, while the cisternal enhancement is better demonstrated on 
postgadolinium MRI images [Fgure2].9 The brain parenchyma immediately beneath the 
exudate shows various degrees of edema. The meningeal enhancement can extend over the 
surface of the brain convexities, along tentorium and the sylvian fissures.6,7 Isolated sylvian 
fissure involvement by tuberculous meningitis is also known.10 Extension into the 
ventricular system may cause ependymitis (abnormal enhancement of ventricular linings), 
or choroid plexitis (enlarged, enhancing choroid plexus).7,8  
 
 
Fig. 1. Tuberculous meningitis. NCCT scan of the brain(a) shows effacement of basal cisterns 
by isodense exudates. CECT scan(b) shows dense enhancement of thickened and inflamed 
basal meninges along the basal cisterns (giving characteristic spider leg appearance), 
tentorium and the sylvian fissure with evidence of hydrocephalus and periventricular ooze.  
 








Fig. 2. Tuberculous meningitis. Axial T2W(a), and Fluid attenuated inversion recovery(b) 
MR images shows abnormal complex hyperintensity in the suprasellar, interpeduncular and 
perimesencephalic cisterns. Axial T1W(c) and corresponding post contrast image 
demonstrates diffuse enhancement of the basal cisterns. Few ring-enhancing tuberculomas 
(arrow) are also noted within the cistern. 
5.1.2 Hydrocephalus 
Hydrocephalus is the most common sequel of tuberculous meningitis. Communicating 
hydrocephalus [Figure1,2] is the most frequently observed form, usually caused by 
obstruction to CSF flow by thick gelatinous inflammatory exudates within the basal cisterns 
and over the brain convexities.11,12 Less commonly, the hydrocephalus may be obstructive, 
due to obstruction of cerebral aqueduct or fourth ventricular foramen by focal parenchymal 
lesion with mass effect or due to entrapment of the ventricle by granulomatous 
ependymitis.13,14 The presence of periventricular ooze suggests high pressure 
hydrocephalus. The incidence of hydrocephalus increases with the duration of disease and 
is associated with poor prognosis especially in children. The progress of hydrocephalus may 
be followed up by sequential CT or MRI scan.15 
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5.1.3 Vasculitis & infarction 
In TB meningitis, the basal exudates are maximally localized to the circle of Willis, and 
produce a vasculitis like syndrome. The vasculitis is initiated by either direct invasion of 
vessel wall by mycobacteria or may result from secondary extension of adjacent 
arachnoiditis. Thus a consequent inflammatory change in the arteries and veins may lead to 
spasm or thrombosis of the vessels with resulting infarction.6 The vessels at the base of the 
brain are most severely affected, including the terminal segment of common carotid artery 
and proximal segment anterior, middle and posterior cerebral arteries.10,16,17 The middle 
cerebral and its branches are most often affected, especially the medial striate and 
thalamoperforating arteries supplying the basal ganglia and thalami.14,16,17 Cortical 
infarctions resulting from the involvement of cortical vessels are less common. The infarcts 
are commonly bilateral, often hemorrhagic, and relatively more common in infants and 
children than in adults. Although both CT and MRI can demonstrate the infarction, MRI is 
more sensitive than CT for demonstration of these infarcts. Infarcts appear as low density 
regions on CT scan, while as areas of prolonged T1 and T2 relaxation on MR images. 
Diffusion weighted images (DWI) are gold standard for the diagnosis of acute infarction, 
which appears bright on DWI, and shows decrease signal on corresponding apparent 
diffusion coefficient(ADC) map[Figure3]. MR angiography is useful in follow-up of patients 
with vasculitis secondary to TB meningitis. The angiogram demonstrates a triad of 
narrowing of arteries at the base of the brain, narrowed or occluded small or medium sized 









Fig. 3. Tuberculous meningitis with acute infarct. Post contrast axial MR image (a) shows 
enhancing basal exudates with associated hydrocephalus. Diffusion weighted image(b) and 
corresponding apparent diffusion coefficient(c) mapping reveals acute infarct in bilateral 
basal ganglia (due to vasculitis) showing high signal intensity on b1000 and low signal 
intensity on ADC map. 
 





Fig. 4. Basal granulomatous meningitis with vascular changes. Axial T1W post contrast MR 
images of the brain at two different levels (a,b) shows basal meningitis with multiple 
conglomerate tuberculomas in suprasellar cistern and along anterior interhemispheric 
fissure. TOF MR angiogram(c) demonstrates severe narrowing of bilateral anterior cerebral 
arteries(thin arrows), and splaying of pericallosal arteries (thick arrows) by these 
conglomerate masses. 
5.1.4 Cranial neuropathies 
Cranial nerve palsies occurs in 20-40% of patients and may be the presenting feature of TB 
meningitis. Cranial nerve involvement is partly due to vascular compromise resulting in 
ischemia of the nerve or may be due to entrapment of the nerves by the exudates. Most 
commonly affected cranial nerves are II, III, IV, VI, VII. The affected cranial nerves are best 
evaluated by MRI. They appear thickened and hyperintense on T2-weighted sequences, and 
show marked enhancement on postgadolinium images. Constructive Interference at Steady 
State (CISS), which is a T2-weighted, 3D-Gradient echo sequence is particularly used for 
evaluating cranial nerves around the brain stem. Optochiasmatic arachnoiditis, compression 
of optic chiasma by third ventricular dilatation (in case of hydrocephalus) and optic nerve 
granuloma are common factors associated with vision loss in these patients. On MRI 
optochiasmatic arachnoiditis is characterized by perichiasmal enhancement (of basal 
exudates), hypertrophy and enhancement of chiasma and cisternal segment of both optic 
nerves. Associated dilatation of third and lateral ventricles is also evident.7,8,19,20 
 




Chronic tubercular infection of dura mater results in pachymeningitis, a rare manifestation, 
seen as focal or diffuse thickening and enhancement of the dura. Common sites include 
cavernous sinus, floor of middle cranial fossa, tentorium and the cerebral convexity. On 
noncontrast CT, the affected dura has plaque like appearance with or without calcification. 
On MRI, thickened dura appears hypointense to gray matter both on T1 and T2-weighted 
images. Post contrast study shows intense homogenous enhancement of thickened 
pachymeninges [Figure5]. Important differential diagnosis includes neurosarcoidosis, 
meningioma and lymphoma. 21 
 
 
Fig. 5. Pachymeningitis. Post contrast T1W axial(a), coronal(b) and sagittal(c) images of 
brain show intensely enhancing, thickened pachymeninges(dura mater)  encircling the left 
temporal lobe(thick white arrow), floor of ipsilateral anterior cranial fossa (thick black 
arrow) and the left cavernous sinus (thin black arrow). The process seems to be progressive 
with further extension to involve ipsilateral tentorium and cerebral convexity, where dura 
appears mild thickened. 
5.3 Granulomatous basal meningitis 
Granulomatous basal meningitis is another, relatively uncommon presentation of 
intracranial tuberculosis. It is characterised by diffuse or circumscribed granulomatous 
involvement of meninges at the skull base. It commonly causes compression of optic nerves 
and the optic chiasma producing visual disturbances. On CT scan, it is seen as an irregular 
lumpy enhancing mass, superimposed on dense basal enhancement. On MRI, the 
granulomatous basal mass is hypointense on T2-weighted images and shows intense but 
heterogeneous postgadolinium enhancement.9,22 
5.4 Parenchymal tuberculosis 
5.4.1 Parenchymal tuberculomas 
Tuberculous granuloma (tuberculoma) is the most common form of parenchymal lesion.6 
Tuberculoma can occur at all age group; however, its incidence is higher in pediatric 
population.11 These are usually located at corticomedullary junction and periventricular 
region, as expected for hematogenous dissemination. They are mostly infratentorial in 
children, and supratentorial in adults.23,24 Common locations where tubercuomas can be 
found includes cerebrum, cerebellum, brainstem, basal ganglia, subarachnoid space, cisterns 
and fissures Rarely, they can be found within the ventricle (lateral ventricle being the most 
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common site), cavernous sinus, sella turcica, hypophysis, hypothalamus, sphenoid sinus 
and mastoid air cells.25,26 Parenchymal  tuberculomas can be single or multiple, with or 
without coexisting meningitis.27 Both the parenchymal and intraventricular tuberculoma 
may be associated with hydrocephalus.28  
On CT, the noncaseating granulomas are solid, isodense or hyperdense in attenuation and 
show homogenous contrast enhancement, while the caseating granulomas enhance 
peripherally. Moderate to marked perilesional edema is frequently present. The ‘target sign’ 
seen on CECT is characterized by a central calcific nidus surrounded by rim of 
enhancement. This sign is highly suggestive of, but not pathognomonic of tuberculosis.29,30 
Solitary ring enhancing lesion on CT in patients presenting with seizures present a 
diagnostic dilemma since the granuloma of tuberculosis and cysticerus both may have 
similar morphological appearances. Some authors have tried to differentiate these two 
entities on basis of clinical signs and radiological (CT) findings. In patients with 
tuberculoma there is evidence of raised intracranial tension with progressive neurological 
deficit. The ring enhancing lesion is usually greater than 20mm in size, show irregular 
margin and cause midline shift. On contrary, neurocysticercus granuloma is less than 20mm 
in size, rounded disc like with no significant mass effect. Enlarging lesions on repeat CT 
after 8-12 weeks of anticonvulsant therapy could be due to different etiologies and should 
be biopsied. 31  
The MR features of individual tuberculoma will depend on whether the lesion is 
noncaseating, caseating with a solid center or caseating with a liquid center.32,33 The 
Noncaseating granuloma is usually hypointense on T1-weighted images(T1WI), 
hyperintense on T2-weighted images(T2WI) and shows homogenous nodular 
enhancement on post gadolinium images. The caseating granuloma(s) with solid center 
[Figure6]. appears hypointense to isointense on T1WI (may have a slight hyperintense 
rim) and strikingly hypointense on T2W images. On contrast administration the lesion 
shows peripheral rim enhancement. The relative hypointensity on T2WI is attributed to 
high cellular density of central core of tuberculoma. The caseating granuloma with central 
liquefaction of caseous material appears hypointense on T1WI and hyperintense on T2WI 
with peripheral hypointense rim which represents the capsule of tuberculoma. The rim 
enhancement occurs after gadolinium administration. These lesions are indistinguishable 
from pyogenic abscess on imaging. At this stage, diffusion weighted images(DWI) may 
reveal diffusion restriction within the tuberculoma [Figure6].34 A variable degree of 
vasogenic edema surrounds the lesion, and is relatively more prominent in the early 
stages of granuloma formation.  
MR spectroscopy has been used to differentiate tuberculoma from pyogenic abscesses and 
neoplasms (both primary and secondary). On proton MRS [Figure6], these lesions show a 
large lipid peak at 0.9, 1.3, 2.0 and 2.8 ppm, highly specific for tuberculomas, more choline 
and less NAA and creatine. The choline/creatine ratio is greater than 1 in all tuberculomas. 
Caseous material typical of tuberculomas has high lipid content.35 Pyogenic brain abscesses 
show lipid and lactate peak at 1.3 ppm and amino acid peak (e.g. valine, leucine and 
isoleucine) at 0.9 ppm.36 The lesions such as metastases and high grade gliomas may show 
lipid peak in addition to significantly elevated Choline/NAA ratio.35    
Magnetization transfer imaging (MTI) improves the detectability of these lesions with more 
number of tuberculomas detected on precontrast T1-weighted MT-SE images, compared to 
routine spin echo (SE) sequences and postcontrast T1-weighted MT-SE images. 
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Conventional SE invisible lesions (isointense on T1-and T2-weighted images) can be easily 
picked up on MT images because of lower transfer of magnetization in tuberculomas as 
compared to surrounding brain parenchyma. The presence of lipid within tuberculoma is 
probably responsible for lowering magnetization transfer. Detection of more lesions on 
precontrast T1-weighted MT-SE image as compared to postcontrast T1-weighted MT-SE 
image suggests lack of breach of the blood-brain barrier in some of the lesions. Thus the 
improved estimate of disease load on precontrast T1-weighted MT-SE images helps to better 
assess to response to specific therapy. The Quantitative MT (i.e. MT ratio) further helps to 
differentiate T2 hypointense tubercular granulomas from similar appearing lesions of 
neurocysticercosis. The MT ratio is significantly lower in tuberculomas as compared to 






Fig. 6. Caseating tuberculoma. Axial T2W MR image(a) of brain shows profoundly 
hypointense lesion in left frontal lobe(black arrow) with marked perilesional oedema. The 
lesion demonstrates isointense core with slight hyperintense rim on T1W image(b), and 
thin peripheral ring enhancement on gadolinium-enhanced image(c). Multiple similar 
lesions were present involving both supra and infratentorial compartments, note similar 
lesion in left occipito-parietal region(white arrow). The solid portion of the lesion shows 
no diffusion restriction on DWI and corresponding ADC mapping(d). Single voxel MR 
spectroscopy(e) done at TE=30 shows large lipid peak at 1.33 ppm (arrow), with marked 
reduction in other metabolites. Large lipid peak corresponds to high lipid content within 
the caseous material. 
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Healed tuberculomas and the inflammatory exudates may calcify (in up to 23% cases) and 
these are more evident on CT [Figure7]. On MRI, the calcifications are better appreciated on 
gradient recalled echo (GRE- T2*WI) and Susceptibility weighted images (SWI).30 Multiple 
conglomerate tuberculomas generally impose no difficulty in making a correct diagnosis; 
however, a solitary parenchymal tuberculoma needs to be differentiated from 
neurocysticercosis, pyogenic abcesses, primary or metastatic neoplasm.  
 
 
Fig. 7. Healed tuberculomas and basal exudates. Axial NCCT brain of two different patients 
demonstrate discrete calcified granulomas (arrow) in suprasellar cistern and left cerebellar 
hemisphere(a), and densely calcified basal exudates(arrow) in suprasellar region and along 
the M1 segment of bilateral middle cerebral arteries(b). 
5.4.2 Tubercular abscesses 
Tubercular abscess is a rare manifestation of CNS tuberculosis, occurring in less than 10% 
cases. They are found more frequently in elderly and immunocompromised patients. The 
patient is acutely ill with focal neurological deficit. TB abscesses have a more accelerated 
clinical course.24  
On imaging, a TB abscess may be indistinguishable from a caseous tuberculoma with central 
liquefaction or a pyogenic abscess. However, a TB abscess is usually solitary and larger than 
tuberculoma. Perilesional edema and mass effect is more as compared to tuberculoma. On 
CT and MRI [Figure 8], it is often multinucleated and shows thin, smooth peripheral wall 
enhancement on post contrast images.38 Proton MRS and MTI help to differentiate 
tuberculous from pyogenic brain abscesses. On MRS, a pyogenic abscess demonstrates 
amino acid peak at 0.9 ppm, which is characteristically absent in tubercular abscess. On 
MTI, MT ratio of a tubercular abscess is lower than that found in pyogenic abscess.36 The 
role of DWI is conflicting in making correct diagnosis of tuberculoma as well as tubercular 
abscess. The reports in the literature vary regarding findings on diffusion weighted images 
with regard to both the tuberculoma and tubercular abscess. Some papers report slightly 
increased diffusivity in tuberculoma, and significantly higher in tubercular abscesses,36 
others report decreased diffusivity, 39 while still others report diffusion characteristic similar 
to the normal brain. 40  
 





Fig. 8. Tubercular abscess. Axial T2W(a), T1W (b), and CEMR(c) images of another patient 
shows solitary ring enhancing lesions with liquified center, involving right basal ganglia 
region(arrow). There is associated marked perilesional edema with mass effect. The lesion 
demonstrates restriction on DWI and corresponding ADC mapping (d). MRS(not shown) 
revealed findings consistent with tubercular abscess. 
5.4.3 Miliary tuberculomas 
Miliary tuberculosis of the brain may be a part of generalized pathological process, with 
primary focus situated in the lung or elsewhere. The condition is subtle with no clinical 
evidence of brain involvement. On imaging, these lesions are small, less than 5mm in size; 
 
 
Fig. 9. Miliary tuberculosis. Post contrast T1W axial MR images of brain at two different 
levels reveal intense nodular enhancing small granulomas (thin arrow) randomly 
distributed throughout the brain parenchyma. Few larger lesions (thick arrow) were also 
seen along with these miliary nodules. 
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located at cortico-medullary junction and in the distribution of perforating vessels. They 
appear as high signal intensity foci throughout the brain parenchyma on T2WI and show 
intense nodular enhancement on post gadolinium images [Figure 9]. Contrast enhanced 
MRI is more sensitive than CECT for detecting these lesions.41,42 
5.4.4 Focal tubercular cerebritis 
This entity was described by Jinskin based on retrospective analysis of five patients. CT 
imaging shows intense focal gyral enhancement. On MRI, focal tuberculous cerebritis 
appears hypointense on T1, hyperintense on T2 and shows small areas of patchy contrast 
enhancement on post gadolinium images.30 
5.4.5 Tubercular encephalopathy 
Tubercular encephalopathy is a diffuse cerebral disorder characterized by convulsion, 
stupor and coma, without signs of meningeal irritation or focal neurological deficit. It is 
exclusively seen in infants and children receiving antitubercular treatment. Imaging shows 
unilateral or bilaterally symmetrical cerebral white matter edema, occasionally with 
perivascular demyelination or hemorrhagic leukoencephalopathy. A picture resembling 
post-infectious demyelinating encephalomyelitis may be observed. The pathological basis 
suggested for TB encephalopathy is an allergic delayed type IV hypersensitivity reaction 
due to cell mediated immunity to tubercular protein.43,44              
5.5 Tuberculoma en plaque 
An en plaque meningeal tuberculoma is a rare manifestation, seen as dural based, mass-
forming localized meningeal process which morphologically resembles en plaque 
meningioma or meningeal metastases. They are commonly seen along the frontal and 
parietal convexities, tentorium, interhemispheric fissures and in the posterior fossa. On 
noncontrast CT, these lesions are hyperdense in appearance. On MRI, they appear isointense 
on T1WI, hypo to hyperintense on T2WI, and show homogenous or peripheral contrast 
enhancement, depending on the presence or absence of central caseation [Figure 10]. 
Prominent feeding meningeal vessels may also be evident.45,46 
 
 
Fig. 10. En-plaque tuberculoma. T2W coronal image(a) shows predominantly hypointense 
dura based lesion widely spread along the right cerebral convexity, with associated marked 
vasogenic white matter edema and mass effect. Post contrast T1W coronal(b) and sagittal(c) 
image shows irregular peripheral rim enhancement of the lesion(thin white arrow). Also 
note, thickened enhancing dura along the falx (thick white arrow) and right cerebral 
convexity; and right sylvian fissure meningitis(thin black  arrow). 
 
Central Nervous System Tuberculosis 
 
479 
5.6 CNS tuberculosis in AIDS 
Although TB infection of CNS in AIDS patients follows a rapidly progressive course, the 
spectrums of imaging findings are similar to those of the non-immunocompromised 
patients. Meningitis, cerebral abscesses and tuberculomas are often observed in combination 
with one another [Figure11]. The differential diagnosis includes other opportunistic 





Fig. 11. CNS tuberculosis in AIDS. Axial T1W(a), T2W(b), post contrast(c) and diffusion 
weighted(d) MR images of brain demonstrate multiple cerebral abscesses (thin white 
arrows), tuberculomas(thick white arrow), choroid plexitis (thin black arrow) and dural 
thickening(thick black arrow). Note associated marked perilesional vasogenic edema with 
significant mass effect. 
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5.7 Tuberculous hypophysitis 
Tubercular hypophysitis is an extremely rare entity that commonly presents with 
enlargement of pituitary gland, mimicking a pituitary adenoma. On MR imaging, the gland 
is diffusely enlarged with a thickened stalk, seen infrequently. The thickening and 
enhancement of stalk and surrounding dura differentiates these lesions from pituitary 
adenoma[Figure12]. However, these are non-specific findings and are also seen with 
tuberculous meningitis, sarcoidosis, syphilis and eosinophilic granuloma.48 
 
 
Fig. 12. Tuberculous hypophysitis. Post contrast T1W coronal MR images of a young adult 
male showing enlarged pituitary gland with intra-glandular ring enhancing tuberculoma 
(thin black arrow), and thick enhancing pituitary stalk(thin white arrow). Thickening and 
enhancement of diaphragma sellae (thick white arrow) is also noted. The patient had 
associated pulmonary tuberculosis and showed complete resolution of the pituitary lesion 
after a course of antitubercular therapy. 
5.8 Tuberculosis of calvarium and base of skull 
Isolated calvarial tuberculosis is a rare condition; and commonly occurs secondary to 
hematogenous spread from primary focus elsewhere. Frontal and parietal bones are most 
commonly involved followed by occipital and sphenoid bone. Calvarial tuberculosis may 
present as a subgaleal swelling (Pott’s puffy tumor) with a discharging sinus when the outer 
table is involved. Inner table involvement which is relatively more common is associated 
with formation of underlying extradural granulation tissue. Both tables involvement is not 
uncommon. The bony lesions are usually osteolytic, and appear as a well defined punched 
out defect with central sequestrum. Rarely sclerosis may be seen. Cranial sutures do not 
prevent the spread of granulation tissue, and hence extensive destruction can occur before a 
sinus or swelling becomes apparent. Despite the dura mate, which is an effective barrier to 
the spread of infection, subdural empyema, meningitis, and parenchymal granulomas may 
be encountered. CT scan of the brain [Figure13] helps in assessing the extent of bone 
destruction, scalp swelling and extent of intracranial involvement.49,50 
Tuberculous ostitis of skull base (spheno-clival) is very rare in occurrence. The usual clinical 
picture is of jugular foramina syndrome. The involvement of skull base may be either by 
contiguous spread of infection from the adjacent site, or via hematogenous route from 
primary focus elsewhere. On imaging [Figure14], there is destruction of the skull base with 
enhancing soft tissue mass that may cause compression of adjacent structures. Associated  
 




Fig. 13. Calvarial tuberculosis. NCCT head (bone window) of two different patients. First 
case(a) shows a large subgaleal soft tissue swelling (Pott’s puffy tumor)(asterix) with 
destruction of both outer and inner table(arrow). Second case(b) shows a well defined lytic 
lesion involving right parietal bone with destruction of inner table but intact outer 




Fig. 14. Spheno-clival tuberculosis. Sagittal plain (a) and post contrast(b) T1W MR image of 
brain demonstrates an intraosseous soft tissue lesion in anterior part of body of clivus, 
showing heterogeneous contrast enhancement(thin white arrow). The dura along the 
superior aspect of the clivus shows thickening and enhancement(thick white arrow). Soft 
tissue along the inferior margin of the clivus also shows inflammatory changes. Note, the 
pituitary gland and the stalk(double white arrow) which appears normal in  morphology 
and signal intensity. Sagittal NCCT skull(c) demonstrates destruction of anterior half of the 
body of clivus(asterix) and erosion of both antero-superior and antero-inferior cortical 
margin of the clivus(thin white arrow). The floor of sella tursica and the posterior clinoid 
process also shows rarefaction (thin black arrow).  
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meningitis may further complicate the disease producing multiple cranial neuropathies. The 
imaging characteristic mimics a malignant tumor (e.g. Cordoma), making the diagnosis of 
tuberculosis difficult, hence a high degree of clinical suspicion is mandatory.51,52 
5.9 Orbital tuberculosis 
Tuberculosis of orbit is rare, usually occurring in pediatric age group. Hematogenous 
spread from a primary tubercular focus or contiguous spread from paranasal sinuses may 
affect the orbit. The disease is usually unilateral and has slow progressive course. The 
imaging findings include involvement of bony orbital wall (producing cortical irregularity, 
destruction, thickening or sclerosis) and lacrimal gland, with extraconal inflammatory mass 
or frank abscess formation. The patient may present with isolated preseptal thickening. 
Infratemporal and intracranial extension is not uncommon [Figure15]. MRI is the imaging 




Fig. 15. Orbital tuberculosis. Axial CECT orbit(a) shows a medially situated extraconal 
orbital abscess(asterix) with extension into preseptal tissue and root of nasion(single thin 
arrow). Adjacent medial rectal muscle is displaced medially by the extraconal mass(arrow 
head). Irregularity and destruction of nasion(double thin arrows) is also present. Coronal 
CECT orbit (b) of another patient shows a laterally situated extraconal lacrimal gland 
abscess(asterix) which extends intracranially as epidural abscess(single arrow head) and 
into the infratemporal fossa (double arrow heads). Ipsilateral zygomatic bone appears 
thickened (double black arrows). (From IJRI 2010; 20:6-10. 
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improve the visualization of subtle masses. Non-tuberculous infection, vascular 
malformations and various neoplasms should always be considered in differential diagnosis 
of orbital masses.53 
5.10 Tubercular otitis media and tuberculosis of temporal bone 
Tubercular otitis media (TOM), a relatively uncommon condition, may be a part of 
widespread central nervous system disease or hematogenous spread from a primary 
tubercular focus elsewhere. The disease is more common in infants and children. It may be 
unilateral or bilateral. The patient usually presents with profuse painless otorrhea. High 
resolution CT is the modality of choice for imaging the temporal bone. Imaging shows 
middle ear soft tissue mass with destruction of bony walls. In addition, mucosal thickening 
of bony external auditory canal (EAC), extension of soft tissue mass into EAC and 
destruction of osscicles may also be documented. However, the scutum is always preserved 
in a case of TOM. T1-weighted post gadolinium MR images demonstrate the extent of 
inflammatory changes, evident as enhancing granulation tissues. Important complications 
include conductive deafness, facial palsy, cochlear involvement with labyrinthitis, sensory 
neural hearing loss and intracranial dissemination of infection. Mastoiditis and sinus 
formation may occur. Important differential includes other bacterial infections, 
cholesteatoma, fungal granulomas, wegener’s granulomatosis, Langerhans cell 
histiocytosis.54  
5.11 Spinal tuberculosis 
5.11.1 Tuberculous Spondylitis (pott’s spine) 
Tuberculous Spondylitis is a leading cause of paraplegia. In developing countries, spinal 
tuberculosis affects younger age groups, including infants and children. In developed 
countries, it mostly affects the elderly. However, due to HIV epidemic, its incidence has 
increased among younger age groups. The disease has insidious onset and indolent course. 
The lower dorsal and lumbar spines are most commonly affected, followed by cervical 
spine. The atlanto-axial region involvement is relatively uncommon. The disease process 
results from hematogenous spread of infection to the vertebral body via paravertebral 
venous plexus of Batson. Infection usually begins in anterior part of vertebral body within 
the cancellous bone adjacent to the end plate or anteriorly under the periosteum of the 
vertebral body. Destruction of end plate allows the spread of infection to the adjacent 
intervertebral disc, and subsequently to the additional spinal segment. Subsequent spread of 
infection to other vertebral bodies may also occur via subligamentous route, with sparing of 
intervertebral disc [Figure16]. Thus the classic pattern of involvement of more than one 
vertebral body together with the intervening disc is seen in TB spine [Figure17]. Skip lesions 
are not uncommon. Occasionally, tuberculous spondylitis affects only one vertebral body, 
sparing the adjacent disc. The pedicle and posterior element involvement is rare. The spread 
of infection into the paraspinal tissues results in the formation of paravertebral soft tissue 
inflammatory mass (phlegmon) and/or frank abscess [Figure16,17]. Intraspinal extension is 
also frequent.55,56,57,58 Neurological deficits are commonly associated with spinal tuberculosis 
of cervical region, particularly when cranio-vertebral junction or C1-C2 spine is involved 
[Figure18]. The neurological deficit is usually caused by significant thecal or cord 
compression by displaced bony fragment, epidural inflammatory mass and/or abscess. 
Death may occur due to atlanto-axial instability or cervico medullary compression.59,60  
 




Fig. 16. Tuberculous spondylitis (Pott’s spine) with subligamentous spread of the disease. 
Sagittal T1W(a), T2W(b), and Coronal T2W(c) image of  dorso-lumbar spine demonstrates 
primary involvement of  D12-L1 vertebral bodies and the intervening discs (thin white 
arrow) by the disease process with contiguous spread if the infection cranially (to involve all 
dorsal vertebrae) and caudally(to involve L2 vertebra) along the subligamentous route(thin 
black arrow) with sparing of intervening discs(except at D12-L1 level). Note, marrow signal 
intensity changes in all the involved vertebral bodies, and an epidural phlegmon at D12-L1 
level causing localized cord compression (thick white arrow). 
Conventional radiograph of spine demonstrates end plate irregularity, destruction of 
vertebral body and involvement of intervertebral disc. Reactive sclerosis is not a feature on 
initial presentation. CT scans [Figure19] characteristically demonstrate extensive bone 
destruction and large paraspinal abscesses. Large paravertebral abscesses and 
subligamentous spread of infection may produce anterior scalloping of the vertebral bodies. 
Calcification within the abscess is virtually diagnostic for tuberculosis. If left untreated, the 
infection eventually results in vertebral collapse and anterior wedging, leading to kyphosis 
and gibbus formation with healing, fusion of vertebral bodies (bony ankylosis) occurs in 
most cases. In patients with neurological deficit CT can define the extent of epidural 
compression, detection of bony fragment within the spinal canal and atlanto-axial 
instability.61,62 MRI is the modality of choice for evaluating intraspinal and subligamentous 
spread of the infection, cervico medullary junction and nerve root compression, 
intervertebral disc changes and vertebral skip lesions. Contrast enhanced MRI is particularly 
useful for demonstrating intraosseous, epidural and paraspinal soft tissue 
involvement.56,57,58 
 








Fig. 17. Tuberculous spondylitis with involvement of intervening disc. Sagittal T2W(a), 
T1W(b) and post contrast(c) MR of lumbar spine demonstrates involvement of L2-L3 
vertebral bodies and the intervening discs by the disease process, showing osseous 
destruction and heterogeneous contrast enhancement(thin white arrow). Associated 
heterogeneous enhancing prevertebral soft tissue(thick white arrow) and an epidural 
phlegmon/abscess(thick black arrow) is also present at the same level. The epidural 
phlegmon/abscess causes severe lumbar canal stenosis and compression of conus and 
cauda equina nerve roots, producing a CSF cut off sign on MR myelogram (d) (thin white 
arrow). Multiple intraosseous lesions (thick white arrow), subligamentous inflammatory 
mass(thick black arrow), bilateral psoas abscesses (thin white arrow) and epidural 
phlegmon causing cord compression (thin black arrow) are well appreciated on axial 
T2W(e) and T1W post contrast image(f). 
 





Fig. 18. Tuberculous spondylitis (C1-C2 vertebrae). Sagittal T2W(a), T1W(b) and post 
contrast(c) image of cervical spine shows enhancing inflammatory soft tissue mass (thin 
arrows) surrounding the anterior arch of C1 vertebra, tip of odontoid process (os 
odontoideum) and posterior part of the clivus, appearing isointense to the cord both on T1W 
and T2W image. Note subligamentous spread of infection along anterior aspect of C2-C3 
vertebral body. There is associated atlanto-axial dislocation and cervicomedullary junction 
compression both by the posteriorly displaced odontoid tip and epidural-intraspinal 
phlegmonatous inflammatory tissue (thick white arrow), best appreciated on post contrast 
sagittal(c), axial(d) and coronal(e) images. The compressed cervical cord shows focal T2 
hyperintense(thick black) signal suggestive of compressive myelopathy. Intraosseous 
marrow signal changes involving anterior arch of atlas, odontoid tip and posterior part of 
clivus is also present. There is severe narrowing of nasopharynx and the oropharynx by the 
prevertebral inflammatory mass. 
 







Fig. 19. Tuberculous spondylitis (Pott’s spine). Axial (a,b) and coronal (c)  noncontrast CT 
spine demonstrates marked osseous and intervertebral disc destruction(thin black arrow), 
and  calcified/ non-calcified paravertebral abscesses(thick white arrows). 
The major differential diagnosis is low grade pyogenic osteomyelitis (e.g. brucellosis), 
metastatic disease and fungal infections. Tuberculosis is characteristically associated with 
little or no reactive sclerosis, a feature that helps to distinguish it from pyogenic infections of 
spine.58 Tuberculosis rarely affects the posterior vertebral elements, including pedicles, in 
contrast to metastatic disease.62 Anterior scalloping of vertebral bodies can also be seen with 
paravertebral lymphadenopthy, metastatic or lymphomatous deposits.58,62 CT guided needle 
biopsy is very useful in establishing the diagnosis  in case of uncertainty. 
5.11.2 Non-osseous spinal tuberculomas 
Spinal tuberculoma are very rare presentation of non-osseous spinal tuberculosis, 
characterized as extradural (64%), intramedullary (8%), or intradural extramedullary 
(IDEM) (1%) according to their location.63 Most of the subdural (IDEM) tuberculomas are 
detected as a result of paradoxical response to antitubercular therapy for meningitis, 
ranging from three months to one year.64  Intramedullary tuberculomas are mostly induced 
by hematogenous dissemination from primary focus in the lung, or via CSF seeding, and 
rarely local spread of spinal tuberculosis.65 MRI is imaging modality of choice for these 
lesions. IDEM tuberculoma may present as a single, dural based ring enhancing lesion or as 
a long segment enhancing soft tissue mass. En plaque IDEM tuberculoma may mimic 
meningioma. IDEM tuberculomas commonly cause spinal cord and nerve root compression; 
however, may or may not be associated with arachnoiditis [figure20].64,66 Concurrent IDEM 
tuberculoma and syringomyelia has also been reported.67 Intramedullary tuberculomas have 
specific findings on MRI, and hence can be diagnosed accurately on imaging. T2WI shows a 
typical “target sign” demonstrating low signal center (caseous material) surrounded by high 
signal rim (peripheral infective granulation tissue). This “target sign” is a valuable indicator 
and differentiates tuberculoma from other intramedullary lesions. Intravenous contrast 
administration shows sharp margin with peripheral rim enhancement. Associated syrinx 
and/or arachnoiditis may or may not be present with these lesions [Figure21].65 
 















Fig. 20. Intradural extramedullary spinal tuberculoma. Contrast enhanced T1-weighted 
Sagittal image demonstrates an intradural extramedullary (arrow) lesion in posterior 
subarachnoid space, at mid-dorsal spine level, showing dense nodular enhancement with a 
linear non-enhancing area. There is localized spinal cord compression and widening of 
dorsal subarachnoid space. No associated syrinx or arachnoiditis is present. 
 






Fig. 21. Intramedullary tuberculoma with arachnoiditis. Sagittal T2W(a), T1W(b) and post 
contrast(c) image of thoracic spine shows an intramedullary space occupying lesion (thin 
white arrow) at D3 level with loss of normal cord-CSF interface posteriorly from D1-D11 
level and few thin septations within posterior subarachnoid space, best appreciated on T2W 
image. The intramedullary SOL appears iso-hypointense on T1W image, shows typical 
“target sign” on T2W image and peripheral rim enhancement on contrast administration. 
There is obliteration and intense enhancement of posterior subarachnoid space from D1-D11 
level with scattered thin CSF loculations consistent with arachnoiditis (thin black arrow). 
Note, a short segment syrinx situated cranial to the intramedullary lesion and T2 
hyperintense signal within the cord caudal to this lesion. Intramedullary tuberculoma is 
well appreciated on axial T2W(d), T1W(e) and post contrast(f) images. 
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5.11.3 Spinal tubercular arachnoiditis (myeloradiculopathy) 
Spinal tuberculous arachnoiditis is an inflammatory condition that involves the 
leptomeninges along the spinal tract and often manifests as myeloradiculopathy. Previously, 
it was known as adhesive spinal arachnoiditis or chronic adhesive arachnoiditis. Clinically 
patient presents with progressive spinal cord and/or nerve root dysfunction, usually 
accompanied by constitutional symptoms. This condition may result from downward 
extension of intracranial tuberculous meningitis (most common) or a tuberculous lesion 
primarily arising in the spinal meninges, or extension from tuberculous spondylitis. The 
thoracic region is most commonly affected followed by the lumber and cervical region. The 
involvement may be focal, multifocal or diffuse. The inflammatory exudate surrounds the 
spinal cord and the nerve roots, causing obliteration of spinal subarachnoid space (SAS). On 
imaging [figure22], there is increased CSF signal intensity within the SAS on T1WI due to 
elevated protein content of CSF with resultant loss of spinal cord outline in cervico-thoracic 
region. Thickening and clumping of nerve roots in the lumber region is frequently seen with 
arachnoiditis. Meningeal involvement has been described in patients with arachnoiditis; it 
represents ongoing meningeal inflammation and may constitute an early sign of 
arachnoiditis. Contrast enhanced MR images show linear enhancement of surface of spinal 
cord and nerve roots, or plaque like enhancement of dura-arachnoid mater complex which 
can obliterate the subarachnoid space.68 Enhancing subarachnoid space nodular lesions may 








Fig. 22. Tuberculous spinal arachnoiditis with ascending infection to the brain. Sagittal 
T2W (a) and T1W post contrast(b) MR image of whole spine demonstrates loss of normal 
cord-CSF interface with obliteration of anterior subarachnoid space(SAS) by thick 
inflammatory exudates appearing hyperintense on T2W image, and showing intense 
enhancement on post contrast image (thin black arrow). Few scattered intervening septae 
are also present within the anterior SAS (at upper cervical and mid thoracic level) forming 
loculations. These loculations containing the inflammatory tissue have pseudomass 
appearance (on sagittal and axial T2W/post contrast image-c,d,e,f), which causes severe 
cord compression (thick black (arrow). Thickening and clumping of cauda equine nerve 
roots is evident in lumbar region (arrow head). The obliteration and intense enhancement 
of anterior subarachnoid space along the entire spinal canal, scattered pseudomasses in 
upper cervical (please see figure5b-sagittal post gad. image) and mid thoracic level, and 
clumping of cauda equine nerve roots in lumbar region is consistent with spinal 
arachnoiditis. 
arachnoiditis, the spinal SAS is irregularly obstructed with formation of CSF loculations.32 
The CSF loculations usually show normal CSF signal intensity on T1-and T2WI and do not 
enhance on post contrast images. The recognition of CSF loculation is important as they may 
cause cord compression, necessitating surgical intervention. The spinal cord changes are 
frequently seen in these patients and may include myelitis, cord edema, syringomyelia, 
infarction, myelomalacia, cavitation or atrophy.32 
Spinal tuberculous arachnoiditis must be distinguished from other possible causes of 
arachnoiditis, for example subarachnoid hemorrhage or iatrogenic cause.  
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5.11.4 Tubercular myelitis 
Tuberculous myelitis, an important cause of paraparesis, and usually occurs as a secondary 
event in the course of common forms of tuberculous meningitis. The cervico-thoracic 
segment of the spinal cord is most commonly involved. MR Imaging features of TB myelitis 
are similar to those of cerebritis. There is diffuse cord swelling with signal abnormality. 
Most spinal cord lesions appear as hyperintense on T2, isointense to hypointense on T1-




Fig. 23. Tuberculous Myelitis. Sagittal T2W(a), T1W(b) and post contrast(c) MRI of dorso-
lumbar spine shows diffuse cord swelling and edema appearing hypointense on T1W and 
hyperintense on T2W image and showing intense central contrast enhancement on post 
gadolinium images(thin white arrow). These changes are better appreciated (thick white 
arrow) on axial T2W(d), T1W(e) and post contrast image(f). 
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Intramedullary abscess demonstrates central necrotic area with clearly defined marginal 
enhancement. Cord atrophy, cavitation and syringomyelia may be associated with poor 
outcome. Differential diagnosis includes cord contusion, cord infarction due to vasculitis, 
acute transverse myelitis, and demyelinating diseases.69,70 
6. Differential diagnosis 
The important differential diagnosis of CNS tuberculosis has been already discussed with 
individual manifestations. Broadly, the conditions which may mimic cranial and spinal 
tuberculosis on imaging include other infectious and non-infectious inflammatory disease 
such as fungal infection, sarcoidosis, primary and metastatic neoplastic disease. 
7. Role of imaging in the evaluation of cns tuberculosis 
Role of imaging has been dealt in detail with individual manifestation of CNS tuberculosis 
(vide supra). In nut shell contrast-enhanced MRI is superior to CT scanning or unenhanced 
MRI for the demonstration of CNS TB, and is currently the best modality for demonstration 
of meningeal disease, parenchymal abnormalities, for assessment of complication and 
monitoring the disease. The multiplanar capability of MRI offers additional advantage for 
localization of lesions. CT is particularly used for evaluation of osseous changes, 
calcification, and intracranial shunt in cases of hydrocephalus. 
8. Management of cns tuberculosis 
Inspite of rapid advances in the management of pulmonary tuberculosis, currently no 
general agreement about the form of chemotherapy or optimal duration of treatment has 
been reached. The World Health Organization71 has put CNS tuberculosis under TB 
treatment category1, and recommended an initial phase therapy with streptomycin, 
isoniazid, rifampicin and pyrazinamide for 2-months, followed by a seven month 
continuation phase with isoniazid and rifampicin. The duration of therapy should be at least 
6-months, and in some cases up to 12-months treatment is required. A similar drug regimen 
has been recommended for all forms of CNS tuberculosis. A four-drug regimen is needed to 
treat atypical mycobacteria (M avium intracellulare) in persons with HIV infection. Current 
recommended therapy for HIV patients include azithromycin and clarithromycin in 
combination with ethambutol or clofazimine.72,73,74 
Role of corticosteroids in the treatment of CNS tuberculosis is controversial. It is believed 
that corticosteroids improve both the survival rate and neurological outcome in patients 
with TB meningitis. However they should be used with caution in pediatric population. The 
response to corticosteroids may be dramatic with rapid resolution of basal exudates and 
tuberculomas on serial imaging. The main argument against using corticosteroids is that 
they decrease meningeal inflammation, and in turn can affect CSF penetration of 
antituberculous drugs.74,75 
Surgical procedures in patients with tuberculous meningitis are primarily directed to the 
treatment of hydrocephalus. Serial lumbar puncture along with diuretics is used as 
temporary measures to relieve raised intracranial pressure. Ventriculo-peritoneal or 
ventriculo-atrial shunts are permanent measures, which relieve the signs and symptoms of 
hydrocephalus and significantly improve the sensorium and neurological deficit. However, 
 
Neuroimaging – Clinical Applications 
 
494 
these shunts may require replacement due to blockage by high protein content of CSF. Early 
shunting in combination with drug therapy offers best therapeutic outcome.  
Intracranial tuberculoma, which may behave as single space occupying lesion causing 
midline shift and increased intracranial pressure, and that fail to respond to chemotherapy 
should be removed surgically.72,76 In chronic adhesive spinal arachnoiditis, the CSF 
loculations  in SAS may cause cord compression, necessitating surgical intervention.32  
9. Paradoxical response of tuberculomas to the treatment 
Paradoxical enlargement of pre-existing tuberculoma or appearance of new intracranial and 
spinal tuberculoma in patients receiving effective antituberculous therapy has been noted in 
the past. This paradoxical phenomenon is thought to be due to result of an immunological 
reaction. These lesions are usually discovered accidently when follow-up scan is performed 
routinely or when new neurological signs develop during the course of antitubercular 
therapy. Concomitant steroid therapy probably has a preventive role against these focal 
lesions. However, with continuation of antituberculous therapy, eventual resolution of these 
tuberculoma usually occurs. In case of unresponsiveness to medical therapy, surgery is 
recommended.77,78  
10. Prognosis 
The single most important factor determining the prognosis in cases of CNS tuberculosis is 
the stage of tuberculous meningitis at which the treatment has been started. If treatment is 
started at stage I (prodromal phase with no definite neurological symptoms) the mortality 
and morbidity is very low, whereas in stage III (loss of sensorium, convulsions, focal 
neurological deficit, and involuntary movements) almost 50% patient die, and those who 
recover may have some form of neurological deficit. Stage II patients (signs of meningeal 
irritation, slight or no clouding of sensorium, minor cranial nerve palsies, and no 
neurological deficit) have intermediate prognosis.74,79 
11. Summary  
CNS tuberculosis is rare but serious complication and its early recognition and treatment is 
imperative. Early diagnosis can prevent further deterioration and result in better prognosis. 
Imaging plays a very important role in establishing the diagnosis of CNS tuberculosis. A 
radiologist should maintain a high degree of suspicion when patients with tuberculosis risk 
factors present with neurologic complains. Various imaging modalities, CSF studies, and 
brain biopsy if necessary, can aid in establishing the diagnosis of CNS tuberculosis. 
Pharmacological regimen is the mainstay of treatment, although various other options such 
as addition of corticosteroid and surgical intervention are also recommended as per 
requirement. 
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1. Introduction   
The ubiquitous amino acid L-glutamate is thought to act as a neurotransmitter at the 
majority of synapses in the brain. It mediates the major excitatory pathways in the brain, 
and is referred to as an excitatory amino acid (EAA). The EAA plays a role in a variety of 
physiological processes, such as long-term potentiation (learning and memory), the 
development of synaptic plasticity, motor control, respiration, cardiovascular regulation, 
emotional states and sensory perception (Bliss & Collingridge, 1993). 
The excessive or inappropriate stimulation of EAA receptors leads to neural cell damage or 
loss by a mechanism known as excitotoxicity (Lucas & Newhouse, 1957; Oney, 1978). EAA 
receptors are classified in two general types (Kornhuber & Weller, 1997). Receptors that are 
directly coupled to the opening of cation channels in the cell membranes of the neuron are 
termed ‘ionotropic’, which include NMDA, AMPA, and kainate receptors. The second type 
of receptors are the G-protein or second messenger-linked ‘metabotropic’ EAA receptors. 
This second type is coupled to multiple second messenger systems that lead to enhanced 
phosphoinositide hydrolysis, activation of phospholipase D, increase or decrease in cAMP 
formation, and changes in ion channel function (Kozikowski et al., 1998). 
Metabotropic glutamate receptors belong to Class C of a superfamily of G-protein coupled 
receptors (GPCRs). Class C GPCRs possess a large extracellular domain that is responsible 
for endogenous ligand recognition (Pin et al., 2003), in addition to the seven strand 
transmembrane domain, which is characteristic of all GPCRs. The mGluRs possess a large 
bi-lobed extracellular N-terminus of ~560 amino acids which has been shown by 
mutagenesis studies to confer glutamate binding, agonist activation of the receptor, and 
subtype specificity for group selective agonists (Schoepp et al., 1999). 
Since mGluRs have neuromodulatory role in the control of both glutamatergic and 
GABAergic neurotransmission, there has been much interest to develop novel mGluR 
ligands for therapeutic purposes of a variety of neurological and psychiatric conditions. The 
mGluRs have been proposed to be involved in physiological and pathophysiological 
processes of a number of CNS disorders, including anxiety, pain, depression, 
neurodegenerative disorders, schizophrenia, epilepsy, and drug abuse. In order to 
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characterize the role of mGluRs in different physiological processes there is a need to 
identify novel compounds, which are highly potent and specific for an mGluR group or a 
subtype. Such compounds are needed to further investigate mGluR function, and as 
potential therapeutic agents for a variety of neurological diseases, which are associated with 
the abnormal activation of mGluRs. A large amount of pharmacological agents acting at 
metabotropic glutamate receptors have been described in the literature (Guitart & 
Khurdayan, 2005; Kew, 2004; Layton, 2005; Marino et al., 2005; Rudd & McCauley, 2005; 
Schoepp et al., 1999; Slassi et al., 2005; Williams & Lindsley, 2005; Yang, 2005). According to 
the mode of binding, these mGluR pharmacological agents can be classified into competitive 
and non-competitive agents. Based on the mode of action, they can be classified into 
agonists, antagonists, and positive/negative/neutral modulators (Layton, 2005). 
Competitive agonists and antagonists bind to the same orthosteric binding site as 
endogenous glutamate (Niswender et al., 2005; Ritzen et al., 2005; Rudd & McCauley, 2005), 
which is a cleft between the two lobes in the extracellular N-terminus. Their binding ability 
depends on how much they can stabilize the closed conformation (Kew, 2004). These 
ligands received earliest research interest and have been well developed (Schoepp et al., 
1999). They are all glutamate analogs or substituted glycines, which imply that they have 
poor selectivity within their group. In addition, competitive agonists and antagonists have 
structural carboxyl and amino groups, which make them too polar to penetrate the blood 
brain barrier (BBB) (Kew, 2004).  
Starting from 1996 (Annoura et al., 1996), a number of different types of non-competitive 
negative, positive and neutral allosteric modulators have been developed as mGluR ligands 
(Niswender et al., 2005; Ritzen et al., 2005). These ligands modulate mGlu receptor activity 
by binding to allosteric binding sites that are located in the seven strand transmembrane 
domain. The allosteric binding sites are structurally distinct from the classical agonist 
orthosteric binding site (Williams & Lindsley, 2005). Positive and negative modulators thus 
offer a potential for improved selectivity for individual mGluR family members compared 
to competitive agonists and antagonists at the glutamate site (Kew, 2004). Positive allosteric 
modulators (PAM)s have little or no effect on the receptor but can significantly enhance the 
effect of endogenous ligand. Correspondingly negative allosteric modulators inhibit the 
activity of orthosteric agonists in a noncompetitive manner. These ligands are structurally 
diverse and not amino acid derivatives. They are lipophilic and have much better CNS 
penetrating ability. Thus, positive and negative modulators with high subtype selectivity, 
and appropriate lipophilicity are good candidates for mGluR radiotracer development. 
There will be no competitive binding of this kind of tracers with endogenous glutamate, 
which might otherwise decrease the availability in vivo, and thus decrease the sensitivity of 
potential ligands. 
During the last fifteen years the subtype selective modulators have been identified for 
mGluR1, mGluR2, mGluR3, mGluR4, mGluR5, mGluR7 and mGluR8. Based on these 
modulators, several positron emission tomography radiotracers have been developed for in 
vivo imaging of specific mGluRs. Presently, three mGluR ligands have been used for human 
studies. They have been developed as negative allosteric modulators for mGluR5. In this 
review we intend to summarize the radiotracers which have characteristics to be developed 
as tracers for in vivo PET imaging to investigate modulation of mGluRs in normal and 
pathological conditions. Emphasis will also be given to the highly potent and subtype 
selective allosteric modulators which are candidates for radiolabeling with 18F or 11C. 
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2. Metabotropic glutamate receptors and their physiological function 
Recent molecular cloning studies have revealed the existence of eight different subtypes 
of mGluRs. The mGluR subtypes can be divided into three different groups according to 
their sequence similarities, signal transduction mechanism, and pharmacological profiles 
to agonists (Pin & Duvoisin, 1995). The first group comprising mGluR1 and mGluR5 is 
coupled to stimulating of phosphoinositide hydrolysis/Ca2+ signal transduction 
(Schoepp et al., 1994). The second group, consisting of mGluR2 and mGluR3, is negatively 
coupled through adenylate cyclase to cAMP formation (Tanabe et al., 1997). The third 
group, containing mGluR4, mGluR6, mGluR7 and mGluR8, is also negatively linked to 
adenylate cyclase activity but shows a different agonist preference (Conn & Pin, 1997; 
Tanabe et al., 1997).  
The neuroanatomical localization of Group I and Group II mGluRs in the rodent brain, as 
assessed by immunohistochemical or in situ hybridization techniques, has revealed 
overlapping, yet distinct patterns of expression of these receptors. In order to better 
characterize the roles of mGluRs in physiological processes, there is a need to identify novel 
compounds that are highly potent and specific for an mGluR group or a subtype. Such 
compounds are needed as pharmacological tools for further investigation of mGluR 
function, and as potential therapeutic agents for the treatment of diseases or conditions 
including epilepsy, cerebral ischemia, pain, spinal cord injury, ‘neurotoxicity’ and chronic 
neurodegenerative diseases (e.g. Parkinson’s and Huntington’s disease), which are 
associated with abnormal activation of mGluRs (Aguirre et al., 2001; Blakely, 2001; Calabresi 
et al., 1999; Keyvani et al., 2001; Marino et al., 2001; O’Neill, 2001; Popoli et al., 2001; Rao et 
al., 2000; Rouse et al., 2000). 
It is known that glutamate can act as a neurotoxin when energy supplies are compromised. 
This has stimulated a hypothesis that injury to neurons in some neurological conditions may 
be caused, partly, by over stimulation of glutamate receptors and/or glutamate transporters. 
These neurological conditions may be acute insult like stroke or chronic neurodegenerative 
states like Parkinson’s or Huntington’s disease or dementia. To better explore the roles of 
mGluRs in physiological and pathological processes, there is a need to learn more about 
functional behavior of these receptors in vivo.  
3. PET radiotracer development  
Positron emission tomography (PET) has become an important clinical diagnostic and 
research modality, and also a valuable technology in drug discovery and development (Cai 
et al., 2008). PET tracers have been used for the imaging and quantification of biochemical 
processes. PET tracers play a critical role for assessing in vivo distribution of specific 
receptors in normal and disease conditions to understand underlying mechanisms of 
physiology and pathology. Moreover, PET tracers serve as invaluable biomarkers during the 
clinical development of potential therapeutic mGluR modulators, in which the receptor 
occupancy of potential drug candidates in the brain is measured (Passchier et al., 2002; 
Sharma & Lindsley, 2007). In vivo receptor occupancy can help to answer many vital 
questions in the drug discovery and development process such as whether potential drugs 
reach their molecular targets, the relationship between therapeutic dose and receptor 
occupancy, the correlation between receptor occupancy and plasma drug levels, and the 
duration of time a drug remains at its target (Passchier et al., 2002). In PET imaging a small 
amount of tracer is injected into a living object. The tracer is labeled with a short-lived 
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radioisotope, which emits positrons as it decays. The positrons collide with electrons 
resulting in high-energy photons that escape from the object and are detected by the PET 
scanner. Carbon-11 (t1/2 = 20.4 min) and fluorine-18 (t1/2 = 109.7 min) are the most 
commonly used radionuclides in PET imaging (Miller et al., 2008). The characteristics of 
successful PET tracers include high affinity, high selectivity over other mGluR subtypes as 
well as other receptors, suitable pharmacological properties including lipophilicity, 
metabolic stability, no radiolabeled metabolites that can penetrate into the brain, and the 
chemical structure of the precursor to allow fast labeling. 
3.1 Allosteric modulators and radiotracers for Group I mGluRs 
The group I receptors mGluR1 and mGluR5 exhibit different patterns of expression in the 
CNS. The distribution of mGluR1 is found throughout the human brain with high levels in 
the olfactory bulb, thalamus, hippocampus, lateral septum, superior colliculus and 
cerebellum (Olive, 2009). Inhibition of mGluR1 has been suggested as potential treatment for 
various psychiatric disorders including schizophrenia, anxiety, and neuropathic pain. 
The mGluR5 is usually found in postsynaptic neurons with moderate to high density in the 
frontal cortex, caudate, putamen, nucleus accumbens, olfactory tubercle, and hippocampus, 
whereas in contrast to expression patterns of mGluR1, the density in the cerebellum is low 
(Olive, 2009). Dysfunction of mGluR5 is implicated in a variety of diseases in the CNS, 
including anxiety, depression, schizophrenia, Parkinson’s disease, and drug addiction or 
withdrawal. 
3.1.1 Allosteric modulators and radiotracers for mGluR1 
A variety of mGluR1 modulators have been reported in the literature. Competitive mGluR1 
agonists and antagonists historically have been amino acid derivatives, which display poor 
potency, lack of selectivity and unsatisfactory BBB penetration (Layton, 2005). Although a 
number of selective competitive mGluR1 ligands appear in literature, they are not good 
candidates for potential PET tracers. None of the existing orthosteric ligands has a binding 
affinity (or potency) of IC50/Ki/Kd less than 20 nM with an acceptable selectivity over other 
members in the same group. There is a consensus that identification of highly potent and 
subtype selective competitive mGluR ligands has been difficult due to a high degree of 
sequence similarity at the orthosteric binding site to which the endogenous agonist binds 
(Layton, 2005; Williams & Lindsley, 2005). Alternatively, several structural types of mGluR1 
allosteric modulators have been reported in literature, including negative and positive 
allosteric modulators which show high binding affinity, high selectivity and good 
lipophilicity (Layton, 2005). 
CPCCOEt (1) was the first reported mGluR1 negative allosteric modulator (Fig.1). Before 
2008, only compound 4 (3,5-dimethyl PPP) (Micheli et al., 2003b) and a quinoline derivative 
5 (JNJ16259685) (Lavreysen et al., 2004b; Mabire et al., 2005) had reported binding affinity 
(or potency) less than 20 nM (Table 1). 2,4-Dicarboxy-pyrrole ester 4 (3,5-dimethyl PPP), as a 
racemic mixture, is a highly potent and subtype-selective noncompetitive antagonist of 
mGluR1, having IC50 of 16 nM at rat mGluR1 and > 1000-fold selectivity over mGluR 2, 4, 
and 5 (Micheli et al., 2003b). Pharmacological studies of its two enantiomers showed that the 
S-enantiomer had the same activity as the racemic mixture, while the R-enantiomer was less 
potent (40 nM). Although compound 4 had a poor stability to rat plasma esterase (t1/2=12 
min versus 2.8 h in mice), a good CNS accumulation was observed 5 min after intravenous 
administration with a brain/plasma ratio of 20 (Micheli et al., 2003b). Compound 5 (JNJ-
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16259685) demonstrated high specificity over other mGlu receptor subtypes and a fast brain 
penetration with high receptor occupancy after subcutaneous administration (Lavreysen et 
al., 2004b). In addition to 5, a series of quinoline derivatives have been synthesized. The in 
vitro pharmacological data showed that they are highly potent noncompetitive mGluR1 
antagonists (Mabire et al., 2005) with high binding affinity. However, the quinoline 
derivatives have issues of poor aqueous solubility and poor stability to human liver 
microsomes (Layton, 2005; Mabire et al., 2005). 
Since 2008, many new compounds (Fig. 1 and Table 1) have been reported having binding 
affinity (or potency) less than 20 nM and high selectivity over other mGluRs. These 
compounds are diverse heterocyclic compounds including mono-, di- and tri-cyclic structures. 
Some of these compounds or their derivatives are amenable to radiolabeling with fluorine-18 
or carbon-11. For example, a series of potent 2-fluoro-3-pyridyl-triazol derivatives such as 
FTIDC (10) and FPTQ (11) have been developed.. These derivatives are relatively easy to label 
with fluorine-18 at 2-pyridine position. Other compounds such as 12 are amenable to 




































































































Fig. 1. Chemical structures of mGluR1 negative modulators. 
MGluR1 expression is localized throughout the nervous system (Layton, 2005; Spooren et al., 
2003). The distribution of mGluR1 in the peripheral nervous system (Bhave et al., 2001; 
Lesage, 2004; Skerry & Genever, 2001) and in the CNS has been studied using various 
methods including radioligand autoradiography and immunohistochemical techniques 
(Lavreysen et al., 2003; Lavreysen et al., 2004a; Shigemoto & Mizuno., 2000; Simonyi et al., 
2005). MGlu1 receptors have been observed in the cerebellum, thalamus, hippocampus and  
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Table 1. In vitro and in vivo pharmacological profiles for mGluR1 negative allosteric modulators. 
 















































Fig. 2. PET ligands for mGluR1 
spinal cord (Karakossian & Otis, 2004; Lavreysen et al., 2003; Shigemoto & Mizuno, 2000; 
Spooren et al., 2003). Tritium-labeled highly potent and subtype-selective radioligands were 
used earlier in mapping mGluR1 ex vivo (Yang, 2005). Presently, demands on PET 
radioligands are increasing due to the advantage of in vivo noninvasive imaging techniques 
to investigate pathophysiological processes. 
In 2002, a carbon-11 labeled CPCCO-Me analog was described in the literature (Yu & 
Brownell, 2002), but no animal studies were conducted. In the series of quinoline derivatives 
(represented by 5), several compounds are amenable to radiolabeling with either fluorine-18 
or carbon-11. Carbon-11 labeling would not be preferred in the methyl ether positions, in 
spite of methyl ether position is very popular in 11C-methylation, since O-demethylation of 
the methoxy groups on the quinoline moiety and the cyclohexyl ring are the major 
metabolic pathways (Mabire et al., 2005). Therefore, practical methods must be developed to 
label the methyl groups elsewhere in the molecule. Accordingly, Huang et al. successfully 
labeled a quinoline derivative, providing the first PET tracer, [11C]JNJ-16567083, suitable for 
in vivo imaging of mGluR1 (Huang et al., 2005). [11C]JNJ-16567083 (17) is an analog of JNJ-
16567083 (5). In vitro binding experiments showed that JNJ16567083 (cold compound) 
possesses high affinity for rat mGluR1 (Ki = 0.87 nM) and low affinity for mGluR5 (Ki = 2366 
nM). Ex vivo biodistribution studies in rats showed that [11C]JNJ-16567083 has high brain 
uptake and its binding in brain is specific to mGluR1. MicroPET imaging experiments in rats 
indicated that radioactivity entered the brain rapidly and was localized over time in brain 
regions with high densities of mGluR1, such as the cerebellum and striatum. Activity in 
cerebellum peaked at ~10 min after intravenous injection. Radioactivity uptake was highest 
in the cerebellum, followed by striatum and hippocampus. However, evaluation of this PET 
tracer in higher species has not been reported. 
Yanamoto et al. have labeled an mGluR1 antagonist YM-202074 (12, Ki = 4.8 nM) with 11C 
and evaluated its potential as a PET ligand for mGluR1 (Yanamoto et al., 2010). In vitro 
autoradiographic study demonstrated that [11C]YM-202074 (21, Fig.2) had high specific 
binding with mGluR1 in the rat cerebellum and its regional distribution was consistent with 
the distribution pattern of mGluR1 in the brain. However, the total accumulation of 
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[11C]YM-202074 in the brain was very low including lipophilic radiometabolites hampering 
its usefulness for in vivo imaging.  
Prahakaran et al. have reported the synthesis for in vitro and in vivo evaluation of 
[11C]MMTP (20) as a potential PET ligand for mGluR1 (Prabhakaran et al., 2010). Synthesis 
of the corresponding desmethyl precursor was achieved by demethylation of the 
methoxyphenyl compound MMTP in 90% yield. Methylation using [11C]MeOTf in presence 
of NaOH afforded [11C]MMTP in 30% yield (EOS) with >99% chemical and radiochemical 
purities and with a specific activity of 3–5 Ci/µmol (n = 6). The total synthesis time was 30 
min from EOB. In vitro autoradiography using phosphor imaging demonstrated that the 
radiotracer bound selectively mGlu1 receptors in slide-mounted sections of postmortem 
human brain containing cerebellum, hippocampus, prefrontal cortex and striatum. PET 
studies in anesthetized baboon showed that [11C]MMTP penetrates the BBB and 
accumulates in cerebellum, a region of high expression of mGluR1. 
Recently, a 18F-labeled triazole analog [18F]FTIDC (19, Ki = 3.9 nM) (Ohgami et al., 2009) was 
presented for imaging of mGluR1 showing high uptake in the rat brain. In addition, 
Fujinaga et al. have labeled a triazole analog, FPTQ (11, IC50 = 3.6 nM and 1.4 nM for human 
and mouse mGluR1, respectively) (Fujinaga et al., 2011). [18F]FPTQ (22) was synthesized by 
[18F]fluorination of the corresponding 2-bromo-3-pyridyl precursor with potassium 
[18F]fluoride. At the end of synthesis, 35-50 mCi (n = 8) of [18F]FPTQ was obtained with 
>98% radiochemical purity and 3.2-6.4 Ci/µmol specific activity using 89-108 mCi of 
[18F]fluoride. In vitro autoradiography showed that [18F]FPTQ had high specific binding with 
mGluR1 in the rat brain. Biodistribution study using a dissection method and small-animal 
PET showed that [18F]FPTQ had high uptake in the rat brain. The uptake of radioactivity in 
the cerebellum was reduced by unlabeled FPTQ and mGluR1-selective ligand JNJ-16259685 
(Fujinaga et al., 2011), indicating that [18F]FPTQ had in vivo specific binding to mGluR1. 
However, because of a low amount of radiolabeled metabolite present in the brain, this 
compound may have limiting use for in vivo imaging of mGluR1 by PET. 
Hostetler et al. have reported a PET radioligand, [18F]MK-1312 (18), which was radiolabeled 
with fluorine-18 via nucleophilic displacement of the corresponding 2-chloropyridine 
precursor with [18F]potassium fluoride (Hostetler et al., 2011). [18F]MK-1312 was synthesized 
(n = 25) in good yield (46 ± 15%) with >98% radiochemical purity and high specific activity 
(2.5 ± 1.4 Ci/µmol). In vitro autoradiographic studies with [18F]MK-1312 in rhesus monkey 
and human brain tissue slices revealed an uptake distribution consistent with the known 
distribution of mGluR1, with the highest uptake in the cerebellum, moderate uptake in the 
hippocampus, thalamus, and cortical regions, and the lowest uptake in the caudate and 
putamen. In vitro saturation binding studies in rhesus monkey and human cerebellum 
homogenates confirmed that [18F]MK-1312 binds to a single binding site with a Bmax/Kd 
ratio of 132 and 98, respectively. PET studies in rhesus monkey with [18F]MK-1312 showed 
high brain uptake and a regional distribution consistent with in vitro autoradiography 
results. Blockade of [18F]MK-1312 uptake with mGluR1 allosteric antagonist MK-5435 dose-
dependently reduced tracer uptake in all regions of gray matter. These results show that 
[18F]MK-1312 is a promising PET tracer for clinical studies to determine mGluR1 occupancy 
of MK-5435. 
In summary, several PET radioligands have been developed using highly potent and 
subtype-selective mGluR1 negative allosteric modulators. Although they showed efficacy in 
studying the distribution of mGluR1, some compounds may have limited applications 
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because of low brain uptake and/or brain penetrating radiometabolites. [18F]MK-1312 is the 
most advanced mGluR1 PET tracer, which has demonstrated efficacy in rhesus monkey. 
Although all the published mGluR1 PET tracers are radiolabeled mGluR1 negative allosteric 
modulators, mGluR1 positive allosteric modulators can also be used for developing mGluR1 
PET tracers. Several papers have been published about the functional differences between 
antagonist and agonist tracers in imaging G-protein coupled receptors, including dopamines 
D2 receptor (Hwang et al., 2004; Wilson et al., 2005), serotonin receptors (Kumar et al., 2006; 
Prabhakaran et al., 2006) and mGlu receptors. GPCRs have been postulated to exist in 
interconvertible high-affinity and low-affinity states. The high-affinity sites are G-protein 
coupled, whereas the low-affinity sites are those uncoupled with G-protein. Antagonist 
radiotracers bind with equal affinity to both the high- and low-affinity forms of the receptor, 
and they do not provide information about in vivo affinity of the receptor for antagonist. On 
the contrary, agonist radioligands bind only to high-affinity form of the receptor, thus 
giving valuable information about in vivo affinity of the receptor for agonists in normal and 
abnormal states. Concerning the binding sites of allosteric modulators in the seven strand 
transmembrane domain, there is no evidence for difference between negative and positive 
modulators in terms of their binding to high-affinity or low-affinity states of mGlu receptors 
(Kew & Kemp, 2005). Fig. 3 illustrates structures of some representative positive allosteric 

































EC50 = 30 nMEC50 = 60 nM EC50 = 10 nM EC50 = 6 nM EC50 = 29 nM  
Fig. 3. Chemical structures of mGluR1 positive allosteric modulators. 
3.1.2 Allosteric modulators and radiotracers for mGluR5 
Since the first selective mGluR5 antagonist was identified in 1999 (Varney et al., 1999), a 
large number of potent, subtype selective and structurally diverse allosteric modulators 
have been described. SIB1757 (28) and SB1893 (29) were discovered through random 
screening. Subsequent optimization by replacement of the trans-olefinic tether in SIB1893 
(29) with a C≡C triple bond led to MPEP (30), which demonstrated a dramatically improved 
mGluR5 antagonist activity (Gasparini et al., 1999). Various structure-activity relationship 
(SAR) studies have been done on MPEP, in which chemical modifications were done to each 
of the three regions of the lead molecule, identifying a series of highly potent and selective 
diaryl (heteroaryl) acetylenes as mGluR5 noncompetitive antagonists. By assumption that 
the (2-methyl-1,3-thiazo-4-yl)ethynyl group is one of the best structural parts to achieve 
mGluR5 antagonist activity further SAR studies on MTEP (31) identified more high-profile 
ligands containing thiazole moiety as mGluR5 noncompetitive antagonists  such as (33) (Iso 
et al., 2006). Many PET tracers have been synthesized by radiolabeling on the derivatives of 
MPEP and MTEP. 
A major concern with acetylenes in potential drugs is the possibility of chemical or 
metabolic reactivity (Milbank et al., 2007). Terminal acetylenes are well known to be 
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mechanism-based CYP-inactivators (Testa & Jenner, 1981) and there is an increasing body of 
information suggesting that internal acetylenes can be activated by CYPs (Fontana et al., 
2005; Foroozesh et al., 1997; Shimada et al., 2007) or even undergo uncatalyzed addition of 
glutathione (Chen et al., 2002; Mutlib et al., 1999). Mutlib et al. reported that incubation of 
MPEP with triple-labeled glutathione gave compounds with molecular weights and 
fragmentations consistent with both activated and unactivated addition of GSH to the 
alkyne (Mutlib et al., 2005). These events are potential sources for hepatic or idiosyncratic 
toxicity. To avoid a potential metabolic liability, many research groups have designed and 
synthesized mGluR5 negative allosteric modulators without the acetylene structure. Some 
structures such as 37 to 48 are given in Fig. 4, which may be useful for development of a 
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Fig. 4. Chemical structures of mGluR5 negative allosteric modulators 
Since the discovery of the first mGluR5 positive modulator, DFB (49, Fig. 5) (O'Brien et al., 
2003), Merck has reported three series of positive allosteric modulators for mGluR5, which 
are benzaldazine, benzamide and pyrazole series, exemplified by DFB, CPPHA (50) (O’Brien 
et al., 2004) and CDPPB (51) (Kinney et al., 2005; Lindsley et al., 2004), respectively. 
Subsequent structure-activity relationship study on CDPPB identified several nanomolar 
potent pyrazole ligands (De Paulis et al., 2006). Although these compounds are potent with 
an EC50 value of less than 20 nM, their poor binding affinity (Ki) and high lipophilicity  
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28 
(SIB1757)    
(Varney et al., 
1999) 
29 
(SIB1893)    
(Varney et al., 
1999) 
30 
(MPEP) Ki = 12 2  
(Cosford et al., 
2003) 
31 
(MTEP) Ki = 16 
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MTEP is more potent than 
MPEP in vivo (rats) in both a 
receptor occupancy assay and 
in the fear-potentiated startle 
model of anxiety.
(Cosford et al., 
2003) 
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Positive data from phase II 
clinical studies in both GERD 
and acute migraine.
(Keywood et al., 
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Ki = 22 
 
Showed efficacy for 
anxiolytic activity in the 
Vogel assay.
(Milbank et al., 
2007) 
38 
(Fenobam)   
Using prepulse inhibition as
an outcome measure for 
treating FXS, 50% of patients 
responded according to the 
predefined criteria of efficacy.
(Berry-Kravis et 
al., 2009; Porter 
et al., 2005) 
39 32   (Spanka et al., 2010) 
40  16 
Showed good brain 
penetration, robust receptor 
occupancy and short half-life 
in rodent. 
(Burdi et al., 
2010) 
41 109Ki = 9.1
  (Galambos et al., 2010) 
42 61  Showed efficacy in the OSS model.
(Lindsley et al., 
2011) 
43 24  Showed a robust anxiolytic-like effect.
(Carcache et al., 
2011) 
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45 <3  Rat B/P ratio=0.085. (Granberg & Holm, 2009) 
46 19  Rat B/P ratio=0.26. (Granberg & Holm, 2010) 
47 Ki=6.7   
(Jimenez et al., 
2010) 
48 7.8 25  (Henrich et al., 2009) 
Table 2. In vitro and in vivo pharmacological profiles for mGluR5 negative allosteric modulators. 
(logP) prevent them from being good candidates for radiotracer because high lipophilicity 
decreases brain penetration. Bessis et al. reported a fourth structural series represented by 
ADX47273 (52) (Bessis et al., 2005). Recently, many mGluR5 positive allosteric modulators, 53–
60, have been reported to have an EC50 value below 20 nM (Fig. 5) (Varnes et al., 2011; Williams 




















































EC50 = 16 nMEC50 = 10 nM
EC50 = 11.5 nM
EC50 = 5.6 nMEC50 = 14 nM
EC50 = 15.8 nM EC50 = 17.4 nM EC50 = 12.4 nM  
Fig. 5. Chemical structures of mGluR5 positive allosteric modulators 
The discoveries of noncompetitive allosteric modulators with high binding affinity and 
subtype-selectivity entitle the exploration of the physiological functions of mGluR5 in 
normal and pathological states. Although in vitro and ex vivo studies using selective mGluR5 
allosteric antagonists labeled with tritium (Cosford, 2003; Gasparini et al., 2002) have played 
important roles in elucidating the distribution and functions of mGluR5, PET tracers are 
needed for the in vivo quantitative visualization of mGluR5 in a living body and to conduct 
longitudinal studies of modulation of mGluR5 expression. 
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3.1.3 PET imaging studies of mGluR5 function 
MPEP and MTEP have provided leads to some radioligand candidates for imaging human 
mGlu5 receptors with PET in vivo. Great effort was done to identify suitable positron-
emitting radiotracers for noninvasive imaging of mGluRs. To date, more than 15 mGluR5-
selective PET ligands labeled with 18F or 11C have been reported (Fig. 6) (Ametamey et al., 
2006; De Paulis et al., 2006; Hamill et al., 2005; Honer et al., 2007; Krause et al., 2003; 
Musachio et al., 2003; Patel et al., 2005; Sanchez-Pernaute et al., 2008; Sime´on et al., 2007; 
Wang et al., 2007a; Yu, 2005; Zhu et al., 2007).  
In 2005, Hamill and colleagues from Merck demonstrated the first successful PET imaging of 
mGluR5 in rhesus monkeys using [18F]F-MTEB (61) (Hamill et al., 2005; Patel et al., 2005). 
This compound was highly selective and bound with high affinity (IC50 = 80 pM) to the 
receptor. However, the synthesis of this tracer in the cyclotron gave low yields (2-5%), which 
limited its potential utility as a ligand for clinical trials in humans. 
Brownell et al. have synthesized and radiolabeled five noncompetitive antagonists for 
mGluR5: [11C]M-MPEP (62) (Yu et al., 2005), [11C]M-PEPy (63) (Sanchez-Pernaute et al., 
2008), [11C]MPEP (64) (Yu et al., 2005), [18F]FMTEP (65) (Zhu et al., 2007) and 18F]FPEB (66) 
(Wang et al., 2007a) and conducted in vivo PET imaging studies in different disease models 
to investigate modulation of mGluR5 function. It was found in these studies that 
accumulation of pyridine derivatives [11C]M-MPEP (62), [11C]M-PEPy (63), [11C]MPEP (64) 
and [18F]FMTEP (65) into the brain was fast and the highest accumulation was reached in 1-5 
min followed by fast washout, suggesting little retention by high affinity receptor binding. 
This creates limitation to obtain statistically meaningful imaging data without overdosing 
the object with radiation or saturating the receptor binding sites with accompanying cold 
compound. These ligands have limitation, due to high lipophilicity, unfavorable brain 
uptake kinetics, or a high rate of metabolism, though they possess favorable in vitro 
pharmacological profiles. For PET ligands to be used in the central nervous system, a 
postulated lipophilicity coefficient (logD or logP) value should be between 2 and 3 for good 
brain accumulation. The compounds [11C]ABP688 (67) (Ametamey et al., 2006) and 
[18F]FPEB (66) (Patel et al., 2007; Wang et al., 2007a) have better binding profile for imaging 
studies of mGluR5. The logD value of 2.3 for [11C]ABP688 and the logP value of 2.8 for 
[18F]FPEB suggest that the two compounds are sufficiently lipophilic for the BBB 
penetrating. Both compounds have good binding properties with a Ki Value of 0.2 nM for 
[18F]FPEB and a Kd value of 1.7 nM for [11C]ABP688. The brain uptake of both compounds is 
highly selective, with high accumulation in mGluR5-rich brain regions such as the 
hippocampus, striatum and cortex. Blocking studies by coinjection of [11C]ABP688 and 
corresponding unlabeled compound revealed up to 80% specific binding in these regions, 
whereas in cerebellum, a region with negligible mGluR5 density, no  significant changes in 
radioactivity uptake were observed (Ametamey et al., 2006). Specific binding of compounds 
[11C]ABP688 and [18F]FPEB were also demonstrated with mGluR5-knockout mice which 
exhibited a homogeneous background level accumulation throughout the brain (Black et al., 
2010). The metabolism studies of [11C]ABP688 and [18F]FPEB indicated that more than 95% 
of the radioactivity found in the brain was parent compound 30 min after injection for 
[11C]ABP688 and 78% for [18F]FPEB. Both compounds have been translated to human 
studies to investigate mGluR5 function.  
Siméon and colleagues of the NIH reported a new high affinity radioligand, [18F]-SP203 (68), 
for mGluR5 (Sime´on et al., 2007). [18F]-SP203 has high affinity (IC50 = 36 pM) and potency in 
a phosphoinositol hydrolysis assay (IC50 = 0.71 pM) for mGluR5. It demonstrates a high 
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uptake in mGlu5 receptor rich regions of the rat and rhesus brain. The major advantage of 
this tracer over [18F]F-MTEB is its high radiochemical yield (87%) and easy radiosynthesis. 
This ligand is presently in NIH administrated  clinical trial. 
[11C]M-FPEP (69, KD 1.2 nM and Bmax 84.5 fmol/mg) has an even biodistribution in all brain 
regions demonstrating that this tracer lacks specific binding (Ametamey et al., 2003). 
Compound 70 showed little retention by the receptor (Krause et al., 2003). Compound 71 
(rat Ki 0.23 nM) had a good brain uptake and slow washout, with high concentration in 
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Fig. 6. Chemical structures of mGluR5 PET tracers. 
 
 
Fig. 7. Expression of mGluR5 in the brain of a naïve (top) and a symptomatic parkinsonian 
primate, using the highly selective tracer [18F]FPEB (3-[18F]fluoro-5-(2-
pyridinylethynyl)benzonitrile). Primate Parkinson’s disease (PD) was introduced by low dose 
long-term systemic administration of MPTP. In PD monkey accumulation of [18F]FPEB was 
enhanced compared to naïve monkey in several brain areas including caudate, putamen, 
accumbens and  SN/VTA. Distribution of [18F]FPEB accumulation is illustrated at 60-70 min 
after administration of radioligand (1.2-1.5 mCi iv., specific activity 1.9 Ci/mol). 
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cerebellum is an area with fairly low mGluR5 expression indicating that 71 may have non-
specific binding. 
Four derivatives, 72-75, were developed of ABP688. PET imaging with 72 (Lucatelli et al., 
2009) did not allow visualization of mGluR5-rich brain regions in the rat brain due to fast 
washout and rapid defluorination. Compound 73 (Baumann et al., 2010a) was reported to 
have the high binding affinity to mGluR5. Further in vitro evaluation and in vivo imaging are 
needed for characterization of this ligand. Baumann et al. (Baumann et al., 2010b) reported 
that although [18F]-FTECMO (74) displayed optimal lipophilicity (log DpH7.4 = 1.6 ± 0.2) and 
high stability in rat and human plasma as well as sufficient stability in rat liver microsomes, 
PET imaging with [18F]-FTECMO in Wistar rats showed low brain uptake. Uptake of 
radioactivity into the skull was observed suggesting in vivo defluorination. Honer et al. 
reported that [18F]-FE-DABP688 (75) have optimal lipophilicity (logD  2.1±0.1) and high 
plasma stability (Honer et al., 2007). Saturation assays of [18F]-FE-DABP688 revealed a single 
high affinity binding site with a dissociation constant (Kd) of 1.6±0.4 nM and a Bmax value of 
119±24 fmol/mg protein. PET scanning indicated radioactivity uptake in mGluR5-rich 
regions such as the hippocampus, striatum and cortex, and radioactivity accumulation in 
the cerebellum, a region with negligible mGluR5 density, was significantly lower. 
Biodistribution studies showed a similar distribution pattern of [18F]-FE-DABP688 binding 
in the brain. The hippocampus-to-cerebellum and striatum-to-cerebellum ratios were 
1.81±0.16 and 1.93±0.36, respectively. Blocking studies using coinjection of [18F]-FE-. 
DABP688 and unlabeled M-MPEP (1 mg/kg) revealed more than 45% replacement in the 
hippocampus and striatum, thus demonstrating the in vivo specificity of tracer binding. This 
result shows that [18F]-FE-DABP688 may be a useful PET tracer for imaging mGluR5 
3.2 Allosteric modulators and radiotracers for group II mGluRs 
Group II mGluRs have been shown to be expressed in several brain areas. The expression 
patterns of Group II receptors in the rodent brain parallel those of mGluR5, although the 
overall abundance of mGluR2/3 receptors appears slightly reduced as compared with that 
of mGluR5 (Olive, 2009). Expression levels of mGluR2/3 receptors are high in the olfactory 
bulb and hippocampus, and moderate in the dorsal striatum, nucleus accumbens, amygdala, 
anterior thalamic nuclei, cerebral cortex and cerebellum. Low levels of mGluR2/3 are found 
in the pallidum, colliculi, ventral midbrain and hypothalamus.  
Group II mGluRs act in the hippocampus to decrease synaptic transmission and glutamate 
release when activated. These receptors have been targeted extensively by potential 
neuroprotective agents to develop treatments for anxiety, schizophrenia, Alzheimer’s disease, 
Parkinson’s disease, pain, drug withdrawal, and epilepsy (Rudd & McCauley, 2005). 
3.2.1 Allosteric modulators for mGluR2 
Over the past decade, a number of highly potent (EC50 in subnanomolar) mGluR2 agonists 
and antagonists with high binding affinity (Ki < 2 nM) have been identified (Rudd & 
McCauley, 2005; Yasuhara et al., 2006). However, their mGluR2-selectivity over mGluR3 in 
the same group is fairly low with the highest potency ratio being 6.5 (Dominguez et al., 
2005). A high potency ratio does not necessarily imply a high binding affinity ratio, whereas 
the specific binding of a radiotracer depends much on the binding affinity ratio. Considering 
a low subtype-selectivity and unfavorable brain penetration of classical mGluR2 agonists 
and antagonists, the focus has presently been to develop noncompetitive allosteric 
modulators. When the allosteric binding sites on glutamate receptors within a group are 
sufficiently different it is possible to develop subtype selectivity modulators. 
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Fig. 8. Chemical structures of mGluR2 positive allosteric modulators 
Many series of selective mGluR2 positive allosteric modulators have been reported to date. 
Figure 8 shows the compounds that were reported to have an EC50 value of less than 30 nM. 
They are N-aryl-N-(pyridylmethyl)ethanesulfonamides (76) (Barda et al., 2004; Johnson et 
al., 2003), biphenyl-indanones (77) (Bonnefous et al., 2005), 1,4-disubstituted 3-cyano-
pyridone derivatives (78) (Imogai et al., 2007), 3-(Imidazolyl methyl)-3-aza-
bicyclo[3.1.0]hexan-6-yl)methyl ethers (79 and 80) (Zhang et al., 2008), 
oxazolobenzimidazoles (81) (Garbaccio et al., 2010), 3-Benzyl-1,3-oxazolidin-2-ones (82 and 
83) (Duplantier et al., 2009), 2-((4-(2-methoxy-4-(trifluoromethyl)phenyl)piperidin-1-
yl)methyl)-5,6-dihydro-4H-imidazo[4,5,1-ij][1,7]naphthyridine (84) (Efremov et al., 2008) 

































































Fig. 9. Chemical structures of mGluR2/3 positive allosteric modulators 
Several series of compounds have been developed as mGluR2 or mGluR2/3 allosteric 
antagonists, which include 8-ethynyl-1,3-dihydrobenzo[b][1,4]diazepin-2-one derivatives 
(86 and 87) (Woltering et al., 2007; Woltering et al., 2008a; Woltering et al., 2008b; Woltering 
et al., 2010), imidazole derivatives (88) (Gatti McArthur et al., 2006b), pyrazolopyrimidines 
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(89) (Gatti McArthur et al., 2006c), Pyridine and pyrimidine derivatives (90 and 91) (Gatti 
Mcarthur et al., 2007), acetylenyl-pyrazolo-pyrimidine derivatives (92 and 93) (Gatti 
McArthur et al., 2006a). Representative compounds listed in Fig. 9 exhibit high binding 
affinity towards mGluR2, however, their binding selectivity over mGluR3 is either very low 
or is not disclosed.  
Currently, no positron emitting radioligand has been developed for imaging mGluR2. 
3.2.2 PET imaging studies of mGluR2/3 expression 
 
 
Fig. 10. To investigate preliminary imaging characteristics of (S,S,S)-2-(2-
carboxycyclopropyl)-2-(3-[11C]methoxyphenethyl) glycine dimethyl ester ([11C]CMG) 0.4-0.5 
mCi of [11C]CMG was administered iv. into the anesthetized (isoflurane 1.5% with O2 flow 
of 1L/min) rats (male Spraque Dawley) in a microPET scanner (P4, Concord Microsystems). 
Dynamic volumetric data were acquired in 6 rats for 60 min. Fast reversible binding was 
observed in several cortical areas, hippocampus, striatum and olfactory bulb, the sites which 
are known to express group II mGluRs. The maximum binding (1.1-1.6% of the injected dose 
per cm3) was observed 2 min after administration. These data provide a foundation for 
future development of specific PET imaging ligands for group II mGluRs. Coronal and axial 
slices of [11C]CMG distribution in the rat brain from 1 min till 40 min after administration of 
the radioligand are illustrated. Color coded images are normalized to each other and 
correspond the acquisition time of 1 min at the same midbrain level (coronal slice at bregma 
-1.6 mm; axial slice at bregma -5.4 mm). 
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3.2.3 Allosteric modulators for mGluR3 
Eli Lilly and Company reported the first series of compounds, 1-(heteroaryl)-3-(2,4-
dichlorobenzyl)amino-pyrolidine, acting as mGluR3 negative allosteric modulators (Britton 
et al., 2006). Figure 11 shows the chemical structures of two most potent ligands reported in 
the patent. Compounds, 94 and 95, have an IC50 value of 77 nM, which is insufficient for in 
vivo detection of the receptors. Further SAR studies are needed to find more potent ligands. 


















IC50 = 77 nM  
Fig. 11. Chemical structures of mGluR3 negative allosteric modulators 
3.3 Allosteric modulators and radiotracers for Group III mGluRs 
Group III metabotropic glutamate receptors are mGluR4, mGluR6, mGluR7 and mGluR8. 
There is no publication reporting mGluR6 allosteric ligands. 
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Fig. 12. Chemical structures of mGluR4 positive allosteric modulators 
MGluR4 has received much attention lately due to its implication in several diseases, such as 
PD, epilepsy, and anxiety. There has been substantial progress in identifying positive 
allosteric modulators for mGluR4. The compound PHCCC (96, Fig. 12), a partial selective 
mGluR4 potentiator, has been studied for many years. Unfortunately PHCCC and other 
early disclosed mGluR4 PAMs such as 98–101 (Fig.12) are deficient in their BBB penetration 
(Engers et al., 2009). The potencies of these compounds are also relatively low (EC50: 0.65 – 
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5.0 M) and SAR studies around these structures have given ‘flat’ results. Addex Pharma 
disclosed a series of heteroaromatic compounds (102 in Fig. 12) as positive allosteric 
modulators for mGluR4, with many compounds having EC50 < 0.5 µM (Bolea & Celanire, 
2009). However, no other information was reported about these compounds. 
Two research groups; Addex Pharma (Bolea, 2009) and Vanderbilt University (Engers et al., 
2009), have independently disclosed a series of small arylamide compounds as a new class 
of mGluR4 PAMs. Engers et al (Vanderbilt University) found from a high-throughput 
screening that there were a number of small arylamide compounds having mGluR4 PAM 
activity (Engers et al., 2009). They reported studies on SAR and in vitro and in vivo 
pharmacokinetic parameters in rat. The most potent compound in this series was 103 shown 
in Fig. 12. Researchers at Merck presented two new compounds, 104A and 105, with 
improved activity (Reynolds, 2008). Engers et al. further studied SAR of 4-
(phenylsulfamoyl)phenylacetamide derivatives and found that 104B was the most potent 
(19.8 nM) mGluR4 positive allosteric modulator reported to date (Engers et al., 2010). Doller 
and co-workers (Lundbeck Research USA) have recently reported on a series of tricyclic 
thiazolopyrazole derivatives including compound 106, which was identified as a very 
potent and orally available compound with excellent brain penetration and good 
physicochemical properties (Hong et al., 2011).  
3.3.2 PET imaging studies of mGluR4 expression 
 
 
Fig. 13. Distribution of [11C]methyl-PHCCC between 10-20 min after administration of 
radioligand in a control (1.2 mCi iv.) and PD (1.1 mCi iv.) rat brain. Coronal and axial views 
localize cortex at the level of S1 and S2 areas. It is noticeable that the accumulation of 
[11C]methyl-PHCCC is enhanced in PD rat in the areas of subthalamic nucleus and spinal cord. 
The motor neurons in the ventral horn in the spinal cord express mGluR4 and the observed 
enhanced accumulation of mGluR4 ligand, [11C]methyl-PHCCC is an indication of excess 
glutamate. This is the first time, when this aspect has been demonstrated in vivo in a PD model.  
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3.3.3 Allosteric modulators for mGluR7 
It is reported that mGluR7 is widely expressed in the central nervous system and is 
primarily located on presynaptic terminals in brain regions such as the hippocampus, 
amygdala, and locus coeruleus. Mitsukawa et al. developed the first selective allosteric 
agonist of mGluR7, AMN082 (107), which has an EC50 value of 64-290 nM and it is brain 
penetrating (Mitsukawa, 2005). However, converting it to a PET tracer is not 
straightforward. Researchers of Banyu Pharmaceutical Co reported a series of 
isoxazolopyridone derivatives as allosteric mGluR7 antagonists (Suzuki et al., 2007b). 
Compound MDIP (108) that was identified by random screening displayed mGluR7 
antagonistic activity (IC50 = 20 nM) and had no detectable activity on other mGluRs at 1000 
nM. However, MDIP showed poor metabolic stability (predicted FH: 34%) on rat hepatocyte 
assay and low aqueous solubility (0.17 µg/mL, pH 7.4). It is assumed that poor metabolic 
stability and low aqueous solubility may be due to its high lipophilicity (clogD7.4: 3.5). 
Recently, Nakamura et al. have identified some isoxazolopyridone derivatives with potent 
mGluR7 antagonistic activity and metabolic stability, in which MMPIP (109) with improved 
physicochemical properties and metabolic stability showed good oral bioavailability and 






















Fig. 14. Chemical structures of mGluR7 modulators 
3.3.4 Allosteric modulators for mGluR8 
Recently, AstraZeneca developed a positive allosteric modulator for mGluR8 (Duvoisin et 
al., 2010; Duvoisin et al., 2011). The compound AZ12216052 as injected into the amygdale, 
reduced measures of anxiety. There is no PET ligand available and AZ12216052 does not 
cross blood brain barrier. 
4. Conclusion 
Glutamate is an interesting transmitter since it can participate also on glutamate metabolism 
to be converted to glutamine and its function as a neurotransmitter can be investigated 
based on its receptor functions. To understand the diverse physiological effects of glutamate 
it is important to know molecular identity of mGluRs expressed in distinct subpopulations 
of neurons. For instance, group I mGluRs are coupled to phospholipase C and subsequent 
production of inositol triphosphates and induces intracellular calcium release in Purkinje 
cells and hippocampal CA1 neurons, but the same receptor types are also coupled to 
inhibition of voltage-dependent calcium channel in hippocampal neurons without 
intracellular diffusible messengers (Choi & Lovinger, 1996). Group II mGluRs can be 
coupled to inhibition of cyclic AMP cascade in neural and glial cells while they are also 
linked to rapid-onset regulation of various channels including calcium channels and G-
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protein. The group III mGluRs-mediated effect is inhibition of neurotransmission through 
suppression of presynaptic voltage-dependent calcium channels (Pekhletski et al., 1996). 
This basic functional information of mGluRs has been obtained with in situ hybridization, 
immunohistochemistry and ex vivo studies with tritium labeled antibodies. While ex vivo 
studies can provide accurate endpoint information in steady state, they cannot provide 
information of the active inhibitory or stimulating effects in the system or interplay with 
other systems. To obtain functional information in real time, the investigation has to be done 
by using in vivo imaging methods. However, a lack of specific agonists and antagonists has 
limited the precise characterization of the role of individual metabotropic glutamate 
receptors in glutamatergic neurotransmission and hampered progress in identifying the 
physiological and pathological roles of mGluRs in vivo.  
Recently, the modern computational chemistry has opened a wide range of technical 
approaches to design and construct molecules for imaging and to simulate their molecular 
targets. This technology has been used to design molecules for tracking different mGluRs. 
Especially, approach of allosteric compounds relies on sophisticated design of three-
dimensional arrangement of the tracer molecules responsible for the biological activity. 
Pharmacophore models can be constructed based on known biological activity. Design of 
novel allosteric modulators is an iterative process where structure-activity relationship 
information generated in the biological assays guides how to make structural alternations 
towards the optimal compound. Recently several non-competitive structurally diverse 
mGluR ligands have been published. These ligands, positive, negative and neutral 
modulators, bind to the allosteric binding sites located in the seven strand transmembrane 
domain. Based on these modulators, a number of radiotracers useful for imaging specific 
metabotropic glutamate receptors have been developed and their in vivo biological 
properties have been characterized. 
Development of metabotropic glutamate receptor ligands will open a new perspective for 
molecular imaging. Modulation of receptor functions might be used as diagnostic tools as 
well as to follow progression/regression of neural diseases. Presently, three mGluR ligands 
have been used in human studies. They are developed as negative allosteric modulators for 
mGluR5. For example, concerning PD, the death of dopamine neurons in the substantia 
nigra pars compacta causes a loss of dopamine in the basal ganglia. Dopamine modulation 
of neurotransmission in the striatum and other basal ganglia structures is crucial to gate 
cortical and thalamic excitatory input through the direct and indirect pathways. By using in 
vivo PET imaging studies and [18F]FPEB we have found an upregulation of mGluR5 
expression following dopamine denervation in animal models of PD (Figures 7 & 13), which 
probably represents a local compensatory mechanism, directed to dampen an excessive 
excitability of striatopallidal neurons. Drugs targeting the mGluR5 might provide new 
approaches by selectively reducing glutamate transmission in the areas where it is 
abnormally enhanced. In addition, we and others have found enhanced mGluR5 expression 
in several brain areas related to the indirect pathway in models of L-DOPA induced 
dyskinesias and some studies have shown promising therapeutic results after using mGluR5 
antagonists. In gut glutamate is the main energy source and its neurotransmission is 
conducted by vagal afferents. The gut expresses also mGlu5 receptors and we have localized 
them with [18F]FPEB. This phenomenon has raised a hypothesis that gut-brain axis as well 
as interplay with dopamine transmission might contribute to obesity. 
Even mGlu2 receptors had the earliest interest as targets for drug development and Eli Lilly 
developed several potent ligands targeted to mGluR2 there is not yet any specific allosteric 
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modulators available for imaging purposes of mGluR2 function. The earlier compounds 
were missing receptor selectivity and sensitivity for imaging purposes since sequence 
similarity at the orthosteric binding site to which endogenous agonists bind.  
Present application of glutamate transmission has evoked an active drug development 
especially to develop allosteric modulators for neurodegenerative disorders, pain and 
schizophrenia. It should be noted that these disorders are affected also by modulation of 
dopaminergic system supporting hypothesis of interplay of these powerful transmitter 
systems. Future pharmacological and imaging studies will show which specific ligands 
acting at individual receptor subtypes could be used as sensitive indicators for diagnostic 
imaging. Therefore, there is an urgent need for development of allosteric modulators as 
imaging ligands for different of mGluRs for human use. 
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1. Introduction 
Nicotine, named after the French diplomat Jean Nicot who brought the tobacco plant 
(Nicotiana tabacum) to France, isolated in 1828 as the major pharmacologically active 
compound in this plant (Posselt & Reimann, 1828), structurally identified between 1890 and 
1893 (Pinner, 1893; Pinner & Wolffenstein, 1891), and first synthesized chemically in 1903 
(Pictet, 1903), acts on various subtypes of nicotinic acetylcholine receptors (nAChRs) in the 
brain and in the periphery (Changeux, 2010; Langley, 1906).  
Besides tobacco, nicotine is found in plants of the nightshade family (solanaceae) such as 
tomato, potato, peppers and aubergine (eggplant) but also in tea plants (Schep et al., 2009). 
Accordingly, it is regularly taken up by the great majority of the human population with a 
mean daily dietary intake of approximately 1.4 µg per day (Siegmund et al., 1999). The 
alkaloid is readily absorbed by the lung or intestinal tissue, distributed by the blood and 
transported across the blood-brain barrier (Allen & Lockman, 2003; Oldendorf et al., 1979). 
When inhaled it takes about seven seconds for nicotine to reach the brain (Rose et al., 2010), 
where it binds with high affinity to the heteromeric α4β2 and the homomeric α7 nAChRs, 
the two most abundant nAChR populations (Changeux, 2010). In the brain, nAChRs are 
involved in attention and cognition, locomotion, vigilance control, and rewarding 
mechanisms (Changeux, 2010; Graef et al., 2011), and they are suggested to play a major role 
in brain development (Hruska et al., 2009; Ross et al., 2010).  
Notably, nicotinic receptors, and in particular α7 nAChR, are not only expressed on neurons 
but virtually on all cell types present in the brain including astrocytes (Sharma & 
Vijayaraghavan, 2001), microglia (De Simone et al., 2005; Suzuki et al., 2006), 
oligodendrocyte precursor cells (Sharma & Vijayaraghavan, 2002), and endothelial cells 
(Hawkins et al., 2005). Accordingly, neuronal and non-neuronal expression of α7 nAChR 
has also been found in peripheral organs (Albuquerque et al., 2009; Sharma & 
Vijayaraghavan, 2002).  
Molecular imaging in vivo as considered in this review relates exclusively to the use of 
radiolabelled receptor ligands, although occasionally optical imaging has been used to 
investigate the cholinergic system (Prakash & Frostig, 2005). Molecular imaging of α4β2 
nAChR in vivo has recently been reviewed (Horti et al., 2010; Sabri et al., 2008). Therefore, 
the current review is focussed on neuroimaging of α7 nAChRs. 
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2. Role of 7 nicotinic receptors in normal brain function 
α7 nAChRs, discovered in 1990 (Couturier et al., 1990), belong to the superfamily of 
multisubunit ligand-gated ion channels and mediate the effects of the endogenous 
neurotransmitter acetylcholine. Homomeric α7 nAChR is functionally distinct from the 
heteromeric nAChRs due to lower affinity to the agonists acetylcholine and nicotine, and 
higher affinity to the antagonistic snake venom α-bungarotoxin (α-BGT). Agonist binding 
induces a change in conformation of all five subunits of the α7 nAChR and leads to opening 
of the cation-conducting channel across the plasma membrane, probably by cis-trans prolyl 
isomerisation (Lummis et al., 2005). Regarding ion selectivity, α7 nAChR is known to have 
the highest permeability to Ca2+ ions within all nAChR subtypes (Dajas-Bailador et al., 2002; 
Gilbert et al., 2009; Sharma & Vijayaraghavan, 2001). Therefore, the activation of α7 nAChR 
changes the intracellular Ca2+ homoestasis both directly as well as indirectly, the latter via 
voltage-dependent membrane-spanning Ca2+ channels as well as Ca2+ release channels and 
pumps in the endoplasmatic reticulum. Downstream events of this Ca2+ signalling result in 
(i) immediate effects, such as neurotransmitter release, (ii) short-term effects, such as 
receptor desensitisation and recovery, and (iii) long-lasting adaptive effects, such as 
neuroprotection or changes in the plasticity of the brain via gene expression (Leonard, 2003; 
Radcliffe & Dani, 1998; Shen & Yakel, 2009). Dependent on the cell-specific pattern of 
intracellular signalling in neurons with α7 nAChRs located post-, pre- and extrasynaptically 
(Berg & Conroy, 2002; Frazier et al., 1998; Schilström et al., 2000), these complex functional 
properties explain the involvement of the α7 nAChR in physiological processes of 

























Fig. 1. Involvement of α7 nAChRs in physiological and pathophysiological processes of 
neurotransmission.  
For example, presynaptic α7 nAChRs regulate, either directly or via modulation of 
glutamate release, the activity profiles of neurotransmitters such as GABA (Albuquerque et 
al., 1997; Liu et al., 2001), noradrenaline (Fu et al., 1999; Li et al., 1998), or dopamine (Kulak 
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et al., 1997; Northrop et al., 2010) and thereby mediate neuronal adaptation related to 
development, learning, memory, attention, pain perception, and reward. Furthermore, α7 
nAChRs mediate postsynaptic responses in serotonergic neurons involved in maintaining 
the waking state (Galindo-Charles et al., 2008). An assumed contribution of α7 nAChRs to 
the formation of endocannabinoids (Stella & Piomelli, 2001) and a proposed regulation of α7 
nAChR activity by anandamide (van der Stelt & Di Marzo, 2005) is consistent with a 
functional interaction of neuromodulating systems involved in drug dependency 
(McPartland et al., 2008). 
 
Species Brain region Radioligand, 
concentration 
Receptor binding* Referenz 
Human Nucleus 
reticularis 
[125I]α-BGT, 1 nM 5-12 nM (Spurden et al., 1997) 
 Nucleus 
geniculatis lat.  
[125I]α-BGT, 1 nM 
 
2 nM (Spurden et al., 1997) 
 Dorsolateral 
prefrontal cortex 
[125I]α-BGT, 5 nM 9-12 nM (Mathew et al., 2007) 
 Cingulate cortex [125I]α-BGT, 2.6 nM ~ 16 nM (Marutle et al., 2001) 
 Temporal cortex [125I]α-BGT, 2.6 nM ~ 8 nM (Marutle et al., 2001) 
 Hippocampus [125I]α-BGT, 1.2 nM 2-8 nM (Hellström-Lindahl & 
Court, 2000) 
 Cerebellum [125I]α-BGT, 1 nM 1-3 nM (Lee et al., 2002)  
Monkey Cortex [125I]iodo-MLA 6 nM (Bmax)  (Kulak et al., 2006) 
 Striatum [125I]iodo-MLA 3-4 nM (Bmax)  (Kulak et al., 2006) 
  [125I]α-BGT, 3 nM 7.5 nM (Quik et al., 2005) 
Rat Cortex [3H]MLA, 5 nM 6-16 nM (Mugnaini et al., 2002)  
  [3H]MLA, 20 nM ~30 fmol/mg protein (Davies et al., 1999) 
  [125I]α-BGT, 10 nM ~40 fmol/mg protein (Davies et al., 1999) 
  [125I]α-BGT ~ 1.1 nM (Bmax) (Christensen et al., 2010) 
 Thalamus [3H]MLA, 5 nM 0.9 - 21 nM (Mugnaini et al., 2002) 
 Hippocampus [3H]MLA, 5 nM 6-182 nM (Mugnaini et al., 2002) 
  [3H]MLA, 20 nM ~ 70 fmol/mg protein (Davies et al., 1999) 
  [125I]α-BGT, 10 nM ~ 70 fmol/mg protein (Davies et al., 1999) 
  [125I]α-BGT ~1.2 nM (Bmax)  (Christensen et al., 2010)  
 Hypothalamus [3H]MLA, 5 nM 14-34 nM (Mugnaini et al., 2002) 
  [3H]MLA, 20 nM ~ 55 fmol/mg protein (Davies et al., 1999) 
  [125I]α-BGT, 10 nM ~ 50 fmol/mg protein (Davies et al., 1999) 
Mouse Cortex [3H]MLA, 2 nM 1-5 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]α-BGT, 1.2 nM ~ 8 nM (Svedberg et al., 2002)  
  [125I]α-BGT, 2 nM 0-3 fmol/mg protein (Whiteaker et al., 1999) 
 Thalamus [3H]MLA, 2 nM 1-20 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]α-BGT, 2 nM 0-12 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]α-BGT, 1.2 nM ~ 3 nM (Svedberg et al., 2002)  
 Hippocampus [3H]MLA, 2 nM 0-9 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]α-BGT, 2 nM 0-4 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]α-BGT, 1.2 nM ~ 12 nM (Svedberg et al., 2002)  
 Hypothalamus [3H]MLA, 2 nM 1-12 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]α-BGT, 2 nM 1-6 fmol/mg protein (Whiteaker et al., 1999) 
 
Table 1. Quantitative in vitro autoradiographic studies on α7 nAChR binding of various 
radioligands in the brains of different species, *nM = fmol/mg wet weight 
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Qualitatively, the expression pattern of α7 nAChR is similar in rodent and primate brain 
(Han et al., 2000), although a comprehensive and parallel quantitative analysis of α7 nAChR 
protein expression in the brain of different species, expected to facilitate the translation of 
experimental data on the imaging of α7 nAChR from in vitro and in vivo animal models into 
clinical application, is still warranted. In general, regions with high- to moderate-density of 
α7 nAChR gene expression and [125I]α-BGT binding are related to learning and memory 
such as thalamic and hippocampal structures, the horizontal limb of the diagonal band of 
Broca, and the nucleus basalis of Meynert (Alkondon et al., 2007; Breese et al., 1997; Fabian-
Fine et al., 2001; Hellström-Lindahl et al., 1999; Schulz et al., 1991; Spurden et al., 1997). 
However, species differences exist regarding the total number of binding sites of α7 nAChR 
specific radioligands (Han et al., 2003) with for example a lower amount of [125I]α-BGT 
binding in the monkey hippocampus or the human thalamus and cortex compared with the 
same regions of rat brain (Breese et al., 1997) (Tab. 1).  
3. Alterations of 7 nAChR in diseased brain  
The World Health Organization has classified dependence on the use of drugs including 
tobacco as a disease in 1965. During the following decades convincing evidence was 
obtained that nicotine is the key factor in tobacco addiction and that nicotinic acetylcholine 
receptors are of importance (Stolerman, 1990). It has been suggested that α7 nAChRs in the 
ventral tegmental area mediate nicotine´s stimulatory effect on mesolimbocortical 
dopaminergic function and consequently its reinforcing and dependence-producing 
properties (Nomikos et al., 2000). As shown in rats, exposure to tobacco smoke not only 
induced nicotine dependence but increased the α7 nAChR density in the CA2/3 area (+ 
25%) and the stratum oriens (+ 18%) of the hippocampus (Small et al., 2010). 
With respect to clinical considerations, a close association between nicotine addiction and 
schizophrenia has been found (Lohr & Flynn, 1992). Consistent with the hypothesis, that a 
gene-mediated dysfunction of α7 nAChR (Dome et al., 2010; Freedman et al., 1997; Stephens 
et al., 2009) underlies impairments seen in schizophrenia (Nomikos et al., 2000),  the density 
of hippocampal [125I]α-BGT binding sites was decreased in schizophrenic patients 
(Freedman et al., 1995) but was at control levels in schizophrenic smokers (Mexal et al., 
2010).  
Evidence for an involvement of α7 nAChR in Alzheimer’s disease (AD) was obtained at 
about 30 years ago from data showing a significantly reduced number of [125I]α-BGT 
binding sites in the mid-temporal gyrus from demented patients (Davies & Feisullin, 1981). 
During the last decade, comparable results were obtained by analysing other 
neurodegenerative diseases. Lewy body dementia (DLB) and Parkinson´s disease have also 
been associated with alterations in the transcription or translation of the α7 subunit 
(Burghaus et al., 2003; Court et al., 2000; Nordberg, 2001; Wevers & Schröder, 1999), 
indicating a hypocholinergic tone due to for example reduced levels of α7 mRNA and 
protein in the hippocampus and reticular nucleus in AD and DLB (Court et al., 1999; Guan 
et al., 2000; Hellström-Lindahl et al., 1999). Functional interactions of β-amyloid with α7 
nAChR, revealed in vitro (Wang et al., 2000), and the colocalization of both in AD support 
the hypothesis that neuronal degeneration in AD might also be triggered by β-amyloid-
initiated and α7 nAChR-mediated inflammatory processes (Bencherif & Lippiello, 2010). 
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Interestingly, also in traumatic brain injury (TBI), regarded as risk factor for AD (Fleminger 
et al., 2003), significantly lowered α7 nAChR densities were found in rats and pigs 
(Hoffmeister et al., 2010). The resulting cholinergic hypofunction may attenuate the anti-
inflammatory effect of acetylcholine (Rosas-Ballina & Tracey, 2009) and thus contribute to 
the process of neurodegeneration (Conejero-Goldberg et al., 2008). 
Other diseases with potential involvement of α7 nAChR include epilepsy and attention 
deficit hyperactivity disorder (ADHD). While some forms of epilepsy have recently been 
associated with alterations of α4 subtype expression (Raggenbass & Bertrand, 2002), there is 
experimental evidence that α7 nAChR may play a role in epileptogenesis (Dobelis et al., 
2003). Based on similarities between schizophrenia and ADHD with regard to a number of 
disturbances in attention it has been hypothesized that the α7 subunit gene may be of 
significance in ADHD although experimental data are still missing (Kent et al., 2001). 
Previous attempts to treat ADHD patients with nicotine (Levin et al., 1996; Potter & 
Newhouse, 2004) are currently repeated in a Phase II study with the selective α7 nAChR 
ligand TC-5619 by Targacept Inc.  
4. 7 nAChR as target for drug development 
Because the activation of α7 nAChR persistently affects synaptic transmission, multiple 
neurotransmitter and neuropeptide systems, and eventually brain plasticity (Leonard, 2003; 
Radcliffe & Dani, 1998; Shen & Yakel, 2009), α7 nAChR has been assessed as a potential 
target for the rational design of drugs for neuroprotective and neuropsychiatric indications. 
The large number of studies on receptor structure and pharmacology makes α7 nAChR an 
extensively investigated receptor protein and the continued development of orthosteric 
ligands and allosteric modulators by the pharmaceutical industry testifies the importance of 
efforts to assess α7 nAChR expression and functionality in the living human brain (Bunnelle 
et al., 2004; Mazurov et al., 2006). 
Evidence of a correlation between α7 nAChR properties and brain performance has been 
provided by studies on the attentional and cognitive enhancement obtained by α7 nAChR 
agonists (Feuerbach et al., 2009; Levin et al., 1999; Roncarati et al., 2009) and positive 
allosteric modulators (Faghih et al., 2008; Timmermann et al., 2007) as well as on α7 nAChR 
related pharmacotherapeutic approaches for schizophrenia (Freedman et al., 2008; Olincy et 
al., 2006; Tregellas et al., 2011), and dementia (Bacher et al., 2010; Kitagawa et al., 2003; 
Thomsen et al., 2010). Furthermore, electrophysiological (Hurst et al., 2005; Ng et al., 2007) 
and behavioural data (Bitner et al., 2010; Pacini et al., 2010; Tietje et al., 2008) highlight the 
potential of α7 nAChR as therapeutic target for neurodegenerative diseases. The close 
connection between α7 nAChR signalling, inflammation, and neurodegeneration makes α7 
nAChR auspicious also for medicinal control of inflammation as an epiphenomenon of 
many brain disorders (Conejero-Goldberg et al., 2008; de Jonge & Ulloa, 2007; Rosas-Ballina 
& Tracey, 2009). 
5. Noninvasive imaging of 7 receptors in normal and diseased brain 
Far beyond what can be analysed postmortem, the non-invasive and real-time investigation 
of α7 nAChR by means of molecular imaging techniques provides the assessment of 
temporal and spatial changes in receptor distribution and density during disease 
progression and drug treatments.  
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5.1 Technical requirements 
The most advanced system for non-invasive diagnostic and therapeutic neuroreceptor 
imaging is positron emission tomography (PET) (Antoni & Langström, 2008; Hagooly et al., 
2008; Heiss & Herholz, 2006). In PET, the quantitative detection of the distribution of 
radiolabeled molecules in vivo with high resolution and sensitivity leads to functional 
images of brain biochemistry and physiology (Spanoudaki & Ziegler, 2008). PET has now 
become an advanced nuclear medicine imaging technique integrated into routine clinical 
use (Galban et al., 2010) and a highly sophisticated tool for experimental animal research 
(Lancelot & Zimmer, 2010; Xi et al., 2011). 
Receptor ligands used for PET are radiolabelled with short-lived positron-emitting isotopes 
such as 15O, 13N, 11C, and 18F with half-lives of 2, 10, 20.4, and 109.6 min, respectively. The 
spatial resolution of recently developed clinical PET systems with about 2-3 mm allows 
tracing of radioligand distribution even within small cerebral nuclei in human brain (Heiss 
et al., 2004; Lecomte, 2009; Wienhard et al., 2002), and a detailed regional analysis also in 
rodents (Lancelot & Zimmer, 2010; Lecomte, 2009; Xi et al., 2011) can be achieved with 
dedicated small-animal PET scanners. To overcome the problem of the anatomic 
classification of areas with increased or diminished radioligand accumulation, co-
registration of brain anatomy with MRI or CT is needed. Software-based approaches used 
for computerized anatomical alignment have been very successful in brain imaging because 
of the relatively fixed and uniform structure of the head, and both manual and automated 
systems have been developed in the last years (Slomka & Baum, 2009). Through the use of 
multimodal approaches delineation of small-sized but receptor-rich brain areas is 
considerably improved (Heiss, 2009). During the last decade hybrid PET-CT scanners have 
been developed, where two gantries for PET and CT are placed back-to-back (Mawlawi & 
Townsend, 2009). Technically even more challenging is the development of hybrid PET-MRI 
scanners because of the sensitivity of the photomultiplier tubes of the standard PET 
detectors to even low magnetic fields. This problem has been solved only recently (Pichler et 
al., 2008; Pichler et al., 2006) and was first successfully accomplished for small-animal 
designs (Judenhofer et al., 2008). Very recently, fully integrated PET-MRI systems which 
allow simultaneous data acquisition have been developed as clinical research instruments, 
and four prototypes of integrated hybrid PET-MRI scanners were installed at two PET 
centres in Europe (Germany) and the United States so far. However, several technological 
and methodical issues have to be addressed before PET-MRI can establish itself as a routine 
clinical tool (von Schulthess & Schlemmer, 2009).  
5.2 Radiotracer development 
PET technology, using radionuclides with high specific radioactivity and the opportunity to 
specifically label a chemical compound by substituting a stable atom with its radioactive 
counterpart, combined with quantitative measurements of radioactivity, is the preferred 
modality for molecular imaging (Antoni & Langström, 2008). Despite of some of the 
limitations in instrumentation discussed above, the bottleneck for broad clinical applications 
in neuroimaging is the limited availability of suitable radioligands. Among positron-
emitting isotopes only 11C and 18F are applicable for imaging of neurotransmitter-related 
components in the brain. Their short half-live (11C: t1/2 = 20.4 min, 18F: t1/2 = 109.6 min) 
allows repeated investigations in the same patient or the same animal with short time 
intervals. Accordingly, the patient or the animal can be considered as its own reference 
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following a pharmacological intervention. For use in a satellite concept (i.e. with no on-site 
cyclotron available at the PET center), there is a special demand for PET radioisotopes with 
longer half-life such as 18F.  
Even though the basic mechanisms of radioligand-target interactions in vitro and in vivo are 
identical, in vivo imaging requires some additional factors that have to be taken into account. 
In addition to high-affinity binding and supreme selectivity towards the biological target, 
key requirements for all types of radioligands, suitable physicochemical properties gain 
special importance for brain imaging with PET. For example not only the transfer of the 
radioligand across the blood-brain barrier (BBB) is determined by its lipophilicity (Davson & 
Segal, 1996; Liu et al., 2010) but also the non-specific binding (Waterhouse, 2003). High 
accumulation and prolonged retention in the target region with target-to-background ratios 
of desirably more than 5 are closely related to both the affinity of the radioligand and the 
density of its potential binding sites, which are small compared to the concentration of non-
target proteins. Because saturation of binding sites may be obtained at comparably low 
radioligand concentrations, the concentration of the radioligand applied has to be about 
1000-fold lower than the pharmacological threshold. In other words, high specific activity in 
the range of 50-500 GBq/µmol has to be achieved, feasible nowadays with both 11C- and 18F-
labeled radioligands (Antoni & Langström, 2008).  
In summary, high target affinity, specificity, sensitivity, metabolic stability and appropriate 
pharmacokinetics are among the most important features for a good in vivo neuroreceptor-
imaging agent. Despite the fact that over the past decade a great variety of α7 nAChR 
selective agents have been developed, so far there are only a few radioligands which fulfil at 
least some of these criteria and will be discussed below.  
5.3 Imaging of 7 nAChR in animal and human brain  
Although a radiopharmaceutical for PET imaging of α7 nAChR that fulfills all the above-
mentioned pre-conditions is still missing, there is general agreement to develop ligands, 
which bind to the orthosteric site of the α7 nAChR. The steric and electronic requirements of 
this site are met by structurally diverse classes of compounds as reviewed recently 
(Toyohara et al., 2010a), and potential ligands originate from for example benzylidene 
anabasein compounds such as GTS-21 (Meyer et al., 1998), or the quinuclidine framework 
such as AR-R-17779, both shown in Fig. 2 (Bodnar et al., 2005; Mazurov et al., 2005; Mullen 
et al., 2000; Tatsumi et al., 2005). A recently developed highly selective fluorescent α7 
nicotinic receptor ligand is restricted to in vitro studies because of its chemical structure 
(Hone et al., 2010). 
Despite this basic knowledge and promising experimental data obtained in vitro, the 
imaging of α7 nAChR in vivo is still in its infancy. This is not only due to the inadequate in 
vivo performance caused by an insufficient target specificity of radioligands such as the non-
negligible 5HT3R binding of otherwise promising quinuclidine-based tracers (Pomper et al., 
2005) (Table 2). 
Compared to the heteromeric α4β2 nAChRs, imaging of α7 nAChR is challenged by the 
much lower expression of this target, which is illustrated by the up to 100-fold lower density 
of binding sites of α7-specific [125I]α-BGT in comparison to α4β2-specific [3H]nicotine in 
different nuclei of human thalamus (Spurden et al., 1997). Furthermore, the outcome of 
preclinical studies in primates can hardly be predicted from biodistribution studies in 
rodents. While in the monkey brain high target-to-nontarget ratios were obtained for the 
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diazabicyclooctane derivatives [11C]A-582941 and [11C]A-844606, both failed with regard to 
regional distribution and selectivity in the mouse brain (Toyohara et al., 2010b) (Tab. 2).  
 
 
Fig. 2. Lead structures for development of radioligands for neuroimaging of α7 nAChR 
Recently, the 1,4-diazabicyclo-[3.2.2]nonane skeleton (Bunnelle et al., 2004) has been 
identified as new structure to improve the receptor-ligand interaction, and both 18F-
substituted compounds such as [18F]NS10743 (Peters et al., 2007) and those for labelling with 
11C such as [11C]CHIBA-1001 (Hashimoto et al., 2008; Toyohara et al., 2009) and 
[11C]NS12857 (Lehel et al., 2009) have been designed (Table 2). As illustrated by the data in 
Tab. 2, the general suitability of these derivatives for imaging of α7 nAChR is supported by 
preclinical PET studies in pigs (Deuther-Conrad et al., 2011; Lehel et al., 2009) and non-
human primates (Hashimoto et al., 2008) as well as a first clinical study (Toyohara et al., 
2009). However, substantial enhancement in the affinity of the α7 nAChR PET ligands is 
required to improve image analysis, modelling, and eventually quantification of α7 nAChR 
in brain diseases. Considering the low density of α7 nAChR in brain, the target affinity of 
the currently most promising tracers [11C]CHIBA-1001 (Ki ~ 35 nM; (Hashimoto et al., 2008; 
Toyohara et al., 2009) and [18F]NS10743 (Ki ~ 10 nM; (Deuther-Conrad et al., 2009) has 
proved insufficient, because dissociation constants of ≥ 10 nM result in baseline binding 
potential values considerably lower than the threshold value of 2 (Koeppe, 2001). NS14490, a 
novel diazabicyclononane derivative which has been developed by NeuroSearch and 
radiolabelled in collaboration with the authors, possesses a Ki value of ~ 3 nM in vitro 
(Deuther-Conrad and colleagues, unpublished), and the ligand distribution pattern of 












Fig. 3. In vitro autoradiography on the distribution of [18F]NS14490 in rat brain (sagittal 
slices, 12 µm). A = [18F]NS14490, total binding; B = Co-incubation of [18F]NS14490 with 20 
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CD1 mice  
Biodistribution 
Very limited uptake of radioactivity 
in the brain; 
No evidence of receptor blockade 











SPRD rats  
Biodistribution
No regionally selective or specific 








High uptake in the pig brain; 
Distribution as reported in primates;
Lack of in vivo displacement 











High uptake in the pig brain; 
Blocking significantly reduced 
binding potential in regions with 
high radioactivity uptake 
(Deuther-Conrad 






Papio anubis  
Dynamic PET 
scan 
Very high initial uptake followed by 
rapid clearance; Radiometa-bolites 
penetrate the BBB;  
High nonspecific binding consistent 
with the low affinity for α7 nAChR 







[11C]MeQAA Macaca mulatta 
Dynamic PET 
scan 
R-enantiomer with high uptake of 
radioactivity in the brain and α7 
nAChR-related distribution 












Substantial and heterogenous brain 
accumulation;  
Uptake reduced to background level 
of the cerebellum by pretreatment 
with the α7 nAChR agonist 
SSR180711 











Regional distribution consistent with 
α7 nAChR expression 
 












Selective uptake in the regions of the 
hippocampus, cortex and basal 
ganglia; gradual washouts; 
cerebellum with lowest binding  
(Toyohara et al., 
2009) 
Table 2. Findings on in vivo biodistribution and PET imaging studies on the binding of α7 
nAChR specific radioligands in brain of different species.  
 
Neuroimaging – Clinical Applications 
 
542 
6. Noninvasive imaging of 7 nAChR in other diseases – Reality and vision  
For another derivative, NS14492, an IC50 value of 4.5 nM was reported. It was radiolabelled 
with 11C and investigated in pigs, where the radioligand showed the capability of measuring 
in vivo occupancy at 7 nAChR (Ettrup et al., 2010). 
With regard to molecular imaging, the development of quantitative approaches to visualise 
α7 nAChR outside the brain is another big challenge because comparably low receptor 
densities have to be expected also in peripheral organs. Experimental radiotracer studies 
discussed above provided evidence of specific α7 receptor binding not only in the adrenals 
with reported receptor densities of less than 10 fmol/mg in human tissue (Mousavi et al., 
2001) but also in heart, muscle, gut, kidney, thymus, pancreas and liver (Deuther-Conrad et 
al., 2009).  
In general, imaging the concentration, distribution and occupancy of neuroreceptors 
involved in respiratory and cardiovascular disorders is a very attractive research area as it 
can provide new insights in the aetiology of these diseases as well as means to diagnose 
them (Hagooly et al., 2008). Regarding α7 nAChR, the presence of these receptors in 
microvascular endothelial cells has been shown and their involvement in the regulation of 
microvascular permeability and angiogenesis has been suggested (Egleton et al., 2009; Li & 
Wang, 2006; Moccia et al., 2004). 
Furthermore, nicotinic α7 receptors are part of a neural circuit where acetylcholine 
transmitted via the vagus nerve is thought to control cytokine release as part of the 
cholinergic anti-inflammatory pathway (Tracey, 2002). This pathway may protect organs 
such as heart or kidney from ischemic injury (Li et al., 2010; Sadis et al., 2007; Yeboah et al., 
2008) and could be of importance in patients with autoimmune diseases known to be 
characterized by suppressed vagus nerve activity (Bruchfeld et al., 2010). Accordingly, 
neuroimmunomodulation mediated by α7 nAChR agonists is regarded as a future 
therapeutic approach (Bencherif et al., 2011; Kumar & Sharma, 2010). 
Nicotinic α7 receptors are also regarded as a powerful regulator of responses that stimulate 
cancer cells (Egleton et al., 2008; Schuller, 2009). In particular, evidence of the involvement 
of nicotinic α7 receptors in the control of basal cell proliferation and differentiation 
pathways in lung and the participation of these receptors in airway remodelling during 
brochopulmonary diseases led to the assumption that α7 nAChRs are of relevance for lung 
development, injury, repair, and carcinogenesis (Maouche et al., 2009). Because the α7 
nAChR is the most predominantly expressed nAChR subtype in bronchial epithelial cells 
(Paleari et al., 2009) and mRNA for α7 nAChR has been detected not only in normal lung 
cells but in most human lung cancer cell lines (Egleton et al., 2008; Plummer et al., 2005), it 
has been hypothesized that a desensitization of α7 nAChR in heavy smokers with a 
prolonged exposure to nicotine could lead to squamous metaplasia (Tournier & Birembaut, 
2011). While in an early investigation of small cell carcinomas of the lung no specific [125I]-α-
bungarotoxin binding could be demonstrated, probably due to a sub-threshold density of 
the α7 receptor protein related to this particular type of cancer (Cunningham et al., 1985),  
not only all of 50 investigated non-small cell lung cancer (NSCLC) cell lines expressed the α7 
subtype (Paleari et al., 2009) but also all out of 52 investigated NSCLC patients expressed α7 
receptor mRNA and protein and the values were higher in smoking patients with squamous 
carcinomas than those with adenocarcinomas (Paleari et al., 2008).  
Besides lung cancer, α7 nAChR-mediated signalling has been implicated in the growth and 
metastasis of colon cancer (Wei et al., 2009; Wei et al., 2011; Ye et al., 2004), probably due to 
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the activity of the endogenous allosteric α7 nAChR modulator SLURP-1 and the 
upregulation of the downstream signalling molecule NF-κB (Chernyavsky et al., 2010; 
Pettersson et al., 2008; Ye et al., 2004). Also the development of keratinocyte carcinoma, the 
most prevalent skin cancer and the most common cancer in United States (Albert & 
Weinstock, 2003), may depend on α7 nAChR expression and regulation. Interestingly, 
antagonisation of nAChR activity by SLURP-1 and -2 prevented the tobacco nitrosamine-
induced malignant transformation of oral keratinocytes (Arredondo et al., 2007), cells 
known to express α7 nAChR (Chernyavsky et al., 2010). Further cancers with known α7 
nAChR expression include breast, pancreas, and prostate carcinomas (Al-Wadei et al., 2009; 
Dasgupta et al., 2009; Hirata et al., 2010; Hruska et al., 2009). 
Based on this evidence, α7 nAChR is considered a primary target in ongoing research on 
pathogenesis of a variety of cancers. Furthermore, the quantitative imaging of disease-
related changes in the expression of peripheral α7 nAChR by PET is highly desirable for the 
validation of novel approaches in diagnostics and development of cancer-specific therapy.  
7. Conclusion 
Generally, the development of imaging approaches to non-invasively quantify α7 nAChR 
receptors in and outside the brain is expected to help in the generation and testing of novel 
hypotheses supporting the understanding of pathogenetic processes and promoting novel 
diagnostic and therapeutic concepts. The clinical significance of a malfunction of α7 nAChR, 
involved in particular cell-type and pathology specific modulating and signalling cascades, 
can be assessed on molecular level with an imaging-supported spatiotemporal 
quantification of α7 nAChR protein. In this context, the imaging technique must be sensitive 
enough not only to identify but also to assess the dynamics and quantity of even subtle 
changes in the amount of functional α7 nAChR, which is despite its physiological 
importance expressed at comparably low levels in the brain and periphery. PET techniques 
offer the highest achievable resolution of functional processes in the body in four 
dimensions by imaging of α7 nAChR with further optimised PET radiotracers, which might 
be based for instance on the currently most promising diazabicyclononane derivatives.  
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1. Introduction 
Leukodystrophies are hereditary disorders of white matter that impair brain that is initially 
normally formed and developed (1, 2). They can affect brain myelin throughout life. The 
disorders are commonly progressive in nature and ultimately fatal. First manifestations are 
often cognitive deterioration and neuropsychological problems. Motor and balance 
difficulties occur, as do visual abnormalities. Classic leukodystrophies lead to a vegetative 
state or death within months to years. In general, the earlier the onset of symptoms, the 
more progressive the disease course.  
Most leukodystrophies are monogenetic disorders. The mutant gene often encodes an 
enzyme or protein that maintains neuronal and/or glial health and is responsible for 
regulation of brain metabolism. Many enzymes involved play a role in lipid metabolism. 
The inability to degrade or synthesize substrate leads to an upstream excess or downstream 
lack of vital lipids. This can cause a wide range of pathology, from inflammatory 
demyelination to axonal degeneration and microglial activation. Hence, the often cited 
prominent demyelination is only one manifestation in leukodystrophies, and myelin-
forming oligodendrocytes are not the only cells affected in these disorders.  
Yet, there are some common characteristics that distinguish the pathology in 
leukodystrophies from that of other disorders. MRI has played a seminal role in 
visualization of the lesion pattern. (3). The demyelinating lesions are usually confluent and 
symmetric. Many of the classic disorders, such as X-linked adrenoleukodystrophy (X-ALD), 
metachromatic leukodystrophy (MLD) and Krabbe, show relative sparing of subcortical 
fibers. Yet again, other disorders have early involvement of the U fibers and other unique 
characteristics, such as cystic rarefaction and degeneration. 
Hereditary disorders that do not show demyelination but rather hypomyelination have 
come to increasing attention (4). Common neurological features in hypomyelinating 
disorders are developmental delay, nystagmus, cerebellar ataxia and spasticity. One of the 
better characterized hypomyelinating disorders is Pelizaeus Merzbacher disease (PMD). 
Beyond this classic disorder, a multitude of other hypomyelinating disorders exist. Only 
about half of the patients with evidence of hypomyelination on MRI come to a definitive 
diagnosis. Yet, specific clinical and MRI features can be pathognomonic and lead to 
diagnosis. 
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The current review aims to present the diagnostic MRI lesion patterns of leukodystrophies, 
as well as the utility of advanced MR techniques. While some of these techniques are 
already established in clinical practice, others are still experimental in nature and require 
future validation.  
2. Conventional brain MRI lesion patterns in LD 
Overall, MR imaging has made an enormous contribution to the field of leukodystrophies 
due to the precise lesion pattern evident on MRI (5). Many leukodystophies classically show 
imaging features that, in some cases, are pathognomonic and, in some cases, highly 
suggestive of the diagnosis. Both demyelinating and hypomyelinating disorders carry 
distinct features and are listed in Tables 1 and 2. While the patterns of maturation of white 
matter are similar on T1 and T2 weighted images, white matter appears to mature at a later 
time on T2 weighted images. This is crucial, as it indicates that T1 weighted imaging may be 
more sensitive to immature myelin than T2 weighted imaging.  
In its most severe form, X-ALD is a lethal neurodegenerative disorder with inflammatory 
demyelination. Defective peroxisomal beta-oxidation causes accumulation of very long-chain 
fatty acids (VLCFA) in tissues and plasma, particularly in the nervous system and adrenal 
glands. At least four clinical phenotypes have been delineated: childhood cerebral (CCALD), 
adult cerebral, adrenomyeloneuropathy (AMN), and female heterozygotes for X-ALD.  
In CCALD, the posterior regions of the brain are involved in 80-90% and the frontal regions 
are involved in 5-10% (6, 7). The lesion evolves in a symmetric confluent fashion starting in 
the splenium or genu of the corpus callosum and spreading into the periventricular white 
matter (Figure 1). The arcuate fibers are most often spared. In the acute phase, a garland of 
contrast enhancement is present. In the final stages, white matter atrophy is seen. The 
systematic progression has given rise to a scoring system of 34 points (8, 9). This pattern is 
markedly different than that seen in the adult form of the disease, AMN, a non-
inflammatory chronic axonopathy.  
In Krabbe disease, the parieto-occipital lesions are also present, although a garland of 
contrast enhancement is never seen (10, 11). MLD shows more diffuse involvement of both 
frontal and posterior regions of the brain (12). Involvement of the corpus callosum is seen 
early, although not as striking as that seen in ALD or GLD. A tigroid pattern is often 
apparent in the centrum semiovale. In contrast to ALD, the outer subarachnoid spaces are 
not enlarged in MLD, even in the most advanced stages of disease.  
Other disorders have characteristic early involvement of the subcortical fibers. Children 
with Canavan disease present with an enlarged head (“megalencephaly”), but show less 
behavioral changes than other leukodystrophies of infancy. (13, 14). Their MRI shows 
diffuse involvement of white matter including the subcortical U fibers (15). There is also 
involvement of basal ganglia and other gray matter structures. Alexander disease is another 
leukodystrophy that often manifests with megalencephaly (16). Imaging studies of the brain 
typically show cerebral white matter abnormalities, preferentially affecting the frontal 
region, although unusual variants are coming to increasing attention (17, 18). 
The MRI of vanishing white matter disease (VWMD) also has a characteristic pattern. It 
shows progressive loss of white matter over time on proton density and FLAIR images 
(19-21). The findings on autopsy confirm the white matter rarefaction and cystic 
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degeneration suggested by the MRI. Regions of relative sparing include the U-fibers, 
corpus callosum, internal capsule, and the anterior commissure. The cerebellar white 




Fig. 1. Lesion Patterns on Conventional MRI in Leukodystrophies and Hypomyelinating 
Disorders 
Brainstem lesion patterns can also often provide critical clues to the diagnosis. 
Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Elevated White 
Matter Lactate (LBSL) has recently been described and shows distinct involvement of the 
pyramidal tracts, medial lemniscus, mesencephalic trigeminal tracts, corticobulbar tracts, 
and superior cerebellar peduncles. (22). Recognition of the distinct lesion pattern led to the 
identification of the responsible gene DARS2, which encodes mitochondrial aspartyl-tRNA 
synthetase.  
In hypomyelinating disorders, the boundaries between gray and white matter often appear 
“blurred” (4). The T2 hypointensity of the white matter is milder in hypomyelination than in 
demyelination and other white matter pathology. Overall, the brain MRI in 
hypomyelination looks like that of a young child, with less well distinguished gray and 
white matter. As opposed to “delayed myelination,” the pattern on brain MRI is unchanged, 
as in myelination is “stuck” on two MRIs 6-12 months apart in a child older than one year of 
age. While at first glance, hypomyelinating disorders may all have a similar MRI 
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appearance, there are a group of disorders for which the MRI scan can provide clues to the 
diagnosis (see Table 2). In these individual disorders attention to the deep gray matter 
structures will often reveal a characteristic “signature” (4).  
 
Leukodystrophy Mutated genes Characteristics on Brain MRI 
Aicardi-Goutières 
syndrome (78, 79) TREX1 
Often with microcephaly and intracranial 
calcifications (CT) 
Alexander Disease GFAP 
Macrocephaly with frequent frontal lesion 
predominance in childhood, variants with 
abnormalities in medulla and spinal cord, 
ventricular garlands 
Canavan Disease ASPA Macrocephaly, subcortical U fibers  and basal ganglia involved 
Cerebral autosomal 
dominant arteriopathy 




Multiple small hemorrhages. Widened 
perivascular spaces in the centrum 
semiovale and basal ganglia 
Cerebrotendineous 
Xanthomatosis CYP27A1 
Cerebellar lesions, calcifications visible on 
CT 
Globoid Leukodystrophy 
(Krabbe Disease) GALC 
Posterior predominance, no contrast 
enhancement 
Leukoencephalopathy 
with Brain Stem and 
Spinal Cord Involvement 
and Elevated Lactate 
DARS2 
Characteristic brainstem pattern: pyramidal 
tracts, cerebellar connections and 




Cysts (80, 81) 
MLC1, 
GLIALCAM 
Macrocephaly with swelling of cerebral 
white matter and cystic lesions (bilateral 
anterior temporal lobes) 
Metachromatic 
leukodystrophy ARSA 
Diffuse with initial subcortical sparing, 
“tigroid pattern” in centrum semiovale 
Vanishing White Matter 
Disease EIF2B1-5 
Confluent cystic degeneration, white 
matter signal appears CSF-like 
X-Linked 
Adrenoleukodystrophy ABCD1 
CCALD: posterior predominance with 
contrast enhancement in acute phase 
AMN: corticospinal tracts and dorsal 
columns, no contrast enhancement 
Table 1. Characteristics on Brain MRI in Leukodystrophies 
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Hypomyelinating Disorder Mutated genes Characteristics on Brain MRI 
Fucosidosis FUCA1 T2 hypointensity globus pallidus 
GM2 gangliosidoses HEXA, HEXB T2 hyperintensity in the basal ganglia 
Hypomyelination with 
atrophy of the basal 
ganglia and cerebellum 





unknown Early cerebellar atrophy with absence of putamen 
Pelizaeus-Merzbacher 
Disease PLP1 
Homogeneous T2 hyperintensity of 




SLC16A2 Pontine T2 hyperintensity 
Table 2. Characteristics on Brain MRI in Hypomyelinating Disorders 
Advanced magnetic resonance (MR) imaging techniques, such as proton MR spectroscopic 
and diffusion tensor (DT) MR imaging, permit the investigation of changes in metabolite 
levels and water diffusion parameters in leukodystrophy patients. Both metabolite measures 
and water diffusion parameters offer an opportunity to assess the degree of axonal loss and 
demyelination in the leukodystrophies.  
3. Proton MR spectroscopy 
Magnetic resonance spectroscopy (MRS) offers the unique ability to measure metabolite 
levels in vivo in a non-invasive manner (23, 24, 25). These metabolite quantifications can be 
used to identify disease, measure the severity of an injury, or monitor a patient’s response to 
treatment. Table 3 shows the most well characterized metabolite abnormalities detected by 
MRS in leukodystrophies.  
The resonances seen in the brain by MRS are typically low weight molecules (see Figure 2). 
In the normal brain, the most prominent peak arises from N-acetylaspartate (NAA) at 2.0 
ppm. The other major peaks include creatine (Cr) and phosphocreatine (phospho-Cr), 
which are observed at 3.0 and 3.3 ppm, respectively, as well as choline containing 
compounds. 1H MR spectra acquired with short echo times are characterized by 
additional resonances from myo-inositol (MI) at 3.5 ppm, and glutamate and glutamine, 
which overlap with each other so  that they are often referred to as Glx, at ~2.5 ppm. 
Under normal conditions, the lactate concentration is very low in the adult brain. This 
resonance (observed as a doublet) occurs at 1.32 ppm.  
NAA within the adult brain is found exclusively in neurons, serving as a marker of neuronal 
density and viability and reported to be decreased in a number of neurological disorders.  
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Leukodystrophy or Hypomyelinating 
Disorder Systemic metabolites 
Brain metabolites abnormalities on 
proton MR spectroscopy 
Alexander Disease Unknown 
Infantile form: myoinositol 
elevations in white and gray 
matter, decreased N-
acetylaspartate










Choline and myoinositol 
elevations, 
decreased N-acetylaspartate 
GM2 gangliosidoses GM2 gangliosides 
Infantile: variable choline, 
myoinositol and N-
acetylaspartate. 
Late onset: decreased N-
acetylaspartate 
Hypomyelination with atrophy of 
the basal ganglia and cerebellum Unknown 
Increased myoinositol and 
creatine
Leukoencephalopathy with Brain 
Stem and Spinal Cord 
Involvement and Elevated Lactate 
Unknown  
Decreased N-acetylaspartate 
and increased myo-inositol, 
choline and lactate  
Leukoencephalopathy associated 
with a disturbance in the 
metabolism of polyols (83, 84) 
Arabinitol and ribitol 
in urine, plasma and 
CSF
Elevated levels of arabinitol and 
ribitol (coupled resonances 
between 3.5 and 4ppm) 
Megalencephalic 
Leukodystrophy with Cysts Unknown 
Decreased ratio of N-
acetylaspartate to Creatine 
Pelizaeus-Merzbacher Disease Unknown Variable reports on changes in N-acetylaspartate and choline 
Vanishing White Matter Disease
Decreased ratio of 
asialotransferrin to 
transferrin in CSF
Within cystic white matter 




Plasma very long 
chain fatty acids 
CCALD: Choline elevations 
within normal appearing white 
matter, elevations of lactate 




Table 3. Brain Metabolites Abnormalities on Proton MR Spectroscopy 
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NAA is the source of acetyl in myelin membrane biosynthesis (26) and is coupled to lipid 
metabolism and energy generation (27). Creatine serves as a marker for energy-dependent 
systems in cells and it tends to be low in processes that have low metabolism, such as 
necrosis and infarction. As Cr and phospho-Cr are in equilibrium, the Cr peak is thought to 
remain stable in size, despite bioenergetic abnormalities that occur with multiple 
pathologies. Consequently, the Cr resonance is often used as an internal standard.  
The choline (Cho) resonance arises from signals of several soluble components that resonate 
at 3.2 ppm. This resonance contains contributions primarily from glycerophosphocholine 
(GPC), phosphocholine (PCho), and Cho. Changes in this resonance are commonly seen 
with diseases that have alterations in membrane turnover and in inflammatory and gliotic 
processes (28, 29). The function of MI is not fully understood, although it is believed to be an 
essential requirement for cell growth, an osmolyte, and a storage form for glucose (30). MI is 
primarily located in glia, and an increase in MI is commonly thought to be a marker of 
gliosis (31). Lactate is produced by anaerobic metabolism, and increased lactate has been 
found during hypoxia (32), mitochondrial diseases (33, 34), seizures (35), and in the first 
hours after birth (36, 37).  
In the developing brain, Cho and MI are the dominant peaks in the MR spectrum. Their levels 
are high compared to Cr. In contrast, NAA levels are low in newborns and increase with age, 
while Cho and MI decrease with age. During the first 6 months of life, these metabolic changes 
are most rapid, leveling off at about 30 months of age (50). These changes are crucial, as both 
hypomyelination and delayed myelination affect changes of these metabolites. 
In X-ALD, proton MRS sometimes shows metabolite abnormalities beyond the margins of 
disease depicted by conventional MR imaging (38). The white matter lesion in children with 
X-ALD shows reduced NAA/Cr and increased  Cho/Cr, MI/Cr and Glx/Cr  (30). 
Spectroscopic changes in normal appearing white matter (NAWM) that precede disease 
progression in patients with X-ALD have been described (39). The changes are an increase in 
choline and a decrease in NAA. They occur in areas where subsequent lesion progression is 
observed, but not in the remainder of the brain. These areas may represent a zone of 
impending or beginning demyelination.  
Adrenomyeloneuropathy (AMN) is the adult variant of X-ALD. The disease pathology is 
usually limited to spinal cord and peripheral nerves (“‘pure AMN”) but shows cerebral 
involvement on histopathology. MRS studies showed reduced global NAA/Cho and 
NAA/Cr compared to controls. These changes are most prominent in internal capsule and 
parieto-occipital white matter. Decreased ratios of NAA in the absence of Cho/Cr elevation 
suggest prominent axonal involvement (40). Furthermore, Dubey et al demonstrated that 
the Expanded Disability Status Scale (EDSS) score inversely correlated with global NAA/Cr, 
suggesting a potential role of axonal injury in clinical disability in pure AMN. (40). Brain 
involvement demonstrable by MRI is rare in female subjects heterozygous for X-ALD, 
including those who have clinical evidence of spinal cord involvement. Nevertheless, NAA 
levels are reduced in the corticospinal projection fibers in female subjects with normal 
results on MRI, suggesting axonal dysfunction (41).  
Canavan disease is caused by a deficiency in aspartoacylase (ASPA), an enzyme involved in 
the process of degrading NAA to aspartate and acetate. Deficiency leads to the 
accumulation of NAA, which impairs normal myelination and results in spongiform 
degeneration of the brain (42, 43). The elevations in NAA can be detected by MR 
spectroscopy in vivo (Figure 2), a diagnostic clue that can then be confirmed by urine 
measurement of NAA. The distinctly higher NAA peak can even be detected in the newborn  
 





Fig. 2. The spectra of a normal brain are shown at both long echo time (top), TE = 250-280 
ms, and short echo time (bottom), TE = 20-50 ms. The spectra for the disease states are as 
follows: the Canavan spectra are acquired at long echo time, and the ALD and CTX spectra 
are acquired at short echo time.  
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although a radiologist only familiar with MR spectra in adults may not recognize the 
elevation in the newborn as pathologic.  
LBSL is a disorder clinically characterized by slowly progressive signs of pyramidal, 
cerebellar and dorsal column dysfunction. LBSL shows a very distinct MRI pattern, with 
selective involvement of cerebral and cerebellar white matter and brainstem and spinal 
tracks, while U-fibers are spared (44). In LBSL, MR spectroscopy characteristically reveals 
decreased NAA and increased lactate, Cho and MI in the white matter, suggesting axonal 
damage and gliosis (45). Lately, mutations in the DARS2 gene, which encodes mitochondrial 
aspartyl-tRNA synthetase, have been identified as the underlying defect. 
Cerebrotendinous xanthomatosis (CTX) is a rare but treatable disorder characterized by a 
defect in the metabolic pathway of cholesterol (46). Symptoms in infancy include diarrhea, 
cataracts and psychomotor retardation. In adulthood, the spectrum of neurologic 
dysfunction includes mental retardation leading to dementia, psychiatric symptoms, 
premature retinal aging, and epileptic seizures. The most distinctive MR imaging 
abnormalities are bilateral T2 hyperintensities in the dentate nuclei and adjacent 
cerebellar white matter (47). An MRS study showed a reduction in NAA levels and the 
presence of a lactate peak (see Figure 2). NAA decreases are attributed to neuroaxonal 
damage due to neurotoxic deposition of cholesterol (48). A recent case report described 
the presence of abnormal lipid peaks at 0.9 and 1.3 ppm in the cerebellar hemisphere (49). 
These peaks can either be attributed to membrane breakdown or they may serve as 
surrogate markers of major lipid storage, with a potential role in monitoring therapeutic 
response. In addition, one patient had an increase in MI concentration, pointing to gliosis 
and astrocytic proliferation (50). 
The MR spectra of patients with 4H-Syndrome, a rare form of hypomyelinating 
leukodystrophy, reveals low Cho/Cr and NAA/Cr, while a prominent MI peak can be 
observed (51, 52). Low Cho levels are indicative of hypomyelination due to decreased 
membrane synthesis and turnover. In a new syndrome characterized by Hypomyelination 
with Atrophy of the Basal Ganglia and Cerebellum (H-ABC), MI and Cr levels are found to 
be elevated in the cerebral white matter, while NAA and choline levels are normal (53). 
These findings suggest that neither axonal loss nor active demyelination occurs in the 
setting of gliosis. In Pelizaeus Merzbacher disease, another hypomyelinating disorder, there 
have been discrepant reports on metabolite abnormalities detected by MRS. In part, these 
findings may be explained by the concurrent pathophysiologic processes of 
hypomyelination, gliosis, and neuronal loss over time (54).  
4. Diffusion tensor imaging 
While conventional MRI and MR spectroscopy show greatest utility in the diagnoses of 
leukodystrophies, other techniques, such as diffusion tensor imaging, are starting to be 
applied to leukodystrophies as well. Diffusion tensor (DT) MRI measures diffusivity of free 
water molecules in the brain. From the diffusion tensor, one can calculate indices that 
describe features of the orientationally averaged water diffusivity (isotropic part) and the 
water molecule displacements affected by the orientation of a regularly ordered structure in 
the tissue (anisotropic diffusion). Compared to gray matter, in which diffusion shows less 
directional dependence, white matter apparent diffusion is very anisotropic. (55). This 
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property, termed fractional anisotropy (FA), depends on the orientation of the white matter 
tracks and on the degree and integrity of myelination (56-59). 
In X-ALD, DT imaging may reflect the different abnormal white matter (AWM) zones in 
patients with X-ALD (60). We and others have observed that FA decreases and the 
isotropic apparent diffusion coefficient (iADC) increases over the zones toward the center 
of the lesion. The decrease in mean FA indicates the loss of an ordered structure 
governing the directionality of water molecule displacement. The increase in mean iADC 
suggests an increase in free water and a decrease in structures that restrict water 
diffusion. 
In X-ALD, a strong correlation exists between NAA levels and FA, reinforcing the concept 
that both reflect axonal integrity. However, proton MR spectroscopic imaging reveals a low 
NAA level in regions with normal MR and DT imaging findings (61). In contrast, DT 
imaging showed no abnormalities outside the lesion on T2-weighted images. Further, the 
membrane turnover and cell accumulation associated with beginning demyelination, 
recognized in the enhanced choline and creatine signal intensity on proton MR 
spectroscopic imaging, did not have an effect on diffusion parameters. This suggests that 
proton MR spectroscopic imaging may have a higher sensitivity than both conventional MR 
and DT imaging in the early detection of abnormalities related to demyelination or axonal 
loss in X-ALD patients.  
However, in other instances, DTI has proven utility over proton MRSI. In pure AMN 
patients, DTI-based three-dimensional fiber tracking has shown occult tract-specific 
cerebral microstructural abnormalities in patients who had a normal conventional brain 
magnetic resonance image (62). This advance in MR imaging demonstrates that the 
corticospinal tract abnormalities in AMN reflect a centripetal extension of the spinal cord 
long-tract distal axonopathy.  
DTI anisotropy has also proved useful in Krabbe disease (63, 64). In particular, 
measurements of white matter metabolites may help assess disease progression and 
determine optimal candidates for treatment options. Patients with Krabbe disease who 
underwent stem cell transplantation within the 1st month of life showed substantially 
smaller decreases in anisotropy ratios than those who were treated later. These findings 
correlate well with global assessments of disease progression as recognized by 
neurodevelopmental evaluations and conventional MR imaging. 
DT MR imaging studies of cerebral white matter development in human premature and 
term infants demonstrated that, in general, the apparent diffusion coefficient decreases 
while relative anisotropy increases with brain maturation. The most prominent regional 
difference at term is the increased relative anisotropy in the internal capsule, indicative 
of high directionality of diffusion, which could in part be related to myelination. Axonal 
diameter increases before and during myelination. This diameter change could also 
contribute in an important way to the diminished water diffusion perpendicular to the 
orientation of the fiber and thereby contribute to the increase in relative anisotropy. As 
anisotropy precedes myelination changes seen on conventional imaging, it is expected 
that quantitative analysis of diffusion parameters would add to the field of 
hypomyelinating disorders. Yet, little or no data is currently available in this group of 
disorders. Clearly, more systematic research is needed in regards to hypomyelination 
and DTI. 
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5. Recent applications of advanced MR technology 
One major technological advance has been imaging at higher field strength. Magnetic 
resonance imaging at 4 and 7T allows for better visualization of lesion architecture, white 
matter tracts, and gray-white matter distinction compared with 1.5T. The field of proton MR 
spectroscopy has also benefited from higher field strength (65, 66). Better spectral resolution 
results from improved signal-to-noise ratio and chemical-shift dispersion, and this in turn 
leads to more reliable detection of metabolites such as myoinositol and glutamine.   
Using 7T MRSI, decreases in NAA in the cortex of X-ALD patients were detected, which 
appears greater in male hemizygotes than in female heterozygotes and most pronounced 
with the occurrence of white matter lesions in males. (66). Although the cytoarchitecture of 
the cerebral cortex generally appears normal in X-ALD, scattered neuronal loss can be seen 
in gray matter during a pathologic examination. Both ratios of myoinositol and choline to 
creatine were found to be higher in normal appearing white matter of adult ALD patients 
with brain lesions compared to those without lesions. Yet, the interpretation of 7T MRSI 
data also poses challenges. Voxels close to the scalp show poor water and lipid suppression. 
Also, the quantification of spectral data in the presence of substantial radiofrequency 
excitation field (B1) variations is difficult. Therefore, focus has shifted on using adiabatic 
pulses to compensate for radiofrequency inhomogeneity and reduce the chemical shift 
displacement error (67, 68).  
Overcoming some of the shortcomings of DTI, novel methods now exist to map complex 
fiber architectures of white matter and other brain tissues. Diffusion spectrum imaging (DSI) 
allows resolution of regions of 3 way fiber crossings (69-71). On DTI this was not possible as 
fiber crossing led to decreases in FA, making it difficult to distinguish pathological changes 
from normal fiber crossings. The years ahead will likely bring more studies employing DSI 
in leukodystrophy patients.  
Advances have also been in the development of ex vivo MRI and novel magnetic resonance 
contrast agents for imaging of autopsy specimen. In metachromatic leukodystrophy, 
postmortem studies have demonstrated the pathological correlate of the “tigroid stripes” 
characteristically seen on conventional imaging (72). Through direct correlation of 
postmortem MR imaging on 1 cm thick blocks with neuropathology staining, the authors 
were able to show that perivascular clusters of glial cells containing lipid material 
corresponded to the stripes on MRI. 
Using contrast agents ex vivo, the corresponding substrate of imaging can be further 
elucidated. One such example is luxol fast blue that displays a binding affinity for 
myelinated constituents of the brain (73). The specificity of luxol fast blue for lipid 
constituents results in an increase in longitudinal and transverse relaxation rates of tissue 
dependent on myelination status. The relaxation rates of white matter increase sufficiently 
to permit T1-weighted images of ex vivo samples that are similar in contrast behavior to 
T1-weighted in vivo imaging. The contrast increases in MR images of LFB-stained ex vivo 
brain tissues enhancing delineation between upper lamina and the more myelinated 
lower lamina.  
Other advances in MR technology have brought great practical benefits. Sedation and 
anesthesia represent risks in advanced brain disease of LD patients. Using new techniques, 
such as propeller MRI, it has become possible to oversample k space and, thereby, 
compensate for motion and allow follow-up MR imaging without sedation (74, 75). As an 
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alternative to these retrospective motion-correction techniques, it is also possible to 
prospectively correct motion in structural imaging and single-voxel spectroscopy using 
image-based navigators (76-78). In patients with more advanced leukodystrophies, these 
advances may allow for imaging without sedation and thereby give insight into the more 
advanced stages of disease. 
Overall, not one advanced imaging technology is expected to bring about a breakthrough in 
the leukodystrophies. Rather, the multimodal approach with coregistration of high 
resolution imaging with advanced spectroscopic and diffusion imaging will lead to new 
pathophysiological insights in the years to come. Different diseases, varying phenotypes, 
and stages within the disease will require varying imaging modalities. 
6. Conclusions 
MRI has allowed for much progress in the field of leukodystrophies. Prior to arrival of MRI, 
the specific vulnerability of brain white matter was not well understood. Today, MRI has 
helped define disorders through the recognition of specific lesion patterns and their 
evolution over time. This has also led to identification of novel leukodystrophies and the 
genes underlying these disorders. Even in previously well characterized disorders, MRI 
patterns have shed light on disease mechanisms.  
The understanding of the pathology and molecular basis of leukodystrophies has in turn 
allowed for new insight into the significance of MRI changes and elucidated the capabilities 
of MR techniques. Brain MRI today is a valuable tool in monitoring disease progression and 
the success of therapeutic interventions in leukodystrophies. Advances in new techniques 
encourage a multimodal approach employing a variety of sequences sensitive to different 
brain tissue characteristics. Together, these techniques will be able to provide clues to the 
early stages of disease – insight not gained by pathology in the past. 
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